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Abstract
Immunosuppressive therapy for kidney transplantation in
adults: a systematic review and economic model
Tracey Jones-Hughes,1* Tristan Snowsill,1 Marcela Haasova,1
Helen Coelho,1 Louise Crathorne,1 Chris Cooper,1
Ruben Mujica-Mota,1 Jaime Peters,1 Jo Varley-Campbell,1
Nicola Huxley,1 Jason Moore,2 Matt Allwood,1 Jenny Lowe,1
Chris Hyde,1 Martin Hoyle,1 Mary Bond1 and Rob Anderson1
1Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK
2Exeter Kidney Unit, Royal Devon and Exeter Foundation Trust Hospital, Exeter, UK
*Corresponding author T.Jones-Hughes@exeter.ac.uk
Background: End-stage renal disease is a long-term irreversible decline in kidney function requiring renal
replacement therapy: kidney transplantation, haemodialysis or peritoneal dialysis. The preferred option is
kidney transplantation, followed by immunosuppressive therapy (induction and maintenance therapy)
to reduce the risk of kidney rejection and prolong graft survival.
Objectives: To review and update the evidence for the clinical effectiveness and cost-effectiveness of
basiliximab (BAS) (Simulect®, Novartis Pharmaceuticals UK Ltd) and rabbit anti-human thymocyte
immunoglobulin (rATG) (Thymoglobulin®, Sanofi) as induction therapy, and immediate-release tacrolimus
(TAC) (Adoport®, Sandoz; Capexion®, Mylan; Modigraf®, Astellas Pharma; Perixis®, Accord Healthcare;
Prograf®, Astellas Pharma; Tacni®, Teva; Vivadex®, Dexcel Pharma), prolonged-release tacrolimus
(Advagraf® Astellas Pharma), belatacept (BEL) (Nulojix®, Bristol-Myers Squibb), mycophenolate mofetil
(MMF) (Arzip®, Zentiva; CellCept®, Roche Products; Myfenax®, Teva), mycophenolate sodium (MPS)
(Myfortic®, Novartis Pharmaceuticals UK Ltd), sirolimus (SRL) (Rapamune®, Pfizer) and everolimus (EVL)
(Certican®, Novartis) as maintenance therapy in adult renal transplantation.
Methods: Clinical effectiveness searches were conducted until 18 November 2014 in MEDLINE (via Ovid),
EMBASE (via Ovid), Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web
of Science (via ISI), Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of
Effects and Health Technology Assessment (The Cochrane Library via Wiley Online Library) and Health
Management Information Consortium (via Ovid). Cost-effectiveness searches were conducted until
18 November 2014 using a costs or economic literature search filter in MEDLINE (via Ovid), EMBASE
(via Ovid), NHS Economic Evaluation Database (via Wiley Online Library), Web of Science (via ISI), Health
Economic Evaluations Database (via Wiley Online Library) and the American Economic Association’s
electronic bibliography (via EconLit, EBSCOhost). Included studies were selected according to predefined
methods and criteria. A random-effects model was used to analyse clinical effectiveness data (odds ratios
for binary data and mean differences for continuous data). Network meta-analyses were undertaken within
a Bayesian framework. A new discrete time–state transition economic model (semi-Markov) was developed,
with acute rejection, graft function (GRF) and new-onset diabetes mellitus used to extrapolate graft survival.
Recipients were assumed to be in one of three health states: functioning graft, graft loss or death.
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Results: Eighty-nine randomised controlled trials (RCTs), of variable quality, were included. For induction
therapy, no treatment appeared more effective than another in reducing graft loss or mortality. Compared
with placebo/no induction, rATG and BAS appeared more effective in reducing biopsy-proven acute
rejection (BPAR) and BAS appeared more effective at improving GRF. For maintenance therapy, no
treatment was better for all outcomes and no treatment appeared most effective at reducing graft loss.
BEL+MMF appeared more effective than TAC+MMF and SRL+MMF at reducing mortality. MMF+CSA
(ciclosporin), TAC+MMF, SRL+ TAC, TAC+AZA (azathioprine) and EVL+CSA appeared more effective
than CSA+AZA and EVL+MPS at reducing BPAR. SRL+AZA, TAC+AZA, TAC+MMF and BEL+MMF
appeared to improve GRF compared with CSA+AZA and MMF+CSA. In the base-case deterministic and
probabilistic analyses, BAS, MMF and TAC were predicted to be cost-effective at £20,000 and £30,000 per
quality-adjusted life-year (QALY). When comparing all regimens, only BAS+ TAC+MMF was cost-effective
at £20,000 and £30,000 per QALY.
Limitations: For included trials, there was substantial methodological heterogeneity, few trials reported
follow-up beyond 1 year, and there were insufficient data to perform subgroup analysis. Treatment
discontinuation and switching were not modelled.
Future work: High-quality, better-reported, longer-term RCTs are needed. Ideally, these would be
sufficiently powered for subgroup analysis and include health-related quality of life as an outcome.
Conclusion: Only a regimen of BAS induction followed by maintenance with TAC and MMF is likely to be
cost-effective at £20,000–30,000 per QALY.
Study registration: This study is registered as PROSPERO CRD42014013189.
Funding: The National Institute for Health Research Health Technology Assessment programme.
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Glossary
Acute kidney rejection When the immune response of the host attempts to destroy the graft, as the
graft is deemed foreign tissue.
Adverse events Any untoward medical occurrence in a patient or clinical investigation subject who is
administered a pharmaceutical product.
Banff Criteria used to grade the severity of an acute rejection following a biopsy of the kidney, with
‘grade I’ being least severe and ‘grade III’ being most severe.
Biopsy-proven acute rejection When an acute kidney rejection is confirmed through a biopsy and
correspondence with the Banff criteria.
Calcineurin inhibitor Ciclosporin or tacrolimus.
Chronic kidney disease Abnormal kidney function and/or structure.
Cold ischaemia time Period during which a donated kidney is transported in ice from donor to recipient.
Duration is related to extent of kidney damage.
Creatinine clearance One method of determining glomerular filtration rate. Urine is collected (usually for
24 hours) to determine the amount of creatinine that was removed from the blood over a given
time interval.
Cytomegalovirus A virus that normally causes only a mild ‘flu-like’ illness. In people with a kidney
transplant, cytomegalovirus can cause a more serious illness, affecting the lungs, liver and blood.
Deceased donor transplant A transplant kidney removed from someone who has died.
Delayed graft function When the graft does not work immediately and dialysis is required during the
first week post transplant. Dialysis has to continue until graft function recovers sufficiently to make it
unnecessary. This period may last for up to 12 weeks in some cases.
Donation after brain death Deceased heart-beating donors who are maintained on a ventilator in an
intensive care unit, with death diagnosed using brainstem tests.
Donation after circulatory death Non-heart-beating donors who cannot be diagnosed as brainstem
dead but whose death is verified by the absence of a heart beat (cardiac arrest).
Donor A person who donates an organ to another person (the recipient).
End-stage renal disease A long-term irreversible decline in kidney function.
Extended criteria donors People who are aged > 60 years without comorbidities, aged > 50 years, with
hypertension or death from cerebrovascular accident, or donors with terminal serum creatinine level of
> 1.5 mg/dl.
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Glomerular filtration rate A test that is used to check how well the kidneys are working. Specifically,
it estimates how much blood passes through the glomeruli each minute. Glomeruli are tiny filters in the
kidneys, which filter waste from the blood.
Graft Surgical transplant of living tissue, in this case the kidney.
Graft loss Loss of function from the transplanted organ.
Haemodialysis An extracorporeal removal of waste products from the blood when the kidneys are in a
state of renal failure.
Human leucocyte antigen The locus of genes that encode for proteins on the surface of cells, which are
responsible for regulation of the immune system in humans.
Immunosuppressant Drugs given to lower the body’s ability to reject a transplanted organ.
Induction drugs Powerful anti-rejection drugs that are taken at the time of transplantation, and close
after, when the risk of rejection is highest.
Kidney transplant Transfer of a healthy kidney from a donor to a recipient.
Living–related transplant A kidney donated by a living relative of the recipient. A well-matched
living–related transplant is likely to last longer than either a living–unrelated transplant or a deceased
donor transplant.
Living–unrelated transplant A kidney transplant from a living person who is biologically unrelated to
the recipient.
Maintenance drugs Less powerful antirejection drugs compared with induction drugs, which are used as
both initial and long-term maintenance therapy.
Mycophenolic acid Mycophenolate mofetil or mycophenolate sodium.
Nephritis A general term for inflammation of the kidneys. Also used as an abbreviation
for glomerulonephritis.
Peritoneal dialysis Dialysis that uses the patient’s peritoneum in the abdomen as a membrane across
which fluids and dissolved substances (electrolytes, urea, glucose, albumin and other small molecules) are
exchanged from the blood.
Post-transplant lymphoproliferative disorder A B-cell proliferation owing to therapeutic
immunosuppression after organ transplantation. Patients with post-transplant lymphoproliferative disorder
may develop infectious mononucleosis-like lesions or polyclonal polymorphic B-cell hyperplasia. Some of
these B cells may undergo mutations that will render them malignant, giving rise to a lymphoma.
Recipient In the context of transplantation, a person who receives an organ from another person
(the donor).
Rejection The process whereby a patient’s immune system recognises a transplant kidney as foreign and
tries to destroy it. Rejection can be acute or chronic.
Renal replacement therapy Dialysis or kidney transplantation.
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List of abbreviations
AE adverse event
AKI acute kidney injury
AR acute rejection
ARD absolute risk difference
ARR acute rejection rate
ATG anti-human thymocyte/
antithymocyte (immune)globulin
AZA azathioprine
BAS basiliximab
BEL belatacept
BENEFIT Belatacept Evaluation of
Nephroprotection and Efficacy as
First-line Immunosuppression Trial
BENEFIT-EXT BENEFIT–Extended Criteria Donors
BKV BK virus
BNF British National Formulary
BPAR biopsy-proven acute rejection
CCS corticosteroid
CEA cost-effectiveness analysis
CI confidence interval
CKD chronic kidney disease
CMU Commercial Medicines Unit
CMV cytomegalovirus
CNI calcineurin inhibitor
CRC creatinine clearance
CrI credibility interval
CSA ciclosporin
CVD cardiovascular disease
DAC daclizumab
DBD donation after brain death
DCD donation after circulatory death
DGF delayed graft function
DIC deviance information criterion
DWFG death with functioning graft
EBV Epstein–Barr virus
EC-MPS enteric-coated mycophenolate
sodium
ECD extended criteria donor
eGFR estimated glomerular filtration rate
eMit Electronic Market Information Tool
EQ-5D European Quality of Life-5
Dimensions (EuroQoL instrument)
ESA erythropoiesis-stimulating agent
ESRD end-stage renal disease
EU European Union
EVL everolimus
GFR glomerular filtration rate
GP general practitioner
GRF graft function
HD haemodialysis
HLA human leucocyte antigen
HMGCoA 3-hydroxy-3-methylglutanyl-
coenzyme A
HR hazard ratio
HRG Healthcare Resource Group
HRQoL health-related quality of life
HTA Health Technology Assessment
ICDF inconsistency degrees of freedom
ICER incremental cost-effectiveness ratio
INHB incremental net health benefit
IQR interquartile range
IL2Mab anti-interleukin-2 receptor
monoclonal antibody
ITT intention to treat
KTR kidney transplant recipient
MD mean difference
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MDRD Modification of Diet in Renal
Disease
ME microemulsion
MMF mycophenolate mofetil
MPA mycophenolic acid
MPS mycophenolate sodium
MTC mixed-treatment comparison
mTOR-I mammalian target of rapamycin
complex 1
NHSBT NHS Blood and Transplant
NHS EED NHS Economic Evaluation Database
NICE National Institute for Health and
Care Excellence
NMA network meta-analysis
NODAT new-onset diabetes after
transplant/transplantation
OR odds ratio
PBO placebo
PCP Pneumocystis jirovecii pneumonia
PCR polymerase chain reaction
PD peritoneal dialysis
PenTAG Peninsula Technology Assessment
Group
PNF primary non-function
PPP purchasing power parity
PRA panel reactive antibody
PSA probabilistic sensitivity analysis
PSS Personal Social Services
PTDM post-transplant diabetes mellitus
PTLD post-transplant lymphoproliferative
disorder
QALY quality-adjusted life-year
rATG rabbit anti-human thymocyte
immunoglobulin
RCT randomised controlled trial
RR relative risk
RRT renal replacement therapy
SE standard error
SRL sirolimus
TAC tacrolimus
TAC-PR prolonged-release tacrolimus
UKPDS UK Prospective Diabetes Study
USRDS United States Renal Data System
UTI urinary tract infection
WMD weighted mean difference
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Plain English summary
K idney transplantation is the preferred treatment for people with end-stage kidney disease. Withoutimmune-suppressing medications, the transplanted kidney would be rejected or lost. To prevent
rejection and loss, a combination of medications to dampen the immune system is used. The objective
of this assessment was to update a previous review aimed at evaluating the clinical benefits and
cost-effectiveness of these medications, using a systematic approach. Relevant studies were searched
for within major databases, trial registries, systematic reviews and references of included studies.
All included studies were assessed for their quality, and data from each study were extracted into a
standardised template. The review included 68 new trials and 21 trials from the previous review. These
trials evaluated nine drugs in a variety of combinations. Results were variable, and statistical methods to
combine study data were applied. Very few studies reported all results beyond 1 year, and the quality of
trials was variable and difficult to assess because not all key information was reported. Owing to the
volume of studies, there was a large amount of information on adverse events and complications, with
some indication that there was more new-onset diabetes mellitus and more cytomegalovirus (member of
the herpes virus family) infections with some medications than others. A statistical model was developed to
compare the cost-effectiveness of 16 different combinations of medications, indicating that only one
combination (basiliximab followed by immediate-release tacrolimus and mycophenolate mofetil)
would be cost-effective.
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Scientific summary
Background
End-stage renal disease is a long-term irreversible decline in kidney function requiring renal replacement
therapy (RRT): kidney transplantation, haemodialysis or peritoneal dialysis. Kidney transplantation is
preferred because of the improved duration and quality of life.
Kidney transplantation is the transfer of a healthy kidney from a donor to a recipient. Kidneys for
transplantation may be obtained via living donation (related or unrelated), donation after brain death
(DBD) or donation after circulatory death (DCD).
In 2013–14, 2464 adult kidney transplant operations were performed in England, 97 in Northern Ireland,
112 in Wales and 242 in Scotland. The number of adult transplants from DCDs has been increasing
over time, reaching 779 in the last financial year. Similarly, the number of adult transplants from DBDs
increased to 1101 and the number of adult living kidney transplants performed increased to 1049.
Patient survival following a kidney transplant, over 5 years, for deceased and living donors is 89%
[95% confidence interval (CI) 88% to 90%] and 95% (95% CI 95% to 96%), respectively.
Following kidney transplantation, the immune response of the host may attempt to destroy the graft
(acute kidney rejection). Therefore, immunosuppressive therapy is implemented. However, side effects
include possible skin cancer, crumbling bones, fatigue, body hair growth, swollen gums and weight gain.
Immunosuppression comprises induction and maintenance therapy. Induction involves powerful
antirejection drugs taken at the time of transplantation, when the risk of rejection is highest.
Maintenance drugs are less powerful and are used as both initial and long-term therapy.
Objectives
To review and update the evidence for the clinical effectiveness and cost-effectiveness of basiliximab
(BAS) (Simulect®, Novartis Pharmaceuticals UK Ltd) and rabbit anti-human thymocyte immunoglobulin
(rATG) (Thymoglobulin®, Sanofi) as induction immunosuppressive therapy, and immediate-release tacrolimus
(TAC) (Adoport®, Sandoz; Capexion®, Mylan; Modigraf®, Astellas Pharma; Perixis®, Accord Healthcare; Prograf®,
Astellas Pharma; Tacni®, Teva; Vivadex®, Dexcel Pharma); prolonged-release tacrolimus (TAC-PR) (Advagraf®,
Astellas Pharma; belatacept (BEL) (Nulojix®, Bristol-Myers Squibb); mycophenolate mofetil (MMF) (Arzip®,
Zentiva; CellCept®, Roche Products; Myfenax®, Teva); generic MMF (Accord Healthcare, Actavis, Arrow
Pharmaceuticals, Dr Reddy’s Laboratories, Mylan, Sandoz and Wockhardt); mycophenolate sodium (MPS)
(Myfortic®, Novartis); sirolimus (SRL) (Rapamune®; Pfizer); and everolimus (EVL) (Certican®, Novartis) as
maintenance immunosuppressive therapy in adult renal transplant.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
xxxv
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Methods
Clinical effectiveness systematic review
Searching was conducted on 14 April 2014 and updated on 18 November 2014, using the terms kidney or
renal transplant, or kidney or renal graft AND the interventions under review AND a study design limit to
randomised controlled trials (RCTs) or controlled trials. The search was date limited to 2002–current, in line
with the previous assessment. The databases searched were MEDLINE (via Ovid), EMBASE (via Ovid),
Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web of Science (via ISI).
Systematic reviews were identified using the terms above AND a limit to systematic reviews. The search was
run from database inception in MEDLINE (via Ovid), EMBASE (via Ovid), Cochrane Database of Systematic
Reviews, Database of Abstracts of Reviews of Effects and Health Technology Assessment (via The Cochrane
Library via Wiley Online Library) and the Health Management Information Consortium (via Ovid).
Records were screened for inclusion independently by two researchers, with disagreements resolved
with a third reviewer. Included full papers were split between five reviewers for data extraction, with
disagreements resolved by consensus. Quality assessment was based on Centre for Reviews and
Dissemination guidance.
Estimates of overall treatment effect and assessment of heterogeneity were performed using a
random-effects model. For binary data, odds ratio (OR) was used and, for continuous data, mean
differences (MDs) were calculated. A narrative synthesis accompanies all included study data.
Network meta-analyses (NMAs) were undertaken within a Bayesian framework. Fixed- and random-effects
NMAs were compared using the deviance information criteria. Outcomes analysed were graft loss,
mortality, biopsy-proven acute rejection (BPAR) and graft function (GRF).
Cost-effectiveness systematic review
Searching was conducted on 8 April 2014 and updated on 18 November 2014, using the terms kidney or
renal transplant, or kidney or renal graft and the interventions under review and a costs or economic
literature search filter. The search was date limited to 2002–current in line with the previous assessment.
The following databases were searched: MEDLINE (Ovid), EMBASE (Ovid), NHS Economic Evaluation
Database (Wiley), Web of Science (ISI), Health Economic Evaluations Database (Wiley) and
EconLit (EBSCOhost).
Records were screened by two reviewers, with disagreements resolved by discussion. Studies meeting the
criteria for inclusion were assessed by one reviewer using the checklist developed by Evers et al. (Evers S,
Goossens M, de Vet H, van Tulder M, Ament A. Criteria list for assessment of methodological quality
of economic evaluations: consensus on health economic criteria. Int J Technol Assess Health Care
2005;21:240–5). Studies based on decision models were quality assessed using the checklist developed by
Philips et al. (Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines
for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess
2004;8(36); Philips Z, Bojke L, Sculpher M, Claxton K, Golder S. Good practice guidelines for
decision-analytic modelling in health technology assessment: a review and consolidation of quality
assessment. Pharmacoeconomics 2006;24:355–71).
Economic studies were extracted, summarised and synthesised using tabulated data and
narrative synthesis.
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Peninsula Technology Assessment Group economic model
A new economic model was developed, utilising a discrete time–state transition model (semi-Markov), with
transition probabilities that are dependent on age and time since initial transplantation. A cycle length of a
quarter year was used, and transitions were assumed to occur mid-cycle. A time horizon of 50 years was
adopted. Costs were included from a UK NHS and Personal Social Services perspective. Health effects were
measured in quality-adjusted life-years (QALYs) and were calculated by assuming health state-specific utility
decrements from a baseline utility, which was age dependent and derived from the Health Survey for
England 2012 (Craig R, Mindell J, editors. Health Survey for England 2012: Health, Social Care and
Lifestyles. Leeds: Health and Social Care Information Centre; 2013). The utility decrements were based on
a published systematic review and meta-analysis of preference-based quality-of-life studies in patients
who were undergoing RRT, with the EQ-5D [European Quality of Life-5 Dimensions, three-level version
(EQ-5D-3L) used for measurement. Costs and QALYs were discounted at 3.5% per annum, and costs were
inflated as necessary to 2014–15 prices. A total of 16 regimens were modelled.
Model structure
Kidney transplant recipients were assumed to be in one of three health states: functioning graft, graft loss
or death. The incidence of acute rejection (AR), cytomegalovirus infection, dyslipidaemia and new-onset
diabetes after transplantation (NODAT) was also estimated.
Up to two retransplantations were modelled, which could take place from the graft loss state or from the
functioning graft state (for the initial graft only). The rate of retransplantations was assumed to reduce
with age past 65 years, reaching zero by the age of 80 years.
Transitions out of the functioning graft state correspond to graft loss/survival, and are either death with
functioning graft (DWFG) or graft loss excluding DWFG.
Uncertainty analyses
A probabilistic sensitivity analysis was conducted to estimate the joint effect of parameter estimation
uncertainty on cost-effectiveness. Structural sensitivity analyses relating to graft survival were conducted.
A scenario analysis – in which list prices were adopted for all drug acquisition costs – was performed and
a two-way threshold analysis was conducted relating to the costs of BEL.
Clinical effectiveness results
The titles and abstracts of 5079 references were screened, with 750 papers retrieved for consideration.
Eighty-nine RCTs matched the inclusion criteria, 14 of which investigated induction therapies,
73 investigated maintenance therapies and two investigated both. The RCTs were of variable quality,
and reporting omissions was frequent.
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Summary of benefits and risks
Following NMA for induction therapy:
l No evidence was found to suggest that BAS or rATG are more effective than placebo (PBO)/no
induction or each other in reducing the odds of graft loss or mortality.
l For BPAR, rATG and BAS were both estimated to be more effective than PBO/no induction, with rATG
being more effective than BAS.
l There was evidence to suggest that BAS is more effective than PBO/no induction at achieving better
GRF. Head-to-head comparison for induction therapy also suggested that rATG and BAS are more
effective than PBO or no induction at reducing BPAR (rATG at 1 year, OR 0.34, 95% CI 0.22 to 0.52;
BAS at 1 year, OR 0.53, 95% CI 0.40 to 0.70).
l BAS was associated with lower odds of severe BPAR than rATG (1 year, OR 0.04, 95% CI 0.00 to 0.65).
For maintenance therapy, the analyses are as follows:
l No evidence was found to suggest that one treatment is more effective at reducing graft loss than any
other. However, head-to-head analysis indicated that, at 0.5 years, there were reduced odds of graft loss
for ciclosporin (CSA)+MMF compared with CSA+ azathioprine (AZA) (OR 0.58, 95% CI 0.04 to 0.59)
and, at 5 years, BEL+MMF may be more effective than CSA+MMF (OR 0.40, 95% CI 0.19 to 0.87).
l The NMA indicated that BEL+MMF may be more effective at reducing the odds of mortality than
TAC+MMF and SRL+MMF. The head-to-head analysis found no evidence of greater effectiveness
between treatments.
l MMF+CSA, TAC+MMF, SRL+ TAC, TAC+AZA and EVL+CSA were estimated to be more effective
than CSA+AZA and EVL+MPS at reducing BPAR. However, the 95% CIs were wide. Head-to-head
analysis for MMF+CSA vs. CSA+AZA indicated a statistically significant difference in favour of MMF
(0.5 years OR 0.50, 95% CI 0.35 to 0.72). TAC was shown to display lower odds of BPAR in the
following comparisons:
¢ TAC+AZA vs. CSA+AZA (at 1 year, OR 0.50, 95% CI 0.39 to 0.64; at 4 years, OR 0.38, 95% CI
0.25 to 0.57)
¢ TAC+MMF vs. CSA+AZA (at 1 year, OR 0.35, 95% CI 0.15 to 0.82)
¢ TAC+MMF vs. CSA+MMF (at 1 year, OR 0.59, 95% CI 0.37 to 0.94)
¢ TAC+MMF vs. SRL+MMF (at 1 year, OR 0.32, 95% CI 0.12 to 0.87)
l For increasing GRF, SRL+AZA, TAC+AZA, TAC+MMF and BEL+MMF were estimated by the NMA to
be more effective than CSA+AZA and MMF+CSA. However, direct evidence was limited and the
95% CIs were wide. The head-to-head analysis for MMF+ TAC compared with MPS+ TAC found MPS
to be more effective [1 year, MD 1.9ml/minute/1.73m2; p< 0.0001; 3 years, estimated glomerular
filtration rate (eGFR) MD 0.5ml/minute/1.73m2; p= 0.0016]. BEL appeared to be more effective for
BEL+MMF than CSA+MMF [at 1 year, eGFR weighted mean difference (WMD) 7.83ml/minute/1.73m2,
95% CI 1.57 to 14.10ml/minute/1.73m2; at 3 years WMD 16.08ml/minute/1.73m2, 95% CI 5.59 to
26.56ml/minute/1.73m2]; however, heterogeneity across studies was substantial. TAC was associated
with a higher level of GRF for the following comparisons:
¢ TAC+MMF vs. CSA+MMF (at 3 years, eGFR WMD 4.60ml/minute/1.73m2, 95% CI 1.35 to
7.85ml/minute/1.73m2)
¢ TAC+MMF vs. TAC-PR+MMF (at 0.5 years, eGFR WMD 1.90ml/minute/1.73 m2, 95% CI 1.70 to
2.10ml/minute/1.73 m2)
¢ TAC+ SRL vs. CSA+ SRL (at 0.5 years, eGFR MD 6.35ml/minute/1.73m2; p< 0.0001; at 1 year MD
5.25ml/minute/1.73 m2; p= 0.0004)
l Time to BPAR and severity of BPAR were generally poorly reported and with substantial heterogeneity.
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Cost-effectiveness results
Summary of cost-effectiveness evidence
Studies were typically economic evaluations of single-centre RCTs of ≤ 1 year, involving small samples with
insufficient data to evaluate their generalisability.
l All studies of initial and maintenance immunosuppression are sponsored by the industry or conducted
by a person affiliated to them.
l Studies of immunosuppression typically use a biomarker as a surrogate to extrapolate
long-term outcomes.
l New evidence has emerged indicating that changes in renal function directly impact on health-related
quality of life and costs.
Peninsula Technology Assessment Group economic model
Base-case analysis
In the base-case deterministic and probabilistic analyses, BAS, TAC and MMF were predicted to be
cost-effective at £20,000 and £30,000 per QALY. Relevant incremental cost-effectiveness ratios (ICERs) do
not exist for these agents because they dominated other agents or were less costly and less effective than
other agents with ICERs that were significantly > £30,000 per QALY.
When all regimens were simultaneously compared, only BAS+ TAC+MMF was predicted to be
cost-effective at £20,000 and £30,000 per QALY.
Scenario analyses
Investigation of the impact of structural uncertainty in the surrogate effect of AR, NODAT and GRF at
12 months on graft survival found that if the surrogate effect was weakened then no induction
and CSA became cost-effective at £20,000 and £30,000 per QALY, respectively, compared with BAS
induction and immediate-release TAC. The duration of surrogate effect had to be limited to 1 year for no
induction to be cost-effective compared with BAS at £20,000 per QALY and eliminated to be cost-effective
at £30,000 per QALY. The duration of surrogate effect had to be limited to ≤ 3–8 years (depending on
the comparison) for CSA to be cost-effective compared with immediate-release TAC at £20,000 or
£30,000 per QALY.
A second structural uncertainty analysis considered that calcineurin inhibitor-free regimens could result in
prolonged graft survival. The graft survival for BAS+ SRL+MMF had to be markedly different from the
base case for SRL to become cost-effective at £20,000 or £30,000 per QALY, and BAS+ BEL+MMF was
not cost-effective at £20,000 or £30,000 per QALY at any point in the analysis.
When list prices were adopted for drug acquisition costs, CSA and AZA became cost-effective at
£20,000–30,000 per QALY in some combinations, with immediate-release TAC and MMF remaining
cost-effective at £20,000–30,000 per QALY in other comparisons.
Belatacept was not found to be cost-effective at £20,000–30,000 per QALY, even at zero price, or at list
price with zero administration cost.
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Limitations of the systematic review of studies of effectiveness
l Owing to level of reporting detail, subgroup analysis was not performed.
l Substantial heterogeneity across studies owing to varying study design and participant characteristics.
l Reporting omissions for most of the trials hampered quality assessment.
l Very few trials reported long-term follow-up.
Limitations of the analyses and uncertainties of Peninsula
Technology Assessment Group economic model
l Inconsistent reporting of adverse events (AEs) in identified RCTs meant that only a minority of AEs
were modelled.
l The severity of ARs was assumed to be the same across regimens.
l Treatment discontinuation and switching were not modelled.
l Long-term outcomes from RCTs are seldom reported, so it has not been possible to externally validate
the predicted survival differences between regimens.
l RCTs identified in the systematic review have not provided sufficient evidence to support
subgroup analyses.
l The costs for diabetes mellitus are highly uncertain, especially as the costs relate to the general diabetic
population rather than transplant recipients with NODAT.
l NHS hospitals might secure discounts from list prices when these are assumed in the model.
Conclusions
The clinical effectiveness review of the two induction agents found that both ATG and BAS were more
effective than PBO/no induction at reducing BPAR, with ATG being more effective than BAS. However, no
evidence was found to suggest either BAS or ATG were more effective than PBO/no induction, or each
other, in reducing the odds of graft loss or mortality.
For the maintenance agents, none of the regimens was consistently better on mortality, graft loss, GRF or
BPAR. For a number of pairwise comparisons, the arm containing TAC had lower odds of BPAR and
reduced loss of GRF.
The cost-effectiveness analyses suggest that only a regimen of BAS induction followed by maintenance
with immediate-release TAC and MMF would be cost-effective at £20,000–30,000 per QALY.
Study registration
This study is registered as PROSPERO CRD42014013189.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Background
Description of the health problem
End-stage renal disease
End-stage renal disease (ESRD) is a long-term irreversible decline in kidney function, for which renal
replacement therapy (RRT) is required if the individual is to survive. ESRD is often the result of an acute
kidney injury (AKI) or primarily a progression from chronic kidney disease (CKD), which describes abnormal
kidney function and/or structure. CKD is common, frequently unrecognised and often exists together with
other conditions [e.g. cardiovascular disease (CVD) and diabetes mellitus]. An estimated 4% of people in
the UK with CKD progress to ESRD over a 5.5-year follow-up period.1
Although RRT can take a number of forms [kidney transplantation, haemodialysis (HD) and peritoneal
dialysis (PD)], the preferred option for people with ESRD is kidney transplantation, rather than dialysis.
This is as a result of improved duration and quality of life with transplantation compared with dialysis.2
Transplantation: patient survival, acute rejection and graft loss
Kidney transplantation is the transfer of a healthy kidney from a donor to a recipient. Kidneys for
transplantation may be obtained via living donation (related or unrelated), donation after brain death
(DBD) (deceased heart-beating donors, who are maintained on a ventilator in an intensive care unit, with
death diagnosed using brainstem tests) or donation after circulatory death (DCD) [non-heart-beating
donors who cannot be diagnosed as brainstem dead but whose death is verified by the absence of a heart
beat (cardiac arrest)]. Most kidneys are primarily obtained from DBD donors, with the donor pool being
extended by using DCD donors, and extended criteria donors (ECDs) (people who aged > 60 years without
comorbidities; aged > 50 years with hypertension or death from cerebrovascular accident; or donors with
terminal serum creatinine levels of > 1.5 mg/dl).
Following kidney transplantation, major clinical concerns are acute kidney rejection and graft loss.
Acute kidney rejection occurs when the immune response of the host attempts to destroy the graft,
as the graft is deemed to be foreign tissue.2 Following renal transplantation, immunosuppressive therapy is
implemented to reduce the risk of kidney rejection and prolong survival of the graft.
Aetiology, pathology and prognosis
Renal disease
Most diseases that cause renal failure fall into five categories: systemic disease, glomerulonephritis,
hypertension, obstruction and genetic disease (Table 1), with diabetes mellitus causing around 20% of all
renal disease.3
When established renal failure is reached, people become tired, nauseated, lose their appetite and cope
less well both physically and mentally. The signs of established renal failure include fluid retention (shown
as swollen ankles or breathlessness), itching, pallor and raised blood pressure. These symptoms are
accompanied by falling haemoglobin levels and abnormality of biochemical markers, for example serum
urea, serum creatinine and potassium. When someone reaches this point they will need RRT within weeks
or months to prevent death. Treatment will continue for the rest of their lives.
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Survival, acute rejection and graft loss after transplantation
Various factors may influence patient survival after kidney transplantation (including factors related to the
donor and to the patient). For example, the type of donor can influence patient survival, with recipients of
a kidney transplant from an ECD having inferior survival outcomes compared with recipients of standard
criteria donor kidneys. However, those from an ECD will still have significantly better survival outcomes
than people on waiting lists who remain on HD.4,5
In people who survive transplantation, acute rejection (AR) may occur when the immune response of the
host attempts to destroy the graft, as the graft is deemed foreign tissue.2 AR is treated using changes to
the immunosuppressive regimen (increasing doses or switching treatments). Untreated AR will ultimately
result in destruction of the graft. However, high levels of immunosuppression may also increase the risk of
other infections and malignancy.2 AR is primarily measured after a biopsy and is graded according to Banff
criteria (grades I–III). The gradings are as follows: grade I, moderate to severe mononuclear cell interstitial
infiltrate and moderate tubulitis; grade II, severe tubulitis and/or intimal arteritis; and grade III, transmural
arteritis.6 Incidences of ARs after a transplant are included in this appraisal; however, the treatment for AR
is outside the scope of this appraisal.
In addition to ARs affecting the survival of the graft, other reasons that may facilitate graft loss include
blood clots, narrowing of an artery, fluid retention around the kidney, side effects of other medications
and recurrent kidney disease (www.kidney.org). A major cause of long-term graft loss is chronic allograft
nephropathy, an ill-defined process, characterised clinically by progressive deterioration in graft function
(GRF), proteinuria and hypertension, and pathologically by changes on biopsy. Chronic allograft
nephropathy is a consequence of immunological and non-immunological injury. Immunological factors
include human leucocyte antigen (HLA) matching, episodes of AR and suboptimal immunosuppression.
Important non-immunological factors implicated are donor organ characteristics, delayed graft function
(DGF), recipient-related factors, hypertension and hyperlipidaemia. Recently, the acute and chronic toxicity
of calcineurin inhibitors (CNIs) has also been implicated.7 People with high titres of preformed circulating
anti-HLA antibodies – which may come about as a result of underlying illness, previous transplantation,
previous pregnancy or multiple blood transfusions – are at high risk of chronic rejection.8
TABLE 1 Renal disease aetiology
Category Description
Systemic disease Diabetes mellitus, autoimmune conditions (e.g. systemic lupus erythematosus and vasculitis),
amyloidosis and multiple myeloma
Glomerulonephritis There are many different causes of glomerulonephritis. Some types are relatively benign and
unlikely to progress to established renal failure, whereas other forms are more aggressive and can
have an impact on disease progression and the development of established renal failure
Hypertension Accelerated hypertension causes CKD; however, early recognition and treatment of high blood
pressure can have a positive effect on the disease. Hypertension is a common cause of renal failure
in people of African origin
Obstruction Any pathology that obstructs the free flow of urine through the urinary system can cause CKD.
Most often obstruction is secondary to enlargement of the prostate gland in elderly men, but other
causes include kidney stones, bladder tumours and congenital abnormalities of the renal tract
Genetic disease Genetic disease accounts for about 8% of all kidney failure in the UK. Polycystic kidney disease is
the most common genetic disease causing CKD
Source: Extracted from UK Renal Registry 16th Annual Report: Chapter 2 UK RRT Prevalence in 2012: National and
Centre-Specific Analyses, p. 328.3
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It is important to note that failing to adhere (or comply) with the immunosuppression regimen prescribed
after a kidney transplant will also significantly increase the risk of an ARs and/or graft loss.9 If the kidney is
lost then, ultimately, the patient will need to return to dialysis where quality of life is lower and overall
costs are higher.2
Incidence and prevalence in the UK
The most recent report by the UK NHS regarding kidney disease stated that there were 1,739,443 people
aged ≥ 18 years in England in 2008–9 who were registered with CKD (stages 3–5). This represents an
overall crude (not adjusted for age) proportion of 4.1% of the UK population in the ≥ 18 years age
group.10 Figure 1 presents the prevalence of people who have detected and registered CKD around
England in 2008–9.10 The actual prevalence that would include those undetected and unregistered would
be much higher.
In 2013, the incidence rate of RRT in the UK was stable, at 109 per million population, reflecting RRT
initiation for 7006 new cases per year.3 There were 56,940 adults receiving RRT in the UK on 31 December
2013, an absolute increase of 4.0% from 2012, although the number of people with a functioning
transplant increased to 7.1%. The UK adult-only prevalence of RRT was 888 per million population.3
Table 2 displays the prevalence of adults in the UK who are receiving HD, PD or living with a transplant
split for age (< 65 years and ≥ 65 years).
Between April 2013 and March 2014 2464 adult kidney transplant operations were performed in England:
97 in Northern Ireland, 112 in Wales and 242 in Scotland.11 Figure 2 shows the total number of adult
kidney only transplants performed in the last 10 years, by type of donor.11 The number of adult transplants
from DCD has been steadily increasing over the time period to 779 in the last financial year. The number
of adult transplants from DBD has increased in the last couple of years to 1101 in 2013–14 after
remaining fairly constant for the previous four financial years. The number of adult living kidney
transplants performed has also increased over the time period, and 1049 were performed in the last
financial year.11
The NHS Blood and Transplant11 annual report (NHSBT) on kidney transplantation reported kidney and
patient survival following a kidney transplant over 1 and 5 years, split for deceased and living donors
(Table 3).
Acute rejection following a kidney transplant is likely to be reported in approximately one-third of
recipients (www.kidney.org). However, the incidences are variable depending on both patient and donor
characteristics, as well as the immunosuppression regimen allocated.
TABLE 2 Number of prevalent renal replacement adults by age and treatment modality in the UK in 2013
Country
< 65 years old ≥ 65 years old
HD PD Transplant HD PD Transplant
England 9121 1720 19,766 10,952 1457 5016
Northern Ireland 261 38 676 389 43 139
Scotland 888 115 2050 972 111 428
Wales 430 91 1158 648 91 359
UK 10,700 1964 23,650 12,961 1702 5942
Source: Annual Report on Kidney Transplantation, Report for 2013/2014, NHS Blood and Transplant.11 Reproduced
with permission.
The data reported here have been supplied by the UK Renal Registry of the Renal Association. The interpretation and
reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or
interpretation of the UK Renal Registry or the Renal Association.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
3
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
2004/5
0
500
1000
1500
2000
2500
3000
3500
4000
2005/6 2006/7 2007/8 2008/9 2009/10 2010/11 2011/12 2012/13 2013/14
1003 932 902 871 877 881 893 894 987 1101
143 214 272 319 452
527 540 638
710
779
427 541
642
780
862
968 955
940
1002
1049
1573 1687
1816
1970
2191
2376 2388
2472
2699
2929
Year
N
u
m
b
er DBD
DCD
Living donor
FIGURE 2 Kidney transplant rates in the UK. Source: Annual Report on Kidney Transplantation, Report for
2013/2014, NHS Blood and Transplant.11 Reproduced with permission.
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FIGURE 1 Chronic kidney disease prevalence by primary care trust, England 2008–9. Source: Kidney Disease: Key
Facts and Figures, NHS Kidney Care, September 2010.10 Produced by EMPHO on behalf of Department of Health.
Based on Ordinance Survey Material. Do not reproduce, © Crown Copyright 2010. All rights reserved. Department
of Health 100020290.
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Impact of health problem
Significance for patients
To a person suffering from ESRD the opportunity to have a kidney transplant is literally a matter of life or
death. In the year 2013–14, in the UK, 239 people died while on the active and suspended waiting lists for
kidney transplantation; 518 people were removed from the list because they were no longer fit enough,
most of whom would go on to die.12 Encouragingly, over the last 5 years there has been a decline in the
number of people waiting for a kidney transplant (Figure 3). This decline has primarily been attributed to
an increase in the number of transplants being performed each year, as the number of people joining the
list each year has remained relatively stable.12 Although this is encouraging, figures from people registered
between April 2007 and March 2011 indicated that the median wait time for a kidney-only transplant in
the UK was over 3 years (1114 days) with a 95% confidence interval (CI) of 1091 to 1137 days.13
Although kidney transplantation relieves the person with ESRD from lengthy dialysis, the strict regimen of
immunosuppressant medication required may produce unpleasant side effects, including possible skin
cancer, crumbling bones, fatigue, body hair growth, swollen gums and weight gain.14 Nevertheless, a large
number of studies have similarly documented, using a variety of instruments, the clear quality-of-life
TABLE 3 Kidney and patient survival in the UK
Donor
Kidney graft survival: % (95% CI) Patient survival: % (95% CI)
1 yeara 5 yearsb 1 yeara 5 yearsb
Deceased 93 (93 to 94) 86 (85 to 87) 96 (95 to 96) 89 (88 to 90)
Living 97 (96 to 97) 91 (89 to 92) 99 (98 to 99) 95 (95 to 96)
CI, confidence interval.
a Includes transplants performed between 1 April 2009 and 31 March 2013.
b Includes transplants performed between 1 April 2005 and 31 March 2009.
Source: Annual Report on Kidney Transplantation, Report for 2013/2014, NHSBT.11
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2013/2014, NHSBT.12 Reproduced with permission.
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improvements of having a functioning kidney transplant compared with being on dialysis.15–27 Overbeck
et al.,26 for example, compared the quality of life of those who had received a kidney transplant with
those dialysing and on the waiting list, and they found that, when measured with the Short Form
questionnaire-36 items (SF-36), people who had received a transplant reported better physical functioning,
perception of general health, social functioning and overall physical component than those still dialysing,
although these scores did not match those of the general population (Table 4).
Acute rejection is common in the first year after kidney transplantation, and treatment of AR involves a
more intensive drug treatment than standard maintenance regimens, which, in turn, increases the possibility
of unpleasant side effects. The treatment for AR is outside the scope of this appraisal. Should a graft be
lost, people face another wait for transplantation (if appropriate), which may be even longer owing to
sensitisation to the mismatched HLA on the failed donor kidney. Furthermore, they will need to undergo
dialysis while waiting for transplantation or for life when transplantation is not possible. This, in effect,
means that people may be in a worse position from when they started their treatment, but with the added
psychological and physical burden from having undergone transplantation. Indeed, many people will
develop depression following the loss of a graft.28
The impact on people of returning to dialysis (with regards psychological burden of graft failure and going
back to a previous treatment modality) is scarcely documented, but necessarily includes the impact of
being on dialysis per se: dialysis is time-consuming and may affect employment, education, normal family
life and require changes in diet and fluid intake. Common side effects to dialysis (either HD or PD) include
fatigue, low blood pressure, invasive staphylococcal infections, muscle cramps, itchy skin, peritonitis, hernia
and weight gain (www.nhs.uk). Quality of life is lower on dialysis than the general population29 and
declines over time as the patient remains on dialysis.30
Significance for the NHS
Treatment for ESRD has been deemed resource intensive for the NHS, as current costs have been
estimated to utilise 1–2% of the total NHS budget to treat 0.05% of the population.10 Data from the
Department of Health estimated that in 2008–9 the total expenditure on ‘renal problems’ in England was
£1.3B, representing 1.4% of the NHS expenditure. An economic evaluation of treatments for ESRD by de
Wit et al.31 showed that transplantation is the most cost-effective form of RRT with increased quality of life
and independence for people.
It is projected that with an increasingly elderly and overweight population the demand for RRT will
increase, with a consequent pressure on services providing renal units and other health-care providers
dealing with comorbidities. Increased resources may be needed for dialysis, surgery, pathology,
immunology, tissue typing, histopathology, radiology, pharmacy and hospital beds. Demand is likely to be
particularly significant in areas where there are large South Asian, African and African Caribbean
communities, and in areas of social deprivation, in which people are more susceptible to kidney disease.32
TABLE 4 Short Form questionnaire-36 items mean scores comparing the quality of life of those on dialysis or
transplanted with the general population
Population
Physical functioning
(p≤ 0.001)
Bodily pain
(p= 0.062)
General health
(p≤ 0.01)
Social functioning
(p≤ 0.01)
Physical well-being
summary (p≤ 0.001)
Dialysis
(n= 65)
62.7 62.8 39.7 71.0 38.9
Transplant
(n= 76)
77.0 73.5 51.0 83.9 45.6
General
population
84.8 77.7 68.5 89.0 50.2
Source: Overbeck et al.26
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Data from the NHS Standard Contract for Adult Kidney Transplant Service indicated that the cost for the
first year of care following a kidney transplant is approximately £17,000 and then £5000 for every
subsequent year. Conversely, the cost of dialysis is approximately £30,800 per year.33 However, should a
graft be lost following a transplant, the NHS would incur increased costs from either the patient returning
to dialysis or requiring a replacement renal transplant (in comparison with successful maintenance of the
kidney graft). Similarly, each AR episode would incur increased costs because of the changes made to the
immunosuppression regimen to treat the rejection.
Measurement of disease
The outcome of kidney transplants (and of the success of immunosuppressive regimens) can be measured
in a variety of ways. These include:
Short term:
l Immediate GRF – the graft works immediately after transplantation, removing the need for
further dialysis.
l DGF – the graft does not work immediately and dialysis is required during the first week post
transplant. Dialysis has to continue until GRF recovers sufficiently to make it unnecessary. This period
may last up to 12 weeks in some cases.
l Primary non-function (PNF) – the graft never works after transplantation.
Long term:
l Graft survival – the length of time that a GRFs in the recipient.
l GRF – a measure of the efficiency of the graft by various markers, for example glomerular filtration rate
(GFR) and serum creatinine levels (Table 5). Measuring serum creatinine concentrations is a simple
method for estimating GFR. Estimated glomerular filtration rate (eGFR) is calculated from serum
creatinine levels, age, sex and race, and provides information on creatinine clearance (CRC). There are
various methods used to calculate eGFR [Modification of Diet in Renal Disease (MDRD), Cockcroft–Gault,
Nankivell methods], although no formula has been shown to be consistently more superior to another.35
l Rejection rates – the percentage of grafts that are rejected by the recipients’ bodies; these can be acute
or chronic.
l Patient survival – how long the recipient survives with the transplanted kidney.
l Quality of life – how a person’s well-being is affected by the transplant.
Figure 4 shows a hypothetical graph to explain the relationship between DGF and PNF. At 7 days post
transplant, some of the people who have needed to dialyse, and whose grafts are therefore classified as
DGF, will, in fact, have grafts that never function. When this has been established, these grafts are
classified as PNF.
TABLE 5 Glomerular filtration rate categories (National Institute for Health and Care Excellence guidelines CG182).
Reproduced from www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf with permission34
GFR category GFR (ml/minute/1.73m2) Terms
1 > 90 Normal or high
2 60–89 Mildly decreased
3a 45–59 Mildly to moderately decreased
3b 30–44 Moderately to severely decreased
4 12–29 Severely decreased
5 < 15 Kidney failure
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Current service provision
Management of disease
Management of end-stage renal disease
End-stage renal disease is primarily managed by RRT. The patient pathway leading to RRT for those with
ESRD can be seen in Figure 5. The distribution of people on differing RRTs in the UK as of 31 December
2012 is shown in Figure 6.
Management of kidney transplant
If transplantation is the chosen method of RRT for a patient with ESRD then, from the perspective of
person receiving the transplant, there are three main service provision steps required for the management
of the transplant.
The first of these steps is organ procurement, which includes the identification of potential donors,
assessment of donor suitability, determination of donor brain death (where applicable) and medical
management of the donor. Donor–recipient compatibility includes an assessment on HLA matching. HLAs
are carried on cells within the body, enabling the body to distinguish between ‘itself’ and ‘non-self’, which
should be attacked. The closer the HLA matching, the less vigorously the body will attack the foreign
transplant; consequently, the chances of graft survival are improved. HLA mismatch refers to the number
of mismatches between the donor and the recipient at the A, B and DR loci, with a maximum of
two mismatches at each locus.11 However, it should be noted that because of improvements in
immunosuppressants, the significance of HLA matching has diminished.37
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FIGURE 5 The care pathway for RRT. Source: The National Service Framework for Renal Services – Part 1: Dialysis
and Transplantation.36
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The second step is the provision of immunosuppressive therapy. Immunosuppressants are the drugs taken
around the time of, and following, an organ transplant. They are aimed at reducing the body’s ability to
reject the transplant, and thus at increasing patient and graft survival and preventing acute and/or chronic
rejection (while minimising associated toxicity, infection and malignancy). Immunosuppressants are required
in some form for all kidney transplant recipients (KTRs) except, potentially, when the donor is an identical
twin. The immunosuppressive drugs can be divided into induction and maintenance drugs. Induction drugs
are powerful antirejection drugs that are taken at the time of transplantation and close after, when the risk
of rejection is highest. Maintenance drugs are less powerful antirejection drugs that are used as both initial
and long-term maintenance therapy.
The final service provision step is short- and long-term follow-up following transplantation. This step
involves looking for indications of any kidney graft dysfunction and/or other complications. Complications
fall into three categories:
l medical follow-ups to monitor for, and treat, rejections; nephrotoxicity of CNIs; and recurrence of the
native kidney diseases
l anatomical complications of surgery, including renal artery thrombosis, renal artery stenosis, urine leaks
from disruption of the anastomosis, ureteral stenosis and obstruction, and lymphocele
l other complications, including infection, malignancy, new onset of diabetes mellitus, liver disease,
hypertension and CVD.
Management of graft loss
As the kidney loses its function, many of the physiological changes that occur mimic those seen with
progressive renal diseases from other aetiologies. Therefore, these symptoms should be managed in a
similar way to the non-transplant population, although it should be noted that the loss of a kidney
transplant carries increased susceptibility to bruising and infection compared with pretransplant
kidney failure.28
Home – HD
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Hospital – HD
19.4%
Satellite – HD
21.3%
CAPD
3.4%
APD
3.5%
Transplant
50.4%
FIGURE 6 Treatment modality in prevalent RRT adults on 31 December 2012 in the UK. Source: The Sixteenth
Annual report from the UK Renal Registry.3 APD, automated peritoneal dialysis; CAPD, continuous ambulatory
peritoneal dialysis. Source: Annual Report on Kidney Transplantation, Report for 2013/2014, NHS Blood and
Transplant.11 Reproduced with permission. The data reported here have been supplied by the UK Renal Registry of
the Renal Association. The interpretation and reporting of these data are the responsibility of the authors and in
no way should be seen as an official policy or interpretation of the UK Renal Registry or the Renal Association.
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Once the kidney is confirmed to have been lost, the graft may or may not need to be surgically removed.
The decision as to whether or not the graft is removed is often made on a case-by-case basis, taking into
consideration all perceived benefits and risks. The immunosuppression regimen can then be tapered and
withdrawn while the patient returns to dialysis and waits for a new kidney to become available. However,
in cases when people have not already formed antibodies to donor HLA, immunosuppression may be
continued to allow access to a wider pool of potential donors. Success rates of a subsequent kidney
transplant are equivocal. Some report that a subsequent transplant will generally be as good as the first,28
whereas others report inferior graft survival for those receiving their second38 or third39 transplant in
comparison with those receiving their first transplant.
Management of graft loss will also include management of the psychological impact of the loss; owing to
an increased risk for depression following the loss of a graft, it is recommended that depressive symptoms
should be actively investigated and managed along conventional lines.28
Current service cost
The overall cost of CKD to the NHS in England was estimated as £1.45B in 2009–10, with more than
half of total estimated expenditure going on RRT.40 The costs of RRT can be divided into the costs
associated with transplantation and the costs associated with dialysis. Transplantation costs can include
the cost of work-up for transplantation (assessing recipient suitability), maintaining and co-ordinating the
waiting list, obtaining donor kidneys (harvesting, storage and transport for deceased donors; nephrectomy
procedure for living donors), cross-matching for donor–recipient compatibility, the transplantation
procedure, induction immunosuppression, hospital inpatient stay following procedure, initial and long-term
maintenance immunosuppression, prophylaxis and monitoring for infections, monitoring of GRF and
general health, adjustment of immunosuppressant dosages, treatment of AR and treatment of associated
adverse events (AEs). Should the kidney be lost, the costs of restarting dialysis (dialysis costs, the cost of
treatment for AEs attributable to dialysis and the cost of dialysis access surgery) would be incurred.
Variation in services
Currently, 71 adult renal centres are operating in the UK (five renal centres in Wales, five in Northern
Ireland, nine in Scotland, 52 in England) offering various levels of renal care. This includes 23 adult
transplant centres in the UK (one in Wales, one in Northern Ireland, two in Scotland, 19 in England). There
is some variation across the services provided between these 71 centres; however, information describing
how the services differ is not readily available.
After kidney transplantation, recipients are prescribed an immunosuppression regimen consisting of both
induction and maintenance therapy. Following this, they are offered check-up appointments with their
clinic (consultant nephrologist) to monitor general health, kidney function, immunosuppressive drugs,
infections (prophylaxis and treatment) and to address any social or psychological concerns. The following
frequency of clinic appointments is suggested for an uncomplicated patient.41
l two or three times weekly for the first month after transplantation
l once or twice weekly for months 2–3 after transplantation
l every 1–2 weeks for months 4–6 after transplantation
l every 4–6 weeks for months 6–12 after transplantation
l 3- to 6-monthly thereafter
l detailed annual postoperative reviews.
Clinician estimations of average frequency of outpatient visits have been reported as 34.3, 6.3 and
4.7 visits, respectively, for the first, second and third years post transplant, with figures from the Cardiff
Transplant Unit suggesting 39.7, 11.0 and 9.2 visits, respectively, for the first, second and third years
post transplant.42
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Service provision (clinic appointments or other services) is likely to increase if AR occurs (possibly requiring
hospital admission and escalating treatment), and, where there is declining GRF (which might necessitate
more regular clinic visits, blood tests and other investigations and changes to treatment regimens). People
may also present to their general practitioner (GP) or accident and emergency department with AEs related
to kidney transplantation or immunosuppressive regimen and this may be followed by an additional
referral to the consultant nephrologist or other appropriate specialist (e.g. renal dietitian), followed by
management as required (e.g. additional prescribing and monitoring).
In addition to these services, all people should have the following:41
l online access to their results via the ‘Renal Patient View’ service (http://rixg.org/patientview2/
patientview-2-2-released/)
l open access to the renal transplant outpatient service
l an established point of contact for enquiries
l access to patient information (which should be available in both written and electronic formats).
Current National Institute for Health and Care Excellence guidance
Current National Institute for Health and Care Excellence (NICE) guidance on ‘Immunosuppressive Therapy
for Renal Transplantation in Adults’ (NICE technology appraisal guidance 85, TA85) has the following
recommendations for induction and maintenance therapy.43
Induction therapy
l Basiliximab (BAS) (Simulect®, Novartis Pharmaceuticals UK Ltd) or daclizumab (DAC), used as part of a
CNI-based immunosuppressive regimen, are recommended as options for induction therapy in the
prophylaxis of acute organ rejection in adults who are undergoing renal transplantation. The induction
therapy (BAS or DAC) with the lowest acquisition cost should be used.43
Maintenance therapy
l Tacrolimus (TAC) (Adoport®, Sandoz; Capexion®, Mylan; Modigraf®, Astellas Pharma; Perixis®, Accord
Healthcare; Prograf®, Astellas Pharma; Tacni®, Teva; Vivadex®, Dexcel Pharma) is an alternative to
ciclosporin (CSA) when a CNI is indicated as part of an initial or a maintenance immunosuppressive
regimen in renal transplantation for adults. The initial choice of TAC or CSA should be based on the
relative importance of their side effect profiles for individual people.43
l Mycophenolate mofetil (MMF) (Arzip®, Zentiva; CellCept®, Roche Products; Myfenax®, Teva) is
recommended for adults as an option as part of an immunosuppressive regimen only:
¢ where there is proven intolerance to CNIs, particularly nephrotoxicity, leading to risk of chronic
allograft dysfunction, or
¢ in situations in which there is a very high risk of nephrotoxicity necessitating minimisation or
avoidance of a CNI.43
l Sirolimus (SRL) (Rapamune®, Pfizer) is recommended for adults as an option as part of an
immunosuppressive regimen only in cases of proven intolerance to CNIs (including nephrotoxicity)
necessitating complete withdrawal of these treatments.43
As a consequence of following this guidance, some medicines may be prescribed outside the terms of their
UK marketing authorisation. Clinicians prescribing these drugs should ensure that people are aware of this,
and that they consent to their use in such circumstances.43
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Since the publication of the current guidance in 2004,43 the marketing authorisation for DAC has been
withdrawn. In addition, new technologies have received marketing authorisations for induction therapy
[rabbit anti-human thymocyte immunoglobulin (rATG) (Thymoglobulin®, Sanofi)] and maintenance therapy
[belatacept (BEL) (Nulojix®, Bristol-Myers Squibb); a prolonged-release formulation of TAC (TAC-PR)
(Advagraf®, Astellas Pharma); and an oral suspension of immediate-release TAC]. In addition, another new
technology [everolimus (EVL) (Certican®, Novartis Pharmaceuticals UK Ltd)] has been studied as an
immunosuppressant in renal transplantation. EVL received UK marketing authorisation in this therapy area
in November 2014.
Description of technology under assessment
Summary of intervention
This technology assessment report considers nine pharmaceutical interventions. Two are used as induction
therapy and seven are used as a part of maintenance therapy in renal transplantation. The two
interventions considered for induction therapy are BAS and rATG. The seven interventions considered for
maintenance therapy are immediate-release TAC and TAC-PR, MMF, mycophenolate sodium (MPS)
(Myfortic®, Novartis Pharmaceuticals UK Ltd), BEL, SRL and EVL.
Induction therapy
Basiliximab is a monoclonal antibody that acts as an interleukin-2 receptor antagonist. It has a UK
marketing authorisation for the prophylaxis of acute organ rejection in de novo allogeneic renal
transplantation in adults. The Summary of Product Characteristics states that it is to be used concomitantly
with CSA for microemulsion (ME)- and corticosteroid (CCS)-based immunosuppression in people with a
panel reactive antibody (PRA) score of < 80%, or in a triple maintenance immunosuppressive regimen
containing CSA for ME, CCSs and either azathioprine (AZA) or MMF. Higher PRA scores indicate higher
immunological risk. BAS is administered intravenously.
Rabbit anti-human thymocyte immunoglobulin is a gamma immunoglobulin generated by immunising
rabbits with human thymocytes. It has a UK marketing authorisation for the prevention of graft rejection in
renal transplantation. The Summary of Product Characteristics states that it is usually used in combination
with other immunosuppressive drugs and is administered intravenously.
Maintenance therapy
Tacrolimus is a CNI. It is available in a prolonged-release formulation and immediate-release formulations.
All of these formulations (see Current National Institute for Health and Care Excellence guidance, above)
have UK marketing authorisations for the prophylaxis of transplant rejection in adults who are undergoing
kidney transplantation, and all are administered orally. Prograf® can also be administered intravenously.
The Commission on Human Medicines advises that all oral TAC medicines in the UK should be prescribed
and dispensed by brand name only.
Belatacept is a soluble fusion protein that is designed to selectively inhibit CD28-mediated co-stimulation
of T cells. BEL has a UK marketing authorisation for prophylaxis of graft rejection in adults who are
receiving a renal transplant, in combination with CCSs and a mycophenolic acid (MPA). The Summary of
Product Characteristics recommends that an interleukin-2 receptor antagonist is added to this BEL-based
regimen. BEL is administered intravenously.
Mycophenolate mofetil is a prodrug of MPA that acts as an antiproliferative agent; generic MMF is
manufactured by Accord Healthcare, Actavis, Arrow Pharmaceuticals, Dr Reddy’s Laboratories, Mylan,
Sandoz and Wockhardt.
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Mycophenolate sodium. Mycophenolate is also available as an enteric-coated formulation:
mycophenolate sodium (EC-MPS).
(Mycophenolate mofetil and MPS have UK marketing authorisations for use in combination with CSA and
CCSs for the prophylaxis of acute transplant rejection in people undergoing kidney transplantation. Both
drugs can be administered orally; MMF can also be administered intravenously.)
Sirolimus is a non-calcineurin-inhibiting immunosuppressant and acts as an antiproliferative agent.
It has a UK marketing authorisation for the prophylaxis of organ rejection in adults – at low to moderate
immunological risk – who are receiving a renal transplant. It is recommended to be used initially in
combination with CSA and CCSs for 2–3 months. It may be continued as maintenance therapy with CCSs
only if CSA can be progressively discontinued. It is administered orally.
Everolimus is an analogue of SRL and therefore is a non-calcineurin-inhibiting immunosuppressant which
acts as an antiproliferative. EVL has recently (November 2014) received UK marketing authorisation for
immunosuppressive treatment in kidney transplantation. It has been studied in clinical trials in numerous
regimens containing one or more additional immunosuppressant (including CSA, TAC, anti-thymocyte
immunoglobulin, mycophenolate, CCSs and BAS) and compared with various alternative
immunosuppressive regimens in adults undergoing kidney transplantation. EVL is administered orally.
Important prognostic factors
A number of important factors that may influence both patient and graft survival have been identified:
l Age – both the age of the recipient and the age of the donor will influence the survival of the
transplant. Graft survival decreases as the age of the recipient or the donor increases.44
l Sex – women have a better graft survival rate than men, whereas men have better patient survival
than women.44
l Recipient ethnicity – black people have worse GRF, shorter graft survival and higher rates of chronic
allograft nephropathy than white people.44
l Waiting time to transplant – the longer a patient is on dialysis, waiting for a kidney transplant, the
poorer his/her outcomes are post transplantation.45
l Cold ischaemia time – the shorter this time (≤ 20 hours), the better the immediate and
long-term outcomes.11
l Donor type – adults receiving donated kidneys from live donors have a better outcome than those who
are receiving kidneys from deceased donors.44 Similarly, people receiving a kidney from ECDs (donors
who may, for example, be older or have a history of diabetes mellitus or hypertension) will have inferior
graft survival rates and increased incidences of AR compared with patients who are receiving a
standard donated kidney.46
l Immunological risk, to include HLA and blood group incompatibility – when the number of mismatches
from the donor to the recipient is higher, there is an increased likelihood of AR and graft loss.44
l Comorbidities, for example diabetes mellitus, cancer and CVD – the higher a patient scores on the
Charlson Comorbidity Index, the lower the patient and graft survival is likely to be. AR is not
significantly correlated to the Charlson Comorbidity Index.47
There is also evidence to suggest that African American people will require a higher dose of TAC,48 MMF49
and SRL50 to achieve the target levels than white people. However, how the prescription of the
immunosuppression regimen offered in the UK differs between subgroups is not readily available.
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Current usage in the NHS
Although the combination of TAC+mycophenolate (MMF or Myfortic)+ prednisolone is widely used,
immunosuppressive regimens tend to vary according to renal centre (thus the use of the drugs under
consideration varies across centres). Some examples of immunosuppressive regimens in the UK are given
below in Table 6, but this is by no means exhaustive, as there are so many possible combinations
of treatments.
Anticipated costs associated with the interventions
The cost of the intervention (immunosuppressive regimen) is determined primarily by the choice and
combination of the drugs and their respective dosages. Indicative costs for different immunosuppressive
agents are given in Table 7. Caution should be exercised in interpreting these, as dosages are commonly
titrated and may differ from those indicated.
In addition, drug administration costs are also incurred for some maintenance agents: CSA, TAC, SRL and
EVL are routinely titrated using therapeutic drug monitoring, which are estimated to cost approximately
£26 per test (testing frequency is reduced as people become stabilised in dosage); BEL requires intravenous
(i.v.) infusion, entailing catheterisation and nursing time. The cost of this is difficult to estimate but
estimates range from £15463 to £320.64 Costs are considered in greater detail in Chapter 7.
TABLE 6 Current immunosuppression prescriptions used in UK hospitals
Hospital Treatment
Royal Devon and Exeter Hospital,
Exetera
Variable baseline immunosuppression depending on transplant centre. Typically, all
kidney-alone transplant patients should have BAS on days 1 and 4 in the transplant
centre. Everyone will receive a combination of prednisolone, CNI (either CSA or TAC)
and/or antiproliferative agent (either AZA or mycophenolate). As an alternative,
people may be offered an mTOR inhibitor (either SRL or EVL)
Derriford Hospital, Plymoutha ‘SYMPHONY study’51 regimen using triple therapy irrespective of immunological risk
or DGF risk with TAC, MMF or MPS, and a reducing course of prednisolone
Nottingham University Hospitals
NHS Trust52
Standard immunological risk:
BAS induction therapy. TAC, AZA and prednisolone maintenance therapy
Oxford Transplant Centre53 Recipients receive alemtuzumab induction
Maintenance immunosuppression is steroid free with TAC-PR and MMF or MPS
Royal Infirmary of Edinburgh54 Methyl prednisolone 500mg intravenously just prior to releasing clamps, and again at
24 hours
Standard immunosuppression is TAC-led triple therapy with prednisolone and AZA
mTOR, mammalian target of rapamycin.
a Source: direct communication with clinical experts.
Note
Alemtuzumab is outside the scope of the present technology appraisal.
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TABLE 7 Indicative cost per week for different immunosuppressive agents
Compound Unit cost (pence)
For 70-kg patient
Estimated weekly dosage Estimated weekly cost (£)
CSA Hospital pharmacy 1.65 per mg;a
community pharmacy 2.55 per mgb
4 mg/kg per dayb= 1960mg Hospital pharmacy 32.28;
community pharmacy 49.95
Immediate-release
TAC
Hospital pharmacy 52.0 per mg;a
community pharmacy 118.6 per mga,c
0.2 mg/kg per dayd= 98mg Hospital pharmacy 50.98;
community pharmacy
116.26
TAC-PR 106.8 per mgb 0.2 mg/kg per dayd= 98mg 52.31
AZA Hospital pharmacy 0.1 per mg;a
community pharmacy 0.1 per mgc
1.75 mg/kg per dayb= 858mg Hospital pharmacy 0.92;
community pharmacy 0.98
MMF Hospital pharmacy 37.7 per g;a
community pharmacy 40.4 per gc
2 g per dayb= 14 g Hospital pharmacy 5.28;
community pharmacy 5.66
MPS 0.5 per mgb 1,440mg per dayb= 705,600mg 45.14
SRL 288.3 per mgb,c 2mg per dayb= 14mg 40.36
EVL 990.0 per mge 2mg per daye= 14mg 138.60
BEL 141.8 per mgb 5 mg/kg per 4 weeksf,g= 125mg 177.25
CCSs Hospital pharmacy 0.3 per mg;a
community pharmacy 0.9 per mgc
15mg/dayb= 105mg Hospital pharmacy 0.35;
community pharmacy 0.92
a Commercial Medicines Unit. Drug and pharmaceutical electronic market information 2014.55
b British National Formulary 68.56
c NHS Business Services Authority. NHS Drug Tariff for England and Wales, February 2015.57
d Novartis’ submission.
e Krämer et al.58
f The Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial (BENEFIT) study.59–62
g BEL comes in 250-mg vials; therefore, dosage rounded up to 500mg per 4 weeks.
Note
Costs are estimated based on units of ‘mg’ or ‘g’, which may not be appropriate if fine dosing is not possible or if
fine-dosing products are substantially more expensive per unit; in particular for BEL, it assumes that perfect vial sharing is
carried out (in which one vial may be used by more than one patient to eliminate wastage).
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Chapter 2 Definition of the decision problem
Decision problem
Interventions
A total of nine interventions are being considered, two for induction therapy and seven for initial and
long-term maintenance therapy.
The two induction treatments are:
l BAS
l rATG.
The seven maintenance treatments are:
l TAC-PR
l TAC immediate-release formulations
l BEL
l MMF
l MPS
l SRL
l EVL.
These treatments are summarised in Chapter 1 (see Summary of intervention). The maintenance treatments
will be appraised as part of combination regimens where appropriate. Under an exceptional directive from
the Department of Health, the Appraisal Committee may consider making recommendations about the use
of drugs outside the terms of their existing marketing authorisation when there is compelling evidence of
their safety and effectiveness. Accordingly, the review will include studies that used drugs outside the
terms of their marketing authorisations.
Populations
The population being assessed is adults undergoing kidney transplantation from a living–related donor,
living–unrelated donor or deceased donor. People receiving multiorgan transplants, and those who have
received transplants and immunosuppression previously, will be excluded. When data allow, the following
subgroups will be considered: level of immunological risk (including HLA compatibility and blood group
compatibility), people at high risk of rejection within the first 6 months, people who have had a
retransplant within 2 years, previous AR and people at high risk of complications from immunosuppression
(including new-onset diabetes mellitus).
Relevant comparators
For induction therapy, the treatments are to be compared with each other as data permit, or with other
regimens that do not include monoclonal or polyclonal antibodies. For maintenance therapy, each
treatment or regimen (combination of treatments) is to be compared with the other treatments or
regimens as data permit, or with a CNI with or without an antiproliferative agent and/or CCSs.
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Outcomes
The health-related outcomes to be included in this report are:
l patient survival
l graft survival
l GRF (eGFR, which is a measure of the kidney’s ability to filter and remove waste products)
l time to and incidence of AR
l severity of AR
l adverse effects of treatment
l health-related quality of life (HRQoL).
Key issues
A number of factors may influence the survival and function of a donated kidney and the survival of
the recipient.
The viability of the kidney may depend on the type of donor (living–related, living–unrelated, DBD, DCD or
ECD), the age of the donor, whether or not he/she had comorbidities (such as diabetes mellitus) and the
length of cold ischaemia. Furthermore, the age, sex, ethnicity and health of the recipient, and the length
of time the recipient is on dialysis prior to transplantation, may affect the outcome of transplantation.
Overall aims and objectives of assessment
The aim of this assessment is to review and update the evidence for the clinical effectiveness and
cost-effectiveness of immunosuppressive therapies in adult renal transplantation. This will be done by
conducting a systematic review of clinical effectiveness studies and a model-based economic evaluation of
induction and maintenance immunosuppressive regimens to update the current guidance (TA85).43 The
current guidance was primarily based on research evidence presented to NICE in the assessment report by
Woodroffe et al.65 We have incorporated relevant evidence that was presented in this previous report and
we report new evidence from 2002 to the present. This will include a new decision-analytic model of
kidney transplantation outcomes to investigate which regimen is the most cost-effective option.
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Chapter 3 Assessment of clinical effectiveness
Methods for reviewing effectiveness
The project was undertaken in accordance with a predefined protocol. There were no major departures
from this protocol.
The aim was to systematically review the effectiveness of immunosuppressive therapies in adult renal
transplantation and determine the effect on patient survival; graft survival; GRF; time to, and incidence
of, AR; severity of AR; the effectiveness in improving HRQoL and the impact of AEs. The review was
undertaken following the principles published by the NHS Centre for Reviews and Dissemination.66
Identification of studies
Bibliographic literature searching was conducted on 14 April 2014. The effectiveness searches took the
following form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the
interventions under review) AND (a study design limit to RCTs or controlled trials). The search was date
limited to 2002 to current, in line with the previous assessment, and the searches were updated on
18 November 2014. The search was not limited by language or human-only studies to ensure that records
were not missed in error. Instead, these exclusion criteria were implemented during the screening process.
The following databases were searched for randomised controlled trials (RCTs) MEDLINE (via Ovid),
EMBASE (via Ovid), Cochrane Central Register of Controlled Trials (via Wiley Online Library) and Web of
Science (via ISI; including conference proceedings). The following trials registries were hand-searched:
ClinicalTrials.Gov (https://clinicaltrials.gov/) and Controlled Trials (www.controlled-trials.com/). The search
strategies (including web-searching) are recorded in Appendix 1.
A separate search was undertaken to identify systematic reviews. These searches took the following form:
(terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under
review) AND (a pragmatic limit to systematic reviews). The search was run from database inception in the
following databases: MEDLINE (via Ovid), EMBASE (via Ovid), Cochrane Database of Systematic Reviews,
Database of Abstracts of Reviews of Effects and Health Technology Assessment (HTA; The Cochrane
Library via Wiley Online Library) and Health Management Information Consortium (via Ovid). The search
was not limited by language and it was not limited to human-only studies. The search strategies are
recorded in Appendix 1.
In addition, the following websites were searched for background information:
Renal societies (UK)
l British Renal Society www.britishrenal.org/.
l Renal Association www.renal.org/.
l UK Renal Registry www.renalreg.com/.
l Kidney Research UK www.kidneyresearchuk.org/.
l British Kidney Patient Association www.britishkidney-pa.co.uk/.
l National Kidney Federation www.kidney.org.uk/.
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Renal societies (international)
l American Society of Nephrology www.asn-online.org/.
l American Association of Kidney Patients www.aakp.org/.
l National Kidney Foundation (USA) www.kidney.org/.
l Canadian Society of Nephrology www.csnscn.ca/.
l Kidney Foundation of Canada www.kidney.ca/.
l Australian and New Zealand Society of Nephrology www.nephrology.edu.au/.
l Kidney Health Australia www.kidney.org.au/.
l Kidney Society Auckland www.kidneysociety.co.nz/.
The database search results were exported to, and deduplicated using EndNote (X5) (Thomson Routers,
CA, USA). Deduplication was also performed using manual checking. The search strategies and the
numbers retrieved for each database are detailed in Appendix 1. After the reviewers completed the
screening process, the bibliographies of included papers were scrutinised for further potentially
includable studies.
Studies included in the previous adult and child HTA reviews65,67 were screened against the inclusion
criteria for the Peninsula Technology Assessment Group (PenTAG) review for includable studies. Reference
lists of included guidelines, systematic reviews and clinical trials were scrutinised for additional studies.
Ongoing studies
A search for ongoing trials was also undertaken. The terms used to search the ClinicalTrials.gov and
Controlled Trials [International Standard Randomised Controlled Trial Number (ISRCTN)] trial registers for
the interventions are included in Appendix 1.
Trials that did not relate to immunosuppressive therapies for kidney transplantation in adults were
removed by hand-sorting. Finally, duplicates, identified via their study identification numbers, where
possible, were removed. Searches were carried out on 19 September 2014.
Inclusion and exclusion criteria
Study design
Only RCTs were included. Systematic reviews of RCTs were also included in order to ensure all relevant
clinical trials were identified.
Population
Adults who were undergoing kidney transplantation only, and receiving immunosuppressive therapy, were
included in this review. Multiorgan transplantation, the treatment of episodes of AR and individuals who
have previously received a renal transplant and immunosuppression (i.e. individuals who were not
undergoing the process of a new renal transplant) are outside the scope of this appraisal.
Interventions
Studies evaluating the use of the following immunosuppressive therapies for renal transplantation were
included (further details in Chapter 1, Induction therapy and Maintenance therapy).
Induction therapy regimens containing:
l BAS
l rATG.
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Maintenance therapy regimens containing:
l MMF
l MPS – EC-MPS
l immediate-release TAC
l TAC-PR
l BEL
l SRL
l EVL.
Under an exceptional directive from the Department of Health, these interventions can be assessed outside
their existing marketing authorisation (to reflect their use in clinical practice) where there was compelling
evidence of safety and effectiveness.
Comparators
The comparators of interest for induction therapies were regimens without monoclonal or polyclonal
antibodies or one of the other interventions under consideration.
For maintenance therapies, the comparators were a CNI with or without an antiproliferative agent and/or
CCSs or a regimen including one of the other interventions under consideration.
Outcomes
Outcomes sought from the studies fell into four main categories: mortality, graft-related outcomes, AEs
data and HRQoL outcomes. Owing to the variability in evidence available and in order to ensure
consistency with the modelling, measurements were restricted as follows:
l Mortality
l Graft-related outcomes:
¢ graft survival – when graft loss is defined as return to chronic dialysis, retransplant, graft removal
or death
¢ GRF – (estimated) eGFR, which is an estimate of actual GFR; a number of formulae are available for
eGFR, which may require age, weight, sex and serum creatinine level
¢ time to, and incidence of, biopsy-proven acute rejection (BPAR)
¢ severity of AR according to the Banff classification (grades I–III).
l AEs:
¢ malignancy and post-transplant lymphoproliferative disorder (PTLD)
¢ diabetes mellitus
¢ infections
¢ cytomegalovirus (CMV).
l HRQoL, including data on validated quality-of-life measures, for example the European Quality of Life-5
Dimensions (EQ-5D), the SF-36 and the Kidney Transplant Questionnaire (KTQ-25).
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Selection of studies
Studies retrieved from the searches were selected for inclusion according to the inclusion/exclusion criteria
specified in Inclusion and exclusion criteria. Initially, titles and abstracts returned by the search strategy
were screened for inclusion independently by two researchers, with TJ-H as first reviewer and LC, MHa,
MB or HC as second reviewer. Disagreements were resolved by discussion, with involvement of a third
reviewer (MHa or HC). Full texts of identified studies were obtained and screened in the same way.
In addition, studies included in the reviews conducted by Woodroffe et al.65 and Yao et al.67 were screened
for inclusion against the eligibility criteria for this review.
Data extraction strategy
Included full papers were split between five reviewers (TJ-H, MHa, LC, MB and HC), with TJ-H as first
reviewer for the purposes of data extraction using a standardised data extraction form, and checked
independently by another reviewer. Discrepancies were resolved by discussion with the involvement of an
additional review team member (MHa or HC) if necessary. Information extracted and tabulated included
details of the study’s design and methodology, baseline characteristics of participants, and results,
including HRQoL and any AEs, if reported.
If several publications were identified for one study, the data were extracted from the most recent
publication and supplemented with information from other publications.
For studies comparing both induction and maintenance, we assigned a separate reference for each study
arm, with the author and publication year of the main publication, and added the suffixes ‘a’ and ‘b’.
Critical appraisal strategy
Four reviewers (TJH, MHa, MB and HC) independently assessed quality for the newly identified studies
(2002 onwards) according to criteria based on Centre for Reviews and Dissemination guidance (Table 8).66
Methods of data synthesis
Where data permitted the results of individual studies were pooled using Stata SE 13.1 (StataCorp LP,
College Station, TX, USA) to investigate:
l estimation of overall treatment effect
l assessment of heterogeneity
l subgroup analysis
l assessment of publication bias.
TABLE 8 Quality assessment
Criteria Assessment question
Treatment allocation 1. Was the assignment to the treatment groups really random?
2. Was treatment allocation concealed?
Similarity of groups 3. Were the groups similar at baseline in terms of prognostic factors?
Implementation of masking 4. Were the care providers blinded to the treatment allocation?
5. Were the outcome assessors blinded to the treatment allocation?
6. Were the participants blinded to the treatment allocation?
Completeness of trial 7. Were all a priori outcomes reported?
8. Were complete data reported [e.g. was attrition and exclusion (including reasons)
reported for all outcomes]?
9. Did the analyses include an ITT analysis?
Generalisability 10. Are there any specific limitations which might limit the applicability of this study’s
findings to the current NHS in England?
ITT, intention to treat.
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Owing to the heterogeneity of population and study characteristics, a random-effects model was assumed
for all meta-analyses. For binary data, odds ratio (OR) was used as a measure of treatment effect and the
DerSimonian–Laird method was used for pooling. For continuous data (eGFR), mean differences (MDs)
were calculated if the outcome was measured on the same scale in all trials.
If a study had two intervention arms that were separately compared with the control arm, when pooling
ORs the number of events and the total sample size in the control arm were divided equally across the
comparisons, and when pooling MDs the total sample size in the control arm was adjusted and divided
equally across the comparisons. However, if only one experimental arm was eligible for the analysis then all
participants assigned to the control arm were included.
A narrative synthesis accompanies all included data.
Network meta-analyses
Network meta-analyses (NMAs) were undertaken within a Bayesian framework in WinBUGS version 1.4.3
(MRC Biostatistics Unit, Cambridge, UK). Where prior distributions were required, they were intended to
be vague.
For all NMAs assessing the effectiveness of induction therapy, the reference treatment was no
induction/placebo (PBO). For networks evaluating the effectiveness of maintenance therapy, the reference
treatment was CSA+AZA. For the outcomes graft loss, mortality and BPAR, fixed- and random-effects
models having a binomial likelihood with logit link were used (see code in Appendix 6). For the outcome
of GRF, models with a normal likelihood and identify link were used (see code in Appendix 6). All models
account for the fact that some RCTs have more than two arms.68
Trials reporting zero events for all arms for a particular outcome were excluded from the analysis, as these
trials would not contribute information to the network. Where a trial had a zero event in at least one,
but not all, treatment arms, 0.5 was added to all cells to allow the model to run within WinBUGS
version 14 (MRC Biostatistics Unit, Cambridge, UK).68
Analyses were run with three chains, a burn-in of 40,000 iterations followed by an additional 100,000
iterations, with thinning of every fifth iteration to help convergence. Convergence of the models was
assessed by visual inspection of autocorrelation and trace plots for all monitored variables.
Fixed- and random-effects NMAs were analysed and compared using the deviance information criteria
(DIC). Models with the lowest DIC were assumed to have a better fit to the data. The posterior medians
and 95% credibility intervals (CrIs) are reported.
To assess inconsistency in the network, the inconsistency degrees of freedom (ICDF) were calculated
(reflecting the number of independent loops in the network) and inconsistency networks (where only
direct evidence for a comparison between treatments is used) were modelled.69 Results from the
inconsistency models were compared with those from the consistency models (where direct and indirect
evidence were combined) to help identify inconsistencies within the network. The model with the lowest
DIC was assumed to be a better fit to the data.
The NMAs that have been conducted to satisfy relevant items on the Decision Support Unit’s Evidence
Synthesis Checklist.70
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Systematic review results
Owing to the number of regimens for both the interventions and comparators, the assessment of
effectiveness will be reported separately for induction and maintenance. All RCT evidence identified for
each intervention is presented.
Identified research for induction and maintenance therapies
We screened the titles and abstracts of 5079 unique references identified by the searches, with 750 papers
retrieved for detailed consideration. As highlighted in Figure 7, a total of 715 papers were excluded (a list
of these, with reasons for their exclusion, can be found in Appendix 2). Overall. 107 studies met the
inclusion criteria. At both stages, initial disagreements were easily resolved by consensus.
Identification
Screening
Data
selection and
appraisal
Records identified through database searching
(n = 5079; including 189 records identified
through SR’s searching)
Records after duplicates
removed
(n = 4459)
Records identified
through update
searching
(n = 375)
Records screened
(n = 4834)
Records excluded
(n = 3985)
Full-text articles
excluded with reasons
(N = 715)
• Abstract, n = 393
• Population, n = 78
• Study design, n = 138
• No usable data, n = 18
• Duplicate, n = 8
• Intervention, n = 7
• Comparator, n = 30
• Outcome, n = 32
• Language, n = 7
• Unobtainable, n = 4
Eligibility
Eligible studies
(n = 134; 107 records for 63 RCTs and
27 records for SRs)
Total RCT records, n = 136; including additional records from
Woodroffe et al.,65 n = 20
Total SRs included, n = 32
RCTs N = 86 (induction, n = 11 maintenance, n = 73, both, n = 2)
Other sources
(n = 10 RCT records
5 SRs)
Full-text assessed for
eligibility
(n = 849)
FIGURE 7 Flow chart: clinical effectiveness review. SR, systematic review.
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We then reassessed included studies from the review conducted by Woodroffe et al.65 (43 studies) (TA85).
Of these, 20 studies were considered eligible for inclusion in the update review.71–90 The scope for the
adult review by Woodroffe et al.65 differed from the final scope issued by NICE; the induction therapy
originally included DAC [European Union (EU) marketing authorisation withdrawn in January 2009] and
not rATG, the maintenance therapy did not include BEL or EVL, and treatment of AR was included but is
outside the scope of this appraisal. Reasons for exclusion from this review include data that were available
only in abstract format, population (either participants receiving multiorgan transplant or mixed population
of age groups) or duplicate (studies also retrieved in the update searches).
Citations of the included systematic reviews were also searched by two reviewers (HC and MHa).
This process revealed an additional two papers.
Update searches were conducted on 18 November 2014 using the same methodology as described earlier.
A total of 375 records were screened by three reviewers (TJH, HC and MHa) and 99 records were selected
for full-text retrieval. Four papers were judged to be eligible on full-text appraisal. A list of these items,
with reasons for their exclusion, can be found in Appendix 2.
The process is illustrated in detail in Figure 7. Note, for the sake of clarity, the figures for the initial and
update searches have been combined.
Quality of included studies
We appraised the newly identified trials and those included in the previous HTA review. The reason for
reappraising trials from the previous HTA review were twofold: first, to ensure consistency with appraisal
of the newer studies, and, second, because we have access to new information from papers that were
published after the inclusion date for the previous review. Only primary studies were appraised. Secondary
analyses of previously published data were not assessed. Similarly, if a trial was reported in multiple
publications, only one quality assessment of the trial was conducted (all publications for that trial were
assessed together). In total, 86 trials were assessed (11 induction studies, 73 maintenance studies and two
studies of both induction and maintenance treatment). Quality assessments of included trials are presented
in Appendix 4. The two trials of both induction and maintenance treatment are repeated in both of
these tables.
Overall assessment
The 86 included RCTs49,51,58,59,71–152 were of variable quality, but all appear to be flawed. However, as a
result of reporting omissions, for most of the trials it was difficult to make a general assessment
regarding quality. The quality appraisal should, therefore, be noted with caution. In fact, six72,73,95–98 of
the 14 induction trials, 4075–85,91–94,99–122,153 of the 74 maintenance trials, and one123 of the two trials of both
induction and maintenance either did not report, or lacked clarity on, at least five of the 10 items
constituting the quality appraisal assessment.
Only four induction studies71–74 and six maintenance studies58,124–127,150 adequately addressed five or more of
the 10 items of the quality appraisal assessment. However, even the reports of these trials omitted
important information relating to quality, with six71–74,124,125 of the seven failing to clearly describe the
procedure used for allocation concealment, and one58 failing to include an intention-to-treat (ITT) analysis.
Seven of the maintenance studies75,76,78,91–94 and two of the induction studies95,96 did not adequately
address any of the items in the quality appraisal assessment. Further details of the quality of included
studies, according to individual quality appraisal items, are described as follows.
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Treatment allocation
Random allocation
The method of random allocation,71,86,128 including the method of sequence generation, was clearly stated
and adequate in only two induction studies71,128 and 18 maintenance studies,86,103,110,112,119,122,124,126,127,129–136,150
whereas 65 studies (nine induction studies72–74,87,95,98,137 and 54 maintenance studies51,58,59,75–85,88,89,91–94,99–102,
104–109,111,113–118,120,121,125,138–147,152–155) and both of the studies of induction and maintenance treatment123,148 did
not clearly specify the method used. The remaining maintenance study149 used a minimisation technique that
included a random element.
Concealment of allocation
The method of concealment of allocation was clearly reported in 12 trials (two induction studies,97,128 nine
maintenance studies,58,114,129,130,133,140,147,150,152 and one study136 of both induction and maintenance treatment).
Fifty-four trials51,72–74,76–79,81–85,87–89,91–93,95,96,98–100,102–106,108–113,115–120,124,127,131,134,135,139,141,143–145,153–155 did not report
any information on allocation concealment, whereas 20 trials71,75,80,86,94,101,107,121–123,125,126,132,136–138,142,146,149,156
provided some information pertaining to allocation concealment but lacked sufficient detail or clarity to
demonstrate that allocation was adequately concealed.
Similarity of groups
Baseline characteristics
Fifty-seven trials (48 maintenance studies,51,58,77,80–82,84,86,94,99,100,102,104–109,113–117,119–121,124–127,131,132,134,138,139,141–147,149,
150,152,154,156,157 eight induction studies71,72,74,87,97,128,137 and one study123 for induction and maintenance) fully
reported baseline characteristics. Nine trials (eight maintenance studies88,89,92,110–112,122,148 and one study148 of
both induction and maintenance) reported significant baseline between-group differences for key factors,
including PRA grade, number of previous transplants, patient age, pretransplant diabetes mellitus, HLA
mismatches and ECD donor kidneys. A further six maintenance studies91,101,130,133,140,155 were rated as ‘partial’
because they reported a baseline difference in patient sex.
The remaining trials (four induction studies,71,95,96,98 26 maintenance studies59,75–80,83–85,93,94,103,107,114,115,118,
126,127,129,131,132,142,150,152,153 and one study123 of both induction and maintenance) did not provide sufficient
information for a judgement to be made about baseline similarity of groups, either by omitting to report
sufficient statistical information, by reporting on a very limited range of patient baseline characteristics or
by not reporting any patient baseline characteristics.
Implementation of masking
Treatment allocation masked from participants
Five induction studies,87,96,98,128,137 47 maintenance studies51,59,76,78–80,82–84,86,88,92–94,103,105–108,111,113,116,118,125,126,
129–135,138–142,144–149,151–153,155 and both of the studies of induction and maintenance treatment123,148 did not
blind participants to treatment allocation.
Only two maintenance studies89,124 and four induction studies71–74 made clear that the participants were
blinded to treatment allocation. A further four maintenance studies58,77,143,150 were rated as ‘partial’ because
it was reported that participants were blinded for a limited period of time only (until 24 weeks for one
study58 and until 12 months for the other three studies.77,143,150
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One further induction study95 was rated as ‘unclear’ because, despite being PBO controlled, no further
details were reported about blinding. The remaining trials (one induction study97 and 20 maintenance
studies75,81,85,91,99–102,104,109,110,112,114,115,117,119–122,127) did not report any information about blinding participants
to treatment allocation.
Treatment allocation masked from clinicians
All of the trials that did not blind participants from treatment allocation also failed to mask treatment
allocation from clinicians.51,59,76,78–80,82–84,86–88,92–94,96,98,103,105–108,111,113,116,118,123,125,126,128–135,137–142,144–149,151–153,155
An additional induction study97 also stated that treatment allocation was not masked from clinicians
(participant blinding was not reported). Similarly, the four induction studies71–74 and two maintenance
studies89,124 that reported blinding participants to treatment allocation also masked treatment allocation from
clinicians. Again, four maintenance studies58,77,143,150 were rated as ‘partial’ for clinician blinding because
blinding occurred for only a limited time, and one induction study95 was rated as ‘unclear’ because, although
it was a PBO-controlled trial, no further details were reported about blinding. The other 20 maintenance
studies75,81,85,91,99–102,104,109,110,112,114,115,117,119–122,127 did not report any details about clinician blinding.
Treatment allocation masked from outcome assessors
The majority of trials (52 maintenance
studies,51,75–77,79–84,86,89,91–94,99–102,104–106,108,109,111–114,116–122,130,131,133,138,140,141,144–149,151–153,155 nine induction
studies,71–73,87,95–98,128 and both of the studies123,148 of induction and maintenance treatment) did not report
whether outcome assessors were blind to treatment allocation.
One induction study137 and five maintenance studies78,132,134,135,139 made it clear that the outcome assessors
were not blinded to treatment allocation. For fifteen trials58,59,74,85,88,103,107,110,115,124–127,129,142 (one induction
study74 and 14 maintenance studies58,59,85,88,103,107,110,115,124–127,129,142) it was clear that outcome assessors were
blinded for at least one outcome, and a further two maintenance studies143,150 were given a ‘partial’ rating
because the outcome assessors were blinded for the first 12 months of the study.
Completeness of trials
Reporting of all a priori outcomes
All trials were rated as ‘unclear’ with regard to reporting of a priori outcomes.51,58,59,71–89,91–135,137–153,155
This was because the trial reports failed to explicitly state whether or not all outcomes defined in the study
protocol were reported.
Reporting of loss to follow-up, withdrawals and dropouts
Fifty-four trials adequately reported loss to follow-up, withdrawals and dropouts (by providing numbers
and reasons by treatment group). Of these, 45 were maintenance studies,51,58,59,80,81,83,84,88,102,104,106–108,111–114,
116,118–120,124–127,130–135,138,139,141,142,144–152,155 eight were induction studies,71–74,87,98,128,137 and one148 was a study
of both induction and maintenance treatment. In 22 trials (20 maintenance studies76,85,86,91–94,99–101,103,105,109,
110,115,121,122,129,140,143 and two induction studies95,96), the reporting of loss to follow-up, withdrawals and
dropouts was inadequate, with key information omitted. A further four trials75,79,97,123 (one induction
study,97 two maintenance studies75,79 and one study of both induction and maintenance treatment123) were
rated as ‘unclear’. For the study of both induction and maintenance, this was because, despite all of the
relevant information being provided, the numbers did not appear to tally. For the other three trials,75,79,97
this was because of the fact that all participants appeared to complete the study but this was not explicitly
stated. For the remaining six maintenance studies,77,78,82,89,117,153 information regarding loss to follow-up,
withdrawals and dropouts was not reported.
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Intention-to-treat analysis
Primarily, a strict definition of ITT was used (all randomised and transplanted participants). According to this
definition, 48 trials (seven induction studies71–74,87,98,137 and 41 maintenance studies51,59,77,79,80,84,86,88,89,100–102,104,
106–108,110,113,115,117,120,121,124–127,129–131,134,135,139,141–143,146,149–153) were rated as adequately performing an ITT analysis,
with 19 trials (three induction studies,128,158,159 14 maintenance studies,58,83,91,114,119,132,133,138,140,144145,147,148,155
and both studies123,148 of induction and maintenance treatment) not performing an adequate ITT analysis.
In 16 cases (two induction studies96,97 and 14 maintenance studies75,76,81,82,92–94,99,103,105,109,111,112,116) there was a
lack of clarity regarding whether or not an ITT analysis had been conducted. The other five trials (one
induction95 and four maintenance studies78,85,118,122) did not report any relevant information regarding
whether or not an ITT analysis had been conducted.
A secondary definition of ITT analysis was also used (all randomised and transplanted participants or < 10%
excluded). When this definition was applied, 13 of the trials previously rated as inadequate were instead rated
as adequate (11 maintenance studies58,83,114,119,132,133,138,140,147,148,155 and both of the studies123,148 of induction
and maintenance treatment). Thus, only four trials91,128,144,145 did not perform an adequate ITT analysis. The
number of trials rated as ‘unclear’ or ‘not reported’ did not change when this definition of ITT was used.
Applicability of trials to the NHS
Applicability to the current NHS in England
Only 11 trials (one induction study,74 nine maintenance studies51,58,86,114,124,125,132,133,155 and one study123 of
both induction and maintenance) were adequately applicable to the current NHS in England. The majority
of trials (seven induction studies,71,87,95,97,98,128,137 41 maintenance studies,59,75,77–82,84,85,88,89,93,94,99,101,109,112,115–118,
120,129–131,134,135,138,139,141,142,144–152 and one study148 of both induction and maintenance) were limited in some
way with regard to applicability to the current NHS in England. In all except one of these trials this was
primarily as a result of the fact that patients, donors or organ characteristics were not representative of the
current NHS in England (e.g. > 90% deceased donors or ‘suboptimal transplants’ or ‘high risk of rejection
population’). In the other trial135 this was primarily owing to a lack of statistical power.
The remaining three induction studies72,73,96 and 23 maintenance studies76,83,91,92,100,102–108,110,111,113,119,121,122,126,127,
140,143,153 were rated as ‘unclear’ regarding applicability to the current NHS in England. The primary reason for
this was as follows: the study lacked clarity regarding key demographic or patient–donor characteristics (two
induction studies73,96 and 10 maintenance studies76,83,91,92,102–104,107,113,140); the study was based on a non-EU
population (two induction studies72,159 and 13 maintenance studies100,105,106,108,110,111,119,121,122,126,127,143,153).
Study characteristics
Induction therapies
Thirteen studies71–74,87,95–98,123,128,137,148 were identified focusing on induction therapies.
Details of study characteristics can be found in Appendix 5.
The majority of trials report outcomes up to 1 year, with the period of induction therapy generally
continued for up to 14 days. No data for HRQoL were identified. It should be noted that, for some studies,
the dose no longer reflects clinical practice; however, there were insufficient data for further analysis.
Where a higher and lower dose was used in the RCT, the lower dose was selected for investigation.
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Overall, no new evidence has been identified for BAS vs. PBO and additional data has been added to both
rATG vs. no induction and BAS vs. no induction (Table 9).96,148,158,160 All data for rATG compared with no
induction has been identified by the PenTAG search.
Maintenance therapies
Seventy-five studies were identified focusing on a combination of 30 maintenance therapy comparisons
(Table 10). Details of study characteristics can be found in Appendix 5.
Outcomes are reported up to a maximum of 5 years, although the majority of data available is reported at
1 year. No data for HRQoL were identified. As for induction therapy RCTs, in some cases the dose no
longer reflects clinical practice; however, there were insufficient data for further analysis. When a higher
and lower dose was used in the RCT, the lower dose was selected for investigation.
Other than for the TAC+AZA against CSA+AZA combination, the majority of data were identified by the
PenTAG search.
TABLE 9 Overview of included studies for induction therapies
Study Induction therapy Included in TA85 Update review na Maintenance used
Bingyi 200395 BAS vs. PBO ✓b 12 CSA+AZA+CCSs
Kahan 199972 ✓ 346 CSA+CCSs
Lawen 200374 ✓c 123 CSA+MMF+CCSs
Nashan 199771 ✓ 380 CSA+CCSs
Ponticelli 200173 ✓ 340 CSA+AZA +CCSs
Albano 2013123 BAS vs. no induction ✓ 1251 CSA+MMF+CCSs
Sheashaa 200397 ✓b 100 CSA+AZA+CCSs
Kyllönen 2007128 ✓ 102 CSA+AZA+CCSs
Charpentier 200196,158 rATG vs. no
induction
✓ 309 TAC+AZA+CCSs
Charpentier 2003148,160 ✓ 371 TAC+AZA+CCSs
Brennan 2006137 BAS vs. rATG ✓ 278 CSA+MMF+CCSs
Lebranchu 200287 ✓c 100 CSA+MMF+CCSs
Mourad 200498,159 ✓ 105 CSA+MMF+CCSs
a Number randomised.
b Identified in TA99.67
c Abstract.
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TABLE 10 Studies identified for maintenance therapy
Study (multiple publications) Maintenance therapy
Included
in TA85
Update
review n
Schleibner 199579 TAC+AZA vs. CSA+AZA ✓ 47
Laskow 199680 (Vincenti 1996161) ✓ 120
Mayer 199788 (Mayer 1999,162 2002163) ✓ 448
Radermacher 199881 ✓ 41
Jarzembowski 200599 ✓ 35
Baboolal 200282 ✓ 51
Campos 200283 ✓ 166
Margreiter 200284 (Krämer 2005,164 2008165) ✓ 560
Van Duijnhoven 200275 ✓ 23
Waller 200276 (Murphy 2003166) ✓ 102
Charpentier 2003148 ✓ 555
Töz 200485 ✓ 35
Hardinger 2005100 (Brennan 2005167) ✓ 200
Sollinger 199577 CSA+MMF low vs. CSA+AZA vs.
CSA+MMF
✓ 499
Tricontinental MMF renal study 199689
(Mathew 1998,168 Clayton 2012169)
✓ 497
Sadek 200286 CSA+MMF vs. CSA+AZA ✓ 477
Tuncer 200278 ✓ 76
Merville 2004138 ✓ 71
Remuzzi 2007101 (The MYSS trial, Remuzzi
2004170)
✓ 336
Wlodarczyk 2005139 (Wlodarczyk 2002171) TAC+MMF vs. CSA+AZA ✓ 489
Vacher-Coponat 2012129 ✓ 289
Zadrazil 2012102 TAC+MMF vs. CSA+MMF ✓ 53
Hernández 2007130 ✓ 240
Rowshani 2006103 ✓ 126
Yang 199990 (Ulsh 1999153) ✓ 60
Weimer 2006104 (Weimer 2005172) TAC+AZA vs. CSA+AZA vs.
CSA+MMF
✓ 81
Wlodarczyk 2009140 TAC+MMF vs. TAC-PR+MMF ✓ 122
Krämer 201058 ✓ 667
Tsuchiya 2013141 ✓ 102
Oh 2014105 ✓ 104
Albano 2013123 (OSAKA trial) TAC+MMF vs. TAC-PR
0.2mg/kg/day+MMF vs. TAC-PR
0.3mg/kg/day
✓ 1251
Ciancio 2008106 (Ciancio 2011173) MMF+ TAC vs. MPS+ TAC ✓ 150
Salvadori 2004124 MMF+CSA vs. MPS+CSA ✓ 423
Vincenti 2005125 (Vincenti 2010156) BEL low+MMF vs. BEL high+MMF
vs. CSA+MMF
✓ 218
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TABLE 10 Studies identified for maintenance therapy (continued )
Study (multiple publications) Maintenance therapy
Included
in TA85
Update
review n
BENEFIT (Vincenti 2010,59 Larsen 2010,60
Vincenti 2012,61 Rostaing 201362)
✓ 686
BENEFIT-EXT (Durrbach 2010,142 Medina
Pestana 2012,174 Charpentier 2013,175
Larsen 201060)
✓ 578
Ferguson 2011126 BEL+MMF vs. BEL+ SRL vs.
TAC+MMF
✓ 89
Lorber 2005143 EVL low+CSA vs. EVL high+CSA
vs. MMF+CSA
✓ 583
ATLAS Vítko 2005150 (Vítko 2004,176 2005177) ✓ 588
Takahashi 2013131 ✓ 122
Chadban 2013152 (SOCRATES) EVL vs. EVL+CSA vs. CSA+MPS ✓ 126
Tedesco-Silva 2010107 EVL low+CSA vs. EVL high+CSA
vs. MPA+CSA
✓ 783
Bertoni 2011144 EVL+CSA vs. MPS+CSA ✓ 106
Budde 2011132 (Budde 2012,178
Liefeldt 2012179)
EVL+MPS vs. CSA+MPS ✓ 300
Mjörnstedt 2012133 ✓ 202
Barsoum 2007108 SRL+CSA vs. MMF+CSA ✓ 113
Stallone 2004109 ✓ 90
Anil Kumar 2005110 SRL+ TAC vs. MMF+ TAC ✓ 150
Mendez 2005111 (Gonwa 2003180) ✓ 361
Sampaio 2008112 ✓ 100
Gelens 2006113 ✓ 54
Gallon 2006145 (Chhabra 2012181) ✓ 83
Van Gurp 2010114 ✓ 634
Flechner 2002127 (Flechner 2004,182 2007183) SRL+MMF vs. CSA+MMF ✓ 61
Noris 2007115 (Ruggenenti 2007184) ✓ 21
Lebranchu 2009149 (Servais 2009,185
Lebranchu 2011,186 Joannides 2011187)
✓ 192
Büchler 2007134 (Lebranchu 2012,188
Joannides 2010189)
✓ 145
Soleimani 201391 ✓ 88
Durrbach 2008146 ✓ 69
Kreis 2000116 – identified from
Campistol 2005190
✓ 78
Guba 2010147 ✓ 140
Martinez-Mier 2006117 ✓ 41
Nafar 2012118 ✓ 100
Larson 2006151 (Stegall 2003191) TAC+MMF vs. SRL+MMF ✓ 162
Schaefer 200692 ✓ 80
continued
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Population characteristics
Induction therapies
Baseline characteristics of trial participants for induction therapy are summarised in Table 11.
Mean age across studies ranges from 30.3 to 51.3 years. Men generally represented a higher proportion
of the participants (57.5–76.3%) other than in the study reported by Mourad et al.,98 in which men
constituted 28.6% and 30.5% of the BAS and rATG arms, respectively.
Earlier papers tended to record cadaveric donors, with no further details; however, newer trials report
deceased donors as DCD, DBD and ECD. Four studies71,87,128,148 used only cadaveric donors and one study97
used only living donors. In the remainder of the studies, the donors were either mixed or not reported.
The majority of studies had a high proportion of white participants: 60.3–96.2%. Brennan et al.167 and
Kahan et al.72 report a comparatively high percentage of black participants in the BAS and rATG arms,
respectively (28.5% and 29.1%; 27% and 34%, respectively).
The mismatching of HLAs ranges from 2.13 to 4 (see Chapter 1, Management of kidney transplant).
Although a close antigen match is no longer considered to be critical because immunosuppressive therapy
is more effective, a better HLA match may lead to longer the graft survival.
Maintenance therapies
Baseline characteristics of trial participants for maintenance therapy are summarised in Table 12.
TABLE 10 Studies identified for maintenance therapy (continued )
Study (multiple publications) Maintenance therapy
Included
in TA85
Update
review n
Heilman 2011135 (Heilman 2012157) ✓ 122
Smith 200893 ✓ 51
Silva 2013119 TAC+MPS vs. SRL+MPS ✓ 204
Hamdy 2005120 (Hamdy 2008,192
Hamdy 2010193)
TAC+ SRL vs. MMF+ SRL ✓ 132
Charpentier 2003136 (Groth 1999194) SRL+AZA vs. CSA+AZA ✓ 83
Chen 2008121 TAC+ SRL vs. CSA+ SRL ✓ 41
Vítko 200694 SRL low+ TAC vs. SRL high+ TAC
vs. MMF+ TAC
✓ 977
Flechner 2011155 (ORION study) SRL+ TAC vs. SRL+MMF vs.
MMF+ TAC
✓ 450
Grinyo 200951 (SYMPHONY study,
Ekberg 2009,195 2010,196 Demirbas 2009,197
Frei 2010,198 Claes 2012199)
MMF+CSA vs. MMF+ low CSA vs.
MMF+ low TAC vs. MMF low SRL
(one study)
✓ 1529
Anil Kumar 2008122 (Anil Kumar 2005110) TAC+MMF vs. TAC+ SRL vs.
CSA+MMF vs. CSA+ SRL
✓ 200
BENEFIT, The Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression Trial; BENEFIT-EXT,
BENEFIT–Extended Criteria Donors; MYSS, Mycophenolate Steroids Sparing; SOCRATES, Steroid or Cyclosporin Removal
After Transplant using Everolimus.
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Mean age across studies ranges from 29.6 to 57.1 years. Men represented 50–80% of participants for the
bulk of the studies. The studies by Baboolal et al.82 and Campos et al.83 fell slightly below this, with men
at 48–49%, whereas Chen et al.121 recruited only 24% and 35% in treatment arms and Grinyo et al.51
recruited 33% and 38%.
As for induction therapies, earlier papers tended to record cadaveric donors, with no further details. Fifteen
studies75,77,80–82,88,89,99,116,129,130,134,136,138,148 used only cadaveric donors and no studies used only living. For the
remainder of the studies, the donors were either mixed or not reported.
The majority of studies had a high proportion of white participants; however, Jarzembowski et al.99
recruited all African American participants, Ciancio et al.106 recruited Hispanic (29.3% and 30.7%) and
African American (26.7% and 32.0%) participants, Chadban et al.152 reported Asian participants to be
38.8%, 46.7% and 40.4% in each arm, Anil Kumar et al.110 recruited 59% and 60% African American
participants, and Anil Kumar et al.122 recruited 50–54% African American participants in each arm.
For the maintenance studies, HLA is reported in a variety of formats, making any comparisons between
studies difficult. As previously mentioned, the matching of HLAs is no longer considered critical, but may
have an impact on graft survival.
Study results
The following outcomes have been addressed for each combination of therapies for both induction and
maintenance, with meta-analysis performed where possible:
l mortality
l graft loss
l BPAR
l GRF
l time to BPAR
l severity of BPAR
l adverse effects of treatment
l HRQoL.
We also sought HRQoL outcome data from included RCTs. However, none was reported, so we do not
have a section for this outcome.
Furthermore, because of an insufficient number of RCTs within each comparison for induction and
maintenance therapies (i.e. 10 or more, as recommended by the Cochrane Handbook201), publication bias
has not been investigated with funnel plots.
For severity of BPAR, reporting is generally very poor and it is unclear if all of the people with BPAR have
received a Banff classification. Therefore, the results as reported are presented with no further analysis.
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Induction therapies
BAS compared with PBO/no induction
The 2005 review identified four RCTs71–74 investigating the effectiveness of BAS compared with PBO.
One RCT95 was identified in the review by Yao et al.67
No additional studies were identified in the PenTAG search. No data were identified for HRQoL and time
to BPAR.
For BAS compared with no induction, one RCT97 was identified in TA99 and two further RCTs123,128 were
identified by the PenTAG search.
Mortality
Participant mortality was recorded at 6 months by three studies.73,74,123 Six studies71–74,97,128 report mortality
at 1 year.
As displayed in Table 13 and Figure 8, the OR at 0.5 years for the studies by Ponticelli et al.,73 Albano
et al.123 and Lawen et al.74 indicates that BAS is associated with lower odds of mortality, although the
results are not statistically significant (OR 0.36, 95% CI 0.13 to 1.01).
Pooled results at 1 year for the studies by Lawen et al.74 and Sheashaa et al.97 also display no statistically
significant difference between BAS and PBO/no induction up to 1 year, which is in agreement with the
previous HTA65 (OR 0.95, 95% CI 0.49 to 1.87). The effect estimate for the Sheashaa et al.97 study at 3, 5,
7 and 10 years also shows no difference between arms.
TABLE 13 Mortality for BAS vs. PBO/no induction
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Albano 2013,123 Ponticelli 2001,73
Lawen 200374
0.5 3a 0.36 0.13 to 1.01 0.0 0
Kyllönen 2007,128 Kahan 1999,72
Nashan 1997,71 Ponticelli 2001,73
Lawen 2003,74 Sheashaa 200397
1 6b 0.95 0.49 to 1.87 0.0 0
Sheashaa 200397 3 1 0.33 0.01 to 8.21 NA
5 0.19 0.01 to 4.10
7 1.00 0.24 to 4.24
10 0.78 0.20 to 3.10
NA, not applicable.
a One trial excluded from pooled analysis as a result of no deaths in either arm.
b Two trials excluded from pooled analysis as a result of no deaths in either arm.
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Graft loss
Of the seven studies in this group,71–74,97,123,128 three studies73,74,123 recorded graft loss at 6 months and
six studies71–74,97,128 at 1 year (Table 14 and Figure 9).
At both time points the OR may indicate some benefit of BAS compared with PBO or no induction in
reducing graft loss (0.5 years: OR 0.78, 95% CI 0.50 to 1.22; 1 year: OR 0.82, 95% CI 0.56 to 1.21).
However, this estimate must be treated with caution because of the wide CIs indicating a lack of
statistical significance.
The one study97 reporting results at 3, 5, 7 and 10 years showed no statistically significant difference
between arms (see Table 14).
TABLE 14 Graft loss for BAS vs. PBO
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Albano 2013,123 Ponticelli 2001,73
Lawen 200374
0.5 3 0.78 0.50 to 1.22 0.0 0.0
Kyllönen 2007,128 Kahan 1999,72
Nashan 1997,71 Ponticelli 2001,73
Lawen 2003,74 Sheashaa 200397
1 6a 0.82 0.56 to 1.21 0.0 0.0
Sheashaa 200397 3 1 3.06 0.12 to 76.95 NA
5 5.21 0.24 to 111.24
7 1.00 0.24 to 4.24
10 0.78 0.20 to 3.10
NA, not applicable.
a One trial excluded owing to no graft loss in either arm.
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Graft function
Pooled analysis for GRF measured as CRC (Table 15 and Figure 10) implies no beneficial effect of
BAS compared with PBO [0.5 years: weighted mean difference (WMD) –1.38ml/minute/1.73m2, 95% CI
–5.96 to 3.20ml/minute/1.73 m2; 1 year: WMD 1.93ml/minute/1.73m2, 95% CI –0.97 to 4.83ml/minute/
1.73m2].71–73,97,123 In particular, results for 0.5 years must be treated with caution because of the substantial
heterogeneity across studies (I2= 83.4%). It should also be noted that, at 1 year, the study reported by
Kahan et al.,72 which indicates an improved GRF for participants on BAS, had a higher percentage of
African American participants (34% and 27%) who generally exhibit poor long-term graft survival
compared with other ethnic groups.72
Data up to 10 years reported by Sheashaa et al.97 (Table 16) indicate no statistically significant difference
between BAS and no induction.
Biopsy-proven acute rejection
The results of BPAR at 0.5 years are inconclusive because of the substantial heterogeneity across studies
(I2= 80.7%).71,73,74,123 In contrast, at 1 year, BAS statistically significantly reduced BPAR compared with
PBO/no induction (OR 0.53, 95% CI 0.40 to 0.70, I2= 0.0%) (Table 17 and Figure 11).72–74,97,128
Furthermore, the report by Sheashaa et al.97 indicates this effect is maintained up to 10 years (OR 0.41,
95% CI 0.18 to 0.96).97
Severity of biopsy-proven acute rejection
Six studies71–74,97,123 report severity of BPAR (Table 18). Overall, Table 18 indicates that BAS may be
associated with less severe exacerbations of BPAR.
TABLE 15 Pooled analysis for BAS vs. PBO/no induction: GRF
Study
Time point
(years) Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
Albano 2013,123 Ponticelli
2001,73 Nashan 199771
0.5 3 –1.38 –5.96 to 3.20 83.4 0.06
Kyllönen 2007,128 Kahan 1999,72
Nashan 1997,71 Ponticelli
2001,73 Lawen 2003,74
Sheashaa 200397
1 4 1.93 –0.97 to 4.83 23.9 5.75
WMD, weighted mean difference.
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TABLE 17 Pooled analysis for BAS vs. PBO: BPAR
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Albano 2013,123 Ponticelli 2001,73
Lawen 2003,74 Nashan 199771
0.5 4 0.59 0.31 to 1.10 80.7 0.064
Kyllönen 2007,128 Kahan 1999,72
Ponticelli 2001,73 Lawen 2003,74
Sheashaa 200397
1 5 0.53 0.40 to 0.70 0.0 0.0
TABLE 16 Graft function for BAS vs. no induction (unpooled)
Study
Time
point
(years)
BAS, mean
ml/minute/1.73m2
(SD)
No induction, mean
ml/minute/1.73m2
(SD)
MD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2)
p-value
(t-test)
Sheashaa
200397
1 75.0 (14.1) 72.0 (12.9) 3.00 –2.30 to 8.30 0.2697
3 76.6 (12.9) 72.3 (13.7) 4.34 –0.88 to 9.56 0.1094
5 73.4 (16.2) 71.3 (12.3) 2.19 –3.44 to 7.82 0.4671
7 71.2 (14.5) 68.6 (14.4) 2.60 –3.06 to 8.26 0.3705
10 64.1 (15.2) 65.5 (15.1) –1.40 –7.15 to 4.35 0.6451
SD, standard deviation.
Note
All methods either reported as CRC or Cockcroft–Gault unless otherwise stated.
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Time to biopsy-proven acute rejection
Only one study128 reported time to BPAR (Table 19). In general, the results seem similar between arms,
although no induction has a broader range (BAS 35–267 days, no induction 10–364 days).
Summary of results for BAS compared with PBO/no induction
Pooled results indicate no statistically significant difference between BAS and PBO/no induction for
mortality up to 1 year (six studies71–74,97,128) (OR 0.95, 95% CI 0.49 to 1.87).
The effect estimate for the Sheashaa et al.97 study at 3, 5, 7 and 10 years also shows no difference
between arms.97
No statistically significant difference is found between BAS and PBO/no induction for graft loss
(six studies71–74,97,128) (0.5 years OR 0.78, 95% CI 0.50 to 1.22; 1 year OR 0.82, 95% CI 0.56 to 1.21).
This is also the case for the single study when follow-up continues up to 10 years.97
Pooled analysis for GRF measured as CRC implies no beneficial effect of BAS compared with PBO
(0.5 years, WMD –1.38ml/minute/1.73m2, 95% CI –5.96 to 3.20ml/minute/1.73 m2; 1 year, 1.93, 95% CI
–0.97 to 4.83ml/minute/1.73 m2).71–73,97,123
TABLE 18 Severity of BPAR for BAS vs. PBO
Study
Time point
(years)
BAS PBO/no induction
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Albano 2013123 0.5 283 36 16 18 2 302 31 13 15 3
aLawen 200374 0.5 59 9 5 1 2 64 17 4 11 1
Nashan 199771 0.5 190 51 20 26 5 186 73 31 31 11
Ponticelli 200173 0.5 168 31 15 12 4 172 49 16 25 8
Kahan 199972 1 173 61 26 31 4 173 85 38 37 10
bSheashaa 200397 1 50 29 27 2 50 45 35 10
5 50 27 24 3 50 36 25 11
7 50 41 3 2 50 55 44 11
10 50 41 3 2 50 55 44 11
a In addition to the reported Banff I–III grades there was one BPAR was of unknown classification in both study arms.
b Numbers of BPAR episodes were reported and Banff II and III grades were reported together, whereas episodes recorded
as Banff I also included borderline BPAR.
TABLE 19 Time to BPAR for BAS vs. no induction
Study
BAS No induction
Statistical test
(p-value)n BPAR Time to BPAR, days n BPAR Time to BPAR, days
Kyllönen 2007128 58 7 Mean 97, median 46,
range 35–267
44 9 Mean 101, median 35,
range 10–364
NR
NR, not reported.
Note
The timing was significantly different between the three groups [BAS vs. rATG Fresenius (Neovil Biotech) vs. no induction]
when divided into early, medium, and late with cut-off points at 30 and 100 days (χ2< 0.005).
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The results of BPAR at 0.5 years are inconclusive because of the substantial heterogeneity across
studies71,73,74,123 (I2= 80.7%). In contrast, at 1 year, BAS statistically significantly reduced BPAR compared
with PBO/no induction (OR 0.53, 95% CI 0.40 to 0.70; I2= 0.0%).72–74,97,128 Furthermore, the report by
Sheashaa et al.97 indicates that this effect is maintained up to 10 years (OR 0.41, 95% CI 0.18 to 0.96).97
In general, severity of BPAR appeared reduced with BAS.
rATG vs. no induction
Both RCTs for this comparison were identified via the PenTAG search.96,148
Mortality
Two trials96,148 provided data on mortality for rATG vs. no induction (Table 20). Follow-up data are provided
to only 1 year.96 No clear evidence of a difference between arms is visible, as the OR is close to ‘1’ and the
CIs are wide.
Graft loss
Two trials96,148 provide graft loss data for rATG vs. no induction (Table 21). For both studies,96,148 CIs are
extremely wide, crossing an OR of 1, indicating no statistical difference between arms.
Graft function
No studies reported GRF.
Biopsy-proven acute rejection
Two studies96,148 report on BPAR for rATG vs. no induction for 0.5 years and 1 year (Table 22). The data at
1 year suggest a statistically significant beneficial effect for rATG (OR 0.41, 95% CI 0.24 to 0.52).96
Severity of biopsy-proven acute rejection
One study148 reports severity of BPAR at 0.5 years (Table 23). For people identified with BPAR, the
occurrence of the most severe classification was 10.7% for rATG and 6.4% for no induction. For Banff
classification II, there is a greater association with no induction (rATG 25%, no induction 36.2%).
TABLE 22 Biopsy-proven acute rejection for rATG vs. no induction
Study Time point (years) Trials OR 95% CI p-value
Charpentier 2003148 0.5 1 0.52 0.31 to 0.88 0.014
Charpentier 200196 1 1 0.41 0.24 to 0.52 0.002
TABLE 21 Graft loss for rATG vs. no induction
Study Time point (years) Trials OR 95% CI p-value
Charpentier 2003148 0.5 1 0.93 0.35 to 2.47 0.878
Charpentier 200196 1 1 0.74 0.25 to 2.17 0.580
TABLE 20 Mortality for rATG vs. no induction
Study Time point (years) Trials OR 95% CI p-value
Charpentier 2003148 0.5 1 0.833 0.22 to 3.16 0.788
Charpentier 200196 1 1 0.995 0.20 to 4.99 0.995
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Time to biopsy-proven acute rejection
Time to BPAR is reported by one study96 (Table 24), in which more participants experience BPAR at
7–10 days with no induction than with rATG.
Summary of results for rATG vs. no induction
Only two studies96,148 report rATG vs. no induction. No statistically significant difference was seen for
mortality, graft loss or GRF. For BPAR, the data at 1 year suggest a statistically significant beneficial effect
for rATG (OR 0.41, 95% CI 0.24 to 0.52) and for severity of BPAR; at Banff classification II, there are
greater odds of association with no induction (1 year: OR 0.09, 95% CI 0.01 to 0.73).
BAS vs. rATG
The RCT reported by Lebranchu et al.87 was identified in the 2005 review. The PenTAG search retrieved a
further two RCTs: Brennan et al.137 and Mourad et al.98 All three RCTs87,98,137 had a maintenance therapy
comprising CSA, MMF and CCSs.
Mortality
The comparison between BAS and rATG for mortality is reported by three studies87,98,137 (Table 25 and
Figure 12). Two studies are pooled with 1-year results where no statistically significant effect is seen
between arms (OR 1.03, 95% CI 0.35 to 3.00).98,137
TABLE 24 Time to BPAR for rATG vs. no induction
Study
Mean time to BPAR, days
p-value (t-test)arATG No induction
Charpentier 200196 7 participants, 0–14 30 participants, 0–14 NA
10 participants, 15–28 10 participants, 15–28
6 participants, 29–365 8 participants, 29–365
NA, not applicable.
a Calculated by PenTAG.
TABLE 23 Biopsy-proven acute rejection for rATG vs. no induction
Study
Time point
(years)
rATG No induction
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Charpentier 2003148 0.5 186 28 18 7 3 185 47 27 17 3
TABLE 25 Mortality for BAS vs. rATG
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Lebranchu 200287 0.5 1 3.06 0.12 to 76.95 NA NA
Mourad 2004,98 Brennan 2006137 1 2 1.03 0.35 to 3.00 0.0 0.0
NA, not applicable.
Note
One trial excluded from pooled analysis as a result of no deaths in either arm.
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Graft loss
Data from three trials87,98,137 were pooled at the 1-year time point (Table 26 and Figure 13). Although the
OR indicates lower odds of graft loss associated with rATG, the effect is not statistically significant (OR
1.36, 95% CI 0.61 to 3.03). There was no evidence of heterogeneity across studies. For the individual
study87 at 0.5 years there was no statistically significant effect for BAS or rATG.
Graft function
Only Lebranchu et al.87 report GRF, with results at 0.5 years and 1 year (Table 27). The MD for CRC of
6.10ml/minute/1.73 m2 at 1 year in favour of BAS is not statistically significant (p= 0.1103).
Biopsy-proven acute rejection
A total of three studies87,98,137 report on BPAR for BAS vs. rATG (Table 28 and Figure 14). At both 0.5 years
and 1 year, the 95% CIs imply a lack of statistically significant difference between treatments (0.5 years,
OR 1.00, 95% CI 0.24 to 4.24; 1 year, OR 1.57, 95% CI 0.95 to 2.61). For Brennan et al.,137 as a much
larger study with narrower CIs, rATG appears to reduce BPAR, although this effect is lost when pooled
with the smaller studies.
Severity of biopsy-proven acute rejection
Two studies87,98 report on severity of BPAR, although results are not provided for all Banff classifications
(Table 29). No difference is seen between treatments.
Time to biopsy-proven acute rejection
Time to BPAR is reported by two studies87,98 (Table 30). Neither of the studies87,98 revealed a statistically
significant difference between BAS and rATG, despite the study by Mourad et al.98 reporting a mean time
for BAS of 155 days (SD 196.27 days) and for rATG of 35 days (SD 30.19 days).
TABLE 26 Graft loss for BAS vs. rATG
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Lebranchu 200287 0.5 1 1.00 0.14 to 7.39 NA NA
Lebranchu 2002,87 Mourad 2004,98
Brennan 2006137
1 3 1.36 0.61 to 3.03 0.0 0.0
NA, not applicable.
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TABLE 27 Graft function for BAS vs. rATG
Study
Time
point
(years)
BAS, mean
ml/minute/1.73m2
(SD)
rATG, mean
ml/minute/1.73m2
(SD)
MD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2)
p-value
(t-test)
Lebranchu
200287
0.5 63 (14.7) 59.1 (20.3) 3.90 –3.13 to 10.93 0.2739
1 66.5 (17.9) 60.4 (19.9) 6.10 –1.42 to 13.612 0.1103
SD, standard deviation.
TABLE 28 Biopsy-proven acute rejection for BAS vs. rATG
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Lebranchu 200287 0.5 1 1.00 0.24 to 4.24 0.0 0.0
Lebranchu 2002,87
Mourad 2004,98
Brennan 2006137
1 3 1.57 0.95 to 2.61 0.0 0.0
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
85
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
N
o
te
: w
ei
g
h
ts
 a
re
 f
ro
m
 r
an
d
o
m
-e
ff
ec
ts
 a
n
al
ys
is
0.
5 
ye
ar
s
Le
b
ra
n
ch
u
 2
00
28
7
1 
ye
ar
B
re
n
n
an
 2
00
61
37
M
o
u
ra
d
 2
00
49
8
Le
b
ra
n
ch
u
 2
00
28
7
Su
b
to
ta
l (
I 2
 =
 0
.0
%
, p
 =
 0
.5
78
)
St
u
d
y
4/
50
4/
50
22
/1
41
5/
53
4/
50
31
/2
44
Ev
en
ts
,
co
n
tr
o
l
10
0.
00
10
0.
00
72
.5
5
15
.1
4
12
.3
1
10
0.
00
% w
ei
g
h
t
1.
00
 (
0.
24
 t
o
 4
.2
4)
1.
00
 (
0.
24
 t
o
 4
.2
4)
1.
86
 (
1.
02
 t
o
 3
.3
7)
1.
02
 (
0.
28
 t
o
 3
.7
6)
1.
00
 (
0.
24
 t
o
 4
.2
4)
1.
57
 (
0.
95
 t
o
 2
.6
1)
O
R
 (
95
%
 C
I)
4/
50
4/
50
35
/1
37
5/
52
4/
50
44
/2
39
Ev
en
ts
,
tr
ea
tm
en
t
Fa
vo
u
rs
 B
A
S
Fa
vo
u
rs
 r
A
TG
0.
23
6
1
4.
24
FI
G
U
R
E
14
Fo
re
st
p
lo
t:
B
PA
R
fo
r
B
A
S
vs
.r
A
TG
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
86
Summary of results for BAS vs. rATG
Three RCTs were identified.87,98,137 No statistically significant difference was seen for any of the outcomes.
Maintenance therapies
TAC+AZA vs. CSA +AZA
Fourteen studies75,76,79–85,88,99,100,104,148 were identified using this combination. Where possible, meta-analysis has
been performed. Results are presented for all outcomes, other than HRQoL where no evidence was reported.
Mortality
Ten studies76,79,80,83,84,88,99,100,104,148 report mortality, with meta-analysis possible at the 0.5- and 1-year time
points (Table 31 and Figure 15). All studies76,79,80,83,84,88,99,100,104,148 are presented graphically on the forest
plot to provide a visual overview (see Figure 15). At 0.5 years, pooled results of only two studies84,148,164,165
generate an OR of 0.54 (95% CI 0.18 to 1.62), indicating lower odds of mortality for TAC; however, the
large CIs indicate a low level of precision, and, as they all overlap, the null value (OR= 1) there is unlikely
to be a significant difference between treatments. Although the OR at 1 year, which includes eight
studies,76,80,83,84,88,99,100,104 has shifted to 1.51, indicating reduced odds of mortality in the CSA arm, the
95% CI of 0.75 to 3.06 also suggests no significant difference between treatments. Heterogeneity across
studies for the 1-year time point is low and may not be important at this level according to the Cochrane
Handbook201 (I2= 14.8%). Mayer et al.88 report mortality up to 5 years; however, the results are consistent
with earlier time points and indicate no difference between arms (OR 1.20, 95% CI 0.69 to 2.07).
TABLE 30 Time to BPAR for BAS vs. no rATG
Study
BAS rATG
χ2 (p-value)an BPAR
Mean time to
BPAR, days (SD) n BPAR
Mean time to
BPAR, days (SD)
bLebranchu 200287 50 4 48.5 (29.8) 50 4 35 (29.7) 0.00 (0.98)
cMourad 200498 52 5 155 (196.3) 53 5 35 (30.2) 0.08 (0.77)
a Log-rank test for equality of survivor functions calculated by PenTAG.
b BPAR recorded on days 19, 41, 44 and 90, and days 8, 11, 56, 65, in BAS and rATG groups, respectively.
c BPAR recorded on days 10, 12, 13, 369 and 371, and days 9, 10, 22, 59 and 75, in BAS and rATG groups, respectively.
TABLE 29 Severity of BPAR for BAS vs. rATG
Study
Time point
(years)
BAS rATG
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Lebranchu 200287 0.5 50 4 3 1 0 50 4 1 3 0
1 50 4 3 1 0 50 4 1 3 0
aMourad 200498 1 52 5 5 NR NR 53 5 5 NR NR
NR, not reported.
a All BPAR recorded were either Banff I or borderline.
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TABLE 31 Mortality for TAC+AZA vs. CSA+AZA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Schleibner 199579 0.08 1a NA NA NA NA
Margreiter 2002,84 Krämer 2005,164 2008,165
Charpentier 2003148
0.5 2 0.54 0.18 to 1.62 0.0 0.0
Laskow 1996;80 Vincenti 1996;161
Mayer 1997,88 1999,162 2002;163
Jarzembowski 2005;99 Campos 2002;83
Margreiter 2002;84 Krämer 2005,164 2008;165
Waller 2002;76 Murphy 2003;166 Hardinger 2005;100
Brennan 2005;167 Weimer 2005,172 2006104
1 8b 1.51 0.75 to 3.06 14.8 0.13
Margreiter 2002;84 Krämer 2005,164 2008165 2 1 0.53 0.15 to 1.85 NA NA
Mayer 1997,88 1999,162 2002163 4 1 1.23 0.68 to 2.21 NA NA
5 1 1.20 0.69 to 2.07 NA NA
NA, not applicable.
a No deaths reported for either arm.
b One trial excluded from pooled analysis as a result of no deaths in either arm.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
88
N
o
te
: w
ei
g
h
ts
 a
re
 f
ro
m
 r
an
d
o
m
-e
ff
ec
ts
 a
n
al
ys
is
0.
08
 y
ea
rs
Sc
h
le
ib
n
er
 1
99
57
9
0.
5 
ye
ar
s
M
ar
g
re
it
er
 2
00
28
4
C
h
ar
p
en
ti
er
 2
00
31
48
Su
b
to
ta
l (
I 2
 =
 0
.0
%
, p
 =
 0
.8
38
)
1 
ye
ar
La
sk
o
w
 1
99
68
0
M
ay
er
 1
99
78
8
Ja
rz
em
b
o
w
sk
i 2
00
59
9
C
am
p
o
s 
20
02
83
M
ar
g
re
it
er
 2
00
28
4
W
al
le
r 
20
02
76
H
ar
d
in
g
er
 2
00
51
00
W
ei
m
er
 2
00
61
01
Su
b
to
ta
l (
I 2
 =
 1
4.
8%
, p
 =
 0
.3
17
)
2 
ye
ar
s
M
ar
g
re
it
er
 2
00
28
4
4 
ye
ar
s
M
ay
er
 1
99
78
8
5 
ye
ar
s
M
ay
er
 1
99
78
8
St
u
d
y
(E
xc
lu
d
ed
)
. (
. t
o
 .)
0/
31
. 0/
16
4/
27
1
5/
19
0
9/
46
1
2/
28
5/
14
5
1/
21
2/
81
6/
27
1
0/
50
0/
66
0/
25
16
/6
87
7/
27
1
7/
27
1
18
/1
45
18
/1
45
21
/1
45
21
/1
45
Ev
en
ts
,
co
n
tr
o
l
0.
00
0.
00
41
.8
1
58
.1
9
10
0.
00
10
.8
7
32
.7
4
7.
28
16
.0
3
23
.0
4
5.
00
5.
04
0.
00
10
0.
00
10
0.
00
10
0.
00
10
0.
00
10
0.
00
10
0.
00
10
0.
00
% w
ei
g
h
t
0.
47
 (
0.
09
 t
o
 2
.5
9)
0.
59
 (
0.
14
 t
o
 2
.5
2)
0.
54
 (
0.
18
 t
o
 1
.6
2)
0.
29
 (
0.
04
 t
o
 2
.1
5)
2.
09
 (
0.
77
 t
o
 5
.6
5)
3.
33
 (
0.
27
 t
o
 4
0.
81
)
3.
54
 (
0.
71
 t
o
 1
7.
60
)
0.
63
 (
0.
17
 t
o
 2
.2
4)
5.
00
 (
0.
23
 t
o
 1
06
.7
8)
2.
51
 (
0.
12
 t
o
 5
3.
02
)
(E
xc
lu
d
ed
)
1.
51
 (
0.
75
 t
o
 3
.0
6)
0.
53
 (
0.
15
 t
o
 1
.8
5)
0.
53
 (
0.
15
 t
o
 1
.8
5)
1.
23
 (
0.
68
 t
o
 2
.2
1)
1.
23
 (
0.
68
 t
o
 2
.2
1)
1.
20
 (
0.
69
 t
o
 2
.0
7)
1.
20
 (
0.
69
 t
o
 2
.0
7)
O
R
 (
95
%
 C
I)
2/
28
6
3/
19
0
5/
47
6
2/
92
21
/3
03
2/
14
7/
85
4/
28
6
2/
52
2/
13
4
0/
28
40
/9
94
4/
28
6
4/
28
6
45
/3
03
45
/3
03
51
/3
03
51
/3
03
Ev
en
ts
,
tr
ea
tm
en
t
Fa
vo
u
rs
 T
A
C
Fa
vo
u
rs
 C
SA
0.
00
93
7
1
10
7
FI
G
U
R
E
15
Fo
re
st
p
lo
t:
m
o
rt
al
it
y
fo
r
TA
C
+
A
ZA
vs
.C
SA
+
A
ZA
.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
89
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Graft loss check
Graft loss is reported for 10 trials76,79,80,83,84,88,99,100,104,148 (Table 32 and Figure 16). Results were pooled for
the 0.5-, 1- and 2-year time points. The pooling of trials reported by Margreiter et al.84 and Charpentier
et al.148 at 0.5 years gives an OR of 0.45 (95% CI 0.24 to 0.84), which is statistically significant in favour
of TAC.84,148 The 1-year time point is more reliable, at which seven studies are pooled (see Table 32),
generating an OR of 1.18 (95% CI 0.72 to 1.93). However, as with mortality, the results for graft loss
suggest no difference between TAC and CSA. This lack of statistical significance for either treatment
remains at 5 years (OR 0.92, 95% CI 0.61 to 1.40).
Graft function
Graft function was measured and reported by four studies,75,76,79,84 with effects measured from 0.08 to
3 years. No meta-analysis is provided for GRF, as the results are presented in a number of ways and are
not appropriate for pooling. In general, Table 33 shows some variation between arms with large SDs; for
example, results presented by Margreiter et al.84 at 1 year imply an improved GRF for TAC as opposed
to CSA [68.9 (SD 23.2) ml/minute/1.73 m2 and 61.8 (SD 23.2) ml/minute/1.73m2, respectively], which
is in contrast with the study of Van Duijnhoven et al.,75 who report 60.2 ml/minute/1.73m2 (range
11.5–86.2ml/minute/1.73 m2) and 64.9ml/minute/1.73 m2 (range 29.5–84.5ml/minute/1.73 m2),
respectively. This conflict between studies is seen at all time points.
Biopsy-proven acute rejection
All time points from 0.08 to 4 years reveal ORs of < 1 for BPAR, indicating that TAC is more effective than
CSA in reducing this outcome (Table 34 and Figure 17).76,79–84,88,99,100,104,148 BPAR outcomes were reported
by nine studies76,81–84,88,99,100,104 at 1 year, where pooled analysis gives an OR of 0.50 and 95% CI 0.39 to
0.64. Minimal heterogeneity is indicated across the studies at year 1 (I2= 8.1%). Mayer et al.88 report BPAR
at 4 years, when the beneficial effect of TAC appears to be maintained (OR 0.38, 95% CI 0.25 to 0.57).
TABLE 32 Graft loss for TAC+AZA vs. CSA+AZA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Schleibner 199579 0.08 1 0.16 0.01 to 4.26 NA NA
Margreiter 2002;84 Krämer 2005,164 2008;165
Charpentier 2003148
0.5 2 0.45 0.24 to 0.84 0.0 0.0
Mayer 1997,88 1999,162 2002;163
Jarzembowski 2005;99 Campos 2002;83
Margreiter 2002;84 Krämer 2005,164 2008;165
Waller 2002;76 Murphy 2003;166 Hardinger 2005;100
Brennan 2005;167 Weimer 2005,172 2006104
1 7a 1.18 0.72 to 1.93 0.0 0.0
Baboolal 2002;82 Margreiter 2002;84
Krämer 2005,164 2008165
2 2 0.71 0.40 to 1.25 0.0 0.0
Mayer 1997,88 1999,162 2002163 4 1 0.96 0.62 to 1.48 NA NA
5 1 0.92 0.61 to 1.40 NA NA
NA, not applicable.
a One trial excluded from pooled analysis as a result of no deaths in either arm.
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TABLE 33 Graft function for TAC+AZA vs. CSA+AZA
Study
Time
point
(years)
TAC, mean
ml/minute/1.73m2
(SD)
CSA, mean
ml/minute/1.73m2
(SD)
MD (ml/minute/
1.73m2)
95% CI (ml/minute/
1.73m2)
p-value
(t-test)
aLaskow 199680 0.08 50.3 (16.25) 48.52 (22.5) 0.0959 –0.5078 to 0.6995 0.3114
bVan Duijnhoven
200275
0.25 41.7 (13.5–100.2) 60.5 (26.8–74.5) NA NA NA
bMargreiter 200284 0.5 44.8 (13.6–106.1) 65.1 (29.6–84.2) NA NA NA
Margreiter 200284 1 68.9 (23.2) 61.8 (23.2) 0.3106 0.1434 to 0.4777 0.003
bVan Duijnhoven
200275
60.2 (11.5–86.2) 64.9 (29.5–84.5) NA NA NA
cWaller 200276 47 (14) 47 (18) 0 –0.392 to 0.392 1.000
Margreiter 200284 2 68.9 (23.2) 61.8 (23.2) 0.3106 0.1434 to 0.4777 0.003
bVan Duijnhoven
200275
60.6 (10.0–99.2) 57.1 (18.8–79.2) NA NA NA
Margreiter 200284 3 67.3 (23.6) 64.0 (23.9) 0.139 –0.0274 to 0.3053 0.1017
bVan Duijnhoven
200275
64.0 (38.9–97.9) 66.9 (9.5–94.2) NA NA NA
NA, not applicable.
a Lothalmate method.
b Median and range.
c Method of estimation unclear.
Note
All methods reported as either CRC or Cockcroft–Gault unless otherwise stated.
TABLE 34 Biopsy-proven acute rejection for TAC+AZA vs. CSA+AZA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Schleibner 1995,79 Laskow 199680 0.08 2 0.67 0.26 to 1.70 0.0 0.00
Margreiter 2002;84 Krämer 2005,164 2008;165
Charpentier 2003148
0.5 2 0.50 0.32 to 0.79 50.1 0.06
Mayer 1997,88 1999,162 2002;163
Radermacher 1998;81 Jarzembowski 2005;99
Baboolal 2002;82 Campos 2002;83
Margreiter 2002;84 Krämer 2005,164 2008;165
Waller 2002;76 Murphy 2003;166 Hardinger 2005;100
Brennan 2005;167 Weimer 2005,172 2006104
1 9 0.50 0.39 to 0.64 8.1 0.01
Baboolal 2002;82 Margreiter 2002;84
Krämer 2005,164 2008165
2 1 0.39 0.27 to 0.56 NA NA
Mayer 1997,88 1999,162 2002163 3 1 0.74 0.52 to 1.07 NA NA
4 1 0.38 0.25 to 0.57 NA NA
NA, not applicable.
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Severity of biopsy-proven acute rejection
Four trials82,84,100,148 report on severity of BPAR from 6 months to 2 years (Table 35). For the studies by
Baboolal et al.82 and Hardinger et al.,100 at 1 year, no participants with BPAR experienced Banff grade III for
either arm.82,100 At 6 months, Charpentier et al.148 report the proportion of people with BPAR classified as
Banff III as 10.7% for TAC and 15.4% for CSA and by 2 years Margreiter et al.84 report 6.4% and 16.8%
of people with BPAR experiencing Banff III, for TAC and CSA, respectively.
Time to biopsy-proven acute rejection
Time to first BPAR is reported by only two studies,82,83 with contrasting results (Table 36). The results
reported by Baboolal et al.82 indicate that BPAR is achieved more quickly for participants receiving TAC
(35 days, SD 13 days) rather than CSA (59 days, SD 38 days).
Summary of results for TAC +AZA vs. CSA+AZA
l Ten studies76,79,80,83,84,88,99,100,104,148 report mortality, with meta-analysis possible at the 0.5- and 1-year
time points. At 0.5 years, pooled results of only two studies84,148 generates an OR of 0.54, 95% CI 0.18
to 1.62, indicating lower odds of mortality for TAC; however, the large CIs overlap the null value
(OR= 1) therefore there is unlikely to be a significant difference between treatments. Although the OR
at 1 year, which includes eight studies,76,80,83,84,88,99,100,104 has shifted to 1.51, indicating reduced odds of
mortality in the CSA arm, the 95% CI of 0.75 to 3.06 also suggest no significant difference between
treatments. Heterogeneity across studies for the 1-year time point is low and may not be important at
this level according to the Cochrane Handbook201 (I2= 14.8%).
TABLE 35 Severity of BPAR at 6 months for TAC+AZA vs. CSA+AZA
Study Time point (years)
TAC+AZA CSA+AZA
n BPAR
Banff
classification
N BPAR
Banff
classification
I II III I II III
Margreiter 200284 0.5 286 56 21 31 4 271 101 34 49 18
Charpentier 2003148 0.5 186 28 18 7 3 184 39 14 19 6
Baboolal 200282 1 27 5 3 2 0 24 8 5 3 0
Hardinger 2005100 1 134 6 3 3 0 66 4 1 3 0
aMargreiter 200284 1 286 60 23 33 4 271 111 39 54 18
2 286 62 23 35 4 271 113 40 54 19
a Recorded Banff grade I BPAR includes two and one borderline BPAR in TAC+AZA and CSA+AZA groups, respectively.
TABLE 36 Time to BPAR for TAC+AZA vs. CSA+AZA
Study
TAC+AZA CSA+AZA
Statistical test
(p-value)n BPAR
Mean time to BPAR,
days (SD) n BPAR
Mean time to BPAR,
days (SD)
Baboolal 200282 27 8 35 (13) 24 5 59 (38) NR
Campos 200283 85 29 14.5 (47.3) 81 31 12.0 (21.0) NRa
NR, not reported.
a Rejection features were comparable in each treatment group.
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l Graft loss is reported for 10 trials.76,79,80,83,84,88,99,100,104,148 Results were pooled for the 0.5-, 1- and 2-year
time points. The pooling of trials reported by Margreiter et al.84 and Charpentier et al.148 at 0.5 years
give an OR of 0.45 (95% CI 0.24 to 0.84), which is statistically significant in favour of TAC.84,148
The 1-year time point, where seven studies76,83,84,88,99,100,104 are pooled, generates an OR of 1.18 and a
95% CI 0.72 to 1.93, which is not statistically significant, and this remains the case at 5 years.
l Graft function was measured and reported by four studies,75,80,84,98 with effects measured from 0.08 to
3 years. No meta-analysis is possible, as the results are presented in a number of ways and are not
appropriate for pooling. In general, there is some variation between arms with large SDs, for example
results presented by Margreiter et al.84 at 1 year imply an improved GRF for TAC as opposed to CSA
[68.9ml/minute/1.73 m2 (SD 23.2ml/minute/1.73m2) and 61.8ml/minute/1.73m2 (SD 23.2ml/minute/
1.73m2), respectively], which is in contrast with Van Duijnhoven et al. 2002, who report 60.2 ml/
minute/1.73m2 (range 11.5–86.2ml/minute/1.73 m2) and 64.9ml/minute/1.73 m2 (range 29.5–84.5ml/
minute/1.73m2), respectively. This conflict between studies is seen at all time points.
l All time points from 0.08 to 4 years reveal ORs of < 1 for BPAR, indicating that TAC is more effective
than CSA in reducing this outcome. BPAR outcomes were reported by nine studies76,81–84,88,99,100,104 at
1 year, where pooled analysis gives an OR of 0.50 and a 95% CI of 0.39 to 0.64. Low heterogeneity is
indicated across the studies at year 1 (I2= 8.1%). Mayer et al.88 report BPAR at 4 years, where the
beneficial effect of TAC appears to be maintained (OR 0.38, 95% CI 0.25 to 0.57).
l Four trials82,84,100,148 report on severity of BPAR from 6 months to 2 years. For the studies by Baboolal
et al.82 and Hardinger et al.,100 at 1 year, no participants with BPAR experienced Banff grade III for
either arm.82,100 At 6 months, Charpentier et al.148 report the proportion of people with BPAR classified
as Banff III as 10.7% for TAC and 15.4% for CSA and, by 2 years, Margreiter et al.84 report 6.4% and
16.8% of people with BPAR experiencing Banff III, for TAC and CSA, respectively.
l Time to first BPAR is reported by only two studies, with contrasting results. However, the difference
between arms for Campos et al.83 is not statistically significant (p= 0.6631). The results reported by
Baboolal et al.82 indicate that BPAR is achieved more quickly for participants receiving TAC (35 days,
SD 13 days) rather than CSA (59 days, SD 38 days).
CSA +MMF vs. CSA+AZA
Seven studies77,78,86,89,101,104,138 report on this combination of immunosuppressive therapies, with a follow-up
of 5 years. All outcomes have been reported other than HRQoL.
Mortality
Seven studies77,78,86,89,101,104,138 report on mortality for CSA+MMF compared with CSA+AZA. Pooling
results of five studies78,86,101,104,138 for this combination imply no difference between arms at 1 year, with no
evidence of heterogeneity across studies (Table 37 and Figure 18). The ORs switch from > 1 to < 1 for the
pooled results at 1 and 3 years; however, the CIs cross ‘OR= 1’ in both cases, suggesting that there may
TABLE 37 Mortality for CSA+MMF vs. CSA+AZA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Sollinger 1995,77 Tricontinental 1996,89
Remuzzi 2007101
0.5 3 1.00 0.42 to 2.35 0 0
Sadek 2002,86 Tuncer 2002,78 Merville 2004,138
Remuzzi 2007,101 Weimer 2006104
1 5a 1.19 0.47 to 3.02 0 0
Tricontinental 1996,89 Tuncer 200278 3 2 0.56 0.26 to 1.23 0 0
5 1 0.73 0.15 to 3.50 NA NA
NA, not applicable.
a Two trials excluded from pooled analysis as a result of no deaths in both arms.
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be no difference between MMF and AZA (OR 1.19, 95% CI 0.47 to 3.02 and OR 0.56, 95% CI 0.26 to
1.23, respectively). The study reported by Tuncer et al.78 provides data at 5 years, which also indicates no
preference for either MMF or AZA (OR 0.73, 95% CI 0.15 to 3.50).
Graft loss
Five studies77,86,89,104,138 report on graft loss, with results pooled at 0.5- and 1-year time points (Table 38
and Figure 19). However, the 0.5-year time point has only two studies77,89 and a substantial level of
heterogeneity (I2= 72.2%), therefore the OR of 0.58 (95% CI 0.04 to 0.59), which indicates that MMF is
more effective at reducing graft loss, must be treated with caution.201 The results for 1 year suggest no
difference between arms (OR 0.76, 95% CI 0.38 to 1.50). Merville et al.138 appear to show more of an
effect in favour of MMF; however, the population is much smaller than that for the Tricontinental study89
and Sadek et al.86 and Weimer et al.104 found no evidence of graft loss in either arm.
Graft function
Only Merville et al.138 reported on this outcome. At both 6 months and 1 year there was no statistically
significant difference in mean GRF (0.5 years; p= 0.7236 and 1 year; p= 0.6584) (Table 39).
TABLE 38 Pooled results of graft loss for CSA+MMF vs. CSA+AZA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Sollinger 1995,77 Tricontinental 199689 0.5 2 0.58 0.04 to 0.59 72.2 1.2684
Tricontinental 1996,89 Sadek 2002,86
Merville 2004,138 Weimer 2006104
1 4 0.76 0.38 to 1.50 32.3 0.1203
Tricontinental 199689 3 1 0.94 0.51 to 1.71 NA NA
NA, not applicable.
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Biopsy-proven acute rejection
Six studies77,86,89,101,104,138 report on BPAR. Unlike mortality and graft loss, BPAR analysis reveals that MMF is
more beneficial than AZA at 0.5 and 1 year (0.5 years OR 0.50, 95% CI 0.35 to 0.72; 1 year OR 0.47,
95% CI 0.36 to 0.62) (Table 40 and Figure 20).104
Severity of biopsy-proven acute rejection
Two studies were available for 0.5 years77,89 and one study138 for 1 year, although sample numbers are low
for this study (Table 41). Overall, at 0.5 years the more severe classification of Banff III appears to be more
likely in the AZA arm for people with BPAR (CSA 9.1%, AZA 15.9% for Sollinger et al.;77 CSA 5.9%, AZA
11.9% for the Tricontinental group 199689).
Time to biopsy-proven acute rejection
Insufficient data are provided for analysis on this outcome. Merville et al.138 report 48.5 days for MMF and
43.7 days for AZA.138
TABLE 39 Graft function for CSA+MMF vs. CSA+AZA
Study Time MMF, mean (SD) AZA, mean (SD) MD 95% CI p-value (t-test)
Merville 2004138 0.5 60.4 (17.3) 58.5 (27.1) 0.08 –0.38 to 0.55 0.72
1 61.3 (15.8) 63.1 (16.8) –0.11 –0.58 to 0.35 0.66
Note
All methods either reported as CRC or Cockcroft–Gault unless otherwise stated.
TABLE 40 Pooled results of BPAR for CSA+MMF vs. CSA+AZA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Sollinger 1995,77 Tricontinental 1996,89
Remuzzi 2007101
0.5 3 0.50 0.35 to 0.72 35.1 0.0361
Tricontinental 1996,89 Sadek 2002,86
Merville 2004,138 Weimer 2006104
1 4 0.47 0.36 to 0.62 0.0 0.00
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Summary of results for CSA +MMF vs. CSA +AZA
l Seven studies77,78,86,101,104,138,202 report on mortality for CSA+MMF vs. CSA+AZA. Pooling results of five
studies78,86,101,104,138 for this combination imply no difference between arms at 1 year, with no evidence
of heterogeneity across studies. The ORs switch from > 1 to < 1, for the pooled results at 1 and
3 years; however, the CIs cross ‘OR= 1’ in both cases, suggesting that there may be no difference
between MMF and AZA (OR 1.19, 95% CI 0.47 to 3.02; and 0.56, 95% CI 0.26 to 1.23). The study
reported by Tuncer et al.78 provides data at 5 years, which also indicate no preference for either MMF
or AZA (OR 0.73, 95% CI 0.15 to 3.50).
l Five studies77,86,104,138,202 report on graft loss, with results pooled at 0.5- and 1-year time points.
However, the 0.5-year time point has only two studies77,89 and a substantial level of heterogeneity
(I2= 72.2%); therefore, the OR of 0.58 (95% CI 0.04 to 0.59), which indicates that MMF is more
effective at reducing graft loss, must be treated with caution.201 The results for 1 year suggest no
difference between arms (OR 0.76, 95% CI 0.38 to 1.50). The study by Merville et al.138 appears to
show more of an effect in favour of MMF; however, the population is much smaller than that for the
Tricontinental study89 and Sadek et al.86
l Only Merville et al.138 reported on this outcome: at 6 months the mean GRF was greater for the MMF
arm; however, this was reversed at 1 year, when AZA had greater GRF.138 There is no significant
difference between arms (0.5 years, p= 0.7236; 1 year, p= 0.6584).
l Six studies report on BPAR.77,86,101,104,138,202 Unlike mortality and graft loss, BPAR analysis reveals that
MMF is more beneficial than AZA at 0.5 and 1 year [0.5 years, OR 0.50 (95% CI 0.35 to 0.72); 1 year,
OR 0.47 (95% CI 0.36 to 0.62)].
l Two studies were available for 0.5 years77,89 and one study138 for 1 year. Overall, at 0.5 years the more
severe classification of Banff III appears to be more likely in the AZA arm for people with BPAR (CSA
9.1%, AZA 15.9% for Sollinger et al.;77 CSA 5.9%, AZA 11.9% for the Tricontinental group89).
Insufficient data are provided for analysis on time to BPAR. Merville et al.138 report a slightly more rapid
rate of 48.5 days for MMF and 43.7 days for AZA.
TAC+MMF vs. CSA+AZA
Two studies129,139 compared these combinations. GRF and time to BPAR are not reported.
Mortality
Wlodarczyk et al.139 report mortality at 0.5 years and Vacher-Caponat et al.129 report at 1 year (Table 42).
At 1 year, there are twice as many deaths for TAC+MMF as for CSA+AZA; however, although the OR is
> 1, the wide 95% CIs imply no statistically significant difference between arms.
Graft loss
As with mortality, there is only one study for each time point of 0.5 years139 and 1 year129 (Table 43).
The wide CIs highlight the low precision and indicate no difference between arms.
TABLE 41 Severity of BPAR at 6 months for CSA+MMF vs. CSA+AZA
Study
Time point
(years)
CSA+MMF CSA+AZA
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Sollinger 199577 0.5 167 33 18 12 3 166 63 29 24 10
Tricontinental 199689 0.5 173 34 16 16 2 166 59 26 26 7
aMerville 2004138 1 37 5 4 1 0 34 7 2 3 2
a Incidences of BPAR were reported.
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Biopsy-proven acute rejection for TAC+MMF vs. CSA +AZA
Only two studies129,139 have reported BPAR: one study at 0.5 years139 and one study at the 1-year time
point129 (Table 44). In both cases the OR is < 1, indicating that TAC+MMF is associated with lower odds
of BPAR (OR 0.64, 95% CI 0.42 to 0.98; OR 0.35, 95% CI 0.15 to 0.83, respectively).
Severity of biopsy-proven acute rejection
This outcome is reported only by Vacher-Caponat et al.,129 with no participants experiencing Banff II and III
in the TAC+MMF arm, but with 14.3% and 4.8% reported in the CSA+AZA arm, respectively (Table 45).
TABLE 42 Mortality for TAC+MMF vs. CSA+AZA
Study Time point (years) TAC+MMF, n/N (%) CSA+AZA, n/N (%) OR 95% CI
Wlodarczyk 2005139 0.5 4/243 (1.6) 4/246 (1.6) 1.01 0.25 to 4.09
Vacher-Caponat 2012129 1 4/143 (2.8) 2/146 (1.4) 2.07 0.37 to 11.49
TABLE 43 Graft loss for TAC+MMF vs. CSA+AZA
Study Time point (years) TAC+MMF, n/N (%) CSA+AZA, n/N (%) OR 95% CI
Wlodarczyk 2005139 0.5 12/243 (5) 16/246 (7) 0.75 0.35 to 1.61
Vacher-Caponat 2012129 1 10/143 (7) 6/146 (4) 1.75 0.62 to 4.96
Note
All percentages calculated by PenTAG.
TABLE 44 Biopsy-proven acute rejection for TAC+MMF vs. CSA+AZA
Study Time point (years) TAC+MMF, n/N (%) CSA+AZA, n/N (%) OR 95% CI
Wlodarczyk 2005139 0.5 46/243 (19) 66/246 (27) 0.6368 0.41 to 0.98
Vacher-Caponat 2012129 1 8/143 (6) 21/146 (14) 0.3527 0.15 to 0.82
Note
All percentages calculated by PenTAG.
TABLE 45 Severity of BPAR at 1 year for TAC+MMF vs. CSA+AZA
Study
Time point
(years)
TAC+MMF CSA+AZA
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
aVacher-Caponat 2012129 1 143 8 9 0 0 146 21 19 3 1
a Recorded Banff I includes three and five borderline episodes in TAC+MMF and CSA+AZA groups, respectively.
Note
Although BPAR summarises the number of first BPARs, the Banff I–III grading records the number of episodes.
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Summary for TAC +MMF vs. CSA+AZA
l Wlodarczyk et al.139 report mortality at 0.5 years and Vacher-Caponat et al.129 report mortality at 1 year.
In both cases the OR is > 1, indicating that TAC+MMF is associated with greater odds of mortality;
however, the 95% CIs cross ‘OR= 1’, implying no statistically significant difference between arms.
l Only one study reporting on graft loss at 0.5 years139 and 1 year.129 No significant difference is evident
between treatments.
l Only two studies have reported BPAR: one study at 0.5 years139 and one study at the 1-year time
point.129 In both cases the OR is < 1, indicating that TAC+MMF is associated with lower odds of BPAR
(OR 0.64, 95% CI 0.42 to 0.98; OR 0.35, 95% CI 0.15 to 0.83, respectively).
l Severity of BPAR is reported by only one study,129 with the greater proportion of people experiencing
Banff II and III in the CSA+AZA arm.
TAC+MMF vs. CSA+MMF
This combination of immunosuppressive therapy was identified in five RCTs,51,102,103,130,203 with all outcomes
other than HRQoL reported. The RCT reported by Grinyo et al.51 is also known as the SYMPHONY study.
Mortality
The effect estimate of five pooled studies51,102,103,130,203 at 1 year suggests that TAC+MMF is associated
with higher odds of mortality (OR 1.62, 95% CI 0.77 to 3.44; Table 46 and Figure 21). However, although
there is no evidence of heterogeneity across studies (I2= 0.0%), the CIs are wide and cross ‘OR= 1’,
indicating low precision and a lack of statistical significance. Results for 2 years and 5 years also
demonstrate no statistically significant difference between treatments.
TABLE 46 Mortality for TAC+MMF vs. CSA+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Hernández 2007,130 Rowshani 2006,103
Kumar 2009,203 Grinyo 2009,51
Zadrazil 2012102
1 5a 1.62 0.77 to 3.44 0.0 0.0
Hernández 2007130 2 1 2.11 0.61 to 7.32 NA NA
Kumar 2009203 5 1 0.87 0.31 to 2.47 NA NA
NA, not applicable.
a One trial excluded from pooled analysis due to no deaths in either arm.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
103
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
N
o
te
: w
ei
g
h
ts
 a
re
 f
ro
m
 r
an
d
o
m
-e
ff
ec
ts
 a
n
al
ys
is
1 
ye
ar
H
er
n
án
d
ez
 2
00
71
30
R
o
w
sh
an
i 2
00
61
03
K
u
m
ar
 2
00
92
03
G
ri
n
yo
 2
00
95
1
Za
d
ra
zi
l 2
01
21
02
Su
b
to
ta
l (
I 2
 =
 0
.0
%
, p
 =
 0
.5
47
)
2 
ye
ar
s
H
er
n
án
d
ez
 2
00
71
30
5 
ye
ar
s
K
u
m
ar
 2
00
92
03
St
u
d
y
2/
80
2/
63
1/
50
7/
39
9
0/
29
12
/6
21
4/
80
4/
80
9/
50
9/
50
Ev
en
ts
,
co
n
tr
o
l
17
.1
0
9.
59
11
.8
2
61
.4
9
0.
00
10
0.
00
10
0.
00
10
0.
00
10
0.
00
10
0.
00
% w
ei
g
h
t
1.
52
 (
0.
25
 t
o
 9
.3
5)
0.
49
 (
0.
04
 t
o
 5
.5
7)
5.
44
 (
0.
61
 t
o
 4
8.
40
)
1.
58
 (
0.
61
 t
o
 4
.1
2)
(E
xc
lu
d
ed
)
1.
62
 (
0.
77
 t
o
 3
.4
4)
2.
11
 (
0.
61
 t
o
 7
.3
2)
2.
11
 (
0.
61
 t
o
 7
.3
2)
0.
87
 (
0.
31
 t
o
 2
.4
7)
0.
87
 (
0.
31
 t
o
 2
.4
7)
O
R
 (
95
%
 C
I)
3/
80
1/
63
5/
50
11
/4
01
0/
24
20
/6
18
8/
80
8/
80
8/
50
8/
50
Ev
en
ts
,
tr
ea
tm
en
t
Fa
vo
u
rs
 T
A
C
Fa
vo
u
rs
 C
SA
0.
02
07
1
48
.4
FI
G
U
R
E
21
Fo
re
st
p
lo
t:
m
o
rt
al
it
y
fo
r
TA
C
+
M
M
F
vs
.C
SA
+
M
M
F.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
104
Graft loss
Graft loss is reported for five studies.51,102,103,130,153,203 The OR for pooled results at 1 year and 2 years (1.43
and 1.63, respectively) implies greater odds of graft loss for TAC+MMF; however, the CIs cross ‘OR= 1’,
indicating no difference between arms (Table 47 and Figure 22).
Kumar et al.203 report graft loss up to 5 years, with similar results of no difference between arms.
TABLE 47 Graft loss for TAC+MMF vs. CSA+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Rowshani 2006,103 Ulsh 1999,153 Kumar
2009,203 Grinyo 2009,51 Zadrazil 2012102
1 5a 1.43 0.37 to 5.52 11.4 0.17
Hernández 2007,130 Anil Kumar 2008122 2 2 1.63 0.73 to 3.65 0.0 0.0
Anil Kumar 2008122 3 1 1.11 0.45 to 2.75 NA NA
4 1 1.10 0.46 to 2.62 NA NA
5 1 1.19 0.53 to 2.69 NA NA
NA, not applicable.
a One trial excluded from pooled analysis as a result of no graft loss in either arm.
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Graft function
Graft function as CRC is reported by three studies51,103,130 up to 3 years (Table 48 and Figure 23). Pooling of
results for 1- and 2-year data demonstrated a statistically significant difference in GRF in favour of TAC
(WMD 4.22ml/minute/1.73m2, 95% CI 1.23 to 7.20ml/minute/1.73 m2; WMD 5.75, 95% CI 2.76
to 8.74ml/minute/1.73 m2, respectively). There is low evidence of heterogeneity across the 1-year
studies (I2= 9.8%).
TABLE 48 Graft function for TAC+MMF vs. CSA+MMF
Study
Time point
(years) Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
Hernández 2007130 0.5 1 4.00 –2.14 to 10.14 NA NA
Hernández 2007,130
Rowshani 2006,103
Grinyo 200951
1 3 4.22 1.23 to 7.20 9.8 0.77
Hernández 2007,130
Grinyo 200951
2 2 5.75 2.76 to 8.74 0.0 0.0
Grinyo 200951 3 1 4.60 1.35 to 7.85 NA NA
NA, not applicable.
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Biopsy-proven acute rejection for TAC +MMF vs. CSA +MMF
Biopsy-proven acute rejection was reported by five studies.51,102,103,153,203 One-year outcomes provided by
four of these studies51,103,153,203 were pooled (Table 49 and Figure 24). The study at 0.5 years by Kumar
et al.203 indicates that lower odds of BPAR are associated with TAC. This is in agreement with the pooled
results at 1 year, although some heterogeneity is noted across studies (OR 0.59, 95% CI 0.37 to 0.94;
I2= 19.3%). The study reported by Hernández et al.130 at 2 years does not demonstrate a statistical
difference between arms (OR 1.22, 95% CI 0.51 to 2.91).
Severity of biopsy-proven acute rejection
Two studies51,130 report severity of BPAR separately at 1 and 2 years (Table 50). For year 1, results indicate
that for people with BPAR, TAC+MMF and CSA+MMF have a similar proportion experiencing Banff III
(TAC+MMF 7.8%; CSA+MMF 7.1%).51 The study by Hernández et al.130 indicates no clear difference for
between arms for all three classifications.130
Time to biopsy-proven acute rejection
Mean time to BPAR was reported by Ulsh et al.153 in favour of TAC (Table 51).
Summary of results for TAC +MMF vs. CSA +MMF
l The effect estimate of five pooled studies51,102,103,130,203 at 1 year suggests that TAC+MMF is associated
with higher odds of mortality (OR 1.62, 95% CI 0.77 to 3.44). However, although there is no evidence
of heterogeneity across studies (I2= 0.0%), the CIs are wide and cross ‘OR= 1’, indicating low precision
and a lack of statistical significance. Results for 2 years and 5 years also demonstrate no statistically
significant difference between treatments.
l Graft loss is reported for five studies.51,102,103,122,153 The OR for pooled results at 1 and 2 years (1.43 and
1.63, respectively) implies greater odds of graft loss for TAC+MMF; however, the CIs cross ‘OR= 1’,
indicating no statistically significant difference between arms. The lack of difference remains at 5 years
for the study reported by Kumar et al.203
l GRF is reported by three studies up to 3 years.51,103,130 Pooling of results for 1- and 2-year data
demonstrated a statistically significant difference in GRF in favour of TAC (WMD 4.22ml/minute/1.73m2,
95% CI 1.23 to 7.20ml/minute/1.73m2; WMD 5.75ml/minute/1.73m2, 95% CI 2.76 to 8.74ml/minute/
1.73m2, respectively).
l BPAR was reported by five studies,51,102,103,122,153 with four studies51,103,122,153 reporting at 1 year as being
suitable for meta-analysis. The study at 0.5 years by Kumar et al.203 indicates that lower odds of BPAR
are associated with TAC. This is in agreement with the pooled results at 1 year, although some
heterogeneity is noted across studies (OR 0.59, 95% CI 0.37 to 0.94; I2= 19.3%). Two studies51,130
report severity of BPAR separately at 1 year and 2 years with no clear difference in proportion of
people with Banff III grading.
l Time to BPAR was reported by Ulsh et al.,153 with a difference in favour of TAC of 88.7 days (p= 0.0001).
TABLE 49 Biopsy-proven acute rejection for TAC+MMF vs. CSA+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Grinyo 200951 0.5 1 0.45 0.31 to 0.67 NA NA
Ulsh 1999,153 Rowshani 2006,103 Kumar 2009,203
Grinyo 200951
1 4 0.59 0.37 to 0.94 19.3 0.06
Hernández 2007130 2 1 1.22 0.51 to 2.91 NA NA
NA, not applicable.
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TAC+MMF vs. TAC-PR +MMF
Four studies105,123,141,204 are reported investigating all outcomes other than time to BPAR and HRQoL for
TAC (immediate release)+MMF vs. TAC-PR (prolonged release)+MMF.
Mortality
Four studies105,123,141,204 report on mortality: two studies report at 0.5 years105,123 and two studies report at
1 year141,204 (Table 52 and Figure 25). At each time point, one of the studies had no deaths in either arm
and both ORs indicate no statistical difference (0.5 years, OR 0.65, 95% CI 0.23 to 1.84; 1 year, OR 0.78,
95% CI 0.31 to 2.01).
TABLE 50 Severity of BPAR at 1 year for TAC+MMF vs. CSA+MMF
Study
Time point
(years)
TAC+MMF CSA+MMF
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
aGrinyo 200951 1 399 102 55 39 8 401 42 24 15 3
Hernández 2007130 2 80 13 7 4 2 80 11 6 4 1
a Missing classification: six and 20 BPARs in TAC+MMF and CSA+MMF groups, respectively.
TABLE 51 Time to BPAR for TAC+MMF vs. CSA+MMF
Study
TAC+MMF CSA+MMF
Statistical test (p-value)n BPAR
Mean time to BPAR,
days (SD) n BPAR
Mean time to BPAR,
days (SD)
Ulsh 1999153 30 4 88.7 (32.3) 30 4 42 (35.3) NS
NS, not significant.
TABLE 52 Mortality for TAC+MMF vs. TAC-PR+MMF
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Albano 2013,123 Oh 2014105 0.5 2a 0.65 0.23 to 1.84 NA NA
Krämer 2010,204 Tsuchiya 2013141 1 2a 0.78 0.31 to 2.01 NA NA
NA, not applicable.
a One trial excluded from pooled analysis as a result of no deaths in either arm.
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Graft loss
Four studies105,123,141,204 report on graft loss: two studies report at 0.5 years105,123 and two studies report at
1 year.141,204 As illustrated by the forest plot (Table 53 and Figure 26), no clear benefit is seen for either
immediate-release or TAC-PR with regard to graft loss at 6 months and 1 year. ORs for both are identical
and < 1; however, CIs cross ‘OR= 1’, indicating no statistical difference between arms (OR 0.83, 95% CIs
0.30 to 2.30 and 0.47 to 1.47).
TABLE 53 Graft loss for TAC+MMF vs. TAC-PR+MMF
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Oh 2014,105 Albano 2013123 0.5 2 0.83 0.30 to 2.30 0.0 0
Krämer 2010,204 Tsuchiya 2013141 1 2a 0.83 0.47 to 1.47 NA NA
NA, not applicable.
a One trial excluded from pooled analysis as a result of no graft loss in either arm.
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Graft function
Graft function is reported by three studies:123,141,204 one study123 for 0.5 years and two studies141,204 for
1 year (Table 54 and Figure 27). Pooling of results at 1 year demonstrated no statistically significant
difference in GRF (WMD 0.21ml/minute/1.73m2, 95% CI –2.10 to 2.53ml/minute/1.73 m2); however, the
single study by Albano et al.123 suggests immediate-release TAC to be more effective than TAC-PR for GRF
(WMD 1.90ml/minute/1.73m2, 95% CI to 5.40ml/minute/1.73 m2).
TABLE 54 Graft function for TAC+MMF vs. TAC-PR+MMF
Study
Time point
(years) Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
Albano 2013123 0.5 1 1.90 –1.60 to 5.40 NA NA
Krämer 2010,204 Tsuchiya 2013141 1 2 0.21 –2.10 to 2.53 0.0 0.0
NA, not applicable.
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Biopsy-proven acute rejection for TAC +MMF vs. TAC-PR +MMF
Three studies105,123,204 report BPAR at 0.5 years and two studies141,204 report at 1 year (Table 55 and Figure 28).
Pooling of results at both time points shows no significant difference between arms (OR 1.37 95% CI
1.00 to 1.87; OR 1.03, 95% CI 0.48 to 2.17). Furthermore, moderate heterogeneity exists across studies
(I2= 34.8% and 44.4%).201
Severity of biopsy-proven acute rejection
Two studies123,204 report severity of BPAR, both of which indicate that, for people with BPAR, the severity
may be reduced with immediate TAC (Table 56).
Summary for TAC +MMF vs. TAC-PR +MMF
l Four studies105,123,141,204 report on mortality: two studies report at 0.5 years123,204 and two studies report
at 1 year.105,141 At each time point, one of the studies had no deaths in either arm and both ORs
indicate no statistical difference (0.5 years, OR 0.65, 95% CI 0.23 to 1.84; 1 year, OR 0.78, 95% CI
0.31 to 2.01).
l Four studies105,123,141,204 report on graft loss: two studies report at 0.5 years105,123 and two studies report at
1 year.141,204 No clear benefit is seen for either immediate-release TAC or TAC-PR with regard to graft loss
at 6 months and 1 year. ORs for both are identical and < 1; however, CIs cross ‘OR= 1’, indicating no
statistical difference between arms (OR 0.83, 95% CI 0.30 to 2.30; and 95% CI 0.47 to 1.47). GRF is
reported by three studies:123,141,205 one study for 0.5 years123 and two studies for 1 year.141,205 Pooling of
results at 1 year demonstrated no statistically significant difference in GRF (WMD 0.21ml/minute/
1.73m2, 95% CI –2.10 to 2.53ml/minute/1.73m2); however, the single study by Albano et al.123
suggests that TAC is more effective than TAC-PR for GRF (WMD 1.90ml/minute/1.73m2, 95% CI
1.70 to 2.10ml/minute/1.73m2).
l Three studies105,123,204 report BPAR at 0.5 years and two studies report141,204 at 1 year. Pooling of results
at both time points shows no significant difference between arms (OR 1.37, 95% CI 1.00 to 1.87;
OR 1.03, 95% CI 0.48 to 2.17).
l Two studies123,204 report severity of BPAR, both of which indicate that, for people with BPAR, the
severity may be reduced with immediate.
MMF+ TAC vs. MPS+ TAC
As only one trial106 reported outcomes for this combination, results are presented in summary tables
(Tables 57 and 58).
In contrast with other outcomes, GRF displays a significant difference in favour of MPS at 0.5 years and
1 year (0.5 years, MD –1.317; 1 year, MD –1.9019; p< 0.0001) (see Table 58). This effect is lost at later
time points.
Overall, there appears to be no discernible difference between arms, as all CIs are wide and cross ‘OR= 1’.
Time to BPAR is not reported.
Summary for MMF + CSA vs. MPS + TAC
Only one study106 was identified for this combination. No difference was identified between interventions,
other than for GRF, where a statistically significant difference in favour of MPS at 0.5 years and 1 year
(p< 0.0001) was noted. This effect is lost at later time points.
TABLE 55 Biopsy-proven acute rejection for TAC+MMF vs. TAC-PR+MMF
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Krämer 2010,204 Oh 2014,105 Albano 2013123 0.5 3 1.37 1.00 to 1.87 34.8 0.04
Krämer 2010,204 Tsuchiya 2013141 1 2 1.03 0.48 to 2.17 44.4 0.16
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
117
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
N
o
te
: w
ei
g
h
ts
 a
re
 f
ro
m
 r
an
d
o
m
-e
ff
ec
ts
 a
n
al
ys
is
0.
5 
ye
ar
s
K
rä
m
er
 2
01
02
04
O
h
 2
01
41
05
A
lb
an
o
 2
01
31
23
 (
lo
w
 T
ac
)
Su
b
to
ta
l (
I 2
 =
 0
.0
%
, p
 =
 0
.5
44
)
1 
ye
ar
K
rä
m
er
 2
01
02
04
Ts
u
ch
iy
a 
20
13
14
1
Su
b
to
ta
l (
I 2
 =
 4
4.
4%
, p
 =
 0
.1
80
)
St
u
d
y
50
/3
36
0/
29
31
/3
02
81
/6
67
59
/3
31
5/
50
64
/3
81
Ev
en
ts
,
co
n
tr
o
l
58
.7
9
1.
08
40
.1
3
10
0.
00
71
.6
7
28
.3
3
10
0.
00
% w
ei
g
h
t
1.
32
 (
0.
88
 t
o
 1
.9
8)
7.
25
 (
0.
36
 t
o
 1
46
.6
4)
1.
38
 (
0.
84
 t
o
 2
.2
5)
1.
37
 (
1.
00
 t
o
 1
.8
7)
0.
81
 (
0.
53
 t
o
 1
.2
2)
1.
88
 (
0.
58
 t
o
 6
.0
7)
1.
03
 (
0.
48
 t
o
 2
.1
7)
O
R
 (
95
%
 C
I)
62
/3
31
3/
31
42
/3
09
10
7/
67
1
50
/3
36
9/
52
59
/3
88
Ev
en
ts
,
tr
ea
tm
en
t
Fa
vo
u
rs
 T
A
C
Fa
vo
u
rs
 T
A
C
-P
R
0.
00
68
2
1
14
7
FI
G
U
R
E
28
Fo
re
st
p
lo
t:
B
PA
R
fo
r
TA
C
+
M
M
F
vs
.
TA
C
-P
R
+
M
M
F.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
118
TABLE 56 Severity of BPAR for TAC+MMF vs. TAC-PR+MMF
Study
Time point
(years)
TAC+MMF TAC-PR+MMF
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Albano 2013123 0.5 309 42 24 18 0 302 31 13 15 3
aKrämer 2010204 0.5 336 50 27 23 0 331 59 31 23 5
a Assumed incidences of BPAR were reported.
TABLE 57 Summary of outcomes for MMF+ TAC vs. MPS+ TAC
Study Outcome Time point (years) MMF MPS OR 95% CI
Ciancio
2008106
Mortality, n/N (%) 1 0/75 (0) 1/75 (1) NA NA
4 2/75 (3) 3/75 (4) 0.6575 0.1067 to 4.0524
Graft loss, n/N (%) 1 2/75 (3) 2/75 (3) NA NA
4 6/75 (8) 8/75 (11) 0.5059 0.1768 to 1.4476
BPAR, n/N (%) 1 2/75 (3) 7/75 (9) 0.2661 0.0534 to 1.3259
2 8/75 (11) 7/75 (9) 1.1599 0.3983 to 3.3783
4 14/75 (19) 13/75 (17) 1.0946 0.4756 to 2.5192
Banff classification, n/BPAR
I 1 1/2 6/7 NA
II 1/2 0/7
III 0/2 1/7
NA, not applicable.
TABLE 58 Graft function for MMF+ TAC vs. MPS+ TAC
Study Time point (years) MMF (SE) MPS (SE) MD 95% CI p-value (t-test)
Ciancio 2008106 0.5 63.3 (2.1) 66.0 (2.0) –1.3167 –1.67 to 0.96 < 0.0001
1 62.10 (2.0) 66.0 (2.1) –1.9019 –2.29 to 1.52 < 0.0001
2 63.7 (2.2) 64.10 (2.4) –0.1737 –0.49 to 0.15 0.2891
3 71.3 (3.0) 69.8 (2.7) 0.5256 0.20 to 0.85 0.0016
SE, standard error.
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MMF+ CSA vs. MPS+ CSA
Only one trial using this combination is reported by Salvadori et al.;124 therefore, all outcomes are included
in a summary table up to 1 year (Table 59). Overall, the OR indicates that MPS is associated with lower
mortality (OR 4.12, 95% CI 0.46 to 37.14); however, the CIs are wide and the effect is not statistically
significant. Graft loss initially has better odds for MPS at 0.5 years; however, this reverses at 1 year. Again,
CIs imply no statistical significance. BPAR and severity of BPAR show no difference between interventions.
GRF and time to BPAR are not reported.
Summary for MMF + CSA vs. MPS + CSA
l Only one trial reported by Salvadori et al.124 uses this combination. GRF and time to BPAR are not
reported. All other results indicate no significant difference between MMF and MPS.
BEL +MMF vs. CSA +MMF
Three studies60,206,207 report on this combination of therapies. Time to BPAR and HRQoL are not reported
Mortality
Three studies60,125,206 report 1-year outcomes, with the Belatacept Evaluation of Nephroprotection and
Efficacy as First-line Immunosuppression Trial (BENEFIT)60 and the BENEFIT–Extended Criteria Donors
(BENEFIT-EXT)142 providing data for up to 5 years. The ORs generally fall at < 1 for all time points,
indicating that BEL has a lower association with mortality than CSA (Table 60 and Figure 29). However,
the CIs indicate that this is not statistically significant.
TABLE 59 Summary of outcomes for MMF+CSA vs. MPS+CSA
Study Outcome Time MMF MPS OR 95% CI
Salvadori 2004124 Mortality, n/N (%) 0.5 2/210 (1) 1/213 (0) 2.04 0.18 to 22.65
1 4/210 (2) 1/213 (0) 4.12 0.45 to 37.14
Graft loss, n/N (%) 0.5 9/210 (4) 7/213 (3) 1.32 0.48 to 3.61
1 6/210 (3) 15/213 (7) 0.39 0.15 to 1.02
BPAR, n/N (%) 0.5 48/210 (23) 46/213 (22) 1.08 0.68 to 1.70
1 51/210 (24) 48/213 (22) 1.10 0.70 to 1.73
Banff Classification, n/BPAR
I 1 31/48 33/46 NA
II 14/48 12/46
III 3/48 2/46
NA, not applicable.
TABLE 60 Mortality for BEL+MMF vs. CSA+MMF
Study Time point (years) Trials OR 95% CI I2 (%)
Vincenti 2005,125 BENEFIT 2010,60 BENEFIT-EXT 2010142 1 3 0.47 0.20 to 1.08 0.0
BENEFIT 2010,60 BENEFIT-EXT 2010142 2 2 0.76 0.41 to 1.41 0.0
3 2 0.80 0.49 to 1.29 0.0
5 2 0.71 0.40 to 1.29 13.85
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Graft loss
The OR for graft loss is also reported by three studies60,125,206 up to 5 years. Pooled results indicate that BEL
may be preferable to CSA, although the results are not statistically significant (1 year, OR 0.74, 95% CI
0.42 to 1.31) (Table 61 and Figure 30). However, at 5 years, there may be more confidence that this effect
is true (OR 0.40, 95% CI 0.19 to 0.87).
TABLE 61 Graft loss for BEL+MMF vs. CSA+MMF
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Vincenti 2005,125 BENEFIT 2010,60
BENEFIT-EXT 2010142
1 3 0.74 0.42 to 1.31 0.0 0.0
BENEFIT 2010,60 BENEFIT-EXT 2010142 2 2 0.85 0.49 to 1.49 0.0 0.0
3 2 0.79 0.48 to 1.32 0.0 0.0
5 2 0.40 0.19 to 0.87 0.0 0.0
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Graft function
Graft function is reported by three studies60,125,206 up to 5 years (Table 62 and Figure 31). The results must
be treated with caution because of substantial heterogeneity across studies, which may be caused by
variations in methods of calculation and measurement of GRF (I2= 73.6–91.2%). Pooling of results for
1- and 3-year data demonstrated a statistically significant difference for GRF in favour of BEL (WMD
7.83ml/minute/1.73 m2, 95% CI 1.57 to 4.10ml/minute/1.73 m2, and WMD 16.08ml/minute/1.73m2,
95% CI 5.59 to 26.56ml/minute/1.73m2, respectively).
Biopsy-proven acute rejection
The results for BPAR indicate substantial heterogeneity for the 1-, 2- and 3-year time points (I2= 58.7%,
38.4% and 62.2%, respectively) (Table 63).60,206,207 Overall, participants in the CSA arm appear to be less
likely to experience BPAR at between 1 and 5 years, as opposed to those in the BEL arm (1 year,
OR 1.53, 95% CI 0.78 to 3.02).
Severity of biopsy-proven acute rejection
Three studies60,125,142 report severity of BPAR at 1 year (Table 64). Overall, there is no clear difference
between arms in the proportion of people with BPAR experiencing Banff II or III classification.201,206
Summary for BEL +MMF vs. CSA +MMF
l Three studies60,125,142 report 1-year outcomes, with two studies60,142 providing data up to 5 years. The
ORs generally fall to < 1 for all time points, indicating that BEL has a lower association with mortality
than CSA. However, the CIs indicate that this is not statistically significant.
l The OR for graft loss up is also reported by three studies60,125,142 up to 4 years. Pooled results indicate
that BEL may be preferable to CSA, although the results are not statistically significant (1 year, OR 0.74,
95% CI 0.42 to 1.31). However, at 5 years, there may be more confidence that this effect is true
(OR 0.40, 95% CI 0.19 to 0.87).
l GRF is reported by three studies60,125,142 up to 5 years. The results must be treated with caution because
of substantial heterogeneity across studies, which may be caused by variations in methods of
calculation and measurement of GRF (I2= 73.6–91.2%). Pooling of results for 1- and 3-year data
demonstrated a statistically significant difference for GRF in favour of BEL (WMD 7.83ml/minute/1.73m2,
95% CI 1.57 to 14.10ml/minute/1.73m2 and WMD 16.08ml/minute/1.73m2, 95% CI 5.59 to
26.56ml/minute/1.73m2, respectively).
l In contrast with previous outcomes, results for BPAR are more clear for the three studies.60,125,142
However, there is substantial heterogeneity across studies at the 1-, 2- and 3-year time points (I2= 58.7%,
38.4% and 62.2%, respectively).60,125,142 Overall, participants in the CSA arm appear to be less likely to
experience BPAR at between 1 and 5 years, as opposed to those in the BEL arm (1 year, OR 1.53, 95% CI
0.78 to 3.02). Three studies60,125,142 report severity of BPAR at 1 year. Overall, there is no clear difference
between arms in the proportion of people with BPAR experiencing Banff II or III classification.60,125,142
TABLE 62 Graft function for BEL+MMF vs. CSA+MMF
Study
Time point
(years) Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
aVincenti 2005,125
bBENEFIT 2010,60
bBENEFIT-EXT 2010142
1 3 7.83 1.57 to 14.10 73.6 21.96
bBENEFIT 2010,60
bBENEFIT-EXT 2010142
2 2 11.06 –1.38 to 23.51 91.2 73.58
3 2 16.08 5.59 to 26.56 89.5 51.23
bBENEFIT 201060 5 1 23.40 20.04 to 26.76 NA NA
NA, not applicable.
a MDRD.
b Measured.
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BEL +MMF vs. BEL + SRL vs. TAC+MMF
This combination is reported only in the Ferguson et al.,126 study therefore results are summarised in below
(Table 65). Time to BPAR is not reported. Analysis indicates no statistical difference between arms for any
outcome; however, the sample size is relatively low (n= 26 and n= 30).
TABLE 63 Biopsy-proven acute rejection for BEL+MMF vs. CSA+MMF
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Vincenti 2005,125 BENEFIT 2010,60
BENEFIT-EXT 2010142
1 3 1.53 0.78 to 3.02 58.7 0.2030
BENEFIT 2010,60 BENEFIT-EXT 2010142 2 2 1.61 0.97 to 2.68 38.4 0.0518
3 2 1.43 0.78 to 2.63 62.2 0.1198
5 2 1.96 1.13 to 3.39 0.0 0.0
TABLE 64 Severity of BPAR for BEL+MMF vs. CSA+MMF
Study
Time point
(years)
BEL+MMF CSA+MMF
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Vincenti 2005125 0.5 71 4 0 4 0 73 6 2 4 0
BENEFIT 201060 1 226 39 12 26 1 221 16 8 8 0
aBENEFIT-EXT 2010142 175 31 6 25 0 184 26 4 22 0
Vincenti 2005125 71 4 0 4 0 73 6 2 4 0
a One new Banff I BPAR was reported in the BEL+MMF arm at 5 years’ follow-up.
TABLE 65 Summary of outcomes for BEL+MMF vs. BEL+ SRL vs. TAC+MMF
Study
Time point
(years) Outcomes
BEL+MMF,
n/N
BEL+ SRL,
n/N
TAC+MMF,
n/N Chi-squared
Ferguson
2011126
0.5 BPAR 4/33 1/26 1/30 2.0751; p= 0.354
Banff classification I 0/33 0/26 0/30 NA
Banff classification II 4/33 1/26 1/30 2.0751; p= 0.354
Banff classification III 0/33 0/26 0/30 NA
1 Mortality 1/33 0/26 0/30 1.6656; p= 0.435
Graft loss 2/33 2/26 0/30 2.0675; p= 0.356
BPAR 5/33 1/26 1/30 3.2067; p= 0.201
NA, not applicable.
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EVL + CSA vs. MMF + CSA
Three RCTs131,143,150 investigating this combination of immunosuppressive therapies were identified. All
outcomes other than time to BPAR were reported.
Mortality
Mortality is reported at 0.5,150 1131 and 3143 years (Table 66 and Figure 32). Results are pooled for the
1- and 2-year time points, where the OR is > 1, indicating a preference in favour of MMF; however, this is
not statistically significant (OR 1.83, 95% CI 0.80 to 4.20; OR 1.06, 95% CI 0.60 to 1.85, respectively).
This trend is reflected at 0.5 years and 3 years.
TABLE 66 Mortality for EVL+CSA vs. MMF+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
ATLAS 2004150 0.5 1 3.13 0.83 to 11.74 NA NA
Lorber 2005,143 ATLAS 2004,150
Takahashi 2013131
1 3 1.83 0.80 to 4.20 0.0 0.0
Lorber 2005,143 ATLAS 2004150 3 2 1.06 0.60 to 1.85 0.0 0.0
NA, not applicable.
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Graft loss
Three RCTs131,143,150 report graft loss for this combination (Table 67 and Figure 33). There is considerable
heterogeneity across studies for 1 and 3 years (I2= 80.0% and 74.3%, respectively) therefore results must
be treated with caution. The study reported by Lorber et al.,143 which favours MMF, appears to be in
contrast with the ATLAS study;150 however, there is no statistically significant difference between arms for
either trial.
Graft function
Lorber et al.143 provide a median and range for GRF rather than a SD; therefore, results could not be
pooled with the ATLAS study150 (Table 68). Overall, there is no significant difference in GRF between
EVL+CSA and MMF+CSA (p= 0.1989 to 0.3703).
Biopsy-proven acute rejection
The pooled and unpooled ORs of < 1 for this outcome all suggest that EVL is associated with lower odds
of BPAR; however, the CIs indicate a lack of statistical significance (Table 69 and Figure 34).131,143,150 There
is no evidence of heterogeneity across studies.
TABLE 67 Graft loss for EVL+CSA vs. MMF+CSA
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
ATLAS 2004150 0.5 1 0.45 0.08 to 1.13 NA NA
Lorber 2005,143 ATLAS 2004,150 Takahashi 2013131 1 3 0.93 0.26 to 3.39 80.0 0.6944
Lorber 2005,143 ATLAS 2004150 3 2 1.07 0.40 to 2.85 74.3 0.3700
NA, not applicable.
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TABLE 68 Graft function for EVL+CSA vs. MMF+CSA
Study
Time
point
(years)
EVL, mean
ml/minute/1.73m2
(SD)
MMF, mean
ml/minute/1.73m2
(SD)
MD,
ml/minute/1.73m2
95% CI,
ml/minute/1.73m2
p-value
(t-test)
aLorber 2005143 1 58 (7–124) 69 (8–153) NA NA NA
ATLAS 2004150 52 (21) 54 (18) –0.1023 –0.30 to 0.10 0.3131
aLorber 2005143 2 60 (5–141) 71 (6–412) NA NA NA
ATLAS 2004150 55 (24) 58 (22) –0.1303 –0.33 to 0.07 0.1989
aLorber 2005143 3 57 (4–140) 70 (8–157) NA NA NA
ATLAS 2004150 55 (23) 57 (21) –0.0908 –0.29 to 0.11 0.3703
NA, not applicable.
a Median and range.
All methods either reported as CRC or Cockcroft–Gault unless otherwise stated.
TABLE 69 Biopsy-proven acute rejection for EVL+CSA vs. MMF+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
ATLAS 2004150 0.5 1 0.90 0.56 to 1.45 NA NA
Lorber 2005,143 ATLAS 2004,150
Takahashi 2013131
1 3 0.84 0.60 to 1.16 0.0 0.0
Lorber 2005,143 ATLAS 2004150 3 2 0.91 0.66 to 1.26 0.0 0.0
NA, not applicable.
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Severity of biopsy-proven acute rejection
Severity of BPAR is reported by only Takahashi et al.131 at 1 year (Table 70). No occurrences of Banff II or III
classification were reported.
Summary for EVL + CSA vs. MMF + CSA
l Results for mortality are pooled for three studies131,143,150 at the 1-year time point. The OR is > 1,
indicating a preference in favour of MMF; however, this is not statistically significant (OR 1.83, 95% CI
0.80 to 4.20). This trend is reflected at 0.5 years and 3 years.
l Three RCTs131,143,150 report graft loss for this combination; however, there is significant heterogeneity
across studies for 1 and 3 years (I2= 80.0% and 74.3%, respectively). The study reported by Lorber
et al.,143 which favours MMF, appears to be in contrast with the ATLAS study,150 which favours EVL;
however, there is no statistical difference between arms for either trial.
l Lorber et al.143 provide a median and range for GRF, rather than a SD; therefore, results could not be
pooled with the ATLAS study.150 Overall, there is no significant difference in GRF between EVL+CSA
and MMF+CSA (p= 0.1989 to 0.3703).
l The pooled and unpooled ORs of < 1 for BPAR all suggest that EVL is associated with lower odds;
however, the CIs indicate a lack of statistical significance.131,143,150 There is no evidence of heterogeneity
across studies. Severity of BPAR is reported only by Takahashi et al.131 at 1 year, when no occurrences
of Banff II or III classifications are reported.131
EVL + CSA vs. MPS+ CSA
Three RCTs107,144,152 were identified reporting on this combination. All outcomes other than time to BPAR
and HRQoL are reported.
Mortality
Pooled analysis of three studies107,144,152 at 1 year for mortality indicates no significant difference between
EVL+CSA and MPS+CSA (OR 1.02, 95% CI 0.42 to 2.45; Table 71 and Figure 35). No heterogeneity was
evident across studies.
TABLE 70 Severity of BPAR for EVL vs. MMF
Study Time point (years) Banff classification EVL, n/BPAR MMF, n/BPAR
Takahashi 2013131 1 None/borderline 2/3 3/5
I 1/3 2/5
TABLE 71 Mortality for EVL+CSA vs. MPS+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Chadban 2014,152 Tedesco-Silva 2010,107
Bertoni 2011144
1 3 1.02 0.42 to 2.45 0.0 0.0
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Graft loss
The OR for graft loss is generated from three pooled studies,107,144,152 which indicates that EVL may be
preferable in reducing graft loss; however, this result is not statistically significant (OR 0.65, 95% CI 0.15
to 2.87) (Table 72 and Figure 36). Furthermore, moderate heterogeneity is noted across studies.
TABLE 72 Graft loss for EVL+CSA vs. MPS+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Chadban 2014,152 Tedesco-Silva 2010,107
Bertoni 2011144
1 3 0.65 0.15 to 2.87 34.8 0.7158
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Graft function
Two studies107,144 report GRF; however, although results are pooled, the heterogeneity between them is
extremely high (I2= 91.2%) (Table 73 and Figure 37). As such, the evidence is unclear as to which
treatment may be beneficial.
TABLE 73 Graft function for EVL+CSA vs. MPS+CSA
Study Time point (years) Trials WMD 95% CI I2 (%) τ2
Tedesco-Silva 2010,107 Bertoni 2011144 1 2 8.56 –10.66 to 27.77 91.2 176.12
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
137
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
N
o
te
: w
ei
g
h
ts
 a
re
 f
ro
m
 r
an
d
o
m
-e
ff
ec
ts
 a
n
al
ys
is
1 
ye
ar
Te
d
es
co
-S
ilv
a 
20
10
10
7
B
er
to
n
i 2
01
11
44
Su
b
to
ta
l (
I 2
 =
 9
1.
2%
, p
 =
 0
.0
01
)
St
u
d
y
27
7,
 6
7.
9 
(2
5.
7)
50
, 6
2.
6 
(2
2.
8)
32
7
n
, m
ea
n
 (
SD
);
 c
o
n
tr
o
l
53
.2
4
46
.7
6
10
0.
00
%
 w
ei
g
h
t
–  0
.6
3 
(–
 4
.7
5 
to
 3
.4
9)
19
.0
2 
(8
.3
8 
to
 2
9.
66
)
8.
56
 (
–  1
0.
66
 t
o
 2
7.
77
)
W
M
D
 (
95
%
 C
I)
27
7,
 6
7.
3 
(2
3.
7)
56
, 8
1.
6 
(3
2.
7)
33
3
n
, m
ea
n
 (
SD
);
 t
re
at
m
en
t
Fa
vo
u
rs
 M
PS
Fa
vo
u
rs
 E
V
L
– 2
9.
7
0
29
.7
FI
G
U
R
E
37
Fo
re
st
p
lo
t:
G
R
F
fo
r
EV
L
+
C
SA
vs
.
C
SA
+
M
PS
.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
138
Biopsy-proven acute rejection
Biopsy-proven acute rejection is reported by three studies107,144,152 at 1 year. Pooling of results indicates no
statistically significant difference between EVL+CSA vs. MPS+CSA (OR 1.01, 95% CI 0.68 to 1.48)
(Table 74 and Figure 38).
Severity of biopsy-proven acute rejection
The study reported by Tedesco-Silva et al.107 suggests that more people with BPAR receiving MPS
experienced Banff II classification; however, there was no difference for Banff III (Table 75). There were no
Banff II or III episodes reported in the EVL treatment for Chadban et al.,152 with only one episode among
those receiving MPS treatment; however, the sample size is small.
Summary for EVL + CSA vs. MPS + CSA
l Pooled analysis of three studies107,144,152 at 1 year indicates no significant difference between EVL+CSA
and MPS+CSA (OR 1.02, 95% CI 0.42 to 2.45). No heterogeneity was evident across studies.
l The OR for graft loss is generated from three pooled studies,107,144,152 which indicates that EVL may be
preferable in reducing graft loss; however, this result is not statistically significant (OR 0.648, 95% CI
0.146 to 2.870). Furthermore, moderate heterogeneity is noted across studies.
l BPAR is reported by three studies107,144,152 at 1 year. Pooling of results indicates no statistically significant
difference between EVL+CSA compared with MPS+CSA (OR 1.01, 95% CI 0.68 to 1.48).
l The study reported by Tedesco-Silva et al.107 suggests that more people with BPAR receiving MPS
experienced Banff II grading; however, there was no difference for Banff III (see Table 78). There were
no Banff II or III episodes reported in the EVL treatment for Chadban et al.,152 with only one episode
among those receiving MPS treatment; however, the sample size is small.107
EVL +MPS vs. CSA+MPS
Only the study reported by Mjörnstedt et al.133 investigated this combination of therapies. Therefore,
outcomes are summarised in Table 76. Time to BPAR is not reported. Data are provided at 1 year, when
there is no statistical difference between arms for mortality or graft loss. There is evidence to indicate
greater odds of BPAR associated with EVL+MPS (OR 19.31, 95% CI 9.09 to 41.04). There is no significant
difference in severity of BPAR.
TABLE 74 BPAR for EVL+CSA vs. MPS+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Chadban 2014,152 Tedesco-Silva 2010,107
Bertoni 2011144
1 3 1.01 0.68 to 1.48 0.0 0.0
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SRL+ CSA vs. MMF + CSA
Three RCTs108,109,122 were identified for this combination of therapies. No time to BPAR or severity of BPAR
was reported.
Mortality
Two studies109,122 were available for pooling at 1 year; however, one of the studies109 had no deaths in
either arm (Table 77 and Figure 39). The ORs appear to indicate lower odds associated with mortality for
SRL; however, this is not statistically significant (1 year, OR 0.49, 95% CI 0.04 to 5.59). The 2- and
5-year time points also show no statistically significant difference (2 years, OR 0.31, 95% CI 0.05 to 1.92;
5 years, OR 1.0, 95% CI 0.36 to 2.77).
TABLE 75 Severity of BPAR for EVL+CSA vs. MPS+CSA
Study
Time point
(years)
EVL+CSA MPS+CSA
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
aChadban 2014152 1 30 5 5 0 0 47 6 7 1 1
bTedesco-Silva 2010107 1 277 47 32 8 1 277 50 29 17 1
a Missing classification for six and three BPARs in EVL+CSA and MPA+CSA groups, respectively.
b BPAR summarises the number of first BPARs. However, it appears that the Banff I–III classification summarises number of
episodes. In addition, one recorded episode in MPS+CSA was not classified.
TABLE 76 Summary of outcomes for EVL+MPS vs. CSA+MPS at 1 year
Study
Time point
(years) Outcome EVL+MPS CSA+MPS OR 95% CI
Mjörnstedt 2012133 1 Mortality, n/N (%) 2/102 (98) 2/100 (98) 1.00 0.14 to 7.24
Graft loss, n/N (%) 0/102 (0) 0/100 (0) NA NA
BPAR, n/N (%) 28/102 (27) 11/100 (11) 3.06 1.43 to 6.56
BPAR – no Banff, n/N (%) 31/102 (30) 6/100 (6) 6.84 2.71 to 17.28
BPAR – Banff I, n/N (%) 5/102 (5) 7/100 (7) 0.68 0.21 to 2.23
BPAR – Banff II, n/N (%) 0/102 (0) 0/100 (0) NA NA
NA, not applicable.
TABLE 77 Mortality for SRL+CSA vs. MMF+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Anil Kumar 2008,122 aStallone 2004109 1 2 0.49 0.04 to 5.59 NA NA
Barsoum 2007108 2 1 0.31 0.05 to 1.92 NA NA
Anil Kumar 2008122 5 1 1.0 0.36 to 2.77 NA NA
NA, not applicable.
a One study excluded as a result of no deaths in either arm.
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Graft loss
Three studies108,109,122 report on graft loss for SRL+CSA vs. MMF+CSA from 1 to 5 years (Table 78 and
Figure 40).108,109,122 The ORs up to 4 years slightly favour MMF; however, there is no statistically significant
effect overall. At 5 years, the OR becomes ‘1’, indicating no benefit for either treatment.
Graft function
Graft function is monitored by one study109 at 1 year (Table 79). No statistical difference is apparent
between SRL and MMF (WMD 0.11ml/minute/1.73 m2; p= 0.5708).
Biopsy-proven acute rejection
The study by Anil Kumar et al.122 reporting on BPAR at 1 year a similar percentage of events in both arms
and therefore no difference between treatments (Table 80).122 At 2 years, Barsoum et al.108 report more
favourable outcomes for SRL; however, this is not statistically significant (OR 0.65, 95% CI 0.22 to 1.87).
Summary for SRL + CSA vs. MMF + CSA
l Two studies109,122 were available for pooling at 1 year; however, one of the studies109 had no deaths in
either arm. The ORs appear to indicate lower odds associated with mortality for SRL; however, this is
not statistically significant (1 year, OR 0.49, 95% CI 0.04 to 5.59). The 2- and 5-year time points also
show no statistically significant difference (2 years, OR 0.31, 95% CI 0.05 to 1.92; 5 years, OR 1.0,
95% CI 0.36 to 2.77).
l Three studies108,122,208 report on graft loss for SRL+CSA compared with MMF+CSA from 1 to 5 years.
ORs slightly favour MMF, but the effect is not statistically significant (1 year, OR 1.53, 95% CI 0.24
to 9.59).
l GRF is monitored by one study109 at 1 year. No statistical difference is apparent between SRL and MMF
(WMD 0.11ml/minute/1.73 m2; p= 0.5708).
l The study by Anil Kumar et al.122 reporting on BPAR at 1 year had eight events in both arms and
therefore no difference between treatment. At 2 years, Barsoum et al.108 report more favourable
outcomes for SRL; however, this is not statistically significant (OR 0.65, 95% CI 0.22 to 1.87).
SRL+ TAC vs. MMF+ TAC
A total of eight RCTs94,110,112,114,122,145,155,180 were identified investigating SRL+ TAC vs. MMF+ TAC with all
outcomes other than HRQoL reported.
TABLE 78 Graft loss for SRL+CSA vs. MMF+CSA
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Anil Kumar 2008,122 Stallone 2004109 1 2 1.53 0.24 to 9.59 NA NA
Barsoum 2007,108 Anil Kumar 2008122 2 2 1.20 0.42 to 3.45 0.0 0.0
Anil Kumar 2008122 3 1 1.36 0.56 to 3.30 NA NA
4 1 1.32 0.57 to 3.10 NA NA
5 1 1.0 0.36 to 2.77 NA NA
NA, not applicable.
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Mortality
Eight RCTs94,110,112,114,122,145,155,180 report mortality from 0.08 years to 3 years (Table 81 and Figure 41). The
ORs vary from < 1 at 0.08 years to > 1 at 3 years; however, the CIs are wide and cross ‘OR= 1’, indicating
no statistical significance at any time point.
TABLE 79 Graft function for SRL+CSA vs. MMF+CSA
Study SRL, n (SD) MMF, n (SD)
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) p-value (t-test)
Stallone 2003109 61.5 (11) 60.3 (9) 0.11 –0.28 to 0.51 0.5708
TABLE 80 Biopsy-proven acute rejection for SRL+CSA vs. MMF+CSA
Study Time point (years) SRL, n (%) MMF, n (%) OR 95% CI
Anil Kumar 2008122 1 4/50 (8) 4/50 (8) NA NA
Barsoum 2007108 2 10/76 (13) 7/37 (19) 0.65 0.22 to 1.87
NA, not applicable.
TABLE 81 Mortality for SRL+ TAC vs. MMF+ TAC
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Anil Kumar 2008122 0.08 1 0.38 0.07 to 2.03 NA NA
Van Gurp 2010114 Vítko 200694 0.5 2 0.83 0.19 to 3.59 6.9 0.08
Anil Kumar 2005,110 Gonwa 2003,180
Sampaio 2008,112 Gallon 2006,145
Flechner 2011155
1 5 0.98 0.47 to 2.02 0.0 0.0
Anil Kumar 2005,110 Flechner 2011155 2 2 1.03 0.37 to 2.89 10.8 0.07
Gallon 2006145 3 1 3.74 0.15 to 94.55 NA NA
NA, not applicable.
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Graft loss
Five RCTs112,114,122,145,180 were identified reporting graft loss (Table 82 and Figure 42). Four RCTs112,122,145,180
are pooled at 1 year, at which increased odds of graft loss are associated with SRL. However, the effect is
not statistically significant (OR 1.43, 95% CI 0.44 to 4.66). There may also be moderate heterogeneity
across studies following pooling (I2= 38.8%). The study by Anil Kumar et al.122 provides follow-up to
5 years, with the OR of < 1 favouring SRL; however, the results are not statistically significant.
TABLE 82 Graft loss for SRL+ TAC vs. MMF+ TAC
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Van Gurp 2010114,180 0.5 1 0.33 0.03 to 3.18 NA NA
Gonwa 2003,180 Sampaio 2008,112
Gallon 2006,145 Anil Kumar 2008122
1 4 1.43 0.44 to 4.66 38.8 0.54
Anil Kumar 2008122 2 1 0.72 0.23 to 2.24 NA NA
Gallon 2006,145 Anil Kumar 2008122 3 2 1.59 0.13 to 19.23 77.2 2.55
Anil Kumar 2008122 4 1 0.58 0.23 to 1.46 NA NA
5 1 0.70 0.30 to 1.61 NA NA
NA, not applicable.
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Graft function
Three RCTs111,114,145 were identified reporting GRF; however, because of the different time points, only two
RCTs111,114 could be pooled at 0.5 years (Tables 83 and 84; Figure 43). The results indicate no statistical
difference between arms (WMD –1.875ml/minute/1.73m2, 95% CI –8.425 to 4.675ml/minute/1.73m2).
Furthermore, substantial heterogeneity across studies is evident (I2= 81.6%).
TABLE 83 Graft function for SRL+ TAC vs. MMF+ TAC (pooled results)
Study Time point Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
Mendez 2005,111
Van Gurp 2010114
6 months 2 –1.875 –8.425 to 4.675 81.6 18.86
TABLE 84 Graft function for SRL+ TAC vs. MMF+ TAC (unpooled results)
Study Time point (years) Trials
GRF, meanml/minute/1.73m2
SRL MMF
Mendez 2005111 1 1 54.3 58.4
Gallon 2006145 3 1 36.9 58.3
8.5 23.5 54.1
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Biopsy-proven acute rejection
Biopsy-proven acute rejection is reported in four studies,112,122,145,180 with three studies112,122,145 pooled at
1 year (Table 85 and Figure 44). The ORs for 0.5 years and 1 year suggest that MMF+ TAC has lower odds
of BPAR; however, the effect is not statistically significant (1 year, OR 1.16, 95% CI 0.56 to 2.60). There is
also a low level of heterogeneity (I2= 27.8%).
Severity of biopsy-proven acute rejection
Four studies94,112,114,155 report severity of BPAR (Table 86). No clear difference is apparent at either time
point for Banff II or III classification between SRL and MMF.
Time to biopsy-proven acute rejection
Time to BPAR is reported by Sampaio et al.,112 which appears to favour MMF (Table 87).
Summary for SRL + TAC vs. MMF + TAC
l Eight RCTs94,110,112,114,122,145,155,180 report mortality from 0.08 years to 3 years. The ORs vary from < 1 at
0.08 years to > 1 at 3 years; however, the CIs are wide and cross ‘OR= 1’, indicating no statistical
significance at any time point.
l Five RCTs were identified reporting graft loss.112,114,122,145,180 Four RCTs are pooled at 1 year where
increased odds of graft loss are associated with SRL; however, the effect is not statistically significant
(OR 1.43, 95% CI 0.44 to 4.66). There may also be moderate heterogeneity across studies following
pooling (I2= 38.8%). The study by Anil Kumar et al.122 provides follow-up to 5 years, with the OR of
< 1 favouring SRL; however, the results are not statistically significant.
l Three RCTs111,114,145 were identified reporting GRF; however, because of the different time points, only
two RCTs111,114 could be pooled at 0.5 years. The results indicate no statistical difference between arms
(WMD –1.875ml/minute/1.73m2, 95% CI –8.425 to 4.675ml/minute/1.73m2). Furthermore,
substantial heterogeneity across studies is evident (I2= 81.6%).
l BPAR is reported in four studies,112,122,145,180 with three studies112,122,145 pooled at 1 year. The ORs for
0.5 years and 1 year suggest that MMF+ TAC has lower odds of BPAR; however, the effect is
not statistically significant (1 year, OR 1.16, 95% CI 0.56 to 2.60). There is also a low level of
heterogeneity (I2= 27.8%).
l Four studies94,112,114,155 report severity of BPAR. No clear difference is apparent for Banff II or III
classification between SRL and MMF. Time to BPAR is reported by Sampaio et al.,112 with a statistically
significant difference demonstrated in favour of MMF (MD 48.6 days; p= 0.0017).
SRL+MMF vs. CSA +MMF
Ten studies91,115–118,127,134,146,147,149 were identified investigating SRL+MMF compared with CSA+MMF.
Mortality
Eight studies115–117,127,134,146,147,149 report on mortality, with seven pooled at 1 year (Table 88 and Figure 45).
No statistically significant difference was evident at this time point (1 year, OR 0.98, 95% CI 0.28 to 3.42).
Data are available up to 5 years; however, the effect is also not statistically significant (5 years, OR 1.15,
95% CI 0.42 to 3.13).115,209
TABLE 85 Biopsy-proven acute rejection for SRL+ TAC vs. MMF+ TAC
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Gonwa 2003180 0.5 1 1.16 0.62 to 2.19 NA NA
Anil Kumar 2008,122 Sampaio 2008,112
Gallon 2006145
1 3 1.21 0.56 to 2.60 27.8 0.13
NA, not applicable.
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TABLE 86 Severity of BPAR for SRL+ TAC vs. MMF+ TAC
Study Time point (years)
SRL+ TAC MMF+ TAC
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
aVan Gurp 2010114 0.5 318 48 30 17 1 316 39 20 17 2
Vítko 200694 0.5 325 82 77 5 327 73 71 2
aFlechner 2011155 1 152 22 17 5 0 139 11 5 6 0
Sampaio 2008112 1 50 7 4 3 0 50 6 2 4 0
aFlechner 2011155 2 152 25 20 5 0 139 16 10 6 0
a Incidences of BPAR were reported.
TABLE 87 Time to BPAR for SRL+ TAC vs. MMF+ TAC
Study
SRL+ TAC MMF+ TAC
Statistical test
(p-value)an BPAR
Mean time to BPAR,
days (SD) n BPAR
Mean time to BPAR,
days (SD)
Sampaio 2008112 50 7 60.9 (104.5) 50 6 12.3 (19.4) NR (0.287)
NR, not reported.
a Calculated by PenTAG.
TABLE 88 Mortality for SRL+MMF vs. CSA+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Durrbach 2008146 0.5 1 3.37 0.13 to 85.63 NA NA
Flechner 2002,127 Noris 2007,115 Lebranchu 2009,149
Büchler 2007,134 Kreis 2000,116 Guba 2010,147
Martinez-Mier 2006117
1 7a 0.98 0.28 to 3.42 0.0 0
Flechner 2002,127 Noris 2007115 2 2 4.02 0.42 to 38.31 0.0 0
Lebranchu 2009149 4 1 1.11 0.15 to 8.05 NA NA
Flechner 2002,127 Büchler 2007134 5 2 1.15 0.42 to 3.13 0.0 0
NA, not applicable.
a Three trials excluded from pooled analysis as a result of no deaths in both arms.
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Graft loss
Eight studies115–117,127,134,146,147,149 report on graft loss from 0.5 years to 5 years (Table 89 and Figure 46).
Seven studies115–117,127,134,147,149 are pooled at 1 year; however, there is no statistically significant difference
between SRL+MMF and CSA+MMF (1 year, OR 1.06, 95% CI 0.44 to 2.56). Flechner et al.127 and
Büchler et al.134 report graft loss at 5 years; however, again, there is no statistically significant difference
and heterogeneity across studies is substantial (5 years, OR 0.57, 95% CI 0.05 to 7.25, I2= 76.6%).
TABLE 89 Graft loss for SRL+MMF vs. CSA+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Durrbach 2008146 0.5 1 4.83 0.51 to 45.62 NA NA
Flechner 2002,127 Lebranchu 2009,149
Büchler 2007,134 Kreis 2000,116 Guba 2010,147
Martinez-Mier 2006,117 Noris 2007115
1 7a 1.06 0.44 to 2.56 0.0 0
Flechner 2002,127 Noris 2007115 2 2 0.18 0.01 to 3.93 NA NA
Lebranchu 2009149 4 1 5.66 0.27 to 119.81 NA NA
Flechner 2002,127 Büchler 2007134 5 2 0.57 0.05 to 7.25 76.6 2.6195
NA, not applicable.
a One trial was excluded from pooled analysis as a result of no deaths in both arms.
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Graft function
Six studies117,118,127,134,146,149 report GRF (note, this includes Lebranchu et al.,67 with 68.9ml/minute/1.73 m2
for SRL and 64.4ml/minute for CSA; however, a SD is not provided). Pooled analysis for 0.5 years and
1 year suggests that improved GRF is associated with CSA, although this effect is not statistically significant
(0.5 year, WMD 6.99ml/minute/1.73 m2, 95% CI 0.45 to 13.53ml/minute/1.73 m2; 1 year, WMD
9.41ml/minute/1.73 m2, 95% CI –1.28 to 20.09ml/minute/1.73m2) (Table 90 and Figure 47). The
individual studies for 2, 3, 4 and 5 years all have OR of < 1 and are statistically significant, therefore CSA
appears beneficial in terms of GRF.
TABLE 90 Graft function for SRL+MMF vs. CSA+MMF
Study
Time point
(years) Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
Durrbach 2008,146
Flechner 2002,127
Martinez-Mier 2006117
0.5 3 6.99 0.45 to 13.53 30.8 10.47
Flechner 2002,127
Büchler 2007,134
Martinez-Mier 2006117
1 3 9.41 –1.28 to 20.09 72.7 64.39
Flechner 2002127 2 1 17.00 9.72 to 24.28 NA NA
Nafar 2012118 3 1 10.00 1.38 to 18.62 NA NA
4 1 9.50 0.50 to 18.50 NA NA
Büchler 2007134 5 1 9.10 1.68 to 16.52 NA NA
NA, not applicable.
Note
The Cockcroft–Gault formula was used for all GRF estimations, other than Büchler et al.,134 for which the Nankivell formula
was used.
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Biopsy-proven acute rejection
Eight studies115–117,127,134,146,147,149 report on BPAR from 0.5 years to 5 years (Table 91 and Figure 48).
Seven studies115–117,127,134,147,149 are pooled at 1 year; however, there is no statistically significant difference
between arms, although the OR falls in favour of CSA+MMF (1 year, OR 1.29, 95% CI 0.81 to 2.04).
Flechner et al.127 and Büchler et al.134 report BPAR at 5 years; however, again, there is no statistically
significant difference and heterogeneity across studies is substantial (5 years, OR 0.77, 95% CI 0.37 to 1.63).
Severity of biopsy-proven acute rejection
Severity of BPAR is reported by three studies116,127,134 at 1 year (Table 92). Flechner et al.127 also report
results for 5 years. Sample sizes are relatively low, with similar proportions of people with BPAR
experiencing Banff II and III classification.
Time to biopsy-proven acute rejection
Time to BPAR is reported by three studies127,134,146 (Table 93). A statistically significant difference is seen by
Durrbach et al.146 (SRL 56 days, SD 57 days; CSA 94 days, SD 47 days; p= 0.0035).146 The studies reported
by Büchler et al.134 and Flechner et al.127 show no statistical difference between treatments (p= 0.3858
and p= 0.982, respectively).
TABLE 91 Biopsy-proven acute rejection for SRL+MMF vs. CSA+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Durrbach 2008146 0.5 1 1.52 0.31 to 7.35 NA NA
Flechner 2002,127 Lebranchu 2009,149 Büchler 2007,134
Kreis 2000,116 Guba 2010,147 Martinez-Mier 2006,117
Noris 2007115
1 7 1.29 0.81 to 2.04 0.0 0
Flechner 2002127 2 1 0.34 0.06 to 1.94 NA NA
Lebranchu 2009149 4 1 1.11 0.15 to 8.05 NA NA
Flechner 2002,127 Büchler 2007134 5 2 0.77 0.37 to 1.63 0.0 0
NA, not applicable.
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TABLE 92 Severity of BPAR: SRL+MMF vs. CSA+MMF
Study Time point (years)
SRL+MMF CSA+MMF
n BPAR
Banff classification
n BPAR
Banff classification
I II III I II III
Büchler 2007134 1 71 9 5 2 2 74 6 2 2 2
aFlechner 2002127 1 31 2 1 0 0 30 5 2 1 0
Kreis 2000116 1 40 11 1 10 0 38 7 2 4 1
bFlechner 2002127 5 31 4 2 0 0 30 7 3 2 0
a Missing classification for one and two BPARs in SRL+MMF and CSA+MMF groups, respectively.
b Missing classification for two and two BPARs in SRL+MMF and CSA+MMF groups, respectively.
TABLE 93 Time to BPAR: SRL+MMF vs. CSA+MMF
Study
SRL+MMF CSA+MMF
Statistical test
(p-value)n BPAR
Mean time to BPAR,
days (SD) n BPAR
Mean time to BPAR,
days (SD)
aDurrbach 2008146 33 4 56 (57) 36 3 94 (47) NR (0.399)
Büchler 2007134 71 12 75 (82) 74 6 87 (84) NS
bFlechner 2002127 31 4 481 (471) 30 7 471 (534) χ2= 1.01
(p= 0.31)
NR, not reported; NS, not significant.
a Assumed that time to BPAR was reported as ‘delay of BPAR’.
b Log-rank test for equality of survivor functions calculated by PenTAG; BPAR recorded on days 44, 53, 806 and 1020, and
days 73, 126, 155, 197, 256, 1170 and1321 in SRL+MMF and CSA+MMF groups, respectively.
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Summary of results for SRL +MMF vs. CSA+MMF
l Eight studies115–117,127,134,146,147,149 report on mortality, with seven studies115–117,127,134,147,149 pooled at
1 year. No statistically significant difference was evident at this time point (1 year, OR 0.98, 95% CI
0.28 to 3.42) or up to 5 years (5 years, OR 1.15, 95% CI 0.42 to 3.13).115,209
l Eight studies115–117,127,134,146,147,149 report on graft loss from 0.5 years to 5 years. Seven
studies115–117,127,134,147,149 are pooled at 1 year; however, there is no statistically significant difference
between SRL+MMF and CSA+MMF (1 year, OR 1.06, 95% CI 0.44 to 2.56). Flechner et al.127 and
Büchler et al.134 report graft loss at 5 years; however, again, there is no statistically significant difference
and heterogeneity across studies is substantial (5 years, OR 0.57, 95% CI 0.05 to 7.25, I2= 76.6%).
l Six studies117,118,127,134,146,149 report GRF (note, this includes Lebranchu et al.,149 with 68.9ml/minute/
1.73m2 for SRL and 64.4ml/minute/1.73 m2 for CSA; however, a SD is not provided). Pooled analysis for
0.5 years and 1 year suggests that improved GRF is associated with TAC, although this effect is not
statistically significant (0.5 year, WMD 6.99ml/minute/1.73m2 95% CI 0.45 to 13.53ml/minute/1.73m2;
1 year, WMD 9.41ml/minute/1.73m2, 95% CI –1.28 to 20.09ml/minute/1.73m2). The individual studies
for 2, 3, 4 and 5 years all have OR of < 1 and are statistically significant, therefore TAC appears to be
beneficial in terms of GRF.
l Eight studies115–117,127,134,146,147,149 report on BPAR from 0.5 years to 5 years. Seven studies115–117,127,134,147,149 are
pooled at 1 year; however, there is no statistically significant difference between arms, although the OR
falls in favour of CSA+MMF (1 year, OR 1.29, 95% CI 0.81 to 2.04). Flechner et al.127 and Büchler et al.134
report BPAR at 5 years; however, again, there is no statistically significant difference and heterogeneity
across studies is substantial (5 years, OR 0.77, 95% CI 0.37 to 1.63).
l Severity of BPAR is reported by three studies116,127,134 at 1 year. Sample sizes are relatively low, with
similar proportions of people with BPAR experiencing Banff II and III classification. Time to BPAR is
reported by three studies.127,134,146 A statistically significant difference is seen by Durrbach et al.146
(SRL 56 days, SD 57 days; CSA 94 days, SD 47 days; p= 0.0035). The studies reported by Büchler
et al.134 and Flechner et al.127 show no statistical difference between treatments (p= 0.3858 and
p= 0.982, respectively).
TAC+MMF vs. SRL+MMF
Four studies92,93,135,154 report outcomes for this combination of treatments. No time to BPAR or HRQoL
is reported.
Mortality
Four studies92,93,135,154 are pooled with 1-year results for mortality; however, two of these studies93,135 had
no deaths for either TAC+MMF or SRL+MMF (Table 94 and Figure 49). Furthermore, analysis suggests
no statistically significant difference between TAC+MMF and SRL+MMF (OR 0.80, 95% CI 0.13 to 4.99).
Heilman et al.135 also present results at 2 years (see Table 99). Again, results are not statistically significant
(OR 2.10, 95% 0.19 to 23.83).
TABLE 94 Mortality for TAC+MMF vs. SRL+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Larson 2006,154 Schaefer 2006,92 Heilman 2011,135
Smith 200893
1 4a,b 0.80 0.13 to 4.99 19.2 0.39
Heilman 2011135 2 1 2.10 0.19 to 23.83 NA NA
NA, not applicable.
a Three-arm trial with high dose excluded.
b Two trials excluded from pooled analysis as a result of no deaths in both arms.
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Graft loss
Four studies92,93,135,154 are pooled with 1-year results for graft loss (Table 95 and Figure 50). Again, two of
these studies93,135 had no graft loss in either arm. Although the OR implies that reduced graft loss is
associated with TAC, this is not statistically significant (OR 0.68, 95% CI 0.18 to 2.58).
TABLE 95 Graft loss for TAC+MMF vs. SRL+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Larson 2006,154 Schaefer 2006,92 Heilmann 2011,135
Smith 200893
1 4a 0.68 0.18 to 2.58 0.0 0.0
Heilman 2011135 2 1b NA NA NA NA
NA, not applicable.
a Three-arm trial.
b No graft loss in either arm.
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Graft function
Two studies135,154 report GRF at 1 year and 2 years (Table 96 and Figure 51). The pooled ORs for both time
points indicate no statistically significant difference between TAC+MMF and SRL+MMF (1 year, WMD
–2.50ml/minute/1.73 m2, 95% CI –6.85 to 1.85ml/minute/1.73m2).
TABLE 96 Graft function for TAC+MMF vs. SRL+MMF
Study
Time point
(years) Trials
WMD
(ml/minute/1.73m2)
95% CI
(ml/minute/1.73m2) I2 (%) τ2
Larson 2006,154 Heilman 2011135 1 2 –2.50 –6.85 to 1.85 0.0 0.0
2 2 0.57 –3.70 to 4.55 0.0 0.0
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Biopsy-proven acute rejection
Biopsy-proven acute rejection is reported by three studies92,93,135 (Table 97 and Figure 52). Pooled results
indicate that there are lower odds of BPAR associated with TAC at 1 year (OR 0.32, 95% CI 0.12 to 0.87).
There does not appear to be any evidence of heterogeneity across studies (I2= 0.0%).
Severity of biopsy-proven acute rejection
Only one study93 reports on severity of BPAR (Table 98). For Banff classification II, there is no difference at
1 year between TAC+MMF and SRL+MMF; however, the sample size is very small.
Summary of results for TAC +MMF vs. SRL +MMF
l Four studies92,93,135,154 are pooled with 1-year results for mortality; however, two of these studies had no
deaths for either TAC+MMF or SRL+MMF. Furthermore, analysis suggests no significant difference
between TAC+MMF and SRL+MMF (OR 0.80, 95% CI 0.13 to 4.99) Heilman et al.135 also present
results at 2 years of mortality for TAC+MMF vs. SRL+MMF. Again, results are not statistically
significant (OR 2.10, 95% 0.19 to 23.83).
l Four studies92,93,135,154 are pooled with 1-year results for graft loss. Again, two of these studies93,135 had
no graft loss in either arm. Although the OR implies reduced graft loss associated with TAC, this is not
statistically significant (OR 0.68, 95% CI 0.18 to 2.58).
l Two studies135,154 report GRF at 1 year and 2 years. The pooled ORs for both time points indicate no
statistically significant difference between TAC+MMF and SRL+MMF (1 year, WMD –2.50ml/minute/
1.73m2, 95% CI –6.85 to 1.85ml/minute/1.73 m2).
l BPAR is reported by three studies.92,93,135 Pooled results indicate that there are lower odds of BPAR
associated with TAC at 1 year (OR 0.32, 95% CI 0.12 to 0.87). There does not appear to be any
evidence of heterogeneity across studies (I2= 0.0%). Only one study93 reports on severity of BPAR.
Banff classification I and II demonstrate no difference at 1 year between TAC+MMF and SRL+MMF;
however, the sample size is very small.
TAC+MPS vs. SRL+MPS
The study by Silva et al.119 is the only one to report on this combination; therefore, a summary of outcomes
at 2 years is presented in Table 99. The OR for BPAR appears to favour TAC (OR 0.63, 95% CI 0.3482 to
1.1397); however, this is not statistically significant. All other outcomes also show no statistically significant
difference between arms.
TABLE 97 Pooled results for BPAR – TAC+MMF vs. SRL+MMF
Study
Time point
(years) Trials OR 95% CI I2 (%) τ2
Schaefer 2006,92 Heilman 2011,135
Smith 200893
1 3 0.32 0.12 to 0.87 0.0 0.0
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TAC+ SRL vs. MMF+ SRL
Hamdy et al.120 is the only study to report on this combination; therefore, a summary of outcomes at
1–5 years is presented in Table 100. The OR for mortality at 3 years appears to favour MMF (OR 4.39,
95% CI 0.48 to 40.39); however, this is not statistically significant. All other outcomes also show no
statistical difference between arms.
TABLE 98 Severity of BPAR for TAC+MMF vs. SRL+MMF
Study Time point (years) Banff classification TAC+MMF, n/BPAR SRL+MMF, n/BPAR
Smith 200893 1 I 2/3 1/3
II 1/1 0/1
TABLE 99 Summary of outcomes for TAC+MPS vs. SRL+MPS
Study
Time point
(years) Outcome TAC+MPS SRL+MPS OR 95% CI
Silva 2013119 2 Patient survival, n/N (%) 3/107 (97) 3/97 (97) 0.9038 0.17 to 4.59
Graft survival, n/N (%) 1/107 (99) 1/97 (99) 0.9057 0.06 to 14.68
BPAR, n/N (%) 29/107 (27) 36/97 (37) 0.63 0.35 to 1.14
Banff classification
none/borderline, n/N (%)
5/107 (5) 8/97 (8) 0.5576 0.18 to 1.77
Banff classification I, n/N (%) 16/107 (15) 17/97(17) 0.8274 0.39 to 1.74
Banff classification II, n/N (%) NR NR
Banff classification III, n/N (%) NR NR
NR, not reported.
TABLE 100 Summary of outcomes for TAC+ SRL vs. MMF+ SRL
Study
Time point
(years) Outcome TAC+ SRL MMF+ SRL OR 95% CI
Hamdy 2005120 1 Mortality, n/N (%) 2/65 (1.5) 0/67 (0) NA NA
BPAR, n/N (%) 12/65 (18) 9/67 (13) 1.4591 0.57 to 3.74
GRF, mean
(ml/minute/1.73m2) (SD)
89 (30) 93 (25.2) p= 0.4078
2 Mortality, n/N (%) 2/65 (1.5) 0/67 (0) NA NA
GRF, mean
(ml/minute/1.73m2) (SD)
79.6 (25.5) 94.9 (28.9) p= 0.0016
3 Mortality, n/N (%) 4/65 (6.1) 1/67 (1.5) 4.3934 0.48 to 40.39
BPAR, n/N (%) 12/65 (18) 9/67 (13) 1.4591 0.57 to 3.74
GRF, mean
(ml/minute/1.73m2) (SD)
76.1a 88a NA
5 Graft loss, n/N (%) 7/65 (11) 7/67 (11) 1.0345 0.34 to 3.13
NA, not applicable.
a SD not reported.
Percentages calculated by PenTAG.
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SRL+AZA vs. CSA+AZA
One trial148 reported investigating SRL+AZA vs. CSA+AZA, and a summary of outcomes at 0.5 years and
1 year is presented (Table 101). There is a statistically significant difference between both arms at 0.5 years
and 1 year in favour of SRL+AZA (p< 0.0001) for GRF. There is no statistically significant difference
between arms for other outcomes.
TAC+ SRL vs. CSA + SRL
Two studies121,122 reported this combination, presenting outcomes at 1 year and 5 years. No severity or
time to AR reported.
Mortality
At both 1 year and 5 years there is no statistically significant difference between TAC+ SRL and CSA+ SRL
for mortality (Table 102).121,122 Notably, for Anil Kumar et al.122 there are no deaths in either arm at 1 year.
TABLE 101 Summary of outcomes for SRL+AZA vs. CSA+AZA
Study
Time point
(years) Outcome
SRL+AZA
(%)
CSA+AZA
(%) OR 95% CI (p-value)
Charpentier
2003148
0.5 BPAR, n/N (%) 17/41 (41) 16/42 (38) 1.151 0.4776 to 2.7742
GRF, mean (ml/minute/1.73m2)
(SD)
67 (4) 59 (3) (p< 0.0001)
Banff classification I, n/N (%) 6/41 (15) 9/42 (21) 0.6286 0.2016 to 1.9599
Banff classification II, n/N (%) 9/41 (22) 6/42 (14) 1.6875 0.5411 to 5.2631
Banff classification III, n/N (%) 2/41 (5) 1/42 (2) 2.1026 0.1832 to 4.1267
1 Patient survival, n/N (%) 41/41 (100) 41/42 (98) NA NA
Graft survival, n/N (%) 40/41 (98) 39/42 (93) 0.325 0.0324 to 3.2603
GRF, mean (ml/minute/1.73m2)
(SD)
69.5 (4.1) 58.7 (3.6) (p< 0.0001)
NA, not applicable.
Percentages calculated by PenTAG.
TABLE 102 Mortality for TAC+ SRL vs. CSA+ SRL
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Anil Kumar 2008,122 Chen 2008121 1 2a 1.00 0.14 to 7.39 NA NA
Anil Kumar 2008122 5 1 1.00 0.36 to 2.77 NA NA
NA, not applicable.
a One trial excluded as a result of no deaths in either arm.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
171
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Graft loss
Two studies121,122 report graft loss, with pooled result at 1 year and individual results up to 5 years (Table 103
and Figure 53). Results are consistent across all time points for lower odds being associated with graft loss
for TAC+ SRL; however, the effect is not statistically significant (1 year, OR 0.68, 95% CI 0.16 to 2.90).
Graft function
Chen et al.121 report GRF at 0.5 years and 1 year (Table 104), which appears to be statistically significantly
greater for TAC+ SRL at 0.5 years and 1 year (p< 0.0001 and p= 0.0004, respectively).
Biopsy-proven acute rejection
This is reported only by Anil Kumar et al.122 at 1 year (Table 105). The OR implies BPAR to be more likely
for CSA+ SRL; however, this is not statistically significant (OR 0.48, 95% CI 0.08 to 2.74).
Summary of results for TAC + SRL vs. CSA+ SRL
l Owing to the same number events in either arm at both time points, there is no difference between
TAC+ SRL and CSA+ SRL for mortality.121,122
l Two studies121,122 report graft loss, with pooled result at 1 year and individual results up to 5 years.
Results are consistent across all time points in showing that lower odds are associated with graft loss
for TAC+ SRL; however, the effect is not statistically significant (1 year, OR 0.68, 95% CI 0.16 to 2.90).
l Chen et al.121 report GRF at 0.5 years and 1 year, which appears to be statistically significantly greater
for TAC+ SRL at 0.5 years and 1 year (p< 0.0001 and p= 0.0004, respectively).
l BPAR is reported only by Anil Kumar et al.122 at 1 year. The OR implies BPAR to be more likely for
CSA+ SRL; however, this is not statistically significant (OR 0.48, 95% CI 0.08 to 2.74).
TABLE 103 Graft loss for TAC+ SRL vs. CSA+ SRL
Study Time point (years) Trials OR 95% CI I2 (%) τ2
Anil Kumar 2008,122 Chen 2008121 1 2 0.68 0.16 to 2.90 0.0 0.0
Anil Kumar 2008122 2 1 0.72 0.23 to 2.24 NA NA
3 1 0.44 0.17 to 1.17 NA NA
4 1 0.49 0.20 to 1.20 NA NA
5 1 0.70 0.30 to 1.61 NA NA
NA, not applicable.
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Induction therapy results
Network meta-analysis was performed for all induction studies reporting graft loss, mortality, BPAR and
eGFR at 1-year follow-up. Figure 54 displays the network for included induction studies.
Graft loss
Ten RCTs71–74,87,95–98,137 informing the effectiveness of three treatments (no induction/PBO, BAS and rATG)
were included in the network for graft loss (Figure 55).
The DIC suggested little difference between the fit of the fixed- and random-effects models, with the fixed
effects being the slightly better fit; thus, only the results of the fixed-effects model are shown in Table 106.
TABLE 104 Graft function for TAC+ SRL vs. CSA+ SRL
Study
Time point
(years)
TAC+ SRL,
ml/minute/1.73m2 (SE)
CSA+ SRL,
ml/minute/1.73m2 (SE) MD p-value
Chen 2008121 0.5 52.77 (3.86) 46.42 (3.95) 6.35 < 0.0001
1 52.04 (4.38) 46.79 (4.38) 5.25 0.0004
SE, standard error.
TABLE 105 Biopsy-proven acute rejection for TAC+ SRL vs. CSA+ SRL
Study
Time point
(years) TAC+ SRL, n/N (%) CSA+ SRL, n/N (%) OR 95% CI
Anil Kumar 2008122 1 2/50 (4) 4/50 (8) 0.48 0.08 to 2.74
rATG
No induction/
PBOBAS
3
7
2
FIGURE 54 Network diagram for all included induction studies. Note: circles denote number of studies.
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From these analyses there is little evidence to suggest that BAS and rATG are more effective than no
induction/PBO in reducing graft loss, as the 95% CrIs include an OR of ‘1’. Furthermore, there is little
evidence to suggest that rATG is more effective than BAS. Of the three treatments analysed in this
network, rATG was estimated as having a 57% probability of being the most effective treatment, with
BAS having a 38% probability of being the most effective treatment. Analyses suggested that there was
little evidence of inconsistency within this network.
Mortality
Ten RCTs71–74,87,95–98,137 informing the effectiveness of three treatments (no induction/PBO, BAS and rATG)
were included in the network for mortality (Figure 56).
TABLE 106 Odds ratios for induction therapy from a fixed-effects model: posterior mean (95% CrI)
Treatment comparison Graft loss Mortality BPAR
BAS vs. PBO/no treatment 0.82 (0.56 to 1.18) 0.99 (0.53 to 1.85) 0.52 (0.41 to 0.65)
rATG vs. PBO/no treatment 0.77 (0.39 to 1.47) 0.84 (0.33 to 2.07) 0.36 (0.24 to 0.54)
rATG vs. BAS 0.94 (0.50 to 1.75) 0.84 (0.36 to 1.96) 0.70 (0.47 to 1.03)
Notes
OR < 1 favours the first treatment in the comparison.
Evidence suggesting a difference between treatments is shown in bold text.
rATG
No induction/
PBOBAS
3
6
1
FIGURE 56 Network diagram for induction studies reporting mortality. Note: circles denote number of studies.
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1
FIGURE 55 Network diagram for induction studies reporting graft loss. Note: circles denote number of studies.
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The DIC suggested little difference between the fit of the fixed- and random-effects models, with the fixed
effects being the slightly better fit, thus only the results of the fixed-effects model are shown in Table 106.
From these analyses there is little evidence to suggest that BAS and rATG are more effective than no
induction/PBO in reducing mortality, as the 95% CrIs include an OR of ‘1’ (see Table 106), and there is
little evidence to suggest that rATG is more effective than BAS. Of the three treatments analysed in this
network, rATG was estimated as having a 54% probability of being the most effective treatment, with
BAS having a 22% probability of being the most effective treatment. Analyses suggested that there was
little evidence of inconsistency within this network.
Biopsy-proven acute rejection
Nine RCTs71–74,87,96–98,137 informing the effectiveness of three treatments (no induction/PBO, BAS and rATG)
were included in the network for mortality (Figure 57).
The DIC suggested little difference between the fit of the fixed- and random-effects models, with the
fixed effects being the slightly better fit, and so only the results of the fixed-effects model are shown in
Table 106.
From these analyses, evidence suggests that BAS and rATG are more effective than no induction/PBO in
reducing BPAR and that rATG is more effective than BAS. Of the three treatments analysed in this
network, rATG was estimated as having a 96% probability of being the most effective treatment, with
BAS having a 3% probability of being the most effective treatment. Analyses suggested that there was
little evidence of inconsistency within this network.
rATG
No induction/
PBOBAS
3
5
1
FIGURE 57 Network diagram for induction studies reporting BPAR. Note: circles denote number of studies.
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Graft function
Five RCTs71–73,87,97 informing the effectiveness of three treatments (no induction/PBO, BAS and rATG) were
included in the network for GRF (Figure 58).
The DIC suggested very little difference between the fit of the fixed- and random-effects models. For
comparison with the above outcomes, the results of the fixed-effects model are shown in Table 107.
There is no evidence to suggest that BAS or rATG is more effective than PBO/no induction, and no
evidence to suggest that one treatment is more effective than the other. BAS has a 89% probability of
being the most effective treatment, whereas rATG has a 5% probability of being the most effective
treatment. Analyses suggested that there was little evidence of inconsistency within this network.
TABLE 107 Mean effects for induction therapy for the outcome GRF from a fixed-effects model: posterior mean
(95% CrI)
Treatment comparison GRF (ml/minute/1.73m2)
BAS vs. PBO/no treatment 2.11 (–0.45 to 4.68)
rATG vs. PBO/no treatment –3.95 (–11.80 to 3.94)
rATG vs. BAS –6.06 (–13.46 to 1.37)
Notes
Posterior mean of > 0 favours the first treatment in the comparison.
Evidence suggesting a difference between treatments highlighted in bold.
rATG
No induction/
PBOBAS
1
4
FIGURE 58 Network diagram for induction studies reporting GRF. Note: circles denote number of studies.
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Maintenance therapy results
Network meta-analysis was performed for all maintenance studies reporting graft loss, mortality, BPAR and
eGFR at 1-year follow-up. Figure 59 displays the network for included induction studies.
Data on 13 treatments from 49 studies51,59,76,80,82–84,86,88–90,92,93,100,102–104,107–112,115,117,118,121,122,125–127,129,131,133–136,138,
142–145,147,149–152,155,210 were potentially includable in the NMA (Figure 60). However, 11 studies had zero
events in all treatment arms, so would not contribute information to the NMA; therefore, they were
excluded from the NMA. Owing to the exclusion of these studies, the treatment EVL+MPS could not be
included in the network. Therefore, data from 40 studies51,59,76,80,82–84,86,88–90,92,100,103,104,107,108,110–112,117,118,122,
125–127,129,134,136,138,142–145,147,149–152,155 (including five three-arm studies51,104,126,152,155 and one four-arm study122)
on the effectiveness of 12 treatments to reduce graft loss informed the NMA. Thirteen82,90,100,104,112,126,127,138,
144,145,147,149,152 of the 40 studies had at least one treatment arm with no graft loss events; therefore, 0.5 was
added to each cell.
MMF + TAC
MMF + SRL
MPS + SRL
MPS + CSA
MPS + TAC
SRL + TAC
SRL + CSA
SRL + AZA
BEL + SRL
BEL + MMF
EVL + MPS
EVL + CSA
CSA + AZATAC + AZATAC-PR EVL CSA
MPS
MMF + CSA
4 4
1
11
1
1
4
1
2
1
1
1
1
1
3
7
6
2
1
13
2
1
1
5
10
FIGURE 59 Network diagram for all included maintenance studies reporting graft loss. Note: circles denote number
of studies.
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The DIC indicated that the random-effects model was a slightly better fit to the data than the fixed-effects
model (154.4 vs. 157.5), and so results from only the random-effects models are presented here. The
results of the fixed-effects models are given in Appendix 6. The probabilities that each treatment was the
most effective in reducing graft loss compared with all other treatments are shown in Table 108.
TABLE 108 Probability that each treatment is the most effective treatment for reducing graft loss
Treatment Probability of being ‘best’ treatment (%)
EVL 60
SRL+AZA 29
SRL+CSA 6
BEL+ SRL 2
BEL+MMF 2
EVL+CSA 1
CSA+AZA < 1
TAC+AZA < 1
MMF+CSA < 1
TAC+MMF < 1
SRL+ TAC < 1
SRL+MMF < 1
MMF + SRL
MMF + TAC
MMF + CSA
BEL + MMF
BEL + SRL
SRL + AZA
SRL + CSA
SRL + TAC
TAC + AZA CSA + AZA
EVL + CSA
2 2
7
1
1
1 1
1
1
1
1
5
7
4
3
3
FIGURE 60 Network diagram for maintenance studies reporting graft loss. Note: circles denote number of studies.
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Although the results suggest that EVL has a 60% probability of being the most effective treatment for
reducing graft loss compared with all other treatments (with SRL+AZA having a 29% probability), there is
little evidence to suggest that treatment with EVL reduces graft loss compared with other treatments.
The posterior median ORs for EVL compared with all of the other treatments are < 1, indicating a
reduction in the odds of having a graft loss; however, the upper 95% CrIs limits are > 1, suggesting that
EVL could increase the odds of a graft loss compared with all other treatments (Table 109). In fact, there is
little evidence from the NMA to suggest that any treatment is more effective at reducing graft loss than
any other treatment.
There is no evidence to suggest that this network is affected by inconsistencies between the direct and
indirect evidence (see Appendix 6). The DICs were very similar between the consistency and inconsistency
models (154.4 vs. 153.7) and the 95% CrIs based on the direct evidence overlapped those based on the
direct and indirect evidence.
Mortality
Data on 13 treatments from 52 studies51,59,76,78,80,83,84,86,88–90,92,93,100,102–104,107–112,115–118,120–122,125–127,129–131,133–136,138,
142,145,147,149–151,155,210 were potentially includable in the NMA (Figure 61). However, 10 trials93,102,104,109,115,117,121,
131,135,149 had zero events in all arms and were excluded from the NMA, resulting in 42 trials51,59,76,78,80,83,84,86,
88–90,92,100,103,107,108,110–112,116,118,120,122,125–127,129,130,133,134,136,138,142–145,147,150–152,155,210 contributing to the NMA
(including four three-arm trials51,104,122,152,155 and one four-arm trial122). Twelve59,76,78,90,92,100,120,126,127,136,145,152 of
the 42 included trials had zero events in at least one treatment arm and so 0.5 was added to all cells in
those trials.
Although the DIC indicated that the fixed-effects model was a slightly better fit to the data than the
random-effects model (137.7 vs. 139.5), the random-effects results are presented here and used in
the economic model for consistency, as the remaining maintenance treatment analyses indicated the
random-effects model to be the best-fitting model. The results of the fixed-effects models are given in
Appendix 6. The probabilities that each treatment was the most effective in reducing graft loss compared
with all other treatments are shown in Table 110.
The regimens SRL+AZA (34%), EVL (30%) and BEL+ SRL (27%) were estimated to have the greatest
probabilities of being the most effective treatments to reduce mortality compared with all others, with the
remaining treatments having a very low probability of being the best treatment. This reflects the findings
presented below (see Table 120), which show that SRL+AZA, EVL and BEL+ SRL are consistently
estimated to have posterior median ORs of < 1 compared with all treatments, but, as the upper 95% CrI
limits are > 1, there is the possibility that these treatments could increase mortality compared with
other treatments.
The NMA suggests that BEL+MMF is more effective than TAC+MMF and SRL+MMF at reducing
mortality. However, there is a great deal of uncertainty associated with many of the results presented
(Table 111), especially for BEL+ SRL.
There is no evidence to suggest that this network is affected by inconsistencies between the direct and
indirect evidence (see Appendix 6). The DICs were slightly lower for the consistency model than for the
inconsistency model (139.5 vs. 143.9) and the 95% CrIs that were based on the direct evidence
overlapped those based on the direct and indirect evidence.
ASSESSMENT OF CLINICAL EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
180
TA
B
LE
10
9
O
d
d
s
ra
ti
o
s
(i
n
te
rv
en
ti
o
n
vs
.c
o
m
p
ar
at
o
r
tr
ea
tm
en
t)
fo
r
th
e
o
u
tc
o
m
e
g
ra
ft
lo
ss
fr
o
m
a
ra
n
d
o
m
-e
ff
ec
ts
N
M
A
:p
o
st
er
io
r
m
ed
ia
n
(9
5%
C
rI
)
In
te
rv
en
ti
o
n
tr
ea
tm
en
t
C
o
m
p
ar
at
o
r
tr
ea
tm
en
t
C
SA
+
A
ZA
TA
C
+
A
ZA
M
M
F
+
C
SA
TA
C
+
M
M
F
B
EL
+
SR
L
B
EL
+
M
M
F
EV
L
+
C
SA
SR
L
+
TA
C
SR
L
+
C
SA
SR
L
+
M
M
F
SR
L
+
A
ZA
TA
C
+
A
ZA
1.
13
(0
.6
7
to
2.
15
)
M
M
F
+
C
SA
0.
76
(0
.3
5
to
1.
44
)
0.
67
(0
.2
4
to
1.
50
)
TA
C
+
M
M
F
0.
69
(0
.2
8
to
1.
55
)
0.
61
(0
.1
9
to
1.
56
)
0.
92
(0
.4
8
to
1.
77
)
BE
L
+
SR
L
1.
41
(0
.1
4
to
13
.1
4)
1.
24
(0
.1
1
to
12
.0
2)
1.
89
(0
.2
0
to
16
.4
9)
2.
05
(0
.2
2
to
18
.0
1)
BE
L
+
M
M
F
0.
62
(0
.2
0
to
1.
78
)
0.
55
(0
.1
4
to
1.
72
)
0.
82
(0
.3
5
to
1.
97
)
0.
89
(0
.3
2
to
2.
53
)
0.
43
(0
.0
5
to
3.
94
)
EV
L
+
C
SA
0.
63
(0
.2
0
to
1.
58
)
0.
56
(0
.1
4
to
1.
58
)
0.
84
(0
.3
9
to
1.
63
)
0.
91
(0
.3
3
to
2.
27
)
0.
44
(0
.0
4
to
4.
47
)
1.
02
(0
.3
1
to
2.
95
)
SR
L
+
TA
C
1.
19
(0
.3
8
to
3.
35
)
1.
05
(0
.2
8
to
3.
27
)
1.
57
(0
.6
4
to
3.
93
)
1.
71
(0
.8
0
to
3.
69
)
0.
83
(0
.0
8
to
8.
57
)
1.
92
(0
.5
6
to
6.
48
)
1.
88
(0
.6
2
to
6.
32
)
SR
L
+
C
SA
0.
54
(0
.1
0
to
2.
56
)
0.
48
(0
.0
7
to
2.
42
)
0.
73
(0
.1
5
to
3.
10
)
0.
79
(0
.1
6
to
3.
36
)
0.
38
(0
.0
3
to
5.
31
)
0.
88
(0
.1
5
to
4.
66
)
0.
87
(0
.1
6
to
4.
54
)
0.
46
(0
.0
9
to
2.
05
)
SR
L
+
M
M
F
1.
06
(0
.3
8
to
2.
43
)
0.
94
(0
.2
7
to
2.
45
)
1.
40
(0
.7
2
to
2.
58
)
1.
52
(0
.7
4
to
2.
92
)
0.
74
(0
.0
8
to
7.
09
)
1.
71
(0
.5
6
to
4.
70
)
1.
67
(0
.6
6
to
4.
40
)
0.
89
(0
.3
4
to
2.
15
)
1.
92
(0
.4
1
to
9.
74
)
SR
L
+
A
ZA
0.
25
(0
.0
1
to
3.
10
)
0.
22
(0
.0
1
to
2.
86
)
0.
33
(0
.0
1
to
4.
71
)
0.
36
(0
.0
1
to
5.
39
)
0.
17
(0
.0
1
to
5.
68
)
0.
40
(0
.0
1
to
6.
53
)
0.
40
(0
.0
1
to
6.
52
)
0.
21
(0
.0
1
to
3.
45
)
0.
46
(0
.0
1
to
9.
83
)
0.
24
(0
.0
1
to
3.
68
)
EV
L
0.
09
(0
.0
1
to
2.
15
)
0.
08
(0
.0
1
to
1.
96
)
0.
13
(0
.0
1
to
2.
67
)
0.
14
(0
.0
1
to
3.
12
)
0.
06
(0
.0
1
to
3.
00
)
0.
15
(0
.0
1
to
3.
65
)
0.
15
(0
.0
1
to
3.
34
)
0.
08
(0
.0
1
to
1.
96
)
0.
17
(0
.0
1
to
5.
60
)
0.
09
(0
.0
1
to
2.
09
)
0.
36
(0
.0
1
to
41
.0
0)
N
o
te
s
O
R
<
1
fa
vo
ur
s
in
te
rv
en
tio
n
tr
ea
tm
en
t,
O
R
>
1
fa
vo
ur
s
co
m
pa
ra
to
r
tr
ea
tm
en
t.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
181
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
MMF + SRL
MMF + TAC
MMF + CSA
BEL + MMF
BEL + SRL
SRL + AZA
SRL + CSA
SRL + TAC
TAC + AZA CSA + AZA
EVL + CSA
3 2
5
1
1
1
1
1
2
1
1
5
1
7
4
4
2
EVL + MPS
FIGURE 61 Network diagram for maintenance studies reporting mortality. Note: circles denote number of studies.
TABLE 110 Probability that each treatment is the most effective treatment for reducing mortality
Treatment Probability of being ‘best’ treatment (%)
SRL+AZA 34
EVL 30
BEL+ SRL 27
EVL+MPS 4
BEL+MMF 3
SRL+CSA 3
CSA+AZA < 1
TAC+AZA < 1
MMF+CSA < 1
EVL+CSA < 1
SRL+ TAC < 1
SRL+MMF < 1
TAC+MMF 0
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Biopsy-proven acute rejection
Thirteen treatments and 42 studies51,59,76,81–83,86,88–90,92,93,100,103,107,110,112,115–118,120,121,125–127,129,131,133–136,142,144,145,147,
149,150,152,210 (including three three-arm studies51,126,152 and one four-arm study122) contribute to this NMA
(Figure 62).
The DIC for the random-effects models was lower than that for the fixed-effects model (156.3 vs. 170.8)
and so the random-effects model results are reported here (see Appendix 6 for fixed-effects results). The
probabilities that each treatment was the most effective in reducing graft loss compared with all other
treatments are shown in Table 112.
MMF + SRL
MMF + TAC
MMF + CSA
BEL + MMF
BEL + SRL
SRL + AZA
SRL + CSA
SRL + TAC
TAC + AZA CSA + AZA
EVL + CSA
EVL + MPS
2 3
1
1
3
1
1
1
1
1
6
3
2
1
7
8
FIGURE 62 Network diagram for maintenance studies reporting BPAR. Note: circles denote number of studies.
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The regimen BEL+ SRL has the highest probability (58%) of being the most effective treatment compared
with all other treatments for reducing BPAR; however, there is no evidence that BEL+ SRL is any more
effective than the other treatments (Table 113). CSA+AZA has a 0% probability of being the best
treatment and there is evidence to suggest that many treatments are more effective than CSA+AZA
(see Table 112). The results from the NMA also indicate that MMF+CSA, TAC+MMF and SRL+ TAC are
all more effective than EVL+MPS at reducing BPAR. However, as with the other NMAs for maintenance
therapy, there is a great deal of uncertainty associated with the estimated ORs. Therefore, apart from
CSA+AZA and EVL+MPS performing poorly in some comparisons, it is difficult to say that any one
treatment is more effective than another, as the 95% CrIs are so wide.
There is no evidence to suggest that this network is affected by evidence inconsistencies (see Appendix 6).
The DIC was slightly lower for the consistency model than for the inconsistency model (156.3 vs. 159.7)
and the 95% CrIs that were based on the direct evidence overlapped those based on the direct and
indirect evidence.
Graft function
Twelve treatments and 35 studies51,59,60,76,82,84,102–104,107,109,115,117,118,120,121,125,126,129–131,133–136,138,142,144,145,147,149,150,152,155
(including four three-arm studies51,104,126,155) contribute to this NMA (Figure 63).
The DIC was lower for the random-effects model than for the fixed-effects model (147.8 vs. 323.7),
suggesting a better fit to the data for the random-effects model. Therefore, the random-effects model
results are reported (see Appendix 6 for fixed-effects model results). The treatment with the highest
probability of being the most effective (Table 114) is BEL+ SRL (44% probability), with SRL+AZA having a
28% probability. The results in Table 115 suggest that a number of treatments (TAC+AZA, TAC+MMF,
BEL+MMF and SRL+AZA) are more effective than CSA+AZA, and also that TAC+AZA, TAC+MMF and
BEL+MMF are more effective than SRL+ TAC. However, because of the limited direct evidence informing
many of the comparisons, the 95% CrIs are very wide for a number of comparisons, limiting conclusions
to be made on the effectiveness of one treatment over another.
For the random-effects model, there was little evidence of inconsistency within the network (see Appendix 6).
TABLE 112 Probability that each treatment is the most effective treatment for reducing BPAR
Treatment Probability of being ‘best’ treatment (%)
BEL+ SRL 58
SRL+CSA 27
SRL+ TAC 5
TAC+MMF 2
EVL+CSA 2
SRL+MMF 2
TAC+AZA 1
MMF+CSA < 1
BEL+MMF < 1
EVL+MPS < 1
SRL+AZA < 1
EVL < 1
CSA+AZA 0
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MMF + SRL
MMF + TAC
MMF + CSA
BEL + MMF
BEL + SRL
SRL + CSA
SRL + AZA
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FIGURE 63 Network diagram for maintenance studies reporting BPAR. Note: circles denote number of studies.
TABLE 114 Probability that each treatment is the most effective treatment for GRF
Treatment Probability of being ‘best’ treatment (%)
BEL+ SRL 44
SRL+AZA 28
BEL+MMF 17
TAC+AZA 9
EVL+MPS 1
TAC+MMF < 1
EVL+CSA < 1
SRL+ TAC < 1
SRL+CSA < 1
SRL+MMF < 1
CSA+AZA 0
MMF+CSA 0
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Summary for network meta-analysis
Induction therapy
l There is no evidence to suggest that BAS or rATG is more effective than PBO/no induction, or each
other, in reducing the odds of graft loss, mortality or CRC-GFR.
l rATG and BAS are both estimated to be more effective than PBO/no induction at reducing BPAR,
but the evidence does not suggest a difference between the two treatments.
l Evidence suggests that although no treatment effect is seen for rATG, BAS is estimated to be more
effective than PBO/no induction for increasing CRC-GFR.
Maintenance therapy
None of the maintenance regimens performed consistently well on all four outcomes. An overview of
probability ranking on the four outcomes is presented (Table 116). However, because the analyses
included 12 or 13 treatment regimens for each of the four outcomes, the results should be treated with
great caution.211 In addition, differences between treatments in probability of being best of < 90% cannot
be given much credence.211
TABLE 116 Probability that each treatment is the most effective treatment for mortality, reducing graft loss,
BPAR and GRF
Treatment
Probability of being ‘best’ treatment (%)
Mortality Graft loss BPAR GFR
SRL+AZA 34 29 < 1 28
EVL 30 60 < 1 < 1
BEL+ SRL 27 2 58 44
EVL+MPS 4 NA < 1 NA
BEL+MMF 3 2 < 1 17
SRL+CSA 3 6 27 < 1
TAC+MMF 0 < 1 2 < 1
MMF+CSA < 1 < 1 < 1 0
SRL+ TAC < 1 < 1 5 < 1
SRL+MMF < 1 < 1 2 < 1
EVL+CSA < 1 1 2 1
TAC+AZA < 1 < 1 1 9
CSA+AZA < 1 < 1 0 0
NA, not applicable.
Note
The order of the treatments is based on the results for mortality.
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In all NMAs for maintenance therapy there is a great deal of heterogeneity:
l There is no evidence to suggest that one treatment is any more effective at reducing the odds of graft
loss than any other treatment.
l There is evidence to suggest that BEL+MMF is more effective at reducing the odds of mortality than
TAC+MMF and SRL+MMF, but no other treatments are estimated to be any more effective at
reducing mortality than any other treatment.
l MMF+CSA, TAC+MMF and SRL+ TAC are estimated to be more effective than CSA+AZA and
EVL+MPS at reducing the odds of BPAR. In addition, TAC+AZA and EVL+CSA are also estimated to
be more effective than CSA+AZA at reducing the odds of BPAR. However, apart from CSA+AZA and
EVL+MPS performing poorly in some comparisons, it is difficult to say that any one treatment is more
effective than another as the 95% CrIs are very wide.
l Similarly, a number of treatments, TAC+AZA, TAC+MMF and BEL+MMF, are estimated to be more
effective than CSA+AZA and MMF+CSA at increasing GRF. In addition, SRL+AZA is estimated to be
more effective than CSA+AZA at increasing GRF. However, because of a lack of direct evidence, the
95% CrIs are wide for a number of comparisons. As a result, conclusions on the effectiveness of one
treatment over another are limited.
Adverse events
Adverse events for each study are presented below. We conducted numerous comparisons and
meta-analyses of the adverse effects of treatment reported in included RCTs at 1 year, as other time points
had insufficient data for pooling. All of the meta-analyses (and associated forest plots) can be found in
Appendix 7, rather than the main body of the report; however, the results are summarised as follows:
l Some evidence suggested more CMV infections in rATG regimens compared with BAS regimens,212
and in rATG regimens than with no induction (study by Charpentier96).128
l The meta-analysis comparing TAC and CSA regimens (including eight studies51,80,83,88,90,100,121,210)
suggested more cases of new-onset diabetes after transplant/transplantation (NODAT) in TAC regimens
than in CSA regimens.
l The meta-analyses comparing BEL with CSA regimens (including three studies59,125,142) suggested more
cases of NODAT in CSA regimens than in BEL regimens.
l The meta-analyses comparing SRL and CSA regimens (including seven studies116,117,134,147,149,194,195)
suggested more cases of NODAT in CSA regimens than in SRL regimens.
l The meta-analysis comparing MMF and EVL (including three studies107,131,177) suggested more cases of
CMV infections in MMF regimens than in EVL regimens.
Induction therapy
All 13 induction studies71–74,87,95–98,123,128,137,148 reported some AE data. The time of follow-up varied from
6 months to 7 years in the individual studies (Table 117). Most studies reported a 1-year follow-up,
although the AEs reported varied across the studies. The following AEs are summarised below: NODAT,
PTLD, malignancy (including PTLD), any infections and CMV.
New-onset diabetes mellitus
Seven studies87,95–97,123,128,148 reported NODAT events and their frequencies are shown in Table 118.
The studies that reported NODAT events showed frequencies ranging from 0 to 5 out of 58 (9%). None of
the comparisons suggests a statistically significant difference.
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TABLE 117 Adverse events overview: induction therapies
Number Study n Maintenance used Time point
BAS vs. PBO (five studies)
1 Bingyi 200395 12 CSA+AZA+CCSs 1 year
2 Kahan 199972 346 CSA+CCSs 1 year
3 Lawen 200374 123 CSA+MMF+CCSs 6 months
4 Nashan 199771 380 CSA+CCSs 1 year
5 Ponticelli 200173 340 CSA+AZA+CCSs 6 months
BAS vs. no induction (three studies)
6 Albano 2013123 1251 CSA+MMF+CCSs 6 months
7 Sheashaa 200397 100 CSA+AZA+CCSs 3, 5 and 7 years
8 Kyllönen 2007128 155 CSA+AZA+CCSs 1 year
rATG vs. no induction (two studies)
9 Charpentier 200196 309 TAC+AZA+CCSs+CSA+MMF 1 year
10 Charpentier 2003148 555 TAC+AZA+CCSs 6 months
BAS vs. rATG (three studies)
11 Brennan 2006137 278 CSA+MMF+CCSs 1 year
12 Lebranchu 200287 100 CSA+MMF+CCSs 6 months, 1 year
13 Mourad 200498 105 CSA+MMF+CCSs 1 year
TABLE 118 New-onset diabetes mellitus: induction regimens
Number Study 6 months 1 year 3 years 5 years 7 years
BAS vs. PBO (five studies)
1 Bingyi 200395 NR 0/6 vs. 0/6 NR NR NR
2 Kahan 199972 NR NR NR NR NR
3 Lawen 200374 NR NR NR NR NR
4 Nashan 199771 NR NR NR NR NR
5 Ponticelli 200173 NR NR NR NR NR
BAS vs. no induction (three studies)
6 Albano 2013123 31/247 vs. 35/265 NR NR NR NR
7 Sheashaa 200397 NR NR 4/50 vs. 7/50 4/50 vs. 7/50 4/50 vs. 7/50
8 Kyllönen 2007128 NR 5/58 vs. 1/44 NR NR NR
rATG vs. no induction (two studies)
9 Charpentier 200196 NR 5/145 vs. 7/154 NR NR NR
10 Charpentier 2003148 13/177 vs. 7/173 NR NR NR NR
BAS vs. rATG (three studies)
11 Brennan 2006137 NR NR NR NR NR
12 Lebranchu 200287 NR 1/51 vs. 1/50 NR NR NR
13 Mourad 200498 NR NR NR NR NR
NR, not reported.
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Malignancy and post-transplant lymphoproliferative disorder
Ten studies71–73,87,95,97,123,128,137,148 reported malignancy, including PTLD. The frequency of these events can be
seen in Table 119. Frequencies ranged from 0 to 3/168 (2%). No statistically significant differences
between treatments were noted.
Infections
Ten studies reported71–74,95,97,98,123,137,148 infections related to the induction therapies (Table 120). Frequencies
ranged from 0 to 129 out of 173 (75%). At 6 months and 1 year, a statistically significant difference in
favour of BAS is indicated.
TABLE 119 Malignancy and PTLD: induction regimens
Number Study 6 months 1 year 3 years 5 years 7 years
BAS vs. PBO (five studies)
1 Bingyi 200395 NR 0/6 vs. 0/6 NR NR NR
2 Kahan 199972 NR 2/173 vs. 6/173 NR NR NR
3 Lawen 200374 No malignancy data
(0/59 vs. 0/64)
NR NR NR NR
4 Nashan 199771 NR 3/190 vs. 2/186 NR NR NR
5 Ponticelli 200173 NR 3/168 vs. 6/172a NR NR NR
BAS vs. no induction (three studies)
6 Albano 2013123 3/283 vs. 2/302 NR NR NR NR
7 Sheashaa 200397 NR NR 1/50 vs. 1/50 1/50 vs. 2/50 1/50 vs. 3/50
8 Kyllönen 2007128 NR 0/58 vs. 1/44 NR NR NR
rATG vs. no induction (two studies)
9 Charpentier 200196 NR NR NR NR NR
10 Charpentier 2003148 4/186 vs. 1/185 NR NR NR NR
BAS vs. rATG (three studies)
11 Brennan 2006137 NR 1/137 vs. 5/141 NR NR NR
12 Lebranchu 200287 0/51 vs. 0/50 0/51 vs. 0/50 NR NR NR
13 Mourad 200498 NR NR NR NR NR
NR, not reported.
a Assumed 1-year data reported.
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Cytomegalovirus
Thirteen studies71–74,87,95–98,123,128,137,148 reported CMV events in induction therapies (Table 121). Frequencies
ranged from 0 to 49 out of 151 (32%), with a statistically significant difference noted for BAS vs. rATG
(three studies). For Lebranchu et al.87 and Mourad et al.98 a reduced occurrence of CMV is seen for the
BAS arm, whereas for the study reported by Brennan et al.,137 fewer occurrences are seen for rATG.
Maintenance therapy
Most of the 75 maintenance studies (Table 122) reported some AE data. The time of follow-up varied from
6 months to 10 years. Most studies reported 1-year follow-up, although the AE reported varied across the
studies. The following AEs are summarised below: NODAT, PTLD, malignancy (including PTLD), any
infections and CMV. All AEs are tabulated and narratively described in the sections below.
New-onset diabetes mellitus
Only one study148 out of 13 found statistically significant difference for TAC+AZA vs. CSA+AZA at the
6-month time point in favour of CSA (Table 123). Vincenti et al.125 found CSA+MMF to have a statistically
significant difference to BEL+MMF, but, again, only at 6 months. There is a statistically significant increase
in NODAT for SRL high+ TAC at 6 months when compared with SRL low+ TAC and MMF+ TAC.94
Two other studies51,122 show an increase in NODAT: Grinyo et al.51 for MMF+ low TAC and Anil Kumar
et al.122 for TAC+MMF.
TABLE 120 Infections: induction therapies
Number Study 6 months 1 year 3 years 5 years 7 years
BAS vs. PBO (five studies)
1 Bingyi 200395 NR 0/6 vs. 0/6 NR NR NR
2 Kahan 199972 NR 129/173 vs. 127/173 NR NR NR
3 Lawen 200374 37/59 vs. 45/64 NR NR NR NR
4 Nashan 199771 NR 161/190 vs. 161/186 NR NR NR
5 Ponticelli 200173 110/168 vs. 113/172 NR NR NR NR
BAS vs. no induction (three studies)
6 Albano 2013123 74/287 vs. 76/309 NR NR NR NR
7 Sheashaa 200397 NR NR NRa NRa NRa
8 Kyllönen 2007128 NR NR NR NR NR
rATG vs. no induction (two studies)
9 Charpentier 200196 NR NRa NR NR NR
10 Charpentier 2003148 126/186 vs. 108/185 NR NR NR NR
BAS vs. rATG (three studies)
11 Brennan 2006137 NR 103/137 vs. 121/141b NR NR NR
12 Lebranchu 200287 33/51 vs. 43/50b NR NR NR NR
13 Mourad 200498 NR 22/52 vs. 28/53 NR NR NR
NR, not reported.
a Different infections reported individually available.
b The p-value is < 0.05.
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TABLE 121 Cytomegalovirus: induction regimens
Number Study 6 months 1 year 3 years 5 years 7 years
BAS vs. PBO (five studies)
1 Bingyi 200395 NR 0/6 vs. 0/6 NR NR NR
2 Kahan 199972 NR 12/173 vs. 16/173 NR NR NR
3 Lawen 200374 8/59 vs. 12/64 NR NR NR NR
4 Nashan 199771 NR 39/190 vs. 50/186 NR NR NR
5 Ponticelli 200173 29/168 vs. 25/172 NR NR NR NR
BAS vs. no induction (three studies)
6 Albano 2013123 9/287 vs. 12/309 NR NR NR NR
7 Sheashaa 200397 NR NR 3/50 vs. 3/50 3/50 vs. 4/50 4/50 vs. 4/50
8 Kyllönen 2007128 NR 9/58 vs. 9/53 vs. 5/44 NR NR NR
rATG vs. no induction (two studies)
9 Charpentier 200196 NR 49/151 vs. 30/158a NR NR NR
10 Charpentier 2003148 45/186 vs. 29/185a NR NR NR NR
BAS vs. rATG (three studies)
11 Brennan 2006137 NR 24/137 vs. 11/141a NR NR NR
12 Lebranchu 200287 6/51 vs. 19/50a NR NR NR NR
13 Mourad 200498 NR 11/52 vs. 22/53a NR NR NR
NR, not reported.
a The p-value is < 0.05.
TABLE 122 Adverse events overview: maintenance therapies
Number Study AEs
TAC +AZA vs. CSA +AZA (13 studies)
1 Schleibner 199579 NR
2 Laskow 199680 1 year
3 Mayer 199788 1 year, 4 years, 5 years
4 Radermacher 199881 1 year
5 Jarzembowski 200599 1 year
6 Baboolal 200282 1 year
7 Campos 200283 1 year
8 Margreiter 200284 6 months, 2 years, 3 years
9 Van Duijnhoven 200275 NR
10 Waller 200276 1 year
11 Charpentier 2003148 6 months
12 Töz 200485 NR
13 Hardinger 2005100 1 year
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TABLE 122 Adverse events overview: maintenance therapies (continued )
Number Study AEs
CSA +MMF low vs. CSA +AZA vs. CSA +MMF (two studies)
14 Sollinger 199577 6 months
15 Tricontinental MMF renal study 199689 6 months, 1 year, 3 years
CSA +MMF vs. CSA +AZA (four studies)
16 Sadek 200286 1 year
17 Tuncer 200278 NR
18 Merville 2004138 1 year
19 Remuzzi 2007101 6 months, 5 years
TAC +MMF vs. CSA +AZA (two studies)
20 Wlodarczyk 2002171 6 months
21 Vacher-Coponat 2012129 1 year, 3 years
TAC +MMF vs. CSA +MMF (four studies)
22 Zadrazil 2012102 NR
23 Hernández 2007130 2 years
24 Rowshani 2006103 NR
25 Ulsh 1999153 1 year
TAC +AZA vs. CSA +AZA vs. CSA +MMF (one study)
26 Weimer 2005172 1 year
TAC +MMF vs. TAC-PR +MMF (four studies)
27 Wlodarczyk 2009140 NR
28 Krämer 201058 1 year
29 Tsuchiya 2013141 1 year
30 Oh 2014105 NR
TAC +MMF vs. TAC-PR 0.2 +MMF vs. TAC-PR 0.3 (one study)
31 Albano 2013123 6 months
MMF + TAC vs. MPS + TAC (one study)
32 Ciancio 2008106 1 year, 4 years
MMF +CSA vs. MPS +CSA (one study)
33 Salvadori 2004124 1 year
BEL low +MMF vs. BEL high +MMF vs. CSA +MMF (three studies)
34 Vincenti 2005125 1 year, 2 years, 3 years, 4 years, 5 years
35 BENEFIT60 1 year, 2 years, 3 years, 5 years
36 BENEFIT-EXT142 1 year, 2 years, 3 years, 5 years
BEL +MMF vs. BEL + SRL vs. TAC +MMF (one study)
37 Ferguson 2011126 1 year
continued
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TABLE 122 Adverse events overview: maintenance therapies (continued )
Number Study AEs
EVL low +CSAvs. EVL high +CSAvs. MMF +CSA (three studies)
38 Lorber 2005143 3 years
39 ATLAS150 1 year, 3 years
40 Takahashi 2013131 1 year
EVL vs. EVL +CSA vs. CSA +MPS (one study)
41 Chadban 2013152 1 year
EVL low +CSA vs. EVL high +CSA vs. MPA +CSA (one study)
42 Tedesco-Silva 2010107 1 year
EVL +CSA vs. MPS +CSA (one study)
43 Bertoni 2011144 1 year
EVL +MPS vs. CSA +MPS (two studies)
44 Budde 2011132 1 year, 2 years, 3 years
45 Mjörnstedt 2012133 1 year
SRL +CSA vs. MMF +CSA (two studies)
46 Barsoum 2007108 2 years
47 Stallone 2004109 NR
SRL + TAC vs. MMF + TAC (six studies)
48 Anil Kumar 2005110 1 year
49 Gonwa 2003180 6 months, 1 year
50 Sampaio 2008112 1 year
51 Gelens 2006113 NR
52 Gallon 2006145 3 years, 8.5 years
53 Van Gurp 2010114 6 months
SRL +MMF vs. CSA +MMF (10 studies)
54 Flechner 2002127 1 year, 5 years
55 Noris 2007115 2 years
56 Lebranchu 2009149 1 year, 4 years
57 Büchler 2007134 1 year, 5 years
58 Soleimani 201391 5 years
59 Durrbach 2008146 6 months
60 Kreis 2000116 1 year
61 Guba 2010147 1 year
62 Martinez-Mier 2006117 1 year
63 Nafar 2012118 NR
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TABLE 122 Adverse events overview: maintenance therapies (continued )
Number Study AEs
TAC +MMF vs. SRL +MMF (four studies)
64 Stegall 2003191 NR
65 Schaefer 200692 1 year
66 Heilman 2011135 1 year
67 Smith 200893 NR
TAC +MPS vs. SRL +MPS (one study)
68 Silva 2013119 2 years
TAC + SRL vs. MMF + SRL (one study)
69 Hamdy 2005120 1 year, 2 years, 5 years
SRL +AZA vs. CSA +AZA (one study)
70 Groth 1999194 1 year
TAC + SRL vs. CSA + SRL (one study)
71 Chen 2008121 1 year
SRL low + TAC vs. SRL high + TAC vs. MMF + TAC (one study)
72 Vítko 200694 6 months
SRL + TAC vs. SRL +MMF vs. MMF + TAC (one study)
73 Flechner 2011155 1 year, 2 years
MMF +CSA vs. MMF + low CSA vs. MMF + low TAC vs. MMF low SRL (one study)
74 Grinyo 200951 1 year, 3 years
TAC +MMF vs. TAC + SRL vs. CSA +MMF vs. CSA + SRL (one study)
75 Anil Kumar 2005110 5 years
NR, not reported.
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Malignancy and post-transplant lymphoproliferative disorder
For all combinations reporting malignancy and PTLD, no statistically significant difference was seen
between arms (Table 124).
Infections
Maintenance therapy studies that reported infection rates gave frequencies of 9 out of 237 (4%) to 85 out
of 85 (100%; Table 125). Despite the relatively common occurrence of infections, only one study150
displayed a statistically significant difference between arms in favour of SRL low+ TAC, as opposed to SRL
high+ TAC and MMF+ TAC.
Cytomegalovirus
Studies that reported the frequencies of CMV showed that this ranged from 0 to 7 out of 27 (26%)
(Table 126).
The CSA+MMF arm of the following trials displayed a statistically significant difference, in terms of
increased episodes of CMV: Sadek et al.,86 Vítko et al.,94 Takahashi et al.,131 Büchler et al.,134 Kreise et al.,116
Tedesco-Silva et al.107 and Grinyo et al.51 Krämer et al.58 reported a statistically significant difference for
TAC-PR+MMF vs. TAC+MMF and Van Gurp et al.114 found increased events for TAC+MMF as opposed
to SRL+ TAC.
Summary of clinical effectiveness
Summary of pairwise comparisons
Overall, we found that, despite the volume of evidence, there is little impact on effectiveness conclusions
from the head-to-head comparisons, particularly for graft loss and mortality. However, this may be a
reflection of the lack of long-term data, as very few studies reported all outcomes beyond 1 year, and also
the frequently substantial level of heterogeneity across studies. Furthermore, the quality of trials was
variable and, as a result of reporting omissions, it was difficult to make a general assessment
regarding quality.
Induction
l We found no evidence to suggest BAS or rATG are more effective than PBO, no induction or each
other in reducing the odds of mortality. Similarly, for graft loss, we found no evidence of a statistically
significant difference for BAS or rATG vs. PBO, no induction or each other.
l Three RCTs98,137,149 were identified for BAS vs. rATG. No statistically significant difference was seen for
any of the outcomes.
l For the head-to-head comparisons, we found evidence to suggest that rATG and BAS are more
effective than PBO or no induction at reducing BPAR (rATG at 1 year, OR 0.41, 95% CI 0.24 to 0.52
BAS at 1 year, OR 0.53, 95% CI 0.40 to 0.70). However, there is no statistically significant difference
between BAS and rATG.
l Time to BPAR is reported only for rATG vs. no induction and BAS vs. rATG. The one study96 for rATG
vs. no induction found that more participants experienced BPAR at 7–10 days with no induction than
with rATG (seven participants for rATG vs. 30 participants for no induction). There was no statistically
significant difference between interventions for BAS vs. rATG.
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Maintenance
l We found no evidence that any maintenance therapies were preferable to others in terms of mortality.
l For graft loss outcomes reported by maintenance studies, we found evidence that at 5 years
BEL+MMF may be superior to CSA+MMF (OR 0.40, 95% CI 0.19 to 0.87, I2= 0.0%). The 0.5-year
time point has only two studies and a substantial level of heterogeneity (I2= 72.2%); therefore, the OR
of 0.58 and 95% CI 0.09 to 3.59, which indicates that MMF is more effective at reducing graft loss,
must be treated with caution.201 The results for 1 year suggest no difference between arms (OR 0.76,
95% CI 0.38 to 1.50). The Merville et al.138 study appears to show more of an effect in favour of MMF;
however, the population is much smaller than that for the Tricontinental study89 and the Sadek et al.86
study. Weimer et al.104 found no evidence of graft loss in either arm.
l Several treatments showed a beneficial effect with regard to reducing BPAR, although this varied across
time points. For all the following combinations, the arm containing TAC displayed lower odds
associated with BPAR:
¢ TAC+AZA vs. CSA+AZA (0.5 years, OR 0.50, 95% CI 0.32 to 0.79; I2= 50.1%; 1 year, OR 0.50,
95% CI 0.39 to 0.64; I2= 8.1%; 4 years, OR 0.38, 95% CI 0.25 to 0.57)
¢ TAC+MMF vs. CSA+AZA (0.5 years, OR 0.64, 95% CI 0.41 to 0.98; 1 year, OR 0.35, 95% CI
0.15 to 0.82)
¢ TAC+MMF vs. CSA+MMF (1 year, OR 0.59, 95% CI 0.37 to 0.94, I2= 19.3%)
¢ TAC+MMF vs. SRL+MMF (1 year, OR 0.32, 95% CI 0.12 to 0.87, I2= 0.0%)
¢ TAC+ SRL vs. TAC+MMF (0.5 years, OR 0.65, 95% CI 0.44 to 0.96).
l For CSA+MMF vs. CSA+AZA, at 0.5 years and 1 year, there is statistically significant evidence to
suggest that MMF is more effective (0.5 years, OR 0.50, 95% CI 0.35 to 0.72, I2= 35.1%).
l TAC is also associated with lower odds of reduced GRF for:
¢ TAC+MMF vs. CSA+MMF (3 years, WMD 4.60ml/minute/1.73m2, 95% CI 1.35 to
7.85ml/minute/1.73m2)
¢ TAC+MMF vs. TAC-PR+MMF (0.5 years, WMD 1.90ml/minute/1.73m2, 95% CI 1.70 to
2.10ml/minute/1.73 m2)
¢ TAC+ SRL vs. CSA+ SRL (0.5 years, MD 6.35ml/minute/1.73 m2, p< 0.0001; 1 year, MD 5.25,
p= 0.0004).
l For MMF+ TAC vs. MPS+ TAC, MPS at 1 year and 3 years is more effective (1 year, MD 1.9ml/minute/
1.73m2, p< 0.0001; 3 years MD 0.5ml/minute/1.73m2, p= 0.0016). BEL appears more effective at
1 year and 3 years for BEL+MMF vs. CSA+MMF (1 year, WMD 7.83ml/minute/1.73m2, 95% CI 1.57
to 14.10ml/minute/1.73m2; I2= 73.6%; 3 years, WMD 16.08ml/minute/1.73m2, 95% CI 5.59 to
26.56ml/minute/1.73m2; I2= 89.5%); however, heterogeneity across studies is substantial. Where
there are two comparisons involving SRL and CSA, the regimen including MMF suggests CSA to be more
beneficial up to 5 years (5 years, WMD 9.10ml/minute/1.73m2, 95% CI 1.68 to 16.52ml/minute/1.73m2),
yet, in contrast, the regimen including AZA suggests SRL to be more effective (1 year, MD
10.8ml/minute/1.73 m2, p< 0.0001).
l Time to BPAR is generally poorly reported and therefore it is challenging to form a conclusion. Again,
TAC+AZA vs. CSA+AZA shows conflicting results for two studies; however, the statistically significant
result suggests that BPAR is achieved more quickly for participants receiving TAC rather than CSA
(MD 24 days; p= 0.0033). This is also true for TAC+MMF vs. CSA+MMF (MD 46.7 days; p< 0.0001).
When SRL+ TAC and MMF+ TAC are compared, a reduced time to BPAR is seen for MMF
(MD 48.6 days; p= 0.0017). For SRL+MMF vs. CSA+MMF, one146 of three studies127,134,146
demonstrates a statistically significant difference in favour of CSA (MD 38 days; p= 0.0035); however,
the other two studies127,134 show no difference.
l For TAC+AZA vs. CSA+AZA, there may be lower odds of the more severe BPAR for the arm
containing TAC. Similarly, for TAC+MMF vs. TAC-PR+MMF, TAC has a lower proportion of people
experiencing the more severe BPAR of Banff III classification.
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Summary for network meta-analysis
Induction therapy
l There is no evidence to suggest BAS or rATG are more effective than PBO/no induction or each other
in reducing the odds of graft loss or mortality, which is in agreement with the pairwise comparisons.
l rATG and BAS are both estimated to be more effective than PBO/no induction, with rATG being more
effective than BAS at reducing BPAR.
l Evidence suggests that although no treatment effect is seen for rATG, BAS is estimated to be more
effective than PBO/no induction for increasing CRC-GFR.
Maintenance therapy
l For all NMAs for maintenance therapy there is a great deal of heterogeneity.
l There is no evidence to suggest that one treatment is any more effective at reducing the odds of graft
loss than any other treatment.
l There is evidence to suggest that BEL+MMF is more effective at reducing the odds of mortality than
TAC+MMF and SRL+MMF, but no other treatments are estimated to be any more effective at
reducing mortality than any other treatment.
l A number of treatments are estimated to be more effective than CSA+AZA and EVL+MPS at
reducing the odds of BPAR, and CSA+AZA and SRL+ TAC at increasing GFR, but no other treatments
are estimated to be any more effective at reducing the odds of BPAR or increasing GFR than any
other treatment.
Comparison between clinical effectiveness analyses
Induction
Network meta-analysis and pairwise comparisons were in agreement for all comparable outcomes other
than GRF, for which NMA suggested that BAS may be more effective than PBO/no induction.
Maintenance
l Pairwise comparisons found no evidence that any maintenance therapies were preferable to others in
terms of mortality; however, NMA found evidence to suggest that BEL+MMF is more effective at
reducing the odds of mortality than TAC+MMF and SRL+MMF.
l Following NMA, there is no evidence to suggest that one treatment is any more effective at reducing
the odds of graft loss than any other treatment. For pairwise comparisons, there is some evidence
that BEL+MMF may be superior to CSA+MMF; CSA+MMF may be superior to CSA+AZA; and
TAC+AZA may be superior to CSA+AZA.
l A number of treatments were estimated to be more effective than CSA+AZA and EVL+MPS at
reducing the odds of BPAR by the NMA, but no treatments found to be any more effective than any
other. As for the pairwise comparisons, the arm containing TAC displayed lower odds associated with
BPAR for TAC+AZA vs. CSA+AZA; TAC+MMF vs. CSA+AZA;TAC+MMF vs. CSA+MMF and
TAC+MMF vs. SRL+MMF.
l The NMA found evidence that CSA+AZA and SRL+ TAC were effective at increasing GFR, but no
other treatments were estimated to be any more effective than any other treatment. Although the
pairwise comparison found that TAC was generally associated with lower odds of reduced GRF
for TAC+MMF vs. CSA+MMF; TAC+MMF vs. TAC-PR+MMF; TAC+ SRL vs. CSA+ SRL. For
MMF+ TAC vs. MPS+ TAC, MPS was more effective.
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Current assessment (Technology Assessment 85)
Relevant to this review, the current assessment (TA85) found that BAS, TAC and MMF consistently reduced
the incidence of short-term (1-year) AR compared with conventional immunosuppressive therapy. The
independent use of BAS, TAC and MMF was associated with a similar absolute reduction in 1-year acute
rejection rate (ARR) (approximately 15%).
The trials did not assess how the improvement in trials, the impact of the newer immunosuppressants on
long-term graft loss and patient survival remain uncertain.
The absence of both long-term outcome and quality of life from trial data makes assessment of the clinical
effectiveness challenging.
Ongoing studies
Searches of ClinicalTrials.gov and Controlled Trials were conducted (see Appendix 1 for the search strategy
used). All searches were carried out in January 2015. A total of 256 trials were considered to be relevant
to this review and were investigated further. Sixty-nine studies were identified as ongoing (active not
recruiting, n= 16; not yet recruiting, n= 7) or recruiting (n= 46). In 26 trials the current status was
recorded as ‘unknown’. Twenty-three trials had terminated, two had been suspended and three had been
withdrawn; of these, five had results available. Finally, 133 studies were completed. A summary of the
trials is provided in Table 127. The search of ongoing studies did not identify any additional RCTs for
inclusion in PenTAG systematic review; 18 studies were already considered in PenTAG review. An overview
of these trials is provided in Appendix 8.
Critique of company submissions’ search strategies
Submissions from four companies were presented, summarising evidence on the effectiveness of
immunosuppressive therapies in renal transplantation: Sandoz, Astellas, Bristol-Myers Squibb and Novartis.
Sandoz
The company’s literature search is primarily focused on finding studies that report on Adoport®, Sandoz’s
licensed version of TAC. The searches presented by Sandoz are transparent, replicable and consistent with the
aims of the company’s submission, which is a systematic review of Adoport with no economic model.
Sandoz’s literature searches have been conducted in a range of bibliographic databases, including
MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and NHS Economic Evaluation
Database (NHS EED). These searches have been supplemented with an unreported search of Sandoz’s
internal databases.
We believe these searches to be adequate but we are unable to exclude the possibility of reporting bias.
The search strategies are geared to locate studies that include the brand name (Adoport) or drug name
(TAC) and company name (Sandoz). It is feasible that a title/abstract might merely mention the drug name
without a brand or company stated and, if such a study existed, this would be missed by the company’s
literature searches. The nature of RCT reporting makes this unlikely for trial data but, for AEs or economic
literature, it is a possibility. However, as the manufacturer made an unreported search of its own databases
it is unlikely it would have missed one of its own trials.
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Sandoz’s submission summarised the evidence on Adoport and compared Adoport with Prograft®,
the Astellas-licensed version of TAC. It identified 26 papers: one RCT (reported in two papers) and
24 non-randomised studies (non-RCTs). The RCT was a pharmacokinetics study and had no clinical
effectiveness data. None of the included studies is considered in PenTAG systematic review (Table 128).
In summary, the results of Sandoz’s submission are not comparable with the results of the current
HTA review.
Astellas
The literature searches have been conducted in the key bibliographic databases, MEDLINE, EMBASE,
The Cochrane Library and Cochrane NHS EED.
The literature searches used minimal free-text search terms without the use of truncation or controlled
indexing, and selected synonyms were used for the interventions/comparators. This reflects poor sensitivity
and, combined with the fact that searching has been conducted on only the abstracts of potentially
includable studies, it is possible that some studies may have been missed.
TABLE 127 Summary of studies
Trial status (N) n included in PenTAG n excluded (reason)
Active, not recruiting (16) 3 13
(7 – no publication, 1 – no data, 1 – mixed transplants,
4 – not relevant)
Not yet recruiting (7) 0 7
(no data)
Recruiting (46) 0 46
(no data)
Unknown (26) 2 24
(12 – no publication, 2 – mixed population, 2 – no data,
1 – dosing studies, 7 – not relevant)
Suspended (2) 0 2
(2 – no publication)
Withdrawn (3) 0 3
(1 – no publication, 2 – not relevant)
Terminated (23) 0 23
[2 – no publication, 1 – mixed population, 6 – treatment
(dosing or conversion), 14 – not relevant]
Completed (133) 13 120
[60 – no publication, 6 – mixed population, 6 – no data,
15 – treatment (dosing or conversion), 33 – not relevant]
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The submission set out to compare the efficacy and safety of TAC (Prograf) therapy with the efficacy and
safety of current alternative treatments [TAC-PR (Advagraf), CSA, SRL and BEL] in addition to EVL, as primary
immunosuppressive therapies in people undergoing renal transplantation.
Thirty-eight RCTs were identified: 19 studies comparing TAC and CSA regimens, 10 studies comparing SRL
and TAC regimens [CNI avoidance (six studies), CNI avoidance and steroids withdrawal (one study), CNI
minimisation (three studies)], three trials comparing TAC-PR and TAC regimens, two studies reporting on
BEL and six studies reporting on EVL. Two studies239,240 included information for two comparisons. No
head-to-head studies comparing TAC with BEL, and TAC with EVL, were identified (Table 129). Two
separate NMAs were performed: one comparing TAC with EVL, and another comparing TAC with BEL.
TABLE 128 Sandoz’s submission: included studies
Study Included in PenTAG review Reason for exclusion
Alloway 2012213 ✗ Study design
Bloom 2013214 ✗ Study design
Connor 2012215 ✗ Study design
Connor 2013216 ✗ Study design
Heavner 2013217 ✗ Study design
Marfo 2013218 ✗ Study design
McDevitt-Potter 2011219 ✗ Study design
Richards 2014220 ✗ Study design
Rosenborg 2014221 ✗ Study design
Spence 2012222 ✗ Study design
Babu 2013223 ✗ Abstract
Betmouni 2012224 ✗ Abstract
Chiu 2012225 ✗ Abstract
Crowther 2012226 ✗ Abstract
Dick 2011227 ✗ Abstract
Heldenbrand 2012228 ✗ Abstract
Jogia 2013229 ✗ Abstract
Kendrew 2013230 ✗ Abstract
Qazi 2012231 ✗ Abstract
Sharma 2013232 ✗ Abstract
Shiu 2013233 ✗ Abstract
Siddiqi 2011234 ✗ Abstract
Storey 2013235 ✗ Abstract
Venkataramanan 2012236 ✗ Abstract
Wilcock 2013237 ✗ Abstract
Marsen 2012238 ✗ Study design
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TABLE 129 Astellas’ submission: included studies
Study Included in PenTAG review Reason for exclusion
Ekberg 2007240 ✓
Abou-Jaoude 2003241 ✗ Study design
Abou-Jaoude 2005242 ✗ Study design
Busque 2001243 ✗ Study design
Campos 200283 ✓
Hardinger 2005100 ✓
Johnson 2000244 ✗ Population
Margreiter 200284 ✓
Martin Garcia 2003245 ✗ Study design
Morris-Stiff 1998246 ✗ Population
Murphy 2003166 ✓
Raofi 1999210 ✓
Silva 2007239 ✗ Population
Töz 200485 ✓
Vincenti 2007247 ✗ Study design
Wang 2000248 ✗ Abstract
White 2000249 ✗ Abstract
Williams 1999250 ✗ Abstract
Yang 199990 ✓
Flechner 2011155 ✓
Glotz 2010251 ✗ Study design
Larson 2006154 ✓
Chhabra 2013252 ✗ Study design
Lo 2004253 ✗ Study design
Hamdy 2005120 ✓
Ciancio 2004 2004254,255 ✗ Population
Gonwa 2003180 ✓
Mendez 2005111 ✓
Vincenti 201059 ✓
Durrbach 2010142 ✓
Bertoni 2011144 ✓
Tedesco-Silva 2010107 ✓
Albano 2013123 ✓
Krämer 2010204 ✓
Langer 2012256 ✗ Study design
Chan 2008257 ✗ Study design
Favi 2012258 ✗ Abstract
Ruiz 2011259 ✗ Abstract
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In summary, Astellas’ results suggest no significant differences between TAC and EVL regimens, and less
BPAR in BEL than in TAC. In the head-to-head comparisons, no differences between TAC and TAC-PR were
identified. In addition, more AR episodes were identified in CSA than in TAC and in SRL than in TAC.
In comparison, the PenTAG NMA found evidence to suggest that BEL+MMF is more effective at reducing
the odds of mortality than TAC+MMF and SRL+MMF, but no other treatments were estimated to be
any more effective at reducing mortality than any other treatment. In addition, BEL+MMF are estimated
to be more effective than CSA+AZA and MMF+CSA at increasing GRF. The head-to-head comparisons
suggested that the clinical effectiveness of TAC-PR and TAC are similar, with TAC having a lower
proportion of people experiencing the more severe BPAR of Banff III classification (OR 0.11, 95% CI 0.01
to 0.87; I2= 0.0%). We also found some benefits to using TAC regimens compared with CSA regimens.
For a full summary of head-to-head comparisons see Summary of pairwise comparisons, above.
Bristol-Myers Squibb
The literature searching used for this submission is not sufficient to provide a systematic and transparent
review of BEL. The literature searching takes the following structure: (terms for TAC) AND (a methodological
search filter to limit to RCTs). The literature search does not include any search terms for BEL, the
intervention under submission by the company, or CSA.
In practice, this means that the searches will pick up studies of BEL only if BEL is in comparison with TAC.
The company states that BEL has not been compared with TAC in head-to-head RCTs, noting that, in the
case of BENEFIT59 and BENEFIT-EXT,142 CSA was the main licensed treatment used in clinical practice. This
statement further confuses the rationale for using TAC as the named intervention in the literature search
for this submission. It is therefore likely that includable trials have been missed (Table 130).
In summary, because of the issues with the literature searches in Bristol-Myers Squibb’s submission,
Bristol-Myers Squibb’s conclusions are not comparable with the results of the current HTA review
(see Table 130).
Novartis
The company’s literature search for this submission is systematic, robust and transparent. The company
has searched all of the required databases and made an exhaustive attempt to locate published and
unpublished studies. The submission compared the efficacy and safety of MPS and EVL, as primary
immunosuppressive therapies in people undergoing renal transplantation. A total of seven RCTs, three
open-label extension studies of RCTs, as well as three non-RCTs with MPS regimen were identified in the
systematic review. A total of 14 studies (25 publications and two unpublished clinical study reports)
with EVL regimen were identified in the systematic review; eight RCTs, five prospective studies and
one observational study (Table 131).
In summary, Novartis’ results suggests that MMF and MPS are comparable. Similar conclusions were made
in the current HTA review in head-to-head studies. In addition, the submission suggested the use of EVL in
early CNI minimisation. The NMA results of the current HTA review did not suggest that EVL regimens
were better in reducing mortality or graft loss and improving GRF than all other treatments. However, the
EVL+MPS regimen was estimated to be less effective than the MMF+CSA regimen in reducing the odds
of BPAR. In addition, the EVL+CSA regimen was estimated to be more effective than the CSA+AZA
regimen in reducing the odds of BPAR. However, apart from the CSA+AZA and EVL+MPS regimens
performing poorly in some comparisons, it is difficult to say that any one treatment is more effective than
another, as the 95% CIs are very wide.
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TABLE 130 Bristol-Myers Squibb’s submission: included studies (RCTs)
First author and year Included in PenTAG review Reason for exclusion
Abou-Jaoude 2003260 ✗ Study design
Busque 2001243 ✗ Study design
Campos 200283 ✓
Charpentier 2003148 ✓
Chen 2008121 ✓
Cheung 2006261 ✗ Study design
Egfjord 2002262 ✗ Abstract
Ekberg 2007240 ✓
El Haggan 2002263 ✗ Abstract
Hardinger 2005100 ✓
Hernández 2007130 ✓
Liu 2003264 ✗ Population
Margreiter 200284 ✓
Mayer 199788 ✓
Murphy 2003166 ✓
Radermacher 199881 ✓
Rowshani 2006103 ✓
Töz 200485 ✓
Tsinalis 2000265 ✗ Abstract
Van Duijnhoven 200275 ✓
Vincenti 1996161 ✓
Vincenti 2007247 ✗ Study design
Wang 2000248 ✗ Abstract
Yang 199990 ✓ Included
Yu 2000266 ✗ Abstract
Nichelle 2002267 ✗ Study design
Heering 1998268 ✗ Data
Ichimaru 2001269 ✗ Study design
Anil Kumar 2008122 ✓
BENEFIT59 ✓
BENEFIT-EXT142 ✓
Vincenti 2005206 ✓
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TABLE 131 Novartis’ submission: included studies
First author and year
Included in
PenTAG review Reason for exclusion
Salvadori 2001,270 2004,124 2006271 ✓
Budde 2004,272 2005,273 2006274 ✗ Intervention
Shehata 2009275 ✗ Study design
Ortega 2011276 ✗ Study design
Langone 2013,277 Chan 2013278 ✗ Study design
Shah 2013279 ✗ Study design
Ciancio 2008,106 2011173 ✓
Langone 2011280 ✗ Study design
Chan 2006281 ✗ Study design
Hwang 2010282 ✗ Study design
Novartis CSR, Tedesco-Silva 2010,283 Cibrik 2013284 ✓
Takahashi 2013,131 Takahara 2012,285 Saito 2013286 ✓
Paoletti 2012,287 2012288 ✗ Study design
Favi 2009,289 2009,290 2010,291 2013292 ✗ Study design
Gonzalez 2010293 ✗ Study design
Miserlis 2008294 ✗ Study design
Watarai 2013295 ✗ Study design
Loriga 2010296 ✗ Study design
Vítko 2005,150 Dantal 2002,297 Vítko 2005,177 Oppenheimer 2003298 ✓
Lorber 2005143 ✓
Novartis CSR, NCT01025817; CRAD001AUS92299 ✗ Data
Tedesco 2012,300 2013301 ✗ Abstract
Favi 2012,258 2013302 ✗ Abstract
Kamar 2005,303 Rostaing 2001304 ✗ Design
CSR, clinical study report.
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Chapter 4 Assessment of cost-effectiveness
Review of cost-effectiveness evidence
The purpose of this section of the report is to review existing evidence on the cost-effectiveness of
immunosuppressive regimens [BAS and rATG as induction therapies, and immediate-release TAC, TAC-PR,
MMF, MPS, SRL, EVL and BEL as maintenance therapies (including a review of TA85)], in renal transplantation
in adults.
Methods
Searches
Bibliographic literature searching was conducted on 8 April 2014. The searches took the following form:
(terms for kidney or renal transplant or kidney or renal graft) AND (terms for the interventions under
review) AND (a costs or economic literature search filter). The search was date limited 2002–current, in line
with the previous assessment, and the searches were updated on 18 November 2014. The search was not
limited by language and it was not limited to human-only studies.
The following databases were searched: MEDLINE (via Ovid), EMBASE (via Ovid), NHS EED (via Wiley Online
Library), Web of Science (via ISI – including conference proceedings), HEED (via Wiley Online Library) and
EconLit (via EBSCOhost). The search strategies are recorded in Appendix 1.
Screening
Inclusion and exclusion criteria were the same as for the clinical effectiveness systematic review
(see Chapter 3, Inclusion and exclusion criteria), with the following exceptions (as specified in the
appraisal protocol):
l Non-randomised studies were included (e.g. decision-model-based analyses, or analyses of
patient-level cost and effectiveness data alongside observational studies).
l Full cost-effectiveness analyses (CEAs), cost–utility analyses and cost–benefit analyses were included.
(Economic evaluations that report only average cost-effectiveness ratios were included only if the
incremental ratios can be easily calculated from the published data.)
l Studies that measure only costs but not health benefits were excluded except for stand-alone cost
analyses from the perspective of the NHS.
l Only economic evaluations from the UK, USA, Canada, Australia and Western Europe were included,
as these settings may include data that are generalisable to the UK.
Titles and abstracts were screened for relevance by two reviewers (RMM and LC), with disagreements
resolved by discussion. Full texts were retrieved for references that were judged to be relevant, and
screened for eligibility by the same reviewers, with disagreements resolved by discussion.
The bibliographies of review articles that were not judged to be eligible for inclusion were examined by
one reviewer (LC) to identify other potentially relevant references. These references were retrieved and
checked for eligibility in the same way as full texts from database searches.
Quality assessment
Studies meeting the criteria for inclusion were assessed by one reviewer (RMM) using the checklist
developed by Evers et al.305 (Table 132). When studies are based on decision models they will be further
quality assessed using the checklist developed by Philips et al.322,323
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Synthesis
Economic studies were summarised and synthesised using tabulated data and narrative synthesis.
Results
Identified studies
The electronic database search for cost-effectiveness evidence identified 2241 records. After deduplication,
1378 records remained, all of which were screened by title and abstract. Of these, 86 full texts were
assessed for eligibility. Nineteen full texts were deemed to meet the eligibility criteria for the review.
The study selection process is detailed in Figure 64.
Twelve economic evaluations were included in the review (published in 14 publications65,306,308–316,319–321).
Update searches, conducted on 18 November 2014, yielded an additional six reports42,307,318,324,325 on
economic evaluations eligible for inclusion in the review. Of these, one report307 was an update on a study
identified by the original search, and another three reports318,324,325 constituted multiple reports on a newly
identified study.
Thirteen studies65,307–310,312,314–319,321 were included in this review. Five were studies of induction
regimens,312,314–317 three of which were studies of UK adults,315–317 and 10 were studies of initial and
maintenance immunosuppression,65,307–310,318,319,321 four of which were of UK adults.65,309,310,318 In what
follows, studies of induction regimens are reviewed before reviewing studies of initial and maintenance
immunosuppressive regimens, by country setting (UK vs. other). Table 133 describes the characteristics of
included studies of induction regimens. Table 134 describes the characteristics of included studies of initial
and maintenance regimens. All studies but one were sponsored by the industry or co-authored by an
individual person who was affiliated with a company manufacturing or commercialising one of the
evaluated treatments.
Induction therapy
UK studies
Walters et al. 2003
In a multi-European country RCT, BAS induction was compared with PBO in people who were given triple
therapy with CSA, AZA and steroids.316 Information on costs of immunosuppressant drugs, hospitalisations,
procedures, outpatient visits, laboratory tests, renal biopsies, concomitant medications, dialysis and
nephrectomy was prospectively collected for the trial follow-up period of 6 months. Retransplantation costs
were not included. A cost-effectiveness analysis (CEA) conducted alongside the trial included all costs up to
6 months and the costs of dialysis up to 12 months. This analysis adopted a NHS hospital perspective; it
pooled the data on clinical outcomes and resource utilisation from all countries and people involved in the
trial (n= 340) but evaluated resource use using UK national and local unit costs (1997–9 prices).
Basiliximab was found to reduce the incidence of first confirmed AR episodes by 6 months (absolute risk
reduction 0.14). The rate of graft failure with BAS was 11% and 18% in the PBO arm (p= 0.24). The
mortality rate was 2% and 3%, respectively (p= 1.00). In terms of the number of people with AEs or
infections reported as serious, the comparisons had p≥ 0.65.
In terms of costs, hospitalisations were the largest element of the total, followed by dialysis and AR.
Comparisons by resource-use category between arms had all p≥ 0.05. Over the 6-month period post
transplantation, BAS had an incremental cost of £231 (95% CI –£1983 to £2446). Including the
6–12 months costs of dialysis, the BAS had an incremental total costs of –£30 (95% CI –£2326 to £2686).
In the 6-month period post transplantation, the incremental costs per case of treatment failure (i.e. no AR,
graft failure or death) avoided with BAS was £1650.
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Identification
Records identified through
database searching
(n = 2241)
Records after
duplicates removed
(n = 1378)
Records screened
(n = 1378)
Eligible publications
(n = 32)
CEA/CUA
(n = 13)
(in 14 publications)
Abstract
(n = 13)
Other economic
evaluationa
(n = 5)
Full-text articles
excluded with reasons
(N = 54)
• Population, n = 8
• Intervention, n = 11
• Comparator, n = 3
• Outcomes, n = 6
• Study design, n = 15
• No usable data, n = 1
• Language, n = 2
• Duplicate, n = 7
• Unobtainable, n = 1
Screening
Full-text articles
assessed for eligibility
(n = 86)
Eligibility
Records excluded
(n = 1292)
FIGURE 64 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow chart.
CUA, cost–utility analysis. a, Includes studies reporting UK costs and effects without economic evaluation, and
stand-alone cost analyses based in the NHS.
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The authors found that, despite the fears of increased AEs from overimmunosuppression, BAS given with
triple therapy resulted in fewer ARs and no difference in costs relative to PBO in the first 6 months.
The study provides valuable evidence of data on resource use and short-term outcomes of induction
therapy with BAS. For our present purposes, the main limitation of this study is the lack of relevant
comparators, such as induction with rATG. Further, as the authors point out, the use of these regimens in
combination with triple-therapy immunosuppressive regimens commonly used in recent years, in particular
a CNI with MMF and steroids, would have added relevance to the study.
The authors do not include the costs of retransplantation in their 1-year analysis, despite including the
costs of dialysis. They also do not provide any evidence of the impact of induction on HRQoL. In addition,
an attempt to investigate the potential long-term implications of ARR prevention with BAS is warranted,
using the framework linking biomarkers to longer-term patient and graft survival outcomes using a
predictive model.
A major limitation of the study is the fact that the quantities of resource utilisation were derived from a
sample of people being treated in the UK and 11 other countries.316 The authors acknowledge that
important differences may exist between these countries, as evidenced by the length of hospital stay such
that ‘whereas prevention of early episodes of AR may save a readmission in the US, this would not
necessarily lead to an earlier hospital discharge following transplantation in some of the countries involved
in this study (e.g. Israel, Poland, Turkey)’ (Walters et al.316). This limits the validity of the results of this
study, which was designed from an English NHS perspective.
Chilcott et al. 2002
In a separate study of a similar design to that used in the study by Walters et al.,316 Chilcott et al.315
compared the costs of renal immunosuppression in centres in Canada and six European countries,
including the UK. The study followed people for 12 months and, unlike the study by Walters et al.,316
which calculated costs for the UK using pooled resource utilisation data from all countries, only resource
utilisation data from each country were used to estimate the respective costs. Country-specific unit costs
were adjusted for purchasing power parity (PPP) to reflect the actual opportunity costs of health-care
resources in each country.315
The study involved 376 people (BAS, n= 190; PBO, n= 186) and, as Walters et al.316 had found for
6-month post-transplantation outcomes, observed that BAS reduced the rate of (suspected) ARs
(BAS 37%, PBO 54.8%; absolute risk difference (ARD) –16.9, 95% CI –29 to –4] without affecting
graft loss (ARD –1.3, 95% CI –8.1 to 5.4) and patient survival (ARD 2.0, 95% CI –1.8 to 5.9) at
12 months. The authors report that no retransplantations were recorded in any group over the 12-month
post-transplantation period studied.
Tests of differences in resource quantities used between the trial arms were all associated with p> 0.05.
The costs estimates were reported in terms of PPP US dollars (US$,1996 prices). After converting them
back to PPP pounds sterling (£) using the £0.4=US$1 conversion rate provided by the Chilcott et al.315
study (see Table 141),315 the mean total per-patient cost in the BAS arm was £19,174 and £18,510 in the
PBO arm (difference £664, 95% CI –£1660 to £2944). The incremental cost per suspected case of AR
avoided at 12 months post transplantation was £3929. In addition, and unlike the similar study by Walters
et al.,316 the study by Chilcott et al.315 presents total cost estimates for the subgroup of UK adults (n= 37)
in the trial. (The report presents these figures only in chart form; Chilcott et al.,315 figure 4). The total
incremental cost of BAS over 12 months is approximately £3500. This implies an incremental cost of £8284
per suspected case of AR avoided. Despite the sampling uncertainty in the subgroup analysis by country,
results presented in figure 4 of the report by Chilcott et al.315 suggest heterogeneous findings
across countries.
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A similar critique applies to this report as that formulated above for the report by Walters et al.,316 with a
couple of qualifications. First, Chilcott et al.315 present results for the subgroup of UK adults. Although
these results are based on small numbers, they suggest possible heterogeneity of findings across countries,
as the point estimate of incremental costs of BAS range from almost US$0 in Germany and France to
US$3500 in the UK, to US$10,000 in Belgium and Switzerland (Chilcott et al.,315 figure 4). A second
strength of the Chilcott et al.315 study relative to the Walters et al.316 study lies in its longer period of
follow-up, during which information on all costs was collected, 12 months post transplantation, compared
with the 6-month period of Walters et al.316 study (the latter also included costs for a 6-month extension
period, but only for dialysis).
Popat et al. 2014
This recent study317 reports evidence of costs and health outcomes that were associated with two
immunosuppressive induction therapies given to recipients of renal transplants from DCD in a single centre
in London. This was a before-and-after comparison of 1-year outcomes after transplantation, between a
anti-interleukin-2 receptor monoclonal antibody (IL2Mab) induction regimen (BAS or DAC) given to people
receiving a renal transplant from January 2007 to July 2008 and induction with ATG given to renal
transplantation people starting from the time of its adoption at the centre in August 2008 to August 2009.
The study included 24 adults in the old induction arm (IL2Mab 2mg/kg) who had a mean age of 54.3 years
compared with 48.0 years in the new (ATG 3.75mg/kg) induction group of 21 adults. There was some
imbalance in terms of sex and race, as 71% in the IL2Mab group were male compared with 38% in those
given ATG, and 62% in the former group were white compared with 33% in the latter group. Forty-two
out of 45 people were given standard immunosuppression with CSA, MMF and prednisolone, and 3 out of
45 were given TAC, MMF and prednisolone. At 1 year post transplantation, 91.7% of people in the IL2Mab
group were alive, whereas at 3 years 83.4% survived. In the ATG group all people were alive at both time
points. In terms of graft survival (censored by death), all people in both groups had a functioning graft at
1 year, whereas 95.8% had a functioning graft at 3 years in the IL2Mab group compared with 95.2% in
the ATG group. The authors interpreted these results as evidence of no significant differences in patient and
graft survival.
The study also looked at DGF, the duration of DGF measured by the number of HD sessions, the rate of
BPAR and incidence of infections requiring hospital admission. ATG resulted in 42.8% of people having
DGF and 62.5% of people treated with IL2Mab experienced such outcome (p= 0.08). More people
required HD sessions, experienced BPAR, had infections requiring admission, were readmitted and
had experienced CMV infections in the latter group than in the former group (p≤ 0.03 for all of
these comparisons).
The study reported a cost analysis associated with observed outcomes up to 12 months post transplantation,
using local NHS unit costs for hospital bed-day and HD sessions and British National Formulary (BNF) drug
prices for induction and maintenance immunosuppression, which were applicable at the time people
received the transplant. Their results are converted to per-patient costs and presented in Table 135.
Antithymocyte (immune)globulin was found to result in savings in inpatient bed-days post transplantation
and those due to readmissions, as well as HD costs and clinic visits, whereas the additional costs of ATG
induction (£479 per patient, calculated by PenTAG) were not found to be statistically significant. The drivers
of the cost savings by ATG were found in the inpatient bed-days after transplantation and clinic visits.
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The main contribution of this study is to provide evidence on health and economic outcomes in a
comparison of two active induction regimens. Owing to its small size, the results may be influenced by
outliers, thus limiting the validity of the reported findings. In addition, lack of power is of concern for
statistical inference of differences in health outcomes, and more so for inference on costs, which tends to
require larger samples than those required by studies of clinical effects.328 Moreover, results may be
confounded by the fact that the IL2Mab arm was treated at an earlier date than the ATG arm; some of the
difference in costs may be because of different discharge practice across the two periods, as opposed to
an effect of the induction regimen.
The importance of clinic visits as a driver of total costs found in this study is consistent with evidence
submitted to NICE by the company sponsoring one of the drugs being evaluated for this appraisal
(Bristol-Myers Squibb), on post-transplantation costs in standard practice from the renal transplant database
in Cardiff, Wales. The same finding is analysed in an international context in a published report42 of the same
evidence. Nevertheless, evidence from a larger study is required to confirm the findings reported by Popat
et al.,317 in which induction regimens are given in combination with current triple therapy, that is, low-dose
TAC with MMF and steroids, and relevant outcomes not measured in their study, especially HRQoL outcomes,
are measured.
Non-UK studies
In a US study by Crompton et al.,329 54 living donor transplant recipients were randomised in a 1 : 1 ratio
to receive BAS induction or no induction, and all were given triple immunosuppressive therapy with CSA
ME, AZA and CCSs. At 12 months post transplantation, the rate of AR episodes in the induction
intervention arm was 22% compared with 15% in the control (p> 0.05). Differences between arms in
serum creatinine measured at 1, 2, 3, 6 and 12 months all had p> 0.05, and no AEs were associated with
BAS. Four graft losses occurred during follow-up, all in the intervention arm; it was stated that only one
was immunological but no additional information was reported. The study329 evaluated differences in
resource use, using charges as opposed to economic costs of the resources consumed. BAS provided no
clear clinical benefit or evidence of being cost-effective in this low-risk patient population. However,
insufficient numbers of people were included in the study to allow one to derive conclusive findings.
Another limitation is its use of BAS in people receiving triple therapy of CSA with AZA and steroids,
instead of current standard regimens combining CNI, MMF and steroids.
TABLE 135 Per-patient cost analysis by induction regimen arm in the Popat et al.317 trial
Cost category IL2Mab arm (£) ATG arm (£)
Immunosuppression (acquisition costs) 1729 2250
Inpatient bed-days post transplantation 6967 4552
Inpatient bed-days for readmission 2867 933
HD sessions 836 494
CMV prophylaxis and treatment 1954 2229
Clinic visits 6967 4465
Total cost per patient at 1 year post transplanta 18,929 14,904
a The p-value is 0.002.
Apart from the results in the bottom row, the study reported the results only as total costs for all patients in each arm, and
presented statistical tests of differences in those totals, without any evidence that the study accounted for the different in
size between the two arms (IL2MAb n= 24; ATG arm n= 21).
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A study330,331 from Spain investigated two regimens of BAS induction: (1) a CNI-avoidance regimen
(CSA 8mg/kg daily was introduced when the creatinine level reached a value of < 3mg/dl) and (2) a
CNI-minimisation regimen (CSA 4mg/kg daily with MMF 500mg/12 hours from day 1). The regimens
were compared against a TAC (Prograf 0.3 mg/kg daily with a trough level of 8–12 ng/ml) with MMF
(500mg/12 hours) and steroids regimen in elderly people. The reports identified for this study330,331 provided
Markov model simulated costs and health outcomes for eight people in each of options ‘1’ and ‘2’, and
15 people for the TAC comparator up to 1 year post transplantation, but were only in summary form
and lacked information on methodology related to model structure, cost definition, sources and values of
unit costs, and effectiveness parameters to allow critical appraisal of the reported cost difference relative to
TAC arm (–€8355 for option ‘1’ and –€5695 for option ‘2’).
Initial and maintenance immunosuppression studies
UK studies
Orme et al. 2003
Orme et al.309 compared the costs and clinical outcomes of TAC (Prograf) vs. CSA ME given in triple-therapy
regimens including AZA and CCSs. Their study309 was based on data from the direct comparison of these
regimens in a RCT that was conducted at a single centre in Wales, in which clinical and resource-use data
were collected prospectively for each patient over a median follow-up of 2.7 years (maximum 4 years).
People in the trial had undergone renal transplantation between 1996 and 2000 (CSA, n= 89; TAC,
n= 90). The resource items for which data were recorded in the study included number of days in
specialised wards (transplant/nephrology and intensive care unit during the initial admissions and
subsequent readmissions), number of dialysis sessions required in cases of a DGF, number of diagnostic
tests (e.g. transplant biopsy, ultrasound scan and other radiological investigations), and minor surgical
procedures and operations for complications. The economic evaluation adopted a 10-year analytical horizon
and extrapolated the trial outcomes from 5 to 10 years using patient and graft survival data from the UK
Transplant Support Service Authority Audit. During the extrapolated period, the rates of change in patient
and graft survival rates were assumed to be the same between the TAC and CSA immunosuppressant
regimens. The analysis also assumed that ARRs changed by the same rates as graft survival rates for the
extrapolation phase of the analysis. The per-patient costs for years 4–10 were extrapolated using an
average of annual costs with functioning graft and costs with graft failure (dialysis) in the trial, weighted by
the proportion of people surviving with a function graft at the end of the year.
According to ITT analysis at 4 years, 89% of people survived in the TAC arm and 80% survived in the CSA
arm. In terms of graft survival, the figures were 81% and 71%, respectively. The proportion of people who
were rejection free was observed to decline annually for the first 4 years of CSA by 48 percentage points
in year 1, 5 in year 2, 2 in year 3 and 1 in year 4, and by 37 percentage points in year 1, 4 in year 2, 1 in
year 3 and 4 in year 4 with TAC. In terms of costs, the observed per-patient costs in the first year post
transplant were £9990 under TAC compared with £9783 under CSA. In the observed years 2–4, the TAC
arm had lower per-patient costs, from £133 to £350 less than in the CSA arm as a result of the higher
proportion of people with a failed graft and receiving dialysis in the latter. The study309 presented results in
terms of incremental cost per additional survivor, per extra patient with a functioning graft, and per
rejection-free patient. Although the number of years of life achieved after transplantation under each
treatment was not presented, PenTAG approximated them by numerical integration using Newton–Cotes
methods (Simpson’s rule332) from the percentages of people alive at the end of each of the 10 years of
analysis reported by the study. This yielded an estimated 8.28 life-years under TAC and 7.61 life-years
under CSA. The information provided in the paper also allowed us to adjust the cost discounting to
convert results from the 6% annual rate used by the study309 to the current NICE recommended rate of
3.5%. Similarly, methods were used to approximate discounted life-years at that rate. The resulting
discounted incremental cost per life-year gained by TAC over CSA was £1457.
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This study309 reported detailed unit cost information, although quantities of resource utilisation were not
provided, which limits the ability to assess the generalisability of results to England. This is regrettable, as
this is one of the studies with the longest prospective follow-up of health-care use and health outcomes in
KTRs, and thus a potential source of longitudinal data on quantities of resource use and their interpatient
variability. Further, the study did not account for HRQoL effects of immunosuppression and did not
consider the importance of outcomes in terms of renal function for costs and benefits. In particular, there
is emerging evidence that CKD stage not only matters for current costs and HRQoL experienced by the
patient, but also has an important role as a prognostic factor and determinant of graft survival.333 It is also
noted that the time horizon of the analysis may now be too short to estimate cost adequately. Despite the
inadequate measure used to synthesise cost-effectiveness in the study report, our calculations suggest that
in the sample studied by Orme et al.,309 TAC is well within the NICE threshold of cost-effectiveness.
Although we did not adjust prices to current levels, these are unlikely to rise beyond £5000 the
incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year (QALY) gained in this sample of
TAC compared with CSA.
Woodroffe et al. 2005 (Assessment Group for NICE Technology Appraisal Guidance 85)
Based on its review of models submitted by four sponsoring companies for the NICE TA85, the assessment
group at Birmingham University performed an analysis based on the model submitted by Novartis, based
on the information in the industry submissions and its own systematic review of the published evidence on
effectiveness and cost-effectiveness.65 The Novartis model simulated the experience of individual people
after renal transplantation, represented by transitions between health states defined by AR, no AR, hospital
dialysis, PD and death. It included a model component that captured the effects on clinical outcomes of
NODAT, which allowed accounting for the clinical implications of the high incidence of NODAT with TAC
that the company found in its systematic review. The model also accounted for cause-specific mortality
risks from five comorbidities that were associated with diabetes mellitus or other causes. Costs and utilities
were specific to each health state. TAC was found to have incremental costs per QALY ratios in the range
of £59,548–166,112 relative to CSA when evaluated as candidate components of triple therapy containing
AZA and CCSs. Larger ICERs were found for the comparison in the context of triple therapy comprising
MMF and CCSs. For the comparison of MMF and AZA, the ICER ranged from £39,297 to dominated,
when evaluated alongside TAC and CCSs, and from £52,166 to £109,549 as part of triple therapy
containing CSA and steroids. The authors refer to these ranges as 95% CIs but, as these did not account
for the variation in costs, they are likely to misrepresent uncertainty.
Difficulties encountered by the Birmingham Assessment Group in implementing its analysis thus prevented
it from satisfactorily accounting for uncertainty.65 The group could obtain 95% CI for incremental QALYs
but not for costs, and thus the degree of uncertainty in its results was left unaddressed. A more
fundamental problem arises, however, with the use of a model, such as that of Novartis, which assumes
that the main clinical outcomes, that is, the years of patient life and with a functioning graft gained, are
adequately predicted by short-term ARRs and post-transplant diabetes mellitus (PTDM). In recent years,
evidence has emerged suggesting that renal function is a predictor of clinically and economically significant
outcomes, and that AR may be less relevant once CKD stage is accounted for.333–335 CEAs published since
the Birmingham Assessment Group’s review was conducted, and reviewed in the rest of this chapter,
reflect these methodological developments, as summarised in Table 133. At the time of the Birmingham
review, the evidence was ambiguous about the prognostic predictive power of renal function relative to AR
and, as the group acknowledges, its analysis reflects this (Woodroffe et al.65).333–335
McEwan et al. 2005, 2006
In two papers, McEwan et al.310,311 evaluate the cost–utility of SRL against CSA, and SRL against TAC, for
maintenance immunosuppression from the NHS perspective using a discrete event simulation model of
individual patient evolution from the time of kidney transplantation until 20 years post transplant.310
This study310,311 was one of the first to account for renal function as a predictor of transplant outcomes.
It simulated the monthly evolution of a patient’s health status by transitions between three mutually
exclusive health states: (1) patient with a functioning graft; (2) patient with failed graft (dialysis);
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and (3) death. In addition, AR events were accounted for. The model allowed for retransplants and
different probabilities of experiencing an AR, patient death, graft failure and transplant after graft failure,
depending on the number of transplants that the patient had received at each point in time. Movements
between health states were associated with changes in costs and HRQoL, whereas the occurrence of
transplant, graft failure, and ARs and graft failure was associated only with costs.
The effects of SRL and CSA on clinical outcomes were assumed to occur through their effects on renal
function, which determined long-term clinical outcomes independently of treatment. The relative efficacy
of SRL compared with CSA was derived from a single trial involving 430 people from 57 centres in Europe,
Canada and Australia (the Rapamune Maintenance Regimen Study, Oberbauer et al.336). People included
in this trial were given the same immunosuppression regimen (CSA+ SRL+ steroids) for the first 3 months
after transplantation and then randomised to continue on the regimen or switch to a regimen of
once-daily SRL and steroids. Serum creatinine values in each trial arm at the time of randomisation,
that is, 3 months post transplantation, and at 1, 2 and 3 years, were used as inputs (surrogate measures)
in estimated equations for predicting the risk of long-term clinical events (Figure 65). The authors also
assumed that in 50% of subjects treated with SRL, graft survival ‘would prevail for the entire
time horizon’.310
The surrogate relationship between renal function and clinical events defining transitions between health
states in the model was estimated from analysis of longitudinal data on outcomes experienced by
937 transplant patients up to 20 years post transplantation in routine practice, recorded at the University
Hospital of Wales, Cardiff (see Appendix 9 for details). People were treated over the period 1982–2001,
during most of which CSA was the standard immunosuppressant therapy.310
The authors found that SRL regimen would cost the NHS £62,120 per patient over 20 years, whereas CSA
would cost £69,525 (at 2003 prices and 6.5% annual discount rate). SRL was found to result in more
discounted years with a functioning graft and in 0.16 additional discounted life-years per patient; it also
resulted in more QALYs than those achieved with CSA. These results were based on the assumption that
50% of SRL patients would maintain their graft survival over the entire modelled period; when this value
was set to 0%, the incremental cost per QALY gained by SRL was £51,778 under the 10-year horizon and
£11,161 under the 20-year horizon. The same analysis was performed for the comparison of SRL and
TAC,311 using the creatinine levels observed in people receiving CSA in the Rapamune trial336 as proxies for
creatinine levels in people receiving TAC in the model, and replacing the price of CSA with that of TAC. The
results were qualitatively similar, with SRL both saving costs and producing health benefits relative to TAC.
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FIGURE 65 Serum creatinine levels used by the McEwan model.311
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The main strength of the study310 is its account for the effect of renal function on long-term outcomes
and use of probabilities of clinical events from observational data of people treated in routine practice.
Further, it is the only study to have accounted for the temporal variation in risk factors for those events
over a 20-year period. However, the internal validity of the results is questionable because of the
differences between the trial population on which the efficacy data were based and the patient population
of the model, as detailed in Appendix 9. In addition, this study310 did not account for the incidence of
clinical conditions, such as malignancy, cardiovascular events and NODAT. This is an important limitation in
the light of the expected benefits of SRL on malignancy. Most important, however, are the safety concerns
(increased death risk) associated with the drug, which suggest that SRL may not be justified in people who
have kidney transplants other than those who are at high risk of cancer.337 It must also be noted that,
although the study accounts for the role of renal function as a predictor of long-term outcomes, it does
not allow for its impact on costs42 and HRQoL.338
Muduma et al. 2014
In a recent study,318 the current UK standard treatment for adults, twice-daily immediate-release TAC
(Prograf), was compared with current options, namely CSA ME, SRL with CNI minimisation, SRL without CNI,
BEL and 1-day TAC-PR (Advagraf), in terms of cost-effectiveness from the perspective of the NHS. The
analysis considered each of these treatment options as part of a regimen that also included MMF and CCSs,
and BAS induction (consisting, in the base case, of 20mg 2 hours before surgery and 20mg 4 days after
surgery; an alternative scenario considered additional doses during the first few days after transplantation).
The study found that, although Prograf resulted in more efficient use of health-care resources relative to CSA
ME and BEL, it was not cost-effective relative to SRL. Although Advagraf produced lower costs and higher
benefits than Prograf, its cost-effectiveness ratio against SRL (CNI minimisation regimen) was £58,350. These
results were found to be sensitive to the time horizon and the effect of adherence.
Costs and health benefits were accumulated according to a Markov model of annual cycles that
represented the evolution of the patient heath status following a successful transplant for up to 25 years.
The model included four health states: (1) functioning graft without a history of BPAR; (2) functioning graft
with a history of BPAR; (3) non-functioning graft; and (4) death. The occurrence of repeat transplantation
was modelled using a tunnel state. The model assigned an excess risk of graft loss for the state of
functioning graft with prior BPAR relative to the functioning graft without prior BPAR state, using
estimates derived from the literature. The model was specified so that BPAR could occur only in the first
year after transplantation, which the authors justified on pragmatic grounds, given the limited data
available from the literature on BPAR outcomes beyond 1 year.
This study318 did not report adequate information on the methods and results of that review, the primary
study sources for the probabilities of AR used, or the actual values used for these parameters. The
treatment-specific outcome data reported related to the advantage of Advagraf over Prograf in terms of
adherence to treatment schedule. The differences in 1-year ARRs were used to predict patient and graft
survival for the first 5 years post transplantation using data from UK renal transplant summary statistics12
and patient survival for the first 10 years after the start of the spell on dialysis were populated using UK
data; the probabilities of retransplantation while in dialysis were obtained from data reported by McEwan
et al.,310,311 reviewed in this chapter.339 Exponential curves were used to extrapolate patient and graft survival
curves and survival time on dialysis to 25 years. Further details of this study are discussed in Appendix 9.
Despite its stated aim to comply with the NICE reference case specifications, this study318 faced limitations
in terms of the availability of data to do so, the adopted model structure, issues of model implementation
and the quality of reporting. The model assumed that the cost-effectiveness was driven by the differences
in the rate of AR between treatment regimens, and that these fundamental differences occurred only
during the first year post transplant. The validity of this assumption and the results of this study hinge on
the quality of the evidence on the relationship between AR and graft and patient survival. In any case, it is
difficult to defend the extrapolation of 1-year surrogate measures to clinical outcomes 25 years into the
future, as generated by the statistical model of AR and graft survival in this study. Another problem with
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this report is its lack of any information on the values of the parameters driving the results, that is, the
relative differences in the risk of AR between regimens. This fact makes it impossible to replicate the
results reported by the paper. Third, based on the information provided, it appears that the amount of
immunosuppressant use in the model might not have reflected the actual total use of the medications
that brought about the AR outcomes which were used to populate the effectiveness model parameters.
The authors do not report any attempt to derive mean daily drug use or dose intensity from the RCT data
from which the AR estimates were derived for populating the model. Another issue arises with the way
in which transition probabilities were derived from the registry data on transplant and patient survival.
As this issue is discussed for one of the industry submissions, which used the same data and model, the
reader is referred to that section (see Chapter 5, Astellas’ submission).
Non-UK studies
Three identified reports investigated the cost-effectiveness of SRL regimens: one report in the USA308 and
two in Germany.307,311 Two studies319,320 evaluated TAC compared with CSA ME in European countries.
One study321 investigated once-daily TAC compared with twice-daily TAC in the USA.321 These studies are
discussed in detail in Appendix 9. Their model characteristics and results are presented in Tables 136–138.
In common with the UK study by McEwan et al.310,311 discussed before, the US study by Earnshaw et al.308
evaluated SRL+ steroids after CNI withdrawal, but, in this case, it compared it against triple therapy
of TAC or CSA combined with MMF and steroids.308,310,311 Applying a decision-analytic model extending
over the lifetime of a 46-year-old first-transplant patient, it found that the regimen was the dominant
treatment for the adult renal transplantation population in general. Its use resulted in 0.30 extra years of
life relative to TAC-containing triple therapy and 0.06 extra years of life relative to triple therapy containing
CSA. In terms of discounted (at 3% per annum) QALYs, the results were 0.30 and 0.12, respectively. SRL
CNI withdrawal produced a cost saving of US$33,000 relative to TAC, and of US$11,000 when compared
with CSA. The same qualitative results were found for the subgroup analysis by donor type (living,
deceased non-ECD and deceased ECD).
The study by Earnshaw et al.308 is different from other reports on the same topic in its attempt to provide
evidence on cost-effectiveness across different donor types. In common with other studies evaluating SRL,
it found the regimen to be cost-effective, in this case relative to current standard triple therapy containing
a CNI. Similar criticisms as those made above to the UK reports by McEwan et al., in relation to the current
perception of SRL as having a restricted use because of issues about safety, may be applied to this
study.310,311 In terms of its methodology, this study used a model to predict long-term graft survival from
1-year renal function outcomes that were specific to the three regimens, accounting for graft survival
differences between donor types. Although the use of renal function as driving clinical outcomes is
supported by recent statistical evidence in samples of people treated in routine practice,333 the model
structure adopted by Earnshaw et al.308 relies on a simplistic assumption of constant (instantaneous)
probability (hazard rates) of graft failure over time, which more recent studies find to be inconsistent with
the data.333,334 In addition, the study does not account for the direct effects of renal function on costs
and HRQoL. Thus, important differences between therapies might not have been captured with this model
as patients accumulated time in the functioning graft state.42,338
One study307,311 presents the results of a Markov model of 10-year outcomes representing the transition
across health states experienced by people after renal transplantation in Germany. The model compares
SRL CSA avoidance with SRL CSA minimisation and low-dose TAC triple therapy with MMF and steroids.
The latter was included in acknowledgement of the changes in immunosuppressant treatment practice
following the publication of results from the SYMPHONY trials.195,196,199 The analysis was conducted from
the perspective of the German statutory health insurance. The study307,311 found that low-dose TAC in
triple therapy with MMF and steroids has a cost per life-year gained in excess of €100,000, relative to
the SRL CSA minimisation regimen. All other comparators were found irrelevant for identifying the
cost-effective treatment option, as they were dominated by these two regimens.
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The study provides new evidence about the cost-effectiveness of low-dose TAC regimens favoured at
present by current practice, which has emerged following the publication of the SYMPHONY trial
results.195,196,199 One of the strengths of this analysis is the attempt to derive comparative evidence for the
effects of the different regimens from evidence synthesis based on indirect comparisons, through NMA.
Another is its account for AEs including graft failure, malignancies, CMV infections, PTDM, wound-healing
disorders, and post-transplant anaemia, 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) and
hypertension treatments. However, the value of this study from an English NHS decision-making point of
view is diminished by their choice of comparators, which excludes CSA-based triple therapy and other new
treatments such as BEL. The study also has limited information use for informing NICE recommendations,
as it did not account for HRQoL outcomes. The model itself is not amenable to account for available
evidence on HRQoL and costs associated with the effects of immunosuppressive regimens on renal
function, as the renal function plays no role in the health status of people in the model or indeed
has no prognostic effect on long-term graft or patient survival outcomes, which were assumed to be
driven by 2-year differences in the rate of AR between model arms.
A study321 co-authored by an affiliate of Astellas’ Pharma US modelled the expected costs and clinical
outcomes of once-daily TAC-PR and twice-daily immediate-release TAC, each given in combination with
MMF, for transplant recipients in the USA. The study used a stochastic state-transition Markov model
extending 5 years post transplantation to predict the amount of time that people with a functioning graft
were alive, receiving dialysis as a result of graft failure, or dead. The total discounted (5% annually) costs
per patient were US$228,734 with once-daily TAC and US$238,144 with twice-daily TAC. The low quality
of reporting by this article321 prevents assessment of its validity. The sources of values for some model
parameters or the methods used to identify them were not reported. Moreover, the values of some
parameters were not provided, preventing the replication of results by the reader.
The remaining study319,320 compared the resource-use costs and health outcomes over 6 months post
transplantation of people who were randomised to receive TAC (n= 286) and CSA ME (n= 287), as part of
triple immunosuppressive therapy with AZA and steroids. This was a multicountry trial, in which TAC was
given at an initial daily dose of 0.3mg/kg, whereas the starting dose of CSA ME was 8–10mg/kg per day. The
study retrospectively measured resource-use quantities and costs of immunosuppressant drugs, concomitant
medications, hospitalisation, dialysis and rejection episodes from the 50 centres in seven Western European
countries that participated in the trial. ITT analysis revealed per-patient cost savings achieved by TAC, ranging
from €1776 in Italy to €524 in Spain (figures in year 2000 prices). The authors attribute part of the variation to
the higher cost of hospitalisation in Italy than in the other countries. Most of the savings with TAC were a
result of fewer days in hospital for the initial stay and readmissions (Italian case 50%), lower costs of
immunosuppressive medication for graft rejection (37%) and incidence of dialysis (13%).320
The length of follow-up in this study319,320 was insufficient to capture important clinical events, such as
graft and patient survival or AEs such as PTDM, with which TAC immunosuppression has been associated.
In addition, the study319,320 did not report any results in terms of changes in renal function, which has been
observed to be associated with costs and HRQoL, as well as a prognostic factor of graft and patient
survival. Moreover, the detailed report on the Italian case found that differences in costs were statistically
insignificant (i.e. p> 0.05), suggesting that the overall reduction in costs may have been due to chance
alone. In any case, the study319,320 may have had insufficient power to perform statistical inference on
cost effects.328 Therefore, the conclusion that ‘the overall costs of treating a patient with TAC during the
6-month post-transplantation period are substantially lower [than that for CSA ME]’ may not be supported
by the results of the study.
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Chapter 5 Critical appraisal of company
submissions
Three companies submitted economic models to NICE: Astellas, Novartis and Bristol-Myers Squibb.
Astellas’ submission
Overview
The submission compared twice-daily immediate-release TAC (Prograf) with once-daily TAC-PR (Advagraf), and
against BEL, EVL and SRL. Immediate-release TAC was considered to be the standard treatment of choice in
adult renal transplantation immunosuppression, based on its UK market share, whereas the comparators
investigated were deemed to be used infrequently. The submission cites evidence of improved outcomes for
TAC-PR relative to the current standard regimen, immediate-release TAC, since the former became available in
2009. In addition, EVL was included in the evaluation despite its lack of market authorisation in the UK, as
requested by the NICE scope.
The analysis found that immediate-release TAC resulted in reduced total costs and health benefits relative
to the comparators, EVL and BEL; it was concluded that TAC-PR is cost-effective and should be the new
standard of care. Although the health benefits of immediate-release TAC were found insufficient to
compensate for its increased cost relative to SRL, the latter regimen was consider to apply to only a
selected subgroup of adults receiving a kidney transplant.
The submission pointed to evidence on the relationship between treatment adherence and acute and
long-term graft rejection, and graft failure as surrogate markers of outcomes. In particular, it stated that
adherence to immunosuppressant regimens positively affects graft survival by preventing the development
of de novo donor-specific antibodies, which have been associated with a reduction in 10-year graft
survival.342 This is then used to translate the observed improvement in adherence with PR TAC relative to
immediate-release TAC into graft and patient survival benefits.343 In addition, the company claims that
TAC-PR has a better pharmacokinetic profile than twice-daily TAC (lower intrapatient variability,344 which
results in a lower risk of long-term graft failure.345 The company also cites analyses from the Collaborative
Transplant Study for Europe presented at the 2014 World Transplant Congress, which shows that people
who are treated with TAC-PR had higher patient and graft survival rates than people treated with
immediate-release TAC over 12 months, following renal transplantation, in Collaborative Transplant Study
data for 2011–13. However, this observation was not robust to the adjustment for multiple confounders
[hazard ratio (HR) 0.76; p= 0.14; 95% CI were not stated].
The submission also cites the results of a meta-analysis pointing to increased risk of PTDM with TAC [relative
risk (RR) at 12 months 1.72, 95% CI 1.17 to 2.52; RR at 36 months 2.71, 95% CI 1.61 to 4.57] relative to
CSA, and acknowledges the evidence on the association between PTDM and reduced graft survival (RR 1.63,
95% CI 1.46 to 1.84).346 The company argues that these estimates may have been the result of people
treated with high doses of TAC relative to current practice. To support this claim the submission cites the
results of a Phase III study204 comparing TAC-PR with immediate-release TAC, which used lower doses of TAC
and found lower incidence rates of PTDM than those in the studies included in the meta-analysis report. It is
noted, however, that the latter evidence had no bearing on the meta-analysis finding of a higher RR of PTDM
with TAC than CSA.
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Efficacy and effectiveness evidence
The submission reports a systematic review of the RCT evidence of effectiveness of immunosuppression
after first kidney-only transplant. The review involved an electronic search of bibliographic databases
covering studies published during the period 2002–June 2014, and was complemented by relevant studies
from two published reviews.65,347
Based on 6-month and 1-year pooled data from 19 RCTs including 3796 people, immediate-release TAC
had a lower rate of BPAR than CSA ME (RR 0.69, 95% CI 0.57 to 0.82). However, based on data from
10 studies that reported the outcome in 1859 people, immediate-release TAC resulted in higher incidence
of PTDM (1.57, 95% CI 1.16 to 2.12). In terms of other outcomes (graft survival, patient survival and
death-censored graft survival) differences were found not to be statistically significant at the 5% level.
Pooled-effect estimates for immediate-release TAC, compared with SRL given as a CNI avoidance regimen,
were obtained from four RCTs of 6–12 months’ follow-up involving 1397 people. Neither patient survival
nor PTDM differed in statistically significant manner between the arms, whereas SRL produced a higher
risk of developing AR (RR 2.28, 95% CI 1.37 to 3.79) and lower survival probability (RR 0.95, 95% CI
0.92 to 0.98). In the SRL CNI minimisation regimen, two studies were found, involving 461 people in the
comparison of immediate-release TAC/SRL and steroids with immediate-release TAC/MMF and steroids.
No differences were found in patient and graft survival, ARs and PTDM at 6–12 months post transplant,
whereas more discontinuations were found in the former arm.
For the comparison between TAC-PR and CSA ME, the submission cites one multicentre study that
compared these two options and an immediate-release TAC option, all in combination with MMF and
steroids. The study found similar efficacy across the three treatment arms in terms of patient and graft
survival and AR but there is no measure of uncertainty reported alongside the event rates presented.
Astellas presents results from its own meta-analysis of two studies comparing immediate-release TAC
with TAC-PR for de novo kidney transplantation in terms of BPAR stratified for people with (RR 1.16,
95% CI 0.82 to 1.63) and without (RR 1.28, 95% CI 0.98 to 1.68) induction. It cites results of a published
meta-analysis that included observational data348 as consistent with the claim that TAC-PR is as effective as
immediate-release TAC in preventing BPAR and graft failure at 12 months post kidney transplantation.
For the TAC minimisation versus EVL comparison, no difference in patient and graft survival at 6–12 months
was found in three studies involving 358 people (RR 1.01). The submission also cites results from the
ASSET trial256 regarding a higher 12-month rate of BPAR (RR 2.19, 95% CI 0.20 to 23.77) with a low-dose
TAC with EVL regimen versus standard-dose TAC with EVL regimen (both regimens were given from
3 months post transplantation after an initial 3-month regimen of standard TAC).256 For the comparison
of TAC withdrawal with EVL introduction versus the continuation of an initial 3-month regimen of TAC,
MPS and steroids, one study259 was cited as reporting no graft failure or patient death in either group at
12 months; renal function, as measured by eGFR of 53.38ml/minute/1.73m2 in the TAC continuation
group and 57.27ml/minute/1.73m2 in the EVL group (p= 0.25); and no BPAR case in the TAC group and
17.5% incidence in the EVL group (RR 0.05, 95% CI 0.00 to 0.79). Given the absence of RCTs of TAC
compared with EVL, Astellas estimated their relative effects indirectly from head-to-head studies of EVL
plus low-dose CSA compared with standard CSA (two studies, reporting RR ratios between 0.98 and 1.01
for AR, graft and patient survival outcomes at 3–12 months) and studies of TAC compared with CSA.
Likewise for TAC compared with BEL, estimates were obtained from indirect comparisons, through studies
of each of these regimens against CSA. The TAC studies have been described in this section. As for BEL,
data from two Phase III trials with 3-year follow-up data were used for the indirect comparison: one
included adults receiving a living donor or standard criteria deceased donor kidney (BENEFIT study59) and
the other was a study of similar design but included ECDs (BENEFIT-EXT study142). The company presented
separate and combined results of analyses of 1-year data from both trials stratified by a more-intensive and
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a less-intensive BEL regimen. In general, BEL was found to have higher BPAR rates, less chronic allograft
nephropathy (for the more intensive BEL regimen) and improved renal function over CSA. BEL also reduced
the incidence of NODAT.
Combining up to 1-year results from BENEFIT59 and BENEFIT-EXT,142 the meta-analysis of immediate-release
TAC compared with CSA (number of studies: AR 19, graft survival 11, patient survival 10, WMD in
GFR, 2), and outcomes of TAC-PR compared with CSA from the Phase III trial reported by Silva et al.,239
TAC-PR was found to result in a lower ARR (RR 0.24, 95% CI 0.12 to 0.51) and lower WMDs in GFR
(MD –10.50, 95% CI –16.57 to –4.43) than both the more-intensive and less-intensive BEL regimens.349
The company also cites the results of an indirect comparative analysis conducted by Bristol-Myers Squibb,
which showed ‘no significant difference’ between BEL and TAC for mortality, graft loss or GFR at 12 and
36 months (All Wales Medicines Strategy Group 2012)350 and higher ARR and lower incidence of NODAT
for BEL than for TAC.
Another indirect comparison by Astellas produced estimates of AR, graft survival and patient survival for
immediate-release TAC relative to EVL. The RR ratios were, respectively, 0.70 (95% CI 0.48 to 1.03),
0.97 (95% CI 0.93 to 1.03) and 0.98 (95% CI 0.95 to 1.02).
Review of economic models and their results in the submission
The submission provides an overview of model structures and conclusions of previous CEAs of renal
transplantation immunosuppressive regimens. From searches of electronic databases (NHS EED, The
Cochrane Collaboration, MEDLINE and other database not specified) Astellas identified and included in its
review 12 ‘representative studies because they met the inclusion criteria’ (Astellas’ submission, p. 28,
chapter 8, Review of economic studies – it states that 11 studies were included in the review but 12 are
actually cited). No details were provided about the inclusion criteria for the review of economic studies;
such criteria, therefore, presumably refer to criteria employed for the effectiveness review in the
submission. One of the included studies compared immediate-release TAC with TAC-PR (this study is
reviewed in section 1.2 of the company’s submission).321 Four studies compared TAC with CSA
(three309,319,320 of which met the criteria for inclusion in the review of section 1.2; the remaining study100
was excluded from the review of section 1.2 because it measured costs only for medication) and seven
studies306–308,311,351–353 examined SRL in CNI avoidance or minimisation strategies compared with TAC
(four studies307,308,311 included in the review of section 1.2) and three studies351–353 that were excluded from
it as a result of the country to which they apply.
The submission briefly described the main results of these studies without critically assessing their validity
and applicability to a UK setting, although a warning is issued about limited transferability of results
from non-UK (10 out of the 12) studies. It concludes that the evidence supports the view that TAC is
cost-effective relative to CSA, but that it is ambiguous in relation to the comparison against SRL in a CNI
avoidance or minimisation strategy. The submission also includes a section in which three published models
are described. No assessment of their strengths and weakness was presented. These models308,351,352 share
the characteristics of models described and discussed in Assessment of cost-effectiveness (one of them308
is reviewed in that section).
Economic evaluation by the company
The CEA submitted by Astellas is an update of a published Markov model-based assessment of the
cost-effectiveness of TAC, in either its prolonged-release formulation, TAC-PR, or the current standard
therapy of immediate release (immediate-release TAC) by Muduma et al.,318 reviewed in Chapter 4
(see Identified studies). The model describes the annual transitions between four health states, starting
from kidney-only transplantation: functioning graft without history of AR; functioning graft having
experienced AR; graft failure (dialysis); and death. The submission extends the effectiveness review for the
model from June 2013, the cut-off date of the published study,318 to June 2014. In addition, the analysis in
the submission to NICE adds EVL in a CNI minimisation regimen to the list of treatments evaluated in the
published paper.
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Efficacy data used in the model
The model represents differences in outcomes between regimens as caused by their impact on BPAR.
The model was based on the assumption that the effects of treatment on this surrogate outcome lasted
for only the first year post transplantation. This assumption was combined with (1) the estimated RR of
graft failure for a functioning graft with previous BPAR compared with no previous BPAR and (2) the
1-year post-transplant BPAR frequency, both from estimates reported by Opelz et al.,354 to derive the graft
survival curves for grafts without prior AR and grafts with history of AR from the 5-year graft survival
profile in UK registry data (NHSBT) 2013355 (Table 139). The model extrapolation was complemented by
exponential survival curves to extend survival from 5 years up to 25 years post transplantation.
With regard to patient survival, the model used the 1-, 2- and 5-year post-transplantation survival rates
from the NHSBT report 2012–13355 as the estimated survival rates with a functioning graft. To populate
survival probabilities in the state of graft failure, the model used annual survival rates of people on dialysis
followed for 10 years from the UK Renal Registry.3 The graft and patient survival rates were extrapolated
to 25 years by estimating an exponential curve on the available data (including graft survival rates for
years 3 and 4 derived by linear interpolation) and projecting survival rates from the last observed rate with
the estimated curve. There is no mention in the submission about adjusting for increases in background
mortality as the cohort in the model ages.
In addition to the difference in efficacy, measured in terms of ARRs, the model allowed for differences in
effectiveness between the TAC arms through the differences in adherence induced by the once-daily,
prolonged-release (Adagraf) compared with the twice-daily immediate-release formulations of the drug
(immediate-release TAC). The model utilised comparative estimates of adherence with TAC-PR with
immediate-release TAC of 88.2% vs. 78.8% from a published study343 and combined them with
an estimated RR of graft failure in non-adherent versus adherent people of 3.47 derived from a
meta-analysis,356 to obtain a RR of graft failure of 0.848, which was applied to the graft survival curves
(until year 5, and by exponential curve extrapolation thereafter) that were common to all of the other
immunosuppressive treatment strategies in the model.
There are two logical inconsistencies with this modelling procedure. First, accounting for the advantages
in adherence with TAC-PR over immediate-release TAC makes comparison of TAC-PR with other
immunosuppressive regimens in the model invalid, as no allowance was made for any effects of adherence
on graft survival for the other regimens analysed in the model. Indeed, this undermines the fundamental
assumption in the model that all significant differences in any drug regimen comparison may be accounted
for by the effect through the surrogate, in this case the rate of AR.357 Thus, regardless of the validity of the
comparative analysis of TAC-PR and immediate-release TAC, the indirect comparisons of model results
between TAC-PR and SRL, EVL and BEL are then invalid.
TABLE 139 One-year acute graft rejection rates used in the model
Product Rate (%) Comment
Immediate-release TAC (base comparator) 12.6 123,204,239
TAC-PR 14.6 123,204,239 and meta-analysis (section 2 of
company submission)
BEL 30.7 123,204,239 and meta-analysis (sections 2 and 3)
EVL (CNI minimisation) 18.0 123,204,239 and meta-analysis (sections 2 and 3)
SRL (CNI minimisation) 16.5 123,204,239 and meta-analysis (section 2)
SRL (CNI avoidance) 28.7 123,204,239 and meta-analysis (section 2)
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Second, although the model was adjusted to include the effect of adherence on graft survival in the
comparison of TAC-PR with immediate-release TAC, the patient survival curves (for the functioning and
failed graft states) were left unchanged, so that the same set of patient survival curves was applied to all
immunosuppressive options analysed. This implies the questionable assumption that improvements in graft
survival, such as those obtained with TAC-PR relative to immediate-release TAC (and indeed relative to all
other model arms), do not translate in direct patient survival benefits. This inconsistent logic in turn leads
to underestimating the benefits of TAC-PR and overestimating its costs.
Inspection of the Microsoft Excel® 2010 version 14 (Microsoft Corporation, Redmond, WA, USA) model
spreadsheets revealed that the TAC drug regimen options (TAC-PR and immediate-release TAC) and EVL
were the only treatment arms populated by data on actual immunosuppressive drug use (from the RCT
sample on which the efficacy for the regimen was estimated); drug consumption values for BEL and SRL
regimens were based on treatment guidelines (BNF or Summary of Product Characteristics).
Adverse events
The model allows for seven types of AE following transplantation: malignancy, diabetes mellitus, anaemia,
CMV infection, hypertension, HMGCoA and wound-healing disorders. These events were assigned costs
(except for the last type of event which had zero cost) but no disutility. The AE incidence rates in the
model, reproduced in Table 140, differed across immunosuppressant treatment arms, although these had
no influence on the probability of graft failure and patient death. Such differences only affected the costs
differences between the treatments.
The incidence rates of AEs were derived from a systematic review and meta-analysis published in 2006,341
the values adopted by the published economic model for Germany by Jurgensen et al.306 reviewed in
section 1.2 of the company’s submission and trial outcomes from the BENEFIT and BENEFIT-EXT trials.207
The rates of AEs were assumed to be the same with TAC-PR and immediate-release TAC and for the two
SRL regimens (CNI avoidance and CNI minimisation). According to the incidence rates in this model, TAC
has the lowest annual incidence of malignancy (except for SRL from the third post-transplantation year
onwards), CMV, anaemia (except for BEL, which had the same annual incidence rates as those of TAC),
dyslipidaemia and hypertension, but was associated with an excess incidence of PTDM over the
other options.
Health-related quality of life and QALY outcomes were calculated from time spent in the graft functioning
state and the graft failure state, which involved dialysis. Based on published estimates,358 the functioning
state was associated with a utility value of 0.71, regardless of any prior experience of AR, and the graft
failure state was associated with a utility of 0.459, which was equal to the weighted average of the utility
of HD (0.44), experienced by 82% of people on dialysis, and PD (0.53) received by the rest.358
The model allows for the occurrence and effects of retransplantation, using the time to retransplantation data
reported by McEwan et al.,310,311 which is reviewed above (see Chapter 4, Review of cost-effectiveness evidence).
However, the states following the first retransplantation (i.e. functioning graft with prior AR on the current
retransplant, functioning graft without prior AR on the current retransplant – regardless of AR of any
previous transplant – and graft failure) face the same transition probabilities, utility values and costs as the
corresponding states before retransplantation.310,311 This is likely to bias the analysis in favour of treatments
with higher rejection rates in the model (as higher ARRs imply higher graft failure rates in this model) and
may be interpreted as a conservative assumption of the relative effectiveness and incremental costs
advantage of TAC over the comparators.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
259
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
In addition, one incorrect calculation was identified in the Excel spreadsheets of the model submitted by
Astellas. The problem was that the model used the data from the NHSBT from 2012 to 2013, on patient
survival rates for kidney-only transplant recipients in the UK (p. 35, table 25, in the submission by Astellas)
to populate the patient survival parameters of people with a functioning graft, ignoring the fact that
such data on survival rates were likely to include deaths of both people with a functioning and those with
a failed graft. Instead, the probability of death in the graft functioning state should have been calculated
as the remainder of the annual probability of death from the NHSBT patient survival data minus the
product of probability of mortality in the graft failure state and the proportion of people with a failed
graft. In other words, the Astellas model is likely to overestimate mortality in the functioning graft states,
which, in turn, underestimates the benefits of any gains in efficacy (i.e. reductions in AR in the model) that
any regimen may have over another (e.g. TAC over the comparators).
TABLE 140 Adverse events in the Astellas model (%)
Product AE Year 1 Year 2 Year 3 and later
TAC-PR/immediate-release TAC Malignancies 0.00 0.00 0.43
CMV infections 3.62 3.62 0.04
PTDM 6.07 6.07 6.27
Wound-healing disorders 4.12 4.12 0.00
Anaemia 14.71 14.71 14.71
HMGCoA 13.84 13.84 3.46
Hypertension 9.17 9.17 9.17
EVL Malignancies 2.43 2.43 0.64
CMV infections 3.19 3.19 0.04
PTDM 5.58 5.58 5.77
Wound-healing disorders 10.72 10.72 0.00
Anaemia 27.30 27.30 27.30
HMGCoA 29.47 29.47 7.37
Hypertension 31.63 31.63 31.63
SRL (CNI minimisation and avoidance regimens) Malignancies 0.20 0.20 0.05
CMV infections 2.11 2.11 0.03
PTDM 5.88 5.88 6.07
Wound-healing disorders 10.72 10.72 0.00
Anaemia 18.68 18.68 18.68
HMGCoA 21.77 21.77 5.44
Hypertension 15.08 15.08 15.08
BEL Malignancies 2.32 2.32 0.61
CMV infections 7.65 7.65 0.09
PTDM 4.00 4.00 4.19
Wound-healing disorders 4.12 4.12 0.00
Anaemia 14.71 14.71 14.71
HMGCoA 18.88 18.88 18.88
Hypertension 31.12 31.12 31.12
Source: Webster et al.,341 Jürgensen et al.,306 Vincenti et al.,59 and Durrbach et al.142
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Unit costs
The cost per mg of TAC-PR used was 23% lower than that of immediate-release TAC. (The authors present
sensitivity analyses of discounts on TAC list prices limited to the first 90 days post transplantation.) Prices for
other immunosuppressant regimens were based on BNF prices.
Treatment of ARs was assigned costs of i.v. steroids plus, for the 20% of steroid-resistant BPAR cases, the
treatment costs of a regimen of rATG and an inpatient hospital stay for AKI without complications (£1737
overall mean cost). This assumed zero medical management costs for the 80% of people with steroid-
sensitive AR and ignores any costs of follow-up to monitor treatment efficacy. The cost per year of dialysis
was £38,387 and the cost of retransplant was £25,953. The costs of AEs adopted are presented in
Table 141 (which reproduces table 35 in the Astellas submission).
Results
The Astellas submission produces life expectancies (censored after 25 years) of 16.60 for TAC (immediate-
release TAC), 16.57 for SRL CNI minimisation, 16.56 for EVL, 16.48 for SRL CNI avoidance, and 16.47 for
BEL in a cohort of people of mean age 45 years, 37% of whom are women. The expected discounted
(at 3.5%) QALYs were 8.01, 7.99, 7.99, 7.94 and 7.94, respectively. For TAC once-daily prolonged-release
formulation (TAC-PR), total life expectancy was 16.96 and discounted QALY was 8.21.
TABLE 141 Costs of AEs (per year)
Variable Value (£) Comment
Malignancies 8801 Skin/non-Hodgkin’s lymphoma
Mabthera concentrate for i.v. infusion, rituximab 10mg/ml, net price 10-ml vial= £174.63,
50-ml vial= £873.15
CMV infections 1863 i.v. ganciclovir (Cymevene®, Roche Products Ltd) 14–21 days then maintenance for 8 weeks
Ganciclovir; i.v. infusion, powder for reconstitution, ganciclovir (as sodium salt). Net price
500-mg vial= £29.77
PTDM 17.38 Tablets, coated, metformin hydrochloride 500mg
Net price 28-tablet pack= 87p, 84-tablet pack= £1.00; 850mg, 56-tablet pack= £1.36
Wound-healing
disorders
0.00 –
Anaemia 1186.61 Epoetin alfa (Binocrit®, Sandoz Ltd) injection maintenance dose 17–33 units/kg three times
weekly, pre-filled syringe
Net price 1000 units= £4.33; 2000 units= £8.65; 3000 units= £12.98; 4000 units= £17.31;
5000 units= £21.64; 6000 units= £25.96; 8000 units= £40.73; 10,000 units= £43.27
LDL cholesterol 235.03 Simvastatin (Zocor®, Merck & Co.) tablets, all f/c, simvastatin 10mg (peach)
Net price 28-tablet pack= £18.03; 20mg (tan), 28-tablet pack= £29.69; 40mg (red),
28-tablet pack= £29.69; 80mg (red), 28-tablet pack= £29.69
Hypertension 15.51 Capsules, ramipril 1.25mg
Net price 28-capsule pack= 99p; 2.5mg, 28-capsule pack= £1.05; 5mg, 28-capsule
pack= £1.12; 10mg, 28-capsule pack= £1.19
f/c, film coated; LDL, low-density lipoprotein.
Source: bnf.org 2014.56
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In the base-case results, immediate-release TAC produced more QALYs than any of the comparators and
lower costs than BEL and EVL, whereas it had higher cost against the SRL regimens. The ICER against SRL
CNI minimisation strategy was in excess of £1M and the ICER against SRL CNI avoidance strategy was
£174,842. In the comparison of TAC regimens, TAC-PR dominated immediate-release TAC, given its lower
costs and higher QALYs (both discounted and undiscounted).
The results were found to be similar after changing assumptions, including the time horizon, from the base
case of 25 years to 10, 15 and 20 years, the exclusion of discounting, AEs and half-cycle corrections.
The results against SRL were found to change significantly when graft survival parameters in the model
were populated with data from the SYMPHONY trial instead of the NHSBT data used in the base-case
analyses: TAC-PR was found to dominate SRL as CNI avoidance regimen when both were given with DAC
induction, 2 g MMF and steroids. In discussing these findings, the authors note that SYMPHONY trial has
reported outcomes up to 3 years and is the largest prospective study in the de novo kidney transplantation
to date, which showed TAC to result in lower AR, better renal function and graft survival outcomes at
1 year than the SRL regimen.
On the basis of these results, the company concludes that TAC is cost-effective and that TAC-PR
should become the standard of care, as it produces lower costs and better health outcomes than
immediate-release TAC. The latter statement is further supported, the submission claims, by the expected
benefits, not accounted for in the Astellas model, arising from the improved pharmacokinetic profile of
TAC-PR relative to immediate-release TAC. In addition, the authors argue that the results of the
SYMPHONY trial have discouraged use of SRL, and that BEL’s high cost and high ARR may do likewise,
citing a report by the All Wales Medicines Strategy Group350 as supportive evidence for this assertion.
Critical appraisal
The analysis presented by Astellas covers a number of appropriate comparators, including new regimens,
BEL, and regimens with modes of action different from that of CNIs, that is, EVL and SRL. However, it
omits one relevant comparator: CSA. There is no justification in the submission as to why this drug
regimen option was not considered in the analysis. Muduma et al.318 present the results of the same
analysis based on data from the literature recorded in electronic databases up to 1 year earlier than the
review in the Astellas submission (i.e. June 2013 vs. June 2014, respectively). The results reported by
Muduma et al.,318 who acknowledge employment by Astellas in the publication, are very similar to those
presented by the Astellas submission for those drug regimens that were common to both reports (i.e.
TAC-PR, immediate-release TAC, BEL, SRL CNI minimisation and SRL CNI avoidance). Unlike the Astellas
submission, Muduma et al.318 report results for CSA. The ICER of immediate-release TAC against CSA was
£21,244 (table 1, base-case results318) and the cost-effectiveness acceptability curve for the comparison
showed that the TAC option had a 59.5% probability of being cost-effective at the £30,000 willingness to
pay for a QALY threshold. The sensitivity analysis showed that the result of this comparison was sensitive
to the inclusion of the AE costs, that is, when omitting them altogether the ICER for TAC increased
to £35,446.
This evidence casts doubt on the robustness of the cost-effectiveness results and conclusions in the Astellas
submission, and suggests that the results presented may be misleading owing to the exclusion of a
relevant comparator. It is unfortunate that the submission did not include CSA, given the previous
published degree of uncertainty in the cost-effectiveness of TAC.
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There is use of inadequate data within the model. As discussed above, the estimates of patient survival in
the functioning graft state may have been underestimated. This works against the more efficacious
treatments, such as TAC, which had the lowest ARRs of all the regimens compared. Thus, the results
reported by Astellas in the submission may be treated as conservative estimates of the costs and benefits
of its TAC regimens. In relation to the evidence presented in support of TAC-PR, this may suffer from
the previous criticism about the incomplete set of comparators, and the fact that the TAC-PR versus
immediate-release TAC comparison is based on what is in effect a different model of the outcomes of
renal transplantation from that used to compare immediate-release TAC against all the other regimens.
In fact, the model used for comparing TAC-PR with immediate-release TAC contradicts the fundamental
premise of the model used to compare immediate-release TAC with all regimens other than TAC-PR: that
AR captures all important drivers of clinically meaningful outcomes.
One other issue relates to the way the model was structured. Although the model allowed repeat
transplantation to occur for a given individual, the costs and HRQoL of subsequent dialysis were accounted
for only the first transplantation. Although the proportion of people with more than one retransplantation
may be small, this assumption could have been important to the conclusions derived from the comparison
with CSA, had such comparator been included.
Another concern relates to how the timing of transplantation was implemented in the model. Markov
models imply that transitions occur at the end of the period represented by each cycle. In the present case,
the cycle length was 1 year and the authors of the Astellas model rightly decided on using half-cycle
corrections to reduce the inaccuracy of calculation of expected costs and benefits that arise from having
a long cycle length given the frequency of state transitions. The model, however, assumed that the
proportion of people who undergo retransplantation in the very first cycle made a transition from the
failed graft state to a functioning graft post-retransplantation state, as if the retransplant had occurred
at the start of the period, so that they spent the whole cycle length (6 months owing to the half-cycle
correction) with a functioning graft after retransplantation in the first cycle. This is wrong, as in a cohort
of people with de novo kidney transplants, the discrete Markov process transition from a functioning first
graft to a functioning retransplant requires two sequential intervening events to occur, that is, graft failure
and retransplantation (i.e. a minimum of two cycles, one for each event, is required).
In summary, the main limitations of the Astellas economic analyses are:
l Omission of CSA as a relevant comparator (without justification).
l Patient survival estimates in the functioning graft state may have been underestimated, which works
against treatments with low rates of AR, such as TAC. The underestimation is, in part, because of an
error in using UK registry data on survival rates of both people with functioning and those with failed
grafts to inform the survival rates for those in the model with a functioning graft.
l The analyses comparing the TAC-PR regimens with other non-TAC regimens are invalid, as the two
TAC regimens incorporate differences in treatment adherence and this is not accounted for in the
other regimens.
l Drug dosage levels for BEL and SRL were based on treatment guidelines, whereas for other regimens
they were based on actual trial data.
l The cost and HRQoL of dialysis were not included for recipients of second or subsequent transplantations.
l The analysis does not account for the role of GRF in (1) long-term graft survival outcomes and
(2) current costs and utilities.
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Novartis’ submission
Novartis, the company that produces EVL, submitted a simulation model of an individual patient’s health
experience for the lifetime remaining after renal transplantation in the English NHS. The following
treatments were evaluated for a group of simulated people of mean age 45.7 years (SD 12.7 years), mean
weight 70 kg (SD 10 kg), 68.5% of whom were male, and mean MDRD eGFR 9.03ml/minute/1.73m2
(SD 7.9ml/minute/1.73 m2):
l EVL+ reduced-dose CSA+ steroids versus:
¢ TAC+MMF+CCSs
¢ Standard-dose CSA+MMF+ steroids
l EC-MPS+ standard-dose CSA+ steroids versus:
¢ Standard-dose CSA+MMF+ steroids.
The model was specified as monthly transitions between six health states:
l stable post-transplant state (functioning graft)
l AR
l graft failure
l dialysis
l retransplantation and
l death (from CKD or other causes).
Moving between these states is associated with changes in direct health-care costs, whereas HRQoL (utility)
changes are accounted for transitions between the states of having a functioning graft to a failed graft,
and from any of these to the absorbing state of death. In addition, the model accounts for the changes in
mortality risks, utilities and monitoring costs (outpatient specialist visit) with renal function. Although the
costs associated with AEs emerging following transplantation were measured for six type of events
[proteinuria, BK virus (BKV) infection, CMV infection, hyperlipidaemia, wound and hypertension], only for
two of these was the loss of utility measured in the analysis (proteinuria and hypertension).
The model assumes that AR may happen up to 3 years after a transplant, and applies the same
probabilities of this type of event to first and subsequent transplantations. The probability of chronic
rejection (i.e. graft failure) is independent of renal function in the model. Once a patient’s graft fails,
dialysis is started and given until the time a new transplant is received, which is determined by a random
normal distribution process with mean of 36 months (SD 12 months). This feature of the model is what
gives it its discrete event simulation nature.
The model allows different rates of change in renal function (eGFR) between the first year (during which
they are specific to the immunosuppressive treatments) and the second, third and subsequent years,
when the rate of eGFR change is common to all treatment arms in the model.
The model parameters for the EVL and MPA regimens were populated with efficacy and safety outcomes at
12 months from the study by Tedesco-Silva et al.,359 a multicountry trial that compared EVL 1.5mg/day with
mycophenolate acid 1.44 g/day in people receiving a primary kidney-only transplant in the period October
2005–October 2008. The values for the TAC regimen were obtained from a trial reported by Larson et al.,154
which compared TAC with SRL in people receiving a kidney-only transplant (79% of whom were primary
transplants in the TAC arm) in the period April 2001–January 2004 in the USA. The source of the efficacy
and safety data for the MMF regimen was the multinational trial report by Vítko et al.,177 which compared
EVL with MMF in primary transplant patients who were recruited between August 1998 and August 1999.
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The indirect nature of the relative efficacy data used as inputs to the cost-effectiveness model of the three
comparisons submitted by Novartis presents some problems for valid estimation. In addition to the different
dates when the trials were conducted and the type of transplant (primary only or mixed) for the EVL–TAC
comparison, there were differences between the two studies in terms of the use of induction. Tedesco-Silva
et al.360 reported that participants in their trial of EVL were administered two BAS 20-mg doses: one within
2 hours before transplantation and the other at 4 days post transplantation ‘or according to local practice’,360
whereas Larson et al.154 reported that all people received thymoglobulin 1.5mg/kg/day on days 0, 1, 2, 4 and
6 post transplant. The sample of TAC participants was also slightly older but more balanced in terms of sex,
and had a higher proportion of living donor transplants. The major issue, however, is the fact that the actual
amount of TAC use in the efficacy trial was different from the dose used to cost the same regimen in the
model. Larson et al.154 report that the TAC was started at a 3mg twice daily. The estimated mean daily dosing
at 1 year, separately reported for the first 59 people randomised to TAC, was 6.3mg per day (SD 0.9mg
per day).361 The model, however, applied costs to the TAC arm at a quoted BNF recommended dose of
0.25mg/kg/day for a group of individuals of 70 kg mean weight, thus resulting in a mean daily dose
of 17.5mg, which is considerably higher than the actual drug use that corresponds to the efficacy outcomes
used by the model. The dose behind the TAC drug acquisition costs used in the Novartis submission is also
larger than the mean daily doses for immediate-release TAC reported by Tedesco-Silva et al.,349 which Astellas
adopted in its submission, and which are consistent with the report of Dean et al.361
In relation to the data sources for the comparison of EVL with the MMF+CSA regimen, the trial samples
differ in terms of the period covered by the study and the country mix. The proportion of cadaveric donors
transplant recipients was 46.6% in the EVL group compared with > 90% in the MMF+CSA regimen.150
Moreover, the MMF regimen was given without induction therapy, in contrast with the trial that provided
the outcome data for the EVL model arm.359 The same issues applied to the comparison of MPA with
MMF+CSA, as the data source for MPA was the same trial as that for EVL.107
Costs
Immunosuppressive costs of the MPS+ EVL treatment regimens were based on the dosing protocols of
the individual trial that was the source of efficacy data, whereas the costs of drug acquisition for the
comparators, that is, the TAC and MMF+CSA regimen, were based on BNF-recommended starting
dosages. Other health-care costs included the costs of monitoring GP visits, which increased with higher
CKD state. The cost of an AR event was taken from that reported by McEwan et al.310 The annual
costs of dialysis, £22,877, were obtained from a 2011 NICE costing report362 on organ donation for
transplantation. Retransplantation involved an estimated cost of £17,736, a weighted average of NHS
reference costs 2012/201364 for transplant procedures for varying ages and donor types.
Utilities
Estimates of utilities were derived from the study by Neri et al.,363 who reported EQ-5D health states measured
in a cross-sectional study of people with kidney-only transplants in the UK, valued using UK tariffs, as a
function of CKD states. As renal function deteriorated so did the HRQoL (utility) values experienced by the
simulated patient in the model. The model accounted for negative impacts on HRQoL (disutilities) of two
adverse effects, proteinuria (reduced utility by 0.043) and hypertension (reduced utility by 0.010).
Results
EVL + reduced CSA vs. TAC +MMF
Novartis reports a life expectancy at transplantation in a patient group of mean age 45.7 years (SD 12.7 years)
of 25.71 life-years under the EVL immunosuppression compared with 23.39 life-years under TAC, and
discounted QALYs of 8.86 and 7.37, respectively (Novartis’ submission, table 5.18, Base-case analysis –
deterministic ICERs). Given the discounted costs per patient that result under these options, £135,358 for EVL
and £140,972 for TAC, EVL was found to be the preferred option, as it is less costly and more effective
than TAC.
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Further results accounting for uncertainty in model inputs relating to uncertain parameters (ARRs, chronic
rejection rates, rate of change in eGFR after 12 months post transplant, health-state utilities and event
costs) confirmed that the probability of EVL being cost-effective was 100% at thresholds ranging from £0
to £200,000 per QALY.
EVL + reduced CSA vs. MMF + standard-dose CSA
The EVL regimen was found to produce 1.76 extra years of life over the MMF with CSA regimen in the base
case of a cohort of mean age 45.7 years. This corresponded to 0.99 extra discounted QALYs (Novartis’
submission, table 5.18, Base-case analysis – deterministic ICERs). The EVL containing triple therapy was also
associated with £59,354 extra discounted costs over the MMF+CSA regimen, and a practically identical
ICER figure, given the 0.99 discounted QALY benefit with EVL.
In probabilistic sensitivity analysis (PSA) accounting for the uncertain parameters (as listed for the results
of the EVL vs. TAC comparison), the EVL had a 0% probability of being cost-effective relative to MMF for
cost-effectiveness thresholds ranging from £0 to approximately £86,000 willingness to pay per QALY, and
was still < 15% at £200,000 per QALY.
The fact that the PSA yielded a willingness to pay per QALY threshold at which EVL had a 50% chance of
being cost-effective (> £200,000 per QALY), which was more than three times its deterministic ICER of
£59,354, indicates that the model has important non-linearities and that using the deterministic values for
decision-making is incorrect. Although this warning would not have made any difference to a decision
based on a £30,000 per QALY threshold (i.e. both determinist and probabilistic results led to the same
conclusion) for this comparison or the previous one discussed (i.e. EVL vs. TAC), the distinction does
matter for interpreting the results of the third comparison presented by Novartis – of EC-MPS vs. MMF,
discussed next.
EC-MPS vs. MMF + standard-dose CSA
In the deterministic base-case analysis, the mycophenolate regimen was found to result in 25.48 life-years,
and 8.69 discounted QALYs per patient (table 5.18, Base-case analysis – deterministic ICERs).
Mycophenolate acid had an extra 1.31 life-years and 0.80 discounted QALYs per treated patient relative to
MMF. Given its additional discounted costs of £10,588, EVL had an ICER of £13,209 per QALY relative to
MMF with CSA.
In the PSA that accounted for the effect of uncertain parameter estimates (as listed in the results of EVL
relative to TAC), mycophenolate acid had a 50% chance of being cost-effective at a threshold value of
around £28,000 willingness to pay per QALY.
Although the deterministic ICER for MPA is below the lower cost-effectiveness threshold adopted by NICE
(£20,000), the willingness-to-pay threshold corresponding to the 50% probability of mycophenolate acid
being cost-effective in the PSA is ≈ £28,000) suggesting that EVL may be borderline cost-effective, in
relation to the £30,000 maximum acceptable amount NICE is willing to pay for a QALY. This comparison
shows that the deterministic results are potentially misleading for informing decisions or deriving model
predictions about treatment outcomes in this model.
Critique
The Novartis model uses a patient simulation model of monthly cycles to calculate the costs and health
outcomes of immunosuppressant regimens over the remaining lifetime (i.e. 50 years post transplantation).
The main strength of the model is its account of the occurrence of clinical events that determine health
status, that is, AR, and graft and patient survival, as well as the effect of renal function on costs
and HRQoL.
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The study failed to conduct adequate evidence synthesis, as their methods of identification of relevant
evidence on efficacy was not systematic, as acknowledged by the authors. The model analyses were based
on data from single trials, and their analyses were restricted to undertake pairwise indirect comparisons
of the treatments investigated in each of those individual trials. This led to results that were at odds with
findings from the systematic review of the clinical evidence undertaken by PenTAG (see Chapter 3,
Summary of pairwise comparisons) which found no statistically significant improvement in efficacy
outcomes (AR, graft failure, death) of EC-MPS compared with MMF, whereas the Novartis model-based
analysis produced an extra 1.31 life-years for EC-MPS. Therefore, the results by Novartis are likely to be
biased, and consideration of additional efficacy evidence from direct and indirect comparisons would have
allowed the company to provide a more reliable technology assessment.
Some errors were identified in the calculation of unit costs of immunosuppression for the CSA component
of the EVL regimen, which was common to two other comparators, but is not part of the current standard
clinical practice in England. This had the effect of underestimating costs for the CSA-containing regimens.
The model accounted for some important AEs, but omitted one of the most important determinants of
patient and graft survival: PTDM.
A major flaw in the model is the assumption that graft failure occurs independently of the GRF or the
occurrence of AR. The probability of graft failure (labelled chronic rejection in the submission) is based on
12-month post-transplantation trial data for each regimen, which, given that this probability is constant
over the 50-year time horizon of the model, casts serious doubt about the validity of the findings.
In summary, the main strength of the Novartis analysis is its account for the effect of differences in GRF
between treatment arms on current costs and utilities. Its main limitations are:
l The use of treatment effectiveness data from single selected RCTs, not systematic reviews or
meta-analysis, and based on pairwise indirect comparisons of those trials. The estimated effectiveness
of EC-MPS compared with MMF is therefore substantially greater than that estimated from the
assessment group’s systematic review and meta-analysis.
l The model structure contains the assumption that graft failure occurs independently of GRF or the
occurrence of AR. Instead, the probability of graft failure is based on the trial-derived rates at 1 year
post transplant, which are then assumed to remain constant throughout the modelled period.
l Regimens involving CSA (including the EVL regimen) had incorrect unit costs for CSA; this would
underestimate the cost of those regimens.
l The estimate of the annual cost of dialysis is from an unusual source, and substantially lower than
current costs as in the NHS reference costs.
l The AE PTDM is not included in the model (despite others being included).
Bristol-Myers Squibb’s submission
The following regimens, all following BAS induction, were compared in the Bristol-Myers Squibb submission:
l BEL (less-intensive dosing)+MMF+ steroids vs. CSA+MMF+ steroids
l BEL (less-intensive dosing)+MMF+ steroids vs. TAC (immediate release)+MMF+ steroids.
Two patient populations were studied, namely standard criteria donor recipients, and the ECDs recipients
of de novo renal transplants. In addition, the submission presented subgroup analyses for people of weight
of > 90 kg.
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In its review of the effectiveness evidence, the company justifies its exclusion of SRL from the analysis
arguing that, in practice, its use ‘is generally restricted to treating renal transplant patients whose renal
function is steadily declining on TAC or CSA, and in whom other measures (such as dose adjustment) have
not been successful’ (Bristol-Myers Squibb’s submission, chapter 3, efficacy section). As for TAC-PR, the
company argued that there was insufficient direct or indirect evidence to include it as a comparator. EVL
was excluded from the analysis because it lacks UK marketing authorisation. As for MMF and MPS, the
company states that they were not included as comparators because they are required to be given with
CCSs as part of triple therapy containing BEL, TAC or CSA.
The evidence used to populate the efficacy and safety parameters in the model used in the Bristol-Myers
Squibb analysis was derived from the BENEFIT59) and BENEFIT-EXT142 trials, which compared BEL with CSA. The
efficacy and safety parameter values for BEL relative to immediate-release TAC were obtained from indirect
comparisons in a NMA of 32 studies, 29 of which compared TAC with CSA and three studies (including
BENEFIT59 and BENEFIT-EXT142) of BEL compared with CSA.
In making the case for BEL the submission argues that the i.v. mode of administration is likely to result in
increased adherence to treatment relative to TAC and CSA, which are administered orally and require
routine monitoring to drug exposure and dose adjustment. The company claims that this would be
expected to result in improved outcomes with BEL over the CNI comparators. Further, in setting the
context of the economic evaluation (Bristol-Myers Squibb’s submission, chapter 6, Cost-effectiveness of
BEL) the company states that the drivers of the evaluation were the acquisition cost of BEL, the number
of years of functioning graft and the costs and utility (HRQoL) of dialysis following graft failure, which
led it to perform subgroup analyses in those whose expected graft survival is short. Therefore, because
‘post-transplant renal function is a well-established predictor of graft survival this analysis focused on
people with a post-transplant eGFR < 30ml/minute/1.73m2 as these people represent those for whom
improved post-transplant renal function is most likely to have significant health and cost benefits’.
The analysis is based on the 3-year outcomes from the pooled data from BENEFIT59 and BENEFIT-EXT,142
including renal function (eGFR), and the cumulative incidence of NODAT, AR, PTLD, graft failure and
death, where eGFR of < 15ml/minute/1.73m2 was assumed to identify people with graft failure. The
Markov model developed by Levy et al.334 was then used to extrapolate these outcomes to the long term.
To avoid repeating the description in Chapter 4 (see Identified studies), the main features of this model are
summarised here.
The model represents annual transitions among the following health states:
1. functioning graft (including distinguishing four categories of renal function according to National
Kidney Foundation Kidney Disease Outcomes Quality Initiative)
¢ GFR stage 2 (GFR2)=≥ 60ml/minute/1.73m2
¢ GFR3a= 45ml/minute/1.73 m2 ≤GFR < 60ml/minute/1.73m2
¢ GFR3b= 30ml/minute/1.73 m2≤GFR < 45ml/minute/1.73 m2
¢ GFR4= 15ml/minute/1.73m2≤GFR < 30ml/minute/1.73m2
2. graft failure/dialysis defined as:
¢ GFR5=GFR < 15ml/minute/1.73 m2
3. functioning re-graft/retransplantation
4. death.
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The probabilities of transitions between these states were populated by time to event models estimated by
Levy et al.334 using US registry data. The survival models were the following:
l Weibull time to event models for graft survival [two models: (1) graft failure 1–4 years after transplant
and (2) graft failure > 4 years]
l Weibull time to event model for patient survival [two models: (1) death with a functioning graft
1–4 years after transplant and (2) death with functioning graft (DWTG) of > 4 years]
l exponential survival model of time from graft failure to retransplant
l exponential survival model of time from retransplant to graft failure
l exponential patient survival on dialysis (after graft failure)
l exponential patient survival after retransplant.
The Weibull survival model adjusted for covariates including patient age, sex, baseline eGFR, weight,
NODAT, AR events, PTLD, donor type and other, calendar year, and patient and donor characteristics.334
The conditioning of these models’ predictions on baseline eGFR allowed the derivation of separate survival
curves for the different starting (i.e. at 3 years post transplant) renal functioning health states in the model.
In order to assign costs and utilities for each starting eGFR group, the total time spent with a functioning
graft predicted from the survival models (adjusted for death risks) was allocated to different eGFR
categories by assuming that eGFR declined linearly over time from its starting level (the midpoint of the
starting eGFR stage) until reaching graft failure, which was associated with an eGFR level of 15ml/minute/
1.73m2. Thus, for example, the group of people who entered the Markov model in GFR2 (at 3 years post
transplant) at the midpoint GFR level of 67.5 ml/minute/1.73 m2; those in these groups who experienced
graft failure, say on the fifth annual cycle (i.e. 8 years post transplant), would be assumed to have
traversed from eGFR2 to eGFR5 at an annual rate of 10.5ml/minute/1.73 m2 [= (67.5 – 15)/5 ml/minute/
1.73m2]. Thus, the members of this illustrative group of modelled people would have made a transition
from GFR2 to GFR3a in the first year (at the end of which they would reach a GFR level of 57ml/minute/
1.73m2), remain in eGFR during the second year (to finish it at a GFR level of 46.5 ml/minute/1.73m2),
then make a transition to, and end the third year in, GFR3b (at a GFR level of 36ml/minute/1.73 m2), make
a transition to GFR4 in the fourth year (to end the year at GFR level of 25.5 ml/minute/1.73 m2) and
experience graft failure at the end of the fifth year (GFR level of 15ml/minute/1.73 m2). In the model, some
people die without graft failure, and they were assumed to have remained in the same eGFR stage as that
in which they entered the model [on the basis of regression analysis of United States Renal Data System
(USRDS) data on which the survival models were estimated].
After calculating expected costs and outcomes in the Markov model for each starting eGFR stage over
37 years (which, added to the initial 3-year period, amounts to the modelled horizon of 40 years adopted
in the base case), the expected costs and outcomes for the whole population were calculated by a
weighted average of the expected costs and QALYs across starting model stages. The proportions
were the frequency distributions of people at 3 years post transplant across functioning graft stages
(approximated by a normal distribution using mean and SD of eGFR values), dialysis stage and death.
Finally, the expected costs and QALYs over the extrapolated Markov phase were added to costs and
QALYs associated with the observed trial outcomes in the trial to calculate total QALYs and costs over
40 years for each trial arm in BENEFIT59 and BENEFIT-EXT.142
Efficacy parameter estimates
The main inputs for the model were those estimated from the NMA at 36 months. These are presented in
Table 142, which reproduces table in the industry submission (Bristol-Myers Squibb’s submission, section 6.1,
Model inputs, table 28). In the model, the effect of NODAT on graft and patient survival curves is accounted
for by applying HRs from the literature.365 PTLD and CVD were accounted for in the model by assigning a
50% chance of death to each of them. The sources of these estimates were not given.
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According to the Bristol-Myers Squibb submission, the distribution of the patient cohort at the start of the
Markov model for each of the three regimens evaluated – BEL, TAC and CSA – was calculated from the
pooled BENEFIT59 and BENEFIT-EXT142 trial data on GFR outcomes at 36 months post transplant. They
assumed that GFR level followed a normal distribution to derive the distribution across functioning graft
states, and used the observed means of 38.6 and SD of 22.93 for CSA, 54.64 for BEL (from the BENEFIT59
trials) and 44.8 for TAC (from NMA relative to CSA). But the assumption of normally distributed GFR is
problematic, as it implies that in the CSA arm, 4.6% of people at the end of the trial phase (and therefore
at the start the Markov model phase) have a negative GFR value. However, inspection of the model’s Excel
spreadsheets revealed that these values were not used in the model, but rather a mean of 50.80 and SD
of 21.80 for CSA, which implies that 0.9% of people have a negative GFR value at 3 years post transplant.
The means for TAC and BEL were, in turn, 58.47 and 66.96, and they also applied the SD 21.80 for CSA
(these imply negative GFR values for < 0.4% of people).
To validate the survival curves underpinning its Markov model, which were estimated from US data, the
company compared the predictions from its Weibull survival models with UK data from the NHSBT 2013
report355 (these have been discussed in relation to the model submitted by Astellas, submission section
6.1). The predicted survival curves from the Bristol-Myers Squibb model by type of donor (DBD and DCD)
are compared with the corresponding UK data points at year 1, 2 and 5 post transplant. Owing to the
difficulty of visualising the chart presented by Bristol-Myers Squibb (Bristol-Myers Squibb’s submission,
figure 22), the 5-year survival curves reported by the NHSBT 2013 report are reproduced in Figure 66,
alongside the corresponding predictions in the survival model informing the Markov model in the
company’s submission. It shows that the model predictions for the DBD graft survival (DBD predictions
based on USRDS) converge towards actual UK data for the corresponding donor type. The model
predictions based on the DCD patient population, however, appear to diverge from the trend observed in
UK data for each donor type. This is of concern, as predictions from this model were used to extrapolate
3-year trial outcomes for 37 years.
Changes in eGFR stages were associated with changes in utilities and costs. Utilities were derived from a
cross-sectional study of UK renal transplant patients.338 AEs including AR, NODAT and PTLD were given
estimated annual utility losses of 0.50, 0.06 and 0.44, respectively, reported from the literature.
TABLE 142 Relative effect of TAC and BEL vs. CSA at 36 months
Outcome
OR (95% CI)
TAC vs. CSA BEL vs. CSA
Graft lossa 0.86 (0.63 to 1.17) 0.92 (0.44 to 1.93)
Patient deatha 1.27 (0.88 to 1.89) 0.77 (0.37 to 1.55)
AR event 0.63 (0.50 to 0.81) 1.57 (0.80 to 3.03)
Difference in true mean value (95% CI)
eGFRa 6.20 (0.64 to 12.47) 16.04 (6.19 to 25.53)
a ORs for graft loss, AR, patient death and difference in eGFR are reported in Goring et al.364
Note
Figures in bold are statistically significant using a 5% significance level.
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Costs
The submission provides actual data on estimated costs of clinical events following transplantation in
standard practice at a single centre in Wales (Table 143). The analysis has been published as part of a
multinational study report (described in Chamberlain et al.42 Assessment of cost-effectiveness, Results),
which shows some common and divergent practice between this site and other European centres. Briefly,
costs were estimated in a retrospective analysis of computerised records from the Cardiff Renal Transplant
Database, related to all individuals aged ≥ 18 years who received a kidney-only transplant recorded
between January 1998 and December 2005. They were followed up to 3 years, and the analysis included
those in whom data were recorded for at least 12 months after transplant and whose data included their
most recent transplant in the studied period.
The study provided evidence that was previously unavailable for the UK on actual costs of post-transplantation
care and events stratified by GFR at 1 year post transplant. The sample for analysis included 370 people in
whom a variety of treatment regimens were used. Of the 20 different treatments used in this period, triple
therapy with TAC steroids and AZA was the most frequent (19%), followed by triple therapy with TAC,
steroids and MMF (18%). The next most frequently used regimens were double therapy with TAC and AZA or
TAC with MMF (9% each). By the second year the proportion of people on these TAC triple regimens had
declined (to 14% and 12% of the sample), whereas the proportion of people on the double therapy TAC
had increased (to 14% and 13%). The same observation was made from 24 months to the 24+ months’
follow-up point.
Another aspect of this data source is the observed number of TAC immunosuppressant doses used over
the follow-up period in this sample. Although, the dose of TAC, given as part of triple therapy alongside
MMF and steroids, was continually reduced over the first year from the mean of 10.31mg at month 1 to
6.36mg at month 12, and was 5.73mg and 5.71mg at month 24 and month 24+, respectively, the
dose was kept at 11.23mg throughout the observation period in the triple regimen that included AZA
(Bristol-Myers Squibb’s submission, appendix 5, Preliminary report PORTRAIT database study Cardiff).
On the basis of the resource-use estimates from the PORTRAIT study report, the TAC drug regimen and
the CSA regimen costs were estimated. Drug use was valued at BNF 67369 prices [for TAC, the average
price of immediate-release TAC 1mg of 50- and 100-capsule packs was used; for CSA, the average prices
of Capimune® (Mylan), Capsorin® (Morningside Pharmaceuticals Ltd), Deximune® (Dexcel Pharma Ltd) and
Neoral® (Novartis), 30-capsule packs, were used]. Administration costs included one laboratory test per
outpatient appointment to determine CNI level, and accounted for the observed number of outpatient
appointments in years 1, 2 and 2+. The costs of BEL administration included the costs of i.v. infusion,
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FIGURE 66 Validation of first adult kidney-only graft survival predictions of the Bristol-Myers Squibb model
(based on US data from the USRDS) with NHS data (NHSBT) by donor type.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
271
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
TABLE 143 Costs and utilities by GFR in the Bristol-Myers Squibb model
Functioning graft
Costs (£)a
UtilitiesbBEL TAC CSA
GFR2, year 1 5580 5677 5600 0.64
GFR3a, year 1 5637 5735 5657 0.58
GFR3b, year 1 7800 7897 7820 0.58
GFR4, year 1 8132 8230 8152 0.49
GFR2, year 2 1562 1659 1582 0.64
GFR3a, year 2 1850 1947 1870 0.58
GFR3b, year 2 3073 3170 3093 0.58
GFR4, year 2 4102 4200 4122 0.49
GFR2, year 3+ 1570 1668 1590 0.64
GFR3a, year 3+ 1922 2019 1942 0.58
GFR3b, year 3+ 3366 3433 3355 0.58
GFR4, year 3+ 4258 4356 4278 0.49
Dialysis 43,650 43,748 43,670 0.28
Functioning regraft 7190 7,288 7210 TAC: 0.59c
BEL or CSA: 0.60c
One-time cost of graft failure
Year 1 1384
Year 2 431
Year 3+ 191
One time costs/disutility of PTLD 4890 0.44
One time costs/disutility of AR 3483.28 0.50
a Costs by GFR function differ slightly (at the third decimal point) between arms because of their different incidence rates
of NODAT between them, which had an annual cost of £1174 (Currie et al.366). For years 1–3 (trial data phase),
differences in terms of costs of these health states between regimens were also affected by the risk of PTLD incidence,
which was an independent death risk factor and was associated with a cost of £4890 (based on off-licence therapy with
rituximab monotherapy based on BNF), and by acute rejection, which incurred a cost of £0.50 (Currie et al.366).
b Utilities by GFR function differ slightly (at the third decimal point) between arms because of their different incidence
rates of NODAT between them, which had a disutility of 0.04 (Currie et al.366). For years 1–3 (trial data phase),
differences in terms of utilities of these health states between regimens were also affected by the risk of PTLD incidence,
which was an independent death risk factor and was associated with a disutility of 0.44,367 and by AR, which incurred
disutility of 0.50.368
c Average of GFR2, GFR3a and GFR3c (after retransplantation no differentiation by renal function is made in the model).
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which were obtained from a previous HTA report on abatacept (from which BEL was derived, and that has
the same method and frequency of administration). Thus, the annual drug acquisition and administration
costs of the regimens in the first year of the model for a 75-kg patient were £13,472 for BEL, £3937 for
TAC (immediate-release TAC) and £1972 for CSA. These costs were smaller in the second and subsequent
years by about 30%, 25% and 15% in the BEL, TAC and CSA arms, respectively.
Results of Bristol-Myers Squibb’s analyses
In the base-case results for a cohort of people with a starting average age of 43 years, at 40 years post
initial transplant 11% of people would be alive under BEL, whereas that would be 8.8% under TAC and
7.4% under CSA. By that point, in 75.6% of people the graft would have failed under BEL, whereas that
would have happened in 73.8% of people under TAC and 76.9% under CSA. Correspondingly, 19.3% of
people received retransplantation under BEL, 19.2% under TAC and 20.6% under CSA.
When comparing total discounted costs, BEL resulted in incremental costs of £91,001 over TAC and
£92,216 over CSA. In turn, the incremental discounted QALYs were 0.62 relative to TAC and 0.97 relative
to CSA. The incremental cost per additional QALY of BEL relative to TAC was £147,334, whereas that for
TAC relative to CSA was £3375.
These results were driven by the higher costs of BEL immunosuppression, which, despite its associated
savings in dialysis costs relative to the other regimens (£15,469 relative to CSA and £2248 relative to TAC),
incurred seven and three times the cost of immunosuppression of the CSA (additional costs £109,402) and
TAC (£95,159 difference) regimens, respectively. These results were confirmed by PSAs and deterministic
sensitivity analyses, which showed the ICER to be insensitive to variation in uncertain parameters.
The submission presented additional analyses for a special group of people with a shorter expected graft
survival than that for the overall patient population. This is referred to as ‘subgroup analysis’ by the
company, and implemented by defining the group as those people with GFR of < 30ml/minute/1.73m2 at
1 year post transplant. They implement a post-hoc adjustment to the model so that the effect of eGFR
improvements within that range may be accounted for in the model, which originally was specified in
discrete eGFR categories and thus restricted all people entering the model in the same category to having
the same benefits. The company found that, in these people, BEL results in higher benefits (0.46 extra
QALYs in both comparisons) and lower costs (–£1478 relative to CSA and –£4166 relative to TAC).
However, this analysis suffers from a logical flaw. It assumes that those people whom the company claims
to have identified as able to benefit from their drug regimen may be identified with precision. In fact
they may not. The meaningful definition of subgroup analyses in a setting where risk and uncertainty
influence the outcomes of treatment such as this, so that the outputs of a decision model are mathematic
expectations of cost and benefits, identifies a selected group of people for special management on the
basis of observable characteristics defined at the outset. The defining characteristic of the selected group
of people in the subgroup analysis by Bristol-Myers Squibb is an outcome of treatment, and thus not
known at the time of transplant (which would be required for sound decision-making analysis about
choice of maintenance treatment).
A subgroup analysis presented by Bristol-Myers Squibb finds that BEL may be cost-effective in people with
body weight of approximately 90 kg and more. At this body weight, BEL use incurs minimal vial wastage,
thus maximising effectiveness for the given cost.
Critique
The model captures all the most important clinical outcomes and AEs arising post transplantation, and
accounts for the role of renal function as a prognostic factor for long-term graft survival and its
contemporaneous effects on HRQoL and costs. It also accounts for the effect of short-term AR on
longer-term graft and patient survival.
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A major strength of the evidence presented by Bristol-Myers Squibb is the cost study used to populate the
costs of immunosuppressant drug use and administration in the model and the costs associated with renal
function. This evidence has been reported as part of a wider study42 in a peer-reviewed publication.
The major limitation of this study is the questionable generalisability of the values used to populate the
transition probabilities of the model used to extrapolate short-term trial outcomes to 40 years. The survival
models that inform the transition probabilities to the key events, that is, graft failure after transplant, time
to retransplantation after graft failure, and possibly patient survival with a functioning graft, may reflect
the experience of a patient population that does not correspond to that of the UK.
Another issue is the use of efficacy differences between regimens at 3 years post transplant to populate
the entire initial 3 years, as if these differences had occurred from day 1 and remained constant until
the end of the third year post transplantation, which we know was not the case, and bias the analysis in
favour of BEL, the company’s drug. In fact, inspection of the model spreadsheet reveals that discounting
was not applied to the first 3-year costs and benefits.
A methodological limitation is the assumed linear, constant decline in eGFR, which was the driver of the
Markov model used to extrapolate outcomes beyond 3 years, in order to estimate quality of life over
the graft survival period conditional on initial eGFR value. This, in turn, reflected the limited information
available on renal function from registry data; studies using multicentre cohorts could potentially address
this issue by measuring, rather than imputing, renal function periods of longer than 2–3 years, which are
typically found in the experimental literature.
In summary, the Bristol-Myers Squibb model has numerous strengths, but has the following main limitations:
l The use of US data to extrapolate the survival data for key transition probabilities to 40 years
(graft failure, time-to-retransplantation after failure).
l The use of efficacy differences between regimens at 3 years post transplant to invalidly calculate
benefit differences throughout the first 3 years in the cost-effectiveness model, which favours the
company’s drug, BEL.
l Lack of accounting for the costs of concomitant regimens used in the triple-therapy regimens
investigated by the RCTs, which served as the source of efficacy values in the model (discussed in
Comparison between the model submissions).
l Lack of discounting of costs and QALYs in the first 3 years of the analysis, which invalidly raises the
benefits of BEL proportionally more than it increases its incremental costs.
l The assumed linear decline in eGFR 3 years post transplant at a rate with no validation or sensitivity
analysis of this assumption.
l A ‘subgroup analysis’ based on people with poor GRF at 1 year, but who would not be identifiable at
the time of starting maintenance immunosuppression (and therefore also outside the scope of this
technology assessment)
l Another subgroup analysis, of those with a body weight of 90 kg, should be disregarded, as this
subgroup is based only on the cost differences that would be affected by the patient’s weight.
Comparison between the model submissions
Besides the treatment comparisons, the company submissions also differ in terms of the models used to
evaluate those treatments (Table 144). Table 145 highlights how useful the evidence provided in each of the
economic evaluations may be to inform the decision-making. Given the necessity to extrapolate short-term
outcomes reported in trials with typical follow-ups of 1–3 years, the main differences between extrapolating
models used by the three companies are reflected in the choice of surrogate outcome used to drive the
disease course in people with renal transplantation and the duration of any relative effects of treatments.
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TABLE 145 Evers checklist: quality of published economic evaluation studies304
Item
Astellas’
submission
Novartis’
submission
Bristol-Myers
Squibb’s submission
I&M I&M I&M
1. Is the study population clearly described? Y Y Y
2. Are competing alternatives clearly described? Y Y Y
3. Is a well-defined research question posed in answerable
form?
Y Y Y
4. Is the economic study design appropriate to the stated
objective?
Y Y Y
5. Is the chosen time horizon appropriate to include relevant
costs and consequences?
Y Y Y
6. Is the actual perspective chosen appropriate? Y Y Y
7. Are all important and relevant costs for each alternative
identified?
Y N Y
8. Are all costs measured appropriately in physical units? Y Y Y
9. Are costs valued appropriately? Y Y N
10. Are all important and relevant outcomes for each
alternative identified?
N N Y
11. Are all outcomes measured appropriately? Y Y Y
12. Are outcomes valued appropriately? Y Y Y
13. Is an incremental analysis of costs and outcomes of
alternatives performed?
Y Y Y
14. Are all future costs and outcomes discounted
appropriately?
Y Y Y
15. Are all important variables, whose values are uncertain,
appropriately subjected to sensitivity analysis?
Y Y N
16. Do the conclusions follow from the data reported? Y Y N
17. Does the study discuss the generalisability of the results to
other settings and patient/client groups?
N Y N
18. Does the article indicate that there is no potential conflict
of interest of study researcher(s) and funder(s)?
N N N
19. Are ethical and distributional issues discussed
appropriately?
N N N
I&M, induction and maintenance; N, no; Y, yes.
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The submission by Astellas uses a Markov structure to model the disease evolution and the effects of
treatment in the relevant cohort of people. In this model the occurrence of BPAR in the first year post
transplant (for the first transplant and any second transplant occurring in the first year of the model)
affects the probability of graft failure in subsequent years. Renal function plays no role in this model.
In contrast, differences in eGFR changes between the triple-therapy regimens in the first year drive the
modelled outcomes of subsequent years in the model by Novartis. Although the risk, costs and HRQoL
consequences associated with ARs are accounted for in this model, these events do not affect graft
survival. Graft failure is thus as likely to occur while individuals are at CKD stages 1 and 2 as when
they are at CKD stage 5, and any state in between those two extremes for that matter. The model by
Bristol-Myers Squibb, unlike that by Novartis, assumes that eGFR at the end of year 1 determines graft
survival. However, unlike Astellas and similarly to Novartis, the Bristol-Myers Squibb model allows for the
costs and consequences of changes in eGFR over time in the functioning graft state and for the effect of
eGRF on the probability of patient death. An additional advantage of the Bristol-Myers Squibb analysis
over that of Novartis is its allowance for the effects of AR in the first year post transplant to affect patient
and graft survival thereafter, as the analysis by Astellas does for the graft survival only.
The figures adopted by the Novartis submission seem to underestimate the costs of twice-daily
immediate-release TAC doses. Their cost per mg for TAC is £0.82, whereas the weighted average figure
for the market share of the different presentations used by Astellas is £1.618. On the other hand,
the mean daily dose at 70 kg body weight for TAC in the Novartis submission is 17.5mg, whereas the
average daily dose for the first year used by Astellas is 7.17mg. This results in an average maintenance
monthly cost of TAC that is 24% higher in the model by Novartis than in the model by Astellas (i.e. £438
vs. £353 per month).
Other differences were found in terms of the unit costs of the MMF therapy. Novartis used a £9.65 price
per pack of 50 tablets of 500mg each, obtained from market data [Commercial Medicines Unit (CMU)
Electronic Market Information Tool (eMit) 2014370], whereas Astellas used a price almost 10 times higher:
£82.26 per pack of 50 capsules of 500mg, citing BNF 2014.56 The effect of the chosen MMF price is also
different across the submitted analyses, as MMF is a concomitant medication across all immunosuppressive
regimens analysed in the evaluation by Astellas, whereas in the Novartis analysis MMF is not part of the
regimens involving the company’s own therapies (i.e. EVL and EC-MPS). Thus, although across submissions
the treatment regimens that include the companies’ drugs may be associated with increased effectiveness,
a higher MMF price has different implications across the submissions: it makes it less attractive for the NHS
to adopt such a regimen (as people live longer and incur higher drug costs) in the Astellas analysis,
whereas the opposite occurs in the Novartis case (as only the cost of comparator regimens increases).
Although the three models submitted to NICE for this assessment varied in terms of the way the health
course of an individual evolved and the use of immunosuppression affected such path, accounting of costs
was similar in some aspects once the cycle length of models was taken into account. Table 146 presents
the most important costs for those elements that were common across the models.
Although the acquisition costs of TAC are comparable across the three industry submissions, only the one
by Bristol-Myers Squibb reports any estimates of drug administration, which have the merit of being based
on observed data as opposed to assumptions about compliance with dosing guidelines or protocols. With
respect to immunosuppression costs, it may be noted that Bristol-Myers Squibb did not account for costs
of other concomitant drugs that are part of triple-therapy immunosuppression (e.g. MMF+CCSs, which
were given in BENEFIT59 and BENEFIT-EXT142).
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TABLE 146 Major cost elements (£) in the model submissions
Company Astellasa Bristol-Myers Squibbb,c Novartisa,c
TAC therapy (per year) 4255d 3937 (first)
2821 (second plus)e
5283
TAC administration 0 386 (first)
89 (second)e
0
MMF therapy (per year) 2402f 0
g
282h
CSA therapy NAi 1971 (first)
1562 (second plus)e
839 (first)
694 (second plus)
CSA administration 0 386 (first)
90 (second)e
0
BEL (per year) 10,966 (first)
6480 (second-plus)
13,472 (first)
9217 (second plus)
NA
BEL administration 0 2457 (first)
1996 (second plus)
NA
CCSs 178 0g 285
AR (event) 1738 3483 1725
Dialysis (per year) 38,387
j
43,586k 22,877l
Retransplantation 25,953 25,908 17,736
Retransplantation: organ procurement 0 12,954 0
NA, not applicable.
a Adopted a 70-kg weight for the representative patient in the model. The cost of BAS induction (20mg within
2 hours before transplantation and at 4 days post transplant, BNF 2014 prices, £1685) was included in all arms.
b Adopted a 75-kg weight for the representative patient in the model.
c Induction costs were not accounted for in the model but their omission might have had negligible effects, as it would
only affect the ICER through the small differences in the proportion of retransplants between arms.
d Immediate-release TAC.
e The Bristol-Myers Squibb submission reports a cost (of drug acquisition or drug administration) for the second year that
is different from the cost for the third and subsequent years, but the model spreadsheet adopts the price given for the
third year in the submission as the price of the second and subsequent years. The figure presented here is the one
adopted by the model.
f Based on 1 g daily, starting within 72 hours of transplantation, valued at £82.26 price for 500mg, 30-capsule pack from
BNF March 2014.
g The Bristol-Myers Squibb model did not include costs of concomitant medications in the triple-therapy regimen for any
treatment arm.
h Based on 1 g daily starting within 72 hours of transplantation, valued at £9.65 price for 500 mg, 50-tablet pack from
CMU eMit 2014.
i Astellas does not evaluate CSA in its submission. However, the model speadsheets include information showing that the
annual costs of CSA are calculated based on market shares of £3731 for the first year and £3514 for subsequent years.
j From Beaudet et al.371
k From Baboolal et al.372
l From supporting evidence of NICE guidance CG135373 (NICE 2011).
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More importantly for the results is the observation that Bristol-Myers Squibb used an estimate of dialysis
costs372 that was twice the size of the estimate adopted by Novartis (NICE costing guideline 2011374)
and almost 13% higher than that of Astellas.371 Given the driving influence of dialysis costs for
cost-effectiveness and an issue to be discussed next in relation to the time spent on dialysis in the models,
the quality of evidence gained by the Bristol-Myers Squibb model in estimating immunosuppression-related
costs and event costs may have been partly offset by an overestimation of the cost savings to be obtained
from reducing the time for which people experienced dialysis.
In Table 147, the key features of the effectiveness elements of the analyses performed by the companies
are presented. A salient aspect of the comparison model specifications is the longer expected time to
retransplantation at the time dialysis starts for those people whose graft fails in the Bristol-Myers Squibb
model. It is noted that this estimate was derived from an exponential survival model from an older patient
sample in the USA (Medicare-covered transplant-only people). This model has a hazard (instantaneous
probability) of receiving a transplant that is constant over time and that is predicted according to donor
and patient characteristics (Levy et al.334). In the Bristol-Myers Squibb model these characteristics are fixed
over time and result in the constant annual probability of 4% of receiving a transplant while on dialysis.
This means that the expected waiting time for a retransplant in a US sample with the Bristol-Myers
Squibb’s model characteristics (which match the BENEFIT59 and BENEFIT-EXT142 sample characteristics), as
detailed in the Bristol-Myers Squibb submission, is 16.5 years at the start of dialysis. This waiting time is
clearly longer than the waiting time currently expected in the UK, which may be closer to the values
adopted by Astellas and Novartis in their models.
TABLE 147 Key features of effectiveness analysis in industry models
Company Astellasa Bristol-Myers Squibbb Novartisc
Time to graft failure (median) Without BPAR at
12 months: 23
Initial GFR2 15.0 EVL: 15.8
Initial GFR3a 11.5 EC-MPS: 21.3
With BPAR at
12 months: > 25c
Initial GFR3b 7.0 MMF+CSA: 7.2
Initial GFR4 2.5 TAC+CSA: 8.3
Time to transplantation from graft failure
(mean unless otherwise stated)
3.5 (median) 16.5d 3 (SD 1)
Annual change in GFR NA –3 (fourth plus) –1.66 (second)
–2.68 (third plus)
Utility of
functioning
state
First transplant 0.71 0.49–0.64 (depending
on GFR stage)
0.49–0.64 (depending
on GFR stage)
Second-plus
transplants
0.71 0.59 0.49–0.64 (depending
on GFR stage)
Utility of dialysis state 0.459 0.28 0.28
NA, not applicable.
a Model was driven by surrogate marker of AR.
b Models driven by GFR change over time.
c Modelled time horizon was 25 years, by which point 53.9% of those with BPAR in the first 12 months still had their
initial graft functioning.
d This value was derived by the company from an exponential survival model (Levy et al.334) with predicted hazard rate for
a person of average age of 40.3 years (Bristol-Myers Squibb’s submission model Excel file). The model had been
estimated on USRDS data for a sample of Medicare-covered KTRs (no information on sample characteristics were
provided), which means that the model predictions are likely to be out of the age range of the sample on which the
model was estimated.
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In any case, the median time to retransplant may also be unrealistic for the USA, even after considering
issues about socioeconomic barriers to access and related features of that system. After inspection of the
estimated coefficients of the exponential model reported by Levy et al.334 (supplementary material, file 1,
and reproduced by the Bristol-Myers Squibb submission as appendix 4, table 1), the age covariate
(which remains fixed at 40.3 years throughout the 40 annual cycles of the Markov model, so that those
proportions of the cohort who experience graft failure early in the model have the same probability of
receiving a retransplant in any given cycle as that people who experience graft failure in the latter part of
the modelled time horizon) is positively associated with the probability of retransplant, which means that
those who start dialysis at older ages have shorter expected waits for a retransplant and suggests that the
model was estimated in a cohort of much older people than the Bristol-Myers Squibb’s modelled age of
40 years (e.g. for graft failure at age 70 years the model yields an expected wait of approximately 10 years
to receive a retransplant).
The overestimation of time to retransplant in the Bristol-Myers Squibb model that was just described has
the implication of overestimating the time on dialysis with its associated costs and loss in quality of life.
This, in turn, means that the model is likely to overestimate the benefits of any advantages in terms of
graft survival that BEL has over its comparators, TAC and CSA. Likewise, this probably exaggerates the
costs savings and quality-of-life gains of TAC over CSA, which suggest that its ICER (£3375; this was not
stated in the Bristol-Myers Squibb submission but implicit in their numbers and calculated from them by
PenTAG) is an underestimate. Table 148 presents a summary of model outputs for the three industry
model submissions.
TABLE 148 Results of model-based analyses submitted by the companies
Submission
Regimen
compared
Patient
characteristics Life-years
QALYs
(discounted)
Discounted
costs (£)
ICER: incremental cost
per QALY
Astellas TAC b.i.d. Mean age
45 years
Weight 70.3 kg
17.88 8.01 130,118 TAC vs. SRL I: £1,651,801
TAC vs. SRL II: £170,681SRL I 17.82 7.99 104,905
EVL 17.80 7.99 142,995
SRL II 17.73 7.94 119,371
BEL 11.72 7.94 163,740
TAC o.d. 18.19 8.21 118,907 TAC o.d. dominates
TAC b.i.d. 17.88 8.01 130,118
Bristol-Myers
Squibb
BEL Mean age
43 years
Weight 75 kg
19.53 7.14 296,503 BEL vs. TAC: £149,182
TAC vs. CSA: £3375TAC 18.02 6.53 205,502
CSA 17.38 6.17 204,287
Novartis EVL+CSA
(low dose)
Mean age
45.7 years
(SD 12.7 years)
Weight 70 kg
(SD 10 kg)
Mean eGFR
9.03ml/
minute/1.73m2
(SD 7.9ml/
minute/1.73m2)
25.71 8.86 135,358 EVL dominant
TAC+MMF 23.39 7.37 140,972
EVL+CSA
(low dose)
25.80 8.89 136,180 MM+CSA vs.
EVE+CSA:> £200,000
MMF+CSA 24.04 7.89 76,826
EC-MPS+
MMF
25.48 8.69 87,359 EC-MPS vs. MMF+CSA:
£29,000
MMF+CSA 24.17 7.89 76,771
b.i.d., twice daily; o.d., once daily.
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Chapter 6 Peninsula Technology Assessment
Group economic assessment
Summary
Methods
A de novo economic model was developed to address the decision problem in a cost–utility analysis.
A discrete time-state transition model (semi-Markov) was used, in which transition probabilities were
dependent on age and time since initial transplantation. A cycle length of a quarter year was used, and
transitions were assumed to occur mid-cycle. A time horizon of 50 years was adopted. Costs were
included from a NHS and Personal Social Services (PSS) perspective. Health effects were measured in
QALYs and were calculated by assuming health state-specific utility decrements from a baseline utility that
was age dependent and derived from the Health Survey for England 2012.375 The utility decrements were
based on a published systematic review and meta-analysis of preference-based quality-of-life studies in
patients undergoing RRT, with the European Quality of Life-5 Dimensions, three-level version (EQ-5D-3L)
used for measurement and most likely valued using the UK valuation tariff based on a representative
sample of the general population (see Estimating resources and costs).376 Costs and QALYs were
discounted at 3.5% per annum and costs were inflated as necessary to 2014–15 prices.
Interventions and comparators
The following induction agents were included:
l BAS
l rATG.
Regimens not including induction by monoclonal or polyclonal antibodies were also included.
The following maintenance agents were included:
l immediate-release TAC
l TAC-PR
l MMF
l MPS
l SRL
l EVL
l BEL.
Regimens including CSA and/or AZA were also included. CCSs were assumed to be used in all regimens,
but at a tapered dose.
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Sixteen regimens were modelled in total:
l CSA+MMF
l TAC+MMF
l CSA+AZA
l TAC+AZA
l CSA+ EVL
l TAC+ SRL
l TAC-PR+MMF
l BAS+CSA+MMF
l BAS+ TAC+MMF
l BAS+CSA+AZA
l BAS+ SRL+MMF
l BAS+ BEL+MMF
l BAS+CSA+MPS
l rATG+CSA+MMF
l rATG+ TAC+MMF
l rATG+CSA+AZA.
Model structure
Kidney transplant recipients were assumed to be in one of three health states at any time: FUNCTIONING GRAFT,
GRAFT LOSS or DEATH (see Finalised structure, and Figure 67). In the FUNCTIONING GRAFT state, KTRs were not
dependent on dialysis, whereas in the GRAFT LOSS state, KTRs were dialysis dependent. In addition to these
health states, for each regimen the incidence of AR, CMV infection, dyslipidaemia and NODAT was
estimated, with corresponding costs (during the first year for AR and CMV infection; ongoing for
dyslipidaemia and NODAT). NODAT was also associated with a utility decrement based on EQ-5D
measurements from kidney transplant patients in a US clinic, valued according to a US valuation tariff
(see Disutility due to diabetes mellitus).7 The incidence of AR and NODAT were also used as surrogate
determinants of graft survival and DWFG (NODAT only).
Up to two retransplantations were modelled, which could take place from the GRAFT LOSS state or from the
FUNCTIONING GRAFT state (for the initial graft only) corresponding to pre-emptive retransplantation. KTRs would
transition to the next FUNCTIONING GRAFT state if the retransplantation was successful or to the next GRAFT LOSS
state if it was unsuccessful (i.e. in the event of PNF). The rate of retransplantations was assumed to reduce
with age > 65 years, reaching zero by age 80 years (see Retransplantation).
Transitions out of the FUNCTIONING GRAFT state correspond to the clinical outcome of graft loss/survival and are
either DWFG or graft loss excluding DWFG (i.e. dependence on dialysis or pre-emptive retransplantation).
The baseline rates of these transitions from functioning graft were calculated from data from the UK
Transplant Registry standard data set.377 The rate of mortality following graft loss was based on UK data
published in the UK Renal Registry 16th Annual Report339 (see Factors included in the model).
Baseline death-censored graft survival was taken directly for the first year from Kaplan–Meier analysis,
and from the first year onwards a Weibull curve was fitted, which was demonstrated to fit the data well.
Death-censored graft survival at 1 year was estimated for each regimen, based on the ORs of graft loss
within 12 months. This was incorporated into the model by applying a proportional odds assumption
to death-censored graft survival in the first year.
A surrogate relationship between AR, NODAT and GRF (eGFR) at 12 months and graft survival was
modelled, based on applying a HR to the Weibull curve after the first year (see Graft survival).
The HR for AR was 1.6,378 for NODAT, 1.12,378 and for eGFR, 1–5.80, depending on the eGFR interval.334
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Patient survival at 1 year was estimated for each regimen based on the OR of mortality within 12 months.
This was incorporated into the model by applying a regimen-specific HR of DWFG within the first year.
A surrogate relationship between NODAT and DWFG after the first year was also modelled, with a HR
of 1.41.378
Source of effectiveness estimates
The ORs for the incidence of BPAR, graft loss and patient mortality, and the absolute difference in eGFR,
were primarily estimated from the NMAs of clinical effectiveness evidence. The results for induction agents
and maintenance regimens were chained assuming independence. The results for TAC-PR+MMF and
BAS+CSA+MPS were based on results for TAC+MMF and BAS+CSA+MMF with additional
adjustment based on head-to-head comparisons (see Effectiveness estimates for further details).
The incidences of NODAT, CMV and dyslipidaemia were also estimated using NMAs of RCTs from the
systematic review of clinical effectiveness, although some simplifying assumptions were made to overcome
the limited amount of evidence.
Costs
See Estimating resources and costs for further details.
Drug acquisition costs were average NHS acquisition costs where these could be estimated (from the CMU
eMit database370) or the list prices (BNF 6856) otherwise.
Drug administration costs included i.v. administration for BAS, rATG and BEL (estimated from NHS
reference costs 2013–14),64 and therapeutic drug monitoring for TAC, SRL, EVL and CSA (estimated from a
price list for NHS patients from University Hospital of Wales).
Costs of procedures and dialysis were estimated from NHS reference costs 2013–14,64 where available, or
from UK sources otherwise.
The costs of AR and CMV infection were taken from a microcosting study commissioned by
Bristol-Myers Squibb.379
The significant costs of NODAT were estimated from a recent publication based on the UK Prospective
Diabetes Study (UKPDS),380 which was conducted in the general population with type 2 diabetes mellitus.
The costs of KTR follow-up and monitoring were estimated based on a database study commissioned by
Bristol-Myers Squibb.
Infection prophylaxis costs were estimated based on the kidney transplant protocol of a UK hospital.
Additional CMV prophylaxis costs for regimens containing rATG induction.
Uncertainty analyses
A PSA was conducted to estimate the joint effect of parameter estimation uncertainty on
cost-effectiveness. Structural sensitivity analyses relating to graft survival were conducted. A scenario
analysis in which list prices were adopted for all drug acquisition costs was performed, and a two-way
threshold analysis was conducted relating to the costs of BEL.
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Results
Base-case analyses
See Base-case analysis for further details.
In the base-case deterministic and probabilistic analyses, the following agents were predicted to be
cost-effective at £20,000 and £30,000 per QALY:
l BAS
l immediate-release TAC
l MMF
Relevant ICERs do not exist for these agents because they dominated other agents or were less costly and
less effective than other agents, with ICERs significantly > £30,000 per QALY.
When all regimens were simultaneously compared, only BAS+ TAC+MMF was predicted to be
cost-effective at £20,000 and £30,000 per QALY.
Deterministic and probabilistic cost-effectiveness results for other agents were:
l No induction (three comparisons) – Dominated in deterministic and probabilistic analyses.
l rATG (three comparisons) – Dominated in deterministic and probabilistic analyses.
l CSA (four comparisons) – Deterministic ICERs of £131,000–205,000 per QALY (three comparisons) or
dominated (one comparison); probabilistic ICERs of £202,000–303,000 per QALY (three comparisons)
or dominated (one comparison)
l TAC-PR (one comparison) – Dominated in deterministic and probabilistic analyses.
l AZA (four comparisons) – Dominated in deterministic and probabilistic analyses.
l MPS (one comparison) – Deterministic ICER of £144,000 per QALY; dominated in probabilistic analysis.
l SRL (two comparisons) – Dominated in deterministic and probabilistic analyses.
l EVL (one comparison) – Deterministic ICER of £1,532,000 per QALY; probabilistic ICER of £3,260,000
per QALY.
l BEL (one comparison) – Deterministic ICER of £424,000 per QALY; probabilistic ICER of £446,000
per QALY.
Scenario analyses
See the Results section (Scenario analyses, below) for further details.
In a scenario analysis investigating the impact of structural uncertainty in the surrogate effect of AR,
NODAT and GRF at 12 months on graft survival, it was found that if the surrogate effect was weakened
(by limiting its duration) then no induction and CSA became cost-effective at £20,000 and £30,000 per
QALY compared with BAS induction and immediate-release TAC, respectively, in some combinations.
When used in combination with immediate-release TAC and MMF, no induction became cost-effective
if the duration of the surrogate effect was limited to 1–2 years. In combination with CSA and MMF
the duration had to be further limited, and in combination with CSA and AZA no induction was not
cost-effective even when the surrogate effect was eliminated entirely. The duration of surrogate effect
had to be limited to 3–7 years or less (depending on the comparison) for CSA to be cost-effective
compared with immediate-release TAC at £20,000 or £30,000 per QALY.
A second structural uncertainty analysis considered the possibility that CNI-free regimens could result
in prolonged graft survival by avoiding the nephrotoxic effects of CNIs. The graft survival for the
SRL-containing regimen BAS+ SRL+MMF had to be markedly different from the base case for SRL to
become cost-effective at £20,000 or £30,000 per QALY and the BEL-containing regimen BAS+ BEL+MMF
was not cost-effective at £20,000 or £30,000 per QALY at any point in the analysis.
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When list prices were adopted instead of average NHS acquisition costs for drug acquisition costs, CSA
and AZA became cost-effective at £20,000–30,000 per QALY in some combinations, with immediate-
release TAC and MMF remaining cost-effective at £20,000–30,000 per QALY in other comparisons.
Belatacept was not found to be cost-effective at £20,000–30,000 per QALY, even at zero price, or at list
price with zero administration cost.
Introduction
The objective of this independent economic assessment was to answer the following study question in line
with the NICE reference case:381
What is the cost-effectiveness of immunosuppressive regimens in renal transplantation in adults,
of basiliximab and rabbit anti-human thymocyte immunoglobulin as an induction therapy and
immediate-release tacrolimus, prolonged-release tacrolimus, mycophenolate mofetil, mycophenolate
sodium, sirolimus, everolimus and belatacept as a maintenance therapy?
Although there have been a number of economic evaluations that partially address the study question
(see Chapter 4), none has independently addressed the full study question in line with the NICE reference
case381 and therefore a new economic assessment was required.
A decision-analytic model was developed in Excel to address the study question in a cost–utility analysis.
Methods
Modelling approach
Target population and subgroups
The target population was adults undergoing kidney-only transplantation (i.e. people receiving multiorgan
transplants are not included). The donor may be living–related, living–unrelated or deceased (following
brain death or cardiac death).
The population included only incident KTRs, and did not include prevalent KTRs (i.e. people who received a
kidney transplant in the past), even those suffering from AR (although a number of the interventions
separately have marketing authorisation for the treatment of AR).
In the base-case analysis, KTRs were assumed to be aged 50 years (the median age of incident KTRs in
2012 was 50.5 years382) and 62% were men (UK Transplant Registry standard data set 2007–12).
The mean weight of KTRs was estimated by identifying RCTs included in the systematic review of clinical
effectiveness (see Chapter 3) which reported weight as a baseline characteristic. A random-effects model
was used, which resulted in estimated mean [standard error (SE)] weight of 70.2 kg (1.2 kg).
Setting and location
The NHS in England and Wales.
Study perspective
In line with the NICE reference case,381 the perspective adopted on outcomes was all direct health effects
for patients and other people, and the perspective adopted on costs was that of the NHS and PSS.
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Comparators
As the immunosuppressive agents are used in combination and in sequence, we used treatment regimens
as comparators rather than individual agents. However, the cost-effectiveness of an individual agent
compared with another individual agent can be evaluated by considering the cost-effectiveness of
regimens that are identical except for the use of the intervention or comparator of interest. Regimens were
included as comparators if they were in current use in the NHS or if they would plausibly be used in the
NHS (as advised by a number of clinical experts) and there was sufficient clinical evidence to estimate
the costs and outcomes for KTRs receiving those regimens.
Table 149 presents the regimens considered in this analysis, as well as an indication of whether or not
the assessment group believes the regimen to be a licensed combination (although no warranty or
representation is given as to the correctness of the information presented in this regard).
Astellas, in their submission, included the following regimens which we have not modelled:
l BAS+CSA+ SRL (although we have modelled TAC+ SRL)
l BAS+CSA+ EVL (although we have modelled CSA+ EVL).
Bristol-Myers Squibb and Novartis did not present any regimens that we have not modelled.
Time horizon
The time horizon was 50 years or age 100 years, whichever is earlier. The median age of incident KTRs in
2012 was 50.5 years.382
TABLE 149 Immunosuppressive regimens included in independent economic assessment
Identifier Induction therapy Maintenance therapya Licensed
CSA+MMF None CSA+MMF Y
TAC+MMF None Immediate-release TAC+MMF U
CSA+AZA None CSA+AZA Y
TAC+AZA None Immediate-release TAC+AZA Y
CSA+ EVL None CSA+ EVL Y
TAC+ SRL None Immediate-release TAC+ SRL N
TAC-PR+MMF None TAC-PR+MMF U
BAS+CSA+MMF BAS CSA+MMF Y
BAS+ TAC+MMF BAS Immediate-release TAC+MMF U
BAS+CSA+AZA BAS CSA+AZA Y
BAS+ SRL+MMF BAS SRL+MMF U
BAS+ BEL+MMF BAS BEL+MMF Ub
BAS+CSA+MPS BAS CSA+MPS U
rATG+CSA+MMF rATG CSA+MMF Y
rATG+ TAC+MMF rATG Immediate-release TAC+MMF U
rATG+CSA+AZA rATG CSA+AZA Y
N, no; U, unclear; Y, yes.
a All maintenance regimens also included CCSs.
b According to its Summary of Product Characteristics, BAS is to be used concomitantly with CSA-based therapy, although
BEL is recommended to be used with an interleukin-2 receptor alpha (of which BAS is the only one currently).
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Discount rate
In line with the NICE reference case381 the discount rate for costs and health effects was 3.5% per annum.
Choice of health outcomes
The primary health outcome of the independent economic assessment was QALYs for each comparator
regimen, in line with the NICE reference case.381 Secondary outcomes included:
l undiscounted life-years (life expectancy)
l undiscounted life-years with a functioning graft
l undiscounted life-years on dialysis
l likelihood of experiencing at least one episode of AR
l likelihood of developing NODAT
l likelihood of receiving a second or third transplant.
Model structure
Conceptualisation
We followed the approach to model conceptualisation described by Kalthenthaler et al.383 in the NICE
Decision Support Unit Technical Support Document 13.
Several meetings were held with Dr Jason Moore (Consultant Nephrologist; the Kidney Unit, Royal Devon
& Exeter NHS Foundation Trust), during which problem-oriented conceptual models for various disease
processes and service pathways were discussed and refined. The problem-oriented conceptual models
were then circulated to the expert advisory group, recruited for the assessment, who made comments and
suggestions. A design-oriented conceptual model was then developed, based heavily on the kidney logic
conceptual model, and this formed the basis for the final model structure.
Finalised structure
In the final model structure, KTRs were assumed at all times to be in one of three principal health states:
l functioning graft (not dialysis dependent)
l graft loss (dependent on dialysis)
l death.
Kidney transplant recipients start in the FUNCTIONING GRAFT unless they suffer PNF, in which case they start in
the GRAFT LOSS state. Transitions can occur from FUNCTIONING GRAFT to GRAFT LOSS, reflecting disease progression;
transitions are not permitted in the opposite direction, except through retransplantation. Up to two
retransplantations are possible and therefore there are three substates for FUNCTIONING GRAFT and GRAFT LOSS,
reflecting the graft number (1–3). As with the initial graft, it is possible that PNF will occur and therefore
transitions can occur directly to GRAFT LOSS following second or third graft. Pre-emptive retransplantation can
occur from the original functioning graft state. Death can occur from any state but the rate of mortality is
greater in the GRAFT LOSS state (see Mortality) and increases with age.
Irrespective of the regimen used for immunosuppression in the first graft, a common regimen was used for
subsequent grafts (BAS+ TAC+MMF). See below (Retransplantation) for our justification of this approach.
Figure 67 gives the model diagram showing the seven states in the model. Self-links are omitted from all
states in both figures for clarity (there are no tunnel states).
A Markov cohort model was used, such that individual KTRs were not simulated. The model was
constructed using Excel.
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In addition to these health states, for each regimen the incidence of AR, CMV infection, dyslipidaemia and
NODAT was estimated.
For each allowable transition, a transition rate was modelled. The probability of each transition was then
calculated using the following formula:
pi = (r i/R) × (1− e
−RΔt ), (1)
where ri is the hazard rate of the specific transition, R is the sum of allowable transition rates (including ri)
and Δt is the time step (cycle length).
In some cases the transition rate was engineered to achieve a desired change in state membership, but in
all cases a transition rate was calculated.
Table 150 gives a summary of how the transition rates were dependent on factors such as age, AR and
NODAT. BAS+ TAC+MMF was assumed to be the baseline regimen that was most close to current
UK practice and outcomes.
Factors included in the model
Overall survival
Overall survival was not explicitly included as an input to the model and therefore emerges from the two
modelled rates of mortality: DWFG (see Mortality) and mortality after graft loss (see Mortality after
graft loss).
The exception to this is that the rate of DWFG in the first year was adjusted using an individual HR for
each regimen to achieve the desired OR of patient mortality as derived from the mixed-treatment
comparison (MTC) and head-to-head comparisons.
Although it would be possible to use numerical methods (e.g. Solver add-in for Excel) to achieve exact
patient mortality, it was felt that it would add significant computational burden, create significant
opportunity for human error (forgetting to re-run Solver every time relevant parameters were changed) and
greatly slow down PSAs.
Therefore, a regression approach was used instead. The two factors driving patient survival at 12 months,
which could vary between regimens, were identified as the OR of graft loss (after returning to dialysis the
mortality rate increases) and the HR of DWFG. The OR of patient mortality within 12 months was plotted
against the HR of DWFG for various different ORs of graft loss, and was found to be linearly dependent on
a log–log plot (Figure 68).
GL1
FG3
GL3
Death
FG1 FG2
GL2
FIGURE 67 Model diagram. FG, FUNCTIONING GRAFT; GL, GRAFT LOSS; dashed arrows indicated PNF; green arrows indicate
pre-emptive retransplantation.
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TABLE 150 Summary of determining factors for transition rates within the PenTAG model
Transition
Corresponding clinical
outcome Dependent on
FUNCTIONING GRAFT TO GRAFT LOSS (first graft) Disease progression
(graft loss/survival)
First
l Time since transplantation
l Regimen-specific OR of graft loss within
12 months
Subsequent
l Time since transplantation
l BPAR within 12 months
l NODAT within 12 months
l eGFR at 12 months
FUNCTIONING GRAFT to GRAFT LOSS
(subsequent graft)
Disease progression
(graft loss/survival)
(Constant)
FUNCTIONING GRAFT to DEATH (first graft) DWFG First
l Time since transplantation
l Regimen-specific HR based on OR of patient
death within 12 months
Subsequent
l Time since transplantation
l Age
l NODAT
FUNCTIONING GRAFT to DEATH
(subsequent graft)
DWFG Age
NODAT
GRAFT LOSS to subsequent FUNCTIONING
GRAFT
Retransplantation Age
GRAFT LOSS to DEATH Mortality while receiving
dialysis
Age
– 0.6
– 0.4
– 0.2
0
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OR[DCGL] = 1.65
OR[DCGL] = 2.72
OR[DCGL] = 3.32
FIGURE 68 Odds ratio of patient mortality is dependent on HR of DWFG and OR of death-censored graft loss.
OR[DCGL], OR of graft loss.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
291
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
For each OR of graft loss, linear regression of ‘ln(odds of patient mortality)’ compared with ‘ln(HR of
DWFG)’ was performed, and the values of the linear regression coefficients were found to be linearly
dependent on the OR of graft loss (Figure 69).
The appropriate HR for DWFG to achieve a desired OR of patient mortality is therefore derived as follows
(where ORDCGL,i is the OR of graft loss, HRDWFG,i is the HR of DWFG and ORPD,i is the OR of patient death):
ai = 0:9412 − 0:0379 × ORDCGL, i
bi = 0:0248 × ORDCGL, i − 0:0217
HRDWFG, i = expf ln(ORPD, i) − biai g.
(2)
As can be seen in Table 151, the regression formulae perform well in most instances.
Graft survival
Graft survival is a key measure of the clinical effectiveness of an immunosuppressive regimen and is critical
also for cost-effectiveness, as graft loss necessitates expensive dialysis treatment, which has a detrimental
impact on HRQoL or retransplantation (a costly procedure).
Use of graft survival in the model
In the model, graft survival drives transitions from FUNCTIONING GRAFT to GRAFT LOSS states for the first graft,
whereas for subsequent grafts a constant rate of graft loss was assumed across all regimens (see
Subsequent grafts).
The transitions for the first graft are calculated by first estimating a graft survival curve (censored for
DWFG) for each regimen then multiplying this with a curve estimating patient survival (censored for graft
loss) to obtain an estimate for how many KTRs should be alive and in the FUNCTIONING GRAFT state in each
cycle. The rate of graft loss for cycle i is then calculated as:
rGL(ti) = ½ln(S(ti))− ln(S(ti+1))/Δt, (3)
where S(ti) is the product of survival curves for the start of cycle i and Δt= ti+1− ti is the cycle length.
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R2 = 0.9982
y = 0.0248x – 0.0217
R2 = 0.9968
FIGURE 69 Linear regression coefficients for ln(OR of patient death) vs. ln(HR of DWFG) plotted vs. OR of graft loss.
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The details for how the survival curves are estimated are given later in this section and in the later section
Death with functioning graft, but, briefly:
l Graft survival censored for DWFG is estimated by adjusting survival estimated from the UK Transplant
Registry standard data set in the first year according to the OR of graft loss within 12 months and
thereafter according to a surrogate relationship based on AR within 12 months, NODAT within
12 months and eGFR at 12 months.
l DWFG is estimated by adjusting survival estimated from the UK Transplant Registry standard data set in
the first year according to the OR of patient death within 12 months and thereafter according to a
surrogate relationship based on NODAT within 12 months.
To account for the possibility of pre-emptive retransplantation the rate of graft loss is partitioned between
transitions from first FUNCTIONING GRAFT to GRAFT LOSS following first graft; first FUNCTIONING GRAFT to second
FUNCTIONING GRAFT (successful pre-emptive retransplantation); and first FUNCTIONING GRAFT to GRAFT LOSS following
second graft (unsuccessful pre-emptive retransplantation). The split between these transitions is age
dependent (as the likelihood of pre-emptive retransplantation decreases with advancing age; Table 152).
The probability that a KTR in each age range is suitable for retransplantation was taken from table 32 of Bond
et al.,384 which was, in turn, estimated from a figure in chapter 5 of the UK Renal Registry Eighth Annual
Report.385 It was then assumed that 20% of these KTRs would receive a pre-emptive retransplantation.386
Estimation of graft survival
Graft survival for most people is now so long that most clinical trials do not follow up or maintain
randomisation sufficiently long to obtain mature estimates for graft survival. AR became the primary end
point in most clinical trials and was treated as a surrogate marker by three of four economic analyses
submitted by companies for the current guidance, TA85.43
TABLE 151 Comparison of HRs for DWFG from regression and calculated using Solver
Regimen
HR for DWFG
From regression Using Solver
CSA+MMF 0.581 0.571
TAC+MMF 0.998 1.002
CSA+AZA 0.606 0.596
TAC+AZA 0.870 0.873
CSA+ EVL 0.907 0.910
TAC+ SRL 0.870 0.873
TAC-PR+MMF 1.307 1.306
BAS+CSA+MMF 0.584 0.575
BAS+ TAC+MMF 0.997 1.000
BAS+CSA+AZA 0.611 0.602
BAS+ SRL+MMF 1.125 1.129
BAS+ BEL+MMF 0.271 0.233
BAS+CSA+MPS 0.364 0.337
rATG+CSA+MMF 0.484 0.468
rATG+ TAC+MMF 0.826 0.827
rATG+CSA+AZA 0.506 0.489
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Subsequently, there have been analyses confirming that AR and NODAT are predictors of graft loss,378 as
well as seemingly contradictory findings that immunosuppressive agents achieving lower ARRs do not
deliver improvements in graft survival.387 In addition, several analyses have suggested that renal function at
1 year post transplant is a good predictor of long-term graft survival.334,340,388–390
Throughout this section it should be noted that graft survival and failure does not include DWFG, that is,
considering only people who are alive and who become dependent on dialysis or require retransplantation.
Baseline
Baseline graft survival for the first year (Figure 70) was estimated from the UK Transplant Registry standard
data set using the Kaplan–Meier method, restricting to first graft for each patient and only transplants
since 2007; survival was calculated separately for four different donor types (DBD, DCD, living–related,
living–unrelated). Graft survival was then calculated as the weighted average according to the donor type
distribution. KTRs with graft failure on the day of transplantation were assumed to have PNF and were also
excluded. Any KTRs dying with a functioning graft were censored at the time of death.
Baseline graft survival was extrapolated by fitting a Weibull curve to conditional survival from 1 year (i.e.
fitted to KTRs whose grafts survived at least 1 year), with proportional hazards covariates for graft number,
donor type and transplant period (1995–2000, 2001–6, 2007–12). The fit of this Weibull curve was
verified with a graphical test of the Cox–Snell residuals (Figure 71), which demonstrated that the fit was
good, as there was little deviation from the diagonal except for long follow-up (when censoring tends to
cause such deviations).
TABLE 152 Estimated split of transitions following loss of first graft
Age group (years) FG1→GL1, % FG1→FG2, % FG1→GL2, %
18–34 89.2 10.5 0.3
35–44 90.2 9.6 0.2
45–54 92.4 7.4 0.2
55–64 94.6 5.3 0.1
≥ 65 98.0 2.0 0.0
FG1, first FUNCTIONING GRAFT; FG2, second FUNCTIONING GRAFT; GL1, GRAFT LOSS following first graft; GL2, GRAFT LOSS following
second graft.
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FIGURE 70 Graft survival in first year according to graft type. LRD, living–related donor; LURD,
living–unrelated donor.
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The baseline model for conditional graft survival from 1 year is then:
S(t) = expf−λtγg, (4)
where t is time after 1 year, λ is the rate parameter and γ is the shape parameter (with a value of 1.105,
implying increasing hazard rate with time).
A different rate parameter is obtained for different covariate values (proportional hazards model), the baseline
rate parameter was obtained by assuming the following covariate values: graft number= 1; donor type= (DBD
0.659), (DCD 0.078), (living–related 0.195), (living–unrelated 0.068)}; transplant period= 2007–12. These led
to a baseline rate parameter value of 0.01809.
Baseline graft survival in the PenTAG model is shown in Figure 72.
Adjustments during the first year
Graft survival for the first year was adjusted using the proportional odds method, such that for each
regimen the ORs of graft loss (excluding death and PNF) throughout the first year matched the ORs of
graft loss as detailed below (see Effectiveness estimates).
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FIGURE 71 Graphical verification of the fit to graft survival.
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Adjustments after the first year
Graft survival for the first graft after the first year was modelled using the surrogate end points renal
function at 12 months, AR within 12 months and NODAT within 12 months, which are all predictors of
graft loss.334,378
The surrogate relationship was implemented using proportional hazards and summarised in Table 153 and
expanded in the sections below. The rate parameters for all regimens (after adjusting according to the
surrogate relationship) are given in Table 154. The resulting graft survival (excluding DWFG) at 1, 3, 5 and
10 years for each regimen are given in Table 155.
TABLE 153 Surrogate relationship HRs for graft survival
Relationship HR Source
AR within 12 months 1.60 Cole 2008378
Renal function (eGFR) at 12 months eGFR≥ 60ml/minute/1.73m2: 1
45ml/minute/1.73m2≤ eGFR< 60ml/minute/1.73m2: 1.409
30ml/minute/1.73m2≤ eGFR< 45ml/minute/1.73m2: 2.406
15ml/minute/1.73m2≤ eGFR< 30ml/minute/1.73m2: 5.801
Levy 2014334
NODAT within 12 months 1.12 Cole 2008378
TABLE 154 Rate parameters for graft survival after 1 year
Regimen Rate parameter (λ)
CSA+MMF 0.0233
TAC+MMF 0.0201
CSA+AZA 0.0264
TAC+AZA 0.0193
CSA+ EVL 0.0212
TAC+ SRL 0.0244
TAC-PR+MMF 0.0202
BAS+CSA+MMF 0.0208
BAS+ TAC+MMF 0.0181
BAS+CSA+AZA 0.0232
BAS+ SRL+MMF 0.0196
BAS+ BEL+MMF 0.0169
BAS+CSA+MPS 0.0192
rATG+CSA+MMF 0.0240
rATG+ TAC+MMF 0.0210
rATG+CSA+AZA 0.0264
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Graft function at 12 months
The average GRF (eGFR) at 12 months for each regimen was estimated by first estimating the baseline
average eGFR at 12 months in the UK. Pruthi et al.382 report (in text and in figures 3.5a–c) the median and
interquartile range (IQR) of eGFR at 12 months between 2005 and 2011 by donor type (DBD, DCD, living).
For each donor type, a normal distribution was fitted by setting the normal distribution mean (µ) to the
median and setting the SD (σ) to IQR/1.349, as shown in Table 156.
To validate the fit, the predicted quartiles were plotted against the reported quartiles (Figure 73). The
scatter points are very close to the dashed line, indicating equality.
To estimate the overall average eGFR (weighted according to the frequency of different donor types), a
mixture distribution was created from the three normal distributions and the following formulae were used
to calculate the mean and variance of the resulting mixture distribution.
TABLE 155 One-, 3-, 5- and 10-year graft survival for each regimen
Regimen
Graft survival, % (excluding DWFG and PNF)
1 year 3 years 5 years 10 years
CSA+MMF 95.37 90.71 85.62 73.23
TAC+MMF 95.72 91.66 87.20 76.18
CSA+AZA 93.87 88.69 83.07 69.58
TAC+AZA 93.04 89.26 85.08 74.73
CSA+ EVL 96.13 91.84 87.14 75.57
TAC+ SRL 92.89 88.13 82.96 70.41
TAC-PR+MMF 94.90 90.86 86.41 75.43
BAS+CSA+MMF 96.19 91.97 87.34 75.94
BAS+ TAC+MMF 96.48 92.79 88.73 78.58
BAS+CSA+AZA 94.93 90.31 85.27 72.97
BAS+ SRL+MMF 94.78 90.87 86.57 75.92
BAS+ BEL+MMF 96.84 93.38 89.54 79.92
BAS+CSA+MPS 96.69 92.77 88.45 77.73
rATG+CSA+MMF 96.42 91.56 86.27 73.41
rATG+ TAC+MMF 96.69 92.42 87.73 76.19
rATG+CSA+AZA 95.25 89.99 84.30 70.61
TABLE 156 Estimating the baseline eGFR distribution after 12 months
Donor type
Reported Fitted normal distribution
Median IQR µ σ
Living 56.4 22.1 56.4 16.40
DBD 52.7 25.8 52.7 19.11
DCD 49.4 25.7 49.4 19.06
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Acute rejection within 12 months
Acute rejection rates within 12 months were estimated using effectiveness estimates as described below
(see Effectiveness estimates) and a baseline ARR for BAS+ TAC+MMF.
The baseline ARR was estimated from Rowshani et al.103 and Tsuchiya et al.,141 as these were the only
studies with the exact regimen of BAS+ TAC+MMF. Simple pooling was used for the deterministic
estimate of the ARR, resulting in an estimate of 12.17%.
The effect of AR on graft survival after the first year was then estimated using the HR of 1.60 from Cole
et al.378 As for GRF, a raw HR was then calculated according to the weighted average of the HRs for AR
and no rejection (1.00) with the weights equal to the ARR for each regimen. These were then normalised
to give HRs compared with the baseline (BAS+ TAC+MMF).
Table 157 summarises the calculations and results for the effect of AR on graft survival.
New-onset diabetes after transplant/transplantation within 12 months
The methods for estimating the incidence of NODAT within the first 12 months since transplantation are
described below (see Diabetes mellitus).
The effect of NODAT on graft survival after the first year was estimated using the HR of 1.12 from Cole
et al.,378 and incorporated using the same methodology as for GRF and AR. Table 158 demonstrates that
the impact of NODAT on graft survival is fairly small, which is to be expected, given that the conclusions
of Cole et al.378 that NODAT primarily increases the rate of DWFG, which is not considered here.
Mortality
Death with functioning graft
In adult KTRs, DWFG is a significant cause of graft loss. Compared with dialysis recipients, more KTRs die
from infection and malignancy, the risk of both being increased by greater immunosuppression.382 CVD is
also a significant cause of mortality in people who have transplants. As with members of the general
population, the mortality rate increases with age, plus there are a number of additional risks factors
affecting patient survival which are adjusted for when comparing survival across different centres.391
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TABLE 157 Acute rejection rates and HR for graft survival attributable to AR for each regimen
Regimen
Graft survival (excluding DWFG and PNF)
1 year 3 years 5 years 10 years
CSA+MMF 95.37 90.71 85.62 73.23
TAC+MMF 95.72 91.66 87.20 76.18
CSA+AZA 93.87 88.69 83.07 69.58
TAC+AZA 93.04 89.26 85.08 74.73
CSA+ EVL 96.13 91.84 87.14 75.57
TAC+ SRL 92.89 88.13 82.96 70.41
TAC-PR+MMF 94.90 90.86 86.41 75.43
BAS+CSA+MMF 96.19 91.97 87.34 75.94
BAS+ TAC+MMF 96.48 92.79 88.73 78.58
BAS+CSA+AZA 94.93 90.31 85.27 72.97
BAS+ SRL+MMF 94.78 90.87 86.57 75.92
BAS+ BEL+MMF 96.84 93.38 89.54 79.92
BAS+CSA+MPS 96.69 92.77 88.45 77.73
rATG+CSA+MMF 96.42 91.56 86.27 73.41
rATG+ TAC+MMF 96.69 92.42 87.73 76.19
rATG+CSA+AZA 95.25 89.99 84.30 70.61
TABLE 158 Incidence of NODAT and effect on graft survival for each regimen
Regimen Incidence of NODAT (%) Raw HR HR vs. baseline
CSA+MMF 4.98 1.006 0.993
TAC+MMF 10.60 1.013 1.000
CSA+AZA 4.98 1.006 0.993
TAC+AZA 10.60 1.013 1.000
CSA+ EVL 4.74 1.006 0.993
TAC+ SRL 16.00 1.019 1.006
TAC-PR+MMF 12.32 1.015 1.002
BAS+CSA+MMF 4.98 1.006 0.993
BAS+ TAC+MMF 10.60 1.013 1.000
BAS+CSA+AZA 4.98 1.006 0.993
BAS+ SRL+MMF 8.57 1.010 0.998
BAS+ BEL+MMF 2.18 1.003 0.990
BAS+CSA+MPS 4.66 1.006 0.993
rATG+CSA+MMF 4.98 1.006 0.993
rATG+ TAC+MMF 10.60 1.013 1.000
rATG+CSA+AZA 4.98 1.006 0.993
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Crude estimates of DWFG will vary according to immunological risk and donor kidney type (i.e. living
donor, DCD, DBD) because of differences in baseline demographics (living donor KTRs tend to be younger)
and in immunosuppression (KTRs at greater immunological risk tend to receive greater immunosuppression
which increases the risk of infection and malignancy).392 The use of steroids is also linked to increased risk
of death from CVD and infection.393
There is also evidence to suggest that the risks of cardiovascular and infectious causes of death are
elevated in KTRs with reduced GRF at 1 year post transplantation.393
The modelling framework employed allowed flexibility in the rate of DWFG in the first graft modelled but
less flexibility for subsequent grafts, for which it could not be dependent on time since transplantation.
The baseline rate of DWFG for the first graft was estimated from the UK Transplant Registry standard data
set for each donor type (DBD, DCD, living–related, living–unrelated) after adjusting for transplant period
(adjusted to 2007–12) and age group (adjusted to 31–50 years). The Kaplan–Meier survival function was
directly used for the first 19 years, followed by an extrapolation based on the estimated rate of DWFG
from 9 to 19 years. The baseline survivor function is shown in Figure 74.
The rate of DWFG was then adjusted by sex, donor type and age based on a Cox proportional hazards
analysis of the UK Transplant Registry data set (Table 159). For the first 12 months an individual HR was
applied for each regimen to achieve a target OR of patient mortality (see Overall survival), and thereafter a
HR for NODAT was applied according to Cole et al.378
Mortality after graft loss
Following graft loss, in the absence of an available kidney for pre-emptive retransplantation, KTRs will be
placed on dialysis. Some KTRs will be waitlisted for retransplantation, whereas others will be judged not fit
for retransplantation as a result of unsuitability for surgery or prohibitively great immunological risk.
The mortality rate for dialysis recipients is known to be significantly greater than that for age-matched
members of the general population.339 An analysis by Webb et al.394 demonstrated that people waiting for
retransplantation following graft loss experience a greater mortality rate than incident dialysis recipients
waitlisted for transplantation for at least 3 years when adjusted for age. It is not clear, however, that
mortality across all dialysis recipients will differ according to whether the recipient has previously lost
a graft.
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As it was not possible to incorporate any temporary increase in mortality rate immediately following graft
loss and there was not sufficient evidence to suggest it should be included, it was assumed that mortality
rates following graft loss would be the same as mortality rates for dialysis recipients and dependent on age
group (Table 160).
For the PSA, the SE of mortality rate in each group was estimated by dividing the square root of the
number of observed deaths by the estimated exposure.
Adverse events
Synthesis of AE data is rarely conducted across studies because of typically low incidence (resulting in low
statistical power to detect differences) and heterogeneity of reporting. For this model it was judged
important to consider the possible impact of different regimens on AE rates because the profile of AEs is
considered highly clinically relevant. For example, the current NICE guidance TA8543 recommends that
‘The initial choice between [immediate-release] TAC and CSA should be based on the relative importance
of their side effect profiles for individual people’.
Given the heterogeneity of reporting of AEs it was felt to be unlikely to be useful to model many AEs but,
instead, to focus where there was established clinical opinion that was also supported by RCTs in our
systematic review (see Chapter 3, Systematic review results). Diabetes (NODAT) was considered very
important to include (and has been included in previous economic evaluations, see Chapter 5), and CMV
infection and dyslipidaemia were judged suitable for inclusion as they had been identified by a recent
Cochrane review8,341 as being linked to mammalian target of rapamycin complex 1 (mTOR-I) use
(decreasing CMV infection incidence and increasing dyslipidaemia).
TABLE 159 HRs applied to rate of DWFG
Covariate HR
NODAT 1.41
Sex: female 0.865
Donor type
DBD 1
DCD 1.083
Living
Related 0.551
Unrelated 0.703
Age (years)
< 18 0.377
18–30 0.369
31–40 0.712
41–50 1
51–60 2.140
61–70 4.128
71–75 7.583
76–80 8.576
81–85 13.751
> 85 23.552
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Anaemia was also included as an AE, as it has been included in previous economic evaluations and is seen
as an important cost relating to RRT, but it was assumed not to vary between regimens.
Cytomegalovirus infection is assumed to be a one-off event occurring in the first year, whereas NODAT,
dyslipidaemia and anaemia are chronic conditions that are modelled for the full time horizon, while
patients are alive. All AEs incur costs, but NODAT additionally results in a utility decrement (see
Adverse events).
Diabetes mellitus
The incidence of diabetes mellitus in individuals receiving dialysis is higher than that in the general
population, at around 6% per year, with incidence marginally higher in individuals receiving HD.395 Kidney
transplantation appears to result in a significant increase in the incidence of diabetes mellitus in the first
year post transplant (and especially in the first 6 months), after which incidence falls to similar levels to
those seen in people on dialysis (see figure 2 of Woodward et al.395). TAC has been repeatedly associated
with the development of NODAT2,378 and the same incidence pattern is observed of significantly elevated
incidence in the first year post transplant.395
Pre-existing diabetes mellitus in the cohort was not modelled, only NODAT within 12 months. Based on a
visual inspection of figure 1 of Woodward et al.,395 it was assumed that 75% of NODAT in the first year
would occur within the first 6 months. Incidence of NODAT after the first year was not modelled.
Two competing factors will affect the proportion of people with diabetes mellitus after the first year.
First, additional incidence of diabetes mellitus will occur at a greater rate than that in the general
population. Second, individuals with diabetes mellitus will face a greater mortality rate than those without
diabetes mellitus. For simplicity we assume that these factors approximately cancel each other out and we
maintain the same prevalence of NODAT from 1 year onwards.
TABLE 160 Mortality rate for dialysis recipients
Age group (years) Hazard rate of mortality (SE)
20–24 0.010 (0.003)
25–29 0.012 (0.003)
30–34 0.009 (0.002)
35–39 0.015 (0.002)
40–44 0.021 (0.002)
45–49 0.027 (0.002)
50–54 0.041 (0.003)
55–59 0.053 (0.003)
60–64 0.079 (0.004)
65–69 0.107 (0.005)
70–74 0.149 (0.006)
75–79 0.211 (0.007)
80–84 0.275 (0.011)
85+ 0.408 (0.019)
Note
Calculated from results in table 8.18 of Pruthi et al.339
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Baseline 12-month incidence of NODAT for BAS+ TAC+MMF was estimated to be 10.6%, based on the
results of the SYMPHONY study.196
We did not find significant evidence to suggest that induction therapies affected the incidence of NODAT,
so the incidence of NODAT was modelled independently of induction agent.
As all modelled maintenance regimens are triple-therapy regimens, and to maximise statistical power, it was
assumed that the incidence of NODAT in each regimen could be estimated by combining independent
estimates for replacing immediate-release TAC and/or MMF in the baseline regimen.
Tables 161 and 162 list the studies (RCTs from the systematic review of clinical effectiveness) informing the
impact of replacing immediate-release TAC and MMF, respectively, on 12-month NODAT incidence.
TABLE 161 Studies included to estimate the impact on NODAT incidence of replacing immediate-release TAC
Study Compares NODAT in 12 months
Laskow 199680 TAC vs. CSA 12/67 vs. 1/20
Mayer 199788 TAC vs. CSA 17/303 vs. 3/145
Campos 200283 TAC vs. CSA 10/85 vs. 3/81
Hardinger 2005100 TAC vs. CSA 5/134 vs. 1/66
Raofi 1999210 TAC vs. CSA 3/14 vs. 4/21
Yang 199990 TAC vs. CSA 1/24 vs. 1/21
Krämer 2010204 TAC vs. TAC-PR 20/336 vs. 22/331
Tsuchiya 2013141 TAC vs. TAC-PR 0/52 vs. 1/50
aVincenti 2005206 CSA vs. BEL 6/73 vs. 1/71
aBENEFIT59 CSA vs. BEL 16/221 vs. 7/226
aBENEFIT-EXT142 CSA vs. BEL 11/184 vs. 7/175
bFerguson 2011126 TAC vs. BEL 1/30 vs. 0/33
Lebranchu 2009149 CSA vs. SRL 2/97 vs. 3/96
Büchler 2007134 CSA vs. SRL 3/74 vs. 9/71
Kreis 2000116 CSA vs. SRL 1/38 vs. 1/40
Guba 2010147 CSA vs. SRL 4/71 vs. 5/69
Martinez-Mier 2006117 CSA vs. SRL 1/21 vs. 1/20
Schaefer 200692 TAC vs. SRL 5/39 vs. 6/41
Groth 1999194 CSA vs. SRL 1/42 vs. 1/41
Chen 2008121 TAC vs. CSA 1/21 vs. 1/20
SYMPHONY240 TAC vs. CSA vs. SRL 34/403 vs. 17/408 vs. 25/380
a Less-intensive BEL arm only (more-intensive BEL arm excluded).
b BEL+ SRL arm excluded.
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Mixed-treatment comparisons were conducted for both; in both cases a fixed-effects model was
considered to be more appropriate as a result of a lower DIC (58.28 vs. 60.39 and 25.52 vs. 27.04).
The results of the MTCs are presented in Tables 163 and 164.
The mean log-ORs were combined from the MTCs to estimate an overall OR for each regimen, as shown
in Table 165, which, when combined with the baseline incidence for BAS+ TAC+MMF, resulted in the
estimated 12-month incidence of NODAT for each regimen as shown in Table 166.
TABLE 162 Studies included to estimate the impact on NODAT incidence of replacing MMF
Study Compares NODAT in 12 months
Ciancio 2008106 MMF vs. MPS 7/61 vs. 6/55
aFerguson 2011126 MMF vs. SRL 0/33 vs. 2/26
Takahashi 2013131 MMF vs. EVL 3/61 vs. 7/61
Tedesco-Silva 2010107 MMF vs. EVL 19/273 vs. 14/274
Anil Kumar 2005110 MMF vs. SRL 2/75 vs. 2/75
Gonwa 2003180 MMF vs. SRL 9/176 vs. 10/185
Sampaio 2008112 MMF vs. SRL 6/50 vs. 12/50
a TAC+MMF arm excluded.
TABLE 163 Mixed-treatment comparison estimates of impact on NODAT incidence of replacing immediate-release
TAC [(WinBUGS 14, MRC Biostatistics Unit, Cambridge, UK); fixed-effects model]
Agent
OR vs. baseline (natural logarithmic scale)
Mean SD Median 95% CrI
TAC (Baseline)
TAC-PR 0.1694 0.3199 0.1687 −0.4546 to 0.8003
CSA −0.8162 0.2086 −0.8136 −1.231 to −0.4129
BEL −1.671 0.381 −1.665 −2.431 to −0.9394
SRL −0.2345 0.2239 −0.2339 −0.6734 to 0.2016
TABLE 164 Mixed-treatment comparison estimates of impact on NODAT incidence of replacing MMF (WinBUGS;
fixed-effects model)
Agent
OR vs. baseline (natural logarithmic scale)
Mean SD Median 95% CrI
MMF (Baseline)
MPS −0.07041 0.6122 −0.0656 −1.291 to 1.126
SRL 0.4739 0.3318 0.4719 −0.1688 to 1.131
EVL −0.05221 0.3194 −0.05309 −0.6831 to 0.5742
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TABLE 165 Calculations for the OR of NODAT in 12 months
Regimen Replace TAC OR Replace MMF OR Overall OR
CSA+MMF CSA 0.442 – 1 0.442
TAC+MMF – 1 – 1 1
CSA+AZA CSA 0.442 AZA 1 (assumed) 0.442
TAC+AZA – 1 AZA 1 (assumed) 1
CSA+ EVL CSA 0.442 EVL 0.949 0.420
TAC+ SRL – 1 SRL 1.606 1.606
TAC-PR+MMF TAC-PR 1.185 – 1 1.185
BAS+CSA+MMF CSA 0.442 – 1 0.442
BAS+ TAC+MMF – 1 – 1 1
BAS+CSA+AZA CSA 0.442 AZA 1 (assumed) 0.442
BAS+ SRL+MMF SRL 0.791 – 1 0.791
BAS+ BEL+MMF BEL 0.188 – 1 0.188
BAS+CSA+MPS CSA 0.442 MPS 0.932 0.412
rATG+CSA+MMF CSA 0.442 – 1 0.442
rATG+ TAC+MMF – 1 – 1 1
rATG+CSA+AZA CSA 0.442 AZA 1 (assumed) 0.442
TABLE 166 Estimated 12-month incidence of NODAT for each regimen
Regimen NODAT incidence (%)
CSA+MMF 4.98
TAC+MMF 10.60
CSA+AZA 4.98
TAC+AZA 10.60
CSA+ EVL 4.74
TAC+ SRL 16.00
TAC-PR+MMF 12.32
BAS+CSA+MMF 4.98
BAS+ TAC+MMF 10.60
BAS+CSA+AZA 4.98
BAS+ SRL+MMF 8.57
BAS+ BEL+MMF 2.18
BAS+CSA+MPS 4.66
rATG+CSA+MMF 4.98
rATG+ TAC+MMF 10.60
rATG+CSA+AZA 4.98
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Cytomegalovirus infection
It was judged, on the basis of examining the incidence of CMV infection in RCTs included in the systematic
review, and on the basis of the Cochrane systematic reviews of maintenance immunosuppression by
Webster et al.,8,341 that CMV infection could be affected by the use of mTOR-I (SRL and EVL) and that the
impact could vary depending on whether replacing a CNI or antimetabolite in the ‘standard triple therapy’.
Table 167 lists the studies (RCTs from the systematic review of clinical effectiveness) that could inform the
estimate of the impact on CMV infection incidence of using mTOR-I.
Fixed- and random-effects MTCs were conducted, and the random-effects model was judged to be
superior on the basis of DIC (54.02 vs. 59.54 for fixed-effects model). The results of the random-effects
MTC are shown in Table 168.
TABLE 167 Studies included to estimate the impact on CMV infection incidence of using mTOR-I (SRL and EVL)
Study Compares CMV infection within 12 months
Vítko 2005150 No mTOR-I vs. mTOR-I replacing antimetabolite 38/196 vs. 10/194
Takahashi 2013131 No mTOR-I vs. mTOR-I replacing antimetabolite 21/61 vs. 3/61
Tedesco-Silva 2010107 No mTOR-I vs. mTOR-I replacing antimetabolite 16/273 vs. 2/274
Chadban 2013152 No mTOR-I vs. mTOR-I replacing antimetabolite 2/47 vs. 4/30
Sampaio 2008112 No mTOR-I vs. mTOR-I replacing antimetabolite 6/50 vs. 6/50
Mjörnstedt 2012133 No mTOR-I vs. mTOR-I replacing CNI 13/100 vs. 9/102
Flechner 2002127 No mTOR-I vs. mTOR-I replacing CNI 2/30 vs. 3/31
Lebranchu 2009149 No mTOR-I vs. mTOR-I replacing CNI 6/97 vs. 4/96
Büchler 2007134 No mTOR-I vs. mTOR-I replacing CNI 17/74 vs. 4/71
Kreis 2000116 No mTOR-I vs. mTOR-I replacing CNI 8/38 vs. 2/40
Guba 2010147 No mTOR-I vs. mTOR-I replacing CNI 20/71 vs. 5/69
Martinez-Mier 2006117 No mTOR-I vs. mTOR-I replacing CNI 0/21 vs. 1/20
SYMPHONY240 No mTOR-I vs. no mTOR-I vs. mTOR-I replacing CNI 39/403 vs. 45/408 vs. 23/380
TABLE 168 Mixed-treatment comparison estimates of impact on CMV infection incidence of using mTOR-I
(WinBUGS; random-effects model)
mTOR-I use
OR vs. baseline (natural logarithmic scale)
Mean SD Median 95% CrI
No mTOR-I (Baseline)
mTOR-I replacing CNI −0.7981 0.3889 −0.806 −1.558 to 0.01047
mTOR-I replacing antimetabolite −1.153 0.4916 −1.175 −2.091 to −0.1184
σ (random effects parameter) 0.7915 0.4085 0.7538 0.08925 to 1.705
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The baseline incidence of CMV infection (i.e. for no mTOR-I use) was estimated by fitting a logistic model
to the absolute incidence of CMV infection in all RCT arms not using mTOR-I and reporting CMV infection
incidence within 12 months (Table 169) with study-level random intercepts. The estimated average
baseline CMV incidence is 10.72% (95% CI 1.87% to 43.09%).
Combining the baseline incidence with the treatment effects results in the incidence rates for each
regimen as shown in Table 170.
TABLE 169 Studies used to estimate the baseline incidence of CMV infection
Study CMV infection within 12 months
Mayer 199788 TAC+AZA: 41/303; CSA+AZA: 24/145
Hardinger 2005100 TAC+AZA: 5/134; CSA+AZA: 4/66
Raofi 1999210 TAC+AZA: 0/14; CSA+AZA: 0/24
Baboolal 200282 TAC+AZA: 7/27; CSA+AZA: 7/24
Merville 2004138 CSA+MMF: 11/37; CSA+AZA: 17/34
Vacher-Coponat 2012129 TAC+MMF: 25/143; CSA+AZA: 28/146
Yang 199990 TAC+MMF: 3/30; CSA+MMF: 0/30
Weimer 2006104 TAC+AZA: 7/28; CSA+AZA: 11/25; CSA+MMF: 13/31
Krämer 2010204 TAC+MMF: 19/336; TAC-PR+MMF: 33/331
Tsuchiya 2013141 TAC+MMF: 7/52; TAC-PR+MMF: 4/50
Ciancio 2008106 TAC+MMF: 1/75; TAC+MPS: 0/75
Salvadori 2004124 CSA+MMF: 43/210; CSA+MPS: 46/213
Vincenti 2005206 BEL+MMF: 11/71; CSA+MMF: 13/73
BENEFIT59 BEL+MMF: 10/226; CSA+MMF: 6/221
BENEFIT-EXT142 BEL+MMF: 24/175; CSA+MMF: 24/184
Ferguson 2011126 BEL+MMF: 1/33; TAC+MMF: 2/30
Vítko 2005150 CSA+MMF: 38/196
Takahashi 2013131 CSA+MMF: 21/61
Tedesco-Silva 2010107 CSA+MPS: 16/273
Chadban 2013152 CSA+MPS: 2/47
Mjörnstedt 2012133 CSA+MPS: 13/100
Sampaio 2008112 TAC+MMF: 6/50
Flechner 2002127 CSA+MMF: 2/30
Lebranchu 2009149 CSA+MMF: 6/97
Büchler 2007134 CSA+MMF: 17/74
Kreis 2000116 CSA+MMF: 8/38
Guba 2010147 CSA+MMF: 20/71
Martinez-Mier 2006117 CSA+MMF: 0/21
SYMPHONY240 CSA+MMF: 45/408; TAC+MMF: 39/403
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Dyslipidaemia
It was judged, on the basis of examining the incidence of CMV infection in RCTs included in the systematic
review, and on the basis of the Cochrane systematic reviews of maintenance immunosuppression by
Webster et al.,8,341 that the incidence of dyslipidaemia could be increased by the use of mTOR-I in the
immunosuppressive regimen. It was considered that it was not necessary to separately estimate the risk,
whether used in combination with a CNI or with an antimetabolite, and therefore to increase statistical
power the effect of mTOR-I use on dyslipidaemia incidence was estimated as the OR of dyslipidaemia
incidence for mTOR-I use compared with no mTOR-I use.
Table 171 details the RCTs from our systematic review (see Chapter 3, Systematic review results) that
compared regimens with and without mTOR-I and which reported dyslipidaemia. The direction of effect is
consistent across the studies.
Fixed- and random-effects meta-analyses were conducted and it was judged on the basis of DIC (28.267
vs. 29.897) that a fixed-effects analysis was appropriate. The results of the fixed-effects meta-analysis are
shown in Table 172.
TABLE 170 Cytomegalovirus infection incidence rates used in the model
Regimen CMV incidence (%) within 12 months
CSA+ EVL 3.65
TAC+ SRL 3.65
BAS+ SRL+MMF 5.13
No mTOR-I 10.72
TABLE 171 Studies included to estimate the impact on dyslipidaemia incidence of mTOR-I use
Study
Incidence of dyslipidaemia within 12 months
No mTOR-I mTOR-I
Vítko 2005150 24/196 51/194
Takahashi 2013131 19/61 28/61
Tedesco-Silva 2010107 43/273 57/274
Mjörnstedt 2012133 9/100 13/102
Sampaio 2008112 8/50 11/50
Flechner 2002127 16/30 20/31
Lebranchu 2009149 4/97 8/96
Büchler 2007134 38/74 50/71
Guba 2010147 5/71 14/69
SYMPHONY240 91/811 60/380
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To estimate the baseline incidence of dyslipidaemia (without mTOR-I use), we identified all of the RCTs
in our systematic review which reported dyslipidaemia and considered at least one regimen without
mTOR-I use (Table 173). A logistic model was fitted, as for CMV incidence, and the average dyslipidaemia
incidence for no mTOR-I use was estimated to be 20.17% (95% CI 3.56% to 63.37%). On this basis,
the incidence of dyslipidaemia for regimens including mTOR-I was estimated to be 30.59%.
Anaemia
Anaemia is an AE that affects KTRs and people on dialysis. As reference costs for dialysis already include
anaemia costs, only anaemia in people with functioning grafts was modelled. It was assumed that there
would be no difference in the prevalence of anaemia between different immunosuppressive regimens.
The prevalence of anaemia requiring treatment with erythropoiesis-stimulating agents (ESAs) was
estimated as 5.2%, based on a study by Vanrenterghem et al.396 This prevalence was assumed to be the
same regardless of time since transplantation, age or other factors.
TABLE 172 Fixed-effects meta-analysis of the impact on dyslipidaemia incidence of mTOR-I use
mTOR-I use
OR vs. baseline (natural logarithmic scale)
Mean SD Median 95% CrI
No mTOR-I (Baseline)
mTOR-I 0.5566 0.1005 0.5555 0.3604 to 0.7533
TABLE 173 Studies included to estimate the incidence of dyslipidaemia without mTOR-I use
Study Dyslipidaemia incidence within 12 months
Hardinger 2005100 TAC+AZA: 40/134; CSA+AZA: 26/66
Vacher-Coponat 2012129 TAC+MMF: 54/128; CSA+AZA: 78/137
Vincenti 2005206 BEL+MMF: 9/71; CSA+MMF: 6/73
Ferguson 2011126 BEL+MMF: 12/33; TAC+MMF: 12/30
Vítko 2005150 CSA+MMF: 24/196
Takahashi 2013131 CSA+MMF: 19/61
Tedesco-Silva 2010107 CSA+MPS: 43/273
Mjörnstedt 2012133 CSA+MPS: 9/100
Sampaio 2008112 TAC+MMF: 8/50
Flechner 2002127 CSA+MMF: 16/30
Lebranchu 2009149 CSA+MMF: 4/97
Büchler 2007134 CSA+MMF: 38/74
Guba 2010147 CSA+MMF: 5/71
SYMPHONY240 CSA+MMF: 51/408; TAC+MMF: 40/403
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Retransplantation
The baseline rate of retransplantation following graft loss was estimated from the UK Transplant Registry
standard data set in the following way:
1. Data cleaning was performed.
2. Living (relationship unspecified), domino, altruistic and unrelated pooled donors were all reclassified as
living–unrelated donors.
i. Transplant recipients who were missing codes for sex or age group were removed.
ii. Transplant recipients whose earliest transplant in the data set was not ‘kidney only’ were removed.
3. Transplant recipients whose first graft was still functioning, who were lost to follow-up or who died
with a functioning graft, were removed.
4. The total number of recipients whose first transplant was recorded as ‘failed’ and who had no
subsequent transplant recorded was calculated as N1= 5085.
5. Recipients whose first transplant failed and had no subsequent transplant were removed if patient
survival was not recorded or if patient survival (actual or censored at follow-up) was not greater than
graft survival, leaving N1*= 1567 recipients with only one transplant recorded and failed.
6. The total time for which those not receiving a subsequent transplant were followed was estimated as:
f½sum(patient survival in days) − sum(graft survival in days) / 365:2425 × ½N1 /N1*g
= 13, 627:61 years.
(5)
7. The total time between graft failure and retransplantation for those with a subsequent transplant was
estimated as {sum(year of second transplant) – [sum(year of first transplant)+ sum(first graft survival in
days)/365.2425]}= 5955.05 years.
8. The total follow-up time was therefore estimated as 13,627.61+ 5681.06= 19,582.66 years;
9. The number of retransplants was calculated by counting the number of recipients with two or more
transplants recorded, N>1= 2031.
10. The rate of retransplantation was estimated as 0.1037 (SE 0.0023).
It was then assumed that the rate of retransplantation would reduce after age 65 years and reach zero
by age 80 years, and that the rate would decline linearly between these ages. This assumption was
corroborated with our evidence advisory group.
Pre-emptive retransplantations were also modelled from the first FUNCTIONING GRAFT state in the event of graft
loss, as described above (see Graft survival).
Subsequent grafts
Owing to limitations of Markov modelling imposed by the memoryless assumption, there is reduced
flexibility in the modelling of costs and outcomes for subsequent grafts. It must be assumed that the
hazard rates of all transitions, costs and utilities are dependent only on time in the model and the arm
under consideration.
Comprehensive information on immunosuppressive regimens used does not appear to be collected;397,398
the UK Renal Registry data set does not include BAS induction and the UK Transplant Registry does not
include any data on immunosuppressive regimens utilised.
It was assumed that the same immunosuppressive regimen would be used for all subsequent grafts,
regardless of the immunosuppressive regimen used for the first graft. BAS+ TAC+MMF was chosen
as the immunosuppressive regimen for subsequent grafts, as it is believed to be the most common
immunosuppressive regimen in use in the UK. People receiving subsequent grafts are more likely to receive
monoclonal or polyclonal antibody induction, as they are likely to be at higher immunological risk. People
can become sensitised to rATG if received as induction for first graft or for treatment of steroid-resistant
AR so it was judged to be less likely to be used as induction compared with BAS.
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Assuming the same immunosuppressive regimen for subsequent grafts for all regimens has the effect that
the cost-effectiveness of regimens is primarily driven by outcomes for the first graft.
Table 174 summarises the parameters affecting subsequent grafts.
Effectiveness estimates
The key effectiveness parameters driving cost-effectiveness in the model are:
l graft loss within 12 months
l patient death within 12 months
l AR within 12 months
l GRF at 12 months
l NODAT at 12 months
l CMV infection within 12 months
l dyslipidaemia at 12 months.
Graft loss, patient death, AR and GRF were primarily estimated from the NMAs for induction and
maintenance regimens (see Chapter 3, Network meta-analyses), assuming independence of treatment
effects (i.e. that the effectiveness for a complete regimen can be decomposed into the effectiveness for the
induction therapy and the maintenance regimen).
Some arms were included in the NMAs that do not correspond to regimens in the model and the results
for these arms were not included but the arms were not dropped from the NMAs, as they could still
contribute indirect effect estimates.
The mean treatment effects from the NMAs are summarised in Table 175.
Head-to-head comparisons for TAC-PR compared with immediate-release TAC, and for MPS compared
with MMF, were additionally used to identify any differences in effectiveness between these agents.
In the NMA, MMF and MPS were assumed to be the same agent to simplify the analysis and increase the
statistical power. The head-to-head comparisons did not identify any statistically significant differences in
effectiveness. The effectiveness of MMF was assumed to be that of mycophenolate in the NMA and the
effectiveness of MPS was estimated by combining the NMA and head-to-head effectiveness estimates.
TABLE 174 Parameters affecting subsequent grafts
Parameter Value Source
Natural history
Baseline rate of DWFG 0.00780 Assumed to be the same as long-running rate of DWFG for
first graft
Rate of graft loss 0.03589 Exponential distribution fitted to UK Transplant Registry
standard data set (first graft and PNF excluded)
Resource use
TAC dosage 0.10mg/kg/day Assumed to be somewhat higher than the long-running
dosage for first graft (0.08 with AZA/MMF, 0.07 with SRI)
because of increased risk of rejection
MMF dosage 2 g/day Recommended daily dose
Prednisolone dosage 16.3mg/day Assumed to be same as first graft
Monitoring (clinic, TAC TDM,
blood test, renal profile, LFT)
Once monthly Assumption
LFT, liver function test; TDM, therapeutic drug monitoring.
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The effectiveness estimates were combined with the following estimated baseline values (for BAS+ TAC+MMF):
mortality within 12 months (odds)= 0.0153; graft loss within 12 months (odds)= 0.0365; eGFR at 12 months
(ml/minute/1.73m2)= 53.4; and AR within 12 months (odds)= 0.139. The resulting absolute effectiveness
estimates are given in Table 176.
The effectiveness estimates for the other outcomes (NODAT, CMV infection and dyslipidaemia) are also
estimated from the RCTs that were identified in the systematic review of clinical effectiveness, as described
above (see Diabetes mellitus, Cytomegalovirus infection and Dyslipidaemia).
Measurement and valuation of preference-based outcomes
Utility was estimated for KTRs by first estimating age-dependent baseline utility for the general population
then applying a utility decrement according to whether KTRs were in the FUNCTIONING GRAFT or GRAFT LOSS
state. In addition, the proportion of the population with NODAT was estimated and a utility decrement
was applied to both FUNCTIONING GRAFT and GRAFT LOSS states to reflect the decreased HRQoL for KTRs
with NODAT.
In the PSA, utility decrements were drawn from gamma distributions to ensure that they did not result in
increased utility.
With the exception of the source for baseline utility (following section), sources of utility estimates were
obtained from sources found through a systematic bibliographic search of the relevant literature.
This search combined established terms and synonyms for identifying studies of utility and HRQoL, with
population search terms for renal transplant, dialysis and ESRD (see syntax for full search strategy in
Appendix 1). No study design filter was used.
TABLE 175 Summary of mean treatment effects from NMAs
Arm
Mortality within
12 monthsa
Graft loss within
12 monthsa
eGFR at
12 monthsb
BPAR within
12 monthsb
Lower is better Lower is better Higher is better Lower is better
Induction (vs. no induction)
BAS −0.0067 −0.2021 2.113 −0.6523
rATG −0.1788 −0.2687 −3.942 −1.0147
Maintenance (vs. CSA+AZA)
TAC+AZA 0.3234 0.1353 9.304 −0.5484
CSA+MPA −0.0569 −0.2971 1.609 −0.7516
TAC+MPA 0.4218 −0.3788 6.531 −0.9205
BEL+MPA −0.7630 −0.4915 10.55 −0.2159
CSA+ EVL 0.3330 −0.4843 4.863 −0.7835
TAC+ SRL 0.3248 0.1587 −0.3523 −0.9574
SRL+MPA 0.5416 0.0321 3.846 −0.8283
MPA=MMF or MPS.
a Presented as log-ORs.
b Presented as MD.
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The search yielded 1311 titles and abstracts, which were screened by an experienced health technology
assessment researcher (RA). Only 99 of these were studies that yielded or used EQ-5D scores (the preferred
preference-based measure for informing NICE technology assessments). Studies that yielded EQ-5D-derived
health state scores (using UK general population valuations) were sought for health states or clinical
events of relevance in our provisional model structure: functioning renal graft, failing renal graft, chronic
allograft injury, acute kidney rejection, NODAT, malignancy following renal transplant and infection
following renal transplant.
Baseline utility
Baseline utility was modelled using the following equation:
Utility = 0:967981− 0:001807 × age− 0:000010 × −age2 + 0:023289 ×male. (6)
This equation was derived from the Health Survey for England – 2012,399 using the well-established
methodology of Ara and Brazier.400
Utility with dialysis
A systematic review and meta-analysis by Liem et al.401 reported pooled estimates of utility for various
health states of people undergoing RRT. It reported random-effects meta-analyses of six studies that had
produced EQ-5D index scores for HD (range 0.44–0.62) and four studies for PD (range 0.53–0.65). The
estimates used in our model are shown in Table 177.
These estimates were then converted into utility decrements from baseline age-related general health in
order that the utility of those on dialysis would always be lower than people in the general population of
the same age and sex.
The estimated utility decrements were [mean (SE)]: HD 0.277 (0.034); PD 0.264 (0.044).
TABLE 176 Summary of absolute effectiveness estimates for each regimen
Regimen
Mortality within
12 months (odds)
Graft loss within
12 months (odds)
Mean eGFR
(ml/minute/1.73m2)
BPAR within
12 months (odds)
CSA+MMF 0.0097 0.0485 46.4 0.315
TAC+MMF 0.0154 0.0446 51.3 0.266
CSA+AZA 0.0103 0.0652 44.8 0.668
TAC+AZA 0.0140 0.0746 54.1 0.386
CSA+ EVL 0.0141 0.0402 49.6 0.305
TAC+ SRL 0.0140 0.0764 44.4 0.256
TAC-PR+MMF 0.0198 0.0536 51.1 0.260
BAS+CSA+MMF 0.0097 0.0396 48.5 0.164
BAS+ TAC+MMF 0.0153 0.0365 53.4 0.139
BAS+CSA+AZA 0.0102 0.0533 46.9 0.348
BAS+ SRL+MMF 0.0173 0.0550 50.7 0.152
BAS+ BEL+MMF 0.0052 0.0326 57.4 0.280
BAS+CSA+MPS 0.0065 0.0342 52.4 0.244
rATG+CSA+MMF 0.0083 0.0371 42.4 0.114
rATG+ TAC+MMF 0.0129 0.0341 47.4 0.096
rATG+CSA+AZA 0.0087 0.0499 40.8 0.242
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Disutility due to established renal failure treated with transplantation
(i.e. functioning graft)
The same systematic review and meta-analysis by Liem et al.401 reported pooled estimates of utility for
people living with a functioning renal graft (Liem meta-analysis). It reported a random-effects meta-analysis
of five studies, which had produced EQ-5D index scores for people living with a functioning renal graft
(range of means, some medians, 0.71–0.86; Table 178).
It was assumed that the HRQoL for KTRs would not exceed that of members of the general population,
so this absolute estimate was converted into a utility decrement from baseline of 0.053 (SE 0.049).
Disutility due to diabetes mellitus
Our literature search for utilities revealed one study looking specifically at disutility of NODAT in renal
transplantation patients.402 This is a recent study402 in the relevant patient population and reports EQ-5D
utility data, with an estimated disutility of 0.06 associated with NODAT. This figure does not adjust for
people with CVD complications and therefore is appropriate to how we model NODAT. We note that
the study402 was conducted in only one hospital in USA and the valuation set for the utility values is
US based,403 so the outcomes may not be generalisable to the UK population. It has been demonstrated
by Johnson et al.404 that US-valued health states are statistically higher than the UK-valued health states
for 31 out of 42 valued EQ-5D health states and that extreme health states are most notably different.404
However, this does not necessarily reflect the differences between health states and we believe that having
utility data from a relevant patient population is the most important factor in choosing this value.
For example, one alternative would be to use diabetes mellitus compared with the general population
using Health Survey for England data. This would be a broader population of comparison and unlikely to
reflect the true utility impact of diabetes mellitus on someone who has received a kidney transplant.
Bristol-Myers Squibb incorporated disutility of 0.041 for NODAT citing Currie et al.366 as their source, which
is a study looking at costs. We believe they intended to cite the other Currie et al. paper,405 but it is still
not clear how they calculated this value. In their model, the deterministic value for disutility of NODAT
appears to be 0.06, which corresponds with our chosen value.
Astellas reports the findings of Wyld et al.,406 which does report utilities, deriving a disutility of 0.10
between ‘no diabetes’ and ‘diabetes’ groups of people with CKD. However, this is not restricted to only
renal transplant population and it is not clear which utility elicitation method is used.
TABLE 178 European Quality of Life-5 Dimensions index utility weights for functioning graft
Health state Pooled mean (95% CI) Number of studies Number of people
Functioning graft 0.81 (0.72 to 0.90) 5 673
Source: Liem et al.,401 table 4 (p. 738).
TABLE 177 European Quality of Life-5 Dimensions index utility weights for dialysis
Type of dialysis Pooled mean (95% CI) Number of studies Number of people
HD 0.56 (0.49 to 0.62) 6 1315
PD 0.58 (0.50 to 0.67) 4 192
Source: Liem et al.,401 table 4 (p. 738).
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Estimating resources and costs
Costs are incurred in the model either in the form of events (e.g. induction therapy, AR, CMV infection,
retransplantation) or in the form of ongoing costs (e.g. maintenance therapy, NODAT, dialysis).
The following costs are incurred exclusively in the FUNCTIONING GRAFT state (ongoing unless otherwise stated):
l induction therapy (event)
l maintenance therapy
l monitoring
l infection prophylaxis
l AR (event)
l CMV infection (event)
l anaemia.
The following costs are incurred exclusively in the GRAFT LOSS state:
l dialysis.
The following costs are incurred in both the FUNCTIONING GRAFT and GRAFT LOSS states:
l NODAT
l dyslipidaemia.
The following costs are incurred only when transitioning between states:
l from FUNCTIONING GRAFT to GRAFT LOSS: explant surgery, dialysis access surgery
l from GRAFT LOSS to FUNCTIONING GRAFT (and other retransplantation transitions): retransplantation.
Currency, price date, and conversion
Costs are all in 2014–15 pounds sterling (£; GBP). Costs in earlier financial years are inflated based on the
Hospital and Community Health Services pay and prices index (Table 179).407
No costs were included in different currencies, so conversion was not necessary.
TABLE 179 Hospital and Community Health Services pay and prices index407
Year Hospital and Community Health Services pay and prices index Inflation factor
2008–9 267.0 1.106
2009–10 268.6 1.099
2010–11 276.7 1.067
2011–12 282.5 1.045
2012–13 287.3 1.028
2013–14 290.5 1.016
2014–15 295.3 (projected based on previous three) 1
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Resource use
Induction therapy
Basiliximab can be administered by i.v. infusion or i.v. injection, but it was assumed that it would be
administered by i.v. infusion in accordance with Brennan et al. (Table 180).137 Intravenous infusion
is a more costly method of administration than i.v. injection, so this may overestimate the costs of
BAS administration.
Rabbit ATG is administered only by i.v. infusion and it was assumed it would be administered as in
Brennan et al.137
Maintenance therapy
Tacrolimus, SRL, EVL and CSA are titrated to achieve target whole blood trough concentrations, as
numerous factors can affect their absorption and removal from the bloodstream and therapeutic windows
can be narrow.
The target whole blood concentrations are usually higher initially to ensure adequate immunosuppression
and are then lowered to reduce the likelihood and impact of AEs (including nephrotoxicity for CNIs).
There is a substantial body of evidence that the dosage required to achieve target whole blood
concentrations is affected by concomitant treatments and, as such, the model includes different dosage
schedules for each agent according to concomitant treatment.
TABLE 180 Resource use for induction therapy
Parameter Value Source
BAS induction
BAS, 20-mg doses 1.964 Brennan 2006137
Administration (i.v. infusion) 1.964
rATG induction
rATG, mg/kg 6.5 Brennan 2006137
Administration (i.v. infusion) 4.525 Assumption based on Brennan 2006137
Number of doses People
1 2
2 6
3 10
4 24
5 97
6 1
7 1
Actual breakdown not given but, given
that 87.9% initiated before reperfusion,
68.8% received the intended five doses,
one patient received six doses. At least
four doses were received by 87.2%
of people.
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It was not possible to estimate the impact of different induction therapies on the required dosage in the
early days and weeks, but this is unlikely to have a significant impact on overall costs.
Belatacept is administered intravenously in accordance with a prescribed schedule. It was assumed that the
‘less-intensive’ regimen from the BENEFIT59 and BENEFIT-EXT142 studies would be used. We were advised
that vial sharing would most likely not be feasible and therefore we assumed full wastage of excess BEL.
Mean weight of KTRs was estimated by identifying RCTs included in the systematic review of clinical
effectiveness that reported weight as a baseline characteristic. A random-effects model was used,
which resulted in estimated mean (SE) weight of 70.2 kg (1.2 kg). The SD of weight of KTRs was estimated
by pooling the SDs reported, resulting in a SD of 14.8 kg. A normal distribution was then assumed to
calculate the expected number of vials required for 10-mg/kg and 5-mg/kg doses. It was estimated that
3.31 vials would be required for a 10-mg/kg dose and 1.91 vials for a 5-mg/kg dose (Table 181).
Overall resource use for maintenance therapy is detailed in Table 182.
Dialysis
Access surgery is required for long-term dialysis. In the case of HD, the creation of an arteriovenous fistula
is common, which requires time to heal and mature after surgery before use. It was therefore assumed
that all people on HD would also incur the cost of one temporary tunnelled central venous catheter.
The mix of HD and PD is known to vary over time, with younger people generally considered better suited
to PD (Table 183). The HD mix was reflected in incident and prevalent people on dialysis, but conversion
costs (between dialysis modes) were not included.
Acute rejection
The number of KTRs suffering at least one AR episode was derived as detailed above (see Acute rejection
within 12 months and Effectiveness estimates).
To account for the fact that some KTRs may experience more than one AR episode, a study148 was
identified which gave both the number of people experiencing at least one AR episode and the total
number of episodes. From this it was estimated that there would be 1.19 ARs expected per person
suffering at least one AR event.
TABLE 181 Expected number of vials of BEL required for patient weighing 70.2 kg± 14.8 kg
Number of vials
Dose
10mg/kg 5mg/kg
1 0.1% 24.7%
2 8.5% 59.6%
3 54.2% 15.3%
4 35.0% 0.3%
5 2.2% 0.0%
Expected 3.31 1.91
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TABLE 182 Resource use for maintenance therapy
Parameter Value Source
Immediate-release TAC
With AZA
TIme (months) Dosage (mg/kg/day)
0–1 0.225
1–3 0.175
3–6 0.135
6–12 0.110
12–36 0.090
36+ 0.080
Margreiter 200284
With MMF
Time Dosage (mg/kg/day)
0–2 weeks 0.168
2–6 weeks 0.176
6–12 weeks 0.110
3–6 months 0.104
6–12 months 0.086
12+ months 0.080
Rowshani 2006103 for 0–12 months;
assumed no higher than with AZA
for 12+ months
With SRL
Time (months) Dosage (mg/kg/day)
0–1 0.175
1–3 0.110
3–6 0.104
6–12 0.080
12+ 0.070
Starting dose from Gonwa 2003180
(0–1 month); assumed no higher
than with MMF (1–6 months);
Gonwa 2003,180 Anil Kumar 2008122
(6+ months)
TAC-PR
With MMF As for immediate-release TAC plus
0.015mg/kg/day for 12 months
Wlodarczyk 2009,140 Krämer 2010,204
Tsuchiya 2013,141 Oh 2014105
CSA
With AZA Time (months) Dosage (mg/kg/day)
0–1 6.38
1–3 4.53
3–6 3.77
6–12 3.38
12–36 2.93
36+ 2.84
Margreiter 200284
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TABLE 182 Resource use for maintenance therapy (continued )
Parameter Value Source
With MMF or MPS
Time Dosage (mg/kg/day)
0–2 weeks 7.62
2–6 weeks 5.72
6–12 weeks 3.06
3–6 2.86
6–12 2.82
12+ 2.82
Rowshani 2006103
With EVL Time (months) Dosage (mg/kg/day)
0–12 3.9
12+ 2.1
Vítko 2005150
AZA
With TAC
Time (months) Dosage (mg/kg/day)
0–6 1.50
6+ 1.20
Starting dose 1–2mg/kg/day;
Laskow 199680
With CSA
Time (months) Dosage (mg/kg/day)
0–6
6–12
12–36
36+
Starting dose 1–2mg/kg/day;
Sadek 2002,86 Vacher-Coponat
2012;129 assumed
MMF
With TAC
Time (months) Dosage (g/day)
0–3 2.00
3–12 1.74
12+ 1.47
Starting dose 2 g/day; SYMPHONY240
With CSA
Time (months) Dosage (g/day)
0–3 2.00
3–12 1.84
12+ 1.67
Starting dose 2 g/day; SYMPHONY240
With SRL
Time (months) Dosage (g/day)
0–3 2.00
3–12 1.73
12+ 1.47
Starting dose 2 g/day; SYMPHONY240
continued
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TABLE 182 Resource use for maintenance therapy (continued )
Parameter Value Source
With BEL
Time Dosage (g/day)
Throughout 2.00
Starting dose 2 g/day; BENEFIT59
MPS
With CSA
Time (months) Dosage (mg/day)
0–3 1440
3–9 1211
9+ 1107
Starting dose; Mjörnstedt 2012133
SRL
With TAC
Time (months) Dosage (mg/day)
0–12 3.70
12–60 2.75
60+ 1.80
Anil Kumar 2008122
With MMF Time (months) Dosage (mg/day)
0–3 5.20
3–6 4.45
6–9 3.50
9–12 3.25
12–48 2.90
48+ 2.60
Lebranchu 2009149
EVL
With CSA
Time (months) Dosage (mg/day)
0–3 2.94
3–6 2.75
6–9 2.53
9–12 2.60
12–24 2.60
24+ 2.00
Tedesco-Silva 2010,107 Lorber 2005143
BEL (with MMF)
Drug acquisition
Time (months) Dosage (vials/quarter)
0–3 16.53
3–6 7.13
6+ 6.24
Dosing schedule: 10mg/kg on days 1
and 5, weeks 2, 4, 8 and 12, then
5mg/kg every 4 weeks thereafter
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Infection prophylaxis
Infection prophylaxis was based on the Royal Devon and Exeter transplant protocol.408
Cytomegalovirus prophylaxis is 200 days’ valganciclovir for high-risk KTRs (donor seropositive and recipient
seronegative). Intermediate- and low-risk KTRs do not receive prophylaxis for CMV, with the exception
of intermediate-risk KTRs receiving rATG, who receive 4.5 months’ CMV prophylaxis.408 The dosage
of valganciclovir is adjusted based on Cockcroft–Gault CRC, being 900mg daily for KTRs with CRC of
> 60ml/minute/1.73 m2; 450mg daily for KTRs with CRC of 40–59ml/minute/1.73m2; 450mg on
alternate days for KTRs with CRC of 25–39ml/minute/1.73m2; and 450mg twice weekly for CRC of
10–24ml/minute/1.73m2. It was assumed that KTRs in the FUNCTIONING GRAFT state were split equally in the
25–39, 40–59 and > 60ml/minute/1.73 m2 bands, and that KTRs in the CHRONIC ALLOGRAFT INJURY state were
all in the 10–24ml/minute/1.73 m2 band. In the model, 23.2% of KTRs were assumed to be at high risk of
CMV infection, based on Harvala et al.409
Pneumocystis jirovecii pneumonia (PCP) and urinary tract infection (UTI) prophylaxis was assumed to be
co-trimoxazole, 480mg daily for 3 months.
TABLE 183 Proportion of dialysis patients receiving HD by age group
Age group (years) Proportion (%) receiving HD
18–24 79.1
25–34 80.4
35–44 84.5
45–54 84.3
55–64 85.2
65–74 85.8
75–84 89.0
85+ 91.5
TABLE 182 Resource use for maintenance therapy (continued )
Parameter Value Source
Drug administration
(i.v. infusion) Time (months) Infusions per quarter
0–3 5
3–6 3
6+ 3.26
Prednisolone
(All maintenance regimens)
Time Dosage (mg/day)
Throughout 16.3
SYMPHONY240
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Monitoring
Kidney transplant recipients receive monitoring on a frequent basis after transplantation, which is gradually
tapered for KTRs with stable grafts.
The following monitoring was included:
l full blood count
l renal profile
l liver function tests
l therapeutic drug monitoring (TAC, CSA, SRL and EVL)
l viral quantitative polymerase chain reaction (PCR) [CMV, BKV, Epstein–Barr virus (EBV)].
In addition KTRs attend regular outpatient clinics.
Kidney transplant recipients with degraded GRF receive more intensive monitoring to maximise graft survival.
A retrospective observational study was conducted by Ling and Chamberlain410 and submitted by
Bristol-Myers Squibb, which detailed the post-transplant outpatient tests conducted according to the
Cardiff Renal Transplant Database.
It was assumed that every monitoring visit would involve full blood count, renal profile, liver function test
and therapeutic drug monitoring (if appropriate) and therefore the test performed the most number of
times in each time period was assumed to be representative of monitoring visits.
The data from the observational study410 clearly show that, when patients are stratified by their eGFR at
12 months, their monitoring is more intensive for lower eGFR ranges, but also that even for the lowest
eGFR groups there is a decrease in monitoring over time. The maximum follow-up in the study is to
36 months and therefore extrapolation methods should be considered carefully. Increased monitoring for
KTRs with lower eGFR at 12 months is caused by, in part, the absolute level of GRF but also to the
trajectory of GRF. KTRs with rapidly declining GRF will receive more monitoring and clinics in an attempt to
slow the rate of decline. It is therefore quite unlikely that costs associated with low eGFR in the first
36 months will be representative of costs in much later years for patients who eventually reach the same
eGFR on a slower trajectory.
This, plus the paucity of data on the evolving eGFR distribution of KTRs over time, is a compelling reason
to avoid having absolute eGFR levels driving costs to the extent that is observed in short-term follow-up.
We decided to use the data from the observational study for the first 36 months but thereafter to assume
four clinics and blood tests a year, based on the Royal Devon and Exeter transplant protocol,408 which
suggests that KTRs with stable GRF should have monitoring tapered to every 3–6 months.
Table 184 details the monitoring visits assumed in the model.
Clinics were assumed to be as frequent as monitoring visits, except for the first 3 months, when they were
assumed to be once weekly on the basis of the Royal Devon and Exeter protocol.
Viral quantitative PCR was modelled based on the Royal Devon and Exeter protocol, in which KTRs at
intermediate risk of CMV infection (i.e. seropositive recipients) receive CMV quantitative PCR once weekly
for 3 months. In the model, 41.5% of KTRs were assumed to be at intermediate risk of CMV infection,
based on Harvala et al.409
All KTRs receive BKV quantitative PCR at 3, 6 and 12 months.
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Kidney transplant recipients at high risk of EBV disease (i.e. seronegative recipients from seropositive
donors) receive monthly quantitative PCR to 6 months, followed by tests at 9 and 12 months. The
proportion of KTRs at high risk of EBV disease was estimated from the Cavallo et al.411 study, in which 289
out of 290 recipients were EBV seropositive and 51 out of 55 donors were EBV seropositive. Assuming that
donor–recipient matching is independent of EBV risk, the chance of a KTR being EBV high risk is
(1/290) × (51/55)= 0.32%.
Explant surgery
Not all grafts are explanted on failure, with the likelihood of nephrectomy decreasing with time since
transplantation. NHSBT provided data on the probability of nephrectomy as a function of time since
transplantation for the PenTAG assessment report for NICE guidance TA165,384 which we have reproduced
in Table 185, and used to estimate resource use of explant surgery following failure of the initial graft.
For the subsequent graft it was estimated that 5.9% would be explanted on failure by applying the
proportions of grafts explanted for the first graft to the exponential graft survival curve for subsequent grafts.
Subsequent retransplantation
Based on the Department for Health reference costs 2013–14,412 it was estimated that there would be
1.44 ‘workups for retransplantation’ for each actual retransplantation (which can include a number of tests
for fitness for transplant surgery, fitness for long-term immunosuppression, immunological assessment and
assessment of risk factors for graft and patient survival) and that living donor costs would be incurred in
34.9% of retransplantations and deceased donor costs in 65.1%.
TABLE 185 Proportion of failed grafts explanted as a function of time since transplantation
Time since transplantation Proportion (%) of grafts explanted
0–3 months 4
3–12 months 23
12–24 months 9
24+ months 4
Subsequent grafts 5.9
Source: Organ Donation and Transplantation Directorate of NHSBT. Statistics prepared by NHSBT from the National
Transplant Database maintained on behalf of transplant services in the UK and Republic of Ireland.
TABLE 184 Monitoring visits assumed in the model
Time, month(s) Number of monitoring visits Rate of monitoring visits (number per year)
0–1 13.07 157
1–2 6.75 81
2–3 4.95 59
3–6 8.99 36
6–12 7.93 16
12–24 10.77 11
24–36 14.00 14
36+ 4 per (based on 3- to 6-monthly clinic plus bloods in Royal Devon and Exeter protocol)
Source: Ling and Chamberlain 2011,410 except where specified.
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Diabetes mellitus medication
It was assumed that KTRs with NODAT would receive three 500-mg metformin tablets daily. Although
this may not be a sophisticated or accurate estimate of the cost of diabetes mellitus medication, it is
considered that the costs of complications incurred in and out of hospital will significantly exceed the cost
of diabetes mellitus medication.
Dyslipidaemia
It was assumed that 60% of people with dyslipidaemia would receive fluvastatin, as the evidence base for
this with regard to safety is greatest according to clinical advice. A dosage of 40mg per day was assumed,
as this is the starting dose in the Riella et al.413 study.
It was assumed that 30% of people would receive pravastatin, as the evidence base for safety is smaller.
A dosage of 20mg per day was assumed, again, as this is the starting dose in the Riella et al.413 study.
It was assumed that 10% of people would receive simvastatin, as there have been safety warnings with
respect to CSA. A dosage of 10mg per day was assumed, again as this is the starting dose in the
Riella et al. study.413
Medical management for dyslipidaemia was assumed to be one dietetics outpatient attendance per year
and one GP appointment per year.
Anaemia
According to Vanrenterghem et al.,396 207 out of 3969 (5.2%) of KTRs required ESA treatment for
anaemia, with a mean weekly dose of 5832 IU. It was assumed, therefore, that KTRs would, on average,
receive 3967 IU of ESA per quarter-year cycle while they were not dependent on dialysis.
The NHS reference costs guidance 2013–14412 indicates that the costs of ESA treatment for anaemia
(and of drug treatments for bone mineral disorders) should be included in Healthcare Resource Group
(HRG) costs. It was therefore assumed that additional ESA therapy would not be included for people in the
GRAFT LOSS state.
Unit costs
The following sources were used to identify unit costs for drug acquisition:
l CMU eMit370
l BNF 68 (January 2015 online update).56
The eMit national database was the preferred source, as it represents the average cost actually paid by
NHS hospitals, including any negotiated discounts.
For procedures the NHS reference costs 2013–1464 (inflated to 2014–15 prices) were the preferred source
of unit costs. When unit costs could not be found within the NHS reference costs then a pragmatic search
of England and UK-wide sources was conducted.
Induction
Drug acquisition costs for induction therapy are given in Table 186.
TABLE 186 Drug acquisition costs for induction therapy
Agent Pack details Units Unit cost (£) Source
BAS Single 20-mg vial= £842.38 20-mg doses 842.38 BNF 6856
rATG Single 25-mg vial= £158.77 mg 6.35
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Maintenance immunosuppression
Historically, the prescribing of maintenance immunosuppression has, in some cases (when people have
stable dosing requirements), been transferred to primary care physicians with dispensing in the community.
The NICE reference case states that for medicines predominantly prescribed in primary care, prices should
be based on the Drug Tariff. Recently, however, the NHS England and the Welsh Health Specialised
Services Committee has directed that prescribing of immunosuppressants should be repatriated to
secondary care on the grounds of patient safety.33,414 As a result, in this analysis it is assumed that hospital
prescribing and dispensing is appropriate for costing and therefore eMit costs are preferred when
available, followed by BNF costs (Table 187).
For TAC-PR there is a significant difference in unit price between 5-mg capsules (£1.07 per mg) and
smaller capsules (£1.43 per mg). In the absence of data on relative quantities purchased, it was assumed
that virtually all KTRs receiving TAC-PR would receive one 5-mg capsule daily, with some KTRs also taking
one or more lower-dose capsules to achieve their target daily dose. The appropriate unit cost would
therefore lie between £1.07 and £1.43 per mg. It was further considered that there may be scope for
negotiated discounts on the more expensive capsules. Therefore, it was assumed that the lower unit price
(£1.07 per mg) would be used in the base-case analyses.
Dialysis
Dialysis access surgery costs were estimated per procedure (Table 188) and ongoing dialysis costs (i.e. the
cost of dialysis sessions) were estimated per quarter-year cycle.
Costs of HD and PD are broken down in NHS reference costs by mode (HD, PD), age (≥ 19 years, ≤ 18 years),
location for HD (hospital, satellite, home), access method for HD (HD catheter, arteriovenous fistula or graft),
complications for HD (blood-borne virus, no blood-borne virus), specific modality for PD (continuous
ambulatory, automated, assisted automated) and overall location (at base, away from base). There are
40 HRG4 currencies for dialysis in total (including four for AKI).
The costs of HD and PD were estimating by dividing the HRG4 currencies by mode and age, making
assumptions about the number of currency units per week and then calculating a weighted average cost
based on activity.
Haemodialysis was assumed to be performed three times weekly unless at home, in which case it was
assumed to be performed 3.23 times per week on average (based on inspection of reported average
number of sessions per week after removing clearly erroneous outliers). PD is explicitly costed per day
according to the reference costs guidance and therefore was assumed to be performed seven times weekly.
The currencies for AKI were included, but these make up a vanishingly small proportion of activity and do
not have a significant impact on overall cost estimates.
It was estimated for adults (in 2013–14 prices) that HD would cost £459.59 per week and PD £452.57
per week. These correspond to £6093 and £6000 per quarter-year cycle in 2014–15 prices for HD
and PD, respectively.
Acute rejection
Costing AR is challenging because, although the initial treatment pathway for T-cell-mediated AR (which is the
most common) is fairly standardised (bolus i.v. methylprednisolone and reassessment of immunosuppressive
agent dosage) there is a great amount of variation in treatment if the AR is steroid resistant and/or antibody
mediated. It is also not clear how many AR episodes require hospitalisation and/or dialysis.
A microcosting study was conducted by Ling et al.379 for Bristol-Myers Squibb, in which 11 UK renal
consultants from nine centres completed a questionnaire estimating resource use for an average transplant
patient. This study379 was submitted by Bristol-Myers Squibb as part of the technology appraisal.
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TABLE 187 Drug acquisition costs for maintenance therapy
Agent Pack details Units Unit cost Source
Immediate-release
TAC
50× 1mg= £28.81
100× 1mg= £55.05
50× 0.5mg= £24.90
50× 5mg= £88.57
mg £0.5201 (based on market share) CMU eMit
TAC-PR 50× 0.5mg= £35.79
50× 1mg= £71.59
100× 1mg= £143.17
50× 3mg= £214.76
50× 5mg= £266.92
mg £1.0677 (based on 50× 5-mg pack) BNF 68
CSA 30× 100mg= £46.15
60× 10mg= £16.61
30× 25mg= £14.55
30× 50mg= £25.26
mg £0.0165 (based on market share) CMU eMit
MMF 50× 500mg= £9.17
100× 250mg= £10.94
g £0.3774 (based on market share) CMU eMit
MPS 120× 180mg= £96.72
120× 360mg= £193.43
mg £0.004478 (based on 120 × 180-mg pack) BNF 68
AZA 28× 25mg= £1.63
100× 25mg= £9.43
56× 50mg= £2.53
100× 50mg= £5.03
mg £0.001075 (based on market share) CMU eMit
SRL 30 × 0.5mg= £69.00
30× 1mg= £86.49
30× 2mg= £172.98
mg £2.8830 (based on 30× 2-mg pack) BNF 68
EVL 60 × 0.25mg= £148.50 mg £9.9000 Novartis’ submission
BEL Single 250-mg
vial= £354.52
Vial £354.52 BNF 68
Prednisolone 28 × 1mg= £0.15
30× 2.5mg= £1.65
100× 2.5mg= £5.33
30× 5mg= £1.61
100× 5mg= £5.41
28× 5mg= £0.39
mg £0.003286 (based on market share) CMU eMit
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With regard to AR, a unit cost was estimated by considering the following possible costs:
l inpatient stay
l additional clinic visits
l laboratory tests
l first-line therapies
¢ methylprednisolone
¢ prednisolone
l second-line therapies
¢ rATG
¢ i.v. immunoglobulin
¢ OKT3 (a murine monoclonal Ig2a anti-T cell antibody)
¢ plasma exchange
¢ rituximab.
The estimated cost for an AR episode was £3217 in 2009 GBP, of which £615 was first-line treatment
(all people), £798 was second-line treatment (significantly more expensive but required by only a small
proportion of people), £797 was extra clinic visits and £1007 was hospitalisation.
This unit cost was inflated to £3557 in 2014–15 prices for use in the model.
Alternative unit costs were considered as follows:
l Astellas assumed that people with steroid-sensitive AR (80%) would receive 4 days of therapy with i.v.
methylprednisolone (500mg/day) at a cost of £38.40, whereas people with steroid-resistant AR (20%)
would receive 10 days of rATG at a dose of 1.5mg/kg/day and incur the cost ‘Acute kidney injury
without [comorbidities or complications]’ from NHS reference costs (total cost for steroid-resistant
AR= £8535). The average cost of an AR episode was therefore estimated to be £1738. It was judged
that the cost of treating steroid-sensitive AR had likely been underestimated, as there were no costs
included for diagnosis, hospitalisation or i.v. administration and, as such, the estimated average cost of
£1738 may be underestimated.
l Novartis assumed a cost of £1725 based on inflating the cost of AR in the McEwan et al.310 study
from 2003 to 2013 costs. The original cost included 2 days’ hospitalisation for all people, increased
immunosuppression using TAC, MMF and methylprednisolone for 33% of people and muromonab-
CD3 (Orthoclone OKT3, Janssen–Cilag) for 5% of people. Given how old the cost estimate is, and that
more therapies are used now beyond muromonab-CD3 for steroid-resistant AR, it was judged that this
cost estimate might not be applicable to current practice.
TABLE 188 Unit costs of dialysis access surgery
Procedure HRG4 currency
Unit cost (£)
2013–14 prices 2014–15 prices
HD access surgery YQ42Z: Open Arteriovenous Fistula, Graft or Shunt
Procedures
1915 1946
HD temporary access
surgery
YR41A: Insertion of Tunnelled Central Venous Catheter,
19 and over
810 823
PD access surgery LA05Z: Renal Replacement PD Associated Procedures 1083 1101
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New-onset diabetes after transplantation
Recent studies of the costs of diabetes mellitus to the NHS – such as Hex et al.,415 or cost–utility studies
such as Davies et al.416 and Gillies et al.417 – demonstrate that the costs of complications associated with
diabetes mellitus far outweigh the direct treatment costs. Therefore, we believe it is important to include
these costs within the model, particularly as this allows us to capture the additional costs of CVD
associated with diabetes mellitus.
In its submission, Astellas costs annually for metformin, applied only to those with a functioning graft.
By comparing this figure to the dose recommendations in the BNF, this value forms a good basis for treatment
costs. Treatment costs for diabetes mellitus are also likely to increase as more people become insulin
dependent, but the data on how many people become insulin dependent and when are poor. Furthermore,
the total cost of diabetes mellitus must include both treatment and complications costs. As the cost of
complications far outweighs the costs of treatment for diabetes mellitus, we believe the inclusion of an insulin
cost would not make a significant difference to the cost-effectiveness results and we therefore do not account
for it in the model.
Bristol-Myers Squibb used the annual cost of diabetes mellitus of £1174, taken from Currie et al.,418
and inflated to 2014 prices. This reflects the annual per-patient cost of all prescriptions and consultations
accrued by the diabetic population. It is not clear whether or not this includes renal costs. It is also
reflective of cost to the NHS per year, as opposed to annual per-patient cost, reflective of their lifetime
costs. We therefore considered alternative sources for our diabetes mellitus costs.
One possible source is Gillies et al.,417 who calculate the annual cost of clinically detected type 2 diabetes
mellitus to be £2756 (2006 costs). This value comes from the UKPDS data reported in Clarke et al.380 and
inflated to 2006 prices. These costs seem to be outdated and the authors did not explicitly state whether
or not renal transplantation costs are included, so we identified a more recent paper419 on the costs of
complications associated with diabetes mellitus from the UKPDS via personal communication with Professor
Alistair Gray of the University of Oxford. This study follows the original UKPDS cohort, since the closing of
the intervention in 1997, to 2007, and includes 10 years of follow-up of over 3000 people with type 2
diabetes mellitus. The list of complications did not include renal disease, but it did include several
complications associated with CVD. The average age of the population is slightly higher than that of the
people in our model (63 as opposed to 50 years) and, as they are no longer newly diagnosed people,
this may make costs higher than expected for the first few cycles of the model. However, given the size of
the trial and the recentness of the data, we believe this source to be appropriate. From the supplementary
tables 4 and 5, the average annual per-patient costs of complications across the study period were given
at 2012 prices as £1352 for inpatient costs (SD £5364) and £676 (SD £1081) for non-inpatient costs.
This demonstrates both the size of these costs compared with the cost of treatment of diabetes mellitus
and also the variation in the cost of diabetes mellitus complications.
Dyslipidaemia
Statin acquisition costs for the treatment of dyslipidaemia are given in Table 189 and medical management
costs are given in Table 190.
Infection prophylaxis
Drug acquisition costs for infection prophylaxis are given in Table 191. Costs for CMV prophylaxis
(valganciclovir) are clearly much higher than costs for PCP and UTI prophylaxis.
Cytomegalovirus infection treatment
Ling et al.379 (in the microcosting study referred to above: see Acute rejection) estimated the cost of CMV
infection treatment to be £2721 in 2009 GBP. This was inflated to £3009 in 2014–15 prices for use in
the model.
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Alternative unit costs were considered as follows:
l Astellas assumes a unit cost of £1863 based on i.v. ganciclovir induction for 14–21 days followed by
i.v. ganciclovir maintenance for 8 weeks. It appears to have included only drug acquisition costs for this
schedule and not administration costs, which would be substantial. It is possible that oral valganciclovir
could be used for maintenance instead of i.v. ganciclovir, reducing the administration costs in this
period, but there would still be 14–21 days of administration costs excluded from this estimate. It was
judged that £1863 is likely to be an underestimate of the true cost of CMV infection.
l Novartis assumes a unit cost of £45 based on a GP visit on presentation of symptoms. This appears to
be a significant underestimation of the true cost of CMV infection.
Anaemia
Costs of ESA therapy were estimated assuming that the ESA with lowest acquisition cost would be used
(following NICE guidance TA323,420 which relates to cancer treatment-induced anaemia) (Table 192).
Based on the BNF list prices, Binocrit® is the cheapest ESA, although it is possible that local pharmacy
negotiations may result in reduced costs to the NHS in practice.
TABLE 190 Medical management unit costs for dyslipidaemia
Attendance Source
Unit cost (£)
2013–14 prices 2014–15 prices
Dietetics outpatient NHS reference costs 2013–14:64 654 [Dietetics] 61.69 62.70
General practice PSSRU Unit Costs 2014:407 GP (excluding direct care staff
costs, without qualification costs, per 17.2-minute clinic)
50.00 50.82
TABLE 189 Medication (statin) unit costs for dyslipidaemia
Statin Pack details Units Unit cost (£) Source
Fluvastatin 28 × 20mg= £1.59
28 × 40mg= £1.79
mg 0.002216 (weighted by market share) CMU eMit
Pravastatin 28 × 10mg= £4.32
28 × 20mg= £1.85
28 × 40mg= £0.79
mg 0.002561 (weighted by market share)
Simvastatin 28 × 10mg= £0.15
28 × 20mg= £0.24
28 × 40mg= £0.34
mg 0.000339 (weighted by market share)
TABLE 191 Drug acquisition costs for infection prophylaxis
Agent Pack details Units Unit cost (£) Source
Co-trimoxazole (Septrin®) 100 × 480mg= £15.52 Per 480-mg tablet 0.1552 BNF 6856
Valganciclovir (Valcyte®) 60 × 450mg= £1081.46 Per 450-mg tablet 18.02
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Drug administration
All maintenance agents except BEL are administered orally (unless people are unable to take medication
orally) and this was assumed to not incur any cost.
Basiliximab is administered by i.v. infusion or injection and rATG is administered by i.v. infusion. BAS is
administered on the day of transplantation and 4 days after transplantation. It is very likely that KTRs will still be
inpatients for the latter administration. rATG is administered by i.v. infusion for 3–9 days. It is likely that KTRs
will be inpatients for all of these infusions (a typical patient is estimated to require 10 days’ inpatient stay).421
Belatacept is administered by i.v. infusion in an outpatient setting after the KTR is discharged from hospital.
It is possible that there would be some efficiency savings by combining administration attendances with
regular attendances for monitoring and clinics in early months but thereafter administrations are likely to be
more frequent than other visits.
The NHS reference costs do not estimate a cost of i.v. infusion for inpatients as it is assumed to be a part
of standard care and costs assigned to procedures taking precedence (e.g. kidney transplant). Nevertheless
it was considered important to estimate the cost of administration separately for induction therapies to
enable fair comparison against no induction and potential future comparisons against other induction with
alternative modes of administration.
We believe that the most appropriate HRG4 currencies for i.v. administration of BAS and rATG are SB12Z
(Deliver simple parenteral chemotherapy at first attendance) and SB15Z (Deliver subsequent elements
of a chemotherapy cycle), which, when inflated to 2014–15 prices, have unit costs of £228.95 and
£325.59, respectively.
For BEL, we believe that the most appropriate HRG4 currency is SB12Z, in the outpatient setting, which,
when inflated to 2014–15 prices, has the unit cost of £167.50.
Kidney transplant recipient follow-up
The unit cost of follow-up clinics was estimated from outpatient attendance costs in the nephrology
service, using a weighted average of the different types of attendance (with weights based on national
activity). When inflated to 2014–15 prices the unit cost of a follow-up clinic was estimated to be £145.27
(Table 193). First face-to-face attendances were included, as well as follow-up clinics on the basis that
some people receive follow-up at a different centre to where they received their transplant and the relative
weight of these clinics in calculating the average is small.
TABLE 192 Drug acquisition costs for anaemia
Agent Pack details Units Unit cost (£) Source
Epoetin alfa (Binocrit®) 1000 IU= £4.33
2000 IU= £8.65
3000 IU= £12.98
4000 IU= £17.31
5000 IU= £21.64
6000 IU= £25.96
8000 IU= £40.73
10,000 IU= £43.27
Per 1000 IU 4.33 (based on 1000 pre-filled syringes) BNF 6856
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Monitoring
The unit cost of viral quantitative PCR was assumed to be the same for CMV, EBV and BKV. The most
appropriate recent cost estimate that could be found was from University College London Hospitals
provider-to-provider service 2013–14 tariff.422 This is a recent cost from a NHS provider. The tariffs are
likely to be slightly higher than the costs of in-house laboratory tests, but this was assumed to be a small
effect and it was also considered that some centres might not have in-house quantitative PCR facilities.
The tariff for CMV quantitative PCR was £46 in 2013–14 prices and this was inflated to £46.75 in
2014–15 prices for use in the model.
The unit costs of therapeutic drug monitoring were estimated from the Department of Biochemistry and
Immunology, University Hospital of Wales, therapeutic drug monitoring test repertoire.423 CSA, TAC and
SRL therapeutic drug monitoring all incurred charges of £26.28, which was inflated to £26.71 in 2014–15
prices for use in the model. The cost of therapeutic drug monitoring was assumed to be the same as that
for SRL.
Other tests (full blood count, renal profile and liver function tests) were estimated based on the costing template
produced by NHS Kidney Care to assist in the costing of renal transplantation,421 as shown in Table 194.
Explant surgery
The cost of explant surgery was estimated using NHS reference costs 2013 to 2014.64 The appropriate
HRG4 currencies were identified using the 2013–14 Reference Cost Grouper Code to Group workbook,424
by mapping from OPCS-4 code M026 (Excision of rejected transplanted kidney) to groups LB60, LB61,
LB62 and LB63 (Table 195). The average cost (weighted by activity) was £4886 in 2013–14 prices, which
was inflated to £4966 in 2014–15 prices for the model.
TABLE 193 Unit costs of follow-up clinics
Type of attendance
Number of
attendances
National average unit
cost (2013–14 prices, £)
Consultant led Non-admitted face to face First 85,206 185.95
Follow-up 652,678 146.59
Non-admitted non-face to face First 1124 143.13
Follow-up 3033 109.24
Non-consultant led Non-admitted face to face First 7770 140.42
Follow-up 109,174 94.15
Non-admitted non-face to face First 246 60.38
Follow-up 5810 42.06
Weighted average 142.93
(In 2014–15 prices) 145.27
TABLE 194 Unit costs of other monitoring tests
Test Unit cost (2008–9 prices, £) Unit cost (2014–15 prices, £)
Full blood count 4.57 5.05
Renal profile 4.11 4.54
Liver function test 4.20 4.64
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Subsequent transplant
Living donor costs fall under three HRG4 currencies:
l LA10Z – Live Donor Kidney Screening
l LA11Z – Kidney Pretransplantation Work-up of Live Donor
l LB46Z – Live Donation of Kidney.
The total living donor costs per live kidney donation were calculated by dividing the total cost for each
currency by the activity for actual live donation, resulting in a combined cost of £8770.60 per live kidney
donation in 2013–14 prices (Table 196). Reference costs and unit costs of transplant surgery and
subsequent transplants can be found in Tables 197 and 198.
Deceased donor costs comprise the cost of retrieval, which may be divided into staffing, consumables
and transport. NHSBT performed a service evaluation of the National Organ Retrieval Service and reported
various costs.355 Staffing costs were reported separately for abdominal retrieval teams and these were used
to estimate the staffing cost of retrieval at £6093.49 in 2012–13 prices (Table 199). The average cost of
consumables per retrieval was reported as £1770.30, although it should be noted that this included
cardiothoracic retrievals also. The total cost of transport was reported as £4,098,473.94 and this was
divided by the total number of retrievals (abdominal and cardiothoracic) for a unit cost of £2005.12 per
retrieval. The total cost of retrieval was therefore estimated to be £9869 in 2012–13 prices, which was
inflated to £10,142 in 2014–15 prices for the model.
TABLE 195 Reference costs informing the unit cost of explant surgery
HRG4 Activity
Unit cost
(2013–14 prices, £)
Total cost
(2013–14 prices, £)
LB61C: Major, Open or Percutaneous, Kidney or Ureter
Procedures, 19 and over, with CC Score 10+
697 8175.72 5,698,474
LB61D: Major, Open or Percutaneous, Kidney or Ureter
Procedures, 19 and over, with CC Score 7–9
796 5593.30 4,452,263
LB61E: Major, Open or Percutaneous, Kidney or Ureter
Procedures, 19 and over, with CC Score 4–6
1661 4984.97 8,280,041
LB61F: Major, Open or Percutaneous, Kidney or Ureter
Procedures, 19 and over, with CC Score 2–3
2391 4123.49 9,859,272
LB61G: Major, Open or Percutaneous, Kidney or Ureter
Procedures, 19 and over, with CC Score 0–1
3947 3694.03 14,580,351
LB62C: Major Laparoscopic, Kidney or Ureter
Procedures, 19 and over, with CC Score 3+
962 6445.46 6,200,531
LB62D: Major Laparoscopic, Kidney or Ureter
Procedures, 19 and over, with CC Score 0–2
3860 5404.85 20,862,707
TABLE 196 Reference costs informing the unit cost of live kidney donation
HRG4 currency Activity Unit cost (£) Total cost (£)
LA10Z: Live Kidney Donor Screening 801 659.61 528,351
LA11Z: Kidney Pretransplantation Work-up of Live Donor 1524 477.95 728,398
LB46Z: Live Donation of Kidney 805 7209.43 5,803,587
Total cost 7,060,337
(Per live donation of kidney) 8770.60
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TABLE 197 Reference costs informing the unit cost of transplant surgery
HRG4 currency Activity Unit cost (£) Total cost (£)
LA01A: Kidney Transplant, 19 and over, from Cadaver Non Heart-Beating
Donor
553 13,603.01 7,522,463
LA02A: Kidney Transplant, 19 and over, from Cadaver Heart-Beating Donor 991 15,520.53 15,380,850
LA03A: Kidney Transplant, 19 and over, from Live Donor 826 17,526.91 14,477,231
Average 15,772.38
TABLE 198 Unit costs for subsequent transplants
Procedure HRG4 currency
Unit cost (£)
2013–14 prices 2014–15 prices
Recipient work-up LA12A: Kidney Pretransplantation Work-up of Recipient,
19 and over
835.06 848.72
Living donor costs See Table 204 8770.60 8914.05
Deceased donor costs See Subsequent transplant 9868.92 10,142.05
Transplant surgery See Table 205 15,772.38 16,030.35
TABLE 199 Abdominal retrieval team staffing costs
Abdominal retrieval team
Number of
retrievals
Average staffing cost
per retrieval (£)
University Hospitals Birmingham NHS FT 215 4440.56
Cambridge University Hospitals NHS FT 245 4082.34
University Hospital of Wales 72 5979.36
King’s College Hospital NHS FT 246 2865.03
Leeds Teaching Hospitals NHS Trust/Central Manchester and
Manchester Children’s Foundation Hospitals NHS Trust
251 8645.29
Newcastle-upon-Tyne NHS FT 179 5158.09
Oxford Radcliffe Hospitals NHS Trust 126 6912.76
Royal Free Hampstead NHS Trust 122 10,800.90
Royal Infirmary of Edinburgh (SORT) 117 10,366.39
Average 6093.49
FT, Foundation Trust.
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Summary of model parameters
Appendix 11 details base-case values, sources and PSA distributions for parameters in the model.
Model verification
The decision model was tested by an independent academic decision modeller (Andy Salmon) twice, once
following development of the deterministic base case and once following the addition of the probabilistic
analyses. Extreme value testing and other black-box testing techniques were applied to ensure the model
performed as expected. The testing checklist was also applied by TS following the addition of the
probabilistic analyses as an additional check on correct implementation.
Results
We first present the base-case analysis, which we believe to be closest to the NICE reference case.
Deterministic results for the base-case analysis are given below (see Deterministic results), as are
probabilistic results (see Probabilistic results).
Next we present scenario analyses that explore structural and other uncertainties in the economic
assessment. Structural uncertainty in the extrapolation of graft survival is explored in two scenario analyses
below (see Graft survival structural scenario analyses). Although it is believed that unit costs for drug
acquisition have been identified appropriately and in line with the reference case, we also explore the
impact of using list prices for all drugs, and conduct a two-way threshold analysis on costs relating to BEL
(see Cost-related scenario analyses).
Summary cost-effectiveness results are presented in the following form throughout, with regimens sorted
in order of ascending effectiveness (total QALYs):
l total costs
l incremental costs compared with the previous regimen
l total QALYs
l incremental QALYs compared with the previous regimen
l ICER (compared with the previous regimen on the cost-effectiveness frontier unless the regimen is
dominated or extended dominated)
l incremental net health benefit (INHB) at £20,000 and £30,000 per QALY compared with the referent
regimen (the regimen on the cost-effectiveness frontier with the lowest total QALYs).
For probabilistic cost-effectiveness results the following are also presented:
l the probability that each regimen is cost-effective (i.e. gives the greatest net health benefit of all
regimens being compared) at £20,000 and £30,000 per QALY.
Note that, throughout, costs and ICERs are reported rounded to the nearest £1 and QALYs are reported
to four decimal places. This should not be taken as an indication of the precision of these estimates, but to
allow for third-party checking of the accuracy of calculations.
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Base-case analysis
Deterministic results
Induction agents
We present the cost-effectiveness of induction agents BAS and rATG and the comparator of no induction
in the context of three different maintenance regimens:
l CSA, AZA and CCSs
l CSA, MMF and CCSs
l TAC, MMF and CCSs.
Note that although other regimens including BAS are modelled (BAS+ SRL+MMF, BAS+ BEL+MMF,
BAS+CSA+MPS) these cannot be meaningfully compared with any other regimens to estimate the
cost-effectiveness of BAS.
Summary cost-effectiveness results are given in Table 200.
BAS
Basiliximab was compared with no induction and with rATG in three comparisons. In all three
comparisons, BAS was predicted to dominate no induction and rATG. Therefore, BAS is predicted to be
cost-effective at £20,000 and £30,000 per QALY.
TABLE 200 Summary of cost-effectiveness results for induction agents
Induction
agent
Discounted costs (£) Discounted QALYs
ICER (cost
per QALY, £)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With CSA +AZA
vs. BAS
No
induction
101,595 – 10.7711 – Dominated –0.2994 –0.2436
rATG 104,570 + 2975 10.8182 + 0.0471 Dominated –0.4011 –0.2956
BAS 98,244 –6326 10.9029 + 0.0848 – – –
With CSA +MMF
vs. BAS
No
induction
97,429 – 10.9145 – Dominated –0.2207 –0.1838
rATG 101,940 + 4511 10.9281 + 0.0135 Dominated –0.4327 –0.3206
BAS 95,219 –6720 11.0247 + 0.0966 – – –
With TAC +MMF
vs. BAS
No
induction
92,226 – 10.8884 – Dominated –0.1906 –0.1603
rATG 97,146 + 4920 10.9047 + 0.0163 Dominated –0.4203 –0.3080
BAS 90,405 –6741 10.9880 + 0.0832 – – –
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rATG
Rabbit ATG was compared with no induction and with BAS in three comparisons. In all three comparisons,
rATG was predicted to be dominated by BAS. Therefore, rATG is not predicted to be cost-effective at
£20,000 and £30,000 per QALY.
As shown in Appendix 10 (see Table 230), rATG induction results in greater induction therapy costs than
BAS and greater costs of infection prophylaxis (as KTRs at intermediate risk of CMV require prophylaxis if
receiving rATG induction). These cost increases are partially offset by a reduction in costs of AR treatment
(owing to reduced incidence of AR).
Summary
In all comparisons, BAS was dominant over no induction and rATG and was the only cost-effective
induction agent.
Maintenance agents
We present the cost-effectiveness results for the following maintenance agents:
l immediate-release TAC
l TAC-PR
l MMF
l MPS
l SRL
l EVL
l BEL.
These are compared with each other as appropriate and also with CSA or AZA. All maintenance agents
were modelled with concomitant treatment, which would be CCSs plus MMF, AZA, CSA or immediate-
release TAC according to the evidence base, plus optional induction therapy (BAS or rATG). Comparisons
are made holding all concomitant treatments equal. Summary results are given in Table 201.
Immediate-release TAC
Immediate-release TAC was compared with CSA (four comparisons), TAC-PR (one comparison), SRL
(one comparison) and BEL (one comparison).
When used in combination with MMF and CCSs, immediate-release TAC dominated TAC-PR and was less
costly and less effective than CSA. The ICER of CSA compared with immediate-release TAC was £199,118
per QALY and therefore immediate-release TAC was the only cost-effective agent in this comparison at
cost-effectiveness thresholds of between £20,000 and £30,000 per QALY.
When used in combination with AZA and CCSs, immediate-release TAC dominated CSA.
When used in combination with BAS induction, MMF and CCSs, immediate-release TAC dominated SRL
and was less costly and less effective than CSA and BEL. The ICERs for CSA and BEL in this comparison
were £131,035 and £423,890 per QALY, respectively, and therefore immediate-release TAC was the only
cost-effective agent in this comparison at cost-effectiveness thresholds of between £20,000 and £30,000
per QALY.
When used in combination with rATG induction, MMF and CCSs, immediate-release TAC was less costly
and less effective than CSA. The ICER of CSA was £255,592 per QALY and therefore immediate-release
TAC was the only cost-effective agent in this comparison at cost-effectiveness thresholds of between
£20,000 and £30,000 per QALY.
PENINSULA TECHNOLOGY ASSESSMENT GROUP ECONOMIC ASSESSMENT
NIHR Journals Library www.journalslibrary.nihr.ac.uk
336
TABLE 201 Summary of cost-effectiveness results for maintenance agents
Maintenance
agent
Discounted costs (£) Discounted QALYs
ICER (cost
per QALY, £)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With MMF
vs. TAC
TAC-PR 106,529 – 10.7920 – Dominated –0.8116 –0.5732
TAC 92,226 –14,303 10.8884 +0.0964 – – –
CSA 97,429 +5203 10.9145 +0.0261 199,118 –0.2340 –0.1473
With AZA
vs. TAC
CSA 101,595 – 10.7711 – Dominated –0.5124 –0.3745
TAC 93,319 –8276 10.8696 +0.0986 – – –
With BAS +MMF
vs. TAC
SRL 114,549 – 10.9010 – Dominated –1.2941 –0.8917
TAC 90,405 –24,144 10.9880 +0.0869 – – –
CSA 95,219 +4815 11.0247 +0.0367 131,035 –0.2040 –0.1237
BEL 209,409 +114,189 11.2941 +0.2694 423,890 –5.6441 –3.6607
With rATG +MMF
vs. TAC
TAC 97,146 – 10.9047 – – – –
CSA 101,940 +4794 10.9281 +0.0234 205,214 –0.2163 –0.1364
With CSA
vs. MMF
AZA 101,595 – 10.7711 – Dominated –0.3518 –0.2824
MMF 97,429 –4166 10.9145 +0.1435 – – –
EVL 176,154 +78,725 10.9659 +0.0514 1,532,379 –3.8849 –2.5728
With TAC
vs. MMF
SRL 125,539 – 10.6023 – Dominated –1.9518 –1.3966
AZA 93,319 –32,220 10.8696 +0.2674 Dominated –0.0734 –0.0552
MMF 92,226 –1093 10.8884 +0.0188 – – –
With BAS +CSA
vs. MMF
AZA 98,244 – 10.9029 – Dominated –0.2730 –0.2226
MMF 95,219 –3025 11.0247 +0.1218 – – –
MPS 111,540 +16,321 11.1377 +0.1130 144,449 –0.7030 –0.4310
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In three comparisons (all with MMF), immediate-release TAC was predicted be less effective than CSA. In
all comparisons, however, immediate-release TAC was predicted to result in greater life expectancy and
more years with functioning graft (see Appendix 10, Table 231). The QALY loss arises because of the
reduction in HRQoL in KTRs who develop NODAT; 10.6% of KTRs are predicted to develop NODAT with
immediate-release TAC, compared with 5.0% of KTRs for CSA. If the utility decrement for NODAT is
removed (and NODAT therefore only affects costs, graft survival and DWFG) then immediate-release TAC
is more effective than CSA in all comparisons and therefore is dominant (see Appendix 10, Table 235).
TAC-PR
Prolonged-release tacrolimus was compared with CSA and immediate-release TAC in combination with
MMF and CCSs. TAC-PR was dominated by both CSA and immediate-release TAC in this comparison.
MMF
Mycophenolate mofetil was compared with AZA (four comparisons), SRL (one comparison), EVL
(one comparison) and MPS (one comparison).
Mycophenolate mofetil dominated (i.e. was more effective and less costly than) AZA in all
four comparisons.
When used in combination with immediate-release TAC and CCSs, MMF dominated SRL.
When used in combination with CSA and CCSs, MMF was less costly and less effective than EVL. The ICER
of EVL was £1,532,379 per QALY and therefore MMF was the only cost-effective agent in this comparison
at cost-effectiveness thresholds of between £20,000 and £30,000 per QALY.
When used in combination with BAS induction, CSA and CCSs, MMF was less costly and less effective
than MPS. The ICER of MPS was £144,449 per QALY and therefore MMF was the only cost-effective agent
in this comparison at cost-effectiveness thresholds of between £20,000 and £30,000 per QALY.
MPS
Mycophenolate sodium was compared with AZA and MMF in combination with BAS induction, CSA and
CCSs. MPS was more costly and more effective than AZA and MMF. The ICER of MPS was £144,449 per
QALY and therefore MPS was not cost-effective at cost-effectiveness thresholds of between £20,000
and £30,000 per QALY.
Mycophenolate sodium was considerably more costly than MMF, with discounted maintenance
immunosuppression costs more than double those of MMF, although there were some predicted savings in
dialysis expenditure (see Appendix 10, Table 230). MPS was predicted to lead to increased time with
functioning graft and increased life expectancy compared with MMF, which is why it was predicted to give
increased QALYs (see Appendix 10, Table 231).
TABLE 201 Summary of cost-effectiveness results for maintenance agents (continued )
Maintenance
agent
Discounted costs (£) Discounted QALYs
ICER (cost
per QALY, £)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With rATG +CSA
vs. MMF
AZA 104,570 – 10.8182 – Dominated –0.2414 –0.1976
MMF 101,940 –2631 10.9281 +0.1099 – – –
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SRL
Sirolimus was compared with CSA, immediate-release TAC and BEL in one comparison (in combination
with BAS induction, MMF and CCSs) and with AZA and MMF in one comparison (in combination with
immediate-release TAC and CCSs).
Sirolimus was dominated by CSA and TAC in the first comparison, and was dominated by AZA and MMF
in the second comparison.
EVL
Everolimus was compared with AZA and MMF in combination with CSA and CCSs. EVL was more costly
and more effective than AZA and MMF. The ICER of EVL was £1,532,739 per QALY and therefore EVL
was not cost-effective at cost-effectiveness thresholds of between £20,000 and £30,000 per QALY.
BEL
Belatacept was compared with CSA, immediate-release TAC and SRL in combination with BAS induction,
MMF and CCSs. BEL was more costly and more effective than all comparators. The ICER of BEL was
£423,890 per QALY and therefore BEL was not cost-effective at cost-effectiveness thresholds of between
£20,000 and £30,000 per QALY.
Summary
Only immediate-release TAC and MMF were cost-effective at cost-effectiveness thresholds of between
£20,000 and £30,000 per QALY.
Prolonged-release tacrolimus and SRL were dominated in their relevant comparisons, whereas MPS, EVL
and BEL were all the most costly and most effective treatment in their relevant comparisons, but with
ICERs of significantly greater than £30,000 per QALY.
Comparing all regimens
When all regimens are simultaneously compared, the following regimens are dominated or extended
dominated (if indicated):
l TAC+ SRL
l TAC-PR+MMF
l CSA+AZA
l TAC+AZA
l TAC+MMF
l CSA+MMF
l BAS+ SRL+MMF
l BAS+CSA+AZA
l rATG+CSA+AZA
l CSA+ EVL
l rATG+ TAC+MMF (extended dominated)
l rATG+CSA+MMF (extended dominated).
Four regimens were neither dominated nor extended dominated and therefore lay on the cost-effectiveness
frontier, and the cost-effectiveness results for these are presented in Table 202. BAS+ TAC+MMF was
predicted to be the only cost-effective regimen at cost-effectiveness thresholds of between £20,000 and
£30,000 per QALY.
Additional results
Additional results for the deterministic base case (including disaggregated discounted costs and additional
clinical outcomes) can be found in Appendix 10.
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Probabilistic results
The PenTAG model was run for 10,000 PSA iterations. Non-linearities in models often manifest in
substantially different results between probabilistic and deterministic analyses. Figure 75 demonstrates
that there are no significant discrepancies in terms of total costs for each regimen. Figure 76 indicates that
there are some discrepancies in terms of total QALYs for each regimen between the probabilistic and
deterministic analyses, but there appears to be no systemic bias.
The most significant outlier appears to be BAS+CSA+MPS+CCSs, which is predicted to result in 11.1377
QALYs in the deterministic analysis, but only 11.0244 in the probabilistic analysis. It was ascertained
that this outlier effect is caused by the significant uncertainty in the probability of mortality within the first
12 months for this regimen: the 95% CI of the OR of mortality for MPS compared with MMF is 0.058 to
7.23. When the probability of mortality drawn from the PSA distribution is extremely low, the regression
formulae for estimating the appropriate HR for DWFG perform badly and, in some cases, even a HR of
zero results in above-target mortality as a result of the mortality following graft loss. Noting that, in the
deterministic base base, MPS was not cost-effective at £20,000 or £30,000 per QALY (the ICER of MPS vs.
MMF was > £100,000 per QALY), we have not attempted to compensate for this discrepancy in our analyses.
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FIGURE 75 Comparison of deterministic and probabilistic costs in the PenTAG model.
TABLE 202 Cost-effectiveness of all regimens on the cost-effectiveness frontier
Regimen
Discounted costs (£) Discounted QALYs
ICER (£)
INHB (£)
Total Incremental Total lncremental 20,000 30,000
BAS+ TAC+MMF 90,405 – 10.9880 – – – –
BAS+CSA+MMF 95,219 +4815 11.0247 +0.0367 131,035 –0.2040 –0.1237
BAS+CSA+MPS 111,540 +16,321 11.1377 +0.1130 144,449 –0.9070 –0.5548
BAS+ BEL+MMF 209,409 +97,869 11.2941 +0.1564 625,761 –5.6441 –3.6607
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Induction agents
Probabilistic cost-effectiveness results for induction agents (Table 203) were not significantly altered from
the deterministic results (see Table 199). No induction and rATG continued to be dominated by BAS in all
three comparisons.
BAS
Basiliximab was predicted to dominate no induction and rATG in all three comparisons (as in the
deterministic results). BAS was cost-effective at £20,000 per QALY in 93.5–94.9% of PSA iterations across
comparisons and at £30,000 per QALY in 92.6–94.6% of iterations.
rATG
Rabbit ATG was predicted to dominate by BAS in all three comparisons (as in the deterministic results).
Rabbit ATG was cost-effective at £20,000 per QALY in 2.8–5.8% of PSA iterations across comparisons and
at £30,000 per QALY in 4.0–6.8% of iterations.
Cost-effectiveness acceptability curves
Cost-effectiveness acceptability curves are shown in Figures 77–79 for the three comparisons. Although
these have not been presented as cost-effectiveness acceptability frontiers (in which only the regimen with
the greatest expected net health benefit is shown for each cost-effectiveness threshold), the only effect
this would have would be to remove the curves for no induction and rATG, as BAS is predicted to give the
greatest expected net health benefit across the cost-effectiveness threshold range explored (£1000–50,000
per QALY).
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FIGURE 76 Comparison of deterministic and probabilistic QALYs in the PenTAG model.
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FIGURE 77 Cost-effectiveness acceptability curves for induction agents in combination with CSA, AZA and CCSs.
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FIGURE 78 Cost-effectiveness acceptability curves for induction agents in combination with CSA, MMF and CCSs.
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FIGURE 79 Cost-effectiveness acceptability curves for induction agents in combination with immediate-release TAC,
MMF and CCSs.
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Summary
Basiliximab is predicted to be cost-effective with an error probability of 5.1–6.5% (cost-effectiveness
threshold of £20,000 per QALY) to 5.4–7.4% (cost-effectiveness threshold of £30,000 per QALY).
‘No induction’ and rATG are predicted not to be cost-effective.
Maintenance agents
A summary of cost-effectiveness results in the probabilistic analysis is given in Table 204. All of the
treatments that were dominated in the deterministic analysis remain dominated in the probabilistic
analysis. In addition, BAS+CSA+MPS is now predicted to be dominated by BAS+CSA+MMF, whereas,
in the deterministic analysis, it was more costly and more effective, with an ICER of > £100,000 per QALY.
The treatment that was cost-effective at £20,000 and £30,000 per QALY in each comparison in the
deterministic analysis remains cost-effective in the probabilistic analysis.
Immediate-release TAC
Immediate-release TAC was compared with CSA (four comparisons), TAC-PR (one comparison), SRL
(one comparison) and BEL (one comparison).
In all comparisons immediate-release TAC was the least costly intervention. It dominated TAC-PR when
used in combination with MMF; it dominated CSA when used in combination with AZA; and it dominated
SRL when used in combination with BAS+MMF. When used in combination with MMF or BAS+MMF or
rATG+MMF, immediate-release TAC was less effective than CSA but the ICERs of CSA compared with
immediate-release TAC were > £200,000 per QALY. Immediate-release TAC was less costly and less
effective than BEL when used in combination with BAS+MMF, but the relevant ICER of BEL (vs. CSA) was
> £400,000 per QALY.
In all comparisons, immediate-release TAC was predicted to be cost-effective at £20,000–30,000
per QALY. The probability of immediate-release TAC being cost-effective (i.e. giving the greatest net health
benefit in each comparison) at £20,000 and £30,000 per QALY ranged from 81.8% to 93.7%.
TAC-PR
Prolonged-release tacrolimus was compared with immediate-release TAC and CSA in combination with
MMF. TAC-PR was predicted to be dominated by immediate-release TAC and CSA, and therefore not
predicted to be cost-effective at any cost-effectiveness threshold. The probability of TAC-PR being
cost-effective was 0.0% at both £20,000 and £30,000 per QALY.
MMF
Mycophenolate mofetil was compared with AZA (four comparisons), MPS (one comparison), EVL
(one comparison) and SRL (one comparison).
Mycophenolate mofetil was predicted to dominate AZA in all comparisons, and to dominate SRL when used
in combination with TAC, and to dominate MPS when used in combination with BAS+CSA. MMF was
predicted to be less costly and less effective than EVL when used in combination with CSA, but the ICER of
EVL (vs. MMF) was > £3,000,000 per QALY and therefore MMF was predicted to be cost-effective at
£20,000–30,000 per QALY.
In all comparisons, MMF was predicted to be cost-effective at £20,000–30,000 per QALY. The probability
of MMF being cost-effective at £20,000 and £30,000 per QALY ranged from 64.3% to 91.8%
across comparisons.
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MPS
Mycophenolate sodium was compared with MMF and AZA in combination with BAS+CSA. MPS was
predicted to be dominated by MMF and therefore was not predicted to be cost-effective at any
cost-effectiveness threshold. The probability of MPS being cost-effective was 0.1% at £20,000 per QALY,
and 0.6% and £30,000 per QALY.
SRL
Sirolimus was compared with immediate-release TAC, BEL and CSA in combination with BAS+MMF. SRL
was predicted to be dominated by immediate-release TAC and CSA and therefore not predicted to be
cost-effective at any cost-effectiveness threshold. The probability of SRL being cost-effective in combination
with BAS+MMF was 0.0% at both £20,000 and £30,000 per QALY.
Sirolimus was also compared with MMF and AZA in combination with TAC. SRL was predicted to be
dominated by MMF and AZA, and therefore not predicted to be cost-effective at any cost-effectiveness
threshold. The probability of SRL being cost-effective in combination with TAC was 0.0% at both £20,000
and £30,000 per QALY.
EVL
Everolimus was compared with MMF and AZA in combination with CSA. EVL was predicted to be more
costly and more effective than all comparators. The relevant ICER for EVL (vs. MMF) was > £3,000,000
per QALY and, therefore, EVL was not predicted to be cost-effective at £20,000–30,000 per QALY.
The probability of EVL being cost-effective was 0.0% at both £20,000 and £30,000 per QALY.
BEL
Belatacept was compared with immediate-release TAC, SRL and CSA in combination with BAS+MMF.
BEL was predicted to be more costly and more effective than all comparators. The relevant ICER for
BEL (vs. CSA) was > £400,000 per QALY and therefore BEL was not predicted to be cost-effective at
£20,000–30,000 per QALY. The probability of BEL being cost-effective was 0.0% at both £20,000 and
£30,000 per QALY.
Cost-effectiveness acceptability curves
Figures 80–87 show the cost-effectiveness acceptability curves for maintenance agents in the probabilistic
analysis. As for induction agents, we have not presented these as cost-effectiveness acceptability frontiers
because the agent with the highest probability of being cost-effective also gives the greatest expected net
health benefit in the range explored.
Summary
As in the deterministic analysis, only immediate-release TAC and MMF were cost-effective at
cost-effectiveness thresholds of between £20,000 and £30,000 per QALY.
Prolonged-release tacrolimus, MPS and SRL were dominated in their relevant comparisons, whereas EVL
and BEL were always the most costly and most effective treatment in their relevant comparisons but with
ICERs that were significantly greater than £30,000 per QALY.
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FIGURE 80 Cost-effectiveness acceptability curves for maintenance agents (CSA, TAC and TAC-PR) in combination
with MMF.
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FIGURE 81 Cost-effectiveness acceptability curves for maintenance agents (CSA and TAC) in combination with AZA.
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FIGURE 82 Cost-effectiveness acceptability curves for maintenance agents (CSA, TAC, SRL and BEL) in combination
with BAS+MMF.
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FIGURE 83 Cost-effectiveness acceptability curves for maintenance agents (CSA and TAC) in combination
with rATG+MMF.
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FIGURE 84 Cost-effectiveness acceptability curves for maintenance agents (AZA, MMF and EVL) in combination
with CSA.
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FIGURE 85 Cost-effectiveness acceptability curves for maintenance agents (AZA, MMF and SRL) in combination
with TAC.
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Comparing all regimens
When all regimens are compared simultaneously, all regimens are dominated or extended dominated
(rATG+ TAC+MMF, rATG+CSA+MMF) except for BAS+ TAC+MMF, BAS+CSA+MMF and
BAS+ BEL+MMF, which lie on the cost-effectiveness frontier. BAS+CSA+MPS is not predicted to be on
the cost-effectiveness frontier in the probabilistic analysis, whereas it was in the deterministic analysis. As
explained above (see Probabilistic results) this may be because of a downwards bias on probabilistic QALYs
compared with deterministic QALYs for this regimen due to non-linearities. The cost-effectiveness results
for the regimens on the cost-effectiveness frontier are given in Table 205.
These results indicate that there is a 78.0–78.8% probability that a regimen on the cost-effectiveness
frontier gives the maximum net health benefit at £20,000–30,000 per QALY. The probability that
BAS+ TAC+MMF gives the maximum net health benefit is 69.0% at £20,000 per QALY and 65.3% at
£30,000 per QALY.
Table 205 also presents the cost-effectiveness results for regimens that are not on the cost-effectiveness frontier.
All incremental costs and QALYs and INHBs are compared with BAS+ TAC+MMF. All of these regimens are, by
definition, dominated or extended dominated, although not in every case by BAS+ TAC+MMF. Interestingly,
at £20,000 per QALY there is a regimen that is not on the cost-effectiveness frontier (TAC+AZA), which is
predicted to be more likely to be cost-effective than BAS+CSA+MMF and BAS+ BEL+MMF (which are both
on the frontier).
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FIGURE 86 Cost-effectiveness acceptability curves for maintenance agents (AZA, MMF and MPS) in combination
with BAS+CSA.
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FIGURE 87 Cost-effectiveness acceptability curves for maintenance agents (AZA and MMF) in combination
with rATG+CSA.
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It is known that when the cost-effectiveness of an intervention is highly uncertain it can result in a
flatteringly high probability of being cost-effective. A graphical representation that helps to identify this
phenomenon is the rankogram,425 which plots the probability distribution for the rank of an intervention
according to a certain measure. We present rankograms of the net health benefit at £20,000 per QALY
for all 16 regimens in Figure 88. These suggest that the ranks of CSA+AZA, CSA+ EVL, TAC+ SRL,
TAC-PR+MMF, BAS+ TAC+MMF, BAS+ SRL+MMF and BAS+ BEL+MMF are fairly well, or extremely
well, estimated (little dispersion in rank probability distribution), whereas the ranks for other regimens
are less well estimated. The mean rank can also be calculated and is also presented in Table 205,
demonstrating that the regimen with the greatest expected rank is BAS+ TAC+MMF.
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FIGURE 88 Rankograms of net health benefit at £20,000 per QALY for each regimen. (a) CSA+MMF (5.8);
(b) TAC+MMF (3.2); (c) proportion of simulations in PSA; (c) CSA+AZA (9.2); (d) TAC+AZA (4.8); (e) CSA+ EVL
(15.0); (f) TAC+ SRL (14.0); (g) TAC-PR+MMF (10.7); (h) BAS+CSA+MMF (3.3); (i) BAS+ TAC+MMF (1.5);
(j) BAS+CSA+AZA (6.1); (k) BAS+ SRL+MMF (12.2); (l) BAS+BEL+MMF (16.0); (m) BAS+CSA+MPS (10.5);
(n) rATG+CSA+MMF (7.9); (o) rATG+ TAC+MMF (5.5); and (p) rATG+CSA+AZA (10.2). (continued )
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FIGURE 88 Rankograms of net health benefit at £20,000 per QALY for each regimen. (a) CSA+MMF (5.8);
(b) TAC+MMF (3.2); (c) proportion of simulations in PSA; (c) CSA+AZA (9.2); (d) TAC+AZA (4.8); (e) CSA+ EVL
(15.0); (f) TAC+ SRL (14.0); (g) TAC-PR+MMF (10.7); (h) BAS+CSA+MMF (3.3); (i) BAS+ TAC+MMF (1.5);
(j) BAS+CSA+AZA (6.1); (k) BAS+ SRL+MMF (12.2); (l) BAS+BEL+MMF (16.0); (m) BAS+CSA+MPS (10.5);
(n) rATG+CSA+MMF (7.9); (o) rATG+ TAC+MMF (5.5); and (p) rATG+CSA+AZA (10.2). (continued )
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FIGURE 88 Rankograms of net health benefit at £20,000 per QALY for each regimen. (a) CSA+MMF (5.8);
(b) TAC+MMF (3.2); (c) proportion of simulations in PSA; (c) CSA+AZA (9.2); (d) TAC+AZA (4.8); (e) CSA+ EVL
(15.0); (f) TAC+ SRL (14.0); (g) TAC-PR+MMF (10.7); (h) BAS+CSA+MMF (3.3); (i) BAS+ TAC+MMF (1.5);
(j) BAS+CSA+AZA (6.1); (k) BAS+ SRL+MMF (12.2); (l) BAS+BEL+MMF (16.0); (m) BAS+CSA+MPS (10.5);
(n) rATG+CSA+MMF (7.9); (o) rATG+ TAC+MMF (5.5); and (p) rATG+CSA+AZA (10.2). (continued )
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FIGURE 88 Rankograms of net health benefit at £20,000 per QALY for each regimen. (a) CSA+MMF (5.8);
(b) TAC+MMF (3.2); (c) proportion of simulations in PSA; (c) CSA+AZA (9.2); (d) TAC+AZA (4.8); (e) CSA+ EVL
(15.0); (f) TAC+ SRL (14.0); (g) TAC-PR+MMF (10.7); (h) BAS+CSA+MMF (3.3); (i) BAS+ TAC+MMF (1.5);
(j) BAS+CSA+AZA (6.1); (k) BAS+ SRL+MMF (12.2); (l) BAS+BEL+MMF (16.0); (m) BAS+CSA+MPS (10.5);
(n) rATG+CSA+MMF (7.9); (o) rATG+ TAC+MMF (5.5); and (p) rATG+CSA+AZA (10.2). (continued )
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Scenario analyses
Graft survival structural scenario analyses
Eliminating graft survival differences after a certain time
To explore what impact the model for death-censored graft survival had on cost-effectiveness, a scenario
analysis was conducted in which after n years the hazard rate of death-censored graft loss was equalised
for all regimens (set equal to the baseline hazard function). This is equivalent to the conditional graft
survival from time n years being identical across the regimens.
The ‘n years’ was varied from 1 to 20; the base case is effectively n= 50. When n= 1 it is therefore
assumed that AR, eGFR and NODAT do not affect graft survival after 1 year and that long-term graft
survival is determined solely by graft survival at 1 year. As n increases, the surrogate relationship from AR,
eGFR and NODAT to graft survival is strengthened towards the base case.
Figure 89 shows the net health benefit of all regimens as n is varied from 1 to 20. Figure 90 shows a
close-up of the regimens with high net health benefit (BAS+CSA+MPS, TAC-PR+MMF,
BAS+ SRL+MMF, TAC+ SRL, CSA+ EVL and BAS+ BEL+MMF are not visible in this figure).
Tables 206 and 207, respectively, indicate the ranges of n for which induction and maintenance agents are
cost-effective (i.e. give the greatest net health benefit in each comparison).
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FIGURE 88 Rankograms of net health benefit at £20,000 per QALY for each regimen. (a) CSA+MMF (5.8);
(b) TAC+MMF (3.2); (c) proportion of simulations in PSA; (c) CSA+AZA (9.2); (d) TAC+AZA (4.8); (e) CSA+ EVL
(15.0); (f) TAC+ SRL (14.0); (g) TAC-PR+MMF (10.7); (h) BAS+CSA+MMF (3.3); (i) BAS+ TAC+MMF (1.5);
(j) BAS+CSA+AZA (6.1); (k) BAS+ SRL+MMF (12.2); (l) BAS+BEL+MMF (16.0); (m) BAS+CSA+MPS (10.5);
(n) rATG+CSA+MMF (7.9); (o) rATG+ TAC+MMF (5.5); and (p) rATG+CSA+AZA (10.2).
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FIGURE 90 Net health benefit of regimens as duration of surrogate effect on graft survival is varied (close-up).
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FIGURE 89 Net health benefit of regimens as duration of surrogate effect on graft survival is varied.
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TABLE 206 Range of n for which each induction agent is cost-effective
Induction agent
Range of n for which induction agent is cost-effective
£20,000/QALY £30,000/QALY
With CSA +AZA
No induction NA NA
BAS 1–20 1–20
rATG NA NA
With CSA +MMF
No induction 1–2 1
BAS 3–20 2–20
rATG NA NA
With TAC +MMF
No induction 1–3 1–2
BAS 4–20 3–20
rATG NA NA
NA, not applicable.
TABLE 207 Range of n for which each maintenance agent is cost-effective
Maintenance agent
Range of n for which maintenance agent is cost-effective
£20,000/QALY £30,000/QALY
With MMF
TAC-PR NA NA
TAC 5–20 8–20
CSA 1–4 1–7
With AZA
CSA 1–4 1–5
TAC 5–20 6–20
With BAS +MMF
SRL NA NA
TAC 6–20 9–20
CSA 1–5 1–8
BEL NA NA
With rATG +MMF
TAC 5–20 8–20
CSA 1–4 1–7
With CSA
AZA NA NA
MMF 1–20 1–20
EVL NA NA
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Table 207 indicates that TAC-PR, SRL, BEL, EVL and MPS were not cost-effective at £20,000 or £30,000
per QALY for any n from 1 to 20. MMF was cost-effective at £20,000 and £30,000 per QALY for all n
from 1 to 20. For lower values of n (up to 4–8), CSA was cost-effective at £20,000 or £30,000 per QALY,
whereas for higher values (towards the base case), TAC was cost-effective at £20,000 and £30,000
per QALY.
As can be seen in Figure 90, once n is ≥ 6, BAS+ TAC+MMF gives the greatest net health benefit. When
n is < 6, BAS+CSA+MMF, CSA+MMF, BAS+CSA+AZA, CSA+AZA and TAC+MMF give greater net
health benefit than BAS+ TAC+MMF for some n, although only BAS+CSA+MMF or CSA+MMF gives
the greatest net health benefit for n< 6. Base-case graft survival curves for CSA+MMF, BAS+CSA+MMF
and BAS+ TAC+MMF are shown in Figures 91 and 92.
TABLE 207 Range of n for which each maintenance agent is cost-effective (continued )
Maintenance agent
Range of n for which maintenance agent is cost-effective
£20,000/QALY £30,000/QALY
With TAC
SRL NA NA
AZA NA NA
MMF 1–20 1–20
With BAS +CSA
AZA NA NA
MMF 1–20 1–20
MPS NA NA
With rATG +CSA
AZA NA NA
MMF 1–20 1–20
NA, not applicable.
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FIGURE 91 Death-censored graft survival for CSA+MMF, BAS+CSA+MMF and BAS+ TAC+MMF (base case).
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When n= 5, BAS+CSA+MMF gives the greatest net health benefit and the graft survival for CSA+MMF,
BAS+CSA+MMF and BAS+ TAC+MMF is shown in Figures 93 and 94. As expected, by reducing the
duration of the surrogate effect, the graft survival curves diverge significantly less than in the base case.
When n= 2, CSA+MMF gives the greatest net health benefit and the graft survival for CSA+MMF,
BAS+CSA+MMF and BAS+ TAC+MMF is shown in Figures 95 and 96. As there is now only 1 year of
graft survival difference extrapolated according to the surrogate relationship, the graft survival curves are
virtually identical. In this scenario CSA+MMF gives the greatest net health benefit but it is noteworthy
that the net health benefit of CSA+MMF is quite sensitive to n and, even in this scenario, only four
regimens are predicted to give greater net health benefit than BAS+ TAC+MMF: CSA+MMF,
TAC+MMF, BAS+CSA+MMF and BAS+CSA+AZA.
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FIGURE 92 Death-censored graft survival for CSA+MMF, BAS+CSA+MMF and BAS+ TAC+MMF (base case;
close-up 0–10 years).
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FIGURE 93 Death-censored graft survival for CSA+MMF, BAS+CSA+MMF and BAS+ TAC+MMF (n= 5).
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FIGURE 94 Death-censored graft survival for CSA+MMF, BAS+CSA+MMF and BAS+ TAC+MMF (n= 5; close-up
0–10 years).
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FIGURE 95 Death-censored graft survival for CSA+MMF, BAS+CSA+MMF and BAS+ TAC+MMF (n= 2).
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Different gamma parameter for calcineurin inhibitor-free regimens
It may be plausible that avoiding CNIs will prolong long-term graft survival by avoiding CNI nephrotoxicity.
This possibility was investigated by reducing the gamma (γ) parameter in the Weibull model for graft
survival (death censored) for regimens without CNI, that is, for BAS+ SRL+MMF and BAS+ BEL+MMF.
An offset was included for ln(γ) of between −2 and 0 (equivalent to the base case). The INHB for
BAS+ SRL+MMF and BAS+ BEL+MMF compared with BAS+ TAC+MMF was calculated (as TAC was
predicted to be the only cost-effective agent in combination with BAS+MMF at cost-effectiveness
thresholds of between £20,000 and £30,000 per QALY). The INHB was calculated at both £20,000 and
£30,000 per QALY. As shown in Figures 97 and 98, there is a crossover for SRL but not for BEL across the
range explored, suggesting that SRL could be cost-effective at £20,000–30,000 per QALY if long-term
graft survival were significantly better than extrapolated in the base case.
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FIGURE 96 Death-censored graft survival for CSA+MMF, BAS+CSA+MMF and BAS+ TAC+MMF (n= 2; close-up
0–10 years).
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FIGURE 97 Incremental net health benefit (at £20,000 per QALY) of SRL and BEL vs. TAC as gamma parameter of
graft survival is varied.
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Crossover at £20,000 per QALY occurs for SRL with a ln(γ) offset of −0.3582 (corresponding to γ= 0.773),
which leads to a reduction in total discounted costs from £114,549 to £99,859 and an increase in total
discounted QALYs from 10.9010 to 11.4607. Death-censored graft survival in this scenario is shown in
Figure 99. In this scenario, TAC and SRL are equally cost-effective at £20,000 per QALY but BEL is not
cost-effective.
Crossover at £30,000 per QALY occurs for SRL with a ln(γ) offset of −0.2767 (corresponding to γ= 0.838),
which leads to a reduction in total discounted costs of £102,065 and an increase in total discounted
QALYs to 11.3766. Death-censored graft survival in this scenario is shown in Figure 100. In this scenario,
TAC and SRL are equally cost-effective at £30,000 per QALY but BEL is not cost-effective.
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FIGURE 98 Incremental net health benefit (at £30,000 per QALY) of SRL and BEL vs. TAC as gamma parameter of
graft survival is varied.
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FIGURE 99 Death-censored graft survival when non-CNI gamma parameter for graft survival is 0.773 for SRL and
BEL vs. 1.105 for TAC.
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Cost-related scenario analyses
List prices for drug acquisition costs
A scenario analysis was conducted in which the drug acquisition costs (for immunosuppression, NODAT
and dyslipidaemia) were taken from list prices (BNF 6856) rather than the CMU eMit database.
Unit costs for CSA, TAC, AZA and MMF increased, which, as expected, increased the total costs for all
regimens (as there were no regimens not including at least one of CSA, TAC, AZA and MMF).
The cost-effectiveness results for induction agents were only marginally affected (Table 208). No induction
and rATG continued to be dominated by BAS.
The cost-effectiveness results for maintenance agents showed some marked differences from the reference
case analysis (Table 209). In general, the INHB (at £20,000 per QALY) of TAC compared with CSA decreased,
in some cases causing it to become negative. Likewise, in general, the INHB of MMF compared with AZA
decreased, in some cases causing it to become negative. The cost-effectiveness of TAC-PR, SRL, EVL and MPS
improved marginally but still none was predicted to be cost-effective in the range of £20,000–30,000 per
QALY. The cost-effectiveness of BEL was virtually unchanged, with an ICER of > £400,000 per QALY.
With a cost-effectiveness threshold in the range of £20,000–30,000 per QALY, the following changes
were observed in cost-effectiveness:
l CSA, instead of TAC, was cost-effective in combination with MMF, BAS+MMF and rATG+MMF
(TAC remained cost-effective in combination with AZA)
l AZA, instead of MMF, was cost-effective in combination with TAC (MMF remained cost-effective in
combination with CSA, BAS+CSA and rATG+CSA).
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
0 5 10 15 20 25 30 35 40 45 50
Time since transplantation (years)
BAS + TAC + MMF
BAS + SRL + MMF
BAS + BEL + MMF
G
ra
ft
 s
u
rv
iv
al
 (
ce
n
so
re
d
 f
o
r 
D
W
FG
)
FIGURE 100 Death-censored graft survival when non-CNI gamma parameter for graft survival is 0.838 for SRL and
BEL vs. 1.105 for TAC.
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TABLE 208 Impact on cost-effectiveness of induction agents of using list prices for drug acquisition costs
Induction
agent
Discounted costs (£) Discounted QALYs
ICER (cost
per QALY, £)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With CSA +AZA
vs. BAS
No induction 104,711 – 10.7711 – Dominated –0.3077 –0.2491
rATG 107,627 +2916 10.8182 +0.0471 Dominated –0.4064 –0.2992
BAS 101,194 –6433 10.9029 +0.0848 – – –
With CSA +MMF
vs. BAS
No induction 103,302 – 10.9145 – Dominated –0.2218 –0.1846
rATG 107,807 +4504 10.9281 +0.0135 Dominated –0.4335 –0.3212
BAS 101,069 –6738 11.0247 +0.0966 – – –
With TAC +MMF
vs. BAS
No induction 104,443 – 10.8884 – Dominated –0.1815 –0.1542
rATG 109,376 +4933 10.9047 +0.0163 Dominated –0.4119 –0.3023
BAS 102,803 –6573 10.9880 +0.0832 – – –
TABLE 209 Impact on cost-effectiveness of maintenance agents of using list prices for drug acquisition costs
Maintenance
agent
Discounted costs (£) Discounted QALYs
ICER (cost
per QALY, £)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With MMF
vs. CSA
TAC-PR 111,581 – 10.7920 – Dominated –0.5365 –0.3985
TAC 104,443 –7139 10.8884 +0.0964 Dominated –0.0831 –0.0641
CSA 103,302 –1140 10.9145 +0.0261 – – –
With AZA
vs. TAC
CSA 104,711 – 10.7711 – Dominated –0.1744 –0.1491
TAC 103,195 –1515 10.8696 +0.0986 – – –
With BAS +MMF
vs. CSA
SRL 119,577 – 10.9010 – Dominated –1.0491 –0.7406
TAC 102,803 –16,773 10.9880 +0.0869 Dominated –0.1235 –0.0946
CSA 101,069 –1734 11.0247 +0.0367 – – –
BEL 215,325 +114,256 11.2941 +0.2694 424,137 –5.4434 –3.5391
continued
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Threshold analysis on costs associated with BEL
A two-way threshold analysis was conducted on the two costs associated with BEL: drug administration
and drug acquisition. It was found that the total discounted costs for BAS+ BEL+MMF were exactly
linearly dependent on both costs according to the following formula:
Cost(BAS + BEL +MMF) = 72, 453:47 + 311:3796 × cost(vial) + 158:5936 × cost(BEL admin). (7)
This formula was used to calculate the ICER of BAS+ BEL+MMF compared with BAS+ TAC+MMF.
ICER isolines (lines of constant ICER) are straight lines in the two-dimensional plot of the costs of i.v.
administration and BEL vials, as shown in Figure 101.
The threshold analysis indicated that if the administration cost in the base case is assumed to be correct,
BAS+ BEL+MMF is not predicted to be cost-effective at £20,000–30,000 per QALY, even at zero
acquisition cost. As the acquisition and administration costs are both NHS costs, and are intrinsically related
to treating the condition of interest with BEL, both of these costs should be included in the reference-case
analysis. The administration cost associated with BEL is a genuine incremental cost associated with BEL and
not with other available treatments.426 Even if administration costs are excluded for BEL, BAS+ BEL+MMF
is not predicted to be cost-effective at £20,000–30,000 per QALY, based on the current list price for drug
acquisition. Bristol-Myers Squibb argues for a cost of administration for BEL of £153.57. At this cost of
administration, BAS+ BEL+MMF is still not predicted to be cost-effective at £20,000 per QALY, even at
zero acquisition cost.
TABLE 209 Impact on cost-effectiveness of maintenance agents of using list prices for drug
acquisition costs (continued )
Maintenance
agent
Discounted costs (£) Discounted QALYs
ICER (cost
per QALY, £)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With CSA
vs. MMF
AZA 104,711 – 10.7711 – Dominated –0.2139 –0.1904
MMF 103,302 –1408 10.9145 +0.1435 – – –
EVL 178,788 +75,486 10.9659 +0.0514 1,469,322 –3.7229 –2.4648
With TAC
vs. AZA
SRL 134,088 – 10.6023 – Dominated –1.8120 –1.2971
AZA 103,195 –30,893 10.8696 +0.2674 – – –
MMF 104,443 +1247 10.8884 +0.0188 66,470 –0.0436 –0.0228
With BAS +CSA
vs. MMF
AZA 101,194 – 10.9029 – Dominated –0.1280 –0.1260
MMF 101,069 –125 11.0247 +0.1218 – – –
MPS 114,174 +13,105 11.1377 +0.1130 115,991 –0.5423 –0.3239
With rATG +CSA
vs. AZA
AZA 107,627 – 10.8182 – – – –
MMF 107,807 +180 10.9281 +0.1099 1633 0.1009 0.1039
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Comparison of Peninsula Technology Assessment Group’s model-based
results with those in company submissions
Below, we compare the main deterministic analyses from three of the company submissions with those
produced by the independent Assessment Group (PenTAG). These have been selected to include the main
maintenance treatments produced and evaluated by the three companies that provided model-based
cost-effectiveness studies: TAC-PR compared with immediate-release TAC (Astellas), EVL (Novartis), EC-MPS
(Novartis) and BEL (Bristol-Myers Squibb). Although some of the PenTAG analyses contained a larger set
of comparator treatments, they are generally comparable, especially after dominated comparators are
excluded from the PenTAG analyses.
Overall, for comparisons with the above treatments and equivalent concomitant drugs, the PenTAG model
led to lower estimations of discounted incremental costs (between 25% and 40% lower) than the
company’s analyses. This largely reflects the lower estimates of incremental graft survival that resulted from
our systematic review and NMA. And all of the models utilised different assumptions to extrapolate from
short-term trial outcomes to the long term (25–50 years, depending on the model).
For reference, three larger tables at the end of this section (see Tables 214–216) compare the main cost
parameters, effectiveness parameters, and main cost and effectiveness results for the three companies’
models and the PenTAG model. These show, for example, that the PenTAG model assumptions tended to
include fuller costing of the administration of the maintenance therapies, and more realistic (NHS reference
cost) relatively lower annual costs of dialysis (except Novartis, which used similar costs for dialysis).
In addition, although applied differently in the models, the approximate utility difference between living
with a functioning graft and living on dialysis was greater in the three companies’ analyses (typical
difference of between ≈ 0.25 to ≈ 0.3) than in the PenTAG model (≈ 0.2 difference). Overall, these
particular differences in the companies’ models will tend to magnify the impact on QALYs of any
incremental effectiveness differences that affect long-term graft survival, and also reduce their associated
incremental cost.
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FIGURE 101 Threshold analysis on costs associated with BEL.
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Peninsula Technology Assessment Group’s and Astellas’ analysis of
immediate-release TAC compared with TAC-PR
Table 210 shows the company’s and the assessment group’s analysis of the cost-effectiveness of
prolonged-release compared with immediate-release TAC. The Astellas analysis estimates TAC-PR to be
both cheaper and more effective than immediate-release TAC (i.e. prolonged-release ‘dominates’
immediate-release TAC). This is the opposite result to the PenTAG analysis.
This opposite result in incremental QALYs mostly arises because of the different trial data used within the
two models and the fact that long-term outcomes in the Astellas model are driven entirely by rates of AR.
For informing the effectiveness parameters of the drugs on BPAR, mortality, graft loss and renal function,
the PenTAG analysis uses meta-analysis of two direct head-to-head trials of the two comparators.141,204
All of the pooled ORs are not statistically significant and all, except the comparison for BPAR, favour
the immediate-release TAC. In contrast, the Astellas review reports using three trials123,204,239 and one
meta-analysis and concludes that the two types of TAC are of ‘similar efficacy and safety’. In their model,
however, these data sources are then used to justify immediate-release TAC having a 2 percentage-point
higher rate of AR than TAC-PR, which then drives differences in long-term graft survival (and costs).
In its modelling it also factors in greater adherence to treatment with TAC-PR, which departs from the
ITT analysis of the trials.
Peninsula Technology Assessment Group’s and Novartis’ analysis of EVL and
of EC-MPS
Table 211 shows the company’s and the assessment group’s analysis of the cost-effectiveness of EVL and
relevant comparators. Novartis conducted two analyses, with different comparators and doses of CSA, and
estimated that EVL either dominates TAC or, when compared with MMF, has an ICER of £59,696 per
QALY. The PenTAG analysis (comparison with MMF shown) produces an ICER of > £1.7M per QALY. As
AZA is dominated in the PenTAG analysis, and omitted from the Novartis analysis, both of these ICERs are
relative to the next most effective and cheaper treatment – MMF.
There is a modest difference in the incremental costs between the two analyses, with the Novartis analysis
estimating the incremental cost of EVL over MMF to be 25% lower than the PenTAG analysis (£59,354 vs.
£78,631). However, most of the difference in the ICER is explained by the Novartis analysis estimating a
20-fold higher incremental QALYs between the two treatments (1 QALY vs. 0.045 QALYs in the
PenTAG analysis).
This large difference in incremental QALYs will be the combined result of a large number of differences
in the parameter values and structural assumptions within each of the models, which led to differences in
TABLE 210 Peninsula Technology Assessment Group’s and Astellas’ analyses compared
Maintenance agent
Discounted costs (£) Discounted QALYs
ICER (£)Total Incremental Total Incremental
PenTAG (assessment group)
TAC-PR (+MMF) 111,499 – 10.6172 – Dominated
TAC (+MMF) 92,827 –18,672 10.8595 +0.2423 –
CSA (+MMF) 98,157 +5330 10.8925 +0.0330 161,408
Astellas
TAC-PR 118,907 –11,211 8.2100 +0.2000 –
TAC 130,118 – 8.0100 – Dominated
CSA Missing from Astellas’ comparators
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incremental graft survival and incremental life-years. The undiscounted incremental time lived with a
functioning graft between EVL and MMF is 0.32 years from the PenTAG analysis and 5.17 years from the
Novartis analysis. Correspondingly, the incremental overall survival (life-years) is 0.09 years from the
PenTAG analysis but 1.76 years from the Novartis analysis. These differences in incremental graft and
overall survival are, in turn, likely to be mainly caused by the use by Novartis of rates of acute and chronic
rejection from single arms of different individual trials (Tedesco-Silva et al.107 for EVL, Vítko et al.150 for
chronic rejection) compared with less clear evidence of such large effect differences for AR or graft survival
from the PenTAG MTC).
Table 212 shows the Novartis and the PenTAG’s analysis of the cost-effectiveness of MPS and relevant
comparators. Although the Novartis analysis estimates at a favourable ICER for its own product, of
£13,235 per QALY, our analysis produces an ICER of £145,072 per QALY. As, again, AZA is dominated in
the PenTAG analysis, and omitted from the Novartis analysis, both of these ICERs are relative to the next
most effective and cheaper treatment – MMF.
TABLE 211 Peninsula Technology Assessment Group’s and Novartis’ analyses of EVL compared
Agent
Discounted costs (£) Discounted QALYs
ICERTotal Incremental Total Incremental
PenTAG
AZA 102,320 – 10.7486 – Dominated
MMF 98,157 –4163 10.8925 +0.1439 –
EVL 176,788 +78,631 10.9376 +0.0451 1,743,739
Novartis
AZA Missing from Novartis’ comparators
MMF 76,826 7.8900
EVL 136,180 +59,354 8.8900 +1.0000 59,354
Both of these analyses are of these drugs in a regimen with CSA and CCSs.
TABLE 212 Peninsula Technology Assessment Group’s and Novartis’ analyses of MPS compared
Agent
Discounted costs (£) Discounted QALYs
ICER (£)Total Incremental Total Incremental
PenTAG
AZA 98,667 – 10.9029 – Dominated
MMF 95,654 –3013 11.0247 +0.1218 –
MPS 112,045 +16,391 11.1377 +0.1130 145,072
Novartis
AZA Missing from Novartis’ comparators
MMF 76,771 – 7.89 – –
MPS 87,359 +10,588 8.69 +0.8000 13,235
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There is a modest difference in the incremental costs between the two analyses, with the Novartis analysis
estimating the incremental cost of MPS over MMF to be 35% lower than the PenTAG analysis (£10,588 vs.
£16,391). However, most of the difference in the ICER is explained by the Novartis analysis estimating a
sevenfold higher incremental QALYs between the two treatments (0.80 vs. 0.113 QALYs).
This large difference in incremental QALYs will be the combined result of a large number of differences
in the parameter values and structural assumptions within each of the models, which led to differences in
incremental graft survival and incremental life-years. The undiscounted incremental time lived with a
functioning graft between MPS and MMF is 0.4 years from the PenTAG analysis and 4.66 years from the
Novartis analysis. Similarly, the incremental overall survival (life-years) is 0.24 years from the PenTAG
analysis but 4.66 years from the Novartis analysis.
For informing the effectiveness of the drugs on BPAR, mortality, graft loss and renal function, the PenTAG
analysis uses meta-analysis of direct head-to-head trials of the two comparators.106,107,150,270
Peninsula Technology Assessment’s and Bristol-Myers Squibb’s analysis of BEL
Table 213 shows the companies’ and the assessment group’s analysis of the cost-effectiveness of BEL and
relevant comparators. Although the Bristol-Myers Squibb analysis estimates an ICER for BEL, of £95,068 per
QALY (compared with TAC), our analysis produces an ICER of £519,094 per QALY (compared with CSA).
There is a large absolute difference in the incremental costs between the two analyses, with the Bristol-Myers
Squibb analysis estimating the incremental cost of BEL to be £47,620 (34%) lower than the PenTAG analysis
(£92,216 vs. £139,836). This will be owing, in part, to the PenTAG model using costs for the i.v. administration
of BEL approximately twice those of the Bristol-Myers Squibb analysis, and the Bristol-Myers Squibb model
using an unusually high annual cost for dialysis (£43,586 – about £19,000 more than the NHS reference cost).
However, most of the difference in the ICER is explained by the Bristol-Myers Squibb analysis estimating a
nearly fourfold higher incremental QALYs between the relevant treatments (0.97 vs. 0.269 QALYs).
TABLE 213 Comparison of PenTAG’s and Bristol-Myers Squibb’s analyses of BEL
Agent
Discounted costs (£) Discounted QALYs
ICER (£)Total Incremental Total Incremental
PenTAG
SRL 114,554 – 10.9010 – Dominated
TAC 90,794 –23,760 10.9880 +0.0869 –
CSA 95,654 +4860 11.0247 +0.0367 132,272
BEL 235,490 +139,836 11.2941 +0.2694 519,094
Bristol-Myers Squibb
TAC 205,502 +1215 6.53 0.36 3375
CSA 204,287 – 6.17
BEL 296,503 +92,216 7.14 0.97 95,068
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This difference in incremental QALYs will be the combined result of a large number of differences in the
parameter values and structural assumptions within each of the models, which led to differences in
incremental graft survival and incremental life-years. The undiscounted incremental time lived with a
functioning graft between BEL and TAC/CSA is 0.95 years from the PenTAG analysis and 1.51 years from
the Bristol-Myers Squibb analysis. Similarly, the incremental overall survival (life-years) is 0.57 years
from the PenTAG analysis and 1.51 years from the Bristol-Myers Squibb analysis. These differences in
incremental graft and overall survival are, in turn, likely to be a result of the Bristol-Myers Squibb analysis
relying on a much longer assumed time between graft failure and retransplantation [16.5 years vs. 5 years
time to retransplantation (or death in the PenTAG analysis)], assumed linear changes in GFR within the
functioning graft state determining long-term outcomes and long-term transition probabilities being based
on US cohort data (not UK registry data, as in the PenTAG analysis).
The following three tables (Tables 214–216) compare the main cost parameters, effectiveness parameters,
and main cost and effectiveness results for the three companies’ models and the PenTAG model.
TABLE 214 Major cost (£) elements in the different analyses
Cost parameter Astellasa Bristol-Myers Squibbb,c Novartisa,c PenTAG
TAC therapy
(per year)
4255d 3937 (first year)
2821 (second year+)e
5283 With AZA
1816 (first year)
1196 (second and third year)
1063 (fourth year+)
With MMF
1378 (first year)
1063 (second year+)
TAC administration 0 386 (first year),
89 (second year)e
0 1114 (first year)
374 (second year)
107 (third year+)
MMF therapy
(per year)
2402f 0g 282h With TAC
249 (first year)
202 (second year+)
With CSA
259 (first year)
230 (second year+)
With SRL
248 (first year)
202 (second year+)
With BEL
276
continued
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TABLE 214 Major cost (£) elements in the different analyses (continued )
Cost parameter Astellasa Bristol-Myers Squibbb,c Novartisa,c PenTAG
CSA therapy NAi 1971 (first year)
1562 (second year+)e
839 (first year),
694 (second year+)
With AZA
1649 (first year)
1233 (second and third year)
1195 (fourth year+)
With MMF/MPS
1374 (first year)
1187 (second year+)
CSA administration 0 386 (first year),
90 (second year)e
0 1114 (first year)
374 (second year)
107 (third year+)
BEL (per year) 10,966 (first year)
6480 (second year+)
13,472 (first year)
9217 (second year+)
NA 12,812 (first year)
8849 (second year+)
BEL administration 0 2457 (first year)
1996 (second year+)
NA 4728 (first year)
4246 (second year+)
CCSs 178 0
g
285 20
AR (event) 1738 3483 1725 3557
Dialysis (per year) 38,387j 43,586k 22,877l 24,372 (HD)
24,000 (PD)
24,314 (mix, age 45–54 years)
Retransplantation 25,953 25,908 17,736 16,030 (procedure)
1226 (work-up)
Retransplantation:
organ procurement
0 12,954 0 8914 (live donor)
10,142 (deceased donor)
NA, not applicable.
a Adopted a 70-kg weight for representative patient in the model. The cost of BAS induction (20mg within 2 hours before
transplantation and at 4 days post transplant, BNF 2014 prices, £1685) was included in all arms.
b Adopted a 75-kg weight for representative patient in the model.
c Induction costs were not accounted for in the model but their omission might have had negligible effects, as it would
affect only ICER through the small differences in the proportion of retransplants between arms.
d Prograf.
e The Bristol-Myers Squibb submission reports a cost (of drug acquisition or drug administration) for the second year that
is different from the cost for the third and subsequent years, but the model spreadsheet adopts the price given for the
third year in the submission as the price of the second and subsequent years. The figure presented here is the one
adopted by the model.
f Based on 1 g daily, starting within 72 hours of transplantation, valued at £82.26 price for 500-mg, 30-capsule pack from
BNF 2014.
g Bristol-Myers Squibb’s model did not include costs of concomitant medications in the triple-therapy regimen for any
treatment arm.
h Based on 1 g daily starting within 72 hours of transplantation, valued at £9.65 price for 500-mg, 50-tablet pack from
CMU eMit 2014.
i Astellas does not evaluate CSA in their submission. However, the model speadsheets include information where the
annual costs of CSA are calculated based on market shares to be £3731 for the first year and £3514 for subsequent years.
j From Beaudet et al.371
k From Baboolal et al.372
l From supporting evidence of NICE guidance CG135 (NICE 2011373).
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TABLE 215 Key effectiveness assumptions and outcomes in economic models compared
Effectiveness
parameter Astellasa
Bristol-Myers
Squibbb Novartisc Assessment group (PenTAG)
Time to graft failure
(median) (years)
Without BPAR at
12 months: 23
With BPAR at
12 months: > 25c
Initial GFR2: 15.0
Initial GFR3a: 11.5
Initial GFR3b: 7.0
Initial GFR4: 2.5
EVL: 15.8
MPS: 21.3
MMF+CSA: 7.2
TAC +CSA: 8.3
(To nearest 0.25)
CSA+MMF: 13.75 years
TAC+MMF: 14.75 years
CSA+AZA: 12.75 years
TAC+AZA: 14.50 years
CSA+ EVL: 14.50 years
TAC+ SRL: 12.75 years
TAC-PR+MMF: 13.25 years
BAS+CSA+MMF: 14.75 years
BAS+ TAC+MMF: 15.50 years
BAS+CSA+AZA: 13.75 years
BAS+ SRL+MMF: 14.75 years
BAS+ BEL+MMF: 16.50 years
BAS+CSA+MPS: 15.50 years
rATG+CSA+MMF: 14.75 years
rATG+ TAC+MMF: 15.50 years
rATG+CSA+AZA: 13.75 years
Time to transplantation
from graft failure (mean
unless otherwise stated)
(years)
3.5 (median) 16.5d 3 (SD 1) Mean time to transplantation or
death following failure of initial
graft
4.97 (range 4.87–5.06)
Annual change in GFR NA –3 (fourth+) –1.66 (second),
–2.68 (third+)
NA
Utility of functioning
graft: first transplant
0.71 0.49–0.64
(depending on
GFR stage)
0.49–0.64
(depending on
GFR stage)
0.815 (age 50 years)
0.786 (age 60 years)
0.755 (age 70 years)
0.723 (age 80 years)
Utility of functioning
graft: second+
transplants
0.71 0.59 0.49–0.64
(depending on
GFR stage)
As first
continued
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TABLE 215 Key effectiveness assumptions and outcomes in economic models compared (continued )
Effectiveness
parameter Astellasa
Bristol-Myers
Squibbb Novartisc Assessment group (PenTAG)
Utility of dialysis state 0.459 0.28 0.28 HD:
l 0.591 (age 50 years)
l 0.562 (age 60 years)
l 0.531 (age 70 years)
l 0.499 (age 80 years)
PD:
l 0.604 (age 50 years)
l 0.575 (age 60 years)
l 0.544 (age 70 years)
l 0.562 (age 80 years)
NA, not applicable.
a Model was driven by surrogate marker of AR.
b Models driven by GFR change over time.
c Modelled time horizon was 25 years, by which point 53.9% of those with BPAR in the first 12 months still had their
initial graft functioning.
d This value was derived by the company from an exponential survival model (Levy et al.334) with predicted hazard rate for
a person of average age 40.3 years (Bristol-Myers Squibb’s submission model Excel file). The model had been estimated
on USRDS data for a sample of Medicare-covered KTRs (no information on sample characteristics were provided),
which means that the model predictions are likely to be out of the age range of the sample on which the model
was estimated.
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Chapter 7 Discussion
Statement of principal findings
Aim
The remit for this report was to review and update the evidence used to inform the current NICE guidance
(TA85) on the clinical effectiveness and cost-effectiveness of immunosuppressive therapies in adult renal
transplantation. The current guidance is Woodroffe et al.65 We have incorporated relevant evidence
presented in this previous report and reported new evidence from 2002 to the present. This includes a
new decision-analytic model of kidney transplantation outcomes to investigate which regimen is the most
cost-effective option.
Clinical effectiveness systematic review
Previous technology assessment for the National Institute for Health and
Care Excellence
The previous assessment (TA85) in 200243 found that BAS, TAC and MMF consistently reduced the
incidence of short-term (1-year) AR compared with conventional immunosuppressive therapy (e.g. dual- or
triple-combination therapy for induction and/or maintenance including CSA, AZA and CCSs). The
independent use of BAS, TAC and MMF was associated with a similar absolute reduction in 1-year ARR
(approximately 15%). However, the effects of these drugs did not appear to be additive (e.g. benefit of
TAC with adjuvant MMF was a 5% reduction in ARR, compared with a 15% reduction with adjuvant
AZA). Thus, the addition of one of these drugs to a baseline immunosuppressant regimen was likely to
affect adversely the incremental cost-effectiveness of the addition of another.
Important gaps in the evidence were identified concerning the impact of the newer immunosuppressants
on long-term graft loss and patient survival. The absence of both long-term outcome and quality of life
from trial data makes assessment of the clinical effectiveness and cost-effectiveness on the newer
immunosuppressants contingent on modelling based on extrapolations from short-term trial outcomes.
Updated systematic review
In total, 67 new RCTs49,51,58,59,74,87,91–135,137–152 were included in the clinical effectiveness review presented in
this report, with an additional 19 RCTs71–73,75–86,88–90,136 meeting our inclusion criteria from the
previous assessment.
For the head-to-head comparisons of induction therapies, from 0.5 years to 10 years post transplant, we
found no evidence to suggest that BAS or rATG is more effective than PBO, no induction or each other in
reducing the odds of mortality (overall survival). Similarly, for graft loss, we found no evidence of
a statistically significant difference for BAS or rATG versus PBO, no induction or each other.
We found evidence to suggest that rATG and BAS are more effective than PBO or no induction at
reducing BPAR (rATG at 1 year, OR 0.34, 95% CI 0.22 to 0.52, I2= 8.9%; BAS at 1 year, OR 0.53, 95% CI
0.40 to 0.70, I2= 0.0%). A statistically significant difference was found for the severity of BPAR, comparing
BAS versus rATG, whereas BAS was associated with lower odds of Banff III classification, the most severe
classification of AR (1 year, OR 0.04, 95% CI 0.00 to 0.65).
We found no evidence that any maintenance therapies were preferable to others in terms of mortality.
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For graft loss outcomes reported by maintenance studies, we found evidence that at 5 years BEL+MMF
may be superior to CSA+MMF (OR 0.40, 95% CI 0.19 to 0.87; I2= 0.0%). At 0.5 years, the odds
of reduced graft loss are greater for CSA+MMF than for CSA+AZA (OR 0.58, 95% CI 0.04 to
0.59; I2= 72.2%).
Several treatments showed a beneficial effect with regard to reducing BPAR, although this varied across
time points. For all the following comparisons, the arm containing TAC displayed lower odds of BPAR:
l TAC+AZA versus CSA+AZA (0.5 years, OR 0.50, 95% CI 0.32 to 0.79, I2= 50.1%; 1 year, OR 0.50,
95% CI 0.39 to 0.64, I2= 8.1%; 4 years, OR 0.38, 95% CI 0.25 to 0.57)
l TAC+MMF vs. CSA+AZA (0.5 years, OR 0.64, 95% CI 0.41 to 0.98; 1 year, OR 0.35, 95% CI 0.15
to 0.82)
l TAC+MMF vs. CSA+MMF (1 year, OR 0.59, 95% CI 0.37 to 0.94, I2= 19.3%)
l TAC+MMF vs. SRL+MMF (1 year, OR 0.32, 95% CI 0.12 to 0.87, I2= 0.0%)
l TAC+ SRL vs. TAC+MMF (0.5 years, OR 0.65, 95% CI 0.44 to 0.96).
For CSA+MMF versus CSA+AZA, at 0.5 years and 1 year, there is statistically significant evidence to
suggest that MMF is more effective (0.5 years, OR 0.50, 95% CI 0.35 to 0.72, I2= 35.1%).
Tacrolimus is also associated with lower odds of reduced GRF for the following regimens:
l TAC+MMF versus CSA+MMF (at 3 years, eGFR WMD 4.60ml/minute/1.73m2, 95% CI 1.35ml/
minute/1.73m2 to 7.85ml/minute/1.73m2)
l TAC+MMF versus TAC-PR+MMF (at 0.5 years, eGFR WMD 1.90ml/minute/1.73 m2, 95% CI
1.70 to 2.10ml/minute/1.73 m2)
l TAC+ SRL versus CSA+ SRL (at 0.5 years, eGFR MD 6.35ml/minute/1.73m2, p< 0.0001; 1 year MD
5.25ml/minute/1.73 m2, p= 0.0004).
For MMF+ TAC versus MPS+ TAC, MPS at 1 year and 3 years is more effective (1 year, MD 1.9ml/minute/
1.73m2, p< 0.0001; 3 years, eGFR MD 0.5ml/minute/1.73m2, p= 0.0016). BEL appears more effective at
1 year and 3 years for BEL+MMF vs. CSA+MMF (1 year, eGFR WMD 7.83ml/minute/1.73 m2, 95% CI
1.57 to 14.10ml/minute/1.73 m2, I2= 73.6%; 3 years, WMD 16.08ml/minute/1.73m2, 95% CI 5.59 to
26.56ml/minute/1.73 m2, I2= 89.5%); however, heterogeneity across studies is substantial. Where there are
two comparisons involving SRL and CSA, the regimen including MMF suggests CSA to be more beneficial
up to 5 years (5 years, eGFR WMD 9.10ml/minute/1.73 m2, 95% CI 1.68 to 16.52ml/minute/1.73 m2), yet,
in contrast, the regimen including AZA suggests SRL to be more effective (1 year, eGFR MD 10.8ml/minute/
1.73m2, p< 0.0001).
Time to BPAR is generally poorly reported and therefore it is challenging to form a conclusion. Again,
TAC+AZA versus CSA+AZA shows conflicting results for two studies; however, the statistically significant
result in one of the two studies suggests that BPAR is achieved more quickly for participants receiving
TAC rather than CSA (MD 24 days, p= 0.0033). This is also true for TAC+MMF versus CSA+MMF
(MD 46.7 days, p< 0.0001). When SRL+ TAC and MMF+ TAC are compared, a reduced time to BPAR is
seen for MMF (MD 48.6 days, p= 0.0017). For SRL+MMF compared with CSA+MMF, one of three
studies demonstrates a statistically significant difference in favour of CSA (MD 38 days, p= 0.0035);
however, the other two studies show no difference.
Regarding BPAR severity, for TAC+AZA versus CSA+AZA, there are lower odds of the more severe BPAR
for the arm containing TAC, although there is substantial heterogeneity across studies (Banff III, OR 0.28,
95% CI 0.12 to 0.66). Similarly, for TAC+MMF compared with TAC-PR+MMF, TAC has a lower
proportion of people experiencing the more severe BPAR of Banff III classification (OR 0.11, 95% CI 0.01
to 0.87, I2= 0.0%).
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Following NMA for induction therapy, there is no evidence to suggest that BAS or rATG is more effective
than PBO/no induction or each other in reducing the odds of graft loss or mortality. rATG and BAS were
both estimated to be more effective than PBO/no induction, with rATG being more effective than BAS
at reducing BPAR. There is evidence to suggest that BAS is more effective than PBO/no induction for
increasing GRF.
With regard to maintenance therapy, the NMA showed that none of the maintenance regimens performed
consistently well on all four outcomes and a great deal of heterogeneity was noted.
l No evidence was found to suggest that one treatment was any more effective at reducing the odds of
graft loss than any other treatment.
l There is evidence to suggest that BEL+MMF is more effective at reducing the odds of mortality than
TAC+MMF and SRL+MMF, but no other treatments are estimated to be any more effective at
reducing mortality than any other treatment.
l MMF+CSA, TAC+MMF and SRL+ TAC are estimated to be more effective than CSA+AZA and
EVL+MPS at reducing the odds of BPAR. In addition, TAC+AZA and EVL+CSA are estimated to be
more effective than CSA+AZA at reducing the odds of BPAR. However, apart from CSA+AZA and
EVL+MPS performing poorly in some comparisons, it is difficult to say that any one treatment is more
effective at reducing BPAR than another, as the 95% CIs are very wide.
l Similarly, a number of treatments (TAC+AZA, TAC+MMF and BEL+MMF) are estimated to be more
effective than CSA+AZA and MMF+CSA at increasing GRF. In addition, SRL+AZA is estimated to be
more effective than CSA+AZA at increasing GRF. However, as a result of the limited direct evidence
informing many of the comparisons and the 95% CIs being very wide, we can conclude only that
CSA+AZA and MMF+CSA are performing poorly in some comparisons.
Analysis of AEs revealed the following:
l Some evidence suggested that there were more CMV infections with rATG regimens than with BAS
regimens,212 and with rATG regimens than with no induction.96 The meta-analysis comparing TAC and
CSA regimens (including eight studies) suggested more cases of NODAT with TAC regimens compared
with CSA regimens.
l The meta-analyses comparing BEL with CSA regimens (including three studies) suggested more cases
of NODAT with CSA regimens than with BEL regimens (including three studies).
l The meta-analyses comparing SRL and CSA regimens (including seven studies) suggested more cases of
NODAT with CSA regimens than with SRL.
l The meta-analysis comparing MMF and EVL (including three studies) suggested more cases of CMV
infections in MMF regimens compared with EVL.
Overall, we found that, despite the volume of evidence, there is little impact on effectiveness conclusions
from the head-to-head comparisons, particularly for graft loss and mortality. However, this may be a
reflection of the lack of long-term data, because very few studies reported all outcomes beyond 1 year,
and also there was frequently a substantial level of heterogeneity across studies. The quality of trials was
variable and, owing to reporting omissions, it was difficult to make a general assessment regarding quality.
Furthermore, all results must be interpreted with caution as multiple testing increases chances of type 1
errors and no corrections for multiple tests were executed.
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Economic evaluations
Published economic evaluations
l There is limited evidence on costs and benefits of induction regimens, as studies are typically economic
evaluations conducted alongside single-centre RCTs of 1 year duration or less, involving small samples
and reporting insufficient data in order to evaluate their generalisability.
l Studies of initial and maintenance immunosuppression are all sponsored by the industry or conducted
by a person affiliated to them (except for the analysis by the Birmingham assessment group, which
reviewed the evidence on behalf of NICE during the previous appraisal on the topic).
l Studies of initial and maintenance immunosuppression typically use a biomarker as a surrogate to
extrapolate outcomes from RCTs of 1–3 years’ duration to the long term (i.e. 10–50 years after
initial transplantation).
l Since the previous NICE appraisal, the main development in economic evaluation modelling of
immunosuppressive regimens is the use of renal function as a surrogate outcome in addition to AR for
extrapolating trial efficacy outcomes to long-term graft and patient survival.
l In addition, new evidence has emerged that changes in renal function directly impact on current
HRQoL and costs and this is now recognised by the more recently published models.
l In the UK, however, only one study of initial and maintenance immunosuppression has accounted for
these methodological developments but it suffers from a lack of a systematic approach to evidence
synthesis on the efficacy of relevant UK treatments in routine use.
l Evidence from other countries is of questionable generalisability because of inadequate reporting of the
regimens being compared.
l A new study would fill a gap the evidence base required to inform NHS decision-making by adopting a
systematic approach to evidence synthesis on all relevant comparators, from an independent standpoint
and incorporating the latest methodological developments and evidence on the topic.
Company submissions
l Three companies developed models of initial and maintenance immunosuppression in adult patients
were submitted to NICE: Astellas, Novartis and Bristol-Myers Squibb.
l The analysis by Astellas compared TAC (Prograf) with SRL CNI avoidance, SRL CNI minimisation, BEL
and EVL. In addition, it presented a comparison of TAC once-daily extended release (Advagraf) and
twice-daily immediate release (Prograf formulations).
l The study found that Prograf is cost-effective against BEL and EVL, but it was not cost-effective relative
to the SRL regimens, against which it found ICERs of > £100,000 per QALY. In turn, Advagraf was
found to cost less and generate more QALYs than Prograf.
l The analysis by Astellas was found to be flawed owing to the structure and the implementation of the
model used to extrapolate short-term efficacy differences between the regimens compared; that is, the
model did not account for the effect of regimens on renal function, and the Markov model included
errors in the way the incidence of retransplantations was modelled.
l In addition, it is questionable whether or not the SRL regimens apply to the general kidney transplant
patient population modelled by Astellas.
l Novartis presented the results of pairwise comparisons between EVL (in combination with reduced dose
CSA and steroids) and TAC or CSA (each combined with MMF and steroids). In addition, it presented
an analysis of EC-MPS (combined with standard-dose CSA and steroids) versus CSA (with MMF and
steroids). Outcomes were modelled over a 50-year time horizon.
l Novartis found that EVL was cost-effective against TAC and CSA. However, when results accounted for
uncertainty in parameter estimates, EVL was borderline cost-effective (as evidenced by the ICER against
CSA being in the vicinity of £30,000 per QALY).
l The analysis of MPS found it not to be cost-effective relative to CSA.
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l The analyses by Novartis were likely to be biased because of the lack of a systematic approach to the
identification of evidence on efficacy, and also because of the assumptions built in the model used to
predict long-term graft and patient survival from short-term efficacy outcomes; the differences in
efficacy between the regimens compared were derived from indirect comparisons of outcomes in trial
arms from single studies. The model assumed that the rate of chronic rejection at 12 months post
transplant for each therapy applied throughout the modelled time horizon, independently of AR and
renal function outcomes.
l Bristol-Myers Squibb compared BEL with TAC and CSA, over a 40-year time horizon, using MTC to
estimate the efficacy of each regimen at 36 months. A model was then used to extrapolate from this
end point to 40 years.
l The analyses found that BEL was not cost-effective, and the company produced additional ‘subgroup
analyses’ by selecting a group of patients at high risk of short graft survival for which BEL may be more
economically attractive. Selecting patients in this way may be impractical in routine practice, as it is by
definition outcome dependent (unknown immediately after transplant). The company also performed
subgroup analysis based on patient weight; in patients with body weight of > 90 kg BEL was found to
be cost-effective.
l The analysis by Bristol-Myers Squibb was strengthened by the use of observational data on resource
utilisation data, which was analysed as a function of renal function.
l Although Bristol-Myers Squibb adopted the more advanced techniques to model long-term graft and
patient survival, including information on renal function and AR in a prognostic model, its analyses
were found to be biased because of the use of surrogate-based models of patient and graft survival
estimated from US data; these were found to differ from graft survival outcomes in the UK kidney
transplant patient population. There were other limitations that related to how the impact on HRQoL
and costs of changes in renal function were measured, as well as how the surrogate long-term
outcome model was used to derive the transition probabilities in the model.
l Owing to the listed limitations of the industry analyses, an independent de novo analysis is warranted,
which synthesises the evidence base on effectiveness outcomes and combines them with observational
routinely available data on long-term outcomes of UK kidney transplant patients with a decision
analysis model from the NHS and PSS perspective.
Peninsula Technology Assessment Group economic assessment
Previous appraisal
The previous appraisal (TA85)43 considered the cost-effectiveness of BAS, DAC, TAC (immediate release),
MMF and SRL. Briefly, the Appraisal Committee considered the following:
l BAS and TAC (immediate release) would probably be cost-effective (vs. no induction and CSA, respectively).
l MMF was unlikely to be cost-effective in the general setting (vs. AZA) but was likely to be cost-effective
in settings in which a reduction in CSA dose is required.
l SRL in combination with CCSs should be considered as an option when proven intolerance to CNIs
necessitates their complete withdrawal.
Update
In this update review we have a slightly different set of interventions under consideration because of the
removal of DAC and the addition of rATG as induction, TAC-PR, MPS, EVL and BEL.
We have constructed an independent economic model that incorporates current costs, evidence published
since the previous appraisal and an updated surrogate relationship that additionally takes into account GRF
following transplantation.
We present our principal findings for each intervention separately, summarising the findings from
deterministic and probabilistic analyses and relevant scenario analyses.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
381
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Induction agents
BAS
Basiliximab is predicted to be cost-effective at £20,000–30,000 per QALY in the deterministic analysis and
the probabilistic analysis. BAS was cost-effective at £20,000 per QALY in 77.2–85.6% of PSA iterations
across comparisons and at £30,000 per QALY in 72.7–80.6% of iterations.
When the duration of the surrogate effect on graft survival was reduced, BAS gradually became less
cost-effective. When in combination with CSA and AZA, BAS remained cost-effective compared with no
induction at £20,000 and £30,000 per QALY. When followed by CSA or immediate-release TAC and
MMF, BAS was no longer cost-effective at £20,000 per QALY when the duration of surrogate effect was
limited to 0 or 1 year, but was cost-effective at £30,000 per QALY unless the surrogate effect
was eliminated.
Adopting list prices for drug acquisition instead of average NHS acquisition costs (from the CMU eMit
database) did not materially affect the cost-effectiveness of BAS.
rATG
Rabbit ATG is not predicted to be cost-effective at £20,000–30,000 per QALY in the deterministic analysis
or the probabilistic analysis. rATG was cost-effective at £20,000 per QALY in 13.7–22.6% of PSA iterations
across comparisons and at £30,000 per QALY in 19.1–27.2% of iterations.
When the duration of surrogate effect on graft survival was varied from 0 to 19 years, at no point was
rATG cost-effective at £20,000–30,000 per QALY in any of the three comparisons.
Adopting list prices for drug acquisition instead of average NHS acquisition costs did not materially affect
the cost-effectiveness of rATG.
Summary for induction agents
Basiliximab is predicted to be cost-effective at £20,000–30,000 per QALY, whereas rATG is not.
Maintenance agents
Immediate-release TAC
Immediate-release TAC is predicted to be cost-effective at £20,000–30,000 per QALY in the deterministic
and PSAs across all comparisons. The probability of immediate-release TAC being cost-effective at £20,000
and £30,000 per QALY ranged from 81.8% to 94.6%.
When the duration of surrogate effect on graft survival was reduced either immediate-release TAC or CSA
was cost-effective at £20,000 or £30,000 per QALY. CSA was cost-effective when the surrogate effect was
shorter, whereas immediate-release TAC was cost-effective when the surrogate effect lasted longer.
Adopting list prices instead of average NHS acquisition costs resulted in immediate-release TAC no longer
being cost-effective at £20,000 or £30,000 per QALY when used in combination with MMF (CSA was
instead cost-effective) but remaining cost-effective when used in combination with AZA.
TAC-PR
Prolonged-release tacrolimus is not predicted to be cost-effective at £20,000 or £30,000 per QALY in any
analyses (including scenario analyses). The probability of TAC-PR being cost-effective was 0.0% at £20,000
and £30,000 per QALY.
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MMF
Mycophenolate mofetil is predicted to be cost-effective at £20,000 and £30,000 per QALY in the
deterministic and probabilistic analyses. The probability of MMF being cost-effective at £20,000 and
£30,000 per QALY ranged from 63.2% to 92.2% across comparisons.
The cost-effectiveness of MMF was robust to structural scenario analyses.
Adopting list prices instead of average NHS acquisition costs resulted in MMF no longer being
cost-effective at £20,000 or £30,000 per QALY when used in combination with immediate-release TAC
(AZA instead was cost-effective) but remaining cost-effective when used in combination with CSA.
MPS
Mycophenolate sodium is not predicted to be cost-effective at £20,000 or £30,000 per QALY in any
analyses (including scenario analyses). The probability of MPS being cost-effective was 0.1% at £20,000
per QALY and 0.8% at £30,000 per QALY.
SRL
Sirolimus is not predicted to be cost-effective at £20,000 or £30,000 per QALY in the deterministic or
probabilistic analyses whether in combination with immediate-release TAC or in combination with BAS
induction and MMF. The probability of SRL being cost-effective in either combination was 0.0% at
£20,000 and £30,000 per QALY.
A threshold analysis was conducted in which the gamma parameter of the Weibull distribution for
death-censored graft survival was allowed to vary independently for regimens not including CNIs. SRL was
included in one of the two affected regimens (BAS+ SRL+MMF). The threshold analysis indicated that
there are values for gamma for which SRL is cost-effective at £20,000 or £30,000 per QALY, but these
result in markedly different survival curves for SRL compared with immediate-release TAC, for which we
are aware of no supporting high-quality evidence.
Other scenario analyses did not lead to SRL becoming cost-effective at £20,000 or £30,000 per QALY.
EVL
Everolimus is not predicted to be cost-effective at £20,000 or £30,000 per QALY in any analyses (including
scenario analyses). The probability of EVL being cost-effective was 0.0% at £20,000 and £30,000
per QALY.
BEL
Belatacept is not predicted to be cost-effective at £20,000 or £30,000 per QALY in the deterministic or
probabilistic analyses. The probability of BEL being cost-effective was 0.0% at £20,000 and £30,000
per QALY.
A threshold analysis was conducted in which the gamma parameter of the Weibull distribution for
death-censored graft survival was allowed to vary independently for regimens not including CNIs. BEL was
included in one of the two affected regimens (BAS+ BEL+MMF). The threshold analysis suggested that no
value of gamma would enable BEL to be cost-effective at £20,000 or £30,000 per QALY.
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Another threshold analysis was conducted to investigate the impact of the administration and acquisition
costs of BEL on cost-effectiveness. With the base-case cost of administration BEL is not cost-effective at
£20,000 or £30,000 per QALY, even at zero acquisition cost. With the list price for acquisition cost, BEL is
similarly not cost-effective at £20,000 or £30,000 per QALY, even at zero administration cost.
Other scenario analyses did not lead to BEL being cost-effective at £20,000 or £30,000 per QALY.
Summary for maintenance agents
Base-case deterministic and probabilistic results suggest that at cost-effectiveness thresholds of between
£20,000 and £30,000 per QALY, only BAS, immediate-release TAC and MMF are likely to be cost-effective.
When structural uncertainty about the surrogate relationship for graft survival was explored it was found that
when the surrogate relationship was weakened, no induction became cost-effective instead of BAS, and CSA
became cost-effective instead of immediate-release TAC. MMF remained cost-effective throughout.
Another structural uncertainty analysis investigating the possibility that CNI-free regimens could prolong
graft survival found that a regimen containing SRL could become cost-effective at £20,000 or £30,000 per
QALY but required potentially implausible gains in graft survival. The analysis also found that BEL could not
become cost-effective at £20,000 or £30,000 per QALY despite the same potentially implausible gains in
graft survival.
When list prices were adopted instead of average NHS acquisition costs (despite this being considered
a deviation from the reference case), CSA was cost-effective instead of TAC in some comparisons and AZA
was cost-effective instead of mycophenolate in some comparisons.
Prespecified subgroup analyses were not possible, based on the RCTs included in the systematic review of
clinical effectiveness, and therefore have not been conducted.
Comparison between the PenTAG and company models
We compared the main deterministic analyses from three of the company submissions with those
produced by the independent assessment group (PenTAG). These assessed the cost-effectiveness of
TAC-PR compared with immediate-release TAC (Astellas), EVL (Novartis), EC-MPS (Novartis) and BEL
(Bristol-Myers Squibb). Although some of the PenTAG analyses contained a larger set of comparator
treatments, they were generally comparable after dominated comparators were excluded from the
PenTAG analyses.
Overall, the PenTAG analyses of cost-effectiveness were considerably less favourable than the companies’
analyses of their own products. This could mostly be attributed to the companies’ analyses basing their
effectiveness assumptions on the results of specific RCTs (rather than meta-analysis), combined with using
different surrogate end points and/or US cohort data to extrapolate long-term outcomes such as
graft survival.
The economic modelling by PenTAG tended to include fuller costing of the administration of the
maintenance therapies, and more realistic, relatively lower, annual costs of dialysis (except Novartis).
In addition, the utility difference between living with a functioning graft and living on dialysis was
generally greater in the three companies’ analyses (typical difference of between ≈ 0.25 and ≈ 0.3) than in
the PenTAG model (≈ 0.2 difference). Overall, these differences in the company’s models will tend to
magnify the impact on QALYs of any incremental effectiveness differences that affect long-term graft
survival, and also reduce their associated incremental cost.
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Strengths and limitations
Systematic review of studies of effectiveness
The strengths of this systematic review are that is was conducted by an independent, experienced research
team using the latest evidence and working to a prespecified protocol (PROSPERO CRD42014013189),
which follows a robust methodology.
There are a number of limitations.
l Owing to the level of reporting detail, we were unable to perform subgroup analysis according to donor
or HLA matching.
l Study design and participant characteristics varied widely across studies, leading to substantial heterogeneity.
l The 86 included RCTs were of variable quality, but all appear to be flawed. However, because of
reporting omissions for most trials, for example on random allocation or a priori outcomes, it was difficult
to make a general assessment regarding quality.
l Very few trials reported longer-term follow-up, with the majority reporting data at 1 year.
Economic modelling by Peninsula Technology Assessment Group
Strengths
l This is an analysis conducted by an independent academic group, adhering to the NICE reference case
where possible.
l All interventions and relevant comparators allowable are included and evaluated for cost-effectiveness
(Table 217).
TABLE 217 Immunosuppressive agents evaluated for cost-effectiveness in PenTAG analysis and industry submissions
Agent PenTAG Astellas Bristol-Myers Squibb Novartis TA8543
BAS Y N N N Y
rATG Y N N N N
(No induction) Y N N N Y
Immediate-release TAC Y Y Y P Y
TAC-PR Y Y N N N
MMF Y N N Y Y
MPS Y N N Y N
SRL Y Y N N Y
EVL Y Y N Y N
BEL Y Y Y N N
CSA Y N Y P Y
AZA Y N N N Y
N, no; P, partial; Y, yes.
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l The natural history of disease (e.g. graft survival, DWFG, mortality while receiving dialysis) is based on
UK data, either published by the UK Renal Registry in its annual reports or from new analyses of the
UK Transplant Registry data set.
l Relative effectiveness parameters are taken directly from the results of the systematic review of
clinical effectiveness when possible (including for key outcomes of graft survival, patient survival,
post-transplantation GRF and AR) and when not possible are synthesised from data reported in RCTs
included in the systematic review.
l The prognostic significance of AR, post-transplantation GRF and NODAT on outcomes is incorporated
into the analysis.
l Pre-emptive retransplantations are included for a minority of KTRs following failure of the initial graft
(avoiding dialysis which is costly and reduces HRQoL).
l Unit costs are those relevant to the NHS (e.g. CMU eMit costs were used where available).
l Dosing of immunosuppressive agents is based on recent RCTs and for many included tapering to low
levels as would be targeted in clinical practice.
l A PSA is presented to reflect the potential impact of parameter uncertainty.
l Structural uncertainty in the modelling of graft survival is addressed through scenario analyses.
Limitations
l We have not modelled eGFR for regimens except at 12 months; the Novartis and Bristol-Myers Squibb
analyses both estimated eGFR over time and used CKD stages (defined by eGFR intervals) to drive
certain costs and HRQoL; the Bristol-Myers Squibb analysis in particular predicts significantly greater
costs in more advanced CKD stages, although it is considered likely that both the absolute eGFR and
the trajectory of eGFR for a patient will determine the level of monitoring and, therefore, the level of
monitoring for CKD stage 4 patients in the 24–36 months after transplantation may not be a good
reflection of the level of monitoring for patients reaching CKD stage 4 much later (with a much
shallower trajectory); in the absence of evidence that any agent or regimen leads to greater time in
higher or lower eGFR ranges other than by extension of graft survival, we consider that our model
adequately incorporates the clinical importance of eGFR through the surrogate relationship with graft
survival and that modelling eGFR further in the model would be rather speculative and unlikely to lead
to significant differences in cost-effectiveness.
l We have not included any analysis of the cost-effectiveness of reducing or eliminating CCSs, although
in many studies informing the model the CCS dose was heavily tapered for long-term maintenance; as
the cost of CCSs is minimal, this would be very unlikely to affect cost-effectiveness results.
l We did not include NHS-funded transport costs for HD, which may constitute around 10% of the total
cost of HD provision; inclusion of transport costs would increase the overall cost of HD and make
regimens with less time dependent on dialysis more cost-effective.
l We did not include any treatment discontinuation or switching except following graft loss; published
RCTs suggest that treatment switching is usually towards immediate-release TAC and MMF.
l We did not differentiate between different severity of AR, that is, if any regimen results in less-severe AR
(but no fewer) episodes then this will not be reflected and the cost-effectiveness will be underestimated.
l We applied HRs for graft survival based on eGFR at 12 months, which were intended for extrapolation
to only 4 years, although justifications are given for not using the HRs intended for further extrapolation.
l We assumed independence of AR, NODAT and eGFR at 12 months within each regimen; if, for
example, patients experiencing AR in the first 12 months are likely to have a lower eGFR at 12 months
than patients who are not experiencing AR then there will be second-order error in the estimated HR
for each regimen (in this example an over-representation of patients with AR and high eGFR, and
patients without AR and with low eGFR, and an under-representation of patients with AR and low
eGFR, and patients without AR and with high eGFR); at the aggregate level AR, NODAT and eGFR
were estimated according to RCTs included in the systematic review and therefore correlation of these
at the aggregate level across regimens would be possible and would be represented in the model.
l We did not include continuing immunosuppression following graft loss (which may happen in
clinical settings).
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l We combined estimates of incremental renal function between comparators, based on different
measurements of GRF (measured GFR, MDRD eGFR, Cockcroft–Gault CRC and measured CRC).
l We assumed that a proportional hazards model for graft survival is appropriate when it is possible that
certain regimens may result in qualitatively different survival curves, for example owing to absence of
CNI nephrotoxicity in CNI-sparing regimens; we conducted a scenario analysis that demonstrated that
markedly (and perhaps implausibly) different survival curves would be required for cost-effectiveness to
be demonstrated.
l We modelled de novo SRL with BAS induction and MMF rather than including initial CSA medication
and delayed SRL initiation, although this may be common in clinical practice while surgical wounds
heal; including delayed SRL initiation would slightly reduce costs and improve cost-effectiveness of the
BAS+ SRL+MMF regimen.
l We made no attempt to explicitly model adherence to immunosuppressive medication owing to the
absence of evidence on this outcome in RCTs included in the systematic review of clinical effectiveness;
there is some evidence that non-adherence is a cause of late AR and graft loss, but at this time any
gains in clinical effectiveness due to improved adherence attributable to any individual agent or
regimen are considered to be speculative.
l It was assumed that there would be no treatment interactions between induction and maintenance
therapies affecting clinical effectiveness outcomes. It is, known, however, for example, that there is a
pharmacokinetic interaction between BAS and MMF, which results in prolonged BAS half-life.
l Owing to inconsistent reporting of AEs in RCTs included in our systematic review only a few AEs
were modelled: NODAT, CMV infection, dyslipidaemia and anaemia. Of these, anaemia was assumed
not to vary between regimens. Induction agents were assumed not to affect the incidence of AEs.
Malignancy, PTLD, proteinuria, hypertension, EBV infection, BKV infection, other infections and
other AEs were not modelled. CVD was included as a potential sequela of NODAT (inpatient and
non-inpatient costs and increased rate of DWFG) but was not included otherwise (including as a
sequelae of dyslipidaemia).
Economic modelling in the company submissions
Uncertainties
l Long-term outcomes from RCTs are seldom reported so it has not been possible to externally validate
the predicted survival differences between regimens.
l No evidence has been identified on the influence of the induction or maintenance therapies on HRQoL.
l RCTs identified in the systematic review have not provided evidence to support subgroup analyses.
l The costs for diabetes mellitus are highly uncertain, especially as the costs relate to the general diabetic
population rather than transplant recipients with NODAT.
l It is not known whether or not NHS hospitals might secure discounts from list prices where these were
assumed in the model (i.e. for BAS, rATG, TAC-PR, MPS, SRL, EVL and BEL).
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Chapter 8 Conclusions
The additional clinical effectiveness evidence identified in this updated systematic review suggests thatthere is little impact on effectiveness conclusions from the head-to-head comparisons, particularly for
graft loss and mortality. Following NMA for induction therapy, there is no evidence to suggest that BAS
or rATG is more effective than PBO/no induction or each other in reducing the odds of graft loss or
mortality. rATG and BAS were both estimated to be more effective than PBO/no induction, with rATG
being more effective than BAS at reducing BPAR. There is evidence to suggest that BAS is more effective
than PBO/no induction for increasing GRF.
With regard to maintenance therapy, the NMA showed that none of the maintenance regimens performed
consistently well on all four outcomes, and a great deal of heterogeneity was noted.
As for cost-effectiveness, the analyses conducted and reported here suggest that only a regimen of BAS
induction followed by maintenance with immediate-release TAC and MMF would be cost-effective at
£20,000–30,000 per QALY. If only these interventions were to be recommended then we believe there
would be very little implication for service provision.
Implication for service provision
It is believed that the immunosuppressive regimen of BAS induction, followed by maintenance with
immediate-release TAC and MMF (with or without CCSs), is in common use at present.
Suggested research priorities
New research in the following areas could reduce the uncertainty noted:
l Good-quality, well-reported, longer-term RCTs up to 10 years for both induction and maintenance,
with adequate sample sizes and clear randomisation are essential.
l RCTs to include HRQoL as an outcome, and sufficiently powered for subgroup analysis by sex, donor
type, ethnicity and HLA matching.
l Improved reporting of trials would be beneficial, in particular the reporting of randomisation methods
and withdrawal, dropouts and loss to follow-up.
l RCTs comparing clinically relevant doses of immunosuppressive therapy would be beneficial.
l Use of real-world data, such as the UK Renal Registry data set, may provide a more sensitive and
specific understanding of immunosuppression and renal transplant outcomes.
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Appendix 1 Literature searching strategies
Clinical effectiveness
The following search strategies were used to identify studies of intervention effectiveness for this appraisal.
They were first run on 14 April 2014 and the same strategy was used on 18 November 2014 to update
the literature base: this most recent search is recorded below. The effectiveness searches take
the following form: (terms for kidney or renal transplant or kidney or renal graft) AND (terms for the
interventions under review) AND (a study design limit to RCTs or controlled trials). The search was not
limited by language and it was not limited to human-only studies because such a limit would have blocked
retrieval of includable studies for rATG (line 8 of the Medline search). The effectiveness searches were
combined with the systematic review searches in our update searches.
Search annex
Database: Ovid MEDLINE In-Process & Other Non-Indexed Citations and
Ovid MEDLINE
Host: Ovid
Data parameters: 1946 to present.
Date searched: 18 November 2014.
Searcher: Chris.
Checked by: Simon/Jenny.
Hits: 73.
Search strategy
# Searches Results
1 Kidney Transplantation/ 81,142
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 34,392
3 (Renal adj3 transplant$).ti,ab,kw,ot. 41,464
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 36,554
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 46,102
6 1 or 2 or 3 or 4 or 5 114,277
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 1063
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
6382
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,
kw,ot.
17,331
10 Tacrolimus/ 13,055
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 219
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
28,176
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# Searches Results
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 21,975
14 Sirolimus/ 14,369
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 3088
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 74,259
17 6 and 16 9593
18 Randomized Controlled Trial.pt. 400,000
19 (random$ or RCT or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab,ot. 850,201
20 clinical trial.pt. 501,246
21 (“controlled trial$” or “clinical trial$”).ti,ab,ot. 348,859
22 18 or 19 or 20 or 21 1,324,400
23 (systematic adj3 review$).ti,ab,kw,ot. 65,381
24 22 or 23 1,361,806
25 17 and 24 2456
26 limit 25 to yr=“2014 -Current” 73
Notes: not applicable.
File: not applicable.
Database: EMBASE
Host: Ovid.
Data parameters: 1974 to 17 November 2014.
Date searched: 18 November 2014.
Searcher: Chris.
Hits: 259.
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Search strategy
# Searches Results
1 kidney transplantation/ 97,441
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 50,853
3 (Renal adj3 transplant$).ti,ab,kw,ot. 55,991
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 51,947
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 65,675
6 1 or 2 or 3 or 4 or 5 153,480
7 basiliximab/ 6681
8 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2311
9 thymocyte antibody/ 20,236
10 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
8854
11 tacrolimus/ 53,638
12 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,
kw,ot.
26,290
13 belatacept/ 989
14 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 547
15 mycophenolic acid/ 9985
16 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
35,917
17 rapamycin/ 36,443
18 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 28,739
19 everolimus/ 14,356
20 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 6988
21 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 148,218
22 6 and 21 25,662
23 randomized controlled trial/ 355,008
24 (random$ or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab,ot. 1,028,637
25 (“controlled trial$” or “clinical trial$”).ti,ab,ot. 428,701
26 23 or 24 or 25 1,300,553
27 (systematic adj3 review$).ti,ab,kw,ot. 77,376
28 26 or 27 1,343,995
29 22 and 28 3537
30 limit 29 to yr=“2014 -Current” 259
Notes: not applicable
File: not applicable
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Database: Cochrane Database of Systematic Reviews, Database of Abstracts of
Reviews of Effects and Cochrane Central Register of Controlled Trials
Host: Wiley Online Library.
Data parameters: Issue 11 of 12, November 2014, Issue 4 of 4, October 2014, Issue 10 of 12,
October 2014
Date searched: 18 November 2014
Searcher: Chris
Hits: 64 (CDSR 10; DARE 3; CENTRAL 51)
ID, Search, Hits
Search strategy
#1 MeSH descriptor: [Kidney Transplantation] this term only (3311)
#2 (Kidney* near/3 transplant*) (5789)
#3 (Renal near/3 transplant*) (4385)
#4 ((kidney or renal) near/3 (recipient* or dono* or donation* or replac*)) (3706)
#5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) (4956)
#6 #1 or #2 or #3 or #4 or #5 8481 (7509)
#7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”) (486)
#8 ((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3 thymocyte*) or
(rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*) (346)
#9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”) (2463)
#10 MeSH descriptor: [Tacrolimus] this term only (1180)
#11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”) (58)
#12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or Myfortic or
Mofetil) (3315)
#13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”) (2034)
#14 MeSH descriptor: [Sirolimus] this term only (1067)
#15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”) (724)
#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (7002)
#17 #6 and #16 Publication Year from 2014 (67)
Notes: not applicable
File: not applicable
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Database: Web of Science
Host: ISI Thompson Reuters.
Data parameters: 1900–2014.
Date searched: 18 November 2014.
Searcher: Chris.
Hits: 2290.
1. TOPIC: ((Kidney* near/3 transplant*))
2. TOPIC: ((Renal near/3 transplant*))
3. TOPIC: (((kidney or renal) near/3 (recipient* or dono* or donation* or replac*)))
4. TOPIC: (((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)))
5. #4 OR #3 OR #2 OR #1
6. TOPIC: ((Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”))
7. TOPIC: (((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3
thymocyte*) or (rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*))
8. TOPIC: ((Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or
Tacni or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”))
9. TOPIC: ((Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”))
10. TOPIC: ((“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or Myfortic
or Mofetil))
11. TOPIC: ((Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”))
12. #12 OR #11 OR #10 OR #9 OR #8 OR #7 OR #6
13. #13 AND #5 (Refined by: PUBLICATION YEARS: (2005 OR 2009 OR 2011 OR 2007 OR 2010 OR 2006
OR 2008 OR 2013 OR 2012 OR 2014))
14. TOPIC: (((random* or rct* or “controlled trial*” or “clinical trial*”)))
15. #16 AND #15
Notes: auto-suggest was turned off.
File: not applicable.
Database: Health Management Information Consortium
Host: Ovid
Data parameters: 1979 to September 2014.
Date searched: Tuesday, 18 November 2014.
Searcher: Chris.
Hits: 0.
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Search strategy
# Searches Results
1 Kidney Transplantation/ 120
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 83
3 (Renal adj3 transplant$).ti,ab,kw,ot. 81
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 152
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 28
6 1 or 2 or 3 or 4 or 5 313
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
1
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni or
Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,kw,ot.
8
10 Tacrolimus/ 0
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 0
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
23
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 10
14 Sirolimus/ 0
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 2
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 32
17 6 and 16 3
18 Randomized Controlled Trial.pt. 0
19 (random$ or RCT or placebo$ or single blind$ or double blind$ or triple blind$).ti,ab,ot. 10,838
20 clinical trial.pt. 0
21 (“controlled trial$” or “clinical trial$”).ti,ab,ot. 5592
22 18 or 19 or 20 or 21 12,088
23 (systematic adj3 review$).ti,ab,kw,ot. 3692
24 22 or 23 14,553
25 17 and 24 2
26 limit 25 to yr=“2014 -Current” 0
Notes: not applicable.
File: not applicable.
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Trials registries
The following search strategies were used in ClinicalTrials.gov and the International Standard Randomised
Controlled Trial Number (ISRCTN) Registry, Controlled Trials. These were hand-searched on 19 October
2014 via: https://clinicaltrials.gov/ and www.controlled-trials.com/, respectively.
(Basiliximab OR Basiliximabum OR Simulect OR “interleukin 2 receptor antibody”) AND (kidney* OR renal)
((rabbit AND Anti-thymocyte*) OR (rabbit AND Antithymocyte*) OR (rabbit AND thymocyte*) OR
(rabbit* AND polyclonal) OR (rabbit* AND ATG) OR RATG OR thymoglobulin*) AND (kidney* OR renal)
(Tacrolimus OR Fujimycin OR Prograf OR Advagraf OR Adoport OR Capexion OR Modigraf OR Perixis
OR Tacni OR Vivadex OR Protopic OR Tsukubaenolide OR “FK 506” OR “FK-506” OR “FK506” OR
“fr-900506”) AND (kidney* OR renal)
(Belatacept OR Nulojix OR “lea29y” OR “lea 29y” OR “bms 224818”) AND (kidney* OR renal)
(“Mycophenolic acid” OR MPA OR Mycophenolate OR Arzip OR CellCep* OR Myfenax OR Myfortic OR
Mofetil) AND (kidney* OR renal)
(Sirolimus OR Rapamune OR Rapamycin OR “ay 22-989”) AND (kidney* OR renal)
(Everolimus OR Zortress OR Certican OR Afinitor OR Evertor OR “SDZ RAD”) AND (kidney* OR renal)
Web searches
The following websites were hand-searched:
Renal societies (UK)
British Renal Society: www.britishrenal.org/
Renal Association: www.renal.org/
UK Renal Registry: www.renalreg.com/
Kidney Research: UK www.kidneyresearchuk.org/
British Kidney Patient Association: www.britishkidney-pa.co.uk/
National Kidney Federation: www.kidney.org.uk/
Renal societies (international)
American Society of Nephrology: www.asn-online.org/
American Association of Kidney Patients: www.aakp.org/
National Kidney Foundation (US): www.kidney.org/
Canadian Society of Nephrology: www.csnscn.ca/
Kidney Foundation of Canada: www.kidney.ca/
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Australian and New Zealand Society of Nephrology: www.nephrology.edu.au/
Kidney Health Australia: www.kidney.org.au/
Kidney Society Auckland: www.kidneysociety.co.nz/
Ongoing trials
The following terms were used to search the ClinicalTrials.gov and Controlled Trials (ISRCTN) trial registers
for the interventions:
(Basiliximab OR Basiliximabum OR Simulect OR “interleukin 2 receptor antibody”) AND (kidney* OR renal)
((rabbit AND Anti-thymocyte*) OR (rabbit AND Antithymocyte*) OR (rabbit AND thymocyte*) OR
(rabbit* AND polyclonal) OR (rabbit* AND ATG) OR RATG OR thymoglobulin*) AND (kidney* OR renal)
(Tacrolimus OR Fujimycin OR Prograf OR Advagraf OR Adoport OR Capexion OR Modigraf OR Perixis
OR Tacni OR Vivadex OR Protopic OR Tsukubaenolide OR “FK 506” OR “FK-506” OR “FK506” OR
“fr-900506”) AND (kidney* OR renal)
(Belatacept OR Nulojix OR “lea29y” OR “lea 29y” OR “bms 224818”) AND (kidney* OR renal)
(“Mycophenolic acid” OR MPA OR Mycophenolate OR Arzip OR CellCep* OR Myfenax OR Myfortic OR
Mofetil) AND (kidney* OR renal)
(Sirolimus OR Rapamune OR Rapamycin OR “ay 22-989”) AND (kidney* OR renal)
(Everolimus OR Zortress OR Certican OR Afinitor OR Evertor OR “SDZ RAD”) AND (kidney* OR renal)
Cost-effectiveness searches
The following search strategies were used to identify studies reporting cost or economic data. They were
first run on 8 April 2014 and the same strategy was used on 18 November 2014 to update the literature
base. The searches took the following form: (terms for kidney or renal transplant or kidney or renal graft)
AND (terms for the interventions under review) AND (a costs or economic literature search filter). The
search was not limited by language and it was not limited to human-only studies because such a limit
would have blocked retrieval of includable studies for rATG (line 8 of the Medline search). Searching was
date limited 2002 to current, in line with the previous assessment.
Search annex
Database: MEDLINE
Host: Ovid
Data parameters: 1946 to present
Date searched: 18 November 2014
Searcher: Chris
Hits: 27
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Search strategy
# Searches Results
1 Kidney Transplantation/ 81,142
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 34,392
3 (Renal adj3 transplant$).ti,ab,kw,ot. 41,464
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 36,554
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 46,102
6 1 or 2 or 3 or 4 or 5 114,277
7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 1063
8 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
6382
9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni or
Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,kw,ot.
17,331
10 Tacrolimus/ 13,055
11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 219
12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
28,176
13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 21,975
14 Sirolimus/ 14,369
15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 3088
16 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 74,259
17 6 and 16 9593
18 Economics/ 27,421
19 exp Economics, Pharmaceutical/ 2601
20 exp Economics, Medical/ 13,982
21 exp Economics, Hospital/ 20,161
22 (pharmacoeconomic* or socioeconomics or economic$).ti,ab,kw. 183,564
23 ec.fs. 349,785
24 exp “Costs and Cost Analysis”/ 189,530
25 (cost* or cba or cea or cua or (value adj2 money) or pric$ or fiscal or funding or financial or finance or
budget$ or (expenditure$ not Energy)).ti,ab,kw.
530,644
26 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 896,638
27 17 and 26 440
28 limit 27 to yr=“2014 -Current” 27
Notes: not applicable.
File: not applicable.
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Database: EMBASE
Host: Ovid.
Data parameters: 1974 to 17 November 2014.
Date searched: 18 November 2014.
Searcher: Chris.
Hits: 131.
Search strategy
# Searches Results
1 kidney transplantation/ 97,441
2 (Kidney$ adj3 transplant$).ti,ab,kw,ot. 50,853
3 (Renal adj3 transplant$).ti,ab,kw,ot. 55,991
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw,ot. 51,947
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw,ot. 65,675
6 1 or 2 or 3 or 4 or 5 153,480
7 basiliximab/ 6681
8 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”).ti,ab,kw,ot. 2311
9 thymocyte antibody/ 20,236
10 ((rabbit$ adj3 Anti-thymocyte$1) or (rabbit$ adj3 Antithymocyte$1) or (rabbit$ adj3 thymocyte$1) or
(rabbit$ adj3 polyclonal) or (rabbit$ and ATG) or RATG or thymoglobulin$2).ti,ab,kw,ot.
8854
11 tacrolimus/ 53,638
12 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”).ti,ab,
kw,ot.
26,290
13 belatacept/ 989
14 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”).ti,ab,kw,ot. 547
15 mycophenolic acid/ 9985
16 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep$1 or Myfenax or Myfortic or
Mofetil).ti,ab,kw,ot.
35,917
17 rapamycin/ 36,443
18 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”).ti,ab,kw,ot. 28,739
19 everolimus/ 14,356
20 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”).ti,ab,kw,ot. 6988
21 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 148,218
22 6 and 21 25,662
23 exp Economics/ 220,356
24 models, economic/ 104,606
25 exp health economics/ 630,542
26 exp “Costs and Cost Analysis”/ 260,530
27 Cost of illness/ 14,509
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# Searches Results
28 resource allocation/ 15,619
29 pe.fs. 61,812
30 (cost$ or cba or cea or cua or (value adj2 money) or pric$ or fiscal or funding or financial or finance or
budget$ or (expenditure$ not Energy)).ti,ab,kw.
665,827
31 23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 1,288,868
32 22 and 31 1464
33 limit 32 to yr=“2014 -Current” 131
Notes: not applicable.
File: not applicable.
Database: Cochrane NHS Economic Evaluation Database
Host: Wiley Online Library.
Data parameters: Issue 4 of 4, October 2014.
Date searched: 18 November 2014.
Searcher: Chris.
Hits: 29.
ID, Search, Hits
Search strategy
#1 MeSH descriptor: [Kidney Transplantation] this term only (3274)
#2 (Kidney* near/3 transplant*) (5590)
#3 (Renal near/3 transplant*) (4265)
#4 ((kidney or renal) near/3 (recipient* or dono* or donation* or replac*)) (3480)
#5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) (4701)
#6 #1 or #2 or #3 or #4 or #5 8481)
#7 (Basiliximab or Basiliximabum or Simulect or “interleukin 2 receptor antibody”) (457)
#8 ((rabbit* near/3 Anti-thymocyte*) or (rabbit* near/3 Antithymocyte*) or (rabbit* near/3 thymocyte*) or
(rabbit* near/3 polyclonal) or (rabbit* and ATG) or RATG or thymoglobulin*) (330)
#9 (Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or Capexion or Modigraf or Perixis or Tacni
or Vivadex or Protopic or Tsukubaenolide or “FK 506” or “FK-506” or “FK506” or “fr-900506”) (2328)
#10 MeSH descriptor: [Tacrolimus] this term only (1168)
#11 (Belatacept or Nulojix or “lea29y” or “lea 29y” or “bms 224818”) (52)
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#12 (“Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep* or Myfenax or Myfortic or
Mofetil) (3143)
#13 (Sirolimus or Rapamune or Rapamycin or “ay 22-989”) (1881)
#14 MeSH descriptor: [Sirolimus] this term only (1037)
#15 (Everolimus or Zortress or Certican or Afinitor or Evertor or “SDZ RAD”) (602)
#16 #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 (6587)
#17 #6 and #16 Publication Date from 2005 to 2014 (1273)
Notes: not applicable.
File: not applicable.
Database: Web of Science
Host: ISI Thompson Reuters.
Data parameters: 1900–2014.
Date searched: 18 November 2014.
Searcher: Chris.
Hits: 40.
Lines 1–13 of the WOS Effectiveness search was used, combined with:
TOPIC: ((pharmacoeconomic* or socioeconomics or economic* or pric* or cost* or cba or cea or cua or
“health utilit*” or “value for money”))
Notes: not applicable.
File: not applicable.
Database: EconLit
Host: EBSCOhost.
Data parameters: 1886–2014.
Date searched: 18 November 2014.
Searcher: Chris.
Hits: 0.
(Basiliximab or Basiliximabum or Simulect or Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or
Capexion or Modigraf or Perixis or Tacni or Vivadex or Protopic or Tsukubaenolide or Belatacept or Nulojix
or “Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep or Myfenax or Myfortic or Mofetil
or Sirolimus or Rapamune or Rapamycin or Everolimus or Zortress or Certican or Afinitor or Evertor) AND
(kidney or renal)
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Notes: not applicable.
File: not applicable.
Database: Health Economic Evaluations Database (HEED)
Host: via The Cochrane Library.
Date searched: Tuesday, 18 November 2014.
Searcher: Chris.
Hits: 3.
(Basiliximab or Basiliximabum or Simulect or Tacrolimus or Fujimycin or Prograf or Advagraf or Adoport or
Capexion or Modigraf or Perixis or Tacni or Vivadex or Protopic or Tsukubaenolide or Belatacept or Nulojix
or “Mycophenolic acid” or MPA or Mycophenolate or Arzip or CellCep or Myfenax or Myfortic or Mofetil
or Sirolimus or Rapamune or Rapamycin or Everolimus or Zortress or Certican or Afinitor or Evertor) AND
(kidney or renal)
Notes: not applicable
File: not applicable
Searches for utility data
The searches for utility data are recorded below. These searches took the following form:
(terms for kidney or renal transplant or kidney or renal graft or renal dialysis) AND (terms for utility
questionnaires such as SF36 or CHU 9D) and were run from database inception.
Search annex
Database: Ovid MEDLINE In-Process & Other Non-Indexed Citations and
Ovid MEDLINE
Host: Ovid
Data parameters: 1946 to present.
Date searched: 3 September 2014.
Volume: 714.
Search strategy
# Searches Results
1 Kidney Transplantation/ 79,870
2 (Kidney$ adj3 transplant$).ti,ab,kw. 33,553
3 (Renal adj3 transplant$).ti,ab,kw. 40,747
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw. 35,663
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw. 45,183
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# Searches Results
6 1 or 2 or 3 or 4 or 5 112,067
7 Renal Dialysis/ 73,812
8 Peritoneal Dialysis/ 14,950
9 ((kidney or renal or peritoneal) and (dialysis or dialyses)).ti,ab,kw. 48,847
10 7 or 8 or 9 107,010
11 6 or 10 201,694
12 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y).ti,ab,kw. 4481
13 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,kw. 1391
14 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form ten).
ti,ab,kw.
77
15 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short form
twelve).ti,ab,kw.
3016
16 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab,kw.
24
17 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty).ti,ab,kw.
341
18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,kw.
17,026
19 (health utilities index$ or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)).ti,ab,kw. 1172
20 (“time trade off” or “time tradeoff” or TTO).ti,ab,kw. 1234
21 standard gamble$.ti,ab,kw. 697
22 (CHU9D or CHU 9D or “Child Health Utility”).ti,ab,kw. 13
23 “discrete choice”.ti,ab,kw. 713
24 (AQoL or “Assessment of Quality of Life”).ti,ab,kw. 1274
25 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 28,980
26 11 and 25 766
27 limit 26 to english language 714
Notes: not applicable.
File name: MEDLINE.txt.
Database: EMBASE
Host: Ovid.
Data parameters: 1974 to 2014, week 34.
Date searched: 3 September 2014.
Volume: 915.
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Search strategy
# Searches Results
1 kidney transplantation/ 96,703
2 (Kidney$ adj3 transplant$).ti,ab,kw. 50,181
3 (Renal adj3 transplant$).ti,ab,kw. 55,376
4 ((kidney or renal) adj3 (recipient$ or dono$ or donation$ or replac$)).ti,ab,kw. 51,117
5 ((graft$ or allograft$ or homograft$ or allogeneic) and (kidney$ or renal)).ti,ab,kw. 64,806
6 1 or 2 or 3 or 4 or 5 151,605
7 renal replacement therapy/ 36,722
8 peritoneal dialysis/ 23,371
9 ((kidney or renal or peritoneal) and (dialysis or dialyses)).ti,ab,kw. 64,637
10 7 or 8 or 9 97,785
11 6 or 10 224,149
12 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y).ti,ab,kw. 7316
13 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six).ti,ab,kw. 1533
14 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form ten).
ti,ab,kw.
109
15 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short form
twelve).ti,ab,kw.
4428
16 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen).ti,ab,kw.
35
17 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty).ti,ab,kw.
333
18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six).ti,ab,kw.
23,918
19 Short Form 36/ 12,496
20 (health utilities index$ or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or hui-3)).ti,ab,kw. 1547
21 (“time trade off” or “time tradeoff” or TTO).ti,ab,kw. 1599
22 standard gamble$.ti,ab,kw. 812
23 (CHU9D or CHU 9D or “Child Health Utility”).ti,ab,kw. 13
24 “discrete choice”.ti,ab,kw. 958
25 (AQoL or “Assessment of Quality of Life”).ti,ab,kw. 1812
26 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24 or 25 43,846
27 11 and 26 991
28 limit 27 to english language 915
Notes: not applicable.
File Name: EMBASE.txt.
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Database: The Cochrane Library (Cochrane Central Register of Controlled
Trials, Health Technology Assessment and NHS Economic
Evaluation Database)
Host: Wiley Online Library.
Data parameters: CENTRAL Issue 8 of 12, August 2014; HTA and NHS EED issue 3 of 4 July 2014.
Date searched: 3 September 2014.
Volume: 174.
Search strategy:
ID, Search, Hits
Search strategy
#1 MeSH descriptor: [Kidney Transplantation] this term only (3298)
#2 (Kidney* near/2 transplant*) (5497)
#3 (Renal near/2 transplant*) (3841)
#4 ((kidney or renal) near/2 (recipient* or dono* or donation* or replac*)) (3399)
#5 ((graft* or allograft* or homograft* or allogeneic) and (kidney* or renal)) (4785)
#6 #1 or #2 or #3 or #4 or #5 (8307)
#7 MeSH descriptor: [Renal Dialysis] this term only (3496)
#8 MeSH descriptor: [Peritoneal Dialysis] this term only (417)
#9 ((kidney or renal or peritoneal) and (dialysis or dialyses)) (8888)
#10 #7 or #8 or #9 (8888)
#11 #6 or #10 (15,502)
#12 (euroqol or euro qol or eq5d or eq 5d or EQ-5D or EQ-5D-Y) (2221)
#13 (sf6 or sf 6 or short form 6 or shortform 6 or sf six or sfsix or shortform six or short form six) (11,746)
#14 (sf10 or sf 10 or short form 10 or shortform 10 or sf ten or sften or shortform ten or short form
ten) (12,533)
#15 (sf12 or sf 12 or short form 12 or shortform 12 or sf twelve of sftwelve or shortform twelve or short
form twelve) (9569)
#16 (sf16 or sf 16 or short form 16 or shortform 16 or sf sixteen or sfsixteen or shortform sixteen or short
form sixteen) (6668)
#17 (sf20 or sf 20 or short form 20 or shortform 20 or sf twenty of sftwenty or shortform twenty of short
form twenty) (7393)
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#18 (sf36 or sf 36 or short form 36 or shortform 36 or sf thirtysix or sf thirty six or shortform thirstysix or
shortform thirty six or short form thirty six or short form thirtysix or short form thirty six) (9081)
#19 (health utilities index* or (hui or hui1 or hui2 or hui3 or hui4 or hui-4 or hui-1 or hui-2 or
hui-3)) (6541)
#20 (“time trade off” or “time tradeoff” or TTO) (512)
#21 standard gamble* (521)
#22 (CHU9D or CHU 9D or “Child Health Utility”) (3)
#23 “discrete choice” (47)
#24 (AQoL or “Assessment of Quality of Life”) (302)
#25 #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 (22,511)
#26 #11 and #25 (847)
Notes: N/A.
File name: Cochrane.txt.
Resource: School of Health and Related Research (ScHARR) Health Utilities
Database (HUD)
URL: (http://update-sbs.update.co.uk/scharr11/index.php?recordsN1&m=search)
Date searched: 3 September 2014.
Volume: 9.
Search strategy: kidney* or renal or dialysis
Notes:
File name:
Resource: Euroqol website
URL: www.euroqol.org/eq-5d-references/reference-search.html
Date searched: 3 September 2014.
Volume: 24.
Search strategy: kidney or renal or dialysis.
Notes: 5/24 were unique when deduplicated against the EMBASE search.
File name:
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Resource: Higher Education Recruitment Consortium (HERC) database of
mapping studies
URL: www.herc.ox.ac.uk/downloads/mappingdatabase
Date searched: 3 September 2014.
Volume: 0.
Search strategy: A hand-search of the Excel database was performed.
Notes: Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online
database. Health Qual Life Outcomes 2013;11:151. HERC database of mapping studies, version 3.0
(last updated 26 June 2014). URL: www.herc.ox.ac.uk/downloads/mappingdatabase.
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Appendix 2 Excluded studies
Study Rationale
Abou-Jaoude MM, Ghantous I, Almawi WY. Tacrolimus (FK506) versus cyclosporin A microemulsion
(Neoral) maintenance immunosuppression: effects on graft survival and function, infection, and metabolic
profile following kidney transplantation (KT). Mol Immunol 2003;39:1095–100
Population
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Appendix 6 Network meta-analysis
WinBUGS code 
Fixed effects binomial likelihood with logit link 
model{                          # *** PROGRAM STARTS 
for(i in 1:ns){                 # LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)      # vague priors for all trial baselines 
    for (k in 1:na[i])  {       # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k])    # binomial likelihood 
# model for linear predictor 
        logit(p[i,k]) <- mu[i] + d[t[i,k]] - d[t[i,1]] 
# expected value of the numerators  
        rhat[i,k] <- p[i,k] * n[i,k] 
#Deviance contribution 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k])) 
             +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k]))) 
      } 
# summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]]) 
     }    
totresdev <- sum(resdev[])      # Total Residual Deviance 
d[1]<-0    # treatment effect is zero for reference treatment 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
for (c in 1:(nt-1)) {  for (k in (c+1):nt) { 
       or[c,k] <- exp(d[k] - d[c]) 
       lor[c,k] <- (d[k]-d[c]) 
      } 
} 
 
# ranking  
for (k in 1:nt) { 
   rk[k] <- rank(d[],k)                           # assumes events are “bad” 
   best[k] <- equals(rk[k],1)                    #calculate probability that 
treat k is best 
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} 
}                            
Random effects binomial likelihood with logit link
model{                               # *** PROGRAM STARTS 
for(i in 1:ns){                      # LOOP THROUGH STUDIES 
    w[i,1] <- 0    # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0             # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)           # vague priors for all trial baselines 
    for (k in 1:na[i]) {             # LOOP THROUGH ARMS 
        r[i,k] ~ dbin(p[i,k],n[i,k]) # binomial likelihood 
        logit(p[i,k]) <- mu[i] + delta[i,k]  # model for linear predictor 
        rhat[i,k] <- p[i,k] * n[i,k] # expected value of the numerators  
#Deviance contribution 
        dev[i,k] <- 2 * (r[i,k] * (log(r[i,k])-log(rhat[i,k]))   
            +  (n[i,k]-r[i,k]) * (log(n[i,k]-r[i,k]) - log(n[i,k]-rhat[i,k])))
} 
#  summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
    for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions (with multi-arm trial correction) 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k 
# adjustment for multi-arm RCTs 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
      } 
  }    
totresdev <- sum(resdev[])           # Total Residual Deviance 
d[1]<-0       # treatment effect is zero for reference treatment 
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# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)   # between-trial precision = (1/between-trial variance) 
 
# pairwise ORs and LORs for all possible pair-wise comparisons 
for (c in 1:(nt-1)) {  for (k in (c+1):nt) { 
       or[c,k] <- exp(d[k] - d[c]) 
       lor[c,k] <- (d[k]-d[c]) 
      } 
} 
 
# ranking  
for (k in 1:nt) { 
   rk[k] <- rank(d[],k)                           # assumes events are “bad” 
   best[k] <- equals(rk[k],1)                    #calculate probability that 
treat k is best 
} 
 
}       
Fixed effects normal likelihood and identify link
model{                               # *** PROGRAM STARTS 
for(i in 1:ns){                      #   LOOP THROUGH STUDIES 
    mu[i] ~ dnorm(0,.0001)           # vague priors for all trial baselines 
    for (k in 1:na[i]) {             #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)   # calculate variances 
        prec[i,k] <- 1/var[i,k]      # set precisions 
        y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
# model for linear predictor 
        theta[i,k] <- mu[i] + d[t[i,k]] - d[t[i,1]] 
#Deviance contribution 
        dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
      } 
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#  summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
  }    
totresdev <- sum(resdev[])            #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for control arm 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
for (c in 1:nt-1){ 
 for (k in 2:nt) { 
  IC[c,k] <- d[k] - d[c] 
 } 
 } 
# ranking  
for (k in 1:nt) { 
     rk[k] <- nt + 1- rank(d[],k)                            
   best[k] <- equals(rk[k],1)  
 } 
 }                      
Random effects normal likelihood and identify link
model{                               # *** PROGRAM STARTS 
for(i in 1:ns){                      #   LOOP THROUGH STUDIES 
    w[i,1] <- 0    # adjustment for multi-arm trials is zero for control arm 
    delta[i,1] <- 0             # treatment effect is zero for control arm 
    mu[i] ~ dnorm(0,.0001)           # vague priors for all trial baselines 
    for (k in 1:na[i]) {             #  LOOP THROUGH ARMS 
        var[i,k] <- pow(se[i,k],2)   # calculate variances 
        prec[i,k] <- 1/var[i,k]      # set precisions 
        y[i,k] ~ dnorm(theta[i,k],prec[i,k]) # binomial likelihood 
        theta[i,k] <- mu[i] + delta[i,k]  # model for linear predictor 
#Deviance contribution 
        dev[i,k] <- (y[i,k]-theta[i,k])*(y[i,k]-theta[i,k])*prec[i,k] 
      } 
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#  summed residual deviance contribution for this trial 
    resdev[i] <- sum(dev[i,1:na[i]])        
    for (k in 2:na[i]) {             # LOOP THROUGH ARMS 
# trial-specific LOR distributions 
        delta[i,k] ~ dnorm(md[i,k],taud[i,k]) 
# mean of LOR distributions, with multi-arm trial correction 
        md[i,k] <-  d[t[i,k]] - d[t[i,1]] + sw[i,k] 
# precision of LOR distributions (with multi-arm trial correction) 
        taud[i,k] <- tau *2*(k-1)/k 
# adjustment, multi-arm RCTs 
        w[i,k] <- (delta[i,k] - d[t[i,k]] + d[t[i,1]]) 
# cumulative adjustment for multi-arm trials 
        sw[i,k] <- sum(w[i,1:k-1])/(k-1) 
      } 
  }    
totresdev <- sum(resdev[])            #Total Residual Deviance 
d[1]<-0       # treatment effect is zero for control arm 
# vague priors for treatment effects 
for (k in 2:nt){  d[k] ~ dnorm(0,.0001) } 
sd ~ dunif(0,5)     # vague prior for between-trial SD 
tau <- pow(sd,-2)   # between-trial precision = (1/between-trial variance) 
for (c in 1:nt-1){ 
 for (k in 2:nt) { 
  IC[c,k] <- d[k] - d[c] 
 } 
 } 
# ranking  
for (k in 1:nt) { 
     rk[k] <- nt + 1- rank(d[],k)                            
    best[k] <- equals(rk[k],1)  
 } 
}          
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Induction therapy results
Graft loss
Results of random-effects model and consistency analyses
As there are direct data for three comparisons and three treatments, but a three-arm trial, there are no
ICDF for this network. Comparing the DIC between the consistency and inconsistency models (Table 218)
suggests that the consistency models provide a slightly better fit to the data for both the fixed- and
random-effects models. Furthermore, the posterior median estimates are similar between the consistency
and inconsistency models and the 95% CrIs overlap considerably.
Mortality
Results of random-effects model and consistency analyses
As there are direct data for three comparisons and three treatments, but a three-arm trial, there are no
ICDF for this network. Comparing the DIC between the consistency and inconsistency models suggests
that the consistency models provide a better fit to the data for both the fixed- and random-effects models.
Furthermore, the posterior median estimates are similar between the consistency and inconsistency models
and the 95% CrIs overlap considerably (Table 219).
Biopsy-proven acute rejection
Results of random-effects model and consistency analyses
As there are direct data for three comparisons and three treatments, but a three-arm trial, there are no
ICDF for this network. Comparing the DIC between the consistency and inconsistency models suggests
that the consistency models provide a better fit to the data for both the fixed- and random-effects models.
Furthermore, the posterior median estimates are similar between the consistency and inconsistency models
and the 95% CrIs overlap considerably (Table 220).
TABLE 218 Comparison of fixed- and random-effects consistency and inconsistency models for induction therapy
on graft loss [posterior median (95% Crl)]
Treatment comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
OR (BAS vs. PBO/no treatment) 0.84 (0.59 to 1.21) 0.81 (0.55 to 1.19) 0.84 (0.55 to 1.30) 0.81 (0.49 to 1.29)
OR (rATG vs. PBO/no treatment) 0.78 (0.45 to 1.34) 0.89 (0.43 to 1.95) 0.78 (0.42 to 1.43) 0.90 (0.40 to 2.03)
OR (rATG vs. BAS) 0.92 (0.53 to 1.59) 0.80 (0.38 to 1.66) 0.93 (0.51 to 1.69) 0.80 (0.40 to 1.80)
Estimate of between-study
heterogeneity
0.15 (0.01 to 0.63) 0.16 (0.01 to 0.70)
Total residual deviance 19.56 20.26 20.44 21.16
Relative number of model
parameters
14.63 15.60 15.71 16.66
DIC 34.19 35.86 36.15 37.82
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Graft function
Results of random-effects model and consistency analyses
As there are direct data for three comparisons and three treatments, the ICDF for this network is 1.
Comparing the DIC between the consistency and inconsistency models suggests very little difference
between the models; however, the mean effect for rATG from the direct evidence (the inconsistency
model) is much larger than that when both direct and indirect evidence are used (the consistency model):
3.44 (95% CrI –2.49 to 9.36) vs. 0.75 (95% CrI –3.99 to 5.48) from the fixed-effects model. Nevertheless,
the 95% CrIs overlap considerably (Table 221).
TABLE 219 Comparison of fixed- and random-effects consistency and inconsistency models for induction therapy
on mortality [posterior median (95% Crl)]
Treatment comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
OR (BAS vs. PBO/no treatment) 0.89 (0.49 to 1.62) 0.91 (0.47 to 1.74) 0.82 (0.28 to 1.77) 0.81 (0.19 to 1.99)
OR (rATG vs. PBO/no treatment) 0.68 (0.28 to 1.39) 0.59 (0.17 to 1.79) 0.56 (0.14 to 0.14) 0.51 (0.07 to 2.01)
OR (rATG vs. BAS) 0.72 (0.34 to 1.47) 0.74 (0.29 to 1.79) 0.68 (0.23 to 1.73) 0.68 (0.15 to 2.32)
Estimate of between-study
heterogeneity
0.39 (0.02 to 1.74) 0.46 (0.02 to 2.20)
Total residual deviance 25.08 26.12 24.66 25.53
Relative number of model
parameters
13.35 14.28 15.41 16.49
DIC 38.43 40.40 40.07 42.02
TABLE 220 Comparison of fixed- and random-effects consistency and inconsistency models for induction therapy
on BPAR [posterior median (95% Crl)]
Treatment comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
OR (BAS vs. PBO/no treatment) 0.50 (0.40 to 0.62) 0.51 (0.40 to 0.64) 0.50 (0.37 to 0.64) 0.50 (0.37 to 0.71)
OR (rATG vs. PBO/no treatment) 0.35 (0.25 to 0.49) 0.34 (0.22 to 0.53) 0.35 (0.24 to 0.51) 0.33 (0.19 to 0.55)
OR (rATG vs. BAS) 0.70 (0.51 to 0.97) 0.73 (0.47 to 1.12) 0.71 (0.49 to 1.04) 0.75 (0.46 to 1.26)
Estimate of between-study
heterogeneity
0.12 (0.01 to 0.46) 0.13 (0.01 to 0.52)
Total residual deviance 21.00 21.96 21.08 21.83
Relative number of model
parameters
14.01 15.00 15.84 16.96
DIC 35.01 36.96 36.92 38.79
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TABLE 221 Comparison of fixed- and random-effects consistency and inconsistency models for induction therapy
on CRC-GRF [posterior median (95% Crl)]
Treatment comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
OR (BAS vs. PBO/no
induction)
2.62 (0.13 to 5.08) 2.11 (–0.46 to 4.67) 2.60 (–1.00 to 6.19) 2.00 (–1.79 to 5.64)
OR (rATG vs. PBO/no
induction)
0.75 (–3.99 to 5.48) 3.44 (–2.49 to 9.36) 0.54 (–5.82 to 6.65) 3.41 (–4.50 to 11.36)
OR (rATG vs. BAS) –1.86 (–6.72 to 3.00) –6.05 (–13.46 to 1.34) –2.03 (–8.53 to 4.19) –6.04 (–15.13 to 3.05)
Estimate of between-study
heterogeneity
2.27 (0.12 to 4.80) 2.14 (0.11 to 4.78)
Total residual deviance 14.28 13.11 12.38 11.95
Relative number of model
parameters
7.98 8.99 9.85 10.41
DIC 22.26 22.10 22.23 22.36
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Consistency analysis results
There are direct data for 18 comparisons and 12 treatments in the network; however, four independent
loops are informed by multiarm trials only and so the ICDF, reflecting the number of independent loops in
the network, is 18 – (12 – 1) – 4= 3. Comparing the DIC between the consistency and inconsistency models
suggests that there is little difference between the random-effects models (154.4 vs. 153.6). Furthermore,
the posterior median estimates are similar between the consistency and inconsistency models and the
95% CrIs overlap considerably (Table 223).
TABLE 223 Comparison of fixed- and random-effects consistency and inconsistency models for maintenance
therapy on graft loss
Comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
TAC+AZA vs. CSA+AZA 1.01 (0.71 to 1.44) 1.00 (0.71 to 1.43) 1.13 (0.67 to 2.15) 1.11 (0.65 to 2.11)
MMF+CSA vs. CSA+AZA 0.83 (0.53 to 1.29) 0.69 (0.42 to 1.10) 0.76 (0.35 to 1.44) 0.59 (0.24 to 1.24)
TAC+MMF vs. CSA+AZA 0.73 (0.41 to 1.27) 1.79 (0.64 to 5.51) 0.69 (0.28 to 1.55) 1.79 (0.40 to 8.47)
SRL+AZA vs. CSA+AZA 0.25 (0.01 to 2.47) 0.25 (0.01 2047) 0.25 (0.01 to 3.10) 0.25 (0.01 to 3.17)
TAC+MMF vs. MMF+CSA 0.87 (0.56 to 1.35) 0.85 (0.50 to 1.42) 0.92 (0.48 to 1.77) 1.14 (0.51 to 3.11)
BEL+MMF vs. MMF+CSA 0.80 (0.45 to 1.39) 0.73 (0.41 to 1.30) 0.82 (0.35 to 1.97) 0.70 (0.27 to 1.71)
EVL+CSA vs. MMF+CSA 0.92 (0.59 to 1.44) 0.92 (0.59 to 1.44) 0.84 (0.39 to 1.63) 0.84 (0.38 to 1.64)
SRL+ TAC vs. MMF+CSA 1.52 (0.77 to 2.97) 0.55 (0.11 to 2.03) 0.57 (0.64 to 3.93) 0.76 (0.11 to 5.21)
SRL+CSA vs. MMF+CSA 0.71 (0.17 to 2.39) 0.55 (0.13 to 1.85) 0.73 (0.15 to 3.10) 0.69 (0.13 to 3.73)
SRL+MMF vs. MMF+CSA 1.49 (0.98 to 2.28) 1.42 (0.91 to 2.23) 1.40 (0.72 to 2.58) 1.13 (0.49 to 2.23)
EVL vs. CSA+AZA 0.13 (0.01 to 2.27) 0.13 (0.01 to 2.28) 0.13 (0.01 to 2.67) 0.12 (0.01 to 2.69)
BEL+ SRL vs. TAC+MMF 2.01 (0.27 to 13.63) 11.82 (0.59 to 5642.03) 2.05 (0.22 to 18.01) 12.33 (0.48 to 6727.78)
BEL+MMF vs. TAC+MMF 0.92 (0.45 to 1.84) 9.13 (0.46 to 4429.31) 0.89 (0.32 to 2.53) 9.55 (0.38 to 5014.05)
SRL+ TAC vs. TAC+MMF 1.73 (0.97 to 3.14) 2.48 (1.22 to 5.31) 1.71 (0.80 to 3.69) 2.59 (1.05 to 6.95)
SRL+MMF vs. TAC+MMF 1.71 (1.10 to 2.67) 2.34 (0.95 to 5.97) 1.52 (0.74 to 2.91) 2.43 (0.78 to 8.17)
Total residual deviance 107.6 103.8 93.64 90.14
Relative number of model
parameters
49.868 53.499 60.791 63.518
DIC 157.498 157.299 154.431 153.658
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Consistency analysis results
There are direct data for 20 comparisons and 13 treatments in the network; however, four independent
loops are informed by multiarm trials only and so the ICDF, reflecting the number of independent loops in
the network, is 20 – (13 – 1) – 4= 4. Comparing the DIC between the consistency and inconsistency models
suggests that the consistency model provides a better fit to the data (139.5 vs. 143.9). Furthermore,
the posterior median estimates are similar between the consistency and inconsistency models and the
95% CrIs overlap considerably (Table 225).
TABLE 225 Comparison of fixed- and random-effects consistency and inconsistency models for maintenance
therapy on mortality
Comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
TAC+AZA vs. CSA+AZA 1.40 (0.80 to 2.54) 1.40 (0.80 to 2.55) 1.38 (0.74 to 2.60) 1.38 (0.73 to 2.61)
MMF+CSA vs. CSA+AZA 0.95 (0.49 to 1.85) 0.89 (0.43 to 1.83) 1.06 (0.45 to 1.95) 0.88 (0.40 to 1.93)
TAC+MMF vs. CSA+AZA 1.53 (0.68 to 3.48) 2.26 (0.40 to 18.76) 1.53 (0.63 to 3.71) 2.32 (0.38 to 6.89)
SRL+AZA vs. CSA+AZA 0.19 (0.01 to 6.02) 0.20 (0.1 to 5.98) 0.20 (0.01 to 6.03) 0.20 (0.01 to 6.60)
TAC+MMF vs. MMF+CSA 1.61 (0.92 to 2.88) 1.84 (0.95 to 3.57) 1.61 (0.89 to 3.00) 1.89 (0.93 to 735.09)
BEL+MMF vs. MMF+CSA 0.50 (0.22 to 1.07) 0.42 (0.17 to 0.93) 0.50 (0.21 to 1.11) 0.41 (0.16 to 0.98)
EVL+MPS vs. MMF+CSA 0.98 (0.10 to 9.46) 0.98 (0.10 to 9.62) 1.00 (0.09 to 10.08) 0.98 (0.10 to 10.43)
EVL+CSA vs. MMF+CSA 1.48 (0.82 to 2.73) 1.48 (0.82 to 2.73) 1.48 (0.77 to 2.83) 1.46 (0.76 to 2.87)
SRL+ TAC vs. MMF+CSA 1.47 (0.69 to 3.13) 0.77 (0.10 to 3.71) 1.46 (0.65 to 3.23) 0.82 (0.10 to 4.48)
SRL+CSA vs. MMF+CSA 0.66 (0.17 to 2.25) 0.63 (0.17 to 2.17) 0.66 (0.17 to 2.37) 0.65 (0.16 to 2.41)
SRL+MMF vs. MMF+CSA 1.83 (1.04 to 3.33) 1.88 (0.99 to 3.63) 1.81 (0.98 to 3.42) 1.84 (0.90 to 3.82)
EVL vs. MMF+CSA 0.26 (0.01 to 5.99) 0.26 (0.01 to 6.05) 0.27 (0.01 to 5.96) 0.24 (0.01 to 6.00)
BEL+ SRL vs. TAC+MMF 0.21 (0.01 to 4.96) 1.15 (0.01 to 740.26) 0.21 (0.01 to 5.21) 1.17 (0.01 to 753.70)
BEL+MMF vs. TAC+MMF 0.31 (0.12 to 0.78) 4.85 (0.16 2421.16) 0.31 (0.11 to 0.83) 4.94 (0.16 2457.75)
SRL+ TAC vs. TAC+MMF 0.91 (0.50 to 1.64) 0.95 (0.47 to 1.88) 0.91 (0.48 to 1.70) 0.94 (0.44 to 1.94)
SRL+MMF vs. TAC+MMF 1.14 (0.67 to 1.95) 1.54 (0.63 to 3.79) 1.13 (0.62 to 2.01) 1.53 (0.58 to 4.06)
Total residual deviance 85.74 85.85 85.17 85.32
Relative number of model
parameters
51.958 56.274 54.343 58.586
DIC 137.698 142.124 139.513 143.906
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Consistency analysis
There are direct data for 21 comparisons and 13 treatments in the network; however, three independent
loops are informed by multiarm trials only and so the ICDF, reflecting the number of independent loops
in the network, is 21 – (13 – 1) – 3= 6. Comparing the DIC between the consistency and inconsistency
random-effects models suggests that the consistency model has a slightly better fit to the data (156.3 vs.
159.7). Furthermore, the posterior median estimates are similar between the consistency and inconsistency
models and the 95% CrIs overlap considerably (Table 227).
TABLE 227 Comparison of fixed- and random-effects consistency and inconsistency models for maintenance
therapy on BPAR
Comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
TAC+AZA vs. CSA+AZA 0.55 (0.41 to 0.74) 0.55 (0.41 to 0.73) 0.58 (0.36 to 0.93) 0.58 (0.35 to 0.94)
MMF+CSA vs. CSA+AZA 0.47 (0.34 to 0.66) 0.49 (0.34 to 0.71) 0.47 (0.25 to 0.88) 0.49 (0.24 to 1.01)
TAC+MMF vs. CSA+AZA 0.43 (0.29 to 0.64) 0.34 (0.14 to 0.78) 0.40 (0.19 to 0.79) 0.34 (0.10 to 1.14)
SRL+AZA vs. CSA+AZA 1.15 (0.47 to 2.81) 1.15 (0.47 to 2.82) 1.16 (0.34 to 3.96) 1.15 (0.33 to 4.00)
TAC+MMF vs. MMF+CSA 0.91 (0.70 to 1.17) 0.99 (0.75 to 1.31) 0.85 (0.52 to 1.35) 0.79 (0.41 to 1.43)
BEL+MMF vs. MMF+CSA 1.75 (1.20 to 2.59) 1.68 (1.15 to 2.50) 1.71 (0.91 to 3.20) 1.56 (0.79 to 3.01)
EVL+MPS vs. MMF+CSA 3.12 (1.48 to 7.01) 3.13 (1.49 to 7.02) 3.14 (1.01 to 10.09) 3.15 (1.00 to 10.19)
EVL+CSA vs. MMF+CSA 0.97 (0.76 to 1.25) 0.97 (0.76 to 1.25) 0.97 (0.61 to 1.54) 0.97 (0.60 to 1.56)
SRL+ TAC vs. MMF+CSA 0.81 (0.49 to 1.36) 0.19 (0.02 to 0.75) 0.82 (0.40 to 1.64) 0.16 (0.02 to 0.89)
SRL+CSA vs. MMF+CSA 0.58 (0.18 to 1.63) 0.43 (0.11 to 1.29) 0.59 (0.15 to 2.03) 0.50 (0.08 to 1.62)
SRL+MMF vs. MMF+CSA 0.68 (0.53 to 0.87) 0.69 (0.54 to 0.34) 0.92 (0.62 to 1.44) 1.05 (0.67 to 1.74)
EVL+MMF+CSA 2.66 (1.10 to 6.67) 2.66 (1.09 to 6.67) 2.67 (0.82 to 8.77) 2.79 (0.79 to 10.27)
BEL+ SRL vs. TAC+MMF 0.41 (0.01 to 3.16) 1.15 (0.03 to 44.21) 0.43 (0.01 to 4.08) 1.16 (0.03 to 50.80)
BEL+MMF vs. TAC+MMF 1.94 (1.23 to 3.07) 6.96 (0.88 to 196.37) 2.02 (0.01 to 4.37) 7.08 (0.73 to 227.01)
SRL+ TAC vs. TAC+MMF 0.90 (0.55 to 1.46) 1.21 (0. 63 to 2.32) 0.96 (0.51 to 1.80) 1.22 (0.54 to 2.78)
SRL+MMF vs. TAC+MMF 0.75 (0.57 to 0.99) 1.07 (0.45 to 2.55) 1.09 (0.67 to 1.89) 1.14 (0.41 to 3.20)
SRL+CSA vs. SRL+ TAC 0.71 (0.21 to 2.04) 1.05 (0.03 to 42.95) 0.72 (0.18 to 2.52) 1.05 (0.02 to 46.43)
SRL+MMF vs. SRL+ TAC 0.84 (0.50 to 1.40) 0.68 (0.25 to 1.75) 1.113 (0.57 to 2.38) 0.68 (0.18 to 2.43)
Total residual deviance 117 115.9 88.44 87.91
Relative number of model
parameters
53.843 59.588 67.828 71.836
DIC 170.843 175.488 156.268 159.746
APPENDIX 6
NIHR Journals Library www.journalslibrary.nihr.ac.uk
504
G
ra
ft
fu
n
ct
io
n
Fi
xe
d
-e
ff
ec
ts
m
o
d
el
re
su
lt
s
TA
B
LE
22
8
M
ea
n
d
if
fe
re
n
ce
s
(f
o
r
in
te
rv
en
ti
o
n
vs
.c
o
m
p
ar
at
o
r
tr
ea
tm
en
t)
fo
r
th
e
o
u
tc
o
m
e
G
R
F
fr
o
m
a
fi
xe
d
-e
ff
ec
ts
N
M
A
[p
o
st
er
io
r
m
ed
ia
n
(9
5%
C
rI
)]
In
te
rv
en
ti
o
n
tr
ea
tm
en
t
C
o
m
p
ar
at
o
r
tr
ea
tm
en
t
C
SA
+
A
ZA
TA
C
+
A
ZA
M
M
F
+
C
SA
TA
C
+
M
M
F
B
EL
+
SR
L
B
EL
+
M
M
F
EV
L
+
M
PS
EV
L
+
C
SA
SR
L
+
TA
C
SR
L
+
C
SA
SR
L
+
M
M
F
TA
C
+
A
ZA
12
.5
4
(1
1.
17
to
13
.9
0)
M
M
F
+
C
SA
4.
34
(3
.1
2
to
5.
57
)
–
8.
19
(–
9.
73
to
–
6.
66
)
TA
C
+
M
M
F
5.
37
(5
.0
7
to
5.
68
)
–
7.
17
(–
8.
56
to
–
5.
77
)
1.
03
(–
0.
21
to
2.
27
)
BE
L
+
SR
L
12
.6
8
(0
.0
2
to
25
.3
2)
0.
14
(–
12
.5
7
to
12
.8
7)
8.
34
(–
4.
35
to
21
.0
4)
7.
31
(–
5.
34
to
19
.9
6)
BE
L
+
M
M
F
13
.0
2
(9
.9
5
to
16
.1
0)
0.
49
(–
2.
73
to
3.
70
)
8.
68
(5
.8
3
to
11
.5
3)
7.
65
(4
.5
8
to
10
.7
3)
0.
34
(–
12
.4
9
to
13
.2
1)
EV
L
+
M
PS
3.
08
(–
3.
18
to
9.
33
)
–
9.
45
(–
15
.7
9
to
–
3.
14
)
–
1.
26
(–
7.
41
to
4.
86
)
–
2.
30
(–
8.
56
to
3.
97
)
–
9.
59
(–
23
.6
9
to
4.
49
)
–
9.
94
(–
16
.7
5
to
–
3.
18
)
EV
L
+
C
SA
6.
01
(3
.3
0
to
8.
73
)
–
6.
53
(–
9.
41
to
–
3.
66
)
1.
67
(–
0.
76
to
4.
09
)
0.
64
(–
2.
09
to
3.
36
)
–
6.
67
(–
19
.6
0
to
6.
24
)
–
7.
01
(–
10
.7
7
to
–
3.
25
)
2.
93
(–
3.
65
to
9.
52
)
SR
L
+
TA
C
1.
12
(–
1.
79
to
4.
02
)
–
11
.4
2
(–
14
.5
7
to
–
8.
28
)
–
3.
22
(–
6.
16
to
–
0.
30
)
–
4.
25
(–
7.
16
to
–
1.
35
)
–
11
.5
6
(–
24
.5
2
to
1.
40
)
–
11
.9
0
(–
15
.9
8
to
–
7.
83
)
–
1.
97
(–
8.
76
to
4.
85
)
–
4.
89
(–
8.
69
to
–
1.
08
)
SR
L
+
C
SA
–
1.
39
(–
4.
53
to
1.
77
)
–
13
.9
3
(–
17
.2
7
to
–
10
.5
9)
–
5.
73
(–
8.
82
to
–
2.
64
)
–
6.
76
(–
9.
90
to
–
3.
61
)
–
14
.0
7
(–
27
.0
8
to
–
1.
05
)
–
14
.4
2
(–
18
.6
to
–
10
.2
1)
–
4.
47
(–
11
.3
4
to
2.
41
)
–
7.
40
(–
11
.3
2
to
–
3.
49
)
–
2.
51
(–
4.
93
to
–
0.
09
)
SR
L
+
M
M
F
1.
94
(0
.0
1
to
3.
87
)
–
10
.6
0
(–
12
.8
4
to
–
8.
36
)
–
2.
40
(–
4.
28
to
–
0.
52
)
–
3.
43
(–
5.
36
to
–
1.
50
)
–
10
.7
4
(–
23
.5
3
to
2.
05
)
–
11
.0
8
(–
14
.5
0
to
–
7.
69
)
–
1.
14
(–
7.
54
to
5.
27
)
–
4.
07
(–
7.
15
to
–
1.
01
)
0.
82
(–
2.
29
to
3.
94
)
3.
33
(–
0.
04
to
6.
69
)
SR
L
+
A
ZA
10
.8
0
(8
.4
0
to
13
.2
0)
–
1.
74
(–
4.
50
to
1.
02
)
6.
45
(3
.7
6
to
9.
15
)
5.
43
(3
.0
1
to
7.
85
)
–
1.
87
(–
14
.7
8
to
11
.0
2)
–
2.
22
(–
6.
12
to
1.
67
)
7.
73
(1
.0
3
to
14
.4
4)
4.
79
(1
.1
7
to
8.
42
)
9.
69
(5
.9
0
to
13
.4
5)
12
.2
0
(8
.2
2
to
16
.1
4)
8.
86
(5
.7
8
to
11
.9
4)
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
505
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
Consistency analysis results
There are direct data for 18 comparisons and 12 treatments in the network; however, two independent
loops are informed by multiarm trials only and so the ICDF, reflecting the number of independent loops in
the network, is 18 – (12 – 1) – 2= 5. Comparing the DIC between the consistency and inconsistency
random-effects models suggests that the consistency model has a slightly better fit to the data (147.8 vs.
150.0). Furthermore, the posterior median estimates are similar between the consistency and inconsistency
models and the 95% CrIs overlap considerably (Table 229).
TABLE 229 Comparison of fixed- and random-effects consistency and inconsistency models for maintenance
therapy on CRC-GRF [posterior median (95% CrI)]
Treatment
comparison
Fixed effects Random effects
Consistency Inconsistency Consistency Inconsistency
TAC+AZA vs.
CSA+AZA
12.54 (11.17 to 13.9) 13.09 (11.7 to 14.48) 9.31 (4.32 to 14.28) 9.78 (4.65 to 14.87)
MMF+CSA vs.
CSA+AZA
4.34 (3.12 to 5.57) 6.00 (4.53 to 7.47) 1.61 (–4.16 to 7.41) 3.60 (–3.88 to 11.09)
TAC+MMF vs.
CSA+AZA
5.37 (5.07 to 5.68) 5.30 (4.99 to 5.61) 6.53 (0.38 to 12.68) 5.29 (–4.13 to 14.71)
SRL+AZA vs.
CSA+AZA
10.80 (8.40 to 13.20) 10.80 (8.40 to 13.20) 10.78 (1.07 to 20.44) 10.77 (1.10 to 20.48)
TAC+MMF vs.
MMF+CSA
1.03 (–0.21 to 2.27) 5.20 (2.56 to 7.84) 4.92 (0.87 to 8.98) 4.98 (–0.75 to 10.70)
BEL+MMF vs.
MMF+CSA
8.68 (5.83 to 11.53) 8.52 (5.55 to 11.48) 8.94 (3.13 to 14.79) 7.83 (1.48 to 14.18)
EVL+MPS vs.
MMF+CSA
–1.26 (–7.41 to 4.86) –1.26 (–7.41 to 4.87) –1.27 (–12.45 to 9.93) –1.25 (–12.49 to 9.91)
EVL+CSA vs.
MMF+CSA
1.67 (–0.76 to 4.09) 1.67 (–0.75 to 4.09) 3.26 (–1.82 to 8.34) 3.25 (–1.82 to 8.34)
SRL+CSA vs.
MMF+CSA
–5.73 (–8.82 to -2.64) 1.20 (–3.08 to 5.47) –3.23 (–11.07 to 4.64) 1.19 (–9.14 to 11.52)
SRL+MMF vs.
MMF+CSA
–2.40 (–4.28 to -0.52) –2.66 (–4.92 to -0.41) 2.24 (–1.55 to 6.05) 2.00 (–2.34 to 6.39)
BEL+ SRL vs.
TAC+MMF
7.31 (–5.35 to 19.96) 7.80 (–5.02 to 20.63) 5.79 (–9.53 to 21.06) 7.76 (–8.18 to 23.79)
BEL+MMF vs.
TAC+MMF
7.65 (4.58 to 10.73) 9.58 (–1.03 to 20.20) 4.02 (–2.72 to 10.73) 9.60 (–4.61 to 23.70)
SRL+ TAC vs.
TAC+MMF
–4.25 (–7.16 to -1.35) –8.36 (–12.11 to -4.60) –6.88 (–13.01 to -0.75) –9.87 (–17.58 to -2.18)
SRL+MMF vs.
TAC+MMF
–3.43 (–5.36 to –1.50) –2.14 (–5.45 to 1.15) –2.69 (–6.92 to 1.57) –0.61 (–7.01 to 5.82)
SRL+CSA vs.
SRL+ TAC
–2.51 (–4.93 to –0.09) –5.24 (–7.92 to –2.57) –1.26 (–8.97 to 6.45) –5.22 (–15.03 to 4.55)
SRL+MMF vs.
SRL+ TAC
0.82 (–2.29 to 3.94) 4.14 (–5.31 to 13.59) 4.20 (–2.02 to 10.41) 4.08 (–9.18 to 17.46)
Total residual deviance 277.7 245.7 82.75 83.42
Relative number of
model parameters
45.987 50.949 65.058 66.594
DIC 323.687 296.649 147.808 150.014
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Appendix 7 Adverse events
Adverse events: meta-analyses at 1-year follow-up
When data permitted, the 1-year follow-up results of individual studies were pooled using meta-analyses;
NODAT, PTLD, malignancy (including PTLD), any infections and CMV were considered. The DerSimonian–Laird
random-effects method was used for pooling. OR was used as a measure of treatment effect.
The number of studies included in the individual meta-analyses was between two and eight, therefore, we
did not investigate publication bias; tests for funnel plot asymmetry should be used only when there are at
least 10 studies included in the meta-analysis, when there are fewer studies the power of the tests is too
low to distinguish chance from real asymmetry (Cochrane Handbook 2008).201 In addition, no corrections
for multiple comparisons were executed. Therefore, any meta-analyses results presented in this section
must be interpreted with caution.
Induction regimens
Nine studies71,72,74,87,95,96,98,128,137 reported some AEs at 1-year follow-up. Four studies71,72,74,95 compared BAS
with PBO or no induction, three studies87,98,137 compared BAS and rATG, one study96 compared rATG with
no induction,96 and one study128 compared BAS, ATG-Fresenius® and no induction (only the comparison of
BAS and no induction was considered in the analyses).
All AEs are summarised in the sections below according to induction therapy used. Similarly to the clinical
effectiveness outcomes, studies comparing BAS with PBO, and BAS with no induction, were combined.
BAS compared with placebo and no induction
New-onset diabetes after transplant/transplantation, malignancy, PTLD, infections and CMV infections
were reported in studies comparing BAS with PBO, and BAS with no induction (results from studies
comparing BAS with PBO, and BAS with no induction were combined). No differences between BAS
and control arms were identified for any AE. The NODAT (Figure 102), malignancy (Figure 103), PTLD
(Figure 104), infections (Figure 105) and CMV results (Figure 106) are presented below. In summary, no
differences in NODAT, PTLD, malignancy, infections and CMV infections were found between BAS and
control arms.
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Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = .)
Bingyi 200395
Study
Kyllönen 2007128
3.79 (0.43 to 33.64)
OR (95% CI)
(Excluded)
3.79 (0.43 to 33.64)
100.00
0.00
% weight
100.00
Favours NODAT BAS Favours NODAT controls
0.0297 1 33.6
FIGURE 102 New-onset diabetes after transplant/transplantation: BAS vs. PBO and no induction. Note:
DerSimonian and Laird random-effects meta-analysis with 1-year follow-up data; studies with no events in both
arms were excluded from the analysis.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.406)
Study
Nashan 199771
Lawen 200374
Kyllönen 2007128
Bingyi 200395
Kahan 199972
0.62 (0.22 to 1.76)
1.31 (0.29 to 5.91)
(Excluded)
0.25 (0.01 to 6.37)
(Excluded)
OR (95% CI)
0.33 (0.07 to 1.67)
100.00
% weight
47.73
0.00
10.48
0.00
41.80
Favours malignancy BAS Favours malignancy controls
0.0101 1 99.1
FIGURE 103 Malignancy: BAS vs. PBO and no induction. Note: DerSimonian and Laird random-effects meta-analysis
with 1-year follow-up data; studies with no events in both arms were excluded from the analysis; the estimate of
between-study variance, τ2, was 0.000.
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Note: weights are from random-effects analysis
Overall (I 2 = 100.0%, p = .)
Bingyi 200395
Nashan 199771
Lawen 200374
Study
0.98 (0.06 to 15.77)
(Excluded)
0.98 (0.06 to 15.77)
(Excluded)
OR (95% CI)
100.00
0.00
100.00
0.00
% weight
Favours PTLD BAS Favours PTLD controls
0.0608 1 16.5
FIGURE 104 Post-transplant lymphoproliferative disorder: BAS vs. PBO and no induction. Note: DerSimonian and
Laird random-effects meta-analysis with 1-year follow-up data; studies with no events in both arms were excluded
from the analysis.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.925)
Lawen 200374
Study
Bingyi 200395
Kahan 199972
Nashan 199771
0.98 (0.80 to 1.20)
0.89 (0.51 to 1.56)
OR (95% CI)
(Excluded)
1.02 (0.74 to 1.40)
0.98 (0.73 to 1.32)
100.00
13.23
% weight
0.00
39.82
46.95
Favours infections BAS Favours infections controls
0.509 1.961
FIGURE 105 Infections: BAS vs. PBO and no induction. Note: DerSimonian and Laird random-effects
meta-analysis with 1-year follow-up data; studies with no events in both arms were excluded from the analysis;
the estimate of between-study variance, τ2, was 0.000.
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BAS compared with rATG
Three studies87,98,137 comparing BAS with rATG reported AEs; NODAT, PTLD, malignancy, infections and
CMV infections were reported. No difference in NODAT was found in one study87 [OR 0.98 (favours BAS,
95% CI 0.06 to 16.11)]. Malignancy (Figure 107), PTLD (Figure 108) infections (Figure 109) and CMV
results (Figure 110) are presented below.
In summary, no difference in NODAT, PTLD, malignancy and infections were found between the two
induction regimens, rATG and BAS. One study137 suggested more CMV infections with rATG regimens
than with BAS regimens [OR 2.25 (favours rATG, 95% CI 1.06 to 4.76)].
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.820)
Study
Lawen 200374
Kahan 199972
Bingyi 200395
Nashan 199771
Kyllönen 2007128
0.80 (0.56 to 1.13)
OR (95% CI)
0.72 (0.28 to 1.89)
0.75 (0.34 to 1.63)
(Excluded)
0.76 (0.48 to 1.22)
1.37 (0.43 to 4.36)
100.00
% weight
13.34
20.42
0.00
57.09
9.15
Favours CMV BAS Favours CMV controls
0.229 1 4.36
FIGURE 106 Cytomegalovirus: BAS vs. PBO and no induction. Note: DerSimonian and Laird random-effects
meta-analysis with 1-year follow-up data; studies with no events in both arms were excluded from the analysis;
the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
Overall (I 2 = 100.0%, p = .)
Brennan 2006137
Study
Lebranchu 200287
0.21 (0.02 to 1.78)
OR (95% CI)
0.21 (0.02 to 1.78)
(Excluded)
100.00
100.00
% weight
0.00
Favours malignancy BAS Favours malignancy rATG
0.0237 1 42.1
FIGURE 107 Malignancy: BAS vs. rATG. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
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Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = .)
Lebranchu 200287
Mourad 200498
Study
Brennan 2006137
0.15 (0.01 to 2.87)
(Excluded)
OR (95% CI)
(Excluded)
0.15 (0.01 to 2.87)
100.00
0.00
0.00
% weight
100.00
Favours PTLD BAS Favours PTLD rATG
0.00752 1 133
FIGURE 108 Post-transplant lymphoproliferative disorder: BAS vs. rATG. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; studies with no events in both arms were excluded from
the analysis.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.818)
Mourad 200498
Brennan 2006137
Study
0.86 (0.63 to 1.17)
0.80 (0.41 to 1.58)
OR (95% CI)
0.88 (0.62 to 1.25)
100.00
21.34
78.66
% weight
Favours infections BAS Favours infections rATG
0.407 1 2.46
FIGURE 109 Infections: BAS vs. rATG. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
511
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
rATG compared with no induction
New-onset diabetes after transplant/transplantation and CMV infections were reported in one study96
comparing rATG with no induction. More CMV infections were reported in the rATG arm than in controls:
(OR 2.11, favours no induction, 95% 1.26 to 3.52) and no difference in NODAT was found between rATG
and no induction (OR 0.75, favours rATG, 95% CI 0.23 to 2.42).
In summary, one study96 suggested more CMV infections with rATG regimens than with no induction.
Maintenance regimens
Thirty-nine studies60,80,82,83,86,88,90,92,100,104,106,107,110–112,116,117,120,121,126,127,131,133,134,136,138,141,144,147,149,152,177,194,195,204,206,207,210,427
(of the 76 maintenance studies) reported some AEs at 1-year follow-up. Twenty-seven studies reported
NODAT,51,58,59,80,83,88,90,92,100,107,110,112,116,117,120,121,125,126,131,134,141,142,147,149,180,194,210 22 studies reported
malignancy,51,58,59,88,90,100,106,112,116,124–126,131,133,134,142,144,147,149,152,180,194 nine studies reported PTLD,60,100,112,125,134,142,
180,195,210 15 studies reported infections51,59,86,88,90,92,100,106,107,124,125,131,133,147,152 and 28 studies reported CMV
infections.51,58,59,82,88,90,100,104,106,107,112,116,117,124–126,131,133,134,138,141,142,147,149,150,152,155,210
Ferguson et al.126 compared three regimens: BEL+MMF, TAC+MMF and BEL+ SRL; however, only
BEL+MMF and TAC+MMF results were used in meta-analyses. Similarly, one study by Chadban et al.152
compared EVL+CSA and MPS+CSA and EVL; however, only results of EVL+CSA and MPS+CSA arms
were used in meta-analyses. Finally, the SYMPHONY trial195 compared low CSA+MMF, low TAC+MMF,
SRL+MMF and CSA+MMF; however, only the results of low CSA+MMF, low TAC+MMF and
SRL+MMF were used in meta-analyses. In addition, one study129 reported AEs at 1-year follow-up, but the
study did not use comparable concomitant therapies and therefore the results of this study could not be
included in meta-analyses.
Tacrolimus compared with ciclosporin
Ten studies80,82,83,88,90,99,100,104,121,195,210 comparing TAC with CSA reported AEs. Six studies80,82,83,88,90,99,100,104,210
used TAC+AZA+CCS and CSA+AZA+CCS regimens, two studies90,104 compared TAC+MMF+CCS and
CSA+MMF+CCS regimens, one study121 compared TAC+ SRL+CCS and CSA+ SRL+CCS regimens
and one study (SYMPHONY comparing four regimens)195 compared low TAC+MMF+CCS and low
CSA+MMF+CCS regimens.
Note: weights are from random-effects analysis
Overall (I 2 = 85.4%, p = 0.009)
Study
Mourad 200498
Brennan 2006137
1.08 (0.25 to 4.62)
OR (95% CI)
0.51 (0.22 to 1.16)
2.25 (1.06 to 4.76)
100.00
% weight
49.37
50.63
Favours CMV BAS Favours CMV rATG
0.21 1 4.76
FIGURE 110 Cytomegalovirus: BAS vs. rATG. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.251.
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The meta-analyses suggested more cases of NODAT in TAC regimens compared with CSA (Figure 111),
no difference for malignancy (Figure 112), no difference for infections (Figure 113) and no difference for
CMV infections (Figure 114). Three studies100,195,210 reported no PTLD cases in both arms. In summary, no
difference in PTLD, malignancy, infections and CMV infection were found between TAC and CSA regimens
at 1-year follow-up. The meta-analysis (including eight studies) suggested more cases of NODAT in TAC
regimens than with CSA.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.574)
Hardinger 2005100
SYMPHONY195
Study
Yang 199990
Mayer 199788
1.36 (0.54 to 3.39)
2.51 (0.12 to 53.02)
2.05 (0.61 to 6.85)
0.28 (0.01 to 7.22)
0.71 (0.12 to 4.33)
OR (95% CI)
100.00
8.99
57.30
% weight
7.90
25.81
Favours TAC Favours CSA
0.0108 1 92.8
FIGURE 112 Malignancy: TAC vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.942)
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Raofi 1999210
Chen 2008121
Laskow 199680
Campos 200283
Yang 199990
Study
2.22 (1.42 to 3.46)
2.52 (0.29 to 22.01)
2.81 (0.81 to 9.76)
2.12 (1.16 to 3.86)
1.16 (0.22 to 6.21)
0.95 (0.06 to 16.29)
4.15 (0.50 to 34.04)
3.47 (0.92 to 13.09)
0.87 (0.05 to 14.82)
OR (95% CI)
100.00
4.22
12.83
55.25
7.05
2.46
4.48
11.24
2.47
% weight
Favours TAC Favours CSA
0.0294 1 34
FIGURE 111 New-onset diabetes after transplant/transplantation: TAC vs. CSA. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
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Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.460)
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1.33 (0.26 to 6.88)
2.89 (0.86 to 9.74)
OR (95% CI)
1.02 (0.65 to 1.62)
1.08 (0.73 to 1.59)
100.00
3.02
% weight
5.51
38.57
52.90
Favours TAC Favours CSA
0.103 1 9.74
FIGURE 113 Infections: TAC vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.602)
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0.80 (0.59 to 1.09)
0.79 (0.46 to 1.36)
OR (95% CI)
(Excluded)
7.76 (0.38 to 157.14)
0.60 (0.16 to 2.32)
0.42 (0.13 to 1.36)
0.86 (0.55 to 1.36)
0.85 (0.25 to 2.91)
100.00
32.45
0.00
1.08
5.35
7.19
47.51
6.43
% weight
Favours TAC Favours CSA
0.00636 1 157
FIGURE 114 Cytomegalovirus: TAC vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with
1-year follow-up data; studies with no events in both arms were excluded from the analysis; the estimate of
between-study variance, τ2, was 0.000. Raofi et al.210 reported 0 out of 14 and 0 out of 24 CMV infections in TAC
and CSA arms, respectively.
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MMF versus CSA
One three-arm study86 comparing MMF with CSA reported AE; this study86 used the following regimens:
MMF+AZA+CCS and CSA+AZA+CCS. No difference was found between the two arms for infections
[OR= 0.86 (favours CSA, 95% CI 0.56 to 1.30)]. No other AEs were reported in this study.
In summary, no difference in infections was found between MMF and CSA regimens at 1-year follow-up.
However, only one study86 reported infection.
BEL versus CSA
Three studies60,206,207 comparing BEL with CSA reported AEs. All three studies60,206,207 used BEL+MMF+CCS
and CSA+MMF+CCS regimens. In addition, two studies60,207 used two BEL regimens: low and high BEL
doses. Only the results of the low-BEL arms (closer to the licence dose) were used in the analyses.
The meta-analyses suggested more cases of NODAT with CSA regimens than with BEL regimens (Figure 115);
no difference for malignancy (Figure 116), no difference for PTLD (Figure 117), no difference for infections
(Figure 118) and CMV infections (Figure 119) between BEL and CSA regimens were identified. In summary,
no difference in malignancy, PTLD, infections and CMV infection were found between BEL and CSA regimens
at 1-year follow-up. The meta-analysis (including three studies) suggested more cases of NODAT with CSA
regimens than with BEL regimens.
EVL compared with CSA
One study133 comparing EVL with CSA reported AEs; this study133 used the following regimens:
EVL+MPS+CCS and CSA+MPS+CCS. No difference was found between the two arms for malignancy
[OR= 1.02 (favours EVL, 95% CI 0.14 to 7.39)], for infections [OR= 0.79 (favours CSA, 95% CI 0.47 to
1.32)] and for CMV infections, [OR= 1.54 (favours EVL, 95% CI 0.63 to 3.78)]. PTLD and NODAT were not
reported in this study.
In summary, no differences in malignancy, infections and CMV infection were found between EVL and CSA
regimens at 1-year follow-up. However, only one study133 reported malignancy, infections and CMV infection.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.466)
BENEFIT60
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Vincenti 2005206
Study
2.17 (1.15 to 4.09)
2.44 (0.98 to 6.06)
OR (95% CI)
1.53 (0.58 to 4.03)
6.27 (0.74 to 53.46)
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% weight
Favours CSA Favours BEL
0.0187 1 53.5
FIGURE 115 New-onset diabetes after transplant/transplantation: BEL vs. CSA. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
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Note: weights are from random-effects analysis
Overall (I 2 = 29.5%, p = 0.242)
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5.00 (0.24 to 106.00)
OR (95% CI)
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FIGURE 116 Malignancy: BEL vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.472.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.871)
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FIGURE 117 Post-transplant lymphoproliferative disorder: BEL vs. CSA. Note: DerSimonian and Laird random-effects
meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000. Vincenti et al.206
reported 0 out of 71 and 0 out of 73 PTLD cases in BEL and CSA arms, respectively.
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SRL versus CSA
Eight studies116,117,127,134,136,147,149,194,195 comparing SRL with CSA reported AEs. Six studies116,117,127,134,147,149
used SRL+MMF+CCS and CSA+MMF+CCS regimens. One study136,194 used SRL+AZA+CCS and
CSA+AZA+CCS regimens, and one study (SYMPHONY comparing four regimens)195 compared
SRL+MMF+CCS and CSA+MMF+CCS regimens.
The meta-analyses suggested more cases of NODAT with SRL regimens than with CSA (Figure 120), no
difference in malignancy (Figure 121), no difference in PTLD (Figure 122), no difference for infections
(Figure 123) and more cases of no difference for infections CMV in CSA than with SRL regimen (Figure 124).
In summary, no difference in malignancy, PTLD, infections or CMV infections were found between SRL and
CSA regimens at 1-year follow-up. The meta-analysis (including seven studies) suggested more cases of
NODAT with CSA regimens than with SRL.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.898)
BENEFIT60
Vincenti 2005206
Study
1.07 (0.75 to 1.53)
1.06 (0.70 to 1.59)
OR (95% CI)
1.12 (0.53 to 2.36)
100.00
77.19
22.81
% weight
Favours CsA Favours BEL
0.424 1 2.36
FIGURE 118 Infections: BEL vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
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FIGURE 119 Cytomegalovirus: BEL vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
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Note: weights are from random-effects analysis
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FIGURE 120 New-onset diabetes after transplant/transplantation: SRL vs. CSA. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
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FIGURE 121 Malignancy: SRL vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with
1-year follow-up data; studies with no events in both arms were excluded from the analysis; the estimate of
between-study variance, tau-squared, was 0.000. Kreis et al.116 reported 0 out of 40 and 0 out of 38 malignancy
cases in SRL and CSA arms, respectively.
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Note: weights are from random-effects analysis
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FIGURE 122 Post-transplant lymphoproliferative disorder: SRL vs. CSA. Note: DerSimonian and Laird random-effects
meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
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FIGURE 123 Infections: SRL vs. CSA. ID, identification. Note: DerSimonian and Laird random-effects meta-analysis
with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.248.
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TAC (short release) compared with TAC-PR
Two studies141,204 comparing TAC with TAC-PR reported AEs; both studies141,204 used TAC+MMF+CCS
and TAC-PR+MMF+CCS regimens.
The meta-analyses suggested no differences for NODAT (Figure 125) and no differences for CMV (Figure 126).
In addition, no difference was found between the two arms in one study204 for malignancy [OR= 1.32
(favours TAC-PR, 95% CI 0.45 to 3.85)]. No results for PTLD were reported.204 In summary, no difference
in NODATs and CMV infection were found between TAC and TAC-PR regimens at 1-year follow-up.
However, only two studies141,204 reported NODATs and CMV infection.
Note: weights are from random-effects analysis
Overall (I 2 = 32.1%, p = 0.183)
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FIGURE 124 Cytomegalovirus: SRL vs. CSA. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.535)
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FIGURE 125 New-onset diabetes after transplant/transplantation: TAC vs. TAC-PR. ID, identification; TAC QD,
once-daily TAC-PR. Note: DerSimonian and Laird random-effects meta-analysis with 1-year follow-up data; the
estimate of between-study variance, τ2, was 0.000.
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MMF compared with TAC
One study120 comparing MMF with TAC reported AEs; this study used the following regimens:
MMF+ SRL+CCS and TAC+ SRL+CCS. No difference was found between the two arms for NODAT
[OR= 1.59 (favours MMF, 95% CI 0.72 to 3.53)]. No other AEs were reported in this study.120
In summary, no difference in NODAT was found between MMF and TAC regimens at 1-year follow-up.
However, only one study120 reported NODAT.
BEL compared with TAC
One three-arm study126 comparing BEL with TAC reported AEs; this study126 used BEL+MMF+CCS and
TAC+MMF+CCS regimens. No difference was found between the two arms for NODAT [OR= 3.42
(favours BEL, 95% CI 0.13 to 87.10)], for malignancy [OR= 3.42 (favours BEL, 95% CI 0.13 to 87.10)]
or for CMV infections [OR= 2.29 (favours BEL, 95% CI 0.20 to 26.47)]. PTLD and infections were not
reported in this study.
In summary, no difference in NODAT, malignancy, infections or CMV infections were found between BEL
and TAC regimens at 1-year follow-up. However, only one study126 reported NODAT, malignancy,
infections and CMV infections.
SRL versus TAC
Two studies92,195 comparing SRL with TAC reported AEs; one study92 used SRL+MMF+CCS and
TAC+MMF+CCS regimens and one study (SYMPHONY comparing four regimens)195 compared
SRL+MMF+CCS and TAC+MMF+CCS regimens.
The meta-analysis suggested no difference for NODAT (Figure 127). However, publication bias was not
explored and the number of pooled studies is small; therefore, the result must be interpreted with caution.
No difference was found between the two arms in one study (SYMPHONY)195 for malignancy [OR= 0.83
(favours TAC, 95% CI 0.32 to 2.19)], for PTLD [OR= 0.31 (favours TAC, 95% CI 0.01 to 7.72)] and for
CMV infections [OR= 1.66 (favours SRL, 95% CI 0.97 to 2.84)].195 More infections were found in the SRL
arm than in the TAC arm for infections [OR= 0.68 (favours TAC, 95% CI 0.47 to 0.98)].
In summary, no difference in NODAT, PTLD, malignancy or CMV infections was found between SRL and
TAC regimens at 1-year follow-up. One study (SYMPHONY)195 found statistically significantly more
infections in the SRL arm than in the TAC arm.195 However, only two studies92,195 reported NODATs, and
only one study195 reported PTLD, malignancy, infections and CMV infections.
Note: weights are from random-effects analysis
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FIGURE 126 Cytomegalovirus: TAC vs. TAC-PR. TAC QD, once-daily TAC-PR. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.452.
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EVL compared with MMF
Three studies107,131,177 comparing EVL with MMF reported AEs; all studies107,131,177 used EVL+CSA+CCS and
MMF+CSA+CCS regimens. Tedesco-Silva et al.107 reported using MPA; it was assumed that MMF
was used.
The meta-analyses suggested no differences for NODAT (Figure 128) and infections (Figure 129);
conversely, a significant difference was found for CMV infections (Figure 130); more CMV infections were
found with MMF than with EVL. No difference was found between the two arms in one study131 for
malignancy [OR= 0.19 (favours MMF, 95% CI 0.01 to 4.11)]. PTLD was not reported in these studies.
In summary, no differences in NODAT, PTLD, malignancy or infection were found between EVL and MMF
regimens at 1-year follow-up. The meta-analysis (including three studies) suggested more cases of CMV
infections with MMF regimens than with EVL.
Note: weights are from random-effects analysis
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FIGURE 127 New-onset diabetes after transplant/transplantation: SRL vs. TAC. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
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FIGURE 128 New-onset diabetes after transplant/transplantation: EVL vs. MMF. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.456.
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Note: weights are from random-effects analysis
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FIGURE 129 Infection: EVL vs. MMF. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.178.
Note: weights are from random-effects analysis
Overall (I 2 = 0.0%, p = 0.465)
Tedesco-Silva 2010107
Study
Takahashi 2013131
Vitko 2005177
OR (95% CI)
5.81 (3.25 to 10.40)
8.47 (1.93 to 37.19)
10.15 (2.84 to 36.32)
4.43 (2.14 to 9.17)
100.00
15.44
% weight
20.80
63.76
Favours MMF Favours EVL
0.0269 1 37.2
FIGURE 130 Cytomegalovirus: EVL vs. MMF. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
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SRL compared with MMF
Three studies110–112 comparing SRL with MMF reported AEs; all studies110–112 used SRL+ TAC+CCS and
MMF+ TAC+CCS regimens.
The meta-analyses suggested no differences for NODAT (Figure 131), malignancy (Figure 132) or PTLD
(Figure 133). However, publication bias was not explored and the number of pooled studies is small;
therefore, all results must be interpreted with caution. No difference was found between the two arms in
one study112 for CMV infections: 6 out of 50 (12%) and 6 out of 50 (12%), respectively. Infections were
not reported in these studies.
In summary, no differences in NODAT, PTLD, malignancy or CMV infections were found between SRL
and MMF regimens at 1-year follow-up. However, only three studies110–112 reported NODAT and PTLD;
two studies reported malignancy;111,112 and only one study112 reported CMV infections.
Note: weights are from random-effects analysis
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FIGURE 131 New-onset diabetes after transplant/transplantation: SRL vs. MMF. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
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FIGURE 132 Malignancy: SRL vs. MMF. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; studies with no events in both arms were excluded from the analysis. Sampaio et al.112 reported
0 out of 0 and 0 out of 50 malignancy cases in SRL and MMF arms, respectively.
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MMF versus MPS
Two studies comparing MMF with MPS reported AEs; one study106 used MMF+ TAC+CCS and
MPS+ TAC+CCS regimens and one study427 used MMF+CSA+CCS and MPS+CSA+CCS regimens.
The meta-analyses suggested no differences for malignancy (Figure 134), infections (Figure 135) or CMV
infections (Figure 136). However, publication bias was not explored and the number of pooled studies is
small; therefore, all results must be interpreted with caution. No difference was found between the two
arms106 for NODAT [OR= 1.06 (favours MPS, 95% CI 0.33 to 3.36)]. In summary, no difference in NODAT,
malignancy, infections or CMV infections was found between MMF and MPS regimens at 1-year
follow-up. However, only two studies106,427 reported malignancy, infections and CMV infections, and only
one study106 reported NODAT.
Note: weights are from random-effects analysis
Overall (I 2 = 100.0%, p = .)
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FIGURE 133 Post-transplant lymphoproliferative disorder: SRL vs. MMF. Note: DerSimonian and Laird
random-effects meta-analysis with 1-year follow-up data. Sampaio et al.112 reported 0/50 and 0/50 PTLD cases in
SRL and MMF arms, respectively.
Note: weights are from random-effects analysis
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FIGURE 134 Malignancy: MMF vs. MPS. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; studies with no events in both arms were excluded from the analysis. Ciancio et al.106 reported 0
out of 61 and 0 out of 55 malignancy cases in MMF and MPS arms, respectively.
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
525
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
MMF versus AZA
Three studies86,104,138 comparing MMF with AZA reported AEs; one study138 used MMF+CSA+CCS
and AZA+CSA+CCS regimens, and two three-arm studies86,104 used MMF+CSA+CCS and
AZA+CSA+CCS regimens.
The meta-analyses suggested no differences for CMV infections (Figure 137). However, publication bias
was not explored and the number of pooled studies is small; therefore, all results must be interpreted
with caution. No difference was found between the two arms for infections in one study86 [OR= 1.60
(favours MMF, 95% CI 0.98–2.60)].86 NODAT, malignancy and PTLD were not reported in these studies.
In summary, no differences in infections and CMV infection were found between MMF and AZA regimens
at 1-year follow-up. However, only three studies86,104,138 reported CMV infections, and only one study86
reported infections.
Note: weights are from random-effects analysis
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FIGURE 135 Infections: MMF vs. MPS. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
Note: weights are from random-effects analysis
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FIGURE 136 Cytomegalovirus: MMF vs. MPS. Note: DerSimonian and Laird random-effects meta-analysis with
1-year follow-up data; the estimate of between-study variance, τ2, was 0.000.
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EVL versus MPS
Two studies144,152 comparing EVL with MPS reported AE; one study144 used EVL+CSA+CCS and MPS+
CSA+CCS regimens and one three-arm study145 also used EVL+CSA+CCS and MPS+CSA+CCS regimens.
The meta-analyses suggested no differences for malignancy (Figure 138). However, publication bias was
not explored and the number of pooled studies is small; therefore, all results must be interpreted
with caution. No difference was found between the two arms in one study152 for NODAT [OR= 0.45
(favours MPS, 95% CI 0.17 to 1.20)], infections [OR= 1.74 (favours MMF, 95% CI 0.72 to 4.20)] or CMV
infections [OR= 0.29 (favours MPS, 95% CI 0.05 to 1.71)].152 PTLD was not reported in either of the two
studies.144,152 In summary, no differences in NODAT, malignancy, infections and CMV infections were
found between EVL and MPS regimens at 1-year follow-up. However, only two studies144,152 reported
malignancy, and only one study152 reported NODAT, infections and CMV infections.
Note: weights are from random-effects analysis
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FIGURE 137 Cytomegalovirus: MMF vs. AZA. Note: DerSimonian and Laird random-effects meta-analysis with
1-year follow-up data; the estimate of between-study variance, τ2, was 0.030.
Note: weights are from random-effects analysis
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FIGURE 138 Malignancy: EVL vs. MPS. Note: DerSimonian and Laird random-effects meta-analysis with 1-year
follow-up data; the estimate of between-study variance, τ2, was 0.000.
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Summary
Induction regimens
No difference in NODAT, PTLD, malignancy and infections were found between the two induction
regimens, rATG and BAS, when compared with each other or with no induction (and/or PBO) regimens
at 1-year follow-up. One study96 suggested more CMV infections with rATG regimens than with no
induction. One study88 suggested more CMV infections in rATG regimens than in BAS regimens, but the
results were not confirmed by other study.98 In addition, publication bias was not explored and the number
of pooled studies is small, therefore all results must be interpreted with caution.
Maintenance regimens
The meta-analyses of AEs at 1-year follow-up suggested significant differences in AEs for the following
regimens. The meta-analysis comparing TAC and CSA regimens (including eight studies51,80,83,88,90,100,121,210)
suggested more cases of NODAT with TAC regimens than with CSA regimens. The meta-analyses comparing
BEL with CSA regimens (including three studies59,125,142) suggested more cases of NODAT with CSA regimens
than with BEL regimens (including three studies). The meta-analyses comparing SRL with CSA regimens
suggested more cases of NODAT with SRL than with CSA (including seven studies51,116,117,134,147,149,194) and more
CMV infections with CSA than with SRL (including seven studies51,116,117,127,134,147,149). The meta-analysis
comparing MMF and EVL (including three studies107,131,177) suggested more cases of CMV infections with MMF
regimens than with EVL. However, publication bias was not explored and the number of pooled studies is
small; therefore, all results must be interpreted with caution.
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Appendix 8 Ongoing trials
Ongoing studies: identified trials
n Study Sponsor/collaborators Trial name
Sample
size Status
1 NCT01780844 Astellas Pharma Global
Development Inc., Kyowa
Hakko Kirin Company Ltd
A Study to Assess the Efficacy and
Safety of ASKP1240 in de Novo
Kidney Transplant Recipients
149 Active, not
recruiting
2 NCT01817322 Samsung Medical Center Kidney Graft Function Under the
Immunosuppression Strategies
(MyLowCSA)
140
3 NCT01354301 Hospital do Rim e
Hipertensão
Efficacy and Safety of Induction
Strategies Combined With Low
Tacrolimus Exposure in Kidney
Transplant Recipients Receiving
Everolimus or Sodium
Mycophenolate
300
4 NCT00494741 Mario Negri Institute for
Pharmacological Research,
Agenzia Italiana del Farmaco
MMF vs. AZA for Kidney
Transplantation (ATHENA)
224
5 NCT00782821 University of Cincinnati
Millennium Pharmaceuticals,
Inc., Genzyme, a Sanofi
Company
Randomized Trial of Induction
Therapies in High Immunological
Risk Kidney Transplant Recipients
40
6 NCT00693446 Nantes University Hospital A Study To Compare Sirolimus
Versus Tacrolimus In De Novo
Simultaneous Pancreas- Kidney
Allograft Recipients Receiving
An Induction Therapy With
Antithymocyte Globulin Plus
Mycophenolate Mofetil Plus
Corticosteroids
118
7 NCT01114529 Novartis Efficacy, Safety and Evolution of
Cardiovascular Parameters in Renal
Transplant Recipients (ELEVATE)
717
8 NCT00256750 Bristol-Myers Squibb Belatacept Evaluation of
Nephroprotection and Efficacy as
First-line Immunosuppression
(BENEFIT)
660
9 NCT00114777 Bristol-Myers Squibb Study of Belatacept in Subjects
Who Are Undergoing a Renal
Transplant (BENEFIT-EXT)
600
10 NCT00514514 Novartis Study Investigating a Standard
Regimen in de Novo Kidney
Transplant Patients Versus a
Calcineurin Inhibitor (CNI)-Free
Regimen and a CNI Low Dose
Regimen
450
11 NCT00533442 University of Miami, Astellas
Pharma Inc.
Rapamycin Versus Mycophenolate
Mofetil in Kidney-Pancreas
Recipients
190
12 NCT01005706 Medical University of South
Carolina, Pfizer (formerly
Wyeth)
Sirolimus Conversions in
African-American Renal Transplant
Recipients
40
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n Study Sponsor/collaborators Trial name
Sample
size Status
13 NCT01878786 Matthew Cooper A Pilot Study Comparing the
Safety and Efficacy of Everolimus
With Other Medicines in Recipients
of ECD/DCD Kidneys (Evered)
50
14 NCT01187953 Veloxis Pharmaceuticals Double-Blind, Double-Dummy,
Effic/Safety, LCP-Tacro™ Vs
Prograf®, Prevention Rejection,
De Novo Adult Kidney Tx
(LCPTacro3002)
540
15 NCT01053221 University of Wisconsin,
Madison
Mycophenolic Acid Monotherapy
in Recipients of HLA-Identical
Living-Related Transplantation
30
16 NCT01062555 University of Minnesota -
Clinical and Translational
Science Institute Roche
Pharma AG, Pfizer
(formerly Wyeth), Genzyme,
a Sanofi Company
Calcineurin Inhibitor Sparing
After Kidney Transplantation
(CNI-Sparing)
600
17 NCT01239563 University of Oxford, Oxford
University Hospitals NHS
Trust Genzyme, a Sanofi
Company
Thymoglobulin Induction in Kidney
Transplant Recipients (TIKT)
40 Not yet
recruiting
18 NCT01837043 Nair, Vinay, DO, Mount Sinai
School of Medicine,
Bristol-Myers Squibb
Early Conversion From CNI to
Belatacept in Renal Transplant
Recipients With Delayed and Slow
Graft Function
90
19 NCT02137239 Bristol-Myers Squibb Evaluation of Acute Rejection
Rates in de Novo Renal
Transplant Recipients Following
Thymoglobulin Induction, CNI-free,
Nulojix (Belatacept)-Based
Immunosuppression
240
20 NCT01875224 University of Arizona,
Bristol-Myers Squibb
Comparison of NODAT in Kidney
Transplant Patients Receiving
Belatacept Versus Standard
Immunosuppression
32
21 NCT01822483 Irmandade Santa Casa de
Misericórdia de Porto Alegre,
Novartis
A Prospective Study to Investigate
Mycophenolic Acid (MPA)
Exposure Through Area Under the
Curve (AUC) in Renal Transplants
Recipients Treated With
Mycophenolate Mofetil (MMF)
and After Conversion to
Mycophenolate Sodium (EC-MPS)
(AUC-MPA)
100
22 NCT02058875 University of Saskatchewan
Novartis Pharmaceuticals,
Canada Inc.
Cardiovascular Risk Following
Conversion to Full Dose Myfortic®
and Neoral® Two-Hour Post Level
Monitoring (COBACAM)
100
23 NCT01895049 Helio Tedesco Silva Junior,
Novartis, Sanofi
Comparison Between
Two Tacrolimus-Based
Immunosuppressant Regimens and
Induction With Thymoglobulin in
Kidney Transplants From Deceased
Donors With Expanded Criteria
200
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n Study Sponsor/collaborators Trial name
Sample
size Status
24 NCT02056938 Nantes University Hospital ATG Versus Basiliximab in Kidney
Transplant Displaying Low
Immunological Risk But
High Susceptibility to DGF
(PREDICT-DGF)
460 Recruiting
25 NCT01856257 National Institute of Allergy
and Infectious Diseases
(NIAID), Clinical Trials in
Organ Transplantation
Safety and Efficacy of a
Steroid-Free, Calcineurin
Inhibitor-Free, Belatacept-Based
Immunosuppressive Regimen
180
26 NCT01560572 University Medical Centre
Groningen, Leiden University
Medical Center, Academisch
Medisch Centrum –
Universiteit van Amsterdam
(AMC-UvA)
Steroid Free Immunosuppression
or Calcineurin Inhibitor
Minimization After Basiliximab
Induction Therapy in Kidney
Transplantation: Comparison
With a Standard Quadruple
Immunosuppressive Regimen
(Allegro)
300
27 NCT00903188 University Hospital, Antwerp,
Novartis Pharmaceuticals
Erasme University Hospital,
University Hospital
Ghent University Hospital of
Liege
Universitair Ziekenhuis
Brussel
Calcineurin Inhibitor (CNI) Versus
Steroid Cessation in Renal
Transplantation (CISTCERT)
152
28 NCT01950819 Novartis Pharmaceuticals Advancing Renal Transplant
Efficacy and Safety Outcomes
With an Everolimus-Based
Regimen (TRANSFORM)
2040
29 NCT01649427 Novartis Pharmaceuticals Comparison of a Tacrolimus
Hexal® Based Regimen Versus a
Prograf® Based Regimen in de
Novo Renal Transplant Recipients
(Spartacus)
326
30 NCT02083991 Vastra Gotaland Region Trial of Steroid Avoidance and
Low-Dose CNI by ATG-Induction in
Renal Transplantation (SAILOR)
200
31 NCT01680861 Gaetano Ciancio Tacrolimus/Everolimus Versus
Tacrolimus/Enteric-Coated
Mycophenolate Sodium
50
32 NCT01265537 University of British
Columbia, Astellas Pharma
Canada Inc.
A Pilot Study Comparing the Use
of Low-Target Versus Conventional
Target Advagraf (Astellas)
30
33 NCT01663805 MARIO ABBUD FILHO Effects of the Use of ‘de novo’
Everolimus in Renal Transplant
Population
80
34 NCT01541176 Nantes University Hospital Impact of the Absence of Steroids
on the Evolution of Renal Function
and on the Progression of Graft
Fibrosis, Quantified by Numerical
Method, in Patients With Renal
Transplant (Astronef)
186
DOI: 10.3310/hta20620 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 62
531
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Jones-Hughes et al. under the terms of a commissioning contract issued by the Secretary of State
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
n Study Sponsor/collaborators Trial name
Sample
size Status
35 NCT01656135 University of Regensburg,
European Commission
Reference Group Trial for The ONE
Study
60
36 NCT02102854 The Methodist Hospital
System
Single Dose rATG for Renal
Allograft Rejection
30
37 NCT00906204 Wright State University
Sanofi
University of Arizona Wake
Forest School of Medicine
University of Nebraska, The
Methodist Hospital System
Safety Trial of Single Versus
Multiple Dose Thymoglobulin
Induction in Kidney
Transplantation (STAT)
165
38 NCT01729494 University of Cincinnati Belatacept Early Steroid
Withdrawal Trial
315
39 NCT02152345 Columbia University Belatacept Compared with
Tacrolimus in Deceased Donor
Renal Transplant Recipients
100
40 NCT01653847 Northwestern University,
Novartis
Impact of Two Prednisone-Free
Maintenance Immunosuppressive
Regimens With Reduced
Dose FK506+ Everolimus vs.
Standard Dose Tacrolimus
(FK506)+Mycophenolate Mofetil
(MMF) on Subpopulation of T and
B Cells, Renal Allograft Function
and Gene Expression Profiles in
Renal Allograft Biopsies at
12 Months Post-transplant.
Prospective Single Center Study in
Recipients of Renal Transplant
Allograft
88
41 NCT01631058 University of Sao Paulo
General Hospital
Immunosuppression in Renal
Transplantation in The Elderly:
Time to Rethink – nEverOld Study
90
42 NCT00866879 Northwestern University,
Pfizer (formerly Wyeth)
Randomized Conversion of
Calcineurin-Inhibitors in Renal
Allograft Recipients
275
43 NCT02062892 University of Colorado,
Denver, Novartis
Pharmaceuticals
Differentiating Everolimus Versus
Sirolimus in Combination With
Calcineurin Inhibitors in Kidney
Transplant Patients (DESIRE)
150
44 NCT00896012 University at Buffalo,
Novartis
University of Washington
Kidney Biopsy Controlled Trial of
Calcineurin Inhibitor Withdrawal
120 Recruiting
(invitation)
45 NCT01860183 Clinical Hospital Merkur
University Medical Centre
Ljubljana
Clinical Hospital Centre
Osijek
University Hospital Rijeka
Effect of 3 g versus 2 g MMF in
Combination With Tacrolimus on
Progression of Renal Allograft
Interstitial Fibrosis
80 Recruiting
46 NCT01820572 Bristol-Myers Squibb A Study in Maintenance Kidney
Transplant Recipients Following
Conversion to Nulojix®
(Belatacept)-Based
600
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n Study Sponsor/collaborators Trial name
Sample
size Status
47 NCT02213068 Lorenzo Gallon
Bristol-Myers Squibb
Belatacept 3 Month Post
Transplant Conversion Study
51
48 NCT01790594 National Institute of Allergy
and Infectious Diseases
(NIAID) Clinical Trials in
Organ Transplantation
Optimization of NULOJIX®
(Belatacept) Usage as a Means of
Minimizing CNI Exposure in
Simultaneous Pancreas and Kidney
Transplantation
60
49 NCT01921218 Andrew B Adams, MD, PhD,
Bristol-Myers Squibb
Belatacept Therapy for the Failing
Renal Allograft (IM103-133)
72
50 NCT02134288 Von Visger, Jon, MD
Bristol-Myers Squibb
Belatacept for Renal Transplant
Recipients With Delayed Graft
Function
40
51 NCT01595984 Centre Hospitalier
Universitaire, Amiens
Novartis
Comparison of Efficacy and Safety
of Treatment With a Calcineurin
Inhibitor (CNI) versus a CNI-free
Treatment in Renal Transplantation
(CIME)
134
52 NCT02221583 University of Cincinnati,
Astellas Pharma Inc.
Pharmacokinetics of
Immunosuppressants in Renal
Transplant Candidates Who
Have Undergone Laparoscopic
Sleeve Gastrectomy
24
53 NCT01935128 University of Toledo Health
Science Campus, Novartis
Pharmaceuticals
Calcineurin-inhibitor Elimination/
Reduction Randomized to
Everolimus/Myfortic® vs.
Everolimus/Reduced Tacrolimus
in Renal Transplant Recipients
Following Campath® Induction
50
54 NCT01169701 Novartis 24 Months Follow-up, Two Arm
Study to Compare the
Cardiovascular Profile
in a Regimen With
Everolimus+Mycophenolic Acid
(MPA) versus (vs.) a Regimen of
CNI+MPA in Maintenance Renal
Transplant Recipients (EVITA)
80
55 NCT01544491 Novartis Pharmaceuticals Efficacy, Tolerability and Safety of
Early Introduction of Everolimus,
Reduced Calcineurin Inhibitors
and Early Steroid Elimination
Compared with Standard CNI,
Mycophenolate Mofetil and
Steroid Regimen in Paediatric
Renal Transplant Recipients
106
56 NCT01842269 Chong Kun Dang
Pharmaceutical
Evaluate the Efficacy and Safety of
My-Rept® Tablet Versus My-Rept®
Capsule in Combination With
Tacrolimus in Kidney Transplant
Patients (My-Rept®_KT_P4)
156
57 NCT01410448 Novartis Pharmaceuticals Everolimus in de Novo Kidney
Transplant Recipients
(NEVERWOUND)
396
58 NCT02036554 Seoul St. Mary’s Hospital,
Novartis
Evaluate Efficacy Study of
Combination Therapy of
Everolimus and Low Dose
Tacrolimus in Renal Allograft
Recipients (PROTECT)
234
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n Study Sponsor/collaborators Trial name
Sample
size Status
59 NCT02077556 National Taiwan University
Hospital
Effect of Everolimus on the
Pharmacokinetics of Tacrolimus
in Renal Transplant Patients
70
60 NCT01843348 Novartis Pharmaceuticals 12 Month Athena Study:
Everolimus vs. Standard Regimen
in de Novo Kidney Transplant
Patients (ATHENA)
612
61 NCT02096107 Medical University of South
Carolina Novartis
Novartis Everolimus Transition 60
62 NCT01680952 Yonsei University Study to Evaluate the Safety and
Efficacy of Extended Release
Tacrolimus (Advagraf®)+ Sirolimus
(Rapamune®), Versus Extended
Release Tacrolimus
(Advagraf®)+Mycophenolate
Mofetil in Kidney Transplant
Patients
60
63 NCT01801280 Klemens Budde Novartis
Pharmaceuticals
Influence of Pantoprazole to the
Bioavailability of Myfortic® and
CellCept®
24
64 NCT01612299 University of Kentucky Effects of Zortress®+ Tacrolimus
vs. Standard Immunosuppression
on Progression of Coronary Artery
Calcifications and Bone Disease in
de Novo Renal Transplant
Recipients
60
65 NCT02208791 University of Sao Paulo
General Hospital
Effects of the Quadruple
Immunosuppression on Peripheral
Blood Lymphocytes and
Development of Anti-HLA
Antibodies in Kidney Transplant
45
66 NCT02084446 Ronaldo de Matos
Esmeraldo, MD, Novartis
Pharmaceuticals
Everolimus+Very Low Tacrolimus
vs. Enteric-coated Mycophenolate
Sodium+ Low Tacrolimus in de
Novo Renal Transplant
120
67 NCT01276834 Dianet Dialysis Centers,
UMC Utrecht
Comparison of
Immunosuppression on
Progression of Arteriosclerosis in
Renal Transplantation (NOCTX-2)
80
68 NCT01976390 Dr Ronald Pelletier, Novartis Comparing Everolimus and
Sirolimus in Renal Transplant
Recipients
60
69 ISRCTN88894088 University of Oxford Campath, Calcineurin inhibitor
reduction and Chronic allograft
nephropathy
800
NCT01120028
70 NCT00724022 University Hospital Freiburg,
Roche Pharma AG, Astellas
Pharma GmbH, Genzyme,
a Sanofi Company
Phase IV Study to Evaluate
Calcineurin Inhibitor Reduced,
Steroid Free Immunosuppression
After Renal Transplantation
(Harmony)
600 Unknown
71 NCT01550445(a) Ajou University School of
Medicine
Steroid Withdrawal
Immunosuppression After Renal
Transplantation
30
72 NCT00302497 McGill University Health
Center
EXTEND Protocol for Transplanted
Patient to Evaluate Kidney
Function
50
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n Study Sponsor/collaborators Trial name
Sample
size Status
73 NCT00199667 University Hospital, Limoges,
Hoffmann-La Roche
Concentration Controlled Versus
Fixed Dose of MMF in Kidney
Transplant Recipients
137
74 NCT00556933 University of Nebraska,
Genzyme, a Sanofi
Company
Improved Induction and
Maintenance Immunosuppression
in Kidney Transplantation
180
75 NCT00807144 Hammersmith Hospitals NHS
Trust
Standard versus Prolonged-Release
Tacrolimus Monotherapy After
Alemtuzumab Induction in Kidney
Transplantation
100
76 NCT00296296 Stanford University Immunosuppression Impact on the
Metabolic Control of First Kidney
Transplant Recipients With
Pre-Existing Type 2 Diabetes (DM)
40
77 NCT01239472 Andre Barreto Pereira,
Novartis
Cytokines Evaluation in Early
Calcineurin Inhibitors Withdrawn
on Renal Transplant
30
78 NCT00707759 Maria Angela Delucchi
Bicocchi, University of Chile,
Fondo Nacional de
Desarrollo Científico y
Tecnológico, Chile
Steroid Withdrawal in
Pediatric Renal Transplant
Immunosuppression: Impact on
Growth, Bone Metabolism and
Acute Rejection
70
79 NCT01334333 University of British
Columbia, Simon Fraser
University, Astellas Pharma
Canada, Inc.
Comparison of Medication
Adherence Between Once and
Twice Daily Tacrolimus in Stable
Renal Transplant Recipients
100
80 NCT01399242 Hospital Universitário São
José
Efficacy of Certican® in
Combination With Myfortic® in
Renal (HUSJ1)
40
81 NCT00737659 Rabin Medical Center CellCept® Dose Adjustment Versus
Fixed Dose (Standard Care) in
Renal Transplant Recipients (MMF)
138
82 NCT00309218 Klinik für Kinder- und
Jugendmedizin
Hoffmann-La Roche
Steroid Withdrawal in Pediatric
Renal Transplant Recipients Under
Cyclosporine (CyA) and
Mycophenolate Mofetil (MMF)
40
83 NCT00166712 Northwestern University
Northwestern Memorial
Hospital
A Trial of Two Steroid-Free
Approaches Toward
Mycophenolate Mofetil-Based
Monotherapy Immunosuppression
40
84 NCT00733733 Radboud University Erasmus
Medical Centre
Maastricht University
Leiden University Medical
Centre
University Medical Centre
Utrecht
University Medical Centre
Groningen
Academisch Medisch
Centrum – Universiteit van
Amsterdam (AMC-UvA)
Anti-T-Lymphocyte Globulin (ATG)
in Renal Transplantation of
Kidneys With a Non-Heart-Beating
(NHB) Donor
180
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n Study Sponsor/collaborators Trial name
Sample
size Status
85 NCT01159080 Asan Medical Center Seoul
National University Hospital,
Samsung Medical Center
Treatment of the Optimum Dose
of Calcineurin Inhibitor and
Mycophenolate Sodium in Kidney
Recipients (OPTIMUM)
350
86 NCT01014234 IRCCS Policlinico S Matteo Rapamycin and Regulatory T Cells
in Kidney Transplantation
56
87 NCT00223678 Vanderbilt University Mycophenolate Mofetil and
Rapamycin as Secondary
Intervention vs. Continuation of
Calcineurin Inhibitors in Patients at
Risk for Chronic Renal Allograft
Failure
30
88 NCT01455649 Deise de Boni Monteiro de
Carvalho
Study to Evaluate the Safety and
Efficacy of Switching Calcineurin
Inhibitor to Everolimus After
Kidney Transplantation in Adults
30
89 NCT00166829 National Taiwan University
Hospital
The Effect of Sirolimus on the
Pharmacokinetics of Tacrolimus
40
90 NCT00541814 University Hospital
Birmingham, Novartis
Calcineurin Inhibitor Minimisation
in Renal Transplant Recipients
With Stable Allograft Function
(CNIM-SRT)
90
ISRCTN60081949
91 NCT01640743 IRCCS Policlinico S Matteo Effect of Different Therapeutic
Strategies on Regulatory T Cells in
Kidney Transplantation
(EVERTWIST)
58
92 NCT00290069 Sociedad Andaluza de
Trasplantes de Organos y
Tejidos
Renal Function Optimization With
Mycophenolate Mofetil (MMF)
Immunosuppressor Regimens
(ALHAMBRA)
94
93 NCT00252655 Wayne State University Use of Sirolimus vs. Tacrolimus For
African-American Renal Transplant
Recipients
40
94 NCT00141804 University Hospital
Muenster, Proverum GmbH
KKS Netzwerk, Fujisawa
GmbH
Efficacy and Safety of Sirolimus in
Combination With Tacrolimus
190
95 NCT00166816 National Taiwan University
Hospital
The Pharmacokinetics of Sirolimus
When Combined With
Cyclosporine or Tacrolimus in
Renal Transplant Patients
40
96 NCT01436305 National Institute of Allergy
and Infectious Diseases
(NIAID)
Optimization of NULOJIX®
(Belatacept) Usage As A Means of
Avoiding Calcineurin Inhibitor
(CNI) and Steroids in Renal
Transplantation
19 Suspended
97 NCT01244659 EMS A Randomized Study Assess the
Safety and Efficacy of Tacrolimus
vs. Prograf® in Renal
Transplantation Treatment
60
98 NCT00729768 Genentech A Study to Evaluate Efalizumab
Compared with Cyclsporine as an
Immunosuppressant Regimen in
De Novo Renal Transplantation
200 Withdrawn
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n Study Sponsor/collaborators Trial name
Sample
size Status
99 NCT01149993 Georgetown University,
Novartis
Attenuating Ischemia Reperfusion
Injury After Living Donor Renal
Transplantation
0
100 NCT01038505 University of Miami, Pfizer
(formerly Wyeth)
Comparison of Tacrolimus and
Myfortic Versus Tacrolimus and
Sirolimus
0
101 NCT00956293 Novartis Pharmaceuticals Study to Evaluate the Efficacy,
Safety and Tolerability of
Everolimus in de Novo Renal
Transplant Recipients Participating
in the Eurotransplant Senior
Program (Senator)
207 Terminated
102 NCT00284921 Novartis Pharmaceuticals MYPROMS-ES02: Safety and
Efficacy of Basiliximab,
Cyclosporine Microemulsion and
Enteric-coated Mycophenolate
Sodium (EC-MPS) versus EC-MPS
and Steroid Therapy in Kidney
Transplant Recipients Who Are
Hepatitis C Positive
60
103 NCT00928811 Drexel University College of
Medicine, Novartis
Study to Evaluate the Safety of
Chronic Administration of Simulect
to Subjects Receiving a First Kidney
Transplant
5
104 NCT00137345(a) Pfizer (formerly Wyeth) Study Comparing Sirolimus With
Cyclosporine in a Calcineurin
Inhibitor (CNI)-Free Regimen in
Kidney Transplant Recipients
500
105 NCT01387659 The University of Texas,
Galveston, Novartis
Pharmaceuticals
Evaluate Tolerability of Myfortic®/
Simulect® and Tacrolimus Without
Steroids in Three Patient
Populations
4
106 NCT00522548 University of Pennsylvania,
Novartis Pharmaceuticals
Study of Gastrointestinal Side
Effects in African American Kidney
Transplant Recipients Treated With
CellCept or Myfortic
37
107 NCT00235781 Washington University
School of Medicine
Single Dose Thymoglobulin for
Induction in Adult Renal Allograft
Recipients
90
108 NCT00332839 Novartis Pharmaceuticals Comparison of CNI-based
Regimen versus CNI-free Regimen
in Kidney Transplant Recipients
93
109 NCT00217152 Mayo Clinic, Roche Pharma
AG
A Kidney Transplant Study to Look
at the Effects of Taking Fixed
Doses of CellCept Versus Taking
Doses of CellCept Based on the
Concentration of CellCept in the
Blood When Taking Full or
Reduced Dose Calcineurin
Inhibitors
12
110 NCT01324934 Neovii Biotech, Eurotrials,
Scientific Consultants,
Recerca Clínica SL,
PsyConsult
Efficacy and Safety of
ATG-Fresenius Following a
Renal Transplantation, Without
Corticosteroids
40
111 NCT00596947 University of Pennsylvania Prednisone Withdrawal Versus
Prednisone Maintenance After
Kidney Transplant
18
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n Study Sponsor/collaborators Trial name
Sample
size Status
112 NCT00311311 Pfizer Study Comparing Effect On
Carotid Atherosclerosis Following
Conversion From Tacrolimus To
Sirolimus Post-Transplant In Kidney
Transplant Patients
72
113 NCT00434590 Novartis Pharmaceuticals Efficacy and Tolerability of Full
Dose Enteric-coated
Mycophenolate Sodium, in
Addition to Cyclosporine for
Microemulsion Reduced Dose,
in Maintenance Renal Transplant
Recipients
10
114 NCT00148252 University of Oslo School of
Pharmacy
Lowering Total Immunosuppressive
Load in Renal Transplant
Recipients More Than
12 Months Posttransplant
298
115 NCT00204230 University Hospital
Muenster,
Hoffmann-La Roche
MMF and Calcineurin Inhibitor
Withdrawal in CAN
86
116 NCT01609673 Helady Pinheiro, MD, PhD,
Novartis
Study of Everolimus in de Novo
Renal Transplant Recipients
1
117 NCT01213394 Ramesh Prasad
Hoffmann-La Roche
Mycophenolate Mofetil for
Reducing Cardiovascular Risk in
Renal Transplant Recipients
(MMCR)
2
118 NCT00991510 Teva Pharmaceutical
Industries, Parexel
Comparative Bioavailability of
Myfenax® and CellCept® in Kidney
Transplant Patients
43
119 NCT00658333 Novartis Pharmaceuticals A Study designed to Compare the
Tolerability of an Increased Dose of
Enteric-coated Mycophenolate
Acid (MPA) in Renal Transplant
Patients Whose Dose of
Mycophenolate Mofetil (MMF)
Was Reduced Due to
Gastrointestinal Symptoms
30
120 NCT00133172 Astellas Pharma Inc. Astellas
Pharma Canada, Inc.
Effect of Rapid Steroid Withdrawal
on Subclinical Markers of Rejection
85
121 NCT00752479 Mario Negri Institute for
Pharmacological Research
Mesenchymal Stem Cells Under
Basiliximab/Low Dose rATG to
Induce Renal Transplant Tolerance
4
122 NCT00928811 Drexel University College of
Medicine Novartis
Study to Evaluate the Safety of
Chronic Administration of Simulect
to Subjects Receiving a First Kidney
Transplant
5
123 NCT00452361 Pfizer (formerly Wyeth) Study Evaluating of Calcineurin
Inhibitors Versus Sirolimus in Renal
Allograft Recipient
31
124 NCT00658320 Novartis Concentration Controlled
Everolimus With Reduced
Dose Cyclosporine Versus
Mycophenolate Mofetil With
Standard Dose Cyclosporine in
de Novo Renal Transplant Adult
Recipients Treated With
Basiliximab and Corticosteroids
122 Completed
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n Study Sponsor/collaborators Trial name
Sample
size Status
125 NCT00113269 Astellas Pharma Inc. Safety/Efficacy of Induction Agents
With Tacrolimus, MMF, and Rapid
Steroid Withdrawal in Renal
Transplant Recipients (INTAC)
501
126 NCT00235300 Genzyme, a Sanofi
Company
An Open-Label, Prospective,
Randomized, Multi-center,
Phase II Comparative Trial of
Thymoglobulin Versus Simulect for
the Prevention of Delayed Graft
Function and Acute Allograft
Rejection in Renal Allograft
Recipients.
240
127 NCT00965094 Novartis Pharmaceuticals Efficacy and Safety of
Everolimus+ EC-MPS After
Early CNI Elimination vs.
EC-MPS+ Tacrolimus in Renal
Transplant Recipients
36
128 NCT00154284 Novartis Everolimus in a Cyclosporine
Microemulsion-free Regimen
Compared with a Low-dose
Cyclosporine Microemulsion
Regimen, in de Novo Kidney
Transplant Patients (CERTES02)
114
129 NCT01079143 Novartis Pharmaceuticals Progression of Renal Interstitial
Fibrosis/Tubular Atrophy (IF/TA)
According to Epithelial-
Mesenchymal Transition (EMT) and
Immunosuppressive Regimen
(Everolimus Based versus CNI
Based) in de Novo Renal
Transplant Recipients (CERTITEM)
194
130 NCT00251004 Novartis Efficacy and Safety Study of
Everolimus Plus Reduced
Cyclosporine Versus Mycophenolic
Acid Plus Cyclosporine in Kidney
Transplant Recipients
833
131 NCT00543569 Astellas Pharma Inc. A Study to Assess the Safety and
Efficacy of Alefacept in Kidney
Transplant Recipients
323
132 NCT01304836 Astellas Pharma Inc. A Study Looking at Diabetes in
Kidney Transplant Recipients
Receiving Immunosuppressive
Regimen With or Without Steroids
(ADVANCE)
1166
133 NCT00369161 Novartis A Twelve-Month, Multicenter,
Open-label, Randomized Study of
the Safety, Tolerability and Efficacy
of Everolimus With Basiliximab,
Corticosteroids and Two Different
Exposure Levels of Tacrolimus in
de Novo Renal Transplant
Recipients
228
134 NCT00284947 Novartis Safety and Efficacy of Basiliximab
in Calcineurin Inhibitor Intolerant
Long-term Kidney Transplant
Recipients Treated With
Mycophenolic Acid and Steroids
7
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n Study Sponsor/collaborators Trial name
Sample
size Status
135 NCT00239031 Novartis Study of Enteric-Coated
Mycophenolate Sodium (EC-MPS)
Plus Reduced-Dose Cyclosporine
Microemulsion (CSA-ME)
Compared with EC-MPS Plus
Standard Dose CSA-ME in Elderly
de Novo Renal Transplant
Recipients Treated With
Basiliximab and Short-Term
Steroids
117
136 NCT00492869 Novartis Pharmaceuticals Efficacy and Safety of AEB071
versus Tacrolimus in Combination
With Mycophenolate Acid Sodium,
Basiliximab and Steroids in
Preventing Acute Rejection After
Kidney Transplantation
124
137 NCT01596062 Novartis Pharmaceuticals Pharmacodynamics, Efficacy and
Safety of Basiliximab 40 or 80mg
in Combination With Ciclosporine
Microemulsion or Everolimus,
in Adult Low Risk de Novo
Renal Transplant Recipients
(IDEALE Study)
16
138 NCT00154232 Novartis Pharmaceuticals Study to Evaluate the Combination
of Enteric-coated Mycophenolate
Sodium (EC-MPS), Basiliximab, and
C2-monitored Cyclosporine in de
Novo Renal Transplant Recipients
at Potential High Risk of Delayed
Graft Function (DGF)
46
139 NCT00634920 Novartis Pharmaceuticals Evaluation of Early Conversion to
Everolimus From Cyclosporine in
de Novo Renal Transplant
Recipients
204
140 NCT00717470 Astellas Pharma Inc. A Study in Kidney Transplant
Subjects to Investigate the Optimal
Suppression of Immunity to Help
Prevent Kidney Rejection (OSAKA)
1252
141 NCT00170833 Novartis Safety, Tolerability and Efficacy of
Everolimus With Lower Versus
Higher Levels of Tacrolimus in de
Novo Renal Transplant Patients
80
142 NCT00308425 Novartis Safety and Efficacy of
Enteric-coated Mycophenolate
Sodium (EC-MPS) Plus Valsartan in
Patients With Kidney Transplants
(MYTHOS)
119
143 NCT00610961 University of Florida, Novartis
Pharmaceuticals
Induction Related BK Viremia in
Renal Transplant Patients
60
144 NCT00842699 Brigham and Women’s
Hospital, Genzyme, a Sanofi
Company
Characterization of Immunological
Profile of Renal Transplant Patients
Undergoing Induction Treatment
With Thymoglobulin vs. IL-2
Receptor Antagonist Basiliximab
40
145 NCT00229138 Novartis Pharmaceuticals Efficacy and Safety of
Enteric-Coated Mycophenolate
Sodium (EC-MPS) in Kidney
Transplant Recipients
291
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n Study Sponsor/collaborators Trial name
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146 NCT00101738 Novartis Pharmaceuticals Freedom Study: Myfortic in Kidney
Transplant Patients
342
147 NCT00820911 Novartis Pharmaceuticals Efficacy and Safety of AEB071
Versus Cyclosporine in de Novo
Renal Transplant Recipients
175
148 NCT00167947 Pfizer (formerly Wyeth) Study Evaluating Sirolimus in
Kidney Transplant Recipients.
150
149 NCT00504543 Novartis Pharmaceuticals Efficacy, Safety and Tolerability of
AEB071 Versus Cyclosporine in the
Novo Renal Transplant Recipients
311
150 NCT00403416 Novartis Pharmaceuticals Efficacy and Safety of AEB071
Plus Tacrolimus (Converted to
Mycophenolic Acid After
3 Months), in Renal Transplant
Patients
215
151 NCT00531440 Novartis Pharmaceuticals This is a 2-year Follow-up Study to
Evaluate the Long-term Effects in
Patients Who Completed the
Study CRAD001A2307
256
152 NCT00106639 Pfizer A 6-Month Study Of CP-690,550
versus Tacrolimus In Kidney
Transplant Patients
61
153 NCT01336296 University of Cincinnati,
Novartis Pharmaceuticals
Evaluate Effects and Safety of
Pre-load Myfortic® in Transplant
Patients
61
154 NCT00552201 Centre Hospitalier
Universitaire, Amiens, Roche
Pharma AG, Astellas Pharma
Inc.
Tacrolimus in Renal
Transplantation: Individualization
by Pharmacogenetic
280
155 NCT01028092 University Hospital, Brest,
Novartis, Roche Pharma AG,
Genzyme, a Sanofi
Company, Ministry of
Health, France
mTor-inhibitor (Everolimus) Based
Immunosuppressive Strategies for
CNI Minimisation in OLD for Old
Renal Transplantation (EVEROLD)
327
156 NCT01435291 Centre Hospitalier
Universitaire de Nice
AADAPT – Analysis of Advagraf
Dose Adaptation Post
Transplantation
45
157 NCT00771875 University of Cincinnati Randomized Trial for Mixed Acute
Rejection
30
158 NCT00261820 Pfizer (formerly Wyeth) Study Comparing Two
Immunosuppressive Regimens in
De Novo Renal Allograft Recipients
160
159 NCT00771745 University of Cincinnati,
Genzyme, a Sanofi
Company
Prospective Pilot Study of
Pre-Transplant Thymoglobulin
Administration in Living Donor
Renal Transplant Recipients
11
160 NCT00076570 National Institute of Diabetes
and Digestive and Kidney
Diseases (NIDDK)
Combination Drug Therapy
Followed by Single Drug Steroid
Free Therapy to Prevent
Organ Rejection in Kidney
Transplantation
31
161 NCT00089947 Genzyme, a Sanofi
Company
A Study to Evaluate the Effect of
Thymoglobulin and Reduced Doses
of Steroids to Prevent Renal
Transplant Rejection
150
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n Study Sponsor/collaborators Trial name
Sample
size Status
162 NCT00007787 National Institute of Allergy
and Infectious Diseases
(NIAID)
Antibody and Delayed
Cyclosporine Versus Initial
Cyclosporine Alone in Patients
Receiving Kidney Transplants
350
163 NCT00284934 Novartis Enteric-coated Mycophenolate
Sodium (EC-MPS) With
Reduced-dose Tacrolimus Versus
EC-MPS With Standard-dose
Tacrolimus in Stable Kidney
Transplant Recipients (OLYMPE)
94
164 NCT00266123 Pfizer (formerly Wyeth) Study Comparing Two Sirolimus
Regimens vs. Tacrolimus and
Mycophenolate Mofetil Regimen
in Kidney Transplant Recipients
420
165 NCT00765661 Veloxis Pharmaceuticals, CTI
Clinical Trial and Consulting
Services, Aptuit Inc.
Pharmacokinetics of LCP-Tacro
(TM) Once Daily And Prograf®
Twice A Day in Adult De Novo
Kidney Transplant Patients
63
166 NCT01363752 Astellas Pharma Inc. A Study Looking at Kidney
Function in Kidney Transplant
Recipients Who Are Taking
Anti-rejection Medication Including
Tacrolimus and With or Without
Sirolimus. (ADHERE)
853
167 NCT00297765 Astellas Pharma Inc. Optimizing Prograf® Therapy in
Renal Transplant Patients
(OPTIMA)
323
168 NCT00213590 University Hospital, Rouen Renal Function Evaluation After
Reduction of Cyclosporine A Dose
in Renal Transplant Patients
(DICAM)
208
169 NCT00273871 Pfizer (formerly Wyeth) Study Comparing Conversion From
Calcineurin Inhibitors to
Rapamune versus Standard
Therapy in Established Renal
Allograft Recipients
190
170 NCT00369382 Pfizer (formerly Wyeth) Study Of The Safety And Efficacy
Of Conversion From a CNI to
Sirolimus In Renally-Impaired Heart
Transplant Recipients
121
171 NCT00717379 Astellas Pharma Inc. Study of Tacrolimus
Immunosuppressive Therapy After
Kidney Transplantation
50
172 NCT00496483 Veloxis Pharmaceuticals, CTI
Clinical Trial and Consulting
Services
Pharmacokinetics of LCP-Tacro in
Stable Kidney Transplant Patients
60
173 NCT01802268 Helio Tedesco Silva Junior,
Pfizer
Planned Conversion From TAC to
SRL-based Regimen in de Novo
Kidney Transplant Recipients
320
174 NCT00296309 Astellas Pharma Inc., Astellas
Pharma Europe BV
Comparing Efficacy & Safety of
Tacrolimus & MMF With/Without
Induction in the Elderly Following
Kidney Transplantation.
267
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n Study Sponsor/collaborators Trial name
Sample
size Status
175 NCT00402168 Bristol-Myers Squibb A Study of BMS-224818
(Belatacept) in Patients Who Have
Undergone a Kidney Transplant
and Are Currently on Stable
Cyclosporine or Tacrolimus
Regimen With or Without
Corticosteroids
171
176 NCT00035555 Bristol-Myers Squibb Study Comparing the Safety and
Efficacy of Belatacept With That of
Cyclosporine in Patients With a
Transplanted Kidney
230
177 NCT00455013 Bristol-Myers Squibb A Phase II Study of Belatacept
(BMS-224818) With a Steroid-free
Regimen in Subjects Undergoing
Kidney Transplantation
93
178 NCT00183248 University of Miami Immune
Tolerance Network (ITN)
Using Donor Stem Cells and
Alemtuzumab to Prevent Organ
Rejection in Kidney Transplant
Patients
9
179 NCT00284934 Novartis Enteric-coated Mycophenolate
Sodium (EC-MPS) With
Reduced-Dose Tacrolimus Versus
EC-MPS With Standard-Dose
Tacrolimus in Stable Kidney
Transplant Recipients (OLYMPE)
94
180 NCT00369278 Novartis Pharmaceuticals Intensified vs. Standard Dose
Therapy With Mycophenolate
Sodium Plus Cyclosporin
Microemulsion and Corticosteroid
Combination in Patients With de
Novo Renal Transplant Patients
128
181 NCT00419926 Novartis Evaluation of the Therapeutic
Benefit of an Initial Intensified
Dosing Regimen of
Mycophenolate Sodium Versus
a Standard Regimen in Renal
Transplant Patients
313
182 NCT00812123 University Hospital, Basel,
Switzerland, Pfizer
(formerly Wyeth)
Calcineurin Free
Immunosuppression in Renal
Transplant Recipients
127
183 NCT00154310 Novartis Efficacy and Safety of Everolimus
With Enteric-Coated
Mycophenolate Sodium (EC-MPS)
in a Cyclosporine Microemulsion-
free Regimen Compared with
Standard Therapy in de Novo
Renal Transplant Patients
300
184 NCT00170846 Novartis Pharmaceuticals ASCERTAIN: Assessment of
Everolimus in Addition to
Calcineurin Inhibitor Reduction in
the Maintenance of Renal
Transplant Recipients
394
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n Study Sponsor/collaborators Trial name
Sample
size Status
185 NCT00425308 Novartis Pharmaceuticals Efficacy and Safety of Everolimus
in Combination With Cyclosporine
Microemulsion Versus Everolimus
in Combination With
Enteric-coated Mycophenolate
Sodium (EC-MPS), in Adult Renal
Transplant Patients in Maintenance
30
186 NCT01064791 Novartis Pharmaceuticals Efficacy, Safety, Tolerability, and
Pharmacokinetics of Sotrastaurin
Combined With Tacrolimus vs. a
Mycophenolic Acid-Tacrolimus
Regimen in Renal Transplant
Patients
298
187 NCT00149903 Novartis Pharmaceuticals Study of Enteric-coated
Mycophenolate Sodium Versus
Mycophenolate Mofetil in Adult de
Novo Renal Transplant Patients
300
188 NCT00275535 Mayo Clinic, Pfizer (formerly
Wyeth), Genzyme, a Sanofi
Company, Roche Pharma
AG
The Comparison of Tacrolimus and
Sirolimus Immunosuppression
Based Drug Regimens in Kidney
Transplant Recipients
165
189 NCT00371826 Novartis Pharmaceuticals SOCRATES: Steroid or
Cyclosporine Removal After
Transplantation Using Everolimus
126
190 NCT00239057 Novartis Study of Enteric-coated
Mycophenolate Sodium
Maintenance Therapy in Patients
With Renal Transplant Receiving
Cyclosporine Microemulsion and
Steroids
23
191 NCT00811915 University Hospital, Rouen Study to Compare the Safety and
Efficacy of Sirolimus (Rapamune)
to Tacrolimus (Advagraf)
Associated to Mycophenolate
Mofetil (CellCept) Between 12
and 36 Months After Kidney
Transplantation (EPARGNE)
65
192 NCT00461825 Poitiers University Hospital Maintenance Neoral Monotherapy
Compared with Bitherapy in Renal
Transplantation
207
193 NCT01742624 Astellas Pharma Korea, Inc. Study to Evaluate the Safety and
Efficacy of Advagraf vs. Prograf in
Kidney Transplantation Patients
1 Month After the Transplantation
(AdProCISE)
60
194 NCT00200551 Nantes University Hospital A Study of Mycophenolate Mofetil
and Cyclosporin, Without
Concomitant Corticosteroids,
After a First Renal Transplant
200
195 NCT00483756Yes Pfizer Study of a JAK3 Inhibitor for the
Prevention of Acute Rejection in
Kidney Transplant Patients
338
196 NCT00138970 University of Oslo School of
Pharmacy
Calcineurin Inhibitor-Free
Immunosuppression in Renal
Transplant Recipients at Low
Immunogenic Risk
70
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n Study Sponsor/collaborators Trial name
Sample
size Status
197 NCT00912678 University of Luebeck,
Astellas Pharma GmbH
Minimizing Immunosuppression in
Old for Old Kidney Transplantation
(ESP-CNI)
90
198 NCT00533624 University of Miami, Novartis Myfortic vs. Cellcept in Kidney
Transplant Recipients
150
199 NCT00413920 Novartis Efficacy and Safety of Enteric-
coated Mycophenolate Sodium
and Cyclosporine in Combination
With and Without Steroids, in
Adult Renal Transplant Recipients
222
200 NCT01025817
CRAD001AUS92
Novartis Pharmaceuticals Non-inferiority Study of Safety and
Efficacy of Everolimus With
Low Dose Tacrolimus to
Mycophenolate Mofetil With
Standard Dose Tacrolimus in
Kidney Transplant Recipients
613
201 NCT00650468 Astellas Pharma Inc. A Study to Compare Early Steroid
Withdrawal and Long-Term Steroid
Maintenance Therapy in Kidney
Transplant Patients
397
202 NCT00087581 Hoffmann-La Roche Study of Therapeutic Monitoring
of CellCept (Mycophenolate
Mofetil) After Kidney
Transplantation
717
203 NCT00374803 University of Cincinnati,
Novartis
Study of Myfortic in Combination
With Tacrolimus and
Thymoglobulin in Early
Corticosteroid Withdrawal
45
204 NCT00693381 Astellas Pharma Inc Mycophenolate Mofetil (MMF)
Discontinuation From a Tacrolimus/
MMF/Steroid Triple Regimen After
Kidney Transplantation (DISTAMP)
152
205 NCT00195273 Pfizer (formerly Wyeth) Study Evaluating Sirolimus in
Kidney Transplant Recipients
61
206 NCT00239083 Novartis Efficacy and Safety of
Enteric-Coated Mycophenolate
Sodium (EC-MPS) in Renal
Transplant Patients
40
207 NCT00885820 Astellas Pharma Inc Astellas
Pharma Canada, Inc.
Benefit of Early Protocol Biopsy
and Treatment of Subclinical
Rejection
240
208 NCT00400647 Novartis Gastrointestinal and Health-related
Quality of Life in Kidney Transplant
Patients Treated With
Mycophenolate Mofetil
136
209 NCT00296361 Astellas Pharma Inc. To Compare the Efficacy and
Safety of a Therapy of Tacrolimus
With Sirolimus or MMF in Kidney
Transplantation (RESTORE)
634
210 NCT00238992 Novartis Pharmaceuticals Study of Enteric-coated
Mycophenolate Sodium (EC-MPS)
With Steroid Withdrawal vs.
EC-MPS With Standard Steroid
Regimen in de Novo Renal
Transplant Recipients
144
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n Study Sponsor/collaborators Trial name
Sample
size Status
211 NCT00817687 Hoffmann-La Roche A Study of the Impact of an Early
Biopsy in Patients Treated With
CellCept (Mycophenolate Mofetil)
After Kidney Transplantation
66
212 NCT00321113 Astellas Pharma Inc. Comparison of Two Tacrolimus
Based Immunosuppressive
Regimens in Recipients Receiving
Marginal Donor Kidneys (TIGRE)
142
213 NCT00064701 Astellas Pharma Inc. Comparative Study of Modified
Release (MR) Tacrolimus/
Mycophenolate Mofetil (MMF) in
de Novo Kidney Transplant
Recipients
668
214 NCT00788567 Hoffmann-La Roche CLEAR Study – A Study of
CellCept (Mycophenolate Mofetil)
in Recipients of Kidney Transplants
136
215 NCT00182559 Medical University of Vienna The Vienna Prograf and
Endothelial Progenitor Cell Study
148
216 NCT00681213 University of Miami,
Wyeth-Ayesrst
Pharmaceuticals, Roche
Laboratories and Fujusawa
Healthcare, Inc.
Tacrolimus/Sirolimus Versus
Tacrolimus/Mycophenolate Mofetil
(MMF) Versus Neoral/Sirolimus
in Adult, Primary Kidney
Transplantation
150
217 NCT00166244(b) Erasmus Medical
Hoffmann-La Roche Center
Fixed Dose MMF vs. Concentration
Controlled MMF After Renal
Transplantation
901
218 NCT00240955 Novartis Extension Study of Enteric-coated
Mycophenolate Sodium With
Short-term or No Steroid Use
Compared With Enteric-coated
Mycophenolate Sodium With
Standard Steroid Therapy in de
Novo Kidney Recipients
79
219 NCT01706471 Yonsei University Safety and Efficacy of the Early
Introduction of Everolimus
(Certican®) With Low Dose of
Cyclosporine in de Novo Kidney
Recipients After 1 Month of
Transplantation
60
220 NCT00400400 Novartis Pharmaceuticals Enteric-Coated Mycophenolate
Sodium (EC-MPS) and
Mycophenolate Mofetil (MMF) in
Renal Transplant Patients With
Gastrointestinal (GI) Intolerance
400
221 NCT00121810 Hoffmann-La Roche Kidney Spare the Nephron (STN)
Study - A Study of CellCept
(Mycophenolate Mofetil) and
Rapamune (Sirolimus) in Kidney
Transplant Recipients
305
222 NCT00189839 Astellas Pharma Inc. A Study to Evaluate the Safety and
Efficacy of FK506E (MR4) in
Patients Undergoing Primary
Kidney Transplantation
699
223 NCT02005562 Hoffmann-La Roche OPERA Study: A Study of Two
Dosing Regimens of CellCept
(Mycophenolate Mofetil) in Kidney
Transplant Patients
263
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n Study Sponsor/collaborators Trial name
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224 NCT00758602 Hoffmann-La Roche A Study of CellCept
(Mycophenolate Mofetil)
Combined With Tacrolimus and
Corticosteroids in Kidney
Transplant Patients
210
225 NCT00717678 Astellas Pharma Taiwan, Inc. A Randomized Study to Assess the
Safety and Efficacy of Prograf vs.
Prograf-XL in de Novo Kidney
Transplant Recipients
73
226 NCT00275522 Mayo Clinic, Pfizer (formerly
Wyeth)
The Comparison of Three Different
Immunosuppressant Regimens in
Kidney Transplant Recipients
16
227 NCT00337493 Hoffmann-La Roche Pharmacogenetic Study of
CellCept (Mycophenolate Mofetil)
in Kidney Transplant Patients
155
228 NCT00305396 Vanderbilt University,
Genzyme, a Sanofi
Company
Calcineurin Inhibitor Avoidance
With Thymoglobulin and Sirolimus
in Kidney Transplantation
80
229 NCT00187941 University of Florida
Hoffmann-La Roche
MPA PK Monitoring Strategy
With MMF/FK Based
Immunosuppression
22
230 NCT01280617 Lahey Clinic Brigham and
Women’s Hospital
Low Dose Thymoglobin in Renal
Transplant Patients
58
231 NCT00777933 Samsung Medical Center Randomized Trial of Cyclosporine
and Tacrolimus Therapy With
Steroid Withdrawal in Living-Donor
Renal Transplantation
131
232 NCT01601821 Pfizer Open Label Comparative Study
of de Novo Renal Allograft
Recipients Receiving
CSA+MMF+Corticosteroids
versus CSA+ Rapamune+
Corticosteroids
245
233 NCT00585468 University of Utah Pharmacokinetic Profile of Myfortic
(Enteric Coated Mycophenolate
Sodium) in a Rapid Steroid
Withdrawal Protocol
24
234 NCT01183247 University Hospital, Basel,
Switzerland Novartis
An Open, Single Centre,
Randomised, Parallel Group Study
to Investigate Three Different
Immunosuppressive Regimens
(SterFreePlus)
63
235 NCT00248313 Pfizer (formerly Wyeth) Study Comparing Cyclosporin
Dose Reduction With Cyclosporin
Elimination in Kidney Transplant
Recipients Taking Sirolimus
470
236 NCT00170885 Novartis Everolimus in Combination With
Cyclosporine Microemulsion in de
Novo Renal Transplant Recipients
NR
237 NCT00895583 Pfizer Study Evaluating A Planned
Transition From Tacrolimus To
Sirolimus In Kidney Transplant
Recipients
254
238 NCT00428064 Pfizer (formerly Wyeth) Study Evaluating Sirolimus and
Cyclosporine in Kidney Transplant
Recipients
408
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n Study Sponsor/collaborators Trial name
Sample
size Status
239 NCT00195429 Pfizer (formerly Wyeth) A Study Comparing the
Withdrawal of Steroids or
Tacrolimus in Kidney Transplant
Recipients
47
240 NCT00195468 Pfizer (formerly Wyeth) Study Comparing Cyclosporine
Dose Reduction vs. Cyclosporine
Elimination in Kidney Transplant
Recipients Taking Sirolimus
280
241 NCT00306397 University Hospital, Basel,
Switzerland
Pilot Study to Investigate a Steroid
Free Immunosuppressive Regimen
for Renal Transplant Recipients
100
242 NCT01023815 Novartis Once-a-Day Regimen With
Everolimus, Low Dose
Cyclosporine and Steroids in
Comparison With Steroid
Withdrawal or Twice-a-Day
Regimen With Everolimus, Low
Dose Cyclosporine and Steroids.
(EVIDENCE)
184
243 NCT00518375 Pfizer (formerly Wyeth) Study Comparing Graft Function in
Renal Allograft Recipients
Receiving Reduced or Standard
Dose CSA With Sirolimus
250
244 NCT00309270 Mario Negri Institute for
Pharmacological Research
Low Dose Sirolimus or CSA-Based
Maintenance Immunosuppression
After Induction With Campath-1 in
Kidney Transplantation
21
245 NCT00507793 Pfizer (formerly Wyeth) Study Evaluating the Efficacy and
Safety of Cyclosporine Reduction
in Kidney Transplant Recipients
Receiving Sirolimus
385
246 NCT00519116 Pfizer (formerly Wyeth) Study Comparing Standard Dose
and Reduced Dose Tacrolimus
With Sirolimus in Renal Transplant
Patients
150
247 NCT00518271 Pfizer (formerly Wyeth) Study Comparing Standard
Dose and Reduced Dose
Tacrolimus+ Sirolimus+
Corticosteroids in Renal Allograft
Recipients
120
248 NCT00254709 Pfizer (formerly Wyeth) Study Evaluating Two
Different Sirolimus-based
Immunosuppressive Regimens in
Elderly Kidney Transplant
Recipients
66
249 NCT00038948 Pfizer (formerly Wyeth) Study Comparing Conversion to
Sirolimus vs. Continued Use of
Calcineurin Inhibitors in Kidney
Transplant Recipients
830
250 NCT00470665 Pfizer (formerly Wyeth) Study Comparing Sirolimus/Prograf
vs. Sirolimus/CSA in High-Risk
Renal Transplant Recipients
460
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n Study Sponsor/collaborators Trial name
Sample
size Status
251 ISRCTN87678078 Hospital Universitario de
Canarias
Efficacy and Security of Low
Toxicity Immunosuppressive
Regimen Using Basiliximab,
Mycophenolate Mofetil, Neoral or
Tacrolimus and Corticosteroids
versus Full Doses of Neoral,
Thymoglobulin, Azathioprine and
Corticosteroids
240
252 ISRCTN94424606 Leeds Teaching Hospitals
NHS Trust (UK)
Steroid Avoidance in Leeds with
Alemtuzumab or Mycophenolate
Mofetil (MMF) Immunosuppression
120
253 ISRCTN76390219 University Hospitals of
Leicester NHS Trust
A randomised controlled trial
comparing the use of sirolimus
based biphasic immunosuppression
with myfortic to allow early
Calcineurin Inhibitor (CNI)
withdrawal in renal transplantation
42
254 ISRCTN55817881 Leiden University Medical
Centre (LUMC)
Calcineurin-inhibitor
Nephrotoxicity and Efficacy Study
126
255 ISRCTN74429508 University of Munich -
Department of Surgery
A randomized multicenter trial to
assess the efficacy of a combined
therapy with Sirolimus
(Rapamune®), MMF (Cellsept®)
and corticosteroids after early
elimination of cyclosporin
compared with a standard
immunosuppression with
cyclosporin, MMF and
corticosteroids in patients after
kidney transplantation
140
256 ISRCTN69188731 Academic Medical Center
(AMC), Renal Transplant
Unit (The Netherlands)
Mycophenolate sodium versus
Everolimus or Cyclosporine with
Allograft Nephropathy as Outcome
255
ID, identifier; IRCCS, Istituto di Ricovero e Cura a Carattere Scientifico; NR, not reported.
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Appendix 9 Detailed narrative review of
cost-effectiveness evidence
Induction regimens
UK studies
Walters et al. 2003
In a multi-European country RCT, BAS induction was compared with PBO in patients who were given triple
therapy with CSA, AZA and steroids.316 Information on costs of immunosuppressant drugs, hospitalisations,
procedures, outpatient visits, laboratory tests, renal biopsies, concomitant medications, dialysis and
nephrectomy was prospectively collected for the trial follow-up period of 6 months. Retransplantation costs
were not included. A CEA, conducted alongside the trial, included all costs up to 6 months and the costs
of dialysis up to 12 months. This analysis adopted a NHS hospital perspective; it pooled the data on clinical
outcomes and resource utilisation from all countries and patients involved in the trial (n= 340), but
evaluated resource use using UK national and local unit costs (1997–99 prices).
Basiliximab was found to reduce the incidence of first confirmed AR episodes by 6 months (absolute risk
reduction 0.14). The rate of graft failure with BAS was 11% and 18%, respectively, in the PBO arm
(p= 0.24). The mortality rate was 2% and 3%, respectively (p= 1.00). In terms of the number of patients
with AEs reported as serious, infections reported as serious, and AEs or infections reported as serious, the
comparisons had p≥ 0.65.
The distribution of costs in each trial arm was as presented in Figure 139. Hospitalisation costs were the
largest element of total costs, followed by dialysis and AR.
Comparisons by resource-use category between arms had all p≥ 0.05. Over the 6-month period
post-transplantation BAS had an incremental cost of £231 (95% CI –£1983 to £2446). [Including the
6–12 months costs of dialysis, the BAS had an incremental total costs of –£30 (95% CI –£2326 to £2686.)]
In the 6-month period post transplantation, the incremental cost per case of treatment failure (i.e. no AR,
graft failure or death) avoided with BAS was £1650.
The authors conclude by stating that, despite the fears of increased AEs from overimmunosuppression,
BAS given with triple therapy resulted in fewer ARs and no difference in costs relative to PBO in the first
6 months.
Critique
The study provides valuable evidence of data on resource use and short-term outcomes of induction
therapy with BAS. For our present purposes, the main limitation of this study is the lack of relevant
comparators such as induction with rATG. Further, as the authors point out, the use of these regimens
in combination with triple-therapy immunosuppressive regimens commonly used in recent years, in
particular a CNI with MMF and steroids, would have added relevance to the study.
The authors do not include the costs of retransplantation in their 1-year analysis, despite including the
costs of dialysis. Inclusion of retransplantation costs incurred even within this study’s short time horizon
(1 year) would have provided an indication of the rate at which the most relevant costs elements accrue
for the present decision problem.
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The study does not provide any evidence of the impact of induction on HRQoL. This prevented an
adequate representation of the cost and benefits balance of BAS. In addition, an attempt to investigate the
potential long-term implications of ARR prevention with BAS is warranted, using the framework linking
biomarkers to longer-term patient and graft survival outcomes using a predictive model.
A major limitation of the study316 is the fact that the quantities of resource utilisation were derived from a
sample of patients being treated in the UK and 11 other countries. The authors316 acknowledge that
important differences may exist between these countries, as evidenced by the length of hospital stay, such
that ‘whereas prevention of early episodes of AR may save a readmission in the US, this would not
necessarily lead to an earlier hospital discharge following transplantation in some of the countries involved
in this study (e.g. Israel, Poland, Turkey)’ (p. 136). This limits the validity of the results of this study, which
was designed from an English NHS perspective.
Chilcott et al. 2002
A separate study315 of a similar design to that of Walters et al.,316 described above, was conducted in
centres from Canada and six European countries, including the UK. The study315 followed patients for
12 months and, unlike the study by Walters et al.,315 valued resource utilisation using country-specific
prices adjusted for PPP to reflect the actual opportunity costs of health-care resources in each country.
Hospitalisation
Immunosuppressive therapies
Procedures
Laboratory tests
Outpatient visits
Post-operative dialysis
Renal biopsies
Concomitant medications
Nephrectomy
(a)
(b)
Hospitalisation
Immunosuppressive therapies
Procedures
Laboratory tests
Outpatient visits
Post-operative dialysis
Renal biopsies
Concomitant medications
Nephrectomy
BAS
FIGURE 139 Proportional breakdown of costs by treatment arm in Walters et al.316
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The study involved 376 patients (BAS, n= 190; PBO, n= 186) and, as Walters et al.316 had found for
6-month post-transplantation outcomes, observed that BAS reduced the rate of (suspected) ARs (BAS 37%,
PBO 54.8%; ARD –16.9%, 95% CI –29% to –4%), without affecting graft loss (ARD –1.3%, 95% CI
–8.1% to 5.4%) and patient survival (ARD 2.0%, 95% CI –1.8% to 5.9%) at 12 months. The authors
report that no retransplantations were recorded in any group over the 12-month post-transplantation
period studied.
The report315 presents the results of statistical tests of differences in resource quantities used between the
trial arms, which were all associated with p-values of > 0.05. The costs estimates were reported in terms of
PPP US$ (1996 prices). Here we present the results of this report after converting them back to PPP (£)
using the £0.4=US$1 conversion rate provided by the report315 (table 1). The mean total per-patient cost
was £19,174 in the BAS arm and £18,510 in the PBO arm (difference £664, 95% CI –£1660 to £2944).
The incremental cost per suspected case of AR avoided at 12 months post transplantation was £3929.
Unlike the study by Walters et al.,316 with which it shares many design features, the study by Chilcott et al.315
presents total cost estimates for the subgroup of UK patients (n= 37) in the trial. (The report presents
these figures only in chart form; see figure 4.315) The total incremental cost of BAS over 12 months is
approximately £3500. This implies an incremental cost per suspected case of AR avoided of £8284.
Although the estimates for the UK subgroup are more susceptible to random sampling variation than those
for the overall sample, these results, and those presented in figure 4 of the report,315 which compare results
across country of origin patient subgroups, hint at heterogeneous findings across countries.
Critique
A similar critique applies to this report as that formulated above for the report by Walters et al.,316 with a
couple of qualifications. First, Chilcott et al.315 present results for the subgroup of UK patients. Although
these results are based on small numbers, they suggest possible heterogeneity of findings across countries,
as the point estimate of incremental costs of BAS range from almost US$0 in Germany and France to
US$3500 in the UK, to US$10,000 in Belgium and Switzerland (see figure 4315). A second strength of the
Chilcott study315 relative to the that by Walters et al.316 lies in its longer period of follow-up, during which
information on all costs was collected 12 months post transplantation, compared with the 6-month period
of the Walters et al.316 study (the latter also included costs for a 6-month extension period, but only
for dialysis).
Popat et al. 2014
A recent study317 reports evidence of costs and health outcomes associated with two immunosuppressive
induction therapies given to recipients of renal transplants from DCD in a single centre in London. This was
a before-and-after comparison of 1-year outcomes after transplantation, between a IL2Mab induction
regimen (BAS or DAC) given to patients receiving a renal transplant from January 2007 to July 2008 and
induction with ATG given to renal transplantation patients starting from the time of its adoption at the
centre in August 2008 to August 2009.
The study included 24 patients in the old induction arm (IL2Mab 2mg/kg) who had a mean age of
54.3 years compared with 48.0 years in the new (ATG 3.75mg/kg) induction group of 21 patients.
There was some imbalance in terms of sex and race, as 71% in the IL2Mab group were male, compared
with 38% of those given ATG, and 62% of the former group were white, compared with 33% of the
latter. Forty-two of 45 patients were given standard immunosuppression with CSA, MMF and
prednisolone, and 3 out of 45 were given TAC, MMF and prednisolone.
At 1 year post transplantation, 91.7% of patients in the IL2Mab group were alive, whereas at 3 years
83.4% survived. In the ATG group all patients were alive at both time points. In terms of graft survival
(censored by death), all patients in both groups had a functioning graft at 1 year, whereas 95.8% in the
IL2Mab group had a functioning graft at 3 years, compared with 95.2% with ATG. The authors
interpreted these results as evidence of no significant differences in patient and graft survival.
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The study also looked at DGF, the duration of DGF measured by the number of HD sessions, the rate of
BPAR, and incidence of infections requiring hospital admission. ATG resulted in 42.8% of patients having
DGF, and 62.5% of patients treated with IL2Mab experienced such an outcome (p= 0.08). More patients
in the latter group required HD sessions, experienced BPAR, had infections requiring admission, were
readmitted and had experienced CMV infections than in the former group (p≤ 0.03 of differences for all
of these outcomes).
The study reported a cost analysis associated with observed outcomes up to 12 months post transplantation,
using local NHS unit costs for hospital bed-day and HD sessions, and BNF drug prices for induction and
maintenance immunosuppression applicable at the time that patients received the transplant.
Anti-thymocyte globulin was found to result in savings in inpatient bed-days post transplantation and
those caused by readmissions, as well as HD costs and clinic visits, whereas the additional costs of ATG
induction were not found to be statistically significant. It is unclear how this statistical test was performed,
as the report presents the difference in the group total acquisition costs of immunosuppression therapy
only between the two arms, which had different numbers of patients, rather than the correct
corresponding total per-patient cost estimates. At 1 year, total per-patient costs were £18,929 and
£14,904 in the IL2Mab and ATG arms, respectively (p= 0.002). The drivers of the cost savings by ATG
were found in the inpatient bed-days after transplantation and clinic visits.
Critique
The main contribution of this study is to provide evidence on health and economic outcomes in a
comparison of two active induction regimens. Owing to its small size, the results may be influenced by
outliers, thus limiting the validity of the reported findings. In addition, lack of power is of concern for
statistical inference of differences in health outcomes and more so for inference on costs, which tends to
require larger samples than those required by studies of clinical effects.328
The importance of clinic visits as a driver of total costs found in this study is consistent with evidence submitted
to NICE by the company sponsoring one of the drugs being evaluated for this appraisal (Bristol-Myers Squibb),
on post-transplantation costs in standard practice from the renal transplant database in Cardiff Wales.
The same finding is analysed in an international context in a published report of the same evidence.42
Further research is warranted to confirm the findings of the present study, in which induction regimens
are given in combination with current triple therapy (i.e. low-dose TAC with MMF and steroids), involving
larger samples, and collecting information on relevant outcomes not measured in this study, especially
HRQoL outcomes.
Non-UK studies
Crompton et al. 2003
In a US study,312 54 living donor transplant recipients were randomised in a 1 : 1 ratio to receive BAS
induction or no induction, and all were given triple immunosuppressive therapy with CSA ME, AZA and
CCSs. At 12 months post transplantation, the rate of AR episodes in the induction intervention arm was
22%, compared with 15% in the control (p> 0.05). Differences between arms in serum creatinine
measured at 1, 2, 3, 6 and 12 months all had p> 0.05, and no AEs were associated with BAS. Four graft
losses occurred during follow-up, all in the intervention arm; only one was immunological.
The study312 evaluated differences in resource use using charges as opposed to economic costs of the
resources consumed. Payments for readmissions were derived from DRG (diagnosis-related group) tariffs.
Infections were assigned drug treatments costs, and the unit costs of drugs were derived from wholesale
prices. Mean initial hospitalisation charges in prices of the year 2000 were US$68,094 in the intervention
group versus US$51,970 in the control (p> 0.05). A lower frequency of readmissions was observed in the
intervention arm (52%) than in the control arm (67%; p= 0.33), although admissions in the former were
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associated with a shorter length of stay (4.5 vs. 5.0; p> 0.05) than those occurring in the control.
The average charge per readmission was US$21,953 compared with US$10,148, respectively (p> 0.05).
The authors note that these differences in mean charges were influenced by an outlier who experienced
steroid-resistant rejection.
The authors conclude that BAS did not provide clear clinical benefit or evidence of being cost-effective in
this patient population. In discussing findings from previous studies, they note that lack of rejection rate
reduction within the 12-month period of analysis explained their contradictory finding of lack of clinical
and economic benefit.
Critique
This study investigates the clinical and economic benefit of BAS in a low-risk patient population
(living-donor kidney recipients). The results appear to suggest that BAS may not be justified in this type of
patient. However, as the authors recognise, an insufficient number of patients was included in the study to
allow one to derive conclusive findings. They also note the susceptibility of their results to outliers.
This study offers limited value for informing NHS decisions as a result of the following caveats relating to
its design: (1) BAS was tested in patients receiving triple-therapy immunosuppression that combined CSA
with AZA and steroids, which reflects the practice from the time these patients received their transplant
(period 1997–2000) – today regimens combining CNI, MMF and steroids are standard; (2) the small sample
studied, as discussed; (3) the use of charges to approximate economic costs, as the former are likely to
deviate from the latter due to hospital market power exercised through mark-ups in prices for their
services; and (4) the omission of any measure of HRQoL effects.
Other studies with limited data
Another study313,330 investigated two regimens of BAS induction – (a) a CNI-free regimen (CSA 8mg/kg daily
was introduced as soon as the creatinine level reached a value of < 3mg/dl) and (b) a CNI-minimisation
regimen (CSA 4mg/kg daily with MMF 500mg/12 hours from day 1) – and compared them against a TAC
(Prograf 0.3mg/kg daily with a trough level of 8–12 ng/ml) with MMF (500mg/12 hours) and steroids
regimen in elderly patients.
Although the study was presented as a Markov model of costs and health benefits up to 1 year post
transplantation, its two identified reports313,330 were in summary form, and provided no information on
methodology related to model structure, source and values of unit costs and effectiveness parameters.
Mean simulated results at 1 year were presented for eight patients in option (a), eight patients in option
(b) and 15 patients in the TAC comparator arm, for CRC (39.6, 37.4 and 31.2ml/minute/1.73 m2,
respectively), the mean hospital stay, rate of rejection (12.5%, 12.5% and 13.2%), patient survival
(100%, 100% and 93%), GRF, and cost difference relative to TAC arm [–€8355 for option (a); –€5695 for
option (b)]. However, as these outcome measures or their constituent elements were not defined, their
interpretation is too uncertain to warrant any further comment.
Critique
This quality of reporting of this study prevented its critical assessment. The most obvious limitations of this
study are its short length of follow-up (1 year), the lack of measures of the patient HRQoL impact of the
therapeutic options, and the very low patient numbers that are simulated (≤ 15 per arm), as a result of
which we were unable to reliably estimate interarm cost differences.
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Initial and maintenance immunosuppression studies
UK studies
Orme et al. 2003
Orme et al.309 compared the costs and clinical outcomes of TAC (Prograf) versus CSA ME given in
triple-therapy regimens including AZA and CCSs. At the time of the study the latter was the standard
treatment in the UK. The study was based on data from the direct comparison of these regimens in a RCT
conducted at a single centre in Wales, in which clinical and resource-use data were collected prospectively
for each patient over a median follow-up of 2.7 years (maximum 4 years). Patients in the trial had
undergone renal transplantation between 1996 and 2000 (CSA, n= 89; TAC arm, n= 90). The authors of
the study state that the clinical results of that trial were comparable to those of other published studies of
the two therapies at the time (before 2003).
The resource items for which data were recorded in the study included number of days in specialised
wards (transplant/nephrology and intensive care unit during the initial admissions and subsequent
readmissions), number of dialysis sessions required in cases of a DGF, number of diagnostic tests
(e.g. transplant biopsy, ultrasound scan and other radiological investigations), and minor surgical
procedures and operations for complications.
The use of medication was estimated based on daily dosages during the entire trial follow-up.
The number of HD sessions and continuous ambulatory PD days observed as a result of graft failure were
also measured, as were concomitant medications such as MMF, ATG, OKT3 and ganciclovir.
The economic evaluation adopted a 10-year analytical horizon and extrapolated the trial outcomes from
5 to 10 years using patient and graft survival data from the UK Transplant Support Service Authority Audit.
During the extrapolated period, the rates of change in patient survival rates were assumed to be the
same between the TAC and CSA immunosuppressant regimens (change from years 4 to 5= –3 percentage
points; and from years 5 to 10= –3.4 percentage points). The same procedure was applied to the
extrapolation of graft survival outcomes in the trial (change from years 4 to 5= –3.5 percentage points;
and from years 5 to 10= –2.4 percentage points). The analysis also assumed that ARRs changed by the
same rates as graft survival rates for the extrapolation phase of the analysis.
The per-patient costs for years 4–10 were extrapolated by the weighted average formula: per-patient costs
in year= [pf × annual costs with functioning graft+ (ps – pf) × annual costs with graft failure (dialysis)]/ps,
where ‘pf’ is the proportion of patients with a function graft at the end of the year and ‘ps’ is the patient
survival rate at the same time point. The annual costs with functioning graft and with graft failure were
estimated from the trial data in the relevant patient subsamples.
Total costs reported by the study reflect unit costs collected by the local NHS Trust in Cardiff and
corresponded to 1999 prices. Costs were discounted as the 6% annual rate and health outcomes at the
3.5% rate, in accordance with the NICE recommendations that were effective at the time of publication.
For the observed trial phase, ITT results were as follows. At 4 years, 89% of patients survived on TAC and
80% did on the CSA arm. In terms of graft survival, the figures were 81% and 71%. The proportion of
patients who were rejection free was observed to decline annually for the first 4 years by 48, 5, 2, 1
percentage points with CSA, and by 37, 4, 1, 4 percentage points with TAC. In terms of costs, the
observed per-patient costs in the first year post transplant were £9990 under TAC compared with £9783
under CSA. In the subsequently observed years 2–4, the TAC arm had lower per-patient costs – from £133
to £350 less – than the CSA arm due to the higher proportion of patients with a failed graft and receiving
dialysis in the latter.
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By the end of 10 years’ follow-up, the model predicted that the cumulative (discounted at 6%) costs
would be £23,803 and £23,204 per patient under the TAC regimen and CSA regimen, respectively. In
terms of clinical outcomes, the model predicted that 64% and 56% of patients receiving TAC and CSA
would be alive, respectively, and that 61% of TAC-treated patients would survive with a functioning graft,
compared with 52% under CSA.
The study presented results in terms of incremental cost per additional survivor, per extra patient with a
functioning graft and per rejection-free patient. Although the number of years of life achieved after
transplantation under each treatment was not presented, the Evidence Review Group approximated them
by numerical integration using Newton–Cotes methods (Simpson’s rule) from the percentages of patients
alive at the end of each of the 10 years of analysis reported by the study. This yielded an estimated 8.28
life-years under TAC and 7.61 life-years under CSA. The information provided in the paper also allows
adjustment to be made to the cost discounting to convert results from the 6% annual rate used by the
study to the current NICE-recommended rate of 3.5%. Similarly discounted life-years were approximated
by applying the discount rate to the end-of-year survival rates provided by the study before applying the
numerical method just described for undiscounted life-years. The resulting discounted incremental cost per
life-year gained by TAC over CSA was £1457.
The authors found that the parameters that affected costs the most were the cost of hospitalisation per
patient and the costs of immunosuppression per patient. The authors used trial information to account
for uncertainty in these and health outcome parameters and performed PSA. In conclusion, TAC
was found to be cost-effective, in terms of numbers of survivors, patients with functioning graft and
rejection-free patients.
Critique
This study had detailed unit cost information reported, although quantities of resource utilisation were not
provided, which limits the value of this study to other researchers who might be interested in replicating
the analysis by applying their local prices or to generalise the results to England. As this is one of the
studies with the longest prospective follow-ups of health-care use and health outcomes by patients, its
value to research activity was also diminished by the lack of information on longitudinal results in terms of
quantities of resource use and interpatient variability.
The study309 did not account for HRQoL effects of immunosuppression, which limited the value of this
study to inform resource allocation decisions. The model does not consider the importance of outcomes in
terms of renal function for costs and benefits. In particular, there is emerging evidence that not only does
CKD stage matter for current costs and HRQoL experienced by the patient, but it also has an important
role as a prognostic factor and determinant of graft survival.333
The time horizon of the analysis may now be too short to estimate cost adequately, especially as the paper
adopted a higher discount rate (6%) than that currently recommended by NICE (3.5%). This means that at
a £1 of extra costs with TAC costs in 10 years post transplant are now worth £0.71 in present value terms,
as opposed to £0.56 when discounting at the 6% rate.
Owing to the lack of reporting of an ICER in terms of life-year gained, we derived this from the information
provided in the report and adjusted the discounting applied originally to obtain the ICER at the 3.5%
discount rate currently recommended by NICE. This suggests that, in the sample studied by Orme et al.,309
TAC is well within the NICE threshold of cost-effectiveness. Although we did not adjust prices to current
levels, in this sample of TAC versus CSA these are unlikely to raise the ICER per QALY gained
beyond £5000.
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Woodroffe et al. 2005
The Evidence Review Group at Birmingham reviewed the models submitted by sponsoring companies to
the previous NICE appraisal process on the topic. Woodroffe et al.65 reviewed and critically appraised
the economic evaluation results from four models developed by the sponsoring companies. They
then developed their own analysis based on their preferred model, based on the information in the
industry submissions, and their own systematic review of the published evidence on effectiveness and
cost-effectiveness. They chose to use one of the submitted models, the one developed by Novartis, to
produce their analysis with some minor modifications.65
The Novartis model simulated the experience of individual patients after renal transplantation, represented
by transitions between five health states: AR, no AR, hospital dialysis, PD and death. A PTDM model
component captured the effects on clinical outcomes of PTDM. (This allowed accounting for the clinical
implications of the high incidence of PTDM with TAC that the company found in its systematic review.)
The model accounted for cause-specific mortality risks from five comorbidities associated with diabetes
mellitus or other causes (not specified). Costs were specific to each health state, allowing for different
costs of dialysis (37.4% of which was ambulatory peritoneal), and severity of AR (steroid responsive vs.
resistant; no details were given) and utilities distinguished between death (0), successful transplant
(i.e. functioning graft, 0.84 utility) and dialysis (i.e. failed graft, 0.65 utility) states.
The Novartis model was driven by a model linking ARR to graft and patient survival outcomes, so that,
conditional on the level of ARR (and PTDM rate), an immunosuppressant drug had no independent effects
on those outcomes. The Birmingham group thus estimated a metamodel of the results of repeatedly
running the Novartis model, each time with different input values for the rate of AR, and covering the
range of values found in its own systematic review of the literature. They carried out a set of runs with the
1-year PTDM rate fixed at 14% and another set at 7%, to reflect the values differences in PTDM outcomes
between TAC and other regimens. By fitting linear regressions to the QALY model outputs against the AR
inputs, the metamodel for QALYs was estimated. This process was also conducted for costs, although this
required carrying out separate sets of model runs for the different levels of monthly immunosuppression
costs corresponding to the different regimens being evaluated.
A summary of the findings reported by the Birmingham group is presented in the tables of Chapter 5 in
the main text. TAC was found to have incremental costs per QALY ratios in the range of £59,548 to
£166,112 relative to CSA when evaluated as candidate components of triple therapy containing AZA and
CCSs. Larger ICERs were found for the comparison in the context of triple therapy constituted by MMF
and CCSs.
For the comparison of MMF with AZA, the ICER ranged from £39,297 to dominated when evaluated
alongside TAC and CCSs, and from £52,166 to £109,549 as part of triple therapy containing CSA and
steroids. The authors refer to these ranges as 95% CIs but, as these did not account for the variation in
costs, they are likely to misrepresent uncertainty.
Critique of Birmingham analysis
The metamodel just described is an efficient way to derive measures of central tendency for costs and
benefits in models that extrapolate short-term surrogate outcomes to long-term clinical health benefits
and costs (Stevenson et al. 2004428). The difficulties encountered by the Birmingham group in
implementing such a meta-model as described in its report65 prevented it from solving satisfactorily the
problem that is common to patient simulation models with many parameters, namely that running them is
costly – in the Novartis case, that means requiring several hours to run each time new values for ARR are
adopted, which means that, at the number of patient simulations that in these models may be run in the
available time, results vary from one run to another despite using identical parameter values and model
specifications. They could obtain 95% CI for incremental QALYs but not for costs, and thus the degree of
uncertainty in their results was left unaddressed.
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A more fundamental problem arises, however, with the use of a model such as that of Novartis, which
assumes that the main clinical outcomes, that is, years of the patient’s life and with a functioning graft
gained, are adequately predicted by short-term ARRs and PTDM. In recent years, evidence has emerged
suggesting that renal function is a predictor of clinically and economically significant outcomes, and that
AR may be less relevant once CKD stage is accounted for.333,334,338 At the time of the Birmingham review,
the evidence was ambiguous about the prognostic predictive power of renal function relative to AR and,
as they acknowledge, their analysis reflects this (Woodroffe et al.,65 p. 52).
McEwan et al. 2005, 2006
A couple of papers by McEwan et al.310,311 evaluate the cost–utility of SRL against CSA, and SRL against
TAC, for maintenance immunosuppression, from the NHS perspective, using a discrete event simulation
model of individual patient evolution from the time of kidney transplantation until 20 years post
transplant. The authors justify their choice of analytical time horizon on the need to account for the
longer-term implications of improved renal function on graft survival. In particular, they notice that the
mean graft survival is > 12 years and argue that a ‘10-year horizon would fail to capture the majority of
benefits that patients within the simulation would gain if extended graft survival is attained’.311
The model represented a contribution to the literature at the time it was published because of its account of
renal function as a predictor of transplant outcomes. The model simulated the evolution of a patient’s health
status by transitions between mutually exclusive health states occurring in monthly cycles. Three health
states were included in the model: (1) patient with a functioning graft; (2) patient with failed graft (dialysis);
and (3) death. In addition, AR events were accounted for. The model allowed for retransplants and, as
described below, different probabilities of experiencing an AR, patient death, graft failure and transplant
after graft failure, depending on the number of transplants that the patient had received at each point
in time. Movements between health states were associated with changes in costs and HRQoL, whereas the
occurrence of transplant, graft failure, and ARs and graft failure were associated only with costs.
The effects of SRL and CSA on clinical outcomes were assumed to occur through their effects on renal
function, which determined long-term clinical outcomes independently of treatment. The relative efficacy
of SRL compared with CSA was derived from a single trial involving 430 patients from 57 centres in
Europe, Canada and Australia (the Rapamune Maintenance Regimen Study, Oberbauer et al.336).
Patients included in this trial were given the same immunosuppression regimen (CSA+ SRL+CCSs) for
the first 3 months after transplantation and then randomised to continue on the regimen or switch to
a regimen of once-daily SRL and steroids. Serum creatinine values in each trial arm at the time of
randomisation, that is, 3 months post transplantation, and at 1, 2 and 3 years, were used as inputs
(surrogate measures) in estimated equations for predicting the risk of long-term clinical events.
The serum creatinine outcomes from the Rapamune Maintenance Regimen Study336 used in the model as
drivers of differences in effectiveness between immunosuppression regimens are illustrated in Figure 140.
The authors also assumed that for 50% of subjects treated with SRL, graft survival ‘would prevail for the
entire time horizon’.310 The authors further state that ‘supporting evidence for this assertion was the
increasing difference and the stability of mean serum creatinine in these subjects within a clinical trial’,
referring to the data in Figure 140.
The surrogate relationship between renal function and clinical events defining transitions between
health states in the model was estimated from analysis of longitudinal data on outcomes experienced by
937 transplant patients up to 20 years post transplantation in routine practice, recorded at the University
Hospital of Wales, Cardiff. The patients were treated over the period 1982–2001, during most of which
time CSA was the standard immunosuppressant therapy.310 Baseline survival curves and Cox proportional
hazards (predictive) models were fitted to individual data on time to AR and time to graft failure from
transplant, time from graft failure to retransplant, and time from first transplant to death. Separate
estimates were obtained from the estimated Cox proportional hazard models for the additional risk (HR) of
graft failure in the first year, years 1–2, years 2–3 and year 3 onwards post transplant for the number of
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transplants and creatinine value (respectively, at 3 months, 1 year, 2 years and 3 years post transplant).
Similarly, separate estimates of the HR of death for the different periods after first transplant were made as
a function of age at first transplant, diabetes mellitus and creatinine values. The graft failure HRs for one
extra previous transplant varied from 7.11 (95% CI 5.53 to 9.14) in the first year to 5.44 (95% CI 3.71 to
7.97) in years 3+ post transplant. The HR for a 100-mol/l increase in creatinine increased monotonically
over time from 1.36 (95% CI 1.29 to 1.44) in the first year to 3.74 (95% CI 3.54 to 3.96) in years 3+ post
transplant. Diabetes mellitus and age at first transplant had estimated constant HRs of death after first
transplant of 2.81 (95% CI 1.88 to 4.19) and 1.05 (95% CI 1.04 to 1.06), whereas the HR for creatinine
increased after the second year post transplant.
Costs
The costs of SRL daily doses included an initial 3-month period at 2mg, 6mg for months 4–12 and 4mg
thereafter. The costs of CSA included daily doses of 6mg/kg for the first 6 months and 4mg/kg thereafter.
The costs of AZA and prednisolone in standard doses were added to these regimens. Costs for other drugs
included prophylaxis regimens given for the first 6 months to CMV-positive and CMV-negative patients at
baseline, as well as antihypertensive medication and cardiovascular treatment with blood pressure therapy
and lipid-lowering drugs for all patients. The cost of treatment for anaemia and bone disease was assigned
to simulated patients who reached creatinine values of ≥ 300 µmol/l. The model also included the costs of
treating AR events, for which a 2-day hospital stay was assumed to occur by expert opinion, and the costs
of retransplants, graft loss and HD. Drug-use quantities were valued at BNF prices. Unit costs of procedures
were derived from NHS reference costs, apart from the hospital charge for AR, which was derived from
local hospital costs at the University Hospital of Wales.
Utilities
A utility value difference of 0.27 was used by this study to account for differences in HRQoL between
patients with a functioning graft and those with a failed graft and on dialysis. No account was made of
any effects of clinical events on HRQoL.311
Results
The authors found that SRL regimen would cost the NHS £62,120 per patient over 20 years, whereas CSA
would cost £7405 more, that is, £69,525 (at 2003 prices and 6.5% annual discount rate). SRL was found
to result in more discounted years with a functioning graft and in 0.16 additional discounted life-years
per patient; it also resulted in more QALYs than those achieved with CSA (no figures were reported).
Extending the horizon of analysis from 10 to 20 years increased savings achieved by SRL 26 times
(from £276 to £7405) and discounted life-years gained twofold (from 0.06 to 0.16). These results were
most sensitive to the critical assumption that 50% of SRL patients would maintain their graft survival over
the entire modelled period. When 0% of patients had their ‘graft survival prevail for the entire horizon’310
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FIGURE 140 Serum creatinine levels (Oberbauer et al.336) used by McEwan model.310
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or ‘graft survival sustained over the full time horizon of the model’311 the incremental cost per QALY
gained by SRL was 51,778 under the 10-year horizon and £11,161 under the 20-year horizon.
The same analysis was performed for the comparison of SRL with TAC.311 In implementing this analysis,
the authors assumed that ‘as TAC and CSA are equivalent in terms of renal function, the creatinine levels
observed in patients receiving CSA in the Rapamune Maintenance Regimen Study trial336 were used as
proxies for creatinine levels in patients receiving TAC within the model. To better reflect outcomes in
normal clinical practice in the UK, the creatinine profile from the Cardiff cohort (i.e. the sample used to
estimate the patient and graft survival equations as a function of creatinine surrogates) was also used as
the basis for an alternative set of TAC analyses. The authors then used the BNF price of TAC as they had
used the price for CSA in the analysis previously described. The results were qualitatively similar with SRL
both saving costs and producing health benefits relative to TAC.
Critique of the model
The model strength lies in its account for the effect of renal function on long-term outcomes. Moreover,
the model derives probability of clinical events from observational data of patients treated in routine
practice and distinguishes the temporal variation in the effect of risk factors for those events over a
20-year period.
As for its weaknesses, the study310,311 does not account for the incidence of clinical conditions, such as
malignancy, cardiovascular events and NODAT. This is an important limitation in the light of the expected
benefits of SRL on malignancy.
Most important, however, are the safety concerns associated with the drug. A recent systematic review of
RCTs comparing SRL-containing regimens with other immunosuppressants found that although SRL
reduced the incidence of malignancy it also increased the risk of mortality, which led researchers to
conclude that use of the treatment may not be justified in kidney transplant patients other than those at
high risk of cancer.337
Although the study310,311 accounts for the role of renal function as a predictor of long-term outcomes,
it does not allow for its impact on costs and HRQoL. For example, recent evidence suggests that CKD stage
is significantly associated with costs42 and HRQoL.338
The analysis relies on a single trial of SRL versus CSA which started 3 months after renal transplantation,
following an initial immunosuppression regimen that combined SRL, CSA and steroids. In addition, the trial
compared a regimen different from that represented in the costs analysis of the model: the trial compared
SRL with CNI withdrawal after 3 months with SRL CNI minimisation, yet the cost analysis in the model
included costs of AZA for both regimens.310,311
In addition to the strengths and flaws just described, the analysis comparing SRL with TAC suffered from
two problems. First, it assumed that TAC and CSA ‘are equivalent in terms of renal function’, citing
three sources,244,429,430 despite having acknowledged in the introduction that the results of these studies
had been contradicted by other studies favouring one or the other regimen.180,327,431 In fact, the authors
acknowledge that ‘the main advantage of tacrolimus over cyclosporine is that it is associated with a
reduction in the incidence and severity of AR’,311 yet the analysis does not account for this difference as it
uses data from the Cardiff cohort that includes primarily CSA-treated patients (TAC had only ‘become
available until very recently’ in the period covered by the McEwan et al.311 cohort) to derive the
probabilities of AR for the TAC arm of the model.
The second problem relates to the use of serum creatinine values from the Cardiff cohort to populate
surrogate outcomes used in the model ‘to better reflect outcomes in normal practice in the UK’. This
ignores the issue that the Cardiff cohort comprised, primarily, CSA patients, as just discussed.
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In fact there is no information in the paper311 that permits the reader to discern the source of variation in
outcomes between the TAC arm of the model and the results previously reported for CSA,310 as all
parameter inputs related to health benefits in the model are the same for the TAC and CSA arms (for the
analysis based on the Rapamune serum creatinine outcome data336).
Muduma et al. 2014
In a recent study306,308–311,313,314,316,318,320,324,325 the current UK standard treatment for adults, twice-daily
immediate-release TAC, Prograf, was compared with current options, namely CSA ME, SRL with CNI
minimisation, SRL without CNI, BEL and 1-day TAC-PR, Advagraf, in terms of cost-effectiveness from the
perspective of the NHS. The analysis considered each of these treatment options as part of a regimen that
also included MMF and CCSs, and BAS induction (consisting, in the base case, of 20mg 2 hours before
surgery, and 20mg 4 days after surgery; an alternative scenario considered additional doses during the
first few days after transplantation). The study found that although Prograf resulted in more efficient use
of health-care resources relative to CSA ME and BEL, it was not cost-effective relative to SRL. Although
Advagraf produced lower costs and higher benefits than Prograf, its cost-effectiveness ratio against SRL
(CNI minimisation regimen) was £58,350. These results were found to be sensitive to the time horizon and
the effect of adherence.
Costs and health benefits were accumulated according to a Markov model of annual cycles that
represented the evolution of the patient heath status following a successful transplant for up to 25 years.
The model included four health states: (1) functioning graft without a history of BPAR; (2) functioning
graft with a history of BPAR; (3) non-functioning graft; and (4) death. The occurrence of repeat
transplantation was modelled using a tunnel state. The model assigned an excess risk of graft loss for the
state of functioning graft with prior BPAR relative to the functioning graft without prior BPAR state, using
estimates derived from the literature. The model was specified so that BPAR could occur only in the first
year after transplantation, which the authors justified on pragmatic grounds given the limited data
available from the literature on BPAR outcomes beyond 1 year.
Although the authors report that relative differences in ARRs between the treatment regimens under
comparison were obtained from a systematic review of the effectiveness literature, the study did not report
any information on the methods and results of that review (apart from stating that the review included
studies published in the period January 2002 to June 2013 and that direct and indirect comparisons were
used), the primary study sources for the probabilities of AR used, or the actual values used for these
parameters. The treatment-specific outcome data reported related to the advantage of Advagraf over
Prograf in terms of adherence to treatment schedule.
The remaining details relating to effectiveness parameter values applied equally to all regimens in the
comparison: graft and patient survival for the first 5 years post transplantation were obtained from UK
renal transplant summary statistics;13 survival parameters for the first 10 years after the start of the spell on
dialysis were populated using UK data;432 the probabilities of retransplantation while in dialysis were
obtained from data by McEwan et al.,310 reviewed in this chapter. Exponential curves were used to
extrapolate modelled graft and patient survival and survival on time on dialysis beyond the 5- and 10-year
periods covered by their data sources.
The costs of immunosuppression regimens were based on the doses reported by a previous study239
(0.12, 0.10 and 0.08mg/kg, respectively, at 1, 6 and 12 months for Prograf; 0.14, 0.11 and 0.09mg/kg,
respectively, for Advagraf). Mean daily doses for the other components of immunosuppressive triple
therapy were based on BNF recommendations. The costs of dialysis (a weighted average of the costs of
ambulatory peritoneal and HD), transplantation and AR, allowing for the excess costs of steroid-resistant
BPAR including the costs of 4 days, hospitalisation (i.e. the NHS reference costs figure for uncomplicated
AKI), completed the list of costs measured by this study. Utility values for the functioning graft state of
0.71 for HD and 0.44 for PD were obtained from a previous study.358
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Critique
Despite its stated aim to comply with the NICE reference case specifications, this study310,311 faced
limitations in terms of the availability of data to do so, the adopted model structure, issues of model
implementation, and the quality of reporting. The model assumed that the cost-effectiveness was driven by
the differences in the rate of AR between-treatment regimens, and that these fundamental differences
occurred only during the first year post transplant. The validity of this assumption and the results of this
study hinge on the quality of the evidence on the relationship between AR and graft and patient survival in
the study that estimated the empirical relationship supporting the present model.354 In any case, it is
difficult to defend extrapolating results from 1 year surrogate measures to clinical outcomes 25 years into
the future, as this study310,311 has done with the statistical model of AR and graft survival.
Another problem with this report is its lack of any information on the values of the parameters driving the
results, that is, the relative differences in the risk of AR between regimens. This fact makes it impossible to
replicate the results reported by the paper.
Third, there are at least two problems with the way the model was populated or implemented. Although
no information was given on the values and sources used to populate the efficacy parameter values,
the information that is provided suggests that the amount of immunosuppressant use in the model might
not have reflected the actual total use of the medications that brought about the AR outcomes that were
used to populate the effectiveness model parameters. The authors do not report any attempt to derive
mean daily drug use or dose intensity from the RCT data from which the AR estimates were derived for
populating the model; the only statement in this regard is ‘Immunosuppression doses of Prograf and
Advagraf were based on a study by Silva et al. For BEL, CSA and SRL, mean daily dosing was based on
the latest version of the BNF16 as were the daily doses of the concomitant medications MMF and
corticosteroids’. A separate issue was also identified in the statement that ‘The model employed an
algorithm in which, for a given patient of a given age, the greatest probability of mortality was selected
from the three possible mortality causes captured by the model: increased mortality with a functioning
graft or dialysis, or the natural mortality of the general population’. In this regard it is difficult to think of a
situation in which the general population of the same age (and presumably, sex) would face higher risks of
death than the average patient on dialysis or a functioning graft. It would have been more natural instead
to account for excess mortality risks for patients after renal transplantation over the background mortality
risks, using registry data such as those utilised by the authors.
Another issue arises with the way transition probabilities were derived from the registry data on transplant
and patient survival. As this issue is discussed for one of the industry submissions that used the same data
and model, the reader is referred to that section (see Chapter 5, Astellas’ submission).
Non-UK studies
Three identified reports investigated the cost-effectiveness of SRL regimens, one in the USA308 and two in
Germany.306,307 Two studies evaluated TAC compared with CSA ME in European countries.319,320 One study321
investigated once-daily TAC compared with twice-daily TAC in the USA.
Earnshaw et al. 2008
As in the UK studies by McEwan et al.,310,311 this US study308 evaluated SRL+CCSs after CNI withdrawal
but, in this case, it compared it against triple therapy of TAC or CSA combined with MMF and steroids.
The cost–utility of these regimens over the lifetime of a 46-year-old first-transplant patient was investigated
for the adult renal transplantation population in general and specific patient groups defined by donor type
(living, deceased non-ECD, deceased ECD).
This study308 used a decision tree model for the first year post transplantation, followed by a Markov model
of annual cycles of health-state transitions between four health states: functioning graft, functioning graft
with AR, failed graft (dialysis while awaiting retransplant) and death. The model allowed for the occurrence
of one retransplant, which was followed by a return to the first year post transplantation decision tree.
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The differences in long-term health outcomes between the regimens were driven by their relative efficacy
in terms of AR and renal function, defined in terms of serum creatinine values. A model of long-term graft
survival as a function of serum creatinine at 12 months was used to populate the transition probabilities of
the Markov model phase.
The model implied that the assumption that no induction regimen was used. Estimates of first-year ARRs
were obtained from the literature for the different regimens and used to populate the first-year model
phase. These ARRs were adjusted to subtract the effect of variable use of induction immunoprophylaxis
across trials of the different immunosuppressive regimens, based on efficacy estimates observed in clinical
trials of the induction agents concerned. The authors acknowledge that the adjustments involved the
simplifying assumption that the use of induction agents did not affect long-term clinical outcomes.
Differences in AR between regimens were assumed to last only until the first year post transplantation.
The probability of AR in the first year of the Markov phase, year 2 post transplantation, was assumed to
be the same across model arms and to decline linearly to a 0% probability over a 10-year time horizon.
The model assumed the same rate of graft loss in the first year post transplant across treatment regimens.
Graft loss in subsequent years was predicted by renal function as measured by creatinine levels at
12 months, based on the relationship estimated by Hariharan et al.340 Means and SDs of serum creatinine
reported in the trials for the different regimens at 12 months127,254,433 were used to derive the distribution of
the patient cohort across serum creatinine categories at the start of the Markov phase of the model. The
probability of graft survival was derived from half-life graft survival rates for the different serum creatinine
groups and donor types and by assuming that graft survival followed an exponential curve, so that the
probabilities of graft failure were constant over time within each regimen arm of the Markov model.
The annual probability of receiving a second transplant after graft failure was estimated from a median
waiting time of 5.08 years, assuming an exponential curve of time to retransplantation from graft failure.
This figure was based on US registry data from 1993 to 2003 (US Organ Procurement and Transplantation
Network 2004434).
The model also accounted for the increased cumulative incidence of diabetes mellitus up to 3 years after
transplantation with TAC-containing regimens (22.1% vs. 14.2% in the first year, 28.2% vs. 19.1%
in the second year and 31.8 vs. 21.0% in the third year), assuming no further incidence of diabetes
mellitus after year 3. This was associated with an annual medical cost of US$14,966 (in 2005 prices),
based on a report by Woodward et al.,395 and also with a RR of 1.46 for graft failure in the model.
The model also accounted for the costs of increased triglyceride and cholesterol levels, as represented by
the 12-month proportion of patients on statins in each model arm, which was assumed to remain constant
until either graft loss or patient death (Earnshaw et al.,308 p. 1813).
Different age-specific mortality rates were adopted according to organ type and for patients on dialysis.
In addition, excess mortality risk with diabetes mellitus was accounted for by means of a RR of 1.87.
The costs of immunosuppressants were derived from the daily allowable consumption for each regimen
from the Surveillance Data Inc.435 data set of March 2005, valued at wholesale acquisition costs. The cost
of patients on statins was derived from the prices for a generic medication. No additional detail was
provided in terms of the unit costs used by the model, apart from stating that they were obtained mainly
from a previous CEA,436 which reported Medicare-based health state costs from the USRDS.
Utility values only varied between the graft functioning state, which received a 0.84 utility, graft failure
state, at 0.44, and death, valued at 0, based on time trade-off estimates from a study published in
1987.437 The graft failure state was calculated by the weighted average HRQoL experienced by patients
across dialysis types.
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In common with the UK studies of SRL CNI withdrawal discussed in this review, Earnshaw et al.308 found
that a dual SRL plus steroids (CNI withdrawal) regimen was the dominant treatment regimen. Its use
resulted in 0.30 extra years of life relative to TAC-containing triple therapy, and 0.06 extra years of life
relative to triple therapy containing CSA. In terms of discounted (at 3% per annum) QALYs, the results
were 0.30 and 0.12, respectively. SRL CNI withdrawal produced a cost savings of US$33,000 relative to
TAC, and US$11,000 when compared against CSA. The same qualitative results were found for the
subgroup analysis by donor type.
Critique
This study308 is different from other reports on the same topic in its attempt to provide evidence on
cost-effectiveness across different donor types. In common with other studies evaluating SRL, it found the
regimen to be cost-effective, in this case relative to current standard triple therapy containing a CNI.
Similar criticisms as those made above to the UK reports by McEwan et al.,310,311 in relation to the current
perception of SRL as having a restricted use due to issues about safety, may be applied to this study.
In terms of its methodology, this study308 used a model to predict long-term graft survival from 1-year renal
function outcomes specific to the three regimens, accounting for graft survival differences between donor
types. Although the use of renal function as driving clinical outcomes is supported by recent statistical
evidence in samples of patients treated in routine practice,333 the model structure adopted by Earnshaw
et al.308 relies on a simplistic assumption of constant (instantaneous) probability (hazard rates) of graft
failure over time, which more recent studies find to be inconsistent with the data.334
In addition, the study does not account for the direct effects of renal function on costs and HRQoL.
Thus, important differences between therapies might not have been captured with this model as patients
accumulated time in the functioning graft state.42,338
A technical issue was found in the way this study implemented the distribution of patients between serum
creatinine categories at the start of the Markov phase (1 year post transplantation). As the authors
assumed that serum creatinine was normally distributed and the mean and SD values adopted for the TAC
arms were, respectively, 1.20 and 1.40, the model implies that 19% of serum creatinine values would be
≤ 0. Therefore, the assumed distribution is likely to underestimate the proportion of patients found in the
higher creatinine value categories at 12 months and, as a result of the role of serum creatinine in the
prediction of graft survival, the amount of time patients were expected to live with a functioning graft in
the TAC arm.
Jurgensen et al. 2010, 2014
A couple of reports306,307 present the results of a Markov model representing the transition across health
states experienced by patients after renal transplantation in Germany. The model compares SRL CSA
avoidance with SRL CSA minimisation and low-dose TAC triple therapy with MMF and steroids. The latter
was included in acknowledgement of the changes in immunosuppressant treatment practice following the
publication of results from the SYMPHONY trials. The analysis was conducted from the perspective of
the German statutory health insurance.
The model is designed as monthly cycles across five health states: functioning graft, AR, graft failure,
dialysis (waiting on retransplant) and death. The time horizon of the analysis was 10 years post
transplantation, and long-term survival outcomes were assumed to be driven by 2-year differences in the
rate of AR between model arms estimated from direct and indirect comparisons of RCT outcome data.
One of the strengths of this analysis is its attempt to derive comparative evidence for the effects of the
different regimens from evidence synthesis based on indirect comparisons, through NMA. The study306,307
provides details account of the probability of AEs including graft failure, malignancies, CMV infections,
PTDM, wound-healing disorders and post-transplant anaemia, HMGCoA and hypertension treatments.
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The evidence synthesis reported by this study306,307 was used by one of the companies to populate the
parameters of its model (see Abecassis et al. 2008, below – the section on the Astellas model).
The study found that low-dose TAC in triple therapy with MMF and steroids has a cost per life-year gained
in excess of €100,000, relative to the SRL CSA minimisation regimen. All other comparators were found
to be irrelevant for identifying the cost-effective treatment option, as they were dominated by these
two regimens.
Critique
The study306,307 provides valuable new evidence about the cost-effectiveness of low-dose TAC regimens
currently favoured by current practice, which has emerged following the publication of the SYMPHONY
trial results. However, the value of this study from an English NHS decision-making point of view is
diminished by the choice of comparators, which excludes CSA-based triple therapy and other new
treatments such as BEL.
The study306,307 also has limited information use for informing NICE recommendations, as it did not account
for HRQoL outcomes. The model itself is not amenable to account for available evidence on important
HRQoL and costs effects associated with the effects of immunosuppressive regimens on renal function,
as the renal function plays no role in the health status of patients in the model.
Abecassis et al. 2008
This study, co-authored by an affiliate of Astellas Pharma US, modelled the expected costs and clinical
outcomes of once-daily TAC-PR and twice-daily immediate-release TAC, each given in combination with
MMF, for transplant recipients in the USA. A stochastic state-transition Markov model extending 5 years
post transplantation was used for that purpose. The model was used to predict the amount of time
patients were alive with a functioning graft, receiving dialysis as a result of graft failure or dead.
The baseline for this model comprised the rate of adherence, incidence of ARs and graft loss up to 5 years
post transplantation in the twice-daily TAC arm of the FK506 trial reported by Vincenti et al.326 To project
the effect of TAC once-daily relative to the baseline, the improved adherence with once-daily relative to
twice-daily immunosuppressant regimens438 was combined with estimates of effect of non-adherence on
graft survival from a systematic review.9
The source of values for other parameters determining clinical events in the model (i.e. incidence of
late AR requiring antibody treatment with once-daily TAC, reduction of 5-year graft survival for
retransplanted organs relative to original graft) was not reported. Moreover, the information reported was
insufficient to allow the reader to replicate the reported findings. For example, values of patient survival
rates under dialysis were not reported or could not be calculated from the reported information. HRQoL
outcomes were not accounted for by the model.
Immunosuppressant drug use and the resource utilisation parameters associated with the occurrence of
clinical events were populated with cost data for medical procedures and hospitalisations from Medicare
and the USRDS, and Medicare Average Sales Price year 2006 prices for drugs. The analysis included the
costs of TAC and MMF immunosuppressant drugs, retransplantations, antibody rejection treatment,
dialysis, graft loss costs other than dialysis, and mortality costs. The analysis applied the same price per
milligram to both regimens for estimating their costs.
The study report 5-year predicted survival rate with once-daily TAC of 69.1%, as opposed to the estimated
rate of 63.0% with TAC twice daily. The amount of time spent alive with a functioning graft was
predicted to be 51.6 months and 50.3 months, respectively; the time spent in dialysis (with a failed graft)
was 2.8 and 3.9 months, respectively. The total time alive was the sum of time with a functioning graft
and time on dialysis (i.e. 54.4 months for once-daily TAC and 54.2 months for twice-daily TAC).
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Once-daily TAC generated discounted (5% annually) total costs per patient of US$228,734. This amount
US$9,411 less than the corresponding costs of twice-daily TAC – US$238,144. The authors report that
‘sensitivity analysis were conducted around key model inputs’ and that ‘throughout all sensitivities tested,
once-daily extended release TAC remained dominant in terms of cost-effectiveness’, but they provide no
other information on these analyses.
Critique
The low quality of reporting in this article prevents the assessment of its validity. The sources of values for
some model parameters or the methods used to identify them were not reported. Moreover, the values
of some parameters were not provided, preventing the replication of results by the reader.
In terms of the patient population, this article stated that the 5-year trial outcomes reported by Vincenti
et al.326 served as the baseline. It is unclear whether event costs, which were derived from an older
population (Medicare), would correspond to the baseline population.
The authors do not discuss their results or their implications for routine patient management. An
explanation for some of their findings seems warranted. In particular, the figures produced imply that, over
5 years, the benefits of improved adherence with once-daily TAC are manifested primarily in terms of
quality of life (i.e. 1.3 extra months with a functioning graft), as the patient life expectancy is improved by
only 0.2 months. Moreover, by the end of the analytical time horizon, 5 years post transplantation,
the graft survival curves of the two regimens show a continuing diverging trend that had started at 1 year
after transplantation. This suggests that the time horizon of the analysis may be insufficient to capture
relevant clinical events, including presumably those relating to patient survival.
The analysis did not account for uncertainty in model parameters. This is a serious limitation owing to the
small differences in graft and patient survival outcomes between the regimens, and more so for estimating
their corresponding QALY difference.
Other studies not meeting the inclusion criteria
Levy et al.334 developed a Markov model to extrapolate short-term trial outcomes (at 36 months) to
20 years, using transition probabilities across health states defined by eGFR ranges. These probabilities
were estimated from Weibull time to event models of graft and patient survival for each initial (3 year)
eGFR category separately estimated from USRDS data; exponential models were also estimates for time
to death and time to retransplantation following graft failure, and for graft failure and death after
retransplantation using the same data. The effect of NODAT model on graft and patient survival was
accounted for separately on the basis of excess risk parameter using values from the literature, as data on
NODAT were not available from ESRDS. The estimated graft survival and patient survival were calibrated
by comparing the model-predicted survival to Kaplan–Meier survival curves fitted to USRDS data over the
first 5 years. The model estimated the time patients spent in the functioning health states by assuming a
constant linear decrease in eGFR until graft failure (eGFR < 15ml/minute/1.73m2) from the initial,
36-month eGFR level. Utility weights derived from the literature were then assigned to health states to
estimate expected QALYs over a 20-year horizon for each initial eGFR state; the results were then
aggregated by applying weights corresponding to the distribution across eGFR categories at 36 months.
The authors illustrated their model application using 3-year follow-up data from the BENEFIT59 trial.
As the authors claim, Levy et al.334 provide a valuable framework to translate trial outcomes for any
immunosuppressive regimen to the long term. In principle this would allow us to subject all analyses to a
common model that was based on observational data from current US practice. On the other hand,
however, the model reflects the experience of a representative sample from the Medicare population in
the USA, practically all of whom are ≥ 65 years old. This raises questions about the applicability of this
model’s outcomes to the UK and other patient populations with access to greater coverage of
immunosuppressive therapy439 and younger patient populations.
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Motivated by the observed lack of gains in graft survival over recent years, Barnieh et al.335 provide
evidence of increasing costs of maintenance immunosuppression over time in a single Canadian centre.
The study335 analysed the change of costs of immunosuppression for first adult kidney-only transplant
patients between the periods of 1998–2001 and 2002–6, which were divided by change from CSA to TAC
as the CSA agent of standard choice in triple therapy with antimetabolite (MMF) and steroid (prednisone)
immunosuppression regimen and from non-routine use of BAS to the routine use of DAC for induction
immunosuppression. Direct costs including medications, laboratory tests, pretransplant diagnostic imaging,
outpatient services (day surgery, ambulatory care and emergency department visits), diagnostic imaging,
hospitalisations, and physician services incurred for these patients, during transplant admission and up to
year 3 after transplant were measured. These were economic costs paid by the provincial government (the
sole funder of hospital and physician services for hospitalised patients) expressed in constant prices of a
single year.
Before-and-after differences in health outcomes were not significant (i.e. before vs. after period, ARR 28%
vs. 20%, p= 0.08; total graft failure, 89% vs. 92%, p= 0.73; mean survival over extended follow-up
of 7 years, 6.1 years vs. 6.2 years, p= 0.57). On the other hand, MD in cumulative costs up to 3 years
was CAN$45,011 (95% CI CAN$30,985 to CAN$59,037; p< 0.001) and was driven by the difference in
immunosuppressant costs during the first year associated with the frequency of use of DAC induction
therapy, which was more expensive than BAS induction therapy. Although DAC is no longer in use
in Canada, the authors argue that results are relevant because of the use of other high-cost
immunosuppressive agents in current general use. In addition, the study found differences in terms
of outpatient services, which the authors suggest may have resulted from increased use of dialysis and
increased use of day medicine facilities for infusions.
Chamberlain et al.42 provide key evidence that direct health care costs vary with renal function using data
from patient cohorts from nine European countries. Specifically, 3-year post-transplantation costs differ by
GFR at 1 year post transplantation. Patients with GFR ≥ 60ml/minute/1.73 m2 at 1 year had total costs that
were 35% lower than those of patients with 30ml/minute/1.73 m2≥GFR≥ 15ml/minute/1.73 m2.
The study reported by Lazzaro et al.320 and Craig et al.319 compared the resource used, costs and health
outcomes over 6 months post transplantation of patients randomised to receive TAC (n= 286) or CSA ME
(n= 287), as part of triple immunosuppressive therapy with AZA and steroids. This was a multicountry trial,
for which TAC was given at an initial daily dose of 0.3mg/kg, whereas the starting dose of CSA ME was
8–10mg/kg per day.
The study retrospectively measured resource-use quantities and costs of immunosuppressant drugs,
concomitant medications, hospitalisation, dialysis, and rejection episodes from the 50 centres in seven
Western European countries that participated in the trial. One report320 presents a CEA from the Italian
hospital perspective, whereas a separate article undertakes the same analysis for Germany and Italy, and
compares the results for the three countries, that is, of using country-specific unit costs in each of them to
value total costs on the pooled trial data across all countries.
Patients in the study had an average age of 43 years, mean weight of 69 kg and 99% were classified as
Caucasian. Thirty-eight (6.8%) of the 557 patients included in the trial had already had one (n= 37) or
two (n= 1) previous transplants. These characteristics were balanced across trial arms.
The costs of immunosuppressants and treatment of AEs were based on hospital prices, which in the Italian
analysis reportedly included a 50% discount on drug retail prices.320 The costs of concomitant medication
were based on the lowest generic price.
By the end of the 6-month post-transplantation period, the incidence of AR was 32.5% in the
TAC arm and 51.3% in the CSA arm. The proportion of patients who switched to the alternative
immunosuppressant regimens, as a result of treatment failure or AEs, was 2.8% and 19.0%, respectively.
Differences in both patient (99.3% vs. 98.5%) and graft survival (94.8% vs. 91.9%) had p> 0.10.
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Intention-to-treat analysis resulted in lower total per-patient costs with TAC than with CSA in all three
countries. The per-patient cost savings achieved by TAC ranged from €1776 in Italy to €524 in Spain
(figures in year 2000 prices). The authors attribute part of the variation to the higher cost of hospitalisation
in Italy than in the other countries.
Most of the savings with TAC were as a result of fewer days in hospital for the initial stay and
readmissions (Italian case 50%), lower costs of immunosuppressive medication for graft rejection (37%)
and incidence of dialysis (13%).320 According to the Italian perspective, €400 (12%) out of the €3200
per-patient costs of immunosuppressant therapy incurred by the TAC trial arm in the first 6 months
post transplantation were caused by switching regimens as a result of treatment failure or AEs.
The corresponding figures in the CSA arm were €1000 (37%) of €2700.320
Critique
The length of follow-up in this study may have allowed it to capture differences in the terms of outcome
measures that serve as surrogates for clinical outcomes, but was sufficient to capture important clinical
events such as graft and patient survival. In addition, the study did not report any results in terms of
changes in renal function, which has been observed to be associated with costs and HRQoL, as well as
serving as a prognostic predictor of graft and patient survival.
In particular, the study may have failed to capture important AEs such as the incidence of PTDM, with
which TAC immunosuppression has been found to be associated. The detailed report on the Italian case
found that differences in costs were statistically insignificant (i.e. p> 0.05), suggesting that the overall
reduction in costs may have been due to chance alone. In any case, in common with many economic and
cost evaluations alongside randomised trials, the study may have been insufficiently powered to enable
statistical inference on cost effects to be performed.328
Therefore, the conclusion that ‘the overall costs of treating a patient with TAC during the 6-month
post-transplantation period are substantially lower [than that for CSA ME]’ may not be warranted.
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Appendix 10 Additional results from the
Peninsula Technology Assessment Group’s
economic model
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Additional outcomes
TABLE 231 Additional clinical outcomes as calculated by the PenTAG model (deterministic base case)
Regimen
Mean
undiscounted
life years (life
expectancy)
Undiscounted
life years with
functioning
graft
Undiscounted
life years on
dialysis AR (%)
NODAT
(%)
Proportion receiving
Second
transplant
Third
transplant
CSA+MMF 22.397 19.070 3.326 24.0 5.0 23.8 2.7
TAC+MMF 22.421 19.407 3.014 21.0 10.6 21.4 2.4
CSA+AZA 22.102 18.471 3.631 40.1 5.0 26.3 3.0
TAC+AZA 22.430 19.342 3.088 27.9 10.6 22.2 2.6
CSA+ EVL 22.509 19.404 3.105 23.4 4.7 22.0 2.4
TAC+ SRL 21.886 18.395 3.491 20.4 16.0 25.4 3.0
TAC-PR+MMF 22.248 19.198 3.051 20.6 12.3 21.8 2.5
BAS+CSA+MMF 22.636 19.554 3.082 14.1 5.0 21.8 2.4
BAS+ TAC+MMF 22.640 19.850 2.790 12.2 10.6 19.6 2.2
BAS+CSA+AZA 22.380 19.041 3.339 25.8 5.0 23.9 2.7
BAS+ SRL+MMF 22.448 19.434 3.014 13.2 8.6 21.4 2.4
BAS+ BEL+MMF 23.206 20.502 2.704 21.9 2.2 18.8 2.1
BAS+CSA+MPS 22.877 19.953 2.923 19.6 4.7 20.5 2.3
rATG+CSA+MMF 22.403 19.065 3.338 10.3 5.0 23.8 2.6
rATG+ TAC+MMF 22.432 19.385 3.046 8.8 10.6 21.6 2.4
rATG+CSA+AZA 22.178 18.609 3.570 19.5 5.0 25.7 2.9
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Using Solver instead of flexible regression to match mortality
at 12 months
TABLE 232 Deterministic results when Solver is used instead of flexible regression to match mortality at 12 months
Regimen Total discounted costs (£) Total discounted QALYs
Net health benefit
£20,000/QALY £30,000/QALY
CSA+MMF 97,441 10.9160 6.0440 7.6680
TAC+MMF 92,222 10.8879 6.2768 7.8138
CSA+AZA 101,607 10.7724 5.6921 7.3855
TAC+AZA 93,315 10.8692 6.2034 7.7586
CSA+ EVL 176,148 10.9655 2.1581 5.0939
TAC+ SRL 125,534 10.6018 4.3251 6.4173
TAC-PR+MMF 106,530 10.7920 5.4656 7.2411
BAS+CSA+MMF 95,230 11.0261 6.2646 7.8517
BAS+ TAC+MMF 90,401 10.9875 6.4674 7.9741
BAS+CSA+AZA 98,254 10.9042 5.9915 7.6291
BAS+ SRL+MMF 114,544 10.9005 5.1733 7.0824
BAS+ BEL+MMF 209,510 11.2998 0.8244 4.3162
BAS+CSA+MPS 111,576 11.1417 5.5629 7.4225
rATG+CSA+MMF 101,959 10.9304 5.8325 7.5318
rATG+ TAC+MMF 97,145 10.9045 6.0473 7.6664
rATG+CSA+AZA 104,590 10.8205 5.5910 7.3342
TABLE 233 Regimens on the cost-effectiveness frontier when Solver is used instead of flexible regression to match
mortality at 12 months
Regimen
Total discounted
costs (£)
Total discounted
QALYs
ICER (cost per
QALY) (£)
INHB
£20,000/QALY £30,000/QALY
BAS+ TAC+MMF 90,401 10.9875 – – –
BAS+CSA+MMF 95,230 11.0261 125,110 –0.2028 –0.1224
BAS+CSA+MPS 111,576 11.1417 141,349 –0.9045 –0.5516
BAS+ BEL+MMF 209,510 11.2998 619,299 –5.6431 –-3.6579
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Removing disutility for NODAT
TABLE 234 Cost-effectiveness of induction agents when there is no disutility applied for NODAT
Induction
agent
Discounted costs (£) Discounted QALYs ICER
(cost per
QALY) (£)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With CSA +AZA
vs. BAS
No induction 101,595 – 10.8127 – Dominated –0.2998 –0.2439
rATG 104,570 2975 10.8600 0.0472 Dominated –0.4013 –0.2959
BAS 98,244 –6326 10.9450 0.0850 – – –
With CSA +MMF
vs. BAS
No induction 97,429 – 10.9566 – Dominated –0.2210 –0.1841
rATG 101,940 4511 10.9702 0.0136 Dominated –0.4329 –0.3209
BAS 95,219 –6720 11.0671 0.0969 – – –
With TAC +MMF
vs. BAS
No induction 92,226 – 10.9778 – Dominated –0.1912 –0.1609
rATG 97,146 4920 10.9942 0.0165 Dominated –0.4208 –0.3084
BAS 90,405 –6741 11.0779 0.0837 – – –
TABLE 235 Cost-effectiveness of maintenance agents when there is no disutility applied for NODAT
Maintenance
agent
Discounted costs (£) Discounted QALYs ICER
(cost per
QALY) (£)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With MMF
vs. TAC
TAC-PR 106,529 – 10.8952 – Dominated –0.7978 –0.5594
CSA 97,429 –9100 10.9566 0.0614 Dominated –0.2813 –0.1946
TAC 92,226 –5203 10.9778 0.0212 – – –
With AZA
vs. TAC
CSA 101,595 – 10.8127 – Dominated –0.5601 –0.4222
TAC 93,319 –8276 10.9590 0.1463 – – –
With BAS +MMF
vs. TAC
SRL 114,549 – 10.9733 – Dominated –1.3118 –0.9094
CSA 95,219 –19,329 11.0671 0.0938 Dominated –0.2516 –0.1713
TAC 90,405 –4815 11.0779 0.0109 – – –
BEL 209,409 119,004 11.3130 0.2350 506,309 –5.7152 –3.7318
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TABLE 235 Cost-effectiveness of maintenance agents when there is no disutility applied for NODAT (continued )
Maintenance
agent
Discounted costs (£) Discounted QALYs ICER
(cost per
QALY) (£)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With rATG +MMF
vs. TAC
CSA 101,940 – 10.9702 – Dominated –0.2637 –0.1838
TAC 97,146 –4794 10.9942 0.0241 – – –
With CSA
vs. MMF
AZA 101,595 – 10.8127 – Dominated –0.3522 –0.2827
MMF 97,429 –4166 10.9566 0.1439 – – –
EVL 176,154 78,725 11.0060 0.0494 1,593,185 –3.8869 –2.5748
With TAC
vs. MMF
SRL 125,539 – 10.7350 – Dominated –1.9084 –1.3532
AZA 93,319 –32,220 10.9590 0.2240 Dominated –0.0734 –0.0552
MMF 92,226 –1093 10.9778 0.0188 – – –
With BAS +CSA
vs. MMF
AZA 98,244 – 10.9450 – Dominated –0.2733 –0.2229
MMF 95,219 –3025 11.0671 0.1221 – – –
MPS 111,540 16,321 11.1776 0.1106 147,616 –0.7055 –0.4335
With rATG +CSA
vs. MMF
AZA 104,570 – 10.8600 – Dominated –0.2417 –0.1979
MMF 101,940 –2631 10.9702 0.1102 – – –
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Using 2007–12 donor type distribution
TABLE 236 Cost-effectiveness of induction agents when the 2007–12 donor type distribution is used
Induction
agent
Discounted costs (£) Discounted QALYs ICER
(cost per
QALY) (£)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With CSA +AZA
vs. BAS
No induction 99,452 – 10.9491 – Dominated –0.2958 –0.2421
rATG 102,558 3106 10.9934 0.0443 Dominated –0.4068 –0.3014
BAS 96,233 –6325 11.0839 0.0905 – – –
With CSA +MMF
vs. BAS
No induction 95,517 – 11.0949 – Dominated –0.2166 –0.1818
rATG 100,114 4598 11.1051 0.0103 Dominated –0.4363 –0.3248
BAS 93,428 –6686 11.2071 0.1020 – – –
With TAC +MMF
vs. BAS
No induction 90,413 – 11.0735 – Dominated –0.1853 –0.1571
rATG 95,394 4980 11.0866 0.0131 Dominated –0.4212 –0.3101
BAS 88,724 –6670 11.1743 0.0877 – – –
TABLE 237 Cost-effectiveness of maintenance agents when the 2007–2012 donor type distribution is used
Maintenance
agent
Discounted costs (£) Discounted QALYs ICER
(cost per
QALY) (£)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With MMF
vs. TAC
TAC-PR 105,133 – 10.9784 – Dominated –0.8311 –0.5857
TAC 90,413 –14,720 11.0735 0.0951 – – –
CSA 95,517 5103 11.0949 0.0214 238,659 –0.2338 –0.1487
With AZA
vs. TAC
CSA 99,452 – 10.9491 – Dominated –0.5164 –0.3802
TAC 91,278 –8175 11.0568 0.1077 – – –
With BAS +MMF
vs. TAC
SRL 113,366 – 11.0876 – Dominated –1.3188 –0.9081
TAC 88,724 –24,642 11.1743 0.0867 – – –
CSA 93,428 4704 11.2071 0.0328 143,420 –0.2024 –0.1240
BEL 211,416 117,987 11.4794 0.2723 433,299 –5.8295 –3.7846
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TABLE 237 Cost-effectiveness of maintenance agents when the 2007–2012 donor type distribution
is used (continued )
Maintenance
agent
Discounted costs (£) Discounted QALYs ICER
(cost per
QALY) (£)
INHB
Total Incremental Total Incremental £20,000/QALY £30,000/QALY
With rATG +MMF
vs. TAC
TAC 95,394 – 11.0866 – – – –
CSA 100,114 4721 11.1051 0.0186 253,976 –0.2174 –0.1388
With CSA
vs. MMF
AZA 99,452 – 10.9491 – Dominated –0.3426 –0.2770
MMF 95,517 –3936 11.0949 0.1458 – – –
EVL 176,982 81,466 11.1500 0.0551 1,477,730 –4.0182 –2.6604
With TAC
vs. MMF
SRL 124,216 – 10.7817 – Dominated –1.9819 –1.4186
AZA 91,278 –32,938 11.0568 0.2751 Dominated –0.0599 –0.0455
MMF 90,413 –864 11.0735 0.0167 – – –
With BAS +CSA
vs. MMF
AZA 96,233 – 11.0839 – Dominated –0.2634 –0.2167
MMF 93,428 –2805 11.2071 0.1232 – – –
MPS 110,393 16,965 11.3211 0.1140 148,867 –0.7343 –0.4515
With rATG +CSA
vs. MMF
AZA 102,558 – 10.9934 – Dominated –0.2339 –0.1932
MMF 100,114 –2444 11.1051 0.1118 – – –
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Appendix 11 Summary of parameters in the
Peninsula Technology Assessment Group’s
economic model
Parameter Value Source PSA distribution
Study characteristics
Patient age (years) 50 Pruthi 2013382 N/A
Patient weight (kg)
Mean 70.18 Multiple RCTs Normal(70.18, 1.118)
SD 14.79 Multiple RCTs N/A
Proportion male 0.617 UK Transplant Registry
standard data set (2007–12)
N/A
Donor type (first graft) UK Transplant Registry
standard data set
DBD 0.664 N/A
DCD 0.079 N/A
Living–related 0.191 N/A
Living–unrelated 0.066 N/A
Donor type (subsequent graft) UK Transplant Registry
standard data set
DBD 0.630 N/A
DCD 0.083 N/A
Living–related 0.198 N/A
Living–unrelated 0.089 N/A
Surrogate relationships
Graft survival (censored for DWFG)
AR 1.60 Cole 2008378 Log-normal(0.47, 0.037)
NODAT 1.12 Cole 2008378 Log-normal(0.113, 0.061)
eGFR Levy 2014334 Multivariate Log-normal
45–60ml/minute/1.73m2 1.409
30–45ml/minute/1.73m2 2.406
15–30ml/minute/1.73m2 5.801
DWFG
NODAT 1.41 Cole 2008378 Log-normal(0.344, 0.061)
Sex: female 0.865 UK Transplant Registry
standard data set
Log-normal(–0.145, 0.036)
Donor type (vs. DBD) UK Transplant Registry
standard data set
DCD 1.083 Log-normal(0.08, 0.061)
Living–related 0.551 Log-normal(–0.595, 0.071)
Living–unrelated 0.703 Log-normal(–0.353, 0.081)
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Parameter Value Source PSA distribution
Age (years) UK Transplant Registry
standard data set
0–17 0.377 Log-normal(–0.975, 0.186)
18–30 0.369 Log-normal(–0.996, 0.117)
31–40 0.712 Log-normal(–0.339, 0.091)
41–50 1 N/A
51–60 2.140 Log-normal(0.761, 0.059)
61–70 4.128 Log-normal(1.418, 0.053)
71–75 7.583 Log-normal(2.026, 0.072)
76–80 8.576 Log-normal(2.149, 0.089)
81–85 13.751 Log-normal(2.621, 0.144)
86–90 23.552 Log-normal(3.159, 0.362)
Effectiveness estimates
Mortality within 12 months [ln(OR)]
Induction agents (vs. no induction) NMA Multivariate normal
BAS –0.117
rATG –0.461
Maintenance agents (vs. CSA+AZA) NMA Multivariate normal
TAC+AZA 0.323
CSA+MPA –0.057
TAC+MPA 0.422
BEL+MPA –0.763
CSA+ EVL 0.333
TAC+ SRL 0.325
SRL+MPA 0.542
Head to head
MPS vs. MMF –0.435 Random-effects meta-analysis
of Ciancio 2008106 and
Salvadori 2001270
Normal(–0.435, 1.231)
TAC-PR vs. TAC 0.245 Krämer 2010204 Normal(0.245, 0.481)
Graft loss within 12 months [ln(OR)]
Induction agents (vs. no induction) NMA Multivariate normal
BAS –0.171
rATG –0.253
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Parameter Value Source PSA distribution
Maintenance agents (vs. CSA+AZA) NMA Multivariate normal
TAC+AZA 0.135
CSA+MPA –0.297
TAC+MPA –0.379
BEL+MPA –0.492
CSA+ EVL –0.484
TAC+ SRL 0.159
SRL+MPA 0.032
Head to head
MPS vs. MMF –0.148 Fixed-effects meta-analysis
of Ciancio 2008106 and
Salvadori 2001270
Normal(–0.148, 0.524)
TAC-PR vs. TAC 0.183 Krämer 2010204 Normal(0.183, 0.29)
BPAR within 12 months [ln(OR)]
Induction agents (vs. no induction) NMA Multivariate normal
BAS –0.688
rATG –1.041
Maintenance agents (vs. CSA+AZA) NMA Multivariate normal
TAC+AZA –0.548
CSA+MPA –0.752
TAC+MPA –0.921
BEL+MPA –0.216
CSA+ EVL –0.784
TAC+ SRL –0.957
SRL+MPA –0.828
Head to head
MPS vs. MMF 0.396 Random-effects meta-analysis
of Ciancio 2008106 and
Salvadori 2001270
Normal(0.396, 0.678)
TAC-PR vs. TAC –0.025 Random-effects meta-analysis
of Krämer 2010204 and
Tsuchiya 2013141
Normal(–0.025, 0.383)
GRF (eGFR) at 12 months [MD (ml/minute/1.73m2)]
Induction agents (vs. no induction) NMA Multivariate normal
BAS 2.615
rATG 0.752
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Parameter Value Source PSA distribution
Maintenance agents (vs. CSA+AZA) NMA Multivariate normal
TAC+AZA 9.304
CSA+MPA 1.609
TAC+MPA 6.531
BEL+MPA 10.550
CSA+ EVL 4.863
TAC+ SRL –0.352
SRL+MPA 3.846
Head to head
MPS vs. MMF 3.900 Ciancio 2008106 Normal(0.396, 0.678)
TAC-PR vs. TAC –0.211 Fixed-effects meta-analysis of
Krämer 2010204 and Tsuchiya
2013141
Normal(–0.025, 0.383)
Baseline effectiveness (BAS + TAC +MMF)
Graft loss within 12 months 0.035 UK Transplant Registry
standard data set
N/A
BPAR within 12 months 0.122 Rowshani 2006103 and
Tsuchiya 2013141
Beta(14, 101)
GRF (eGFR) at 12 months
(ml/minute/1.73 m2)
Pruthi 2013382
Mean 53.4 N/A
SD 18.5 N/A
AEs
NODAT within 12 months
Baseline (BAS+ TAC+MMF) 0.106
Maintenance agents (vs. TAC) [ln(OR)] NMA Multivariate normal
TAC-PR 0.169
CSA –0.816
BEL –1.671
SRL –0.234
Maintenance agents (vs. MMF) [ln(OR)] NMA Multivariate normal
MPS –0.070
SRL 0.474
EVL –0.052
CMV infection within 12 months
Baseline (BAS+ TAC+MMF) 0.107 Multiple RCTs Logit-normal(–2.12, 0.94)
mTOR-I use (vs. no use) [ln(OR)] NMA Multivariate normal
As CNI –0.798
As antimetabolite –1.153
APPENDIX 11
NIHR Journals Library www.journalslibrary.nihr.ac.uk
584
Parameter Value Source PSA distribution
Dyslipidaemia within 12 months
Baseline (BAS+ TAC+MMF) 0.202 Multiple RCTs Logit-normal(–1.376, 0.982)
mTOR-I use (vs. no use) [ln(OR)] 0.557 Fixed-effects meta-analysis Normal(0.557, 0.101)
Anaemia requiring ESA therapy 0.052 Vanrenterghem 2003396 Beta(207 3762)
Retransplantation
Probability of pre-emptive
retransplantation on loss of first graft
Bond 2009384 and Johnston
2013386
Aged 18–34 years 0.108 Beta(3.46, 28.58)
Aged 35–44 years 0.098 Beta(3.51, 32.31)
Aged 45–54 years 0.076 Beta(3.62, 44.01)
Aged 55–64 years 0.054 Beta(3.73, 65.34)
Aged 65+ years 0.020 Beta(3.9, 191.1)
Rate of retransplantation
Aged < 65 years (rate declines linearly
from age 65 to 80 years after which no
retransplantation)
0.104 UK Transplant Registry
standard data set
Normal(0.104, 0.0023)
Baseline rate of DWFG (subsequent
grafts)
0.0078 UK Transplant Registry
standard data set
Log-normal(–4.965, 0.472)
Baseline rate of graft loss (subsequent
grafts)
0.0359 UK Transplant Registry
standard data set
Log-normal(–3.327, 0.084)
Mortality
Rate of death on dialysis following graft
loss (by age, years)
Pruthi 2013339
20–24 0.01 Normal(0.01, 0.0032)
25–29 0.012 Normal(0.018, 0.0042)
30–34 0.009 Normal(0.018, 0.0042)
35–39 0.015 Normal(0.043, 0.0066)
40–44 0.021 Normal(0.089, 0.0094)
45–49 0.027 Normal(0.141, 0.0119)
50–54 0.041 Normal(0.226, 0.015)
55–59 0.053 Normal(0.284, 0.0169)
60–64 0.079 Normal(0.437, 0.0209)
65–69 0.107 Normal(0.553, 0.0235)
70–74 0.149 Normal(0.682, 0.0261)
75–79 0.211 Normal(0.792, 0.0281)
80–84 0.275 Normal(0.652, 0.0255)
85+ 0.408 Normal(0.452, 0.0213)
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Parameter Value Source PSA distribution
Other natural history parameters
Probability of PNF UK Transplant Registry
standard data set
DBD 0.026 Beta(147 5489)
DCD 0.033 Beta(99 2858)
Living–related 0.015 Beta(53 3541)
Living–unrelated 0.012 Beta(27 2149)
Proportion of NODAT in first 6 months 0.75 Woodward 2003395 Beta(75, 25)
Risk stratification for CMV infection Harvala 2013409 Dirichlet(52, 93, 79)
High risk (D+/R–) 0.232
Intermediate risk (D+/R+ or D–/R+) 0.415
Low risk (D–/R–) 0.353
Risk stratification for EBV infection Cavallo 2010411
Seropositive donors 0.927 Beta(51, 4)
Seropositive recipients 0.997 Beta(289, 1)
Utilities
Baseline utility Health Survey for England
2012399
Multivariate normal
Constant 0.9679812
Coefficient for age –0.001807
Coefficient for age2 –9.71× 106
Coefficient for sex=male 0.0232887
Disutilities Liem 2008401
Functioning graft 0.053 Gamma(1.179, 0.0453)
HD 0.277 Gamma(66.9, 0.0041)
PD 0.264 Gamma(35.73, 0.0074)
Resource use
Immunosuppression (first transplant)
Induction therapy Brennan 2006137
BAS (20mg dose+ i.v. administration) 1.964 Normal(1.964, 0.016)
rATG
Drug acquisition (mg/kg) 6.5 Normal(6.5, 0.126)
Intravenous administration 4.525 Normal(4.525, 0.079)
Maintenance therapy:
TAC (with AZA; mg/kg/day) Margreiter 200284
0–1 month 0.225 Log-normal(–1.497, 0.0998)
1–3 months 0.175 Log-normal(–1.748, 0.0998)
3–6 months 0.135 Log-normal(–2.007, 0.0998)
6–12 months 0.11 Log-normal(–2.212, 0.0998)
12–36 months 0.09 Log-normal(–2.413, 0.0998)
36+ months 0.08 Log-normal(–2.531, 0.0998)
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Parameter Value Source PSA distribution
TAC (with MMF; mg/kg/day) Rowshani 2006103
0–2 weeks 0.168 Log-normal(–1.789, 0.0998)
2–6 weeks 0.176 Log-normal(–1.742, 0.0998)
6–12 weeks 0.11 Log-normal(–2.212, 0.0998)
3–6 months 0.104 Log-normal(–2.268, 0.0998)
6–12 months 0.086 Log-normal(–2.458, 0.0998)
12+ months 0.08 Log-normal(–2.531, 0.0998)
TAC (with SRL; mg/kg/day) Gonwa 2003,180 Anil Kumar
2008122
0–1 month 0.175 Log-normal(–1.748, 0.0998)
1–3 months 0.11 Log-normal(–2.212, 0.0998)
3–6 months 0.104 Log-normal(–2.268, 0.0998)
6–12 months 0.08 Log-normal(–2.531, 0.0998)
12+ months 0.07 Log-normal(–2.664, 0.0998)
TAC-PR (with MMF)
As TAC plus 0.015 mg/kg/day for first
12 months
0.015 Wlodarczyk 2009,140 Krämer
2010,204 Tsuchiya 2013,141
Oh 2014105
Normal(0.015, 0.0075)
CSA (with AZA; mg/kg/day) Margreiter 200284
0–1 month 6.375 Log-normal(1.847, 0.0998)
1–3 months 4.525 Log-normal(1.505, 0.0998)
3–6 months 3.765 Log-normal(1.321, 0.0998)
6–12 months 3.375 Log-normal(1.211, 0.0998)
12–36 months 2.93 Log-normal(1.07, 0.0998)
36+ months 2.84 Log-normal(1.039, 0.0998)
CSA (with MMF/MPS; mg/kg/day) Rowshani 2006103
0–2 weeks 7.62 Log-normal(2.026, 0.0998)
2–6 weeks 5.72 Log-normal(1.739, 0.0998)
6–12 weeks 3.06 Log-normal(1.113, 0.0998)
3–6 months 2.86 Log-normal(1.046, 0.0998)
6–12 months 2.82 Log-normal(1.032, 0.0998)
12+ months 2.82 Log-normal(1.032, 0.0998)
CSA (with EVL; mg/kg/day) Vítko 2005150
0–12 months 3.9 Log-normal(1.356, 0.0998)
12+ months 2.1 Log-normal(0.737, 0.0998)
AZA (with TAC; mg/kg/day) Laskow 199680
0–6 months 1.5 Log-normal(0.4, 0.0998)
6+ months 1.2 Log-normal(0.177, 0.0998)
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Parameter Value Source PSA distribution
AZA (with CSA; mg/kg/day) Sadek 200286 and
Vacher-Coponat 2012129
0–6 months 1.5 Log-normal(0.4, 0.0998)
6–12 months 1.4 Log-normal(0.331, 0.0998)
12–36 months 1.215 Log-normal(0.19, 0.0998)
36+ months 1.215 Log-normal(0.19, 0.0998)
MMF (with TAC; g/day) SYMPHONY240
0–3 months 2 Log-normal(0.688, 0.0998)
3–12 months 1.736 Log-normal(0.547, 0.0998)
12+ months 1.472 Log-normal(0.382, 0.0998)
MMF (with CSA; g/day) SYMPHONY240
0–3 months 2 Log-normal(0.688, 0.0998)
3–12 months 1.836 Log-normal(0.603, 0.0998)
12+ months 1.672 Log-normal(0.509, 0.0998)
MMF (with SRL; g/day) SYMPHONY240
0–3 months 2 Log-normal(0.688, 0.0998)
3–12 months 1.7335 Log-normal(0.545, 0.0998)
12+ months 1.467 Log-normal(0.378, 0.0998)
MMF (with BEL; g/day) BENEFIT59
Throughout 2 Log-normal(0.688, 0.0998)
MPS (with CSA;mg/day)
0–3 months 1440 Log-normal(7.267, 0.0998)
3–9 months 1211 Log-normal(7.094, 0.0998)
9+ months 1107 Log-normal(7.004, 0.0998)
SRL (with TAC;mg/day) Anil Kumar 2008122
0–12 months 3.7 Log-normal(1.303, 0.0998)
12–60 months 2.75 Log-normal(1.007, 0.0998)
60+ months 1.8 Log-normal(0.583, 0.0998)
SRL (with MMF;mg/day) Lebranchu 2009149
0–3 months 5.2 Log-normal(1.644, 0.0998)
3–6 months 4.45 Log-normal(1.488, 0.0998)
6–9 months 3.5 Log-normal(1.248, 0.0998)
9–12 months 3.25 Log-normal(1.174, 0.0998)
12–48 months 2.9 Log-normal(1.06, 0.0998)
48+ months 2.6 Log-normal(0.951, 0.0998)
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Parameter Value Source PSA distribution
EVL (with CSA;mg/day) Tedesco-Silva 2010107 and
Lorber 2005143
0–3 months 2.937 Log-normal(1.072, 0.0998)
3–6 months 2.75 Log-normal(1.007, 0.0998)
6–9 months 2.533 Log-normal(0.925, 0.0998)
9–12 months 2.6 Log-normal(0.951, 0.0998)
12–24 months 2.6 Log-normal(0.951, 0.0998)
24+ months 2 Log-normal(0.688, 0.0998)
BEL (with MMF) Dosing schedule
Drug acquisition (250-mg vials per quarter)
0–3 months 16.53 Log-normal(2.805, 0.02)
3–6 months 7.13 Log-normal(1.964, 0.02)
6+ months 6.24 Log-normal(1.83, 0.02)
Drug administration (per quarter)
0–3 months 5 Log-normal(1.609, 0.02)
3–6 months 3 Log-normal(1.098, 0.02)
6+ months 3.26 Log-normal(1.182, 0.02)
Prednisolone (mg/day) SYMPHONY240
Throughout 16.3 Log-normal(2.786, 0.0998)
Subsequent transplants
Proportion of failed grafts explanted
(time since transplantation)
Bond 2009384
0–3 months 0.41 Beta(1.95, 2.81)
3–12 months 0.23 Beta(2.85, 9.54)
12–24 months 0.09 Beta(3.55, 35.9)
24+ months 0.04 Beta(3.8, 91.2)
Subsequent graft 0.059
Subsequent retransplantation
Workup for retransplantation 1.444 NHS reference costs
2013–1464
Normal(1.444, 0.025)
Living donor costs 0.349 NHS reference costs
2013–1464
Normal(0.349, 0.012)
Deceased donor costs 0.651 NHS reference costs
2013–1464
1 – living donor costs
Maintenance immunosuppression
TAC (mg/kg/day) 0.1 Assume somewhat higher
than for original graft because
of increased risk of rejection
Log-normal(–2.308,
0.0998)
MMF (g/day) 2 Recommended daily dose Log-normal(0.688, 0.0998)
Prednisolone (mg/day) 16.3 SYMPHONY240 Log-normal(2.786, 0.0998)
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Parameter Value Source PSA distribution
Infection prophylaxis
Co-trimoxazole (PCP and UTI
prophylaxis)
Septrin (480-mg tablets in first
3 months)
90 Log-normal(4.495, 0.0998)
Valganciclovir (CMV prophylaxis):
Valcyte 450-mg tablets
Full dose 0–3 months (D+/R– or D
[+/–]/R+with rATG)
182.6 N/A
Full dose 3–6 months (D+/R–) 182.6 N/A
Full dose 3–6 months (D[+/–]/R+with
rATG)
91.3 Uniform(0, 182.6)
Full dose 6–9 months (D+/R–) 34.8 N/A
Dose adjustment for renal function 0.473 Log-normal(–0.779, 0.246)
Adverse events
Expected number of AR events per
patient experiencing 1+ AR events
1.193 Charpentier 2003148 Normal(1.193, 0.102)
Antidiabetic medication: metformin
500-mg tablets per 3 months
273.9 Log-normal(5.608, 0.0998)
Dyslipidaemia
Statins Riella 2012413
Fluvastatin (mg per cycle for affected
patient)
2191 Log-normal(7.662, 0.246)
Pravastatin (mg per cycle for affected
patient)
548 Log-normal(6.276, 0.246)
Simvastatin (mg per cycle for affected
patient)
91.3 Log-normal(4.484, 0.246)
Medical management
Dietetics outpatient attendance
(number per cycle)
0.25 Log-normal(–1.417, 0.246)
GP appointment (# per cycle) 0.25 Log-normal(–1.417, 0.246)
Anaemia requiring ESA therapy
Mean weekly dose (× 1000 IU) 5.832 Vanrenterghem 2003396 Normal(5.832, 0.067)
Monitoring
Clinic (per cycle)
0–3 months 13.0 Log-normal(2.567, 0.05)
Thereafter as for blood tests (below)
Subsequent grafts 3 Log-normal(1.068, 0.246)
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Parameter Value Source PSA distribution
Blood tests Ling and Chamberlain 2011410
0–1 months 13.07 Normal(13.07, 0.259)
1–2 months 6.75 Normal(6.75, 0.186)
2–3 months 4.95 Normal(4.95, 0.159)
3–6 months 8.99 Normal(8.99, 0.215)
6–12 months 3.97 Normal(7.93, 0.202)
12–24 months 2.69 Normal(10.77, 0.235)
24–36 months 3.5 Normal(14, 0.268)
≥ 36 months 1 Log-normal(–0.03, 0.246)
Subsequent grafts 3 Log-normal(1.068, 0.246)
Viral PCR (per cycle)
0–3 months (CMV) 5.42 Log-normal(2.538, 0.246)
0–6 months (BKV) 1 Log-normal(–0.03, 0.246)
6–12 months (BKV) 0.5 Log-normal(–0.723, 0.246)
0–6 months (EBV) 0.0096 Log-normal(1.068, 0.246)
6–12 months (EBV) 0.0032 Log-normal(–0.03, 0.246)
Dialysis
Proportion receiving HD by age (years) UK Renal Registry 16th Annual
Report (figure 2.7)3
18–24 0.791 Beta(276, 73)
25–34 0.804 Beta(913, 223)
35–44 0.845 Beta(1853, 340)
45–54 0.843 Beta(3358, 624)
55–64 0.852 Beta(4408, 768)
65–74 0.858 Beta(5824, 967)
75–84 0.890 Beta(5533, 681)
≥ 85 0.915 Beta(1246, 116)
Unit costs
Dialysis NHS reference costs
2013–1464
HD
Access surgery £1946.32 Normal(1946.32, 97.81)
Temporary access £823.25 Normal(823.25, 40.43)
Per quarter £6093.11 Normal(6093.11, 163.99)
PD
Access surgery £1100.71 Normal(1100.71, 119.76)
Per quarter £6000.00 Normal(6000, 183.24)
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Parameter Value Source PSA distribution
Induction agents
BAS
Simulect (per 20mg) £842.38 BNF 6856 N/A
rATG
Thymoglobulin (permg) £6.35 BNF 6856 N/A
Maintenance agents
TAC (immediate-release
capsules)
NHS acquisition cost (permg) £0.5201 eMit370 Mixture model
CSA (immediate-release
capsules)
NHS acquisition cost (permg) £0.0165 eMit370 Mixture model
MMF
NHS acquisition cost (per g) £0.3774 eMit370 Mixture model
MPS
Myfortic (permg) £0.0045 BNF 6856 N/A
AZA
NHS acquisition cost (permg) £0.0011 eMit370 Mixture model
SRL
Rapamune (permg) £2.883 BNF 6856 N/A
EVL
Certican (permg) £9.90 Novartis’ submission N/A
BEL
Nulojix (per 250-mg vial) £354.52 BNF 6856 N/A
Prednisolone
NHS acquisition cost (permg) £0.0033 eMit370 Mixture model
AR (per episode) £3557.39 Ling 2011379 Log-normal(8.146, 0.246)
Infection prophylaxis
Co-trimoxazole (PCP and UTI
prophylaxis)
Septrin (per 480-mg tablet) £0.155 BNF 6856 N/A
Valganciclovir (CMV prophylaxis)
Valcyte (per 450-mg tablet) £18.02 BNF 6856 N/A
CMV infection £3008.91 Ling 2011379 Log-normal(7.979, 0.246)
Anaemia requiring ESA therapy
Erythropoietin
Binocrit (per 1000 IU) £4.33 BNF 6856 N/A
NODAT
Anti-diabetic treatment
Metformin (per 500-mg tablet) £0.0054 eMit370 Normal(0.0054, 0.00001)
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Parameter Value Source PSA distribution
Annual cost of complications Alva 2014419
Inpatient £1388.92 Normal(1388.92, 99.42)
Non-inpatient £694.92 Normal(694.92, 18.54)
Dyslipidaemia
Statins
Fluvastatin (permg) £0.0022 eMit370 Mixture model
Pravastatin (permg) £0.0026 eMit370 Mixture model
Simvastatin (permg) £0.0003 eMit370 Mixture model
Medical management
Dietetics outpatient attendance £62.70 NHS reference costs
2013–1464
Normal(62.7, 2.66)
GP appointment £50.82 PSSRU Unit Costs 2014407 Normal(50.82, 5.08)
Drug administration
Intravenous infusion
First infusion £228.95 NHS reference costs
2013–1464
Normal(228.95, 15.83)
Subsequent infusions £325.59 NHS reference costs
2013–1464
Normal(325.59, 45.79)
BEL £167.50 NHS reference costs
2013–1456
Normal(167.50, 11.58)
Monitoring
Clinic £145.27 NHS reference costs
2013–1464
Viral PCR University College London
Hospitals NHS Foundation Trust
Provider to provider services:
2013–14 tariff. 2013
EBV £46.75 Equal to CMV PCR
CMV £46.75 Log-normal(3.815, 0.246)
BKV £46.75 Equal to CMV PCR
Therapeutic drug monitoring (TDM) Dept of Medical Biochemistry
and Immunology, University
Hospital of Wales
Therapeutic drug monitoring
test repertoire 2013/2014.
2013
CSA TDM £26.71 Log-normal(3.255, 0.246)
TAC TDM £26.71 Equal
SRL TDM £26.71 Equal
EVL TDM £26.71 Equal
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Parameter Value Source PSA distribution
General tests NHS Kidney Care 2011421
Full blood count £5.05 Log-normal(1.615, 0.0998)
Renal profile £4.54 Log-normal(1.509, 0.0998)
Liver profile £4.64 Log-normal(1.531, 0.0998)
Explant surgery £4965.59 NHS reference costs
2013–1464
Normal(4965.59, 496.56)
Subsequent retransplantation
Recipient work-up £848.72 NHS reference costs
2013–1464
Normal(848.72, 84.87)
Living donor costs £8914.05 NHS reference costs
2013–1464
Normal(8914.05, 891.41)
Deceased donor costs £10,142.05 NHSBT 2013355 Normal(10,142.05,
1014.21)
Transplant surgery £16,030.35 NHS reference costs
2013–1464
Normal(16,030.35,
1603.04)
D–, CMV seronegative donor; D+, CMV seropositive donor; N/A, not applicable; R–, CMV seronegative recipient;
R+, CMV seropositive recipient; TDM, therapeutic drug monitoring.
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